{
  "nbformat": 4,
  "nbformat_minor": 0,
  "metadata": {
    "colab": {
      "provenance": []
    },
    "kernelspec": {
      "name": "python3",
      "display_name": "Python 3"
    },
    "language_info": {
      "name": "python"
    }
  },
  "cells": [
    {
      "cell_type": "code",
      "source": [
        "!pip install transformers\n",
        "!pip install sacremoses"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "BIGlFp3x-wNc",
        "outputId": "8f290566-3ffe-4f65-d3a7-bac09beaaf68"
      },
      "execution_count": 216,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Requirement already satisfied: transformers in /usr/local/lib/python3.10/dist-packages (4.34.1)\n",
            "Requirement already satisfied: filelock in /usr/local/lib/python3.10/dist-packages (from transformers) (3.12.4)\n",
            "Requirement already satisfied: huggingface-hub<1.0,>=0.16.4 in /usr/local/lib/python3.10/dist-packages (from transformers) (0.17.3)\n",
            "Requirement already satisfied: numpy>=1.17 in /usr/local/lib/python3.10/dist-packages (from transformers) (1.23.5)\n",
            "Requirement already satisfied: packaging>=20.0 in /usr/local/lib/python3.10/dist-packages (from transformers) (23.2)\n",
            "Requirement already satisfied: pyyaml>=5.1 in /usr/local/lib/python3.10/dist-packages (from transformers) (6.0.1)\n",
            "Requirement already satisfied: regex!=2019.12.17 in /usr/local/lib/python3.10/dist-packages (from transformers) (2023.6.3)\n",
            "Requirement already satisfied: requests in /usr/local/lib/python3.10/dist-packages (from transformers) (2.31.0)\n",
            "Requirement already satisfied: tokenizers<0.15,>=0.14 in /usr/local/lib/python3.10/dist-packages (from transformers) (0.14.1)\n",
            "Requirement already satisfied: safetensors>=0.3.1 in /usr/local/lib/python3.10/dist-packages (from transformers) (0.4.0)\n",
            "Requirement already satisfied: tqdm>=4.27 in /usr/local/lib/python3.10/dist-packages (from transformers) (4.66.1)\n",
            "Requirement already satisfied: fsspec in /usr/local/lib/python3.10/dist-packages (from huggingface-hub<1.0,>=0.16.4->transformers) (2023.6.0)\n",
            "Requirement already satisfied: typing-extensions>=3.7.4.3 in /usr/local/lib/python3.10/dist-packages (from huggingface-hub<1.0,>=0.16.4->transformers) (4.5.0)\n",
            "Requirement already satisfied: charset-normalizer<4,>=2 in /usr/local/lib/python3.10/dist-packages (from requests->transformers) (3.3.0)\n",
            "Requirement already satisfied: idna<4,>=2.5 in /usr/local/lib/python3.10/dist-packages (from requests->transformers) (3.4)\n",
            "Requirement already satisfied: urllib3<3,>=1.21.1 in /usr/local/lib/python3.10/dist-packages (from requests->transformers) (2.0.7)\n",
            "Requirement already satisfied: certifi>=2017.4.17 in /usr/local/lib/python3.10/dist-packages (from requests->transformers) (2023.7.22)\n",
            "Requirement already satisfied: sacremoses in /usr/local/lib/python3.10/dist-packages (0.0.53)\n",
            "Requirement already satisfied: regex in /usr/local/lib/python3.10/dist-packages (from sacremoses) (2023.6.3)\n",
            "Requirement already satisfied: six in /usr/local/lib/python3.10/dist-packages (from sacremoses) (1.16.0)\n",
            "Requirement already satisfied: click in /usr/local/lib/python3.10/dist-packages (from sacremoses) (8.1.7)\n",
            "Requirement already satisfied: joblib in /usr/local/lib/python3.10/dist-packages (from sacremoses) (1.3.2)\n",
            "Requirement already satisfied: tqdm in /usr/local/lib/python3.10/dist-packages (from sacremoses) (4.66.1)\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "import json\n",
        "import torch\n",
        "from transformers import BertTokenizer, BertModel\n",
        "from transformers import GPT2Tokenizer, GPT2LMHeadModel\n",
        "from transformers import AutoTokenizer\n",
        "from transformers import BioGptTokenizer, BioGptForCausalLM\n"
      ],
      "metadata": {
        "id": "L_Mf1Iol2H3D"
      },
      "execution_count": 217,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "# Load pre-trained model tokenizer (vocabulary)\n",
        "bert_tokenizer = BertTokenizer.from_pretrained('bert-base-uncased')\n",
        "biobert_tokenizer = AutoTokenizer.from_pretrained(\"dmis-lab/biobert-v1.1\")\n",
        "gpt2_tokenizer = GPT2Tokenizer.from_pretrained('gpt2')\n",
        "gpt2_model = GPT2LMHeadModel.from_pretrained('gpt2')\n",
        "bioGPT_tokenizer = BioGptTokenizer.from_pretrained(\"microsoft/biogpt\")\n",
        "bioGPT_model = BioGptForCausalLM.from_pretrained(\"microsoft/biogpt\")\n",
        "clinBERT_tokenizer = AutoTokenizer.from_pretrained(\"medicalai/ClinicalBERT\")"
      ],
      "metadata": {
        "id": "EJX3s2L_58-q"
      },
      "execution_count": 218,
      "outputs": []
    },
    {
      "cell_type": "code",
      "execution_count": 219,
      "metadata": {
        "id": "ORzruLnd4xpp"
      },
      "outputs": [],
      "source": [
        "f = open('data.json')\n",
        "data = json.load(f)"
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "x_key_to_extract = \"abstract\"\n",
        "\n",
        "for data_key, data_serial in data.items():\n",
        "    for level1_key, level1_data in data_serial.items():\n",
        "        if x_key_to_extract in level1_data:\n",
        "            abstract = level1_data[x_key_to_extract]\n",
        "            print(f\"{data_key}: {x_key_to_extract}: {abstract}\")"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "q4wewEyeERWq",
        "outputId": "db4969a9-370c-4e2f-b97f-087adf50d94e"
      },
      "execution_count": 220,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "1: abstract: {'1': 'Muscle cramps are a common problem characterized by a sudden, painful, involuntary contraction of muscle.', '2': 'These true cramps, which originate from peripheral nerves, may be distinguished from other muscle pain or spasm.', '3': 'Medical history, physical examination, and a limited laboratory screen help to determine the various causes of muscle cramps.', '4': 'Despite the \"benign\" nature of cramps, many patients find the symptom very uncomfortable.', '5': 'Treatment options are guided both by experience and by a limited number of therapeutic trials.', '6': 'Quinine sulfate is an effective medication, but the side-effect profile is worrisome, and other membrane-stabilizing drugs are probably just as effective.', '7': 'Patients will benefit from further studies to better define the pathophysiology of muscle cramps and to find more effective medications with fewer side-effects.'}\n",
            "1: abstract: {'1': 'The dystonias are a group of disorders characterized by excessive involuntary muscle contractions leading to abnormal postures and/or repetitive movements.', '2': 'A careful assessment of the clinical manifestations is helpful for identifying syndromic patterns that focus diagnostic testing on potential causes.', '3': 'If a cause is identified, specific etiology-based treatments may be available.', '4': 'In most cases, a specific cause cannot be identified, and treatments are based on symptoms.', '5': 'Treatment options include counseling, education, oral medications, botulinum toxin injections, and several surgical procedures.', '6': 'A substantial reduction in symptoms and improved quality of life is achieved in most patients by combining these options.'}\n",
            "1: abstract: {'1': 'Muscle cramps result in continuous, involuntary, painful, and localized contraction of an entire muscle group, individual single muscle, or select muscle fibers.', '2': 'Generally, the cramp can last from minutes to a few seconds for idiopathic or known causes with healthy subjects or in the presence of diseases.', '3': 'Palpating the muscle area of the cramp will present a knot.', '4': 'Exercise-associated muscle cramps are the most frequent condition requiring medical/therapeutic intervention during sports.', '5': 'The specific etiology is not well understood and possible causes depend on the physiological or pathological situation in which the cramps appear.', '6': 'It is important to note that a painful contraction that is limited to a specific area does not mean that the cause of the cramp is necessarily local.', '7': 'A cramp is almost never a local effect but involves the whole body system, such as somatic and emotional.'}\n",
            "1: abstract: {'1': 'Exercise-Associated Muscle Cramps (EAMC) are a common painful condition of muscle spasms.', '2': 'Despite scientists tried to understand the physiological mechanism that underlies these common phenomena, the etiology is still unclear.', '3': 'From 1900 to nowadays, the scientific world retracted several times the original hypothesis of heat cramps.', '4': 'However, recent literature seems to focus on two potential mechanisms: the dehydration or electrolyte depletion mechanism, and the neuromuscular mechanism.', '5': 'The aim of this review is to examine the recent literature, in terms of physiological mechanisms of EAMC.', '6': 'A comprehensive search was conducted on PubMed and Google Scholar.', '7': 'The following terminology was applied: muscle cramps, neuromuscular hypothesis (or thesis), dehydration hypothesis, Exercise-Associated muscle cramps, nocturnal cramps, muscle spasm, muscle fatigue.', '8': 'From the initial literature of 424 manuscripts, sixty-nine manuscripts were included, analyzed, compared and summarized.', '9': 'Literature analysis indicates that neuromuscular hypothesis may prevails over the initial hypothesis of the dehydration as the trigger event of muscle cramps.', '10': 'New evidence suggests that the action potentials during a muscle cramp are generated in the motoneuron soma, likely accompanied by an imbalance between the rising excitatory drive from the muscle spindles (Ia) and the decreasing inhibitory drive from the Golgi tendon organs.', '11': 'In conclusion, from the latest investigations there seem to be a spinal involvement rather than a peripheral excitation of the motoneurons.'}\n",
            "1: abstract: {'1': 'Muscular cramp is a common symptom in healthy people, especially among the elderly and in young people after vigorous or peak exercise.', '2': 'It is prominent in a number of benign neurological syndromes.', '3': 'It is a particular feature of chronic neurogenic disorders, especially amyotrophic lateral sclerosis.', '4': 'A literature review was undertaken to understand the diverse clinical associations of cramp and its neurophysiological basis, taking into account recent developments in membrane physiology and modulation of motor neuronal excitability.', '5': 'Many aspects of cramping remain incompletely understood and require further study.', '6': 'Current treatment options are correspondingly limited.'}\n",
            "1: abstract: {'1': 'Dystonia is a neurological condition characterized by abnormal involuntary movements or postures owing to sustained or intermittent muscle contractions.', '2': 'Dystonia can be the manifesting neurological sign of many disorders, either in isolation (isolated dystonia) or with additional signs (combined dystonia).', '3': 'The main focus of this Primer is forms of isolated dystonia of idiopathic or genetic aetiology.', '4': 'These disorders differ in manifestations and severity but can affect all age groups and lead to substantial disability and impaired quality of life.', '5': 'The discovery of genes underlying the mendelian forms of isolated or combined dystonia has led to a better understanding of its pathophysiology.', '6': 'In some of the most common genetic dystonias, such as those caused by TOR1A, THAP1, GCH1 and KMT2B mutations, and idiopathic dystonia, these mechanisms include abnormalities in transcriptional regulation, striatal dopaminergic signalling and synaptic plasticity and a loss of inhibition at neuronal circuits.', '7': 'The diagnosis of dystonia is largely based on clinical signs, and the diagnosis and aetiological definition of this disorder remain a challenge.', '8': 'Effective symptomatic treatments with pharmacological therapy (anticholinergics), intramuscular botulinum toxin injection and deep brain stimulation are available; however, future research will hopefully lead to reliable biomarkers, better treatments and cure of this disorder.'}\n",
            "1: abstract: {'1': 'Muscle cramp is a temporary but intense and painful involuntary contraction of skeletal muscle that can occur in many different situations.', '2': 'The causes of, and cures for, the cramps that occur during or soon after exercise remain uncertain, although there is evidence that some cases may be associated with disturbances of water and salt balance, while others appear to involve sustained abnormal spinal reflex activity secondary to fatigue of the affected muscles.', '3': 'Evidence in favour of a role for dyshydration comes largely from medical records obtained in large industrial settings, although it is supported by one large-scale intervention trial and by field trials involving small numbers of athletes.', '4': 'Cramp is notoriously unpredictable, making laboratory studies difficult, but experimental models involving electrical stimulation or intense voluntary contractions of small muscles held in a shortened position can induce cramp in many, although not all, individuals.', '5': 'These studies show that dehydration has no effect on the stimulation frequency required to initiate cramping and confirm a role for spinal pathways, but their relevance to the spontaneous cramps that occur during exercise is questionable.', '6': 'There is a long history of folk remedies for treatment or prevention of cramps; some may reduce the likelihood of some forms of cramping and reduce its intensity and duration, but none are consistently effective.', '7': 'It seems likely that there are different types of cramp that are initiated by different mechanisms; if this is the case, the search for a single strategy for prevention or treatment is unlikely to succeed.'}\n",
            "1: abstract: {'1': 'Background: Skeletal muscle cramps are common and often occur in association with pregnancy, advanced age, exercise or motor neuron disorders (such as amyotrophic lateral sclerosis).', '2': 'Typically, such cramps have no obvious underlying pathology, and so are termed idiopathic.', '3': 'Magnesium supplements are marketed for the prophylaxis of cramps but the efficacy of magnesium for this purpose remains unclear.', '4': 'This is an update of a Cochrane Review first published in 2012, and performed to identify and incorporate more recent studies.'}\n",
            "1: abstract: {'1': 'Background: Muscle cramp is a painful, involuntary muscle contraction, and that occurs during or following exercise is referred to as exercise-associated muscle cramp (EAMC).', '2': 'The causes of EAMC are likely to be multifactorial, but dehydration and electrolytes deficits are considered to be factors.', '3': 'This study tested the hypothesis that post-exercise muscle cramp susceptibility would be increased with spring water ingestion, but reduced with oral rehydration solution (ORS) ingestion during exercise.', '4': 'Methods: Ten men performed downhill running (DHR) in the heat (35-36 °C) for 40-60 min to reduce 1.5-2% of their body mass in two conditions (spring water vs ORS) in a cross-over design.', '5': 'The body mass was measured at 20 min and every 10 min thereafter during DHR, and 30 min post-DHR.', '6': 'The participants ingested either spring water or ORS for the body mass loss in each period.', '7': 'The two conditions were counter-balanced among the participants and separated by a week.', '8': 'Calf muscle cramp susceptibility was assessed by a threshold frequency (TF) of an electrical train stimulation to induce cramp before, immediately after, 30 and 65 min post-DHR.', '9': 'Blood samples were taken before, immediately after and 65 min after DHR to measure serum sodium, potassium, magnesium and chroride concentrations, hematocrit (Hct), hemoglobin (Hb), and serum osmolarity.', '10': 'Changes in these varaibles over time were compared between conditions by two-way repeated measures of analysis of variance.', '11': 'Results: The average (±SD) baseline TF (25.6 ± 0.7 Hz) was the same between conditions.', '12': 'TF decreased 3.8 ± 2.7 to 4.5 ± 1.7 Hz from the baseline value immediately to 65 min post-DHR for the spring water condition, but increased 6.5 ± 4.9 to 13.6 ± 6.0 Hz in the same time period for the ORS condition (P < 0.05).', '13': 'Hct and Hb did not change significantly (P > 0.05) for both conditions, but osmolarity decreased (P < 0.05) only for the spring water condition.', '14': 'Serum sodium and chloride concentrations decreased (< 2%) at immediately post-DHR for the spring water condition only (P < 0.05).', '15': 'Conclusions: These results suggest that ORS intake during exercise decreased muscle cramp susceptibility.', '16': 'It was concluded that ingesting ORS appeared to be effective for preventing EAMC.'}\n",
            "1: abstract: {'1': 'Dystonia is a complex neurological movement disorder characterized by involuntary muscle contractions.', '2': 'Increasing studies implicate the microbiome as a possible key susceptibility factor for neurological disorders, but the relationship between the gut microbiota and dystonia remains poorly explored.', '3': 'Here, the gut microbiota of 57 patients with isolated dystonia and 27 age- and environment-matched healthy controls was analyzed by 16S rRNA gene amplicon sequencing.', '4': 'Further, integrative analysis of the gut microbiome and serum metabolome measured by high-performance liquid chromatography-mass spectrometry was performed.', '5': 'No difference in α-diversity was found, while β-diversity was significantly different, with a more heterogeneous community structure among dystonia patients than among controls.', '6': 'The most significant changes in dystonia highlighted an increase in Clostridiales, including Blautia obeum, Dorea longicatena, and Eubacterium hallii, and a reduction in Bacteroides vulgatus and Bacteroides plebeius.', '7': 'The functional analysis revealed that genes related to tryptophan and purine biosynthesis were more abundant in gut microbiota from patients with dystonia, while genes linked to citrate cycle, vitamin B6, and glycan metabolism were less abundant.', '8': 'The evaluation of serum metabolites revealed altered levels of l-glutamic acid, taurine, and d-tyrosine, suggesting changes in neurotransmitter metabolism.', '9': 'The most modified metabolites strongly inversely correlated with the abundance of members belonging to the Clostridiales, revealing the effect of the gut microbiota on neurometabolic activity.', '10': 'This study is the first to reveal gut microbial dysbiosis in patients with isolated dystonia and identified potential links between gut microbiota and serum neurotransmitters, providing new insight into the pathogenesis of isolated dystonia.', '11': \"IMPORTANCE Dystonia is the third most common movement disorder after essential tremor and Parkinson's disease.\", '12': 'However, the cause for the majority of cases is not known.', '13': 'This is the first study so far that reveals significant alterations of gut microbiome and correlates the alteration of serum metabolites with gut dysbiosis in patients with isolated dystonia.', '14': 'We demonstrated a general overrepresentation of Clostridiales and underrepresentation of Bacteroidetes in patients with dystonia in comparison with healthy controls.', '15': 'The functional analysis found that genes related to the biosynthesis of tryptophan, which is the precursor of the neurotransmitter serotonin, were more active in isolated dystonia patients.', '16': 'Altered levels of several serum metabolites were found to be associated with microbial changes, such as d-tyrosine, taurine, and glutamate, indicating differences in neurotransmitter metabolism in isolated dystonia.', '17': 'Integrative analysis suggests that neurotransmitter system dysfunction may be a possible pathway by which the gut microbiome participates in the development of dystonia.', '18': 'The gut microbiome changes provide new insight into the pathogenesis of dystonia, suggesting new potential therapeutic directions.'}\n",
            "2: abstract: {'1': 'Urinary incontinence is the inability to willingly control bladder voiding.', '2': 'Stress urinary incontinence (SUI) is the most frequently occurring type of incontinence in women.', '3': 'No widely accepted or approved drug therapy is yet available for the treatment of stress urinary incontinence.', '4': 'Numerous studies have implicated the neurotransmitters, serotonin and norepinephrine in the central neural control of the lower urinary tract function.', '5': 'The pudendal somatic motor nucleus of the spinal cord is densely innervated by 5HT and NE terminals.', '6': 'Pharmacological studies confirm central modulation of the lower urinary tract activity by 5HT and NE receptor agonists and antagonists.', '7': 'Duloxetine is a combined serotonin/norepinephrine reuptake inhibitor currently under clinical investigation for the treatment of women with stress urinary incontinence.', '8': 'Duloxetine exerts balanced in vivo reuptake inhibition of 5HT and NE and exhibits no appreciable binding affinity for receptors of neurotransmitters.', '9': \"The action of duloxetine in the treatment of stress urinary incontinence is associated with reuptake inhibition of serotonin and norepinephrine at the presynaptic neuron in Onuf's nucleus of the sacral spinal cord.\", '10': 'In cats, whose bladder had initially been irritated with acetic acid, a dose-dependent improvement of the bladder capacity (5-fold) and periurethral EMG activity (8-fold) of the striated sphincter muscles was found.', '11': 'In a double blind, randomized, placebo-controlled, clinical trial in women with stress urinary incontinence, there was a significant reduction in urinary incontinence episodes under duloxetine treatment.', '12': 'In summary, the pharmacological effect of duloxetine to increase the activity of the striated urethral sphincter together with clinical results indicate that duloxetine has an interesting therapeutic potential in patients with stress urinary incontinence.'}\n",
            "2: abstract: {'1': 'Duloxetine, a potent reuptake inhibitor of serotonin (5-HT) and norepinephrine, is effective for the treatment of major depressive disorder, diabetic neuropathic pain, stress urinary incontinence, generalized anxiety disorder and fibromyalgia.', '2': 'Duloxetine achieves a maximum plasma concentration (C(max)) of approximately 47 ng/mL (40 mg twice-daily dosing) to 110 ng/mL (80 mg twice-daily dosing) approximately 6 hours after dosing.', '3': 'The elimination half-life of duloxetine is approximately 10-12 hours and the volume of distribution is approximately 1640 L.', '4': 'The goal of this paper is to provide a review of the literature on intrinsic and extrinsic factors that may impact the pharmacokinetics of duloxetine with a focus on concomitant medications and their clinical implications.', '5': 'Patient demographic characteristics found to influence the pharmacokinetics of duloxetine include sex, smoking status, age, ethnicity, cytochrome P450 (CYP) 2D6 genotype, hepatic function and renal function.', '6': 'Of these, only impaired hepatic function or severely impaired renal function warrant specific warnings or dose recommendations.', '7': 'Pharmacokinetic results from drug interaction studies show that activated charcoal decreases duloxetine exposure, and that CYP1A2 inhibition increases duloxetine exposure to a clinically significant degree.', '8': 'Specifically, following oral administration in the presence of fluvoxamine, the area under the plasma concentration-time curve and C(max) of duloxetine significantly increased by 460% (90% CI 359, 584) and 141% (90% CI 93, 200), respectively.', '9': 'In addition, smoking is associated with a 30% decrease in duloxetine concentration.', '10': 'The exposure of duloxetine with CYP2D6 inhibitors or in CYP2D6 poor metabolizers is increased to a lesser extent than that observed with CYP1A2 inhibition and does not require a dose adjustment.', '11': 'In addition, duloxetine increases the exposure of drugs that are metabolized by CYP2D6, but not CYP1A2.', '12': 'Pharmacodynamic study results indicate that duloxetine may enhance the effects of benzodiazepines, but not alcohol or warfarin.', '13': 'An increase in gastric pH produced by histamine H(2)-receptor antagonists or antacids did not impact the absorption of duloxetine.', '14': 'While duloxetine is generally well tolerated, it is important to be knowledgeable about the potential for pharmacokinetic interactions between duloxetine and drugs that inhibit CYP1A2 or drugs that are metabolized by CYP2D6 enzymes.'}\n",
            "2: abstract: {'1': 'In addition to treating depression, antidepressant drugs are also a first-line treatment for neuropathic pain, which is pain secondary to lesion or pathology of the nervous system.', '2': 'Despite the widespread use of these drugs, the mechanism underlying their therapeutic action in this pain context remains partly elusive.', '3': 'The present study combined data collected in male and female mice from a model of neuropathic pain and data from the clinical setting to understand how antidepressant drugs act.', '4': 'We show two distinct mechanisms by which the selective inhibitor of serotonin and noradrenaline reuptake duloxetine and the tricyclic antidepressant amitriptyline relieve neuropathic allodynia.', '5': 'One of these mechanisms is acute, central, and requires descending noradrenergic inhibitory controls and α2A adrenoceptors, as well as the mu and delta opioid receptors.', '6': 'The second mechanism is delayed, peripheral, and requires noradrenaline from peripheral sympathetic endings and β2 adrenoceptors, as well as the delta opioid receptors.', '7': 'We then conducted a transcriptomic analysis in dorsal root ganglia, which suggested that the peripheral component of duloxetine action involves the inhibition of neuroimmune mechanisms accompanying nerve injury, including the downregulation of the TNF-α-NF-κB signaling pathway.', '8': 'Accordingly, immunotherapies against either TNF-α or Toll-like receptor 2 (TLR2) provided allodynia relief.', '9': \"We also compared duloxetine plasma levels in the animal model and in patients and we observed that patients' drug concentrations were compatible with those measured in animals under chronic treatment involving the peripheral mechanism.\", '10': 'Our study highlights a peripheral neuroimmune component of antidepressant drugs that is relevant to their delayed therapeutic action against neuropathic pain.', '11': 'SIGNIFICANCE STATEMENT In addition to treating depression, antidepressant drugs are also a first-line treatment for neuropathic pain, which is pain secondary to lesion or pathology of the nervous system.', '12': 'However, the mechanism by which antidepressant drugs can relieve neuropathic pain remained in part elusive.', '13': 'Indeed, preclinical studies led to contradictions concerning the anatomical and molecular substrates of this action.', '14': 'In the present work, we overcame these apparent contradictions by highlighting the existence of two independent mechanisms.', '15': 'One is rapid and centrally mediated by descending controls from the brain to the spinal cord and the other is delayed, peripheral, and relies on the anti-neuroimmune action of chronic antidepressant treatment.'}\n",
            "2: abstract: {'1': 'This chapter covers antidepressants that fall into the class of serotonin (5-HT) and norepinephrine (NE) reuptake inhibitors.', '2': 'That is, they bind to the 5-HT and NE transporters with varying levels of potency and binding affinity ratios.', '3': 'Duloxetine is a more potent 5-HT and NE reuptake inhibitor with a more balanced profile of binding at about 10:1 for 5HT and NE transporter binding.', '4': 'It is also a moderate inhibitor of CYP2D6, so that modest dose reductions and careful monitoring will be needed when prescribing duloxetine in combination with drugs that are preferentially metabolized by CYP2D6.', '5': 'The most common side effects identified in clinical trials are nausea, dry mouth, dizziness, constipation, insomnia, asthenia, and hypertension, consistent with its mechanisms of action.', '6': 'Clinical trials to date have demonstrated rates of response and remission in patients with major depression that are comparable to other marketed antidepressants reviewed in this book.', '7': 'In addition to approval for MDD, duloxetine is approved for diabetic peripheral neuropathic pain, fibromyalgia, and musculoskeletal pain.', '8': 'All medications in the class can cause serotonin syndrome when combined with MAOIs.'}\n",
            "2: abstract: {'1': 'Duloxetine is a medication used to manage major depressive disorder (MDD), generalized anxiety disorder (GAD), fibromyalgia, diabetic peripheral neuropathy, and chronic musculoskeletal pain.', '2': 'Off-label uses for duloxetine include chemotherapy-induced peripheral neuropathy and stress urinary incontinence.', '3': 'It is in the Serotonin and norepinephrine reuptake inhibitors (SNRIs) class of medications.', '4': 'This activity describes the indications, mechanism of action, and contraindications for duloxetine as a valuable agent in treating multiple health conditions.', '5': 'This activity will highlight the mechanism of action, adverse event profile, and other key factors (e.g., off-label uses, dosing, pharmacodynamics, pharmacokinetics, monitoring, relevant drug-drug interactions) pertinent for members of the interprofessional team in the treatment of patients with major depressive disorder (MDD), generalized anxiety disorder (GAD), fibromyalgia, diabetic peripheral neuropathy, chronic musculoskeletal pain, and related conditions.'}\n",
            "2: abstract: {'1': 'Background: Antidepressants-induced movement disorders are rare and imperfectly known adverse drug reactions.', '2': \"The risk may differ between different antidepressants and antidepressants' classes.\", '3': \"The objective of this study was to assess the putative association of each antidepressant and antidepressants' classes with movement disorders.\", '4': \"Methods: Using VigiBase®, the WHO Pharmacovigilance database, disproportionality of movement disorders' reporting was assessed among adverse drug reactions related to any antidepressant, from January 1967 to February 2017, through a case/non-case design.\", '5': 'The association between nine subtypes of movement disorders (akathisia, bruxism, dystonia, myoclonus, parkinsonism, restless legs syndrome, tardive dyskinesia, tics, tremor) and antidepressants was estimated through the calculation first of crude Reporting Odds Ratio (ROR), then adjusted ROR on four potential confounding factors: age, sex, drugs described as able to induce movement disorders, and drugs used to treat movement disorders.', '6': 'Results: Out of the 14,270,446 reports included in VigiBase®, 1,027,405 (7.2%) contained at least one antidepressant, among whom 29,253 (2.8%) reported movement disorders.', '7': 'The female/male sex ratio was 2.15 and the mean age 50.9 ± 18.0 years.', '8': 'We found a significant increased ROR for antidepressants in general for all subtypes of movement disorders, with the highest association with bruxism (ROR 10.37, 95% CI 9.62-11.17) and the lowest with tics (ROR 1.49, 95% CI 1.38-1.60).', '9': 'When comparing each of the classes of antidepressants with the others, a significant association was observed for all subtypes of movement disorders except restless legs syndrome with serotonin reuptake inhibitors (SRIs) only.', '10': 'Among antidepressants, mirtazapine, vortioxetine, amoxapine, phenelzine, tryptophan and fluvoxamine were associated with the highest level to movement disorders and citalopram, paroxetine, duloxetine and mirtazapine were the most frequently associated with movement disorders.', '11': 'An association was also found with eight other antidepressants.', '12': 'Conclusions: A potential harmful association was found between movement disorders and use of the antidepressants mirtazapine, vortioxetine, amoxapine, phenelzine, tryptophan, fluvoxamine, citalopram, paroxetine, duloxetine, bupropion, clomipramine, escitalopram, fluoxetine, mianserin, sertraline, venlafaxine and vilazodone.', '13': 'Clinicians should beware of these adverse effects and monitor early warning signs carefully.', '14': 'However, this observational study must be interpreted as an exploratory analysis, and these results should be refined by future epidemiological studies.'}\n",
            "2: abstract: {'1': 'We present a case of hypertensive urgency in a diabetic patient with painful diabetic neuropathy on duloxetine treatment.', '2': \"The patient's blood pressure was high after taking 1-day dose of duloxetine and the patient was diagnosed with hypertensive urgency.\", '3': 'The patient was treated with labetalol, leading to reduction in blood pressure.', '4': \"The patient's medication was switched to telmisartan and metoprolol, which leads to resolution of increased blood pressure.\", '5': 'This case report is a possible case of hypertensive urgency after the initiation of duloxetine managed with antihypertensives and resolves with the discontinuation of the duloxetine.'}\n",
            "2: abstract: {'1': 'Purpose: Several studies have previously reported the association between dry eye and depression along with the treatment of depression.', '2': 'The aim of this study was to investigate the effects of different antidepressant drugs on tear parameters in patients with major depressive disorder.', '3': 'Methods: We recruited 132 patients who were using different antidepressants and 58 healthy controls.', '4': 'Venlafaxine, duloxetine, escitalopram, and sertraline were used by 34, 28, 36, and 34 patients, respectively.', '5': 'The participants filled out and completed the Beck Depression Scale.', '6': 'We recorded Schirmer test, tear breakup time (TBUT) and corneal staining values of the participants.', '7': 'The Ocular Surface Disease Index was completed by the participants.', '8': 'In addition, we evaluated the tear meniscus parameters by using anterior segment optical coherence tomography.', '9': 'Results: All conventional dry eye tests and tear meniscus parameters were significantly lesser in the depression group than in the control group (Schirmer test, 11.41 ± 6.73 mm and 22.53 ± 4.98 mm; TBUT, 5.29 ± 2.92 seconds and 13.38 ± 1.72; Corneal staining, tear meniscus area, 0.026 ± 0.012 mm2 and 0.11 ± 0.025 mm2; tear meniscus depth, 182.75 ± 78.79 μm and 257.48 ± 90.1 μm; tear meniscus height, 290.3 ± 133.63 μm and 459.78 ± 180.26 μm, in patients and controls, respectively).', '10': 'The tear parameters of the duloxetine group were lowest among the drug groups and Schirmer test, and TBUT of the venlafaxine group was statistically significantly different from the duloxetine group (P = 0.028 and P = 0.017, respectively).', '11': 'Ocular Surface Disease Index score of the depression group was significantly higher than the control group (31.12 ± 21.15 and 17.43 ± 11.75 in depression and control group, respectively.).', '12': 'Conclusions: We found that the usage of selective serotonin reuptake inhibitors and serotonin noradrenaline reuptake inhibitors affects the ocular surface by a mechanism other than the anticholinergic system.', '13': 'Besides serotonin blockage, the noradrenaline blockade of serotonin noradrenaline reuptake inhibitors may increase the dry eye findings on the ocular surface.'}\n",
            "2: abstract: {'1': 'Atraumatic trismus can be one of the presentations of medication-induced acute dystonia, particularly by antipsychotics and less commonly antidepressants.', '2': 'A case of an unusual emergency presentation of atraumatic trismus on initiation of duloxetine is reported.', '3': 'The patient was a 40-year-old woman experiencing sudden difficulty in mouth opening and speaking due to a stiffened jaw after taking 5 days of duloxetine prescribed for her fibromyalgia-related chest pain.', '4': 'Assessment of vital signs is prudent to ensure there is no laryngeal involvement.', '5': 'Other physical examinations and her recent investigations were unremarkable.', '6': 'She was treated for acute dystonia and intravenous procyclidine was given together with oral diazepam.', '7': 'Her symptoms improved immediately and her duloxetine was suggested to be stopped.', '8': 'To our knowledge, this is the first case of isolated trismus induced by duloxetine.', '9': 'Clinicians should be aware of this risk, especially considering the limitation of important physiological functions (such as swallowing, eating, etc) associated with this condition.'}\n",
            "2: abstract: {'1': 'Background: In antidepressant trials for pediatric patients with depression or anxiety disorders, the risk of suicidal events and other severe psychiatric adverse events such as aggression and agitation is increased with antidepressants relative to placebo.', '2': 'Objective: To examine whether largely mentally healthy adolescents treated for a non-psychiatric condition are also at increased risk of suicidality and other severe psychiatric disorders.', '3': 'Methods: This is a re-analysis of a placebo-controlled duloxetine trial for juvenile fibromyalgia based on the main journal article and additional data published in the online supplementary material and on ClinicalTrials.gov.', '4': 'Both serious adverse events related to psychiatric disorders and adverse events leading to treatment discontinuation were defined as severe treatment-emergent psychiatric adverse events.', '5': 'Results: We found that a significant portion of adolescents had treatment-emergent suicidal ideation and behaviour as well as other severe psychiatric adverse events with duloxetine, but no such events were recorded on placebo.', '6': 'The incidence of severe treatment-emergent psychiatric adverse events was statistically significantly higher with duloxetine as compared to placebo.', '7': 'Conclusions: Antidepressants may put adolescents at risk of suicidality and other severe psychiatric disorders even when the treatment indication is not depression or anxiety.'}\n",
            "3: abstract: {'1': 'Hyperkalemia is a potentially life-threatening metabolic problem caused by inability of the kidneys to excrete potassium, impairment of the mechanisms that move potassium from the circulation into the cells, or a combination of these factors.', '2': 'Acute episodes of hyperkalemia commonly are triggered by the introduction of a medication affecting potassium homeostasis; illness or dehydration also can be triggers.', '3': 'In patients with diabetic nephropathy, hyperkalemia may be caused by the syndrome of hyporeninemic hypoaldosteronism.', '4': 'The presence of typical electrocardiographic changes or a rapid rise in serum potassium indicates that hyperkalemia is potentially life threatening.', '5': 'Urine potassium, creatinine, and osmolarity should be obtained as a first step in determining the cause of hyperkalemia, which directs long-term treatment.', '6': 'Intravenous calcium is effective in reversing electrocardiographic changes and reducing the risk of arrhythmias but does not lower serum potassium.', '7': 'Serum potassium levels can be lowered acutely by using intravenous insulin and glucose, nebulized beta2 agonists, or both.', '8': 'Sodium polystyrene therapy, sometimes with intravenous furosemide and saline, is then initiated to lower total body potassium levels.'}\n",
            "3: abstract: {'1': 'Hyperkalemia is a clinically important electrolyte abnormality that occurs most commonly in patients with chronic kidney disease.', '2': 'Due to its propensity to induce electrophysiological disturbances, severe hyperkalemia is considered a medical emergency.', '3': 'The management of acute and chronic hyperkalemia can be achieved through the implementation of various interventions, one of which is the elimination of medications that can raise serum potassium levels.', '4': 'Because many such medications (especially inhibitors of the renin-angiotensin aldosterone system) have shown beneficial effects in patients with cardiovascular and renal disease, their discontinuation for reasons of hyperkalemia represent an undesirable clinical compromise.', '5': 'The emergence of 2 new potassium-binding medications for acute and chronic therapy of hyperkalemia may soon allow the continued use of medications such as renin-angiotensin-aldosterone system inhibitors even in patients who are prone to hyperkalemia.', '6': 'This review article provides an overview of the physiology and the pathophysiology of potassium metabolism and hyperkalemia, the epidemiology of hyperkalemia, and its acute and chronic management.', '7': 'We discuss in detail emerging data about new potassium-lowering therapies, and their potential future role in clinical practice.'}\n",
            "3: abstract: {'1': 'Purpose: Emerging treatment options for the management of chronic hyperkalemia in the outpatient setting are reviewed.', '2': 'Summary: Current treatment options for the management of hyperkalemia are limited and often accompanied by serious adverse effects.', '3': 'Two investigational drugs for the treatment of hyperkalemia are being evaluated in Phase III trials: sodium zirconium cyclosilicate and patiromer.', '4': \"Both of these drugs are administered orally and act by enhancing potassium's removal, predominantly through the gastrointestinal tract.\", '5': 'The safety and efficacy of sodium zirconium cyclosilicate and patiromer were evaluated in Phase II and III trials.', '6': 'Both agents were studied in patients with chronic mild-to-severe hyperkalemia, chronic kidney disease (CKD), or heart failure as well as those taking a renin-angiotensin system (RAS) inhibitor, an aldosterone antagonist, or both therapies.', '7': 'These clinical trials found that sodium zirconium cyclosilicate and patiromer normalized serum potassium levels quickly and maintained normalized serum potassium levels over several weeks.', '8': 'Both medications caused a rapid decrease in serum potassium, with two studies examining efficacy endpoints for 12 weeks or longer.', '9': 'The overall frequency of adverse effects in these clinical trials was low, with gastrointestinal adverse events being the most commonly observed.', '10': 'Conclusion: Options for the management of hyperkalemia, particularly chronic hyperkalemia in the outpatient setting, are limited.', '11': 'Both sodium zirconium cyclosilicate and patiromer are emerging therapies that may provide long-term management of hyperkalemia, particularly in patients with underlying heart failure or CKD as well as those taking an RAS inhibitor, an aldosterone antagonist, or both.'}\n",
            "3: abstract: {'1': 'Hyperkalemia is a frequent clinical abnormality in patients with chronic kidney disease, and it is associated with higher risk of mortality and malignant arrhythmias.', '2': 'Severe hyperkalemia is a medical emergency, which requires immediate therapies, followed by interventions aimed at preventing its recurrence.', '3': 'Current treatment paradigms for chronic hyperkalemia management are focused on eliminating predisposing factors, such as high potassium intake in diets or supplements, and the use of medications known to raise potassium level.', '4': 'Among the latter, inhibitors of the renin-angiotensin aldosterone system are some of the most commonly involved medications, and their discontinuation is often the first step taken by clinicians to prevent the recurrence of hyperkalemia.', '5': 'While this strategy is usually successful, it also deprives patients of the recognized benefits of this class, such as their renoprotective effects.', '6': 'The development of novel potassium binders has ushered in a new era of hyperkalemia management, with a focus on chronic therapy while maintaining the use of beneficial, but hyperkalemia-inducing medications such as renin-angiotensin aldosterone system inhibitors.', '7': 'This review article examines the incidence and clinical consequences of hyperkalemia, and its various treatment options, with special emphasis on novel therapeutic agents and the potential benefits of their application.'}\n",
            "3: abstract: {'1': 'Hypokalemia (ie, potassium levels less than 3.5 mEq/L) occurs in fewer than 1% of healthy individuals, but is present in up to 20% of hospitalized patients, 40% of patients taking diuretics, and 17% of patients with cardiovascular conditions.', '2': 'Hypokalemia often is asymptomatic; symptoms are more common in older adults.', '3': 'Common symptoms are cardiac arrhythmias and muscle weakness or pain.', '4': 'Management consists of intravenous potassium replacement during cardiac monitoring for patients with marked symptoms, echocardiogram (ECG) abnormalities, or severe hypokalemia (ie, level less than 3.0 mEq/L).', '5': 'Oral replacement is appropriate for asymptomatic patients with less severe hypokalemia.', '6': 'Hyperkalemia (ie, level greater than 5.5 mEq/L) also can cause cardiac arrhythmias and muscle symptoms.', '7': 'Urgent management is warranted for patients with potassium levels of 6.5 mEq/L or greater, if ECG manifestations of hyperkalemia are present regardless of potassium levels, or if severe muscle symptoms occur.', '8': 'Urgent management includes intravenous calcium, intravenous insulin, and inhaled beta agonists.', '9': 'Hemodialysis can be used in urgent situations.', '10': 'For patients with less severe hyperkalemia, renal elimination drugs sometimes are used, as are gastrointestinal elimination drugs.', '11': 'For all patients with hypokalemia or hyperkalemia, drug regimens should be reevaluated and, when possible, hypokalemia- or hyperkalemia-causing drugs should be discontinued.'}\n",
            "3: abstract: {'1': 'Hyperkalemia results either from the shift of potassium out of cells or from abnormal renal potassium excretion.', '2': 'Cell shift leads to transient increases in the plasma potassium concentration, whereas decreased renal excretion of potassium leads to sustained hyperkalemia.', '3': 'Impairments in renal potassium excretion can be the result of reduced sodium delivery to the distal nephron, decreased mineralocorticoid level or activity, or abnormalities in the cortical collecting duct.', '4': 'In some instances, all 3 of these perturbations are present.', '5': 'Excessive intake of potassium can cause hyperkalemia but usually in the setting of impaired renal function.', '6': 'We discuss the clinical manifestations of hyperkalemia and outline an approach to its diagnosis and treatment.'}\n",
            "3: abstract: {'1': 'Purpose of review: Hyperkalemia is a potentially fatal electrolyte disorder, more commonly present when the potassium excretion capacity is imparied.', '2': 'Hyperkalemia can lead to adverse outcomes, especially due to severe cardiac arrhythmias.', '3': 'It can also impair the cardiovascular effects of renin-angiotensin-aldosterone system inhibitors (RAASis) and potassium rich diets, as hyperkalemia frequently leads to their discontinuation.', '4': 'Recent findings: Potassium is a predictor of mortality and should be monitored closely for patients who are at risk for hyperkalemia.', '5': 'Acute hyperkalemia protocols have been revised and updated.', '6': 'Randomized trials have shown that the new anti-hyperkalemic agents (patiromer and zirconium cyclosilicate) are effective hyperkalemia treatment options.', '7': 'The use of anti-hyperkalemic agents may allow for a less restrictive potassium diet and lower RAASi discontinuation rates.', '8': 'Summary: Hyperkalemia should be monitored closely for high-risk patients, as it is associated with adverse outcomes.', '9': 'New therapies have demonstrated effective control, offering hope for potential use in patients that would benefit from diet or medications associated with an increase in serum potassium, indicating that the use of hyperkalemic agents can be associated with better outcomes.'}\n",
            "3: abstract: {'1': 'Patients with end-stage renal disease (ESRD) on maintenance dialysis have a high risk of developing hyperkalemia, generally defined as serum potassium (K+) concentrations of >5.0 mmol/l, particularly those undergoing maintenance hemodialysis.', '2': 'Currently, the key approaches to the management of hyperkalemia in patients with ESRD are dialysis, dietary K+ restriction, and avoidance of medications that increase hyperkalemia risk.', '3': 'In this review, we highlight the issues and challenges associated with effective management of hyperkalemia in patients undergoing maintenance dialysis using an illustrative case presentation.', '4': 'In addition, we examine the potential nondialysis options for the management of these patients, including use of the newer K+ binder agents patiromer and sodium zirconium cyclosilicate, which may reduce the need for the highly restrictive dialysis diet, with its own implication on nutritional status in patients with ESRD, as well as reducing the risk of potentially life-threatening hyperkalemia.'}\n",
            "3: abstract: {'1': 'In patients with advanced-stage chronic kidney disease (CKD), progressive kidney function decline leads to increased risk for hyperkalemia (serum potassium > 5.0 or >5.5 mEq/L).', '2': 'Medications such as renin-angiotensin-aldosterone system inhibitors pose an additional hyperkalemia risk, especially in patients with CKD.', '3': 'When hyperkalemia develops, clinicians often recommend a diet that is lower in potassium content.', '4': 'This review discusses the barriers to adherence to a low-potassium diet and the impact of dietary restrictions on adverse clinical outcomes.', '5': 'Accumulating evidence indicates that a diet that incorporates potassium-rich foods has multiple health benefits, which may also be attributable to the other vitamin, mineral, and fiber content of potassium-rich foods.', '6': 'These benefits include blood pressure reductions and reduced risks for cardiovascular disease and stroke.', '7': 'High-potassium foods may also prevent CKD progression and reduce mortality risk in patients with CKD.', '8': 'Adjunctive treatment with the newer potassium-binding agents, patiromer and sodium zirconium cyclosilicate, may allow for optimal renin-angiotensin-aldosterone system inhibitor therapy in patients with CKD and hyperkalemia, potentially making it possible for patients with CKD and hyperkalemia to liberalize their diet.', '9': 'This may allow them the health benefits of a high-potassium diet without the increased risk for hyperkalemia, although further studies are needed.'}\n",
            "3: abstract: {'1': 'Hyperkalemia is an electrolyte abnormality with potentially life-threatening consequences.', '2': 'Despite various guidelines, no universally accepted consensus exists on best practices for hyperkalemia monitoring, with variations in precise potassium (K+) concentration thresholds or for the management of acute or chronic hyperkalemia.', '3': 'Based on the available evidence, this review identifies several critical issues and unmet needs with regard to the management of hyperkalemia.', '4': 'Real-world studies are needed for a better understanding of the prevalence of hyperkalemia outside the clinical trial setting.', '5': 'There is a need to improve effective management of hyperkalemia, including classification and K+ monitoring, when to reinitiate previously discontinued renin-angiotensin-aldosterone system inhibitor (RAASi) therapy, and when to use oral K+-binding agents.', '6': 'Monitoring serum K+ should be individualized; however, increased frequency of monitoring should be considered for patients with chronic kidney disease, diabetes, heart failure, or a history of hyperkalemia and for those receiving RAASi therapy.', '7': 'Recent clinical studies suggest that the newer K+ binders (patiromer sorbitex calcium and sodium zirconium cyclosilicate) may facilitate optimization of RAASi therapy.', '8': 'Enhancing the knowledge of primary care physicians and internists with respect to the safety profiles of these newer K+ binders may increase confidence in managing patients with hyperkalemia.', '9': 'Lastly, the availability of newer K+-binding agents requires further study to establish whether stringent dietary K+ restrictions are needed in patients receiving K+-binder therapy.', '10': 'Individualized monitoring of serum K+ among patients with an increased risk of hyperkalemia and the use of newer K+-binding agents may allow for optimization of RAASi therapy and more effective management of hyperkalemia.'}\n",
            "4: abstract: {'1': 'New recommendations for the classification and diagnosis of diabetes mellitus include the preferred use of the terms \"type 1\" and \"type 2\" instead of \"IDDM\" and \"NIDDM\" to designate the two major types of diabetes mellitus; simplification of the diagnostic criteria for diabetes mellitus to two abnormal fasting plasma determinations; and a lower cutoff for fasting plasma glucose (126 mg per dL [7 mmol per L] or higher) to confirm the diagnosis of diabetes mellitus.', '2': 'These changes provide an easier and more reliable means of diagnosing persons at risk of complications from hyperglycemia.', '3': 'Currently, only one half of the people who have diabetes mellitus have been diagnosed.', '4': 'Screening for diabetes mellitus should begin at 45 years of age and should be repeated every three years in persons without risk factors, and should begin earlier and be repeated more often in those with risk factors.', '5': 'Risk factors include obesity, first-degree relatives with diabetes mellitus, hypertension, hypertriglyceridemia or previous evidence of impaired glucose homeostasis.', '6': 'Earlier detection of diabetes mellitus may lead to tighter control of blood glucose levels and a reduction in the severity of complications associated with this disease.'}\n",
            "4: abstract: {'1': 'In 1997 the American Diabetes Association lowered the threshold for diagnosis of diabetes from a fasting plasma glucose concentration of 7.8 mmol/l to 7.0 mmol/l and advised that the oral glucose tolerance test no longer be used in routine clinical practice.', '2': 'In 1999 the World Health Organization endorsed the reduction in fasting plasma glucose threshold but recommended retaining the oral glucose tolerance test for anyone with impaired fasting glucose (6.1 mmol/l-6.9 mmol/l).', '3': 'This Review discusses the impact of these changes on the prevalence of diabetes and examines the implications for individuals and specific high-risk groups.', '4': 'The phenotype of those diagnosed with diabetes and the predictive value for the development of complications according to the different criteria are compared.', '5': 'It is clear that these changes in diagnostic criteria have major importance both for individuals and for resource planning at a national level.'}\n",
            "4: abstract: {'1': 'The International Expert Committee recommends that the diagnosis of diabetes be made if hemo globin A1c (HbA1c) level is greater, similar 6.5% and confirmed with a repeat HbA1c test.', '2': 'The committee recommends against \"mixing different methods to diagnose diabetes\" because \"the tests are not completely concordant: using different tests could easily lead to confusion\".', '3': 'Fasting plasma glucose, 2-hour postglucose-load plasma glucose, and oral glucose tolerance tests are recommended for the diagnosis of diabetes only if HbA1c testing is not possible due to unavailability of the assay, patient factors that preclude its inter pretation, and during pregnancy.', '4': 'HbA1c testing has the advantages of greater clinical convenience, preanalytic stability, and assay standardization, but when used as the sole diagnostic criterion for diabetes, it has the potential for systematic error.', '5': 'Factors that may not be clinically evident impact HbA1c test results and may systematically raise or lower the value relative to the true level of glycemia.', '6': 'For this reason, HbA1c should be used in combination with plasma glucose determinations for the diagnosis of diabetes.', '7': 'If an HbA1c test result is discordant with the clinical picture or equivocal, plasma glucose testing should be performed.', '8': 'A diagnostic cut-off point of HbA1c greater, similar 6.5% misses a substantial number of people with type 2 diabetes, including some with fasting hyperglycemia, and misses most people with impaired glucose tolerance.', '9': 'Combining the use of HbA1c and plasma glucose measurements for the diagnosis of diabetes offers the benefits of each test and reduces the risk of systematic bias inherent in HbA1c testing alone.'}\n",
            "4: abstract: {'1': 'Highly sensitive and specific radioimmunoassays have been validated for autoantibodies reacting with the four major autoantigens identified so far in autoimmune diabetes.', '2': 'However, the analysis of this large number of autoantigens has increased the costs and time necessary for complete autoantibody screenings.', '3': 'Our aim was to demonstrate that it is possible to detect the immunoreactivity against a combination of four different autoantigens by a single assay, this representing a rapid, low-cost first approach to evaluate humoral autoimmunity in diabetes.', '4': 'By using this novel multi-autoantigen radioimmunoassay (MAA), in subsequent steps we analysed 830 sera, 476 of known and 354 of unknown diabetes-specific immunoreactivity, collected from various groups of individuals including type 1 and type 2 diabetes patients, autoantibody-positive patients with a clinical diagnosis of type 2 diabetes (LADA), prediabetic subjects, individuals at risk to develop autoimmune diabetes, siblings of type 1 diabetic patients, coeliac patients and healthy control subjects.', '5': 'All sera reacting with one or more of the four autoantigens by single assays also resulted positive with MAA, as well as eight of 24 type 1 diabetic patients classified initially as autoantibody-negative at disease onset based on single autoantibody assays.', '6': 'In addition, MAA showed 92% sensitivity and 99% specificity by analysing 140 blinded sera from type 1 diabetic patients and control subjects provided in the 2010 Diabetes Autoantibody Standardization Program.', '7': 'MAA is the first combined method also able to evaluate, in addition to glutamic acid decarboxylase (GAD) and tyrosine phosphatase (IA)-2, insulin and islet beta-cell zinc cation efflux transporter (ZnT8) autoantibodies.', '8': 'It appears to be particularly appropriate as a first-line approach for large-scale population-based screenings of anti-islet autoimmunity.'}\n",
            "4: abstract: {'1': 'Diagnostic criteria for diabetes in children have not been established with nearly the rigor as that employed in adults.', '2': 'Recently revised American Diabetes Association (ADA) criteria allowed utilization of hemoglobin A(1c) (HbA1c) ≥ 6.5 % for diagnosis of diabetes.', '3': 'A recent series of pediatric studies appear to show that HbA1c has lower sensitivity than Fasting plasma glucose (FPG) or oral glucose tolerance test (OGTT).', '4': 'However, FPG and OGTT have themselves never been validated in children.', '5': 'Studies to validate diagnostic thresholds in children appear unlikely to take place.', '6': 'Thus, accepting the major ADA diagnostic criteria appears to be the best course of action for the pediatric community.', '7': \"One area in which correlation studies between HbA1c and FPG or OGTT might shed light is in the definition of criteria for intervention in 'pre-diabetes,' as the Diabetes Prevention Program Trial did not use HbA1c.\", '8': 'However, such treatment, and the exact diagnostic thresholds at which it should be initiated in children, remains unproven.'}\n",
            "4: abstract: {'1': 'Diabetes mellitus is a common disease whose complications are severe.', '2': 'For decades, the diagnosis of diabetes and prediabetes was using only fasting glucose or glucose two hours during an oral glucose tolerance test.', '3': 'Recently, it is possible to use HbA1c.', '4': 'Each of these tests has advantages and limitations that must be well known by clinicians for better care for patients.', '5': 'So they could use one, two or three of this tests to reach to a proper diagnosis.', '6': 'The aim of this article is about the strong and weak points of these tests.'}\n",
            "4: abstract: {'1': 'Objective: The objective of this study was to compare the use of hemoglobin A1C to oral glucose tolerance testing to diagnose overt type 2 diabetes in the first trimester of pregnancy.', '2': 'The study used a nonexperimental descriptive design to compare the use of the hemoglobin A1C test results to oral glucose tolerance test results.', '3': 'Methods: The study used a sample of 45 women at high risk for type 2 diabetes in the first trimester of pregnancy.', '4': \"Participants were consented to draw a hemoglobin A1C with their ordered oral glucose tolerance testing for comparison of the two tests' ability to diagnose overt type 2 diabetes.\", '5': 'Results: Hemoglobin A1C tests were highly positively correlated with oral glucose tolerance testing for diagnosis of type 2 diabetes in women in the first trimester of pregnancy.', '6': 'Conclusion: The research provides beginning evidence that the hemoglobin A1C should be considered as a first-tier diagnostic test for overt type 2 diabetes in the first trimester of pregnancy.'}\n",
            "4: abstract: {'1': 'Introduction: Maturity onset diabetes of the young (MODY) is a rare form of monogenic diabetes.', '2': 'Being clinically and genetically heterogeneous, it is often misdiagnosed as type 1 or type 2 diabetes, leading to inappropriate therapy.', '3': 'MODY is caused by a single gene mutation.', '4': 'Thirteen genes, defining 13 subtypes, have been identified to cause MODY.', '5': 'A correct diagnosis is important for the right therapy, prognosis, and genetic counselling.', '6': 'Material and methods: Twenty-nine unrelated paediatric patients clinically suspected of having MODY diabetes were analysed using TruSight One panel for next-generation sequencing (NGS) and multiplex ligation-dependent probe amplification (MLPA) assay.', '7': 'Results: In this study we identified variants in MODY genes in 22 out of 29 patients (75.9%).', '8': 'Using two genetic tests, NGS and MLPA, we detected both single nucleotide variants and large deletions in patients.', '9': 'Most of the patients harboured a variant in the GCK gene (11/22), followed by HNF1B (5/22).', '10': 'The rest of the variants were found in the NEUROD1 and HNF1A genes.', '11': 'We identified one novel variant in the GCK gene: c.596T>C, p.Val199Ala.', '12': \"The applied genetic tests excluded the suspected diagnosis of MODY in two patients and revealed variants in other genes possibly associated with the patient's clinical phenotype.\", '13': 'Conclusions: In our group of MODY patients most variants were found in the GCK gene, followed by variants in HNF1B, NEUROD1, and HNF1A genes.', '14': 'The combined NGS and MLPA-based genetic tests presented a comprehensive approach for analysing patients with suspected MODY diabetes and provided a successful differential diagnosis of MODY subtypes.'}\n",
            "4: abstract: {'1': 'Polyuria-polydipsia syndrome consists of the three main entities: central or nephrogenic diabetes insipidus and primary polydipsia.', '2': 'Reliable distinction between these diagnoses is essential as treatment differs substantially, with the wrong treatment potentially leading to serious complications.', '3': 'Past diagnostic measures using the classical water deprivation test had several pitfalls and clinicians were often left with uncertainity concerning the diagnosis.', '4': 'With the establishment of copeptin, a stable and reliable surrogate marker for arginine vasopressin, diagnosis of the polyuria-polydipsia syndrome has been newly evaluated.', '5': 'Whereas unstimulated basal copeptin measurement reliably diagnoses nephrogenic diabetes insipidus, two new tests using stimulated copeptin cutoff levels showed a high diagnostic accuracy in differentiating central diabetes insipidus from primary polydipsia.', '6': 'For the hypertonic saline infusion test, osmotic stimulation via the induction of hypernatraemia is used.', '7': 'This makes the test highly reliable and superior to the classical water deprivation test, but also requires close supervision and the availability of rapid sodium measurements to guarantee the safety of the test.', '8': 'Alternatively, arginine infusion can be used to stimulate copeptin release, opening the doors for an even shorter and safer diagnostic test.', '9': 'The test protocols of the two tests are provided and a new copeptin-based diagnostic algorithm is proposed to reliably differentiate between the different entities.', '10': 'Furthermore, the role of copeptin as a predictive marker for the development of diabetes insipidus following surgical procedures in the sellar region is described.'}\n",
            "4: abstract: {'1': 'The classification of diabetes was originally limited to only two categories called juvenile-onset diabetes mellitus, now known as type 1 diabetes mellitus, and adult-onset diabetes mellitus, now known as type 2 diabetes mellitus.', '2': 'This has grown to a recognition of more than 50 subcategories caused by various pathogenic mechanisms or accompanying other diseases and syndromes.', '3': 'The diagnosis of diabetes has evolved from physician recognition of typical symptoms to detection of ambient hyperglycemia and, thence, to the definition of excessive plasma glucose levels after an overnight fast and/or following challenge with a glucose load (oral glucose tolerance test or OGTT), and more recently, by measurement of glycated hemoglobin (A1c).', '4': 'Screening has uncovered a much higher prevalence of diabetes in the United States and elsewhere, as well as its enormous public health impact.', '5': 'Modern testing has defined individuals at high risk for the development of diabetes and pregnant women whose fetuses are at increased risk for mortality and morbidity.', '6': 'Diagnostic glycemic criteria for presymptomatic diabetes have been set using diabetic retinopathy as a specific complication of the disease: A1c ≥6.5%; fasting plasma glucose (FPG) ≥126 mg/dL; or plasma glucose measured 2 hours after an OGTT (2-hour PG) ≥200 mg/dL.', '7': 'For patients with typical symptoms, a random plasma glucose ≥200 mg/dL is diagnostic.', '8': 'The 2-hour PG yields the highest prevalence and A1c the lowest.', '9': 'A1c is the most convenient and practical test, requiring no preparation, is analytically superior, and has the lowest intraindividual variation.', '10': 'It is more expensive than the FPG, but the same or less than the OGTT.', '11': 'The 2-hour PG is the most burdensome to the patient and has the highest intraindividual variation.', '12': 'Standardized measurement of A1c is not available everywhere.', '13': 'Confirmation of an abnormal test with the same test is recommended.', '14': 'Studies in various populations show inconsistency among the glycemic tests.', '15': 'Of people meeting the A1c criterion, 27%–98% meet plasma glucose criteria.', '16': 'Of people meeting plasma glucose criteria, 17%–78% meet the A1c criterion.', '17': 'These discrepancies occur because each test measures different aspects of hyperglycemia that may vary among patients.', '18': 'While the risk of future diabetes is continuously associated with plasma glucose and A1c, the areas between the upper limits of normal and the diabetes cutpoints have been called “prediabetes” or “high risk for diabetes.” These have been defined categorically as A1c 6.0%–6.4% or 5.7%–6.4%; impaired fasting glucose (IFG), FPG 100–125 mg/dL; and impaired glucose tolerance (IGT), 2-hour PG 140–199 mg/dL. A1c 6.0%–6.4% increases the odds ratio (OR) for progression to diabetes (OR 12.5–16) more than the range of 5.7%–6.4% (OR 9.2).', '19': 'In U.S. studies, the incidence of type 2 diabetes averages approximately 6% per year in people with IGT and can reverse spontaneously.', '20': 'IFG is more prevalent than IGT in the United States, though IGT rises more sharply with age.', '21': 'IFG increases the risk of future diabetes to various degrees in different countries, with odds ratios ranging from 2.9 to 18.5.'}\n",
            "5: abstract: {'1': 'Objective: To review the results of arthroscopic treatment of popliteal cysts in our centre and analyse outcomes including complications.', '2': 'Patients: From July 2007 to July 2009, 11 patients with symptomatic popliteal cysts were treated arthroscopically.', '3': 'All of them had preoperative magnetic resonance imaging to confirm the diagnosis, identify the valvular opening, and the associated intra-articular pathology.', '4': 'We used the Rauschning and Lindgren criteria for evaluation.', '5': 'Results: Intra-articular pathology like cartilage degeneration and meniscus tear were commonly associated with popliteal cysts.', '6': 'All patients achieved symptomatic improvement after treatment and the recurrence rate was low.', '7': 'No major complications were encountered.', '8': 'We failed to identify (and correct) any valvular opening in one patient.', '9': 'Conclusion: From our experience, we conclude that arthroscopic treatment of popliteal cyst with correction of the valvular opening and treatment of associated intra-articular pathology is effective and safe.'}\n",
            "5: abstract: {'1': \"Context: Popliteal synovial cysts, also known as Baker's cysts, are commonly found in association with intra-articular knee disorders, such as osteoarthritis and meniscus tears.\", '2': 'Histologically, the cyst walls resemble synovial tissue with fibrosis evident, and there may be chronic nonspecific inflammation present.', '3': 'Osteocartilaginous loose bodies may also be found within the cyst, even if they are not seen in the knee joint.', '4': \"Baker's cysts can be a source of posterior knee pain that persists despite surgical treatment of the intra-articular lesion, and they are routinely discovered on magnetic resonance imaging scans of the symptomatic knee.\", '5': 'Symptoms related to a popliteal cyst origin are infrequent and may be related to size.', '6': 'Conclusion: A capsular opening to the semimembranosus-medial head gastrocnemius bursa is a commonly found normal anatomic variant.', '7': 'It is thought that this can lead to the formation of a popliteal cyst in the presence of chronic knee effusions as a result of intra-articular pathology.', '8': 'Management of symptomatic popliteal cysts is conservative.', '9': 'The intra-articular pathology should be first addressed by arthroscopy.', '10': 'If surgical excision later becomes necessary, a limited posteromedial approach is often employed.', '11': 'Other treatments, such as arthroscopic debridement and closure of the valvular mechanism, are not well studied and cannot yet be recommended.'}\n",
            "5: abstract: {'1': 'Background: The purpose of this study was to evaluate the efficacy of arthroscopic knee cavity internal drainage and cyst cavity debridement operation of popliteal cyst in knee osteoarthritis patients.', '2': 'Methods: From August 2007 to March 2013, 58 knee osteoarthritis patients with popliteal cyst were treated with arthroscopic knee cavity internal drainage through posteromedial portal and popliteal cyst cavity debridement through superior posteromedial portal.', '3': 'In all patients, preoperative magnetic resonance imaging (MRI) was performed to detect combined intra-articular pathology and the communication between popliteal cyst and knee cavity.', '4': 'Clinical efficacy was evaluated through VAS score and Lysholm score.', '5': 'Results: All patients had neither recurrence of popliteal cyst nor complaints of pain, swelling, or functional impairment at average 24 months follow-up after surgery.', '6': 'Postoperatively, VAS score was decreased significantly and Lysholm score was raised significantly comparing preoperatively.', '7': 'Conclusion: Arthroscopic knee cavity internal drainage operation through posteromedial portal and popliteal cyst cavity debridement through superior posteromedial portal is an effective minimally invasive surgery method for the treatment of popliteal cyst without recurrence in knee osteoarthritis patients.'}\n",
            "5: abstract: {'1': 'Purpose: The purpose of this study was to introduce a modified arthroscopic treatment technique for popliteal cyst and hypothesize that this modified technique would provide good clinical efficacy and low recurrence rate.', '2': 'Methods: From January 2013 to January 2017, 34 patients with symptomatic popliteal cysts were treated with our technique.', '3': 'A figure-of-four position and double posteromedial portals were used to achieve adequate enlargement of the posteromedial valvular opening between the cyst and the joint cavity and complete excision of the cyst wall.', '4': 'MRI was used to detect the recurrence of the popliteal cyst, and the Rauschning and Lindgren score was recorded to evaluate the clinical outcome.', '5': 'Results: All patients were followed up with a mean period of 14.8 months (range, 12 to 36 months).', '6': 'Associated intra-articular lesions were found and treated in all cases.', '7': 'Degenerative cartilage damage was the most common pathology, which affected 23 (67.6%) of the cases.', '8': 'The Rauschning and Lindgren score improved significantly after surgery, and no evidence of recurrence was found from MRI in any case.', '9': 'Conclusions: Our modified arthroscopic treatment technique, using a figure-of-four position and double posteromedial portals, is effective and safe for treating popliteal cyst.'}\n",
            "5: abstract: {'1': \"Purpose: Osteoarthritis of the knee is a common disease, often associated with a Baker's cyst.\", '2': \"Besides osteoarthritis, also other joint pathologies of the knee can be causative for a Baker's cyst.\", '3': 'Radiotherapy is known to be an effective treatment for osteoarthritis, with an anti-inflammatory effect.', '4': \"As the excessive production of synovia usually is associated with intraarticular inflammation, our hypothesis was that radiotherapy might positively influence the synovial production and reduce the volume of a Baker's cyst.\", '5': 'Materials and methods: We performed a prospective trial, including 20 knees receiving radiotherapy for knee arthritis.', '6': \"Besides documentation of NRS (numeric rating scale), WOMAC (Western Ontario and McMaster Universities Osteoarthritis Index) score and Knee Society Score, the volume of the Baker's cyst was calculated for a short- (6 to 12 weeks) and long-term (9 to 12 months) follow-up.\", '7': 'Ultrasonic volumetry was performed using an ultrasound device with a high-resolution multifrequency linear probe (6-9 MHz).', '8': 'Results: Low-dose radiotherapy improved NRS, WOMAC score and Knee Society Score significantly.', '9': \"The mean volume of Baker's cyst decreased from 22.3 ml to 10.7 respectively 3.1 ml during follow-up.\", '10': 'A decrease in volume of more than 25% compared to the baseline could be achieved for 75% of the patients in the short-term and 79% of the patients in the long-term follow up.', '11': \"Conclusion: Radiotherapy of knee osteoarthritis is an effective treatment that decreases the volume of a Baker's cyst.\", '12': 'Most patients respond to the treatment.', '13': \"Whether radiotherapy is an effective treatment for Baker's cyst without associated osteoarthritis has to be further examined.\"}\n",
            "5: abstract: {'1': 'To reduce the damage to posteromedial knee capsule, we developed a direct extra-articular arthroscopic approach for excision of symptomatic popliteal cysts.', '2': 'This study aimed to demonstrate the surgical technique and present the 2-year follow-up results.', '3': 'Cystectomy is performed by extra-articular surgical approach through a high posteromedial portal.', '4': 'Twenty-one consecutive patients diagnosed of symptomatic popliteal cysts with failed initial conservative treatments were included.', '5': 'At a median follow-up of 29.4 months, all knees had improved clinical function assessed by Rauschning and Lindgren knee classification (p<0.001).', '6': 'The cysts were either disappeared (95.2%) or reduced in size (4.8%).', '7': 'Only one (4.8%) patient had recurrent cyst, which was solved after ultrasound-guided aspiration.', '8': 'This direct extra-articular arthroscopic technique could be a feasible alternative for treatment of symptomatic popliteal cysts.'}\n",
            "5: abstract: {'1': \"Popliteal cyst is a common peri-knee cyst, also known as a Baker's cyst.\", '2': 'With the current development of popliteal cysts, the pathogenesis is mainly due to increased pressure in the knee joint caused by various reasons, leading to a fluid-filled sac that can form behind the knee as a result of enlargement of the gastrocnemius-semimembranosus bursa.', '3': 'The current diagnostic methods include X-ray computed, ultrasound, and magnetic resonance.', '4': 'Among them, magnetic resonance imaging is considered the gold standard for the diagnosis of popliteal cysts.', '5': 'There are various treatments, including conservative treatment, traditional surgical resection and arthroscopic surgery.', '6': 'In recent years, the focus of the treatment of popliteal cysts has gradually shifted from the simple removal of cysts to arthroscopic treatment of intra-articular lesions and the treatment of joint-cyst communication, and achieved a good effect.', '7': 'However, there are still controversies about the most effective treatment, and the best surgery method is still uncertained.', '8': 'It is hoped that high quality prospective studies will be able to directly compare different surgery methods, so as to select the best treatment for popliteal cyst.', '9': 'This article reviews past literature research and describes in detail the epidemiology, pathological mechanism, clinical manifestations and signs, auxiliary examination, diagnosis and differential diagnosis and clinical treatment of popliteal cysts.', '10': 'Different diagnosis methods and treatment methods are compared and summarized to provide basis for clinical diagnosis and treatment.'}\n",
            "5: abstract: {'1': 'Although popliteal cysts are most frequently identified in patients with osteoarthritis (OA), they may occur in patients with rheumatoid arthritis (RA), in which serious complicated cases such as cyst rupture can be developed.', '2': 'The objective of this study was to report four patients with RA (six knees) in combination with OA with a brief review of literature of previous similar published cases.', '3': 'This is a retrospective review of case records of patients with refractory and/or complicated popliteal cysts, who have successfully treated with arthroscopic intervention.', '4': 'We suggest that arthroscopic interventions such as radical debridement, synovectomy, biomechanical valve excision, and/or cystectomy should be considered in patients with refractory and complicated popliteal cysts associated with RA or RA in combination with OA.'}\n",
            "5: abstract: {'1': 'There is a lack of research comparing the clinical effects of arthroscopic treatment of popliteal cysts between the one posteromedial portal (OPP) technique and the two posteromedial portals (TPP) technique.', '2': 'The aim of this study was to evaluate and compare the clinical efficacy of arthroscopic treatment for popliteal cysts between the 2 techniques.', '3': 'Patients with symptomatic popliteal cysts after surgery were retrospectively invited to participate in this study.', '4': 'They received arthroscopy treatment via the OPP technique or the TPP technique.', '5': 'At the final follow-up, the Rauschning and Lindgren criteria and the Lysholm score were used for clinical evaluation.', '6': 'Moreover, magnetic resonance imaging was performed to detect the recurrence of cysts postoperatively.', '7': 'Finally, 53 patients with symptomatic popliteal cysts were included in this study, including 25 in the OPP group and 28 in the TPP group.', '8': 'The operation time of the TPP group was significantly longer than that of the OPP group (P < .001).', '9': 'In the OPP group, the cysts disappeared in 17 patients and reduced in size in 8 patients.', '10': 'In the TPP group, the cysts disappeared in 23 patients and reduced in size in 5 patients.', '11': 'According to the Rauschning and Lindgren classification, the recurrence rate was significantly lower in the TPP group (0%) than in the OPP group (4%) (P = .03).', '12': 'In addition, there was no significant difference in the Lysholm score between the OPP group and the TPP group (P = .77).', '13': 'TPP technique is more effective and superior than OPP technique for the treatment of popliteal cysts.'}\n",
            "5: abstract: {'1': 'Background: This study aimed to compare the arthroscopic internal drainage of popliteal cysts alone or in combination with cyst wall resection in terms of clinical outcomes.', '2': 'Methods: Forty-two consecutive patients with symptomatic popliteal cysts received arthroscopic treatment.', '3': 'Specifically, 20 of them received arthroscopic internal drainage (AI group) alone and 22 received arthroscopic internal drainage combined with cyst wall resection (AICR group) through double posteromedial portals.', '4': 'Magnetic resonance imaging (MRI) was performed to identify recurrence of popliteal cysts.', '5': 'The Lysholm score and Rauschning-Lindgren grade were used to assess the clinical outcomes.', '6': 'The median of the follow-up period was 24 months (12-48 months).', '7': 'Results: The two groups (AI group and AICR group) were similar in age, gender, cyst diameter, associated joint disorder, preoperative Lysholm score, preoperative Rauschning-Lindgren grade and follow-up period (P > 0.05).', '8': 'Relative to the AI group, the AICR group had a significantly prolonged operation time (P < 0.05) and a higher incidence of complications (P < 0.05).', '9': 'In both groups, the Rauschning-Lindgren grade at the last follow-up significantly differed from the preoperative grade (P < 0.05) and the Lysholm knee score remarkably increased compared to the preoperative score (P < 0.05); however, there were no differences between the two groups at the last follow-up (P > 0.05).', '10': 'According to the MRI results, the cyst disappeared in 11 (55%), shrank in size in 6 (30%) and existed in 3 (15%) patients in the AI group, and was absent in 18 (81.8%) and shrank in size in 4 (18.2%) patients in the AICR group, suggesting a significant difference between the two (P < 0.05).', '11': 'Conclusion: Additional resection of cyst wall can result in a lower recurrence rate of cysts but extend the operation time and increase the incidence of perioperative complications compared with arthroscopic internal drainage of popliteal cysts alone.'}\n",
            "6: abstract: {'1': 'The proper treatment of hyperthyroidism depends on recognition of the signs and symptoms of the disease and determination of the etiology.', '2': \"The most common cause of hyperthyroidism is Graves' disease.\", '3': 'Other common causes include thyroiditis, toxic multinodular goiter, toxic adenomas, and side effects of certain medications.', '4': 'The diagnostic workup begins with a thyroid-stimulating hormone level test.', '5': 'When test results are uncertain, measuring radionuclide uptake helps distinguish among possible causes.', '6': 'When thyroiditis is the cause, symptomatic treatment usually is sufficient because the associated hyperthyroidism is transient.', '7': \"Graves' disease, toxic multinodular goiter, and toxic adenoma can be treated with radioactive iodine, antithyroid drugs, or surgery, but in the United States, radioactive iodine is the treatment of choice in patients without contraindications.\", '8': 'Thyroidectomy is an option when other treatments fail or are contraindicated, or when a goiter is causing compressive symptoms.', '9': 'Some new therapies are under investigation.', '10': \"Special treatment consideration must be given to patients who are pregnant or breastfeeding, as well as those with Graves' ophthalmopathy or amiodarone-induced hyperthyroidism.\", '11': \"Patients' desires must be considered when deciding on appropriate therapy, and dose monitoring is essential.\"}\n",
            "6: abstract: {'1': 'Thyroiditis is a general term that encompasses several clinical disorders characterized by inflammation of the thyroid gland.', '2': 'The most common is Hashimoto thyroiditis; patients typically present with a nontender goiter, hypothyroidism, and an elevated thyroid peroxidase antibody level.', '3': 'Treatment with levothyroxine ameliorates the hypothyroidism and may reduce goiter size.', '4': 'Postpartum thyroiditis (occurring within one year of childbirth, miscarriage, or medical abortion) can be short-lived or long-lasting.', '5': 'Release of preformed thyroid hormone into the bloodstream may result in hyperthyroidism.', '6': 'This may be followed by transient or permanent hypothyroidism as a result of depletion of thyroid hormone stores and destruction of thyroid hormone-producing cells.', '7': 'Patients should be monitored for changes in thyroid function.', '8': 'Beta blockers can treat symptoms in the initial hyperthyroid phase; in the subsequent hypothyroid phase, levothyroxine should be considered in women with a serum thyroid-stimulating hormone level greater than 10 mIU per L, or in women with a thyroid-stimulating hormone level of 4 to 10 mIU per L who are symptomatic or desire fertility.', '9': 'Subacute thyroiditis is a transient thyrotoxic state characterized by anterior neck pain, suppressed thyroid-stimulating hormone, and low radioactive iodine uptake on thyroid scanning.', '10': 'Many cases of subacute thyroiditis follow an upper respiratory viral illness, which is thought to trigger an inflammatory destruction of thyroid follicles.', '11': 'In most cases, the thyroid gland spontaneously resumes normal thyroid hormone production after several months.', '12': 'Treatment with high-dose acetylsalicylic acid or nonsteroidal anti-inflammatory drugs is directed toward relief of thyroid pain.'}\n",
            "6: abstract: {'1': 'Hyperthyroidism is an excessive concentration of thyroid hormones in tissues caused by increased synthesis of thyroid hormones, excessive release of preformed thyroid hormones, or an endogenous or exogenous extrathyroidal source.', '2': 'The most common causes of an excessive production of thyroid hormones are Graves disease, toxic multinodular goiter, and toxic adenoma.', '3': 'The most common cause of an excessive passive release of thyroid hormones is painless (silent) thyroiditis, although its clinical presentation is the same as with other causes.', '4': 'Hyperthyroidism caused by overproduction of thyroid hormones can be treated with antithyroid medications (methimazole and propylthiouracil), radioactive iodine ablation of the thyroid gland, or surgical thyroidectomy.', '5': 'Radioactive iodine ablation is the most widely used treatment in the United States.', '6': \"The choice of treatment depends on the underlying diagnosis, the presence of contraindications to a particular treatment modality, the severity of hyperthyroidism, and the patient's preference.\"}\n",
            "6: abstract: {'1': \"Background: Hashimoto's thyroiditis is an autoimmune disorder and the most common cause of hypothyroidism.\", '2': 'The use of Nigella sativa, a potent herbal medicine, continues to increase worldwide as an alternative treatment of several chronic diseases including hyperlipidemia, hypertension and type 2 diabetes mellitus (T2DM).', '3': \"The aim of the current study was to evaluate the effects of Nigella sativa on thyroid function, serum Vascular Endothelial Growth Factor (VEGF) - 1, Nesfatin-1 and anthropometric features in patients with Hashimoto's thyroiditis.\", '4': \"Methods: Forty patients with Hashimoto's thyroiditis, aged between 22 and 50 years old, participated in the trial and were randomly allocated into two groups of intervention and control receiving powdered Nigella sativa or placebo daily for 8 weeks.\", '5': 'Changes in anthropometric variables, dietary intakes, thyroid status, serum VEGF and Nesfatin-1 concentrations after 8 weeks were measured.', '6': 'Results: Treatment with Nigella sativa significantly reduced body weight and body mass index (BMI).', '7': 'Serum concentrations of thyroid stimulating hormone (TSH) and anti-thyroid peroxidase (anti-TPO) antibodies decreased while serum T3 concentrations increased in Nigella sativa-treated group after 8 weeks.', '8': 'There was a significant reduction in serum VEGF concentrations in intervention group.', '9': 'None of these changes had been observed in placebo treated group.', '10': 'In stepwise multiple regression model, changes in waist to hip ratio (WHR) and thyroid hormones were significant predictors of changes in serum VEGF and Nesgfatin-1 values in Nigella sativa treated group (P < 0.05).', '11': \"Conclusions: Our data showed a potent beneficial effect of powdered Nigella sativa in improving thyroid status and anthropometric variables in patients with Hashimoto's thyroiditis.\", '12': 'Moreover, Nigella sativa significantly reduced serum VEGF concentrations in these patients.', '13': \"Considering observed health- promoting effect of this medicinal plant in ameliorating the disease severity, it can be regarded as a useful therapeutic approach in management of Hashimoto's thyroiditis.\"}\n",
            "6: abstract: {'1': 'Objective: To describe the historical refinements, understanding of physiology and clinical outcomes observed with thyroid hormone replacement strategies.', '2': 'Methods: A Medline search was initiated using the search terms, levothyroxine, thyroid hormone history, levothyroxine mono therapy, thyroid hormone replacement, combination LT4 therapy, levothyroxine Bioequivalence.', '3': 'Pertinent articles of interest were identified by title and where available abstract for further review.', '4': 'Additional references were identified in the course of review of the literature identified.', '5': 'Results: Physicians have intervened in cases of thyroid dysfunction for more than two millennia.', '6': 'Ingestion of animal thyroid derived preparations has been long described but only scientifically documented for the last 130 years.', '7': 'Refinements in hormone preparation, pharmaceutical production and regulation continue to this day.', '8': 'The literature provides documentation of physiologic, pathologic and clinical outcomes which have been reported and continuously updated.', '9': 'Recommendations for effective and safe use of these hormones for reversal of patho-physiology associated with hypothyroidism and the relief of symptoms of hypothyroidism has documented a progressive refinement in our understanding of thyroid hormone use.', '10': 'Studies of thyroid hormone metabolism, action and pharmacokinetics have allowed evermore focused recommendations for use in clinical practice.', '11': 'Levothyroxine mono-therapy has emerged as the therapy of choice of all recent major guidelines.', '12': 'Conclusions: The evolution of thyroid hormone therapies has been significant over an extended period of time.', '13': 'Thyroid hormone replacement is very useful in the treatment of those with hypothyroidism.', '14': 'All of the most recent guidelines of major endocrine societies recommend levothyroxine mono-therapy for first line use in hypothyroidism.'}\n",
            "6: abstract: {'1': 'Objective: Hypothyroidism is relatively common, occurring in approximately 5% of the general US population aged ≥12 years.', '2': 'Levothyroxine (LT4) monotherapy is the standard of care.', '3': 'Approximately, 5%-10% of patients who normalise thyroid-stimulating hormone levels with LT4 monotherapy may have persistent symptoms that patients and clinicians may attribute to hypothyroidism.', '4': 'A long-standing debate in the literature is whether addition of levotriiodothyronine (LT3) to LT4 will ameliorate lingering symptoms.', '5': 'Here, we explore the evidence for and against LT4/LT3 combination therapy as the optimal approach to treat euthyroid patients with persistent complaints.', '6': 'Methods: Recent literature indexed on PubMed was searched in March 2017 using the terms \"hypothyroid\" or \"hypothyroidism\" and \"triiodothyronine combination\" or \"T3 combination.\"', '7': 'Relevant non-review articles published in English during the past 10 years were included and supplemented with articles already known to the authors.', '8': 'Findings: Current clinical evidence is not sufficiently strong to support LT4/LT3 combination therapy in patients with hypothyroidism.', '9': 'Polymorphisms in deiodinase genes that encode the enzymes that convert T4 to T3 in the periphery may provide potential mechanisms underlying unsatisfactory treatment results with LT4 monotherapy.', '10': 'However, results of studies on the effect of LT4/LT3 therapy on clinical symptoms and thyroid-responsive genes have thus far not been conclusive.', '11': 'Conclusions: Persistent symptoms in patients who are biochemically euthyroid with LT4 monotherapy may be caused by several other conditions unrelated to thyroid function, and their cause should be aggressively investigated by the clinician.'}\n",
            "6: abstract: {'1': 'Hypothyroidism is one of the most common hormone deficiencies in adults.', '2': 'Most of the cases, particularly those of overt hypothyroidism, are easily diagnosed and managed, with excellent outcomes if treated adequately.', '3': 'However, minor alterations of thyroid function determine nonspecific manifestations.', '4': 'Primary hypothyroidism due to chronic autoimmune thyroiditis is largely the most common cause of thyroid hormone deficiency.', '5': 'Central hypothyroidism is a rare and heterogeneous disorder characterized by decreased thyroid hormone secretion by an otherwise normal thyroid gland, due to lack of TSH.', '6': 'The standard treatment of primary and central hypothyroidism is hormone replacement therapy with levothyroxine sodium (LT4).', '7': 'Treatment guidelines of hypothyroidism recommend monotherapy with LT4 due to its efficacy, long-term experience, favorable side effect profile, ease of administration, good intestinal absorption, long serum half-life and low cost.', '8': 'Despite being easily treatable with a daily dose of LT4, many patients remain hypothyroid due to malabsorption syndromes, autoimmune gastritis, pancreatic and liver disorders, drug interactions, polymorphisms in DIO2 (iodothyronine deiodinase 2), high fiber diet, and more frequently, non-compliance to LT4 therapy.', '9': 'Compliance to levothyroxine treatment in hypothyroidism is compromised by daily and fasting schedule.', '10': 'Many adult patients remain hypothyroid due to all the above mentioned and many attempts to improve levothyroxine therapy compliance and absorption have been made.'}\n",
            "6: abstract: {'1': \"Hashimoto's thyroiditis (HT) is the most prevalent autoimmune disorder characterized by the destruction of thyroid cells caused by leukocytes and antibody-mediated immune processes accompanied by hypothyroidism.\", '2': 'In recent years, evidence has emerged pointing to various roles for vitamin D, including, proliferation and differentiation of normal and cancer cells, cardiovascular function, and immunomodulation.', '3': 'Vitamin D deficiency has been especially demonstrated in HT patients.', '4': 'The aim of this study was to investigate the effect of vitamin D on circulating thyroid autoantibodies and thyroid hormones profile (T4, T3, and TSH) in females with HT.', '5': 'Forty-two women with HT disease were enrolled in this randomized clinical trial study and divided into vitamin D and placebo groups.', '6': 'Patients in the vitamin D and placebo groups received 50 000 IU vitamin D and placebo pearls, weekly for 3 months, respectively.', '7': 'The serum levels of 25-hydroxy vitamin D [25(OH) D], Ca++ion, anti-thyroperoxidase antibody (anti-TPO Ab), anti-thyroglobulin antibody (anti-Tg Ab), T4, T3, and TSH were measured at the baseline and at the end of the study using enzyme-linked immunosorbent assays.', '8': 'The results of this study showed a significant reduction of anti-Tg Ab and TSH hormone in the Vitamin D group compared to the start of the study; however, there was a no significant reduction of anti-TPO Ab in the Vitamin D group compared to the placebo group (p=0.08).', '9': 'No significant changes were observed in the serum levels of T3 and T4 hormones.', '10': 'Therefore, vitamin D supplementation can be helpful for alleviation of the disease activity in HT patients; however, further well controlled, large, longitudinal studies are needed to determine whether it can be introduced in clinical practice.'}\n",
            "6: abstract: {'1': 'In the 1990s, selenium was identified as a component of an enzyme that activates thyroid hormone; since this discovery, the relevance of selenium to thyroid health has been widely studied.', '2': 'Selenium, known primarily for the antioxidant properties of selenoenzymes, is obtained mainly from meat, seafood and grains.', '3': 'Intake levels vary across the world owing largely to differences in soil content and factors affecting its bioavailability to plants.', '4': 'Adverse health effects have been observed at both extremes of intake, with a narrow optimum range.', '5': 'Epidemiological studies have linked an increased risk of autoimmune thyroiditis, Graves disease and goitre to low selenium status.', '6': 'Trials of selenium supplementation in patients with chronic autoimmune thyroiditis have generally resulted in reduced thyroid autoantibody titre without apparent improvements in the clinical course of the disease.', '7': 'In Graves disease, selenium supplementation might lead to faster remission of hyperthyroidism and improved quality of life and eye involvement in patients with mild thyroid eye disease.', '8': 'Despite recommendations only extending to patients with Graves ophthalmopathy, selenium supplementation is widely used by clinicians for other thyroid phenotypes.', '9': 'Ongoing and future trials might help identify individuals who can benefit from selenium supplementation, based, for instance, on individual selenium status or genetic profile.'}\n",
            "6: abstract: {'1': 'Purpose of review: The aim of the article is to present the basics of oral levothyroxine (LT4) absorption, reasons why patients may have persistently elevated serum thyroid stimulation hormone (TSH) levels, and alternative strategies for LT4 dosing.', '2': 'Recent findings: Although oral LT4 tablets are most commonly used for thyroid hormone replacement in patients with hypothyroidism, case studies report that liquid oral LT4, intravenous, intramuscular, and rectal administration of LT4 can successfully treat refractory hypothyroidism.', '3': 'Summary: Hypothyroidism is one of the most common endocrine disorders encountered by primary care physicians and endocrinologists.', '4': 'LT4 is one of the most widely prescribed medications in the world and it is the standard of care treatment for hypothyroidism.', '5': 'Generally, hypothyroid patients will be treated with LT4 tablets to be taken orally, and monitoring will occur with routine serum thyroid tests, including TSH concentrations.', '6': 'However, many patients fail to maintain serum TSH levels in the target range while managed on oral LT4 tablets.', '7': 'A subset of these patients would be considered to have poorly controlled hypothyroidism, sometimes termed refractory hypothyroidism.', '8': 'For these patients, optimization of ingestion routines and alternative formulations and routes of administration of LT4 can be considered, including oral liquid, intravenous, intramuscular, and even rectal formulations.'}\n",
            "7: abstract: {'1': 'Most patients who seek medical attention for sore throat are concerned about streptococcal tonsillopharyngitis, but fewer than 10% of adults and 30% of children actually have a streptococcal infection.', '2': 'Group A beta-hemolytic streptococci (GAS) are most often responsible for bacterial tonsillopharyngitis, although Neisseria gonorrhea, Arcanobacterium haemolyticum (formerly Corynebacterium haemolyticum), Chlamydia pneumoniae (TWAR agent), and Mycoplasma pneumoniae have also been suggested as possible, infrequent, sporadic pathogens.', '3': 'Viruses or idiopathic causes account for the remainder of sore throat complaints.', '4': 'Reliance on clinical impression to diagnose GAS tonsillopharyngitis is problematic; an overestimation of 80% to 95% by experienced clinicians typically occurs for adult patients.', '5': 'Overtreatment promotes bacterial resistance, disturbs natural microbial ecology, and may produce unnecessary side effects.', '6': 'Existing data suggest that rapid GAS antigen testing as an aid to clinical diagnosis can be very useful.', '7': 'When used appropriately, it is sensitive (79% to 88%) in detecting GAS-infected patients and is specific (90% to 96%) and cost-effective.', '8': 'Penicillin has been the treatment of choice for GAS tonsillopharyngitis since the 1950s; 10 days of treatment are necessary for bacterial eradication.', '9': 'A single IM injection of benzathine penicillin is effective and obviates compliance issues.', '10': 'Until the early 1970s, the bacteriologic failure rate for the treatment of GAS tonsillopharyngitis ranged from 2% to 10% and was attributed to chronic GAS carriers.', '11': 'Since the late 1970s, the penicillin failure rate has frequently exceeded 20% in published reports.', '12': 'Explanations for recurrent GAS tonsillopharyngitis include poor patient compliance; reacquisition from a family member or peer, copathogenic colonization by Staphylococcus aureus, Haemophilus influenzae, Moraxella catarrhalis, anaerobes that inactivate penicillin with beta-lactamase, or all these organisms; suppression of natural immune response by too-early administration of antibiotics; GAS tolerance to penicillin; antibiotic eradication of normal pharyngeal flora that normally act as natural host defenses; and establishment of a true carrier state.', '13': 'When therapy fails, milder symptoms may occur during the relapse.', '14': 'Several antimicrobials have demonstrated superior efficacy compared with penicillin in eradicating GAS and are administered less frequently to enhance patient compliance.', '15': 'In previously untreated GAS throat infections, cephalosporins produce a 5% to 22% higher bacteriologic cure rate; after a penicillin treatment failure, these differences are greater.', '16': 'Amoxicillin/clavulanate and the extended-spectrum macrolides clarithromycin and azithromycin may also produce enhanced bacteriologic eradication in comparison to penicillin.'}\n",
            "7: abstract: {'1': 'We conducted a meta-analysis of 9 randomized controlled trials (involving 2113 patients) comparing cephalosporins with penicillin for treatment of group A beta -hemolytic streptococcal (GABHS) tonsillopharyngitis in adults.', '2': 'The summary odds ratio (OR) for bacteriologic cure rate significantly favored cephalosporins, compared with penicillin (OR,1.83; 95% confidence interval [CI], 1.37-2.44); the bacteriologic failure rate was nearly 2 times higher for penicillin therapy than it was for cephalosporin therapy (P=.00004).', '3': 'The summary OR for clinical cure rate was 2.29 (95% CI, 1.61-3.28), significantly favoring cephalosporins (P<.00001).', '4': 'Sensitivity analyses for bacterial cure significantly favored cephalosporins over penicillin in trials that were double-blinded and of high quality, trials that had a well-defined clinical status, trials that performed GABHS serotyping, trials that eliminated carriers from analysis, and trials that had a test-of-cure culture performed 3-14 days after treatment.', '5': 'This meta-analysis indicates that the likelihood of bacteriologic and clinical failure in the treatment of GABHS tonsillopharyngitis is 2 times higher for oral penicillin than for oral cephalosporins.'}\n",
            "7: abstract: {'1': 'In patients with symptoms and signs suggestive of streptococcal pharyngitis a specific diagnosis should be determined by performing a throat culture or a rapid antigen-detection test with a throat culture if the rapid antigen-detection test is negative, at least in children.', '2': 'Penicillin is the preferred treatment, and a first-generation cephalosporin is an acceptable alternative unless there is a history of immediate hypersensitivity to a beta-lactam antibiotic.'}\n",
            "7: abstract: {'1': 'The European Society for Clinical Microbiology and Infectious Diseases established the Sore Throat Guideline Group to write an updated guideline to diagnose and treat patients with acute sore throat.', '2': 'In diagnosis, Centor clinical scoring system or rapid antigen test can be helpful in targeting antibiotic use.', '3': 'The Centor scoring system can help to identify those patients who have higher likelihood of group A streptococcal infection.', '4': 'In patients with high likelihood of streptococcal infections (e.g. 3-4 Centor criteria) physicians can consider the use of rapid antigen test (RAT).', '5': 'If RAT is performed, throat culture is not necessary after a negative RAT for the diagnosis of group A streptococci.', '6': 'To treat sore throat, either ibuprofen or paracetamol are recommended for relief of acute sore throat symptoms.', '7': 'Zinc gluconate is not recommended to be used in sore throat.', '8': 'There is inconsistent evidence of herbal treatments and acupuncture as treatments for sore throat.', '9': 'Antibiotics should not be used in patients with less severe presentation of sore throat, e.g. 0-2 Centor criteria to relieve symptoms.', '10': 'Modest benefits of antibiotics, which have been observed in patients with 3-4 Centor criteria, have to be weighed against side effects, the effect of antibiotics on microbiota, increased antibacterial resistance, medicalisation and costs.', '11': 'The prevention of suppurative complications is not a specific indication for antibiotic therapy in sore throat.', '12': 'If antibiotics are indicated, penicillin V, twice or three times daily for 10 days is recommended.', '13': 'At the present, there is no evidence enough that indicates shorter treatment length.'}\n",
            "7: abstract: {'1': 'Acute pharyngitis/tonsillitis, which is characterized by inflammation of the posterior pharynx and tonsils, is a common disease.', '2': 'Several viruses and bacteria can cause acute pharyngitis; however, Streptococcus pyogenes (also known as Lancefield group A β-hemolytic streptococci) is the only agent that requires an etiologic diagnosis and specific treatment.', '3': 'S. pyogenes is of major clinical importance because it can trigger post-infection systemic complications, acute rheumatic fever, and post-streptococcal glomerulonephritis.', '4': 'Symptom onset in streptococcal infection is usually abrupt and includes intense sore throat, fever, chills, malaise, headache, tender enlarged anterior cervical lymph nodes, and pharyngeal or tonsillar exudate.', '5': 'Cough, coryza, conjunctivitis, and diarrhea are uncommon, and their presence suggests a viral cause.', '6': \"A diagnosis of pharyngitis is supported by the patient's history and by the physical examination.\", '7': 'Throat culture is the gold standard for diagnosing streptococcus pharyngitis.', '8': 'However, it has been underused in public health services because of its low availability and because of the 1- to 2-day delay in obtaining results.', '9': 'Rapid antigen detection tests have been used to detect S. pyogenes directly from throat swabs within minutes.', '10': 'Clinical scoring systems have been developed to predict the risk of S. pyogenes infection.', '11': 'The most commonly used scoring system is the modified Centor score.', '12': 'Acute S. pyogenes pharyngitis is often a self-limiting disease.', '13': 'Penicillins are the first-choice treatment.', '14': 'For patients with penicillin allergy, cephalosporins can be an acceptable alternative, although primary hypersensitivity to cephalosporins can occur.', '15': 'Another drug option is the macrolides.', '16': 'Future perspectives to prevent streptococcal pharyngitis and post-infection systemic complications include the development of an anti-Streptococcus pyogenes vaccine.'}\n",
            "7: abstract: {'1': 'Background: Diagnosing group A streptococcus (Strep A) throat infection by clinical examination is difficult, and misdiagnosis may lead to inappropriate antibiotic use.', '2': 'Most patients with sore throat seek symptom relief rather than antibiotics, therefore, therapies that relieve symptoms should be recommended to patients.', '3': 'We report two clinical trials on the efficacy and safety of flurbiprofen 8.75 mg lozenge in patients with and without streptococcal sore throat.', '4': 'Methods: The studies enrolled adults with moderate-to-severe throat symptoms (sore throat pain, difficulty swallowing and swollen throat) and a diagnosis of pharyngitis.', '5': 'The practitioner assessed the likelihood of Strep A infection based on historical and clinical findings.', '6': 'Patients were randomised to flurbiprofen 8.75 mg or placebo lozenges under double-blind conditions and reported the three throat symptoms at baseline and at regular intervals over 24 h.', '7': 'Results: A total of 402 patients received study medication (n = 203 flurbiprofen, n = 199 placebo).', '8': 'Throat culture identified Strep A in 10.0% of patients and group C streptococcus (Strep C) in a further 14.0%.', '9': \"The practitioners' assessments correctly diagnosed Strep A in 11/40 cases (sensitivity 27.5%, and specificity 79.7%).\", '10': 'A single flurbiprofen lozenge provided significantly greater relief than placebo for all three throat symptoms, lasting 3-4 h for patients with and without Strep A/C.', '11': 'Multiple doses of flurbiprofen lozenges over 24 h also led to symptom relief, although not statistically significant in the Strep A/C group.', '12': 'There were no serious adverse events.', '13': 'Conclusions: The results highlight the challenge of identifying Strep A based on clinical features.', '14': 'With the growing problem of antibiotic resistance, non-antibiotic treatments should be considered.', '15': 'As demonstrated here, flurbiprofen 8.75 mg lozenges are an effective therapeutic option, providing immediate and long-lasting symptom relief in patients with and without Strep A/C infection.'}\n",
            "7: abstract: {'1': 'Group A beta-hemolytic streptococcal (GABHS) infection causes 15% to 30% of sore throats in children and 5% to 15% in adults, and is more common in the late winter and early spring.', '2': 'The strongest independent predictors of GABHS pharyngitis are patient age of five to 15 years, absence of cough, tender anterior cervical adenopathy, tonsillar exudates, and fever.', '3': 'To diagnose GABHS pharyngitis, a rapid antigen detection test should be ordered in patients with a modified Centor or FeverPAIN score of 2 or 3.', '4': 'First-line treatment for GABHS pharyngitis includes a 10-day course of penicillin or amoxicillin.', '5': 'Patients allergic to penicillin can be treated with firstgeneration cephalosporins, clindamycin, or macrolide antibiotics.', '6': 'Nonsteroidal anti-inflammatory drugs are more effective than acetaminophen and placebo for treatment of fever and pain associated with GABHS pharyngitis; medicated throat lozenges used every two hours are also effective.', '7': 'Corticosteroids provide only a small reduction in the duration of symptoms and should not be used routinely.'}\n",
            "7: abstract: {'1': 'Objective: To compare azithromycin (AZT) and benzathine penicillin (BP) in the treatment of recurrent tonsillitis in children.', '2': 'Methods: The study comprised of 350 children with recurrent streptococcal tonsillitis, 284 of whom completed the study and 162 children received conventional surgical treatment.', '3': 'The rest of the children, 122, were divided randomly into two equal main groups.', '4': 'Group A children received a single intramuscular BP (600,000 IU for children≤27kg and 1,200,000IU for ≥27kg) every two weeks for six months.', '5': 'Group B children received single oral AZT (250mg for children≤25kg and 500mg for ≥25kg) once weekly for six months.', '6': 'Results: Both groups showed marked significant reduction in recurrent tonsillitis that is comparable to results of tonsillectomy.', '7': 'There were no statistical differences between group A and B regarding the recurrence of infections and drug safety after six-month follow-up.', '8': 'Group B showed better compliance.', '9': 'Conclusion: AZT proved to be good alternative to BP in the management of recurrent tonsillitis with results similar to those obtained after tonsillectomy.'}\n",
            "7: abstract: {'1': 'Chronic GAS carrier state is best defined as the prolonged presence of group A β-haemolytic Streptococcus (GAS) in the pharynx without evidence of infection or inflammation.', '2': 'Chronic GAS carriers have a low risk of immune mediated complications.', '3': 'Persistent pharyngeal carriage often raises management issues.', '4': 'In this study, we review the evidence on the management of persistent GAS carriage in children and propose a management algorithm.', '5': 'Areas covered: Chronic GAS pharyngeal carriage is quite common affecting 10-20% of school-aged children.', '6': 'Pathogenesis of carriage has been related to the pharynx microflora and to special properties of GAS, but several aspects are yet to be elucidated.', '7': \"Management greatly depends on whether the individual child belongs to a 'high-risk' group and might benefit from eradication regimens or not, when observation-only and reassurance are enough.\", '8': 'Penicillin plus rifampin and clindamycin monotherapy have been recommended for eradication; limited evidence of effectiveness of azithromycin has been reported.', '9': 'Surgical intervention is not indicated.', '10': 'Expert commentary: GAS infection is a common reason for antibiotic use and abuse in children and asymptomatic carriers constitute the major reservoir of GAS in the community.', '11': 'Several aspects are yet to be elucidated and well-designed studies are needed for firm conclusions to be drawn.'}\n",
            "7: abstract: {'1': 'The most common bacterial cause of pharyngitis is infection by Group A β-hemolytic streptococcus (GABHS), commonly known as strep throat.', '2': '5-15% of adults and 15-35% of children in the United States with pharyngitis have a GABHS infection.', '3': 'The symptoms of GABHS overlap with non-GABHS and viral causes of acute pharyngitis, complicating the problem of diagnosis.', '4': 'A careful physical examination and patient history is the starting point for diagnosing GABHS.', '5': 'After a physical examination and patient history is completed, five types of diagnostic methods can be used to ascertain the presence of a GABHS infection: clinical scoring systems, rapid antigen detection tests, throat culture, nucleic acid amplification tests, and machine learning and artificial intelligence.', '6': 'Clinical guidelines developed by professional associations can help medical professionals choose among available techniques to diagnose strep throat.', '7': 'However, guidelines for diagnosing GABHS created by the American and European professional associations vary significantly, and there is substantial evidence that most physicians do not follow any published guidelines.', '8': 'Treatment for GABHS using analgesics, antipyretics, and antibiotics seeks to provide symptom relief, shorten the duration of illness, prevent nonsuppurative and suppurative complications, and decrease the risk of contagion, while minimizing the unnecessary use of antibiotics.', '9': 'There is broad agreement that antibiotics with narrow spectrums of activity are appropriate for treating strep throat.', '10': 'But whether and when patients should be treated with antibiotics for GABHS remains a controversial question.', '11': 'There is no clearly superior management strategy for strep throat, as significant controversy exists regarding the best methods to diagnose GABHS and under what conditions antibiotics should be prescribed.'}\n",
            "8: abstract: {'1': 'The chemical structure of a neuroleptic does not relaibly predict the exact profile of its therapeutic action.', '2': 'We considered the question whether the biochemical action of a neuroleptic, and specifically the ratio between DA-receptor block and NA-receptor block, might have a higher predictive value in this respect.', '3': 'In this context we carried out a double-blind study of the therapeutic value of clozapine and perphenazine in acute psychoses of varying symptomatology and aetiology.', '4': 'There are strong indications that clozapine has only a slight inhibitory effect on transmission in central DA-ergic neurons, but markedly inhibits transmission in central NA-ergic neurons, and that the reverse applies to perphenazine.', '5': 'In view of these data we expected perphenazine to be a stronger antipsychotic and a weaker sedative than clozapine, and vice versa.', '6': 'The plausibility of this hypothesis was demonstrated.', '7': 'Partly also on the basis of earlier research, we concluded that the biochemical action of a neuroleptic is a more faithful predictor of its therapeutic action profile than the chemical structure.'}\n",
            "8: abstract: {'1': 'CLINICAL experience with tranquilizers has shown the need for prolonged therapy for chronic neurotic and psychotic disorders.', '2': 'Since phenothiazine derivatives such as perphenazine are being employed in this manner and since there have been rare reports of jaundice and leukopenia associated with its administration, questions about a potential deleterious effect of this drug on the liver and blood have to be answered.'}\n",
            "8: abstract: {'1': 'Background: Antipsychotic drugs are usually given orally but compliance with medication given by this route may be difficult to quantify.', '2': 'The development of depot injections in the 1960s gave rise to extensive use of depots as a means of long-term maintenance treatment.', '3': 'Perphenazine decanoate and enanthate are depot antipsychotics that belong to the phenothiazine family and have a piperazine ethanol side chain.', '4': 'Objectives: To assess the effects of depot perphenazine decanoate and enanthate versus placebo, oral antipsychotics and other depot antipsychotic preparations for people with schizophrenia in terms of clinical, social and economic outcomes.', '5': \"Authors' conclusions: Depot perphenazine is in clinical use in the Nordic countries, Belgium, Portugal and the Netherlands.\", '6': 'At a conservative estimate, a quarter of a million people suffer from schizophrenia in those countries and could be treated with depot perphenazine.', '7': 'The total number of participants in the four trials with useful data is 313.', '8': 'None of the studies observed the effects of oral versus depot antipsychotic drugs.', '9': 'Until well conducted and reported randomised trials are undertaken clinicians will be in doubt as to the effects of perphenazine depots and people with schizophrenia should exercise their own judgement or ask to be randomised.'}\n",
            "8: abstract: {'1': 'Background and objective: despite the introduction of newer antiemetics in the prevention of postoperative nausea and vomiting (PONV), perphenazine is recommended in current guidelines, as the concept of multimodal management of PONV in high-risk patients requires more than two drugs to be combined.', '2': 'The aim of this quantitative systematic review was to assess the efficacy and safety of perphenazine in the prophylaxis of PONV in adults and children.', '3': 'Results: eleven trials published between 1965 and 1999 including a total of 2081 participants fulfilled the inclusion criteria and were further analysed.', '4': 'In children, perphenazine 0.07 mg kg was effective in preventing vomiting (RR, 0.31; 95% CI, 0.18-0.54), whereas in adults, a dose of about 5 mg was effective for the prevention of PONV (RR, 0.50; 95% CI, 0.37-0.67).', '5': 'When compared with established newer drugs, for example, ondansetron, dexamethasone or droperidol, no significant differences were observed in the pooled analysis with limited data.', '6': 'Reporting of adverse events was poor.', '7': 'Transient sedation was reported in three eligible trials (RR, 0.9; 95% CI, 0.40-2.05).', '8': 'Conclusion: there is evidence that perphenazine is effective in the prevention of PONV in children and adults without serious adverse effects compared with placebo.'}\n",
            "8: abstract: {'1': 'We present here a potential new treatment adjunct for glioblastoma.', '2': 'Building on murine studies, a series of papers appeared recently showing that therapeutic irradiation of the ipsilateral subventricular zone (SVZ) retards growth of more peripherally growing cortical glioblastomas in humans, suggesting a tumor trophic function for the SVZ.', '3': 'Further studies showed that SVZ cells migrate out towards a peripheral glioblastoma.', '4': 'Dopamine signaling through D3 subtype receptor indirectly drives this centrifugal migration in humans.', '5': 'Since psychiatry has several drugs with good D3 blocking attributes, such as fluphenazine, or perphenazine, we suggest that adding one of these D3 blocking drugs to current standard treatment of resection followed by temozolomide and irradiation might prolong survival by depriving glioblastoma of the trophic functions previously subserved by dopaminergic signaling on SVZ cells.'}\n",
            "8: abstract: {'1': 'Background: Antipsychotic drugs are the core treatment for schizophrenia.', '2': 'Treatment guidelines state that there is no difference in efficacy between the various first-generation antipsychotics, however, low-potency first-generation antipsychotic drugs are sometimes perceived as less efficacious than high-potency first-generation compounds by clinicians, and they also seem to differ in their side effects.', '3': \"Authors' conclusions: The results do not show a superiority in efficacy of high-potency perphenazine compared with low-potency first-generation antipsychotics.\", '4': 'There is some evidence that perphenazine is more likely to cause akathisia and less likely to cause severe toxicity, but most adverse effect results were equivocal.', '5': 'The number of studies as well as the quality of studies is low, with quality of evidence for the main outcomes ranging from moderate to very low, so more randomised evidence would be needed for conclusions to be made.'}\n",
            "8: abstract: {'1': 'Background: Perphenazine is an old phenothiazine antipsychotic with a potency similar to haloperidol.', '2': 'It has been used for many years and is popular in the northern European countries and Japan.', '3': 'Objectives: To examine the clinical effects and safety of perphenazine for those with schizophrenia and schizophrenia-like psychoses.', '4': \"Authors' conclusions: Although perphenazine has been used in randomised trials for more than 50 years, incomplete reporting and the variety of comparators used make it impossible to draw clear conclusions.\", '5': 'All data for the main outcomes in this review were of very low quality evidence.', '6': 'At best we can say that perphenazine showed similar effects and adverse events as several of the other antipsychotic drugs.', '7': 'Since perphenazine is a relatively inexpensive and frequently used compound, further trials are justified to clarify the properties of this classical antipsychotic drug.'}\n",
            "8: abstract: {'1': 'Endometrial cancer (EC) is one of the most common and fatal gynecological cancers worldwide, but there is no effective treatment for the EC patients of progesterone resistance.', '2': 'Repurposing of existing drugs is a good strategy to discover new candidate drugs.', '3': 'In this text, perphenazine (PPZ), approved for psychosis therapy, was identified as a potential agent for the treatment of both progesterone sensitive and resistant endometrial cancer for the first time.', '4': 'Specifically, perphenazine exhibited good cell proliferation inhibition in Ishikawa (ISK) and KLE cell lines according to the CCK-8 assay and colony formation assay.', '5': 'It also reduced the cell migration of ISK and KLE cell lines in the light of the transwell migration assay.', '6': 'Annexin-V/PI double staining assay suggested that perphenazine could effectively induce ISK and KLE cell apoptosis.', '7': 'Moreover, results of western blot assay indicated perphenazine obviously inhibited the phosphorylation of Akt.', '8': 'Delightedly, PPZ also could significantly attenuate xenograft tumor growth at both 3 mg/kg and 15 mg/kg in mice without influencing the body weights.'}\n",
            "8: abstract: {'1': 'In the effort to improve treatment effectiveness in glioblastoma, this short note reviewed collected data on the pathophysiology of glioblastoma with particular reference to intersections with the pharmacology of perphenazine.', '2': 'That study identified five areas of potentially beneficial intersection.', '3': 'Data showed seemingly 5 independent perphenazine attributes of benefit to glioblastoma treatment - i) blocking dopamine receptor 2, ii) reducing centrifugal migration of subventricular zone cells by blocking dopamine receptor 3, iii) blocking serotonin receptor 7, iv) activation of protein phosphatase 2, and v) nausea reduction.', '4': 'Perphenazine is fully compatible with current chemoirradiation protocols and with the commonly used ancillary medicines used in clinical practice during the course of glioblastoma.', '5': \"All these attributes argue for a trial of perphenazine's addition to current standard treatment with temozolomide and irradiation.\", '6': 'The subventricular zone seeds the brain with mutated cells that become recurrent glioblastoma after centrifugal migration.', '7': 'The current paper shows how perphenazine might reduce that contribution.', '8': \"Perphenazine is an old, generic, cheap, phenothiazine antipsychotic drug that has been in continuous clinical use worldwide since the 1950's.\", '9': 'Clinical experience and research data over these decades have shown perphenazine to be well-tolerated in psychiatric populations, in normals, and in non-psychiatric, medically ill populations for whom perphenazine is used to reduce nausea.', '10': 'For now (Summer, 2020) the nature of glioblastoma requires a polypharmacy approach until/unless a core feature and means to address it can be identified in the future.', '11': 'Conclusions: Perphenazine possesses a remarkable constellation of attributes that recommend its use in GB treatment.'}\n",
            "8: abstract: {'1': 'We have found oral perphenazine 8 mg (OP8) useful as follows: (1) as a nonsedating antiemetic; (2) as a preventative measure similar to the antihistamine promethazine against ketamine-induced psychotomimetic effects; and (3) as a safe single-dose drug (only 1.3 extrapyramidal events per 10,000 patients receiving 4–8 mg oral dose, with all events easily treated).', '2': 'Additionally, we evaluated the efficacy of single-dose OP8 to a single 40 mg dose of aprepitant given preoperatively in colorectal surgery patients at our academic center within an enhanced recovery protocol, which was designed to mitigate opioid utilization, reduce Postoperative Nausea and Vomiting (PONV), and optimize patient recovery.', '3': 'In this retrospective study, no differences were noted in antiemetic requirement on postoperative days 0 and 1 between patients receiving OP8 versus aprepitant.', '4': 'As enhanced recovery protocols become more widespread and continue to be applied to other surgical specialties, effective PONV prevention is imperative for improving patient outcomes.', '5': 'OP8 deserves to be properly evaluated (by clinical study, and/or in routine clinical practice) as a part of a cost-effective multimodal enhanced recovery strategy.'}\n",
            "9: abstract: {'1': 'Management of 242 foreign bodies of the upper gastrointestinal tract are reported.', '2': 'Thirty-nine were in the pharynx, 181 in the esophagus, 19 in the stomach, and 3 in the small bowel.', '3': 'The flexible panendoscope was used 211 times (87.2%) to manage these foreign bodies, while the rigid esophagoscope was used 12 times (5.0%).', '4': 'Two hundred thirty-nine foreign bodies (98.8%) were successfully managed endoscopically.', '5': 'The surgery rate was 0.4%.', '6': 'There was no morbidity or mortality.', '7': 'Twenty-five percent of the cases were done under general endotracheal anesthesia.', '8': 'Coins in the esophagus are removed promptly if in the cervical or mid esophagus, and within 12 hours if in the distal esophagus.', '9': 'Once in the stomach, they will usually pass without difficulty.', '10': 'Meat impaction resulting in an obstructed esophagus is an urgent problem and the bolus should be removed within hours.', '11': 'Sharp and pointed foreign bodies can be very difficult to manage.', '12': 'Dry runs with a reproduction of the foreign body are essential to successful removal.', '13': 'Button batteries lodged in the esophagus represent an emergency and should be removed without delay.', '14': 'Once in the stomach, they will usually pass through the gastrointestinal tract without difficulty.', '15': 'The forward-viewing flexible panendoscope has become the instrument of choice in managing foreign bodies in most tertiary medical centers as well as in the community hospitals.'}\n",
            "9: abstract: {'1': 'Objective: To evaluate management of foreign bodies in the upper gastrointestinal tract.', '2': 'Patients and methods: A total of 103 patients with history of foreign body ingestion were included in this study.', '3': 'X-ray neck and rigid oesophagoscopy was carried out in all patients for diagnosis and removal of foreign bodies.', '4': 'A structured questionnaire was designed to record all information.', '5': 'Results: Dysphagia (92%) and tenderness in neck (60%) were the most common clinical features.', '6': 'Majority (89%) patients had come to the hospital within 24 hours.', '7': 'X-ray of the neck (lateral view) was the most useful investigation with presence of air in the esophagus being a significant finding.', '8': 'Post-cricoid region was the site of impaction of foreign bodies in 84% of the subjects.', '9': 'The procedure of esophagoscopy was successful in 90 patients (97%) and failed in 3 patients (3%).', '10': 'Coins were the most common foreign bodies (60%), followed by meat related foreign bodies (22.5%) and dentures in 5% cases.', '11': 'Complications occurred in 18% patients and were more common in adults (37.1%) compared to children (8.8%).', '12': 'The most serious complication was pneumomediastinum.', '13': 'Maximum complications occurred with dentures (80%) and bone chips (42%).', '14': 'Conclusion: Foreign body in the esophagus is a serious condition and early removal by rigid esophagoscopy is recommended which is a safe and effective procedure.'}\n",
            "9: abstract: {'1': 'Foreign bodies in the ear, nose, and throat are occasionally seen in family medicine, usually in children.', '2': 'The most common foreign bodies are food, plastic toys, and small household items.', '3': 'Diagnosis is often delayed because the causative event is usually unobserved, the symptoms are nonspecific, and patients often are misdiagnosed initially.', '4': 'Most ear and nose foreign bodies can be removed by a skilled physician in the office with minimal risk of complications.', '5': 'Common removal methods include use of forceps, water irrigation, and suction catheter.', '6': 'Pharyngeal or tracheal foreign bodies are medical emergencies requiring surgical consultation.', '7': 'Radiography results are often normal.', '8': 'Flexible or rigid endoscopy usually is required to confirm the diagnosis and to remove the foreign body.', '9': 'Physicians need to have a high index of suspicion for foreign bodies in children with unexplained upper airway symptoms.', '10': 'It is important to understand the anatomy and the indications for subspecialist referral.', '11': 'The evidence is inadequate to make strong recommendations for specific removal techniques.'}\n",
            "9: abstract: {'1': 'Objective: In the present study, an attempt was made to examine the effects of aural stimulation with ointment containing capsaicin on swallowing function in order to develop a novel and safe treatment for non-obstructive dysphagia in elderly patients.', '2': 'Patients and methods: The present study included 26 elderly patients with non-obstructive dysphagia.', '3': 'Ointment containing 0.025% capsaicin (0.5 g) was applied to the external auditory canal with a cotton swab under otoscope only once or once a day for 7 days before swallowing of a bolus of colored water (3 mL), which was recorded by transnasal videoendoscopy and evaluated according to the endoscopic swallowing score.', '4': 'Results: After a single application of 0.025% capsaicin ointment to the right external auditory canal, the endoscopic swallowing score was significantly decreased, and this effect lasted for 60 minutes.', '5': 'After repeated applications of the ointment to each external auditory canal alternatively once a day for 7 days, the endoscopic swallowing score decreased significantly in patients with more severe non-obstructive dysphagia.', '6': 'Of the eight tube-fed patients of this group, three began direct swallowing exercises using jelly, which subsequently restored their oral food intake.', '7': 'Conclusion: These findings suggest that stimulation of the external auditory canal with ointment containing capsaicin improves swallowing function in elderly patients with non-obstructive dysphagia.', '8': \"By the same mechanism used by angiotensin-converting enzyme inhibitors to induce cough reflex, which has been shown to prevent aspiration pneumonia, aural stimulation with capsaicin may reduce the incidence of aspiration pneumonia in dysphagia patients via Arnold's ear-cough reflex stimulation.\"}\n",
            "9: abstract: {'1': 'Most swallowing problems can be treated, although the treatment depends on the type of dysphagia.', '2': 'A multidisciplinary team of surgeons, phoniatrists, and speech-language therapists is necessary to develop the appropriate treatment strategy.', '3': 'A thorough medical history, clinical investigation of the swallowing muscles, and fiberoptic endoscopic evaluation of swallowing with foods of different consistencies help to decide whether swallowing exercises alone are sufficient, or whether an additional pharmacologic or surgical treatment is needed to prevent aspiration, malnutrition, and dehydration.'}\n",
            "9: abstract: {'1': 'Foreign bodies to the ear, nose, and throat often can be managed in the emergency department, particularly if the patient offers a history consistent with foreign body and is calm and compliant with the examination and removal attempts.', '2': \"Tips for success include analgesia, adequate visualization, immobilization of the patient's head, dexterity and experience level of the provider, and minimizing attempts at removal.\", '3': 'It is critical to recognize the risks involved with certain retained objects (button batteries or sharp objects) and when to call a consultant to help facilitate safe, successful removal of objects to the ear, nose, and throat.'}\n",
            "9: abstract: {'1': 'Background: Patients with foreign bodies in their ear, nose or throat typically present to general practitioners.', '2': 'The safe and timely removal of foreign bodies ensures good patient outcomes and limits complications.', '3': 'Objectives: The aim of this paper is to outline common foreign objects and review the associated anatomy that may make removal difficult.', '4': 'A description of instruments and indications for use is provided, along with circumstances where specialist referral is warranted.', '5': 'Discussion: The use of appropriate techniques for removal of foreign bodies reduces the complications of removal and associated distress, and limits the number of cases that require surgical input.'}\n",
            "9: abstract: {'1': 'Objective: This study was designed to explore the clinical application of video laryngoscopy in the diagnosis and treatment of throat foreign bodies (FBs).', '2': 'Method: In total, 1572 patients diagnosed with throat FBs at the Department of Otolaryngology of Nanjing Drum Tower Hospital were retrospectively analysed.', '3': 'The covariables collected were the time from FB ingestion to admission, age, sex, duration of admission, and site of impaction.', '4': 'Result: The most common FBs were fish bones, which accounted for 1446 (91.98%) of 1572 FBs.', '5': 'Among all 1572 FBs, 1004 (63.87%) were successfully removed by video laryngoscopy without complications.', '6': 'A shorter duration of admission was associated with a higher diagnostic rate under video laryngoscopy.', '7': 'The diagnostic rate of sharp FBs was significantly higher than that of non-sharp FBs.', '8': 'The most common sites of throat FBs were the tongue root (42.29%), epiglottic vallecula (19.40%), tonsil (18.21%), and piriform fossa (10.65%).', '9': 'Conclusion: Video laryngoscopy is a powerful tool for the diagnosis and treatment of throat FBs, allowing for identification of rare locations of FBs as well as refractory FBs.'}\n",
            "9: abstract: {'1': 'Achalasia is an esophageal motility disorder characterized by aberrant peristalsis and insufficient relaxation of the lower esophageal sphincter.', '2': 'Patients most commonly present with dysphagia to solids and liquids, regurgitation, and occasional chest pain with or without weight loss.', '3': 'High-resolution manometry has identified 3 subtypes of achalasia distinguished by pressurization and contraction patterns.', '4': 'Endoscopic findings of retained saliva with puckering of the gastroesophageal junction or esophagram findings of a dilated esophagus with bird beaking are important diagnostic clues.', '5': 'In this American College of Gastroenterology guideline, we used the Grading of Recommendations Assessment, Development and Evaluation process to provide clinical guidance on how best to diagnose and treat patients with achalasia.'}\n",
            "9: abstract: {'1': 'Dysphagia is common but may be underreported.', '2': 'Specific symptoms, rather than their perceived location, should guide the initial evaluation and imaging.', '3': 'Obstructive symptoms that seem to originate in the throat or neck may actually be caused by distal esophageal lesions.', '4': 'Oropharyngeal dysphagia manifests as difficulty initiating swallowing, coughing, choking, or aspiration, and it is most commonly caused by chronic neurologic conditions such as stroke, Parkinson disease, or dementia.', '5': 'Symptoms should be thoroughly evaluated because of the risk of aspiration.', '6': 'Patients with esophageal dysphagia may report a sensation of food getting stuck after swallowing.', '7': 'This condition is most commonly caused by gastroesophageal reflux disease and functional esophageal disorders.', '8': 'Eosinophilic esophagitis is triggered by food allergens and is increasingly prevalent; esophageal biopsies should be performed to make the diagnosis.', '9': 'Esophageal motility disorders such as achalasia are relatively rare and may be overdiagnosed.', '10': 'Opioid-induced esophageal dysfunction is becoming more common.', '11': 'Esophagogastroduodenoscopy is recommended for the initial evaluation of esophageal dysphagia, with barium esophagography as an adjunct.', '12': 'Esophageal cancer and other serious conditions have a low prevalence, and testing in low-risk patients may be deferred while a four-week trial of acid-suppressing therapy is undertaken.', '13': 'Many frail older adults with progressive neurologic disease have significant but unrecognized dysphagia, which significantly increases their risk of aspiration pneumonia and malnourishment.', '14': 'In these patients, the diagnosis of dysphagia should prompt a discussion about goals of care before potentially harmful interventions are considered.', '15': 'Speech-language pathologists and other specialists, in collaboration with family physicians, can provide structured assessments and make appropriate recommendations for safe swallowing, palliative care, or rehabilitation.'}\n",
            "10: abstract: {'1': 'The local, systemic, and referred causes of finger pain are generally recognizable by historical features and physical examination findings, although radiographs and laboratory evaluation are often required to support the diagnostic impression.', '2': 'Most minor traumatic causes of finger pain require only conservative management, including immobilization followed by exercise.', '3': 'Infectious causes of finger pain include cellulitis, tendinitis, paronychia, felon, and infectious emboli, which generally require antibiotics with or without drainage.', '4': 'Certain patients with finger pain resulting from infection should be referred to a hand surgeon.', '5': 'Vascular and ischemic causes of finger pain represent true emergencies, because tissue viability is dependent on prompt intervention.', '6': 'Whereas any sensory neuropathy may present with finger pain, carpal tunnel syndrome is among the most common.', '7': 'Systemic rheumatic disease, such as rheumatoid arthritis or vasculitis, may begin with finger pain.', '8': 'In addition, such pain may be the first manifestation of a serious systemic illness, as in hypertrophic pulmonary osteoarthropathy.', '9': 'Reflex sympathetic dystrophy is an example of referred pain, presumably by way of neural mechanisms.', '10': 'Certain infectious, traumatic, and ischemic causes of finger pain must be diagnosed promptly to avoid significant morbidity; depending upon the cause of the symptoms, referral to a hand surgeon, rheumatologist, or neurologist may be appropriate.', '11': 'Symptomatic and functional improvement may also be hastened by the input of an occupational therapist.'}\n",
            "10: abstract: {'1': 'Objective: To identify through case study the presentation and possible pathophysiological cause of complex regional pain syndrome and its preferential response to stellate ganglion blockade.', '2': 'Setting: Complex regional pain syndrome can occur in an extremity after minor injury, fracture, surgery, peripheral nerve insult or spontaneously and is characterised by spontaneous pain, changes in skin temperature and colour, oedema, and motor disturbances.', '3': 'Pathophysiology is likely to involve peripheral and central components and neurological and inflammatory elements.', '4': 'There is no consistent approach to treatment with a wide variety of specialists involved.', '5': 'Diagnosis can be difficult, with over-diagnosis resulting from undue emphasis placed upon pain disproportionate to an inciting event despite the absence of other symptoms or under-diagnosed when subtle symptoms are not recognised.', '6': 'The International Association for the Study of Pain supports the use of sympathetic blocks to reduce sympathetic nervous system overactivity and relieve complex regional pain symptoms.', '7': 'Educational reviews promote stellate ganglion blockade as beneficial.', '8': 'Three blocks were given at 8, 10 and 13 months after the initial injury under local anaesthesia and sterile conditions.', '9': 'Physiotherapeutic input was delivered under block conditions to maximise joint and tissue mobility and facilitate restoration of function.', '10': 'Conclusion: This case demonstrates the need for practitioners from all disciplines to be able to identify the clinical characteristics of complex regional pain syndrome to instigate immediate treatment and supports the notion that stellate ganglion blockade is preferable to upper limb intravenous regional anaesthetic block for refractory index finger pain associated with complex regional pain syndrome.'}\n",
            "10: abstract: {'1': 'Background and aims: In previous studies, we successfully applied Low Level Laser Therapy (LLLT) in patients with non-specific chronic pain of the shoulder joint and lower back.', '2': 'The purpose of the present study was to assess the effectiveness of LLLT for chronic joint pain of the elbow, wrist, and fingers.', '3': 'Subjects and methods: Nine male and 15 female patients with chronic joint pain of the elbow, wrist, or fingers, who were treated at the rehabilitation outpatient clinic at our hospital from April, 2007 to March, 2009 were enrolled in the study.', '4': 'We used a 1000 mW semiconductor laser device.', '5': 'Each tender point and three points around it were irradiated with laser energy.', '6': 'Each point was irradiated twice for 20 s per treatment, giving a total of three minutes for all 4 points.', '7': 'Patients visited the clinic twice a week, and were evaluated after four weeks of treatment.', '8': 'Pain was evaluated with a Visual Analogue Scale (VAS).', '9': \"Statistical analysis of the VAS scores after laser irradiation was performed with Wilcoxon's signed rank sum test, using SPSS Ver.17.\", '10': 'Results: All VAS scores were totaled and statistically analyzed.', '11': 'The average VAS score before irradiation was 59.2±12.9, and 33.1±12.2 after the irradiation, showing a significant improvement in VAS score (p<0.001) after treatment.', '12': 'The treatment effect lasted for about one and a half days in the case of wrist pain, epicondylitis lateralis (tennis elbow), and carpal tunnel syndrome.', '13': 'In other pain entities, it lasted for about three to fifteen hours.', '14': 'No change in the range of motion (ROM) was seen in any of the 24 subjects.', '15': 'Conclusion: We concluded that LLLT at the wavelength and parameters used in the present study was effective for chronic pain of the elbow, wrist, and fingers.'}\n",
            "10: abstract: {'1': 'Upper extremity neuropathic pain states greatly impact patient functionality and quality of life, despite appropriate surgical intervention.', '2': 'This article focuses on the advanced therapies that may improve pain care, including advanced treatment strategies that are available.', '3': 'The article also surveys therapies on the immediate horizon, such as spinal cord stimulation, peripheral nerve stimulation, and dorsal root ganglion spinal cord stimulation.', '4': 'As these therapies evolve, so too will their placement within the pain care algorithm grounded by a foundation of evidence to improve patient safety and management of patients with difficult neuropathic pain.'}\n",
            "10: abstract: {'1': 'Background: Hand osteoarthritis (OA) is a prevalent joint disease that may lead to pain, stiffness and problems in performing hand-related activities of daily living.', '2': 'Currently, no cure for OA is known, and non-pharmacological modalities are recommended as first-line care.', '3': 'A positive effect of exercise in hip and knee OA has been documented, but the effect of exercise on hand OA remains uncertain.', '4': \"Authors' conclusions: When we pooled results from five studies, we found low-quality evidence showing small beneficial effects of exercise on hand pain, function and finger joint stiffness.\", '5': 'Estimated effect sizes were small, and whether they represent a clinically important change may be debated.', '6': 'One study reported quality of life, and the effect is uncertain.', '7': 'Three studies reported on adverse events, which were very few and were not severe.'}\n",
            "10: abstract: {'1': 'When patients present with acute or chronic hand and/or finger pain after an injury, try placing a pencil first over and then under the proximal phalanx of the finger that is generating the pain.', '2': 'Ask the patient to flex and extend the fingers several times.', '3': 'Putting the affected metacarpal phalangeal (MP) joint more relatively flexed or extended than the other MP joints will often take away the pain with active movement with the pencil in place.', '4': 'When this happens, our hand therapist builds a relative motion splint that simulates the effect of the pencil.', '5': 'These are very functional splints that patients wear 24 hours a day, 7 days a week.', '6': 'Most people can work with these splints on.'}\n",
            "10: abstract: {'1': 'Background: Rheumatoid arthritis (RA) is characterized by pain, functional disability, poor quality of life (QoL), high socioeconomic impact, and annual costs of over $56 billion in the United States.', '2': 'Acupuncture (AC) is widely in use; however, studies show severe methodological shortcomings, did not consider the functional diagnosis for the allocation of acupoints and their results showed no differences between verum and control groups.', '3': 'Objective: The authors aimed to objectively assess the safety and efficacy of AC treatments for RA.', '4': 'Methods: 105 RA patients with a functional diagnosis of a \"Pivot syndrome\" or \"Turning Point syndrome\" were randomly assigned to (1) verum-AC (verum acupoints), (2) control-AC (sham acupoints-points outside of the conduits/meridians and of the extra-conduits), or (3) waiting list (each group n = 35).', '5': 'AC groups experienced the exact same number, depth, and stimulation of needles.', '6': 'Assessments took place before and 5 min after AC with follow-ups over 4 weeks.', '7': 'Results: (1) Verum-AC significantly improved self-reported pain (Z = -5.099, p < 0.001) and pressure algometry (Z = -5.086, p < 0.001); hand grip strength (Z = -5.086, p < 0.001) and arm strength (Z = -5.086, p < 0.001); health status improved significantly (p < 0.001, Z = -4.895); QoL improved significantly in 7/8 survey domains; and number of swollen joints (Z = -2.862, p = 0.004) and tender joints (Z = -3.986, p < 0.001) significantly decreased.', '8': '(2) Control-AC showed no significant changes, except in self-reported pain improvement.', '9': '(3) Waiting list group showed an overall worsening.', '10': 'Conclusion: This is the first double-blind controlled study on AC in RA of the hand that objectively and specifically assesses positive effects supporting its integration in rheumatology.', '11': 'Acupoint allocation according to Chinese Medicine functional diagnoses is extremely relevant to assess AC effectiveness in a patient group primarily defined by a \"western\" medicine diagnosis.', '12': 'Based on clear allocation criteria for acupoints, the authors minimized the possible bias of unspecific and suggestive effects on the control group, showed the specific effects of the points chosen, improved efficacy, and identified an evidence base for AC.'}\n",
            "10: abstract: {'1': 'Pain and a loss of feeling in your thumb, index finger, middle finger, and part of your ring finger may be a sign of carpal tunnel syndrome.', '2': 'This syndrome and the pain, numbness, tingling, and weakness in your hand that result from it are caused by pressure on the median nerve as it travels through the carpal tunnel.', '3': 'Guidelines published in the May 2019 issue of JOSPT make recommendations, based on best practices from the published literature, for evaluating, diagnosing, and treating carpal tunnel syndrome.', '4': 'For you as a patient, these guidelines outline the best rehabilitation treatment options based on the scientific research.', '5': 'Ultimately, the best care is a combination of the leading science, the clinical expertise of your health care provider, and your input as the patient.', '6': 'These guidelines help inform the first step in that process.', '7': 'Practical Advice: Physical therapists are well trained to assess and evaluate people with carpal tunnel syndrome.', '8': 'Although some patients (anywhere from 28% to 62%) recover without treatment, others (from 32% to 58%) get worse.', '9': 'A key to nonsurgical treatment shown to help those with carpal tunnel syndrome is the use of a night brace; a night brace should hold your wrist in a neutral position and only be worn for short-term symptom relief.', '10': 'If you have mild to moderate carpal tunnel syndrome, stretching exercises and the night brace can help, as can manual therapy of your cervical spine and upper extremity performed by a therapist.', '11': 'Education on the proper setup of your computer, especially the mouse, and how hard you strike the keyboard may also help control your symptoms of pain and loss of feeling.', '12': 'The literature review for these guidelines found that low-level laser therapy, thermal ultrasound, iontophoresis, and magnets provided no consistent benefit in treating carpal tunnel syndrome.', '13': 'If nonsurgical treatment does not help, you may need surgery.', '14': 'Your physical therapist can help guide your recovery, decreasing your symptoms.'}\n",
            "10: abstract: {'1': 'This compilation presents a comprehensive review of the literature on common chronic pain conditions of the hand.', '2': 'It briefly presents these common conditions with their biological background, diagnosis, and common management options.', '3': 'It then presents and compares the latest literature available for injection techniques to treat these diagnoses and compares the available evidence.', '4': 'Results: Hand pain is a common condition with 9.7% prevalence in men and 21.6% in women and can cause significant morbidity and disability.', '5': 'It also carries a significant cost to the individuals and the healthcare system, totaling in $4 billion dollars in 2003.', '6': 'Injection therapy is an alternative when conservative treatment fails.', '7': 'Osteoarthritis is the most common chronic hand pain syndrome and affects about 16% of the population.', '8': 'Its mechanism is largely mechanic, and as such, there is controversy if steroid injections are of benefit.', '9': 'Hyaluronic acid (HA) appears to provide substantial relief of pain and may increase functionality.', '10': 'More studies of HA are required to make a definite judgment on its efficacy.', '11': 'Similarly, steroid ganglion cyst injection may confer little benefit.', '12': 'Carpal tunnel syndrome is a compressive neuropathy, and only temporarily relieved with injection therapy.', '13': 'US-guidance provides significant improvement and, while severe cases may still require surgery, can provide a valuable bridge therapy to surgery when conservative treatment fails.', '14': 'Similar bridging treatments and increased efficacy under US-guidance are effective for stenosing tenosynovitis (\"trigger finger\"), though, interestingly, inflammatory background is associated with decreased effect in this case.', '15': 'When the etiology of the pain is inflammatory, such as in RA, corticosteroid (CS) injections provide significant pain relief and increased functionality.', '16': 'They do not, however, change the course of disease (unlike DMARDs).', '17': 'Another such example is De-Quervain tenosynovitis that sees good benefit from CS injections, and an increased efficacy with US-guidance, and similarly are CS injections for gout.', '18': \"For Raynaud's phenomenon, Botox injections have encouraging results, but more studies are needed to determine safety and efficacy, as well as the possible difference in effect between primary and secondary Raynaud's.\", '19': 'Conclusions: Chronic hand pain is a prevalent and serious condition and can cause significant morbidity and disability and interferes with independence and activities of daily living.', '20': 'Conservative treatment remains the first line of treatment; however, when first-line treatments fail, steroid injections can usually provide benefit.', '21': 'In some cases, Hyaluronic acid or Botox may also be beneficial.', '22': 'US-guidance is increasing in hand injection and almost ubiquitously provides safer, more effective injections.', '23': 'Hand surgery remains the alternative for refractory pain.'}\n",
            "10: abstract: {'1': 'Importance: Hand osteoarthritis is a musculoskeletal problem that is associated with hand pain, stiffness, functional limitation, decreased grip strength, and reduced quality of life.', '2': 'Objective: To evaluate the effectiveness of nighttime orthoses on the second or third finger of the dominant hand in controlling pain in women with symptomatic osteoarthritis (OA) in the interphalangeal joint.', '3': 'Design: Randomized controlled trial.', '4': 'Setting: Outpatient clinic.', '5': \"Participants: Fifty-two women with symptomatic OA and presence of Heberden's and Bouchard's nodes, allocated randomly to the intervention group or the control group.\", '6': 'Intervention: The intervention group used a nighttime orthosis on the second or third finger of the dominant hand.', '7': 'Both groups participated in an educational session.', '8': 'Outcomes and measures: The following parameters were measured: pain (numerical rating scale, Australian/Canadian Osteoarthritis Hand Index), grip and pinch strength, function (Cochin Hand Functional Scale), and manual performance (Moberg Pick Up Test).', '9': 'Results: The intervention group showed a statistically significant improvement in pain (p < .001) and hand function.', '10': \"The improvement in pain correlated with Cochin Hand Functional Scale scores and the absence of Bouchard's nodes in the third finger, which are predictors of the best prognosis for treatment with a nighttime orthosis.\", '11': 'Conclusions and relevance: This study demonstrates that nighttime orthoses are effective in reducing pain and lead to improvement in hand function in women with hand OA.', '12': 'They are therefore specifically recommended for nonpharmacological treatment of hand OA.', '13': 'What this article adds: Orthoses can be considered, together with manual exercises and joint protection, as an intervention to reduce symptoms and improve hand function in people with hand OA.', '14': 'This study is an important step in empowering occupational therapists to determine appropriate and effective intervention for clients with OA.'}\n",
            "11: abstract: {'1': 'Treatment of PDH deficiency rarely influences the course of the disease.', '2': 'It is usually possible to reverse or minimize systemic lactic acid accumulation by giving a high fat/low carbohydrate \"ketogenic\" diet, but this does not alleviate the neurological symptoms as structural damage in the brain is present from before birth and many patients do not have significant metabolic problems.', '3': 'There is some evidence that dichloroacetate (which inhibits the specific PDH kinase and thereby activates any residual functioning complex) will also reduce the metabolic disturbance in some patients, but, again, this is rarely accompanied by any objective improvement in neurological performance.', '4': 'A more favorable outcome can be expected in the extremely rare patients with a thiamine responsive form of the disease and, for this reason, a short therapeutic trial of thiamine is worth trying in all cases.'}\n",
            "11: abstract: {'1': 'We determined the ability of self-complementary adeno-associated virus (scAAV) vectors to deliver and express the pyruvate dehydrogenase E1alpha subunit gene (PDHA1) in primary cultures of skin fibroblasts from 3 patients with defined mutations in PHDA1 and 3 healthy subjects.', '2': 'Cells were transduced with scAAV vectors containing the cytomegalovirus promoter-driven enhanced green fluorescent protein (EGFP) reporter gene at a vector:cell ratio of 200.', '3': 'Transgene expression was measured 72h later.', '4': 'The transduction efficiency of scAAV2 and scAAV6 vectors was 3- to 5-fold higher than that of the other serotypes, which were subsequently used to transduce fibroblasts with wild-type PDHA1 cDNA under the control of the chicken beta-action (CBA) promoter at a vector:cell ratio of 1000.', '5': 'Total PDH-specific activity and E1alpha protein expression were determined 10 days post-transduction.', '6': 'Both vectors increased E1alpha expression 40-60% in both control and patient cells, and increased PDH activity in two patient cell lines.', '7': 'We also used dichloroacetate (DCA) to maximally activate PDH through dephosphorylation of E1alpha.', '8': 'Exposure for 24h to 5mM DCA increased PDH activity in non-transduced control (mean 37% increase) and PDH deficient (mean 44% increase) cells.', '9': 'Exposure of transduced patient fibroblasts to DCA increased PDH activity up to 90% of the activity measured in untreated control cells.', '10': 'DCA also increased expression of E1alpha protein and, to variable extents, that of other components of the PDH complex in both non-transduced and transduced cells.', '11': 'These data suggest that a combined gene delivery and pharmacological approach may hold promise for the treatment of PDH deficiency.'}\n",
            "11: abstract: {'1': 'Mitochondria are the energy-producing organelles of the cell, generating ATP via oxidative phosphorylation mainly by using pyruvate derived from glycolytic processing of glucose.', '2': 'Ketone bodies generated by fatty acid oxidation can serve as alternative metabolites for aerobic energy production.', '3': 'The ketogenic diet, which is high in fat and low in carbohydrates, mimics the metabolic state of starvation, forcing the body to utilize fat as its primary source of energy.', '4': 'The ketogenic diet is used therapeutically for pharmacoresistant epilepsy and for \"rare diseases\" of glucose metabolism (glucose transporter type 1 and pyruvate dehydrogenase deficiency).', '5': 'As metabolic reprogramming from oxidative phosphorylation toward increased glycolysis is a hallmark of cancer cells; there is increasing evidence that the ketogenic diet may also be beneficial as an adjuvant cancer therapy by potentiating the antitumor effect of chemotherapy and radiation treatment.'}\n",
            "11: abstract: {'1': 'Objectives: Our aime was to study the short- and long-term effects of ketogenic diet on the disease course and disease-related outcomes in patients with pyruvate dehydrogenase complex deficiency, the metabolic factors implicated in treatment outcomes, and potential safety and compliance issues.', '2': 'Methods: Pediatric patients diagnosed with pyruvate dehydrogenase complex deficiency in Sweden and treated with ketogenic diet were evaluated.', '3': 'Study assessments at specific time points included developmental and neurocognitive testing, patient log books, and investigator and parental questionnaires.', '4': 'A systematic literature review was also performed.', '5': 'Results: Nineteen patients were assessed, the majority having prenatal disease onset.', '6': 'Patients were treated with ketogenic diet for a median of 2.9 years.', '7': 'All patients alive at the time of data registration at a median age of 6 years.', '8': 'The treatment had a positive effect mainly in the areas of epilepsy, ataxia, sleep disturbance, speech/language development, social functioning, and frequency of hospitalizations.', '9': 'It was also safe-except in one patient who discontinued because of acute pancreatitis.', '10': 'The median plasma concentration of ketone bodies (3-hydroxybutyric acid) was 3.3 mmol/l.', '11': 'Poor dietary compliance was associated with relapsing ataxia and stagnation of motor and neurocognitive development.', '12': 'Results of neurocognitive testing are reported for 12 of 19 patients.', '13': 'Conclusion: Ketogenic diet was an effective and safe treatment for the majority of patients.', '14': 'Treatment effect was mainly determined by disease phenotype and attainment and maintenance of ketosis.'}\n",
            "11: abstract: {'1': 'Pyruvate dehydrogenase complex deficiency (PDCD) is a rare neurodegenerative disorder associated with abnormal mitochondrial metabolism.', '2': 'Structural brain abnormalities are common in PDCD.', '3': 'A case of a patient with PDCD with an unusual presentation is described.', '4': 'A 20-month-old boy with hypotonia and developmental delay, presented with hypoxia and respiratory distress due to bronchiolitis.', '5': 'During hospitalisation, he was prescribed PediaSure® feeds.', '6': 'Two days after starting these feeds, he developed respiratory arrest requiring intubation.', '7': 'His blood gas before arrest revealed lactate of 8.9 mmol/L despite normal haemodynamics.', '8': 'After stabilisation and a period of compulsory fasting, subsequent feeding with PediaSure® resulted in the recurrence of lactic acidosis.', '9': 'A metabolic workup revealed an elevated serum pyruvate level.', '10': 'Brain MRI was normal.', '11': 'Skeletal muscle biopsy confirmed PDCD.', '12': 'The most common cause of PDCD is a mutation in the X-linked PDHA1 gene.', '13': 'The severity of PDCD can range from neonatal death to more delayed onset of symptoms as in our index case.', '14': 'Normal brain MRI is reported in only 2% of patients with PDCD.', '15': 'There is no effective treatment for PDCD.', '16': \"In patients with proximal muscle weakness and feeding intolerance with glucose-containing feeds, the presence of lactic acidosis should raise the suspicion of PDCD irrespective of the patient's age and normal MRI.\"}\n",
            "11: abstract: {'1': 'Diets low in carbohydrates and proteins and enriched in fat stimulate the hepatic synthesis of ketone bodies (KB).', '2': 'These molecules are used as alternative fuel for energy production in target tissues.', '3': 'The synthesis and utilization of KB are tightly regulated both at transcriptional and hormonal levels.', '4': 'The nuclear receptor peroxisome proliferator activated receptor α (PPARα), currently recognized as one of the master regulators of ketogenesis, integrates nutritional signals to the activation of transcriptional networks regulating fatty acid β-oxidation and ketogenesis.', '5': 'New factors, such as circadian rhythms and paracrine signals, are emerging as important aspects of this metabolic regulation.', '6': 'However, KB are currently considered not only as energy substrates but also as signaling molecules.', '7': 'β-hydroxybutyrate has been identified as class I histone deacetylase inhibitor, thus establishing a connection between products of hepatic lipid metabolism and epigenetics.', '8': 'Ketogenic diets (KD) are currently used to treat different forms of infantile epilepsy, also caused by genetic defects such as Glut1 and Pyruvate Dehydrogenase Deficiency Syndromes.', '9': 'However, several researchers are now focusing on the possibility to use KD in other diseases, such as cancer, neurological and metabolic disorders.', '10': 'Nonetheless, clear-cut evidence of the efficacy of KD in other disorders remains to be provided in order to suggest the adoption of such diets to metabolic-related pathologies.'}\n",
            "11: abstract: {'1': 'Objectives: To report 2 additional cases of pyruvate dehydrogenase complex deficiency with reversible deep gray matter lesions following initiation of ketogenic diet and to perform a literature review of serial imaging in patients with pyruvate dehydrogenase complex.', '2': 'Methods: Clinical data on 3 previously unpublished cases of patients with pyruvate dehydrogenase complex deficiency and with serial magnetic resonance imagings (MRIs) before and after institution of ketogenic diet were reported.', '3': 'A systematic literature review was performed to search for published cases of patients with confirmed pyruvate dehydrogenase complex deficiency who underwent serial MRIs.', '4': 'Results: The 3 subjects in this series demonstrated clinical improvement on ketogenic diet.', '5': 'Two subjects showed reversal of some brain lesions on repeat MRI following initiation of ketogenic diet.', '6': 'Of the 21 published cases with serial MRIs, 13 patients underwent some form of treatment, and of this smaller subset 4 patients had repeat MRIs that showed definitive improvement.', '7': 'In both our described cases and those published in the literature, improvement occurred in lesions in the basal ganglia.', '8': 'Conclusions: In patients with pyruvate dehydrogenase complex deficiency, basal ganglia lesions on MRI are reversible with treatment in some cases and could serve as a biomarker for measuring response to treatment.'}\n",
            "11: abstract: {'1': 'The main source of energy for brain and other organs is glucose.', '2': 'To obtain energy for all tissue, glucose has to come through glycolysis; then as pyruvate it is converted to acetyl-CoA by pyruvate dehydrogenase complex (PDC) and finally enters citric acid cycle.', '3': 'What happens when one of these stages become disturb?', '4': 'Mutation in genes encoding subunits of PDC leads to pyruvate dehydrogenase deficiency.', '5': 'Abnormalities in PDC activity result in severe metabolic and brain malformations.', '6': 'For better understanding the development and mechanism of pyruvate dehydrogenase deficiency the murine model of this disease has been created.', '7': 'Studies on a murine model showed similar malformation in brain structures as in the patients suffered from pyruvate dehydrogenase deficiency such as reduced neuronal density, heterotopias of grey matter, reduced size of corpus callosum and pyramids.', '8': 'There is still no effective cure for PDC-deficiency.', '9': 'Promising therapy seemed to be ketogenic diet, which substitutes glucose to ketone bodies as a source of energy.', '10': 'Studies have shown that ketogenic diet decreases lactic acidosis and inhibits brain malformations, but not the mortality in early childhood.', '11': 'The newest reports say that phenylbutyrate increases the level of PDC in the brain, because it reduces the level of inactive form of PDH.', '12': 'Experiments on human fibroblast and zebra fish PDC-deficiency model showed that phenylbutyrate is promising cure to PDC-deficiency.', '13': 'This review summarizes the most important findings on the metabolic and morphological effects of PDC-deficiency and research for treatment therapy.'}\n",
            "11: abstract: {'1': 'Metabolic epilepsies arise in the context of rare inborn errors of metabolism (IEM), notably glucose transporter type 1 deficiency syndrome, succinic semialdehyde dehydrogenase deficiency, pyruvate dehydrogenase complex deficiency, nonketotic hyperglycinemia, and mitochondrial cytopathies.', '2': 'A common feature of these disorders is impaired bioenergetics, which through incompletely defined mechanisms result in a wide spectrum of neurological symptoms, such as epileptic seizures, developmental delay, and movement disorders.', '3': 'The ketogenic diet (KD) has been successfully utilized to treat such conditions to varying degrees.', '4': 'While the mechanisms underlying the clinical efficacy of the KD in IEM remain unclear, it is likely that the proposed heterogeneous targets influenced by the KD work in concert to rectify or ameliorate the downstream negative consequences of genetic mutations affecting key metabolic enzymes and substrates-such as oxidative stress and cell death.', '5': 'These beneficial effects can be broadly grouped into restoration of impaired bioenergetics and synaptic dysfunction, improved redox homeostasis, anti-inflammatory, and epigenetic activity.', '6': 'Hence, it is conceivable that the KD might prove useful in other metabolic disorders that present with epileptic seizures.', '7': 'At the same time, however, there are notable contraindications to KD use, such as fatty acid oxidation disorders.', '8': 'Clearly, more research is needed to better characterize those metabolic epilepsies that would be amenable to ketogenic therapies, both experimentally and clinically.', '9': 'In the end, the expanded knowledge base will be critical to designing metabolism-based treatments that can afford greater clinical efficacy and tolerability compared to current KD approaches, and improved long-term outcomes for patients.'}\n",
            "11: abstract: {'1': 'Background: The pyruvate dehydrogenase complex (PDC) catalyzes the irreversible decarboxylation of pyruvate into acetyl-CoA.', '2': 'PDC deficiency can be caused by alterations in any of the genes encoding its several subunits.', '3': 'The resulting phenotype, though very heterogeneous, mainly affects the central nervous system.', '4': 'The aim of this study is to describe and discuss the clinical, biochemical and genotypic information from thirteen PDC deficient patients, thus seeking to establish possible genotype-phenotype correlations.', '5': 'Results: The mutational spectrum showed that seven patients carry mutations in the PDHA1 gene encoding the E1α subunit, five patients carry mutations in the PDHX gene encoding the E3 binding protein, and the remaining patient carries mutations in the DLD gene encoding the E3 subunit.', '6': 'These data corroborate earlier reports describing PDHA1 mutations as the predominant cause of PDC deficiency but also reveal a notable prevalence of PDHX mutations among Portuguese patients, most of them carrying what seems to be a private mutation (p.R284X).', '7': 'The biochemical analyses revealed high lactate and pyruvate plasma levels whereas the lactate/pyruvate ratio was below 16; enzymatic activities, when compared to control values, indicated to be independent from the genotype and ranged from 8.5% to 30%, the latter being considered a cut-off value for primary PDC deficiency.', '8': 'Concerning the clinical features, all patients displayed psychomotor retardation/developmental delay, the severity of which seems to correlate with the type and localization of the mutation carried by the patient.', '9': 'The therapeutic options essentially include the administration of a ketogenic diet and supplementation with thiamine, although arginine aspartate intake revealed to be beneficial in some patients.', '10': 'Moreover, in silico analysis of the missense mutations present in this PDC deficient population allowed to envisage the molecular mechanism underlying these pathogenic variants.', '11': 'Conclusion: The identification of the disease-causing mutations, together with the functional and structural characterization of the mutant protein variants, allow to obtain an insight on the severity of the clinical phenotype and the selection of the most appropriate therapy.'}\n",
            "12: abstract: {'1': 'Bronchial hyperresponsiveness (BHR) as the main condition for the development of asthma may be modulated either by intrinsic or by extrinsic stimuli as well as by climatic and meteorologic factors.', '2': 'Proinflammatory mediators in combination with alterations of airway mucosa induce or amplify BHR.', '3': 'Upper airway viral infections, exposure to allergens in atopic subjects, chronic hyperplastic changes of the upper airways, airway irritants and analgesics are supposed to be the most likely asthma triggers in predisposed children and adults.', '4': 'There is the suggestion that BHR can be improved not only by treatment with steroidal and nonsteroidal antiinflammatory drugs but also by maritime climatotherapy.', '5': 'The latter could be the result not only of the reduction of inhalative irritants, e.g. of allergen concentration, but also by the involvement or more complex mechanisms.', '6': 'Possible theoretic approaches and hypotheses regarding the mode of action of maritime climatic cures are discussed.', '7': 'First preliminary results obtained in a mediterranean region have demonstrated a negative impact of metereologic events like passages of cold weather fronts or increase of wind velocity on the course of asthma disease.', '8': 'An improvement of BHR assessed by histamine challenge test has been observed at the end of climatotherapy in the Baltic sea area.', '9': 'Prospective studies about asthma prevention in subjects at risk with BHR and atopy that have been starting should contribute to the evaluation of the therapeutic effects and the prognostic importance of maritime climatotherapy for getting exact scientific indications for climatotherapy in patients with bronchial asthma.'}\n",
            "12: abstract: {'1': 'With the exception, perhaps, of measures for the avoidance of infrequent forms of asthma caused by very specific types of exposure (e.g., occupational or aspirin-induced asthma), no single action has been irrefutably demonstrated to decrease the risk of the development of persistent asthma in persons who do not already have the disease.'}\n",
            "12: abstract: {'1': 'The National Disease Management Program (NDM Program) represents the basic content of structured, cross-sectoral healthcare.', '2': 'In particular, the NDM Program is directed towards coordinating different disciplines and areas of healthcare.', '3': 'The recommendations are developed through interdisciplinary consensus of the scientific medical societies on the basis of the best available evidence.', '4': 'Within this scope the scientific medical societies concerned with the prevention, diagnosis, therapy and rehabilitation of asthma consented upon a National Disease Management Guideline for Asthma in 2005.', '5': 'Among other things, the following cornerstones of asthma prevention were agreed upon: Breastfeeding and non-smoking were suggested as primary prevention measures for (expectant) parents.', '6': 'With respect to secondary prevention, recommendations have been made for allergen avoidance, active/passive smoking and immunotherapy.', '7': 'Regarding tertiary prevention, position statements on vaccination and specific immunotherapy are developed.', '8': 'The present paper presents both the original texts of the recommendations and the evidence underlying them.'}\n",
            "12: abstract: {'1': 'Purpose of review: The prevalence of asthma is increasing in many parts of the world, particularly in developed countries.', '2': 'The present review focuses on recent literature regarding asthma prevention in childhood.', '3': 'Recent findings: Several environmental exposures in infancy or early childhood are associated with reduced prevalence of asthma, but the mechanisms leading to these associations remain unknown.', '4': 'Recent studies have demonstrated limited success in the prevention of asthma or asthma symptoms with the use of asthma medications, once the therapy is discontinued.', '5': 'Immunotherapy offers another strategy for asthma prevention, and groups treated with this intervention have demonstrated reduced atopy and asthma.', '6': 'Several multi-interventional trials have demonstrated a reduced asthma symptom burden but have not demonstrated significant differences in objective measures such as lung function or bronchial hyper-responsiveness between intervention groups.', '7': 'Summary: The most promising asthma prevention strategies to date have been those that use a multi-interventional approach employing both dietary and environmental manipulations.', '8': 'More research is needed to assess the long-term follow-up of multi-interventional trials and to evaluate novel intervention strategies in the primary or secondary prevention of asthma in childhood.'}\n",
            "12: abstract: {'1': 'Asthma, which typically begins in childhood and is the most common chronic disease of childhood, has reached epidemic proportions.', '2': 'Asthma is associated with gene-environment interactions, and there is consensus that a \"window of opportunity\" exists early in life when environmental factors may influence its development.', '3': 'This review considers biologic and sociologic factors in the development of allergy and asthma.', '4': 'Meta-analysis of studies demonstrates that monoallergen reduction does not impact asthma prevention.', '5': 'However, multifaceted allergen reduction studies have shown clinical benefit.', '6': 'We propose that allergic diseases, including asthma, represent a dysfunctional interaction with our environment and that the increasing prevalence of asthma and allergy herald increased population risk for the development of other inflammatory and autoimmune diseases.', '7': 'Better understanding of the complex factors for asthma and allergies may provide insight into many other chronic complex diseases.'}\n",
            "12: abstract: {'1': 'Asthma is the most common chronic disease of childhood and, in the latter part of the 20th century, reached epidemic proportions.', '2': 'Asthma is generally believed to result from gene-environment interactions.', '3': \"There is consensus that a 'window of opportunity' exists during pregnancy and early in life when environmental factors may influence its development.\", '4': 'We review multiple environmental, biologic and sociologic factors that may be important in the development of asthma.', '5': 'Meta-analyses of studies have demonstrated that multifaceted interventions are required in order to develop asthma prevention.', '6': 'Multifaceted allergen reduction studies have shown clinical benefits.', '7': 'Asthma represents a dysfunctional interaction with our genes and the environment to which they are exposed, especially in fetal and early infant life.', '8': 'The increasing prevalence of asthma also may be an indication of increased population risk for the development of other chronic non-communicable autoimmune diseases.', '9': 'This review will focus on the factors which may be important in the primary prevention of asthma.', '10': 'Better understanding of the complex gene-environment interactions involved in the development of asthma will provide insight into personalized interventions for asthma prevention.'}\n",
            "12: abstract: {'1': 'Lower respiratory tract infections by respiratory syncytial virus (RSV) are the foremost cause of infant hospitalization and are implicated in lasting pulmonary impairment and the development of asthma.', '2': 'Neutrophils infiltrate the airways of pediatric patients with RSV-induced bronchiolitis in vast numbers: approximately 80% of infiltrated cells are neutrophils.', '3': 'However, why neutrophils are recruited to the site of viral respiratory tract infection is not clear.', '4': 'In this review we discuss the beneficial and pathologic contributions of neutrophils to the immune response against RSV infection.', '5': 'Neutrophils can limit viral replication and spread, as well as stimulate an effective antiviral adaptive immune response.', '6': 'However, low specificity of neutrophil antimicrobial armaments allows for collateral tissue damage.', '7': 'Neutrophil-induced injury to the airways during the delicate period of infant lung development has lasting adverse consequences for pulmonary architecture and might promote the onset of asthma in susceptible subjects.', '8': 'We suggest that pharmacologic modulation of neutrophils should be explored as a viable future therapy for severe RSV-induced bronchiolitis and thereby prevent the inception of subsequent asthma.', '9': 'The antiviral functions of neutrophils suggest that targeting of neutrophils in patients with RSV-induced bronchiolitis is best performed under the umbrella of antiviral treatment.'}\n",
            "12: abstract: {'1': 'Purpose of review: This article presents recent findings and perspectives on the relationship between early-life respiratory infections and asthma inception, and discusses emerging concepts on strategies that target these infectious agents for asthma prevention.', '2': 'Recent findings: Cumulative evidence supports the role of early-life viral infections, especially respiratory syncytial virus and human rhinovirus, as major antecedents of childhood asthma.', '3': 'These viruses may have different mechanistic roles in the pathogenesis of asthma.', '4': 'The airway microbiome and virus-bacteria interactions in early life have emerged as additional determinants of childhood asthma.', '5': 'Innovative strategies for the prevention of these early-life infections, or for attenuation of acute infection severity, are being investigated and may identify effective strategies for the primary and secondary prevention of childhood asthma.', '6': 'Summary: Early-life infections are major determinants of asthma development.', '7': 'The pathway from early-life infections to asthma is the result of complex interactions between the specific type of the virus, genetic, and environmental factors.', '8': 'Novel intervention strategies that target these infectious agents have been investigated in proof-of-concepts trials, and further study is necessary to determine their capacity for asthma prevention.'}\n",
            "12: abstract: {'1': 'It has been 15 years since the first prevention of allergy (PAT) study was published, exploring the dream of the allergist: determining whether allergen-specific immunotherapy (AIT) can alter the natural course of disease and prevent the development of asthma in children with seasonal allergic rhino-conjunctivitis.', '2': 'Two hundred five children aged 6 to 14 years with grass and/or birch pollen allergy were randomized to receive either allergen-specific injection immunotherapy with aluminum-adsorbed native allergen extract subcutaneous immunotherapy for 3 years or to an open control group.', '3': 'Subjects had moderate-to-severe hay fever symptoms, but none of them reported asthma at the time of inclusion.', '4': 'Actively treated children had significantly fewer asthma symptoms after 3 years, as evaluated by clinical diagnosis (odds ratio, 2.52; P < .05).', '5': 'Methacholine bronchial provocation test results were significantly better in the active group.', '6': 'Thus a 3-year course of injection AIT in children with hay fever to grass, birch pollen, or both significantly reduced the risk of asthma.'}\n",
            "12: abstract: {'1': 'Several risk factors for asthma have been linked with exposures during pregnancy, making their true effects similarly hard to elucidate given the constraints of conducting research in this particular group, and the difficulty of interpreting any findings.', '2': 'A report published in Pediatrics outlined the effects of maternal and infant nutrition on the development of atopic disease (including asthma) in children, reflecting that multiple factors could act in concert to influence disease development.', '3': 'Maternal exposure to vitamin D has been investigated as a risk factor for childhood asthma and wheeze, with conflicting findings; several studies have reported that vitamin D could protect against asthma attacks or prevent worsening asthma symptoms.', '4': 'Many studies have investigated such associations with risk of disease, but the reporting in the media of the study findings often leaves much to be desired in terms of nuance and balance.'}\n",
            "13: abstract: {'1': 'Background: For patients presenting with atrial fibrillation of only a few weeks duration, the use of transesophageal echocardiography offers the opportunity to markedly abbreviate the duration of atrial fibrillation before cardioversion.', '2': 'We sought to determine if the shorter duration of atrial fibrillation allowed by a transesophageal echocardiography strategy had an impact on the recurrence of atrial fibrillation and prevalence of sinus rhythm during the first year following cardioversion.', '3': 'Methods: Transesophageal echocardiography was attempted in 539 patients (292 men, 247 women; 71.6 +/- 13.0 years.) with atrial fibrillation > or =2 days (66.1% <3 weeks) or of unknown duration before elective cardioversion of atrial fibrillation.', '4': 'Therapeutic anticoagulation at the time of transesophageal echocardiography was present in 94.6% of patients, and 73.4% of subjects were discharged on warfarin.', '5': 'Results: Atrial thrombi were identified in 70 (13.1%) patients.', '6': 'Successful cardioversion in 413 patients without evidence of atrial thrombi was associated with clinical thromboembolism in 1 patient (0.24%, 95% confidence interval: 0.0--0.8%).', '7': 'In patients with atrial fibrillation <3 weeks at the time of cardioversion (a duration incompatible with conventional therapy of 3 to 4 weeks of warfarin before cardioversion), the 1-year atrial fibrillation recurrence rate was lower (41.1% vs. 57.9%, P <0.01), and the prevalence of sinus rhythm at 1 year was increased (65.8% vs. 51.3%, P <0.03).', '8': 'No other clinical or echocardiographic index was associated with recurrence of atrial fibrillation or sinus rhythm at 1 year.', '9': 'Conclusions: Early cardioversion facilitated by transesophageal echocardiography has a favorable safety profile and provides the associated benefit of reduced recurrence of atrial fibrillation for patients in whom the duration of atrial fibrillation is <3 weeks.'}\n",
            "13: abstract: {'1': 'In the treatment of arrhythmia, beta-blockers are mainly used to regulate the heart rate.', '2': 'However, beta-blockers are also known as drugs with an antiarrhythmic effect due to the suppression of sympathetic activity.', '3': 'We evaluated the antiarrhythmic effects of a highly selective beta(1)-blocker, bisoprolol, in patients with diurnal paroxysmal atrial fibrillation (P-AF).', '4': 'A total of 136 patients with symptomatic diurnal P-AF were enrolled.', '5': 'Patients were divided into a diurnal-specific P-AF group and a diurnal & nocturnal P-AF group, as well as into a bisoprolol single use group and a combined use group with an antiarrhythmic drug.', '6': 'The effects of bisoprolol were evaluated in 3 categories: subjective symptom improvement, quality of life (QOL) improvement, and elimination of P-AF episode in Holter electrocardiograms (ECGs).', '7': 'For patients with effective treatment, a long-term effect up to 24 months was evaluated.', '8': 'Five patients (3.7%) discontinued bisoprolol due to side effects.', '9': 'Following administration of bisoprolol, 109 patients (80%) experienced subjective symptom improvement, 103 patients (76%) experienced QOL improvement, and elimination of P-AF episodes in ECGs was observed in 84 patients (62%).', '10': 'The elimination rate of P-AF episodes in ECGs was higher in the diurnal P-AF group than in the diurnal & nocturnal P-AF group (P=0.042).', '11': 'There was no significant difference between the bisoprolol single use group and the combined use group.', '12': 'A long-term suppressive effect by bisoprolol was observed in 70 of 83 patients (84%).', '13': 'The results demonstrate that bisoprolol has an antiarrhythmic effect against sympathetic diurnal P-AF, improving subjective symptoms and QOL and eliminating P-AF episodes in ECGs.'}\n",
            "13: abstract: {'1': 'Background: Dronedarone is a new multichannel blocker for atrial fibrillation (AF) previously demonstrated to have both rhythm and rate control properties in paroxysmal and persistent AF.', '2': 'The Efficacy and safety of dRonedArone for The cOntrol of ventricular rate during atrial fibrillation (ERATO) trial assessed the efficacy of dronedarone in the control of ventricular rate in patients with permanent AF, when added to standard therapy.', '3': 'Methods: In this randomized, double-blind, multinational trial, dronedarone, 400 mg twice a day (n = 85), or matching placebo (n = 89) was administered for 6 months to adult patients with permanent AF, in addition to standard therapy.', '4': 'The primary end point was the change in mean ventricular rate between baseline and day 14, as assessed by 24-hour Holter.', '5': 'Ventricular rate was also assessed during submaximal and maximal exercise.', '6': 'Results: Dronedarone significantly decreased mean 24-hour ventricular rate.', '7': 'Compared with placebo, the mean treatment effect at day 14 was a reduction of 11.7 beats per minute (beat/min; P < .0001).', '8': 'Comparable reductions were sustained throughout the 6-month trial.', '9': 'During maximal exercise and compared to placebo, there was a mean reduction of 24.5 beat/min (P < .0001), without any reduction in exercise tolerance as measured by maximal exercise duration.', '10': 'The effects of dronedarone were additive to those of other rate-control agents, including beta-blockers, calcium antagonists, and digoxin.', '11': 'Dronedarone was well tolerated, with no organ toxicities or proarrhythmia.', '12': 'Conclusion: In addition to its reported rhythm-targeting and rate-targeting therapeutic actions in paroxysmal and persistent AF, dronedarone improves ventricular rate control in patients with permanent AF.', '13': 'Dronedarone was well tolerated with no evidence of organ toxicities or proarrhythmias in this short-term study.'}\n",
            "13: abstract: {'1': 'Obstructive sleep apnea syndrome (OSA) is associated with different types of cardiac arrhythmias.', '2': 'The original studies, concentrated mostly on nocturnal brady- and tachyarrhythmias.', '3': 'More recent studies documented high prevalence of atrial fibrillation (AF) and its association with obesity and other risk factors for AF.', '4': 'In addition, continuous positive airway pressure (CPAP) prevents recurrence of AF after cardioversion.', '5': 'In, OSA the highest risk for sudden death is at night in comparison to general population most of who die suddenly between six and noon.', '6': 'This observation suggests that hypoxia or other nocturnal abnormality, trigger sudden death.', '7': 'An important recent finding is the beneficial effect of CPAP on sudden death.', '8': 'The role of pacing in OSA remains controversial.', '9': 'In general, pacemaker therapy is not indicated in patients with nocturnal bradyarrhythmias.', '10': 'However, some authors recommend pacing in those with severe nocturnal bradyarrhythmias not tolerating or not responding to CPAP.', '11': 'According to a recent study, 59% of patients with permanent pacemaker have OSA.'}\n",
            "13: abstract: {'1': 'Circadian variation in atrial fibrillation (AF) frequency is explored in this paper by employing recent advances in signal processing.', '2': 'Once the AF frequency has been estimated and tracked by a hidden Markov model approach, the resulting trend is analyzed for the purpose of detecting and characterizing the presence of circadian variation.', '3': 'With cosinor analysis, the results show that the short-term variations in the AF frequency exceed the variation that may be attributed to circadian.', '4': 'Using the autocorrelation method, circadian variation was found in 13 of 18 ambulatory ECG recordings (Holter) acquired from patients with long-standing persistent AF.', '5': 'Using the ensemble correlation method, the highest AF frequency usually occurred during the afternoon, whereas the lowest usually occurred during late night.', '6': 'It is concluded that circadian variation is present in most patients with long-standing persistent AF though the short-term variation in the AF frequency is considerable and should be taken into account.'}\n",
            "13: abstract: {'1': 'Objective: Nighttime onset of atrial fibrillation (AF) is sometimes associated with obstructive sleep apnea accompanied by a characteristic heart rate (HR) pattern known as cyclical variation of HR.', '2': 'The aim of this study was to evaluate whether cyclical variation of HR is prevalent in patients with nocturnal AF.', '3': 'Methods: The subjects consisted of 34 patients (68±12 years) with paroxysmal AF, including 14 patients with daytime AF and 20 patients with nighttime AF.', '4': 'Holter electrocardiogram (ECGs) were examined for the presence of cyclical variation in HR and to quantify the HR variability within the 40-minute period preceding each AF episode using a fast Fourier transform (FFT) methods.', '5': 'Results: Cyclical variation in HR was observed in 12 of 20 (60%) nighttime episodes and in only two of 14 (14%) daytime episodes.', '6': 'The prevalence of cyclical variation in HR was significantly greater in the nighttime AF episodes than in the daytime AF episodes (Chi=5.34, p<0.05).', '7': 'The mean frequency of cyclical variation in HR was 0.015±0.003 Hz.', '8': 'The mean power of the VLF (very low frequency) component (0.008-0.04 Hz) before the onset of AF was significantly greater in the nighttime AF episodes than in the daytime AF episodes.', '9': 'Among the nighttime AF episodes, the power of the HF (high frequency), LF (low frequency) and very low frequency (VLF) components increased significantly just before the onset of AF compared with that observed 40 minutes before onset.', '10': 'Conclusion: The high prevalence of cyclical variation in HR observed before nocturnal AF episodes suggests that sleep apnea may play a role in the onset of nighttime AF.'}\n",
            "13: abstract: {'1': 'Introduction: Sleep apnea-hypopnea syndrome (SAHS) is one of the extracardiac reasons of atrial fibrillation (AF), and the prevalence of AF is high in SAHS-diagnosed patients.', '2': 'Nocturnal hypoxemia is associated with AF, pulmonary hypertension, and nocturnal death.', '3': 'The rate of AF recurrence is high in untreated SAHS-diagnosed patients after cardioversion (CV).', '4': 'In this study, we present a patient whose SAHS was diagnosed with an apnea test performed in the intensive care unit (ICU) and who did not develop recurrent AF after the administration of standard AF treatment and bi-level positive airway pressure (BiPAP).', '5': 'Case presentation: A 57-year-old male hypertensive Caucasian patient who was on medical treatment for 1.5 months for non-organic AF was admitted to the ICU because of high-ventricular response AF (170 per minute), and sinus rhythm was maintained during the CV that was performed two times every second day.', '6': 'The results of the apnea test performed in the ICU on the same night after the second CV were as follows: apnea-hypopnea index (AHI) of 71 per hour, minimum peripheral oxygen saturation (SpO2) of 67%, and desaturation period (SpO2 of less than 90%) of 28 minutes.', '7': 'The patient was discharged with medical treatment and nocturnal BiPAP treatment.', '8': 'The results of the apnea test performed under BiPAP on the sixth month were as follows: AHI of 1 per hour, desaturation period of 1 minute, and minimum SpO2 of 87%.', '9': 'No recurrent AF developed in the patient, and his medical treatment was reduced within 6 months.', '10': 'After gastric bypass surgery on the 12th month, nocturnal hypoxia and AF did not re-occur.', '11': 'Thus, BiPAP and medical treatments were ended.', '12': 'Conclusions: SAHS can be diagnosed by performing an apnea test in the ICU.', '13': 'SAHS should be investigated in patients developing recurrent AF after CV.', '14': 'Recovery of nocturnal hypoxia may increase the success rate of standard AF treatment.'}\n",
            "13: abstract: {'1': 'Background: Paroxysmal atrial fibrillation (AF) can be caused by gain-of-function mutations in genes, encoding the cardiac potassium channel subunits KCNJ2, KCNE1, and KCNH2 that mediate the repolarizing potassium currents Ik1, Iks, and Ikr, respectively.', '2': 'Methods: Linkage analysis, whole-exome sequencing, and Xenopus oocyte electrophysiology studies were used in this study.', '3': 'Results: Through genetic studies, we showed that autosomal dominant early-onset nocturnal paroxysmal AF is caused by p.S447R mutation in KCND2, encoding the pore-forming (α) subunit of the Kv4.2 cardiac potassium channel.', '4': 'Kv4.2, along with Kv4.3, contributes to the cardiac fast transient outward K+ current, Ito.', '5': 'Ito underlies the early phase of repolarization in the cardiac action potential, thereby setting the initial potential of the plateau phase and governing its duration and amplitude.', '6': \"In Xenopus oocytes, the mutation increased the channel's inactivation time constant and affected its regulation: p.S447 resides in a protein kinase C (PKC) phosphorylation site, which normally allows attenuation of Kv4.2 membrane expression.\", '7': 'The mutant Kv4.2 exhibited impaired response to PKC; hence, Kv4.2 membrane expression was augmented, enhancing potassium currents.', '8': 'Coexpression of mutant and wild-type channels (recapitulating heterozygosity in affected individuals) showed results similar to the mutant channel alone.', '9': 'Finally, in a hybrid channel composed of Kv4.3 and Kv4.2, simulating the mature endogenous heterotetrameric channel underlying Ito, the p.S447R Kv4.2 mutation exerted a gain-of-function effect on Kv4.3.', '10': \"Conclusions: The mutation alters Kv4.2's kinetic properties, impairs its inhibitory regulation, and exerts gain-of-function effect on both Kv4.2 homotetramers and Kv4.2-Kv4.3 heterotetramers.\", '11': 'These effects presumably increase the repolarizing potassium current Ito, thereby abbreviating action potential duration, creating arrhythmogenic substrate for nocturnal AF.', '12': 'Interestingly, Kv4.2 expression was previously shown to demonstrate circadian variation, with peak expression at daytime in murine hearts (human nighttime), with possible relevance to the nocturnal onset of paroxysmal AF symptoms in our patients.', '13': 'The atrial-specific phenotype suggests that targeting Kv4.2 might be effective in the treatment of nocturnal paroxysmal AF, avoiding adverse ventricular effects.'}\n",
            "13: abstract: {'1': 'Background: Sleep-disordered breathing (SDB) and atrial fibrillation (AF) are associated.', '2': 'This study investigated the impact of AF intervention on 6-month home sleep testing data.', '3': 'Methods: Sixty-seven patients (aged 66 to 86, 53% male) with persistent AF were randomized (1:1:1) to direct current cardioversion (DCCV) (22 patients), permanent pacemaker (PPM) + atrioventricular node ablation (AVNA) + DCCV (22 patients) or AF ablation (23 patients).', '4': 'Baseline and 6-month multichannel home sleep tests with the Watch-PAT200 (Itamar Medical Lts., Caesarea, Israel) were recorded.', '5': \"Implantable cardiac monitors (ICMs) (Medtronic Reveal XT, Minneapolis, Minnesota) in the DCCV and AF ablation groups, and PPM Holters in the 'pace and ablate' group were utilized to assess cardiac rhythm beat-to-beat throughout the study period.\", '6': 'Results: The prevalence of moderate-to-severe SDB [apnoea-hypopnoea index (AHI) ≥ 15/h] was 60%.', '7': 'At 6 months there was no change in AHI, Epworth sleepiness scale, sleep time, % REM sleep, respiratory desaturation index or central apnoeic events.', '8': 'Twenty-five patients (15 AF ablation, 9 DCCV and 1 following DCCV post-AVNA) maintained SR at 6 months confirmed on ICMs in these patients.', '9': 'AHI fell from 29.8 ± 26.6/h to 22.2 ± 20.4/h; P = 0.049.', '10': 'Conclusions: SDB is highly prevalent in patients with persistent AF.', '11': 'Restoration of sinus rhythm, and the associated long-term recovery of haemodynamics, is associated with a significant reduction in AHI.', '12': 'This implicates reversal of fluid shift from the lower limbs to the neck region, a key mechanism in the pathogenesis of SDB.'}\n",
            "13: abstract: {'1': 'The normal sleep-wake cycle is characterized by diurnal variations in blood pressure, heart rate, and cardiac events.', '2': 'Sleep apnea disrupts the normal sleep-heart interaction, and the pathophysiology varies for obstructive sleep apnea (OSA) and central sleep apnea (CSA).', '3': 'Associations exist between sleep-disordered breathing (which encompasses both OSA and CSA) and heart failure, atrial fibrillation, stroke, coronary artery disease, and cardiovascular mortality.', '4': 'Treatment options include positive airway pressure as well as adaptive servo-ventilation and phrenic nerve stimulation for CSA.', '5': 'Treatment improves blood pressure, quality of life, and sleepiness, the last particularly in those at risk for cardiovascular disease.', '6': 'Results from clinical trials are not definitive in terms of hard cardiovascular outcomes.'}\n",
            "14: abstract: {'1': 'The coronavirus-disease 2019 (COVID-19) was announced as a global pandemic by the World Health Organization.', '2': 'Challenges arise concerning how to optimally support the immune system in the general population, especially under self-confinement.', '3': 'An optimal immune response depends on an adequate diet and nutrition in order to keep infection at bay.', '4': 'For example, sufficient protein intake is crucial for optimal antibody production.', '5': 'Low micronutrient status, such as of vitamin A or zinc, has been associated with increased infection risk.', '6': 'Frequently, poor nutrient status is associated with inflammation and oxidative stress, which in turn can impact the immune system.', '7': 'Dietary constituents with especially high anti-inflammatory and antioxidant capacity include vitamin C, vitamin E, and phytochemicals such as carotenoids and polyphenols.', '8': 'Several of these can interact with transcription factors such as NF-kB and Nrf-2, related to anti-inflammatory and antioxidant effects, respectively.', '9': 'Vitamin D in particular may perturb viral cellular infection via interacting with cell entry receptors (angiotensin converting enzyme 2), ACE2.', '10': 'Dietary fiber, fermented by the gut microbiota into short-chain fatty acids, has also been shown to produce anti-inflammatory effects.', '11': 'In this review, we highlight the importance of an optimal status of relevant nutrients to effectively reduce inflammation and oxidative stress, thereby strengthening the immune system during the COVID-19 crisis.'}\n",
            "14: abstract: {'1': 'Suggested food, vaccination, drugs, and supplementary for the immune system for COVID-19.', '2': 'According to the World Health Organization, healthy foods and hydration are vital.', '3': 'Individuals consuming a well-balanced diet are healthier with a strong immune system and have a reduced risk of chronic illness, infectious diseases.', '4': 'Vitamins and minerals are vital.', '5': 'Vitamin B, insoluble in water, protects from infection.', '6': 'Vitamin C protects from flu-like symptoms.', '7': 'Insufficient vitamin D and vitamin E can lead to coronavirus infection.', '8': 'Vitamin D can be found in sunlight, and vitamin E can be found in, for example, oil, seeds, and fruits.', '9': 'Insufficient iron and excess iron can lead to risk.', '10': 'Zinc is necessary for maintaining the immune system.', '11': 'Food rich in protein should be the top priority because it has immune properties (immunoglobulin production) and potential antiviral activity.', '12': 'Therefore, in a regular meal, individuals should eat fruit, vegetables, legumes, nuts, whole grains, and foods from animal sources.', '13': 'Food from plants containing vitamin A should be consumed, and 8–10 cups of water should be drunk daily.', '14': 'Malnutrition is dangerous for patients with COVID-19 and thus proper nutrition should be provided.', '15': 'Fruit juice, tea, and coffee can also be consumed.', '16': 'Too much caffeine, sweetened fruit juices, fruit juice concentrates, syrups, fizzy drinks, and still drinks must be avoided.', '17': 'Unsaturated fats, white meats, and fish should be consumed.', '18': 'Saturated fat, red meat, more than 5 g salt per day, and industry processed food should be avoided.', '19': 'Along with diet, physical activity is another factor.', '20': 'Individuals should be active and perform physical exercise regularly to boost the immune system and should have proper sleep.'}\n",
            "14: abstract: {'1': 'COVID-19 may cause pneumonia, acute respiratory distress syndrome, cardiovascular alterations, and multiple organ failure, which have been ascribed to a cytokine storm, a systemic inflammatory response, and an attack by the immune system.', '2': 'Moreover, an oxidative stress imbalance has been demonstrated to occur in COVID-19 patients.', '3': 'N- Acetyl-L-cysteine (NAC) is a precursor of reduced glutathione (GSH).', '4': 'Due to its tolerability, this pleiotropic drug has been proposed not only as a mucolytic agent, but also as a preventive/therapeutic agent in a variety of disorders involving GSH depletion and oxidative stress.', '5': 'At very high doses, NAC is also used as an antidote against paracetamol intoxication.', '6': 'Thiols block the angiotensin-converting enzyme 2 thereby hampering penetration of SARS-CoV-2 into cells.', '7': 'Based on a broad range of antioxidant and anti-inflammatory mechanisms, which are herein reviewed, the oral administration of NAC is likely to attenuate the risk of developing COVID-19, as it was previously demonstrated for influenza and influenza-like illnesses.', '8': 'Moreover, high-dose intravenous NAC may be expected to play an adjuvant role in the treatment of severe COVID-19 cases and in the control of its lethal complications, also including pulmonary and cardiovascular adverse events.'}\n",
            "14: abstract: {'1': 'Novel coronavirus (COVID-19) is causing global mortality and lockdown burdens.', '2': 'A compromised immune system is a known risk factor for all viral influenza infections.', '3': 'Functional foods optimize the immune system capacity to prevent and control pathogenic viral infections, while physical activity augments such protective benefits.', '4': 'Exercise enhances innate and adaptive immune systems through acute, transient, and long-term adaptations to physical activity in a dose-response relationship.', '5': 'Functional foods prevention of non-communicable disease can be translated into protecting against respiratory viral infections and COVID-19.', '6': 'Functional foods and nutraceuticals within popular diets contain immune-boosting nutraceuticals, polyphenols, terpenoids, flavonoids, alkaloids, sterols, pigments, unsaturated fatty-acids, micronutrient vitamins and minerals, including vitamin A, B6, B12, C, D, E, and folate, and trace elements, including zinc, iron, selenium, magnesium, and copper.', '7': 'Foods with antiviral properties include fruits, vegetables, fermented foods and probiotics, olive oil, fish, nuts and seeds, herbs, roots, fungi, amino acids, peptides, and cyclotides.', '8': 'Regular moderate exercise may contribute to reduce viral risk and enhance sleep quality during quarantine, in combination with appropriate dietary habits and functional foods.', '9': 'Lifestyle and appropriate nutrition with functional compounds may offer further antiviral approaches for public health.'}\n",
            "14: abstract: {'1': 'The coronavirus are a wide group of viruses among that the SARS-CoV-2 is included (family Coronaviridae, subfamily Coronavirinae, genus Betacoronavirus and subgenus Sarbecovirus).', '2': 'Its main structural proteins are the membrane (M), the envelope (E), the nucleocapsid (N) and spike (S).', '3': 'The immune response to SARS-CoV-2 involves the cellular and the humoral sides, with neutralizing antibodies fundamentally directed against the S antigen.', '4': 'Although the seroprevalence data are frequently assumed as protection markers, no necessarily they are.', '5': 'In Spain, it is estimated that, to assure the herd immunity, at least four-fifths of the population should be immunoprotected.', '6': 'Due the high fatality rate of COVID-19, the acquisition of the protection only by the natural infection it not assumable and other measures as the mass immunization are required.', '7': 'Currently, there are several vaccine prototypes (including life virus, viral vectors, peptides and proteins and nucleic acid) in different phase of clinical evaluation.', '8': 'Foreseeably, some of these news vaccines would be soon commercially available.', '9': 'In this text, aspects related to these issues are reviewed.'}\n",
            "14: abstract: {'1': 'Vitamin D is a key regulator of the renin-angiotensin system that is exploited by SARS-CoV-2 for entry into the host cells.', '2': 'Further, vitamin D modulates multiple mechanisms of the immune system to contain the virus that includes dampening the entry and replication of SARS-CoV-2, reduces concentration of pro-inflammatory cytokines and increases levels of anti-inflammatory cytokines, enhances the production of natural antimicrobial peptide and activates defensive cells such as macrophages that could destroy SARS-CoV-2.'}\n",
            "14: abstract: {'1': 'Coronavirus Disease 2019 (COVID-19) caused by a novel betacoronavirus SARS-CoV-2 has been an ongoing global pandemic.', '2': 'Several vaccines have been developed to control the COVID-19, but the potential effectiveness of the mucosal vaccine remains to be documented.', '3': 'In this study, we constructed a recombinant L. plantarum LP18: RBD expressing the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein via the surface anchoring route.', '4': 'The amount of the RBD protein was maximally expressed under the culture condition with 200 ng/mL of inducer at 33 °C for 6 h.', '5': 'Further, we evaluated the immune response in mice via the intranasal administration of LP18:RBD.', '6': 'The results showed that the LP18:RBD significantly elicited RBD-specific mucosal IgA antibodies in respiratory tract and intestinal tract.', '7': 'The percentages of CD3 + CD4+ T cells in spleens of mice administrated with the LP18:RBD were also significantly increased.', '8': 'This indicated that LP18:RBD could induce a humoral immune response at the mucosa, and it could be used as a mucosal vaccine candidate against the SARS-CoV-2 infection.', '9': 'We provided the first experimental evidence that the recombinant L. plantarum LP18: RBD could initiate immune response in vivo, which implies that the mucosal immunization using recombinant LAB system could be a promising vaccination strategy to prevent the COVID-19 pandemic.'}\n",
            "14: abstract: {'1': 'As COVID-19 continues to spread rapidly worldwide and variants continue to emerge, the development and deployment of safe and effective vaccines are urgently needed.', '2': 'Here, we developed an mRNA vaccine based on the trimeric receptor-binding domain (RBD) of the SARS-CoV-2 spike (S) protein fused to ferritin-formed nanoparticles (TF-RBD).', '3': 'Compared to the trimeric form of the RBD mRNA vaccine (T-RBD), TF-RBD delivered intramuscularly elicited robust and durable humoral immunity as well as a Th1-biased cellular response.', '4': 'After further challenge with live SARS-CoV-2, immunization with a two-shot low-dose regimen of TF-RBD provided adequate protection in hACE2-transduced mice.', '5': 'In addition, the mRNA template of TF-RBD was easily and quickly engineered into a variant vaccine to address SARS-CoV-2 mutations.', '6': 'The TF-RBD multivalent vaccine produced broad-spectrum neutralizing antibodies against Alpha (B.1.1.7) and Beta (B.1.351) variants.', '7': 'This mRNA vaccine based on the encoded self-assembled nanoparticle-based trimer RBD provides a reference for the design of mRNA vaccines targeting SARS-CoV-2.'}\n",
            "14: abstract: {'1': 'The COVID-19 epidemic is the greatest pandemic that human kind experienced for decades, with high morbidity and mortality.', '2': 'Despite recent development of vaccines there is still many severe cases of COVID-19.', '3': 'Unfortunately there is still no standardized therapies and treatment of severe cases is very challenging.', '4': 'The aim of this study is to indicate if herbs administered alone or as a complementary therapy could be used as prophylaxis or treatment of SARS-CoV-2 infection.', '5': 'Over 85% of patients with COVID-19 in China used Traditional Chinese Medicine (TCM), and a most common herb is Glycyrrhiza glabra, which in vitro inhibits replication of different enveloped viruses, including coronaviruses.', '6': 'Glycyrrhizin in vitro connects and changes conformation of ACE2 receptors, which are vital for SARS-CoV-2 penetration into host cells.', '7': 'Pelargonium sidoides show immunomodulatory and antiviral properties in clinical and in vitro studies, and it inhibits replication of HCo-229E coronavirus.', '8': 'Glycyrrhiza glabra in combination with standard therapies significantly reduces the hospitalization rate and occurrence of COVID-19 symptoms.', '9': 'As complementary therapies lianhuaqingwen capsules and jinhua qinggan granules reduces hospitalization rates, time to symptoms recovery and improve patient psychological comfort.', '10': 'In view of SARS-CoV-2 other herbs are not effective, e.g. maxingshigan-yinqiaosan, or therapeutic concentration would be impossible to achieve, e.g. ephedra herb, or there is simply no proper data.', '11': 'Therefore, Liquorice and Pelargonium sidoides are effective against coronaviruses and could be possibly used as prophylaxis and treatment of COVID-19, while lianhuaqingwen capsules and jinhua qinggan granules can be useful as a complementary therapy to conventional treatment.'}\n",
            "14: abstract: {'1': 'Natural killer (NK) cells are important early responders against viral infections.', '2': 'Changes in metabolism are crucial to fuel NK cell responses, and altered metabolism is linked to NK cell dysfunction in obesity and cancer.', '3': 'However, very little is known about the metabolic requirements of NK cells during acute retroviral infection and their importance for antiviral immunity.', '4': 'Here, using the Friend retrovirus mouse model, we show that following infection NK cells increase nutrient uptake, including amino acids and iron, and reprogram their metabolic machinery by increasing glycolysis and mitochondrial metabolism.', '5': 'Specific deletion of the amino acid transporter Slc7a5 has only discrete effects on NK cells, but iron deficiency profoundly impaires NK cell antiviral functions, leading to increased viral loads.', '6': 'Our study thus shows the requirement of nutrients and metabolism for the antiviral activity of NK cells, and has important implications for viral infections associated with altered iron levels such as HIV and SARS-CoV-2.'}\n",
            "15: abstract: {'1': 'STE20 (Sterile 20)/SPS-1 related proline/alanine-rich kinase (SPAK) and oxidative stress-response kinase-1 (OSR1) activate the renal cation cotransporters Na(+) -K(+) -2Cl(-) cotransporter (NKCC2) and Na(+) -Cl(-) cotransporter (NCC) via phosphorylation.', '2': 'Knockout mouse models suggest that OSR1 mainly activates NKCC2, while SPAK mainly activates NCC, with possible cross-compensation.', '3': 'We tested the hypothesis that disrupting both kinases causes severe polyuria and salt-wasting by generating SPAK/OSR1 double knockout (DKO) mice.', '4': 'DKO mice displayed lower systolic blood pressure compared with SPAK knockout (SPAK-KO) mice, but displayed no severe phenotype even after dietary salt restriction.', '5': 'Phosphorylation of NKCC2 at SPAK/OSR1-dependent sites was lower than in SPAK-KO mice, but still significantly greater than in wild type mice.', '6': 'In the renal medulla, there was significant phosphorylation of NKCC2 at SPAK/OSR1-dependent sites despite a complete absence of SPAK and OSR1, suggesting the existence of an alternative activating kinase.', '7': 'The distal convoluted tubule has been proposed to sense plasma [K(+) ], with NCC activation serving as the primary effector pathway that modulates K(+) secretion, by metering sodium delivery to the collecting duct.', '8': 'Abundance of phosphorylated NCC (pNCC) is dramatically lower in SPAK-KO mice than in wild type mice, and the additional disruption of OSR1 further reduced pNCC.', '9': 'SPAK-KO and kidney-specific OSR1 single knockout mice maintained plasma [K(+) ] following dietary potassium restriction, but DKO mice developed severe hypokalaemia.', '10': 'Unlike mice lacking SPAK or OSR1 alone, DKO mice displayed an inability to phosphorylate NCC under these conditions.', '11': 'These data suggest that SPAK and OSR1 are essential components of the effector pathway that maintains plasma [K(+) ].'}\n",
            "15: abstract: {'1': 'We recently described a novel thiazide-sensitive electroneutral NaCl transport mechanism resulting from the parallel operation of the Cl-/HCO3- exchanger pendrin and the Na+-driven Cl-/2HCO3- exchanger (NDCBE) in β-intercalated cells of the collecting duct.', '2': 'Although a role for pendrin in maintaining Na+ balance, intravascular volume, and BP is well supported, there is no in vivo evidence for the role of NDCBE in maintaining Na+ balance.', '3': 'Here, we show that deletion of NDCBE in mice caused only subtle perturbations of Na+ homeostasis and provide evidence that the Na+/Cl- cotransporter (NCC) compensated for the inactivation of NDCBE.', '4': 'To unmask the role of NDCBE, we generated Ndcbe/Ncc double-knockout (dKO) mice.', '5': 'On a normal salt diet, dKO and single-knockout mice exhibited similar activation of the renin-angiotensin-aldosterone system, whereas only dKO mice displayed a lower blood K+ concentration.', '6': 'Furthermore, dKO mice displayed upregulation of the epithelial sodium channel (ENaC) and the Ca2+-activated K+ channel BKCa.', '7': 'During NaCl depletion, only dKO mice developed marked intravascular volume contraction, despite dramatically increased renin activity.', '8': 'Notably, the increase in aldosterone levels expected on NaCl depletion was attenuated in dKO mice, and single-knockout and dKO mice had similar blood K+ concentrations under this condition.', '9': 'In conclusion, NDCBE is necessary for maintaining sodium balance and intravascular volume during salt depletion or NCC inactivation in mice.', '10': 'Furthermore, NDCBE has an important role in the prevention of hypokalemia.', '11': 'Because NCC and NDCBE are both thiazide targets, the combined inhibition of NCC and the NDCBE/pendrin system may explain thiazide-induced hypokalemia in some patients.'}\n",
            "15: abstract: {'1': 'Purpose of review: Renal potassium (K) secretion plays a key role in maintaining K homeostasis.', '2': 'The classic mechanism of renal K secretion is focused on the connecting tubule and cortical collecting duct, in which K is uptaken by basolateral Na-K-ATPase and is secreted into the lumen by apical ROMK (Kir1.1) and Ca-activated big conductance K channel.', '3': 'Recently, genetic studies and animal models have indicated that inwardly rectifying K channel 4.1 (Kir4.1 or Kcnj10) in the distal convoluted tubule (DCT) may play a role in the regulation of K secretion in the aldosterone-sensitive distal nephron by targeting the NaCl cotransporter (NCC).', '4': 'This review summarizes recent progresses regarding the role of Kir4.1 in the regulation of NCC and K secretion.', '5': 'Recent findings: Kir4.1 is expressed in the basolateral membrane of the DCT, and plays a predominant role in contributing to the basolateral K conductance and in participating in the generation of negative membrane potential.', '6': 'Kir4.1 is also the substrate of src-family tyrosine kinase and the stimulation of src-family tyrosine kinase activates Kir4.1 activity in the DCT.', '7': 'The genetic deletion or functional inhibition of Kir4.1 depolarizes the membrane of the DCT, inhibits ste20-proline-alanine rich kinase, and suppresses NCC activity.', '8': 'Moreover, the downregulation of Kir4.1 increases epithelial Na channel expression in the collecting duct and urinary K excretion.', '9': 'Finally, mice with low Kir4.1 activity in the DCT are hypomagnesemia and hypokalemia.', '10': 'Summary: Recent progress in exploring the regulation and the function of Kir4.1 in the DCT strongly indicates that Kir4.1plays an important role in initiating the regulation of renal K secretion by targeting NCC and it may serves as a K sensor in the kidney.'}\n",
            "15: abstract: {'1': 'Background: Potassium (K(+)) is the major intracellular cation, with 98% of the total pool being located in the cells at a concentration of 140-150 mmol/l, and only 2% in the extracellular fluid, where it ranges between 3.5 and 5 mmol/l.', '2': 'A fine regulation of the intracellular-extracellular gradient is crucial for life, as it is the main determinant of membrane voltage; in fact, acute changes of K(+) plasma levels may have fatal consequences.', '3': \"Summary: An integrated system including an 'internal' and 'external' control prevents significant fluctuations of plasma levels in conditions of K(+) loading and depletion.\", '4': 'The internal control regulates the intra-extracellular shift, a temporary mechanism able to maintain a constant K(+) plasma concentration without changing the total amount of body K(+).', '5': 'The external control is responsible for the excretion of the ingested K(+), and it has the kidney as the major player.', '6': 'The kidney excretes nearly 90% of the daily intake.', '7': \"Along the proximal tubule and the thick ascending limb on Henle's loop, the amount of K(+) reabsorption is quite fixed (about 80-90%); conversely, the distal nephron has the ability to adjust K(+) excretion in accordance with homeostatic needs.\", '8': 'The present review analyzes: (1) the main molecular mechanisms mediating K(+) reabsorption and secretion along the nephron; (2) the pathophysiology of the principal K(+) derangements due to renal dysfunction, and (3) the effect of ingested K(+) on blood pressure and renal electrolyte handling.', '9': 'Key messages: Maintaining plasma K(+) levels in a tight range is crucial for life; thus, multiple factors are implicated in K(+) homeostasis, including kidney function.', '10': 'Recent studies have suggested that K(+) plasma levels, in turn, affect renal salt absorption in animal models; this effect may underlie the reduction of blood pressure observed in hypertensive subjects under K(+) supplementation.'}\n",
            "15: abstract: {'1': 'Potassium is the most abundant cation in the intracellular fluid and it plays a vital role in the maintenance of normal cell functions.', '2': 'Thus, potassium homeostasis across the cell membrane, is very critical because a tilt in this balance can result in different diseases that could be life threatening.', '3': 'Both Oxidative stress (OS) and potassium imbalance can cause life threatening health conditions.', '4': 'OS and abnormalities in potassium channel have been reported in neurodegenerative diseases.', '5': \"This review highlights the major factors involved in potassium homeostasis (dietary, hormonal, genetic, and physiologic influences), and discusses the major diseases and abnormalities associated with potassium imbalance including hypokalemia, hyperkalemia, hypertension, chronic kidney disease, and Gordon's syndrome, Bartter syndrome, and Gitelman syndrome.\"}\n",
            "15: abstract: {'1': 'Kidneys play a pivotal role in the maintenance and regulation of acid-base and electrolyte homeostasis, which is the prerequisite for numerous metabolic processes and organ functions in the human body.', '2': 'Chronic kidney diseases compromise the regulatory functions, resulting in alterations in electrolyte and acid-base balance that can be life-threatening.', '3': 'In this review, we discuss the renal regulations of electrolyte and acid-base balance and several common disorders including metabolic acidosis, alkalosis, dysnatremia, dyskalemia, and dysmagnesemia.', '4': 'Common disorders in chronic kidney disease are also discussed.', '5': 'The most recent and relevant advances on pathophysiology, clinical characteristics, diagnosis, and management of these conditions have been incorporated.'}\n",
            "15: abstract: {'1': 'Potassium is mainly an intracellular ion.', '2': 'The sodium-potassium adenosine triphosphatase pump has the primary responsibility for regulating the homeostasis between sodium and potassium, which pumps out sodium in exchange for potassium, which moves into the cells.', '3': 'In the kidneys, the filtration of potassium takes place at the glomerulus.', '4': 'The reabsorption of potassium takes place at the proximal convoluted tubule and thick ascending loop of Henle.', '5': 'Potassium secretion occurs at the distal convoluted tubule.', '6': 'Aldosterone increases potassium secretion.', '7': 'Potassium channels and potassium-chloride cotransporters at the apical membrane also secrete potassium.', '8': 'Potassium disorders are related to cardiac arrhythmias.', '9': 'Hypokalemia occurs when serum potassium levels under 3.6 mmol/L—weakness, fatigue, and muscle twitching present in hypokalemia.'}\n",
            "15: abstract: {'1': 'Total-body potassium (K+) content and appropriate distribution of K+ across the cell membrane is vitally important for normal cellular function.', '2': 'Total-body K+ content is determined by changes in excretion of K+ by the kidneys in response to intake levels.', '3': 'Under normal conditions, insulin and β-adrenergic tone also make important contributions in maintaining internal distribution of K+.', '4': 'However, despite these homeostatic pathways, disorders of altered K+ homeostasis are common.', '5': 'Appreciating the pathophysiology and regulatory influences that determine the internal distribution and external balance of K+ is critical in designing effective treatments to restore K+ homeostasis.', '6': 'We provide an up-to-date review of the regulatory aspects of normal K+ physiology as a preface to highlighting common disorders in K+ homeostasis and their treatment.', '7': 'This review of K+ homeostasis is designed as a resource for clinicians and a tool for educators who are teaching trainees to understand the pivotal factors involved in K+ balance.'}\n",
            "15: abstract: {'1': 'Background: The basolateral potassium channel in the distal convoluted tubule (DCT), comprising the inwardly rectifying potassium channel Kir4.1/Kir5.1 heterotetramer, plays a key role in mediating the effect of dietary potassium intake on the thiazide-sensitive NaCl cotransporter (NCC).', '2': 'The role of Kir5.1 (encoded by Kcnj16) in mediating effects of dietary potassium intake on the NCC and renal potassium excretion is unknown.', '3': 'Methods: We used electrophysiology, renal clearance, and immunoblotting to study Kir4.1 in the DCT and NCC in Kir5.1 knockout (Kcnj16-/- ) and wild-type (Kcnj16+/+ ) mice fed with normal, high, or low potassium diets.', '4': 'Results: We detected a 40-pS and 20-pS potassium channel in the basolateral membrane of the DCT in wild-type and knockout mice, respectively.', '5': 'Compared with wild-type, Kcnj16-/- mice fed a normal potassium diet had higher basolateral potassium conductance, a more negative DCT membrane potential, higher expression of phosphorylated NCC (pNCC) and total NCC (tNCC), and augmented thiazide-induced natriuresis.', '6': \"Neither high- nor low-potassium diets affected the basolateral DCT's potassium conductance and membrane potential in Kcnj16-/- mice.\", '7': 'Although high potassium reduced and low potassium increased the expression of pNCC and tNCC in wild-type mice, these effects were absent in Kcnj16-/- mice.', '8': 'High potassium intake inhibited and low intake augmented thiazide-induced natriuresis in wild-type but not in Kcnj16-/- mice.', '9': 'Compared with wild-type, Kcnj16-/- mice with normal potassium intake had slightly lower plasma potassium but were more hyperkalemic with prolonged high potassium intake and more hypokalemic during potassium restriction.', '10': \"Conclusions: Kir5.1 is essential for dietary potassium's effect on NCC and for maintaining potassium homeostasis.\"}\n",
            "15: abstract: {'1': 'Histone deacetylase (HDAC) enzymes regulate transcription through epigenetic modification of chromatin structure, but their specific functions in the kidney remain elusive.', '2': 'We discovered that the human kidney expresses class I HDACs.', '3': 'Kidney medulla-specific inhibition of class I HDACs in the rat during high-salt feeding results in hypertension, polyuria, hypokalemia, and nitric oxide deficiency.', '4': 'Three new inducible murine models were used to determine that HDAC1 and HDAC2 in the kidney epithelium are necessary for maintaining epithelial integrity and maintaining fluid-electrolyte balance during increased dietary sodium intake.', '5': 'Moreover, single-nucleus RNA-sequencing determined that epithelial HDAC1 and HDAC2 are necessary for expression of many sodium or water transporters and channels.', '6': 'In performing a systematic review and meta-analysis of serious adverse events associated with clinical HDAC inhibitor use, we found that HDAC inhibitors increased the odds ratio of experiencing fluid-electrolyte disorders, such as hypokalemia.', '7': 'This study provides insight on the mechanisms of potential serious adverse events with HDAC inhibitors, which may be fatal to critically ill patients.', '8': 'In conclusion, kidney tubular HDACs provide a link between the environment, such as consumption of high-salt diets, and regulation of homeostatic mechanisms to remain in fluid-electrolyte balance.'}\n",
            "16: abstract: {'1': 'The mechanisms and kinetics of the immunosuppressive effects of alternate-day prednisone were investigated in a group of patients with a variety of inflammatory diseases receiving a range of alternate-day prednisone doses from 5 to 120 mg.', '2': 'Total circulating lymphocyte and monocyte counts, as well as proportions of lymphocyte subpopulations defined both by surface markers and by in vitro functional capacities, were studied.', '3': 'At 8 a. m. of the day on prednisone, just before drug administration, lymphocyte and monocyte counts, proportions of lymphocyte subpopulations, as well as in vitro lymphocyte blastogenic responses to various mitogenic and antigenic stimuli were normal.', '4': '4 h after the administration of prednisone, there was a profound lymphocytopenia and monocytopenia, with a differential depletion of thymus-derived lymphocytes as well as various functionally defined lymphocyte subpopulations.', '5': 'Lymphocyte kinetic studies using a radioactive chromium-labeled autologous lymphocytes showed that the lymphocytopenia was due predominantly to a transient depletion of the recirculating portion of the intravascular lymphocytepool.', '6': 'All these parameters returned to normal by 8 a.m. of the following day (off prednisone) and remained normal throughout the day.', '7': 'This very transient lymphocytopenia and monocytopenia after prednisone, with normal cell numbers, proportions, and functions throughout the remainder of the 2-day cycle, was associated with suppression of disease activity, yet did not affect cutaneous delayed hypersensitivity in these patients nor increase the likelihood of infectious complications.', '8': 'This drug-associated cyclic and transient monocytopenia and selective lymphocytopenia is best explained by a redistribution of recirculating lymphocytes to other body compartments, particularly the bone marrow.'}\n",
            "16: abstract: {'1': 'Lymphocyte kinetic studies employing 51-chromium-labeled autologous lymphocytes were performed in nine normal volunteers in order to determine the effects of hydrocortisone administration on the recirculating versus the nonrecirculating intravascular lymphocyte pools.', '2': 'Following infusion of labeled cells, the recirculating portion of the labeled cells rapidly equilibrated with the total intravascular lymphocyte pool and the vastly larger total-body recirculating lymphocyte pool, so that by 1 hr following infusion 21.8% plus or minus 3.2% of the labeled lymphocytes were left in the circulation.', '3': 'Four hundred milligrams of intravenous hydrocortisone administered 24 hr after infusion of labeled cells caused a profound but transient lymphocytopenia which was maximal at 4 hr with return of lymphocyte counts to normal by 24 hr after injection.', '4': 'Concomitant with the lymphocytopenia there was a dramatic increase in lymphocyte specific activity (cpm per 10-6 lymphocytes), while the total lymphocyte-associated radioactivity remaining in the circulation was unchanged, indicating that corticosteroid administration depleted the unlabeled recirculating cells.', '5': 'As the lymphocyte counts returned to normal following hydrocortisone, the specific activity also returned to normal.', '6': 'These studies indicated that hydrocortisone administration caused a transient lymphocytopenia by a preferential depletion of the recirculating portion of the intravascular lymphocyte pool.'}\n",
            "16: abstract: {'1': 'It is thought that glucocorticosteroids impair the clearance of immune complexes by the mononuclear phagocyte system (MPS).', '2': 'We studied the effect of a five day course of prednisone (1 mg/kg body weight per day) on MPS function in 10 healthy volunteers, using soluble radiolabeled aggregates of human immunoglobulin G as a probe.', '3': 'MPS function was assessed before steroid treatment, and again 24 hours after the last dose of prednisone.', '4': 'Elimination kinetics and the uptake of the immunoglobulin aggregates by liver and spleen did not change after prednisone treatment.', '5': 'This suggests that, in contrast to general belief, high doses of glucocorticosteroids have no direct, acute effect on MPS function.'}\n",
            "16: abstract: {'1': 'The growth of knowledge in the field of the pharmacokinetics of prednisolone/prednisone has been slow for several reasons.', '2': 'First, convenient and specific methods for measuring these steroids only became available with the development of high performance liquid chromatographic methods.', '3': 'Secondly, prednisolone is nonlinearly bound to transcortin and albumin: since the unbound concentrations of prednisolone are biologically relevant, it was necessary to determine the free fraction in each plasma sample.', '4': 'Thirdly, due to the short half-life of prednisolone no steady-state is achieved, and therefore area under the concentration-time curve needed to be determined in all studies.', '5': 'Fourthly, prednisolone and prednisone are interconvertible and prednisolone is given intravenously as an ester prodrug, features which created controversies about the correct interpretation of pharmacokinetic results.', '6': 'Finally, the total body clearances of total and (to a lesser degree) of unbound prednisolone increase with increasing concentrations of prednisolone.', '7': 'Therefore, in order to compare pharmacokinetic results between different subjects, standardised doses had to be administered.', '8': \"The investigations performed so far have revealed that: (1) the dose-dependent pharmacokinetics partly explain the clinical observation that an alternate-day regimen with prednisone yields fewer biological effects; (2) the interconversion of prednisone into prednisolone is not a limiting factor, even in patients with severely impaired liver function; (3) hypoproteinaemia per se does not cause increased unbound concentrations of prednisolone in vivo; (4) patients with liver failure, renal failure or a renal transplant, subjects older than 65 years, women on estrogen-containing oral contraceptive steroids or subjects taking ketoconazole have increased unbound concentrations of prednisolone-whereas hyperthyroid patients, some patients with Crohn's disease, subjects taking microsomal liver enzyme-inducing agents or patients on intravenous prednisolone phthalate (instead of prednisolone phosphate) or on some brands of enteric coated prednisolone tablets have decreased concentrations of prednisolone.\", '9': 'The biological relevance of the altered pharmacokinetics is supported in part by altered clinical effects and altered effects on cellular immunofunctions.'}\n",
            "16: abstract: {'1': 'The effects of single oral doses of 10, 15, or 30 mg of prednisone on circulating mononuclear cells, autologous MLR, mitogen responses, and allogeneic MLR were studied in healthy volunteers.', '2': 'Doses as low as 10 mg were immunosuppressive, causing diminution of circulating T cells and monocytes, and significant reduction in autologous but not allogeneic MLR responses.', '3': 'These effects were maximal 6 hr after drug administration and gone by 24 hr.', '4': 'Autologous MLR responses were particularly sensitive to the effects of prednisone being significantly and consistently suppressed 2 hr after drug administration, before significant cell redistribution had occurred.', '5': 'Macrophage-enriched stimulating cells were more easily suppressed than responding T cells.', '6': 'Since the autologous MLR may be important in in vivo regulation of immune responses, its reduction by low-dose glucocorticoids may be of clinical relevance.', '7': 'This suppressive effect must be considered in studies of the autologous MLR in patients receiving glucocorticoid therapy.'}\n",
            "16: abstract: {'1': 'Six healthy male volunteers were given 5, 20, and 50 mg of oral prednisone and 5, 20, and 400 mg doses of intravenous prednisolone.', '2': 'Plasma and urine concentrations of prednisone and prednisolone were determined by HPLC, and the binding of prednisolone to plasma proteins was measured by radioisotopic and equilibrium dialysis techniques.', '3': 'The pharmacokinetics of both oral prednisone and intravenous prednisolone were dose-dependent.', '4': 'The mean oral dose plasma clearances of prednisone ranged from 572 ml/min/1.73 m 2 for the 5 mg dose to 2271 ml/min/1.73 m 2 for the 50 mg dose.', '5': 'Changes in prednisone half-life were insignificant, but increases in the half-life of its metabolite were dose-dependent.', '6': 'The systemic plasma clearance of i.v. prednisolone was dose-dependent and increased from 111 to 194 ml/min/1.73 m 2 over the 5 to 40 mg i.v. dosage range.', '7': 'The steady-state volume of distribution also increased, but little change in mean transit time and half-life was found.', '8': 'The binding of prednisolone to plasma proteins was markedly concentration-dependent, and a two compartment, nonlinear equation was used to characterize the effective binding of prednisolone to transcortin and albumin.', '9': 'The apparent pharmacokinetic parameters of protein-free and transcortin-free prednisolone were relatively constant with dose.', '10': 'The interconversion of prednisone and prednisolone varied with time and dose, although prednisolone concentrations dominated by 4- to 10-fold over prednisone.', '11': 'In urine, 2-5% of either administered drug was excreted as prednisone and 11-24% as prednisolone.', '12': 'The apparent renal clearances of both steroids were also nonlinear and unrelated to protein binding.', '13': 'These studies indicate that the pharmacokinetics of prednisone and prednisolone are dose-dependent and that protein binding does not fully explain their apparent nonlinear distribution and disposition.'}\n",
            "16: abstract: {'1': 'The aim of this study was to estimate the influence of corticosteroids on Th1 and Th2 serum cytokine balance in patients with GO: IFNgamma, TNFalpha, IL-4 and IL-10.', '2': \"Further, we tested the hypothesis of an up-regulation of Th2 immune response during successful treatment with corticosteroids to explain their beneficial effect in Graves' ophthalmopathy.\", '3': \"Serum cytokines were detected in three groups of subjects: 20 patients with Graves' disease without ophthalmopathy (Gd), 16 patients with clinical symptoms of ophthalmopathy (GO) (CAS over 3 points, last consultation record for GO less than a year old) and 16 healthy volunteers.\", '4': 'Corticosteroid therapy consisted of intravenous infusions of methylprednisolone (MP) (2 series, 3 g each time) and subsequent treatment with oral prednisone (60 mg per day) in a tapering schedule.', '5': 'The serum samples were collected 24 hours before MP, 24 hours after MP, 14 days of treatment with prednisone and at the end of corticosteroid therapy.', '6': 'The levels of IFNgamma, TNFalpha, IL-4 and IL-10 in the serum were determined using ELISA.', '7': 'Statistical significance was estimated by the Mann-Whitney U-test.', '8': \"Our findings show a deviation to systemic Th2 profile cytokines in Graves' disease.\", '9': 'In patients with GO, we found a significantly increased serum IL-10 concentration.', '10': 'In corticosteroid-responsive patients, the balance of serum cytokines IL-4/IFNgamma, IL-4/TNFalpha, IL-10/IFNgamma and IL-10/TN Falpha increased and remained upregulated until the end of the study.', '11': 'In non-responders, the balance of serum cytokines studied increased after methylprednisolone but declined markedly during continuation of the therapy with prednisone.', '12': 'In summary, our results show that efficient corticosteroid therapy may be related to its influence on Th2/Th1 profile cytokine balance.', '13': \"The upregulation of serum IL-4 and IL-10 during successful treatment with corticosteroids indicate the possibility of using these cytokines as predictors of the beneficial effect of corticosteroids in Graves' ophthalmopathy.\"}\n",
            "16: abstract: {'1': 'Background: Renal transplant recipients were noted to appear cushingoid while on low doses of steroid as part of a triple therapy immunosuppression of cyclosporin A (CsA), prednisolone, and azathioprine.', '2': 'Methods: The study group comprised adult renal transplant recipients with stable graft function who had received their renal allograft a minimum of 1 year previously (43 studies undertaken in 22 men and 20 women) with median daily prednisone dose of 7 mg (range 3-10).', '3': 'The control group was healthy nontransplant subjects [median dose 10 mg (10-30)].', '4': 'Prednisolone bioavailability was measured using a limited 6-hour area under the curve (AUC), with prednisolone measured using specific HPLC assay.', '5': 'Results: The median prednisolone AUC/mg dose for all transplant recipients was significantly greater than the control group by approximately 50% (316 nmol x h/L/mg prednisolone versus 218).', '6': 'AUC was significantly higher in female recipients (median 415 versus 297 for men) and in recipients receiving cyclosporin (348 versus 285).', '7': 'The highest AUC was in women on estrogen supplements who were receiving cyclosporin (median 595).', '8': 'A significantly higher proportion of patients on triple therapy had steroid side effects compared with those on steroid and azathioprine (17/27 versus 4/15), more women than men had side effects (14/16 versus 7/22), and the AUC/mg prednisone was greater in those with side effects than without (median 377 versus 288 nmol x h/L/mg).', '9': 'Discussion: The results are consistent with the hypothesis that CsA increases the bioavailability of prednisolone, most likely through inhibition of P-glycoprotein.', '10': 'The increased exposure to steroid increased the side-effect profile of steroids in the majority of patients.', '11': 'Because the major contributor to AUC is the maximum postdose concentration, it may be possible to use single-point monitoring (2 hours postdose) for routine clinical studies.'}\n",
            "16: abstract: {'1': 'In rheumatoid arthritis (RA), nocturnal release of proinflammatory cytokines is not adequately counteracted by endogenous glucocorticoid and is associated with symptoms of morning stiffness and pain.', '2': 'Taking exogenous glucocorticoid during the night reduces morning stiffness significantly more than treatment at the conventional time in the morning, although waking to take tablets is unacceptable for patients.', '3': 'Modified-release prednisone tablets were developed to allow administration at bedtime for programmed delivery of glucocorticoid during the night.', '4': 'Single-center crossover studies were conducted, each in ≤24 healthy subjects, to compare the pharmacokinetics of a single 5-mg oral dose of modified-release prednisone and conventional prednisone, as well as the effect of food on bioavailability.', '5': 'There was no substantial difference in pharmacokinetic parameters of the formulations apart from the programmed delay in release of glucocorticoid from the modified-release tablets (C(max) 97%, AUC(0-∞) 101%, 90% confidence intervals within the requisite range for bioequivalence).', '6': 'Administration after a full or light meal did not affect pharmacokinetic characteristics, but bioavailability was reduced under fasted conditions.', '7': 'Pharmacokinetic evaluation in 9 patients with RA confirmed that modified-release prednisone tablets taken at bedtime (around 22:00 h) with or after an evening meal result in programmed release of glucocorticoid 4 to 6 hours after intake.'}\n",
            "16: abstract: {'1': 'Corticosteroids have been used for decades to modulate inflammation therapeutically, yet there is a paucity of data on their effects in humans.', '2': 'We examined the changes in cellular and molecular immune system parameters, or \"immunome\", in healthy humans after systemic corticosteroid administration.', '3': 'We used multiplexed techniques to query the immunome in 20 volunteers at baseline, and after intravenous hydrocortisone (HC) administered at moderate (250 mg) and low (50 mg) doses, to provide insight into how corticosteroids exert their effects.', '4': 'We performed comprehensive phenotyping of 120 lymphocyte subsets by high dimensional flow cytometry, and observed a decline in circulating specific B and T cell subsets, which reached their nadir 4-8 hours after administration of HC.', '5': 'However, B and T cells rebounded above baseline 24 hours after HC infusion, while NK cell numbers remained stable.', '6': 'Whole transcriptome profiling revealed down regulation of NF-κB signaling, apoptosis, and cell death signaling transcripts that preceded lymphocyte population changes, with activation of NK cell and glucocorticoid receptor signaling transcripts.', '7': 'Our study is the first to systematically characterize the effects of corticosteroids on the human immunome, and we demonstrate that HC exerts differential effects on B and T lymphocytes and natural killer cells in humans.', '8': 'Fauci et al. reported that 400\\u2009mg and 100\\u2009mg doses of HC cause a transient nadir in circulating peripheral blood lymphocytes at 4–6\\u2009hours and recovery to baseline after 24\\u2009hours.', '9': 'Our data are consistent with these observations.', '10': 'We also observed differential effects of the two steroid doses on lymphocyte recovery at 24\\u2009hours, with total T cells, CD4+ T cells, and B cells rebounding above baseline after the 250\\u2009mg dose and total NK cells showing no increase above baseline at 24\\u2009hours.', '11': 'HC induced a rapid decline in circulating monocytes and mRNAs related to innate immune signaling as early as one hour after infusion.', '12': 'These effects preceded neutrophil demargination and lymphocyte depletion.'}\n",
            "17: abstract: {'1': 'The tongue is the most common cause of upper airway obstruction, a situation seen most often in patients who are comatose or who have suffered cardiopulmonary arrest.', '2': 'Other common causes of upper airway obstruction include edema of the oropharynx and larynx, trauma, foreign body, and infection.', '3': 'The management of the patient with upper airway obstruction depends upon the cause of the obstruction, the training and skills of the rescuer, and the availability of adjuncts necessary to perform advanced airway techniques.', '4': 'In most cases, merely positioning the patient or performing one of the three maneuvers designed to elevate the tongue will open the airway of the comatose patient or the victim of cardiac arrest.', '5': 'In patients with suspected foreign body obstruction, abdominal or chest compression should be performed immediately, with digital extraction of the foreign body reserved for those in whom these maneuvers are unsuccessful.', '6': 'Most patients with obstruction secondary to edema, trauma, or infection can be managed initially with orotracheal or nasotracheal intubation.', '7': 'Intubation should be attempted prior to surgical management of the airway in most cases of upper airway obstruction.', '8': 'Occasionally, however, cricothyroidotomy or tracheostomy is necessary to establish an airway.', '9': 'The choice of technique depends primarily on the experience and skills of the rescuing physician or paramedic.', '10': 'In most cases, cricothyroidotomy is technically more simple and more easily performed than tracheotomy, especially for the physician who has not been trained in surgery or otolaryngology and for the nonphysician rescuer.', '11': 'No matter what the method employed in establishing an airway in a patient with upper airway obstruction, it must be performed quickly and a source of ventilation provided for the patient once the airway has been secured.'}\n",
            "17: abstract: {'1': '180 cases of head trauma were classified according to the degree of impairment of consciousness, clinical and neurological symptoms and EEG patterns.', '2': 'Based on the radiological and clinical findings and blood gas analyses a study was made of the incidence and extent of aspiration of blood, vomit or debris into the tracheo-bronchial tree and of the resultant pulmonary complications.', '3': 'As loss of consciousness became more complete the incidence of aspiration and the amount of material inhaled increased.', '4': 'Clinically and radiologically proven aspiration occurred in 60 per cent of cases of severe head trauma.', '5': 'A comparison of two groups after they had been given first aid and artificial respiration showed that the paO2 values were significantly lower in patients with radiologically proven aspiration and infiltration of the lungs than they were in those with normal chest radiograms.', '6': 'These observations point to the relationship between the quantity of material inhaled and the extent of intra-pulmonary shunting.', '7': 'There was no difference in the incidence of aspiration between persons who had been intubated and those who had not been intubated prior to admission to hospital.', '8': 'Although in many cases of head trauma aspiration of blood immediately after the accident can not be prevented prompt intubation is the only measure that will mitigate the consequences of aspiration and prevent its recurrence.', '9': 'As the latter is a very real risk in the unconscious person intubation in these cases is a \"must\".', '10': 'The study also showed that aspiration of foreign material into the tracheobronchial system and the resultant pulmonary complications can be successfully treated even if the head trauma is very severe.', '11': 'In none of the cases studied was death attributable to these causes.', '12': 'Apart from intubation and bronchial toilet artificial respiration with oxygen-enriched gas mixtures has a decisive influence on the course of the aspiration-induced pulmonary complications.'}\n",
            "17: abstract: {'1': 'Study objectives: Many factors influence the rate of gastric emptying and therefore the rate of drug absorption in the orally poisoned patient.', '2': 'Limited studies have evaluated the effect of body position on the rate of gastric emptying of radiographically marked foods and contrast media, but effects on drug absorption have not been studied previously.', '3': 'Our hypothesis was that body position would have an effect on the rate of drug absorption in an oral overdose model.', '4': 'Design: A blinded, within-subjects (crossover) design.', '5': 'Participants: Six male and six female healthy, adult volunteer subjects with no concurrent drug use or medications affecting gastrointestinal function.', '6': 'Interventions: Five body positions commonly used in prehospital and emergency department settings were examined: left lateral decubitus, right lateral decubitus, supine, prone, and sitting.', '7': 'All were performed by all subjects in random order with a three-day washout phase between trials.', '8': 'To simulate an acute overdose, fasted subjects ingested 80 mg/kg acetaminophen in the form of 160-mg pediatric tablets.', '9': 'Each subject then remained in the body position for that trial for two hours.', '10': 'Acetaminophen levels were obtained at 15-minute intervals, and a two-hour area under the curve (AUC) was calculated for each subject trial to represent total drug absorption during each study period.', '11': 'Investigators were blinded to all results until all trials were completed.', '12': 'Measurements and main results: All subjects completed the study.', '13': 'Group mean drug absorption as represented by two-hour AUC (mg.L.min) was calculated for each body position.', '14': 'AUC for left lateral decubitus (6,006 +/- 2,614) was lowest but did not significantly differ from that for supine (6,649 +/- 2,761).', '15': 'Both were significantly less than those for prone (7,432 +/- 1,809), right lateral decubitus (8,950 +/- 1,405), and sitting (8,608 +/- 1,725) positions (P less than .05 by one-way analysis of variance and follow-up paired t tests).', '16': 'Conclusion: Initial drug absorption as determined by two-hour AUC was lowest in the left lateral decubitus position.', '17': 'Although the difference between the left lateral decubitus and supine positions did not reach statistical significance, both left lateral decubitus and supine were significantly lower than three other common patient body positions tested.', '18': 'Because the left lateral decubitus position has other advantages (eg, prevention of aspiration) in addition to minimizing drug absorption, we recommend that orally poisoned patients be placed in the left lateral decubitus position for prehospital and initial ED management.'}\n",
            "17: abstract: {'1': 'Ensuring free passage of air is the first priority in emergency care of patients.', '2': 'Removing obstruction to softtissue, dislodging obstructing foreign bodies and positioning the patient correctly usually secure open airways and respiration in trauma patients.', '3': 'If respiration has ceased, oroendotracheal intubation is necessary and should be performed by trained personnel.', '4': 'Correct control of airways may reduce morbidity and mortality.', '5': 'The author discusses the practical aspects of control of airways and unobstructed respiration.'}\n",
            "17: abstract: {'1': 'Definitive management of the unconscious choking victim, whether in hospital or in the field, should include removal of the foreign body by instrumentation under direct visualization.', '2': 'However, there is debate as to the best management of the conscious victim with an obstructed upper airway and of the unconscious victim for whom such definitive instrumentation is not available.', '3': 'Which artificial-cough maneuver is the most eficacious in clearing the obstructed airway?', '4': 'Which maneuver should be used first?', '5': 'What are the complications of the various techniques?', '6': 'Is any maneuver dangerous or deleterious?', '7': 'To date there is no consensus on any of these issues.', '8': 'There are significant discrepancies in the literature as to which technique produces the highest intrathoracic pressures and airflow rates.', '9': 'Most of the data seem to support the conclusion that blows to the back generate the highest intrathoracic pressure, whereas chest or abdominal thrust produces the highest airflow rate.', '10': 'Clinically, all the maneuvers are somewhat efficacious in clearing the obstructed airway when used alone; however, each maneuver seems to be substantially more efficacious when used in combination with another maneuver.', '11': 'Also, the results appear to be more successful when pressure is applied as a series of jolts rather than applied steadily.'}\n",
            "17: abstract: {'1': 'The patient who presents with a serious head injury is often very difficult to manage.', '2': 'The airways is of primary concern; adequate ventilation must be provided and aspiration protected against.', '3': 'Recent studies suggest that hyperventilation may be as beneficial as was earlier believed.', '4': 'As the pCO2 level decreases, vasoconstriction occurs.', '5': 'If the level falls too low, cerebral perfusion is restricted, and profound cerebral anoxia may ensue.', '6': 'Current standards call for a ventilatory rate to allow for moderate respiratory alkalosis, in theory to mildly constrict teh vessels but still provide adequate perfusion.', '7': 'Arterial blood gas analysis in the ED is the definitive measurement of airway management in the field.', '8': 'Remember that the anatomy of the meningeal layers places the arteries primarily in the epidural space and the veins in the subdural space.', '9': 'A bleed in the epidural space often presents with a rapid onset of signs and symptoms, as was obvious in this traumatized patient.', '10': 'When a bleed occurs in the subdural space, the onset is usually more insidious, and an accurate history is a key to field diagnosis.', '11': 'As the hemorrhage expands, compression displaces the brain within the cranial vault.', '12': 'This displacement causes pressure to be exerted on the medulla of the brainstem.', '13': \"Cushing's Traid is a result of this pressure on the medulla and is evidence by the pulse slowing while systolic blood pressure rises and respirations become ataxic.\", '14': 'Vomiting is often associated, and as the bleed continues, herniation syndrome begins.', '15': 'Decorticate posturing is displayed, followed by decerebrate posturing if relief is not provided.', '16': 'It is important to distinguish between decorticate and decerebrate posturing.', '17': 'It is important to distinguish between decorticate and decerebrate posturing.', '18': 'An easy way to remember the differences is to picture the anatomy of the brain.', '19': 'The cerebral cortex lies above the cerebellum, so when a patient\\'s arms flexed up toward the face , he is pointing to his \"core\" (de-cor-ticate).', '20': 'As the arms extend downward, he is pointing to his cerebellum(de-cere-brate).', '21': 'T o manage the head-injured patient, it is imperative to anticipate potential developments, as well as protect against underlying injuries that may not be fully evaluated until arrival at the ED.', '22': 'Cervical spine often accompany head injuries, and full spinal immobilization is a mandatory precaution in all presentations.', '23': \"With the expanding hematoma found on this patient's neck, vascular damage ws obvious and contributed to the suspicion of spinal injury.\", '24': 'As the intracranial pressure rise, vomiting and seizures are common.', '25': 'Placement of an endotracheal tube and having suction equipment ready are the best tools to prevent against aspiration.', '26': \"It is possible to angle the long spine board 10-15 degrees, exercising caution to ensure the patient's spinal alignment is not manipulated during the process.\", '27': 'Seizures are usually treated with anticonvulsants like Valium.', '28': 'When a seizure accompanies a head injury, it is a direct result of the increased intracranial pressure and has a generally poor response to Valium, as the underlying cause of the seizure still exists.', '29': 'In this case, the patient had a full neuromuscular blockade, and any seizure would not have been recognized as long as the paralytics were on board.', '30': 'Early notification to the ED is essential, reporting all findings and interventions.', '31': 'This can alert them and give them the opportunity to prepare specialized equipment, such as CT scanners, mechanical ventilators, etc.', '32': 'Also, consider transportation options and the length of time to definitive care, including neurosurgical evaluation.', '33': 'This patient needs to be seen in a trauma center capable of the most thorough evaluation and management.', '34': 'Evacuation by air ambulance may be the most appropriate method of transport.'}\n",
            "17: abstract: {'1': 'The airway obstruction concerns any situation that clogs partially or totally the normal pulmonary ventilation.', '2': 'In this way, it is an absolute emergency which in case of not being solved leads to death in afew minutes.', '3': 'One of the most common airway obstructions is the one that results from an extrinsic cause to the airway--food, blood or vomit.', '4': 'Any solid object can work as a foreign body and cause an airway obstruction--mechanical obstruction.', '5': 'Evaluation and control of the airway are carried out through quick and simple procedures.', '6': 'Initially there is no need for any equipment, being just enough the application of manual techniques for control and disobliteration.', '7': 'Interscapular claps, the Heimlich Manoeuvre and the Thoracic Compressions, are manual techniques used in the disobliteration of the respiratory tract due to a solid body.'}\n",
            "17: abstract: {'1': 'Abdominal thrusts or the Heimlich maneuver is a first-aid procedure used to treat upper airway obstruction caused by a foreign body.', '2': 'This skill is commonly taught during basic life support (BLS) and advanced cardiac life support (ACLS) classes, but it never receives as much attention as chest compressions and rescue breaths do.', '3': 'The abdominal thrust maneuver can be performed in both children and adults via different techniques.', '4': 'In the 1960s, choking on food, toys, and other objects was the sixth leading cause of accidental death in the United States.', '5': 'Slapping individuals on the back was the main response and was frequently found to be ineffective, at times even lodging the object further down.', '6': 'The Heimlich maneuver was initially introduced in 1974 by Dr. Henry Heimlich after proving his theory that the reserve of air in the lung could serve to dislodge objects from the esophagus by quick upwards thrust under the ribcage.', '7': 'The medical community of the time did not embrace the maneuver right away.', '8': 'The American Red Cross (ARC) and the American Heart Association (AHA) continued to promoted backslaps for ten years after the introduction of the Heimlich maneuver.', '9': 'Today, the Heimlich maneuver is accepted and taught during BLS and ACLS for conscious adults, but backslaps are still a recommendation for infants, and chest compressions are recommended for unconscious patients.', '10': 'Furthermore, different techniques of the maneuver have been developed with conflicting effectiveness results.'}\n",
            "17: abstract: {'1': 'Background: Oral poisoning is a major cause of mortality and disability worldwide, with estimates of over 100,000 deaths due to unintentional poisoning each year and an overrepresentation of children below five years of age.', '2': 'Any effective intervention that laypeople can apply to limit or delay uptake or to evacuate, dilute or neutralize the poison before professional help arrives may limit toxicity and save lives.', '3': 'Objectives: To assess the effects of pre-hospital interventions (alone or in combination) for treating acute oral poisoning, available to and feasible for laypeople before the arrival of professional help.', '4': \"Authors' conclusions: The studies included in this review provided mostly low- or very low-certainty evidence about the use of first aid interventions for acute oral poisoning.\", '5': 'A key limitation was the fact that only one included study actually took place in a pre-hospital setting, which undermines our confidence in the applicability of these results to this setting.', '6': 'Thus, the amount of evidence collected was insufficient to draw any conclusions.'}\n",
            "17: abstract: {'1': 'Introduction: In acute oral poisoning, any first aid intervention that limits or delays the uptake of the ingested substance, and which can be performed by bystanders as first responders, might assist in reducing morbidity if a toxic substance has been ingested.', '2': 'The current recommendation by the International Federation of Red Cross/Red Crescent Societies is to place a victim in the left lateral decubitus position.', '3': 'Conclusions: The identified studies provide evidence of very low certainty.', '4': 'However, based on the evidence that the left lateral decubitus position may be effective in decreasing the absorption of several drugs, the simplicity of the intervention and the generally low perceived risk of this intervention, the recommendation of the first aid guidelines of the International Federation of Red Cross and Red Crescent Societies can remain unchanged.'}\n",
            "18: abstract: {'1': 'The extent to which given levels of caloric restriction will improve glycemic status but increase plasma ketone bodies in gestational diabetic women has received little attention.', '2': 'After reviewing the underlying physiology, we present data on two feeding studies investigating the question.', '3': 'In the first, a weight-maintaining approximately 2400-kcal/day diet was fed on a metabolic ward to 12 gestational diabetic women for 1 week.', '4': 'In the second week, subjects were randomized to a continuation of the 2400-kcal/day diet or to a 1200-kcal/day diet.', '5': 'Twenty-four-hour mean glucose levels remained unchanged in the control group but declined in the calorie-restricted group (6.7 mM or 121 mg/dl in week 1 vs 5.4 mM or 97.3 mg/dl in week 2) (p less than 0.01).', '6': 'Nine-hour overnight fasting plasma insulin also declined but oral glucose tolerance did not improve with caloric restriction.', '7': 'Fasting plasma beta-hydroxybutyrate rose in the calorie-restricted group, along with an increase in ketonuria, but not in the control group.', '8': 'A second study compared the impact of a 33% calorie-restricted diet or insulin to a full-calorie diet in a similar 2-week experimental design and measured hepatic glucose output and insulin sensitivity with dideuterated glucose before and during an insulin clamp.', '9': 'Diet in three subjects improved fasting and 24-hr mean glucose by 22 and 10%, respectively, whereas prophylactic insulin in three subjects produced 0 and 4% reductions, respectively.', '10': 'On average, ketonuria after a 9-hr fast declined to an equivalent degree with both treatments.', '11': 'Hepatic glucose output and insulin sensitivity were not statistically significantly altered by gestational diabetes or the therapeutic interventions compared to nondiabetic normal weight or obese pregnant controls.', '12': 'In conclusion, 50% caloric restriction improves glycemic status in obese women with gestational diabetes but is associated with an increase in ketonuria, which is of uncertain significance.', '13': 'An intermediate 33% level of caloric restriction (to 1600-1800 kcal daily) may be more appropriate in dietary management of obese woman with gestational diabetes mellitus and more effective than prophylactic insulin.', '14': 'Further studies are required to confirm these findings.'}\n",
            "18: abstract: {'1': 'Objective: To determine the effect of carbohydrate restriction on perinatal outcome in patients with diet-controlled gestational diabetes mellitus (GDM).', '2': 'Methods: Women with diet-controlled GDM were divided non-randomly into two groups based on their dietary carbohydrate content: those with low dietary carbohydrate content (below 42%) and those with high dietary carbohydrate content (exceeding 45%).', '3': 'Subjects kept dietary accounts and were followed with daily fasting and postprandial glucose assessments.', '4': 'Subjects also were tested daily for urinary ketones.', '5': 'Glycosylated hemoglobin, mean fasting and postprandial glucose values, incidence of macrosomia and large for gestational age (LGA) infants, cesarean deliveries for cephalopelvic disproportion and macrosomia, and need for insulin therapy were compared between the groups.', '6': 'Results: The two groups were identical in terms of demographic characteristics.', '7': 'Significant reductions in the postprandial glucose values were seen among subjects in the low-carbohydrate group (P < .04).', '8': 'Fewer subjects in the low-carbohydrate group required the addition of insulin for glucose control (P < .047; relative risk [RR] 0.14; 95% confidence interval [CI] 0.02, 1.00).', '9': 'The incidence of LGA infants was significantly lower in the low-carbohydrate group (P < .035; RR 0.22; 95% CI 0.05, 0.91).', '10': 'Subjects in the low carbohydrate group also had a lower rate of cesarean deliveries for cephalopelvic disproportion and macrosomia (P < .037; RR 0.15; 95% CI 0.04, 0.94).', '11': 'Conclusion: Carbohydrate restriction in patients with diet-controlled GDM results in improved glycemic control, less need for insulin therapy, a decrease in the incidence LGA infants, and a decrease in cesarean deliveries for cephalopelvic disproportion and macrosomia.'}\n",
            "18: abstract: {'1': 'Objective: The object of the study was to determine whether time of day, interval after a standard meal, and maternal body mass influence plasma glucose concentrations in women with gestational diabetes mellitus.', '2': \"Study design: Identical mixed meals were administered on 2 separate occasions 1 week apart to 30 women with dietarily treated gestational diabetes and pregnancies between 28 and 38 weeks' gestation.\", '3': 'One meal was administered at 7 AM (morning meal) and the other was administered at 9 PM (evening meal), each after a fast of >/=5 hours.', '4': 'The order of the meals (morning first versus evening first) was assigned randomly.', '5': 'Sixteen of the women had a body mass index >/=27 kg/m(2) (overweight) and 14 women had a body mass index <27 kg/m(2) (lean).', '6': 'Venous plasma concentrations of glucose, insulin, free fatty acids, beta-hydroxybutyrate, and bound and free cortisol were measured hourly for 9 hours after each of the test meals.', '7': 'Results: When all women were considered together glucose concentrations after the morning meal were significantly greater at 1 hour, were not different at 2 hours, and were significantly lower from 3 through 9 hours postprandially than those at corresponding times after the evening meal.', '8': 'Plasma beta-hydroxybutyrate and free fatty acid concentrations were higher between 5 and 9 hours after the morning meal than at the same times after the evening meal.', '9': 'Total and free cortisol levels were higher for the first 7 hours after the morning feeding, reflecting known diurnal variation in cortisol concentrations.', '10': \"Overweight patients' glucose values were significantly greater than those of lean subjects during the last 4 hours of the overnight fast.\", '11': 'Conclusions: Among women with dietarily treated gestational diabetes the glucose concentrations were significantly higher from 3 to 9 hours after an evening meal, whereas suppression of free fatty acids and beta-hydroxybutyrate was less sustained after a morning feeding.', '12': 'The mechanisms underlying these differences remain to be determined but may involve diurnal influences of counterregulatory hormones.', '13': 'The relationships between measurements of maternal glycemia and maternal and perinatal outcomes in pregnancies complicated by gestational diabetes may be clarified by establishing a uniform duration of a fast and by developing meal-specific preprandial and postprandial maternal glucose targets for these patients.'}\n",
            "18: abstract: {'1': 'Aim: To measure ketonemia in a control population of pregnant women and in a population of women with gestational diabetes (GDM).', '2': 'To define a normal ketonemia threshold for the controls and to determine whether or not this value could play a role in the clinical management of women with GDM.', '3': 'Method: Fifty-six women with a normal OGTT and 49 women with GDM were included and monitored from the 25th to the 37th week of pregnancy.', '4': 'Control subjects agreed to perform glycaemia and ketonemia self-monitoring 3 times a day.', '5': 'In addition, women with GDM were asked to measure their postprandial glycaemia.', '6': 'Glycaemia and ketonemia measurements were performed using Optium meters.', '7': 'Subjects kept a 24-hour food record twice a week.', '8': 'Results: The mean ketonemia was lower in the control group than in the GDM group (0.01+/-0.10 vs. 0.04+/-0.009 mmol/l; P<0.001).', '9': 'Ketonemia values measured before the midday meal and prior to the evening meal were lower for control subjects than for GDM patients (P=0.002 and P=0.005).', '10': 'Fasting ketonemia was unrelated to ketonuria in the GDM group, whereas there was a correlation in the control group (P=0.006).', '11': 'At least one chronic increase in ketonemia levels was observed in 47% of the women with GDM, compared with only 12% of controls.', '12': 'The lowest levels of evening glycaemia correlated with the highest levels of ketonemia; women with GDM reported lower food and carbohydrate intakes than controls (P<0.001).', '13': 'Conclusion: This work has enabled the establishment of ketonemia reference standards in non-diabetic pregnant women.', '14': 'If ketonemia does indeed indicate overly restrictive dietary behavior, this parameter could be employed for monitoring adherence to the nutritional recommendations for GDM.'}\n",
            "18: abstract: {'1': 'Nutrient intake plays a significant role in the health outcomes of all pregnant women.', '2': 'In a pregnancy complicated by gestational diabetes mellitus (GDM), excellent glucose control is as foundational as appropriate weight gain and adequate nutrient intake.', '3': 'The controversies in GDM management include the following: how far to manipulate energy intake, dietary composition (carbohydrates and fats), and gestational weight gain.', '4': 'Signs that food restrictions have gone too far include weight loss or lack of weight gain, undereating to avoid insulin therapy, positive urinary ketones, and intentional restriction of healthy foods.', '5': 'If a balance between nutrient needs and glucose control cannot be achieved, then concurrent medication therapy is needed to assist in reducing insulin resistance and supplementing insulin production to provide normoglycemia and improved pregnancy outcomes.', '6': 'Medical nutrition therapy is a self-management therapy.', '7': 'Education, support, and follow-up are required to assist the woman to make lifestyle changes essential to successful nutrition therapy.', '8': 'Women with GDM are at increased risk for type 2 diabetes; learning to manage GDM with lifestyle change provides an opportunity to affect personal risk factors and the health of the whole family.'}\n",
            "18: abstract: {'1': 'Introduction: Nutrition therapy is an integral part of the management of gestational diabetes mellitus (GDM).', '2': 'Most women with GDM are treated by nutritional management alone.', '3': 'The goal of our study was to compare low and high carbohydrate diets in their effectiveness, safety and tolerability in women with GDM.', '4': 'Material and methods: The study group consisted of 30 Caucasian women newly diagnosed with GDM, with a mean age of 28.7 +/- 3.7 years and pregnancy duration of 29.2 +/- 5.4 weeks.', '5': 'The patients were randomised into two groups: those on a low and those on a high carbohydrate diet (45% vs. 65% respectively of energy supply coming from carbohydrates).', '6': 'The presence of urine ketones was controlled every day.', '7': 'After two weeks daily glucose profiles and compliance with the recommended diets were analysed.', '8': 'Results: Glucose concentration before implementation of the diet regimen did not differ between groups.', '9': 'No changes in fasting blood glucose were noticed in the group that had followed a low carbohydrate diet, although a significant decrease in glucose concentration was observed after breakfast (102 +/- 16 vs. 94 +/- 11 mg/dl), lunch (105 +/- 12 vs. 99 +/- 9 mg/dl) and dinner (112 +/- 16 vs. 103 +/- 13 mg/dl) (p < 0.05).', '10': 'In the high carbohydrate diet group fasting and after-breakfast glucose concentration did not change.', '11': 'A significant decrease in glycaemia was noticed after lunch (106 +/- 15 vs. 96 +/- 7 mg/dl) and dinner (107 +/- 12 vs. 97 +/- 7 mg/dl) (p < 0.05).', '12': 'Ketonuria was not observed in either group.', '13': 'Obstetrical outcomes did not differ between groups.', '14': 'Conclusions: Both high and low carbohydrate diets are effective and safe.', '15': 'A diet with carbohydrate limitation should be recommended to women who experience the highest glycaemia levels after breakfast.'}\n",
            "18: abstract: {'1': 'Current controversies for medical nutrition therapy in pregnancies complicated by diabetes include the composition and amount of carbohydrates and fats as well as optimal gestational weight gain and energy restriction.', '2': 'Although carbohydrate is the macronutrient with the greatest effect on glycemic control, there is little evidence for a recommended amount and type of carbohydrate or its distribution.', '3': 'This lack of evidence prompts an issue of debate among practitioners over the type of carbohydrate and its percent distribution throughout the day.', '4': 'The best indicators at this time are the results of self-monitoring of blood glucose, ketone testing, food records, and weight gain.', '5': 'A review of the literature provides the most current information available for medical nutrition therapy during a pregnancy complicated by diabetes and reinforces the need for further research in the form of randomized controlled trials to answer questions regarding carbohydrate modification and distribution, energy needs, and weight gain.'}\n",
            "18: abstract: {'1': 'Group 1 (All Types of CHO) The intervention followed the American Dietetic Association nutrition practice guidelines for gestational diabetes.', '2': 'Women received an individual food plan based on CHO restriction (40–45% of TEI), using a CHO counting strategy (basic level).', '3': 'Moderate energy restriction was recommended only for overweight and obese women (24\\u2009kcal/kg).', '4': 'Breakfast CHO intake was limited to 15–30\\u2009g, and adequate fiber intake was promoted (20–35\\u2009g/day).', '5': 'Women in this group were advised to choose any type of CHO, except added refined sugars.', '6': 'Energy and CHO prescriptions were revised at every visit and changes were done according to weight gain and whether or not ketonuria was present.', '7': 'If ketones were present and weight gain was subnormal, energy prescription was increased (200 to 300\\u2009kcal/day).', '8': 'If weight gain was adequate, energy was not modified and carbohydrates were increased (no more than 45% of TEI).', '9': 'Fat intake recommendation was maintained (<40% of TEI), and protein recommendation adjustment was made accordingly (20–25% of TEI).', '10': 'Group 2 (Low GI CHO) Women in this group received the same intervention as women in Group 1, but were counseled to eliminate all moderate and high GI foods (GI > 55).', '11': 'Tropical fruits, refined breads, breakfast cereals, flour tortilla, white rice, refined cookies and pastries, potatoes, carrots, beets, and refined sugars were eliminated from their plan.', '12': 'Papaya was the only moderate GI fruit permitted because it is one of the most frequently consumed high-fiber foods in this population.', '13': 'Corn tortillas were included only when combined with beans, as well as corn flakes combined with milk, according to some evidence that the combination of these foods decreases their GI.', '14': 'Conclusions. Inclusion of low GI CHO as part of a comprehensive nutrition intervention is equally effective in improving glycemic control as compared to all types of CHO.', '15': 'This strategy had a positive effect in preventing excessive maternal weight gain but increased the risk of prematurity.'}\n",
            "18: abstract: {'1': 'Medical nutrition therapy (MNT) plays an important role in the management of gestational diabetes mellitus (GDM), and accordingly, it has a significant impact on women and newborns.', '2': 'The primary objective of MNT is to ensure adequate pregnancy weight gain and fetus growth while maintaining euglycemia and avoiding ketones.', '3': 'However, the optimal diet (energy content, macronutrient distribution, its quality and amount, among others) remains an outstanding question.', '4': 'Overall, the nutritional requirements of GDM are similar for all pregnancies, but special attention is paid to carbohydrates.', '5': 'Despite the classical intervention of restricting carbohydrates, the latest evidence, although limited, seems to favor a low-glycemic index diet.', '6': 'There is general agreement in the literature about caloric restrictions in the case of being overweight or obese.', '7': 'Randomized controlled trials are necessary to investigate the optimal MNT for GDM; this knowledge could yield health benefits and cost savings.'}\n",
            "18: abstract: {'1': 'Background: Lower carbohydrate diets have the potential to improve glycemia but may increase ketonemia in women with gestational diabetes (GDM).', '2': 'We hypothesized that modestly lower carbohydrate intake would not increase ketonemia.', '3': 'Objective: To compare blood ketone concentration, risk of ketonemia, and pregnancy outcomes in women with GDM randomly assigned to a lower carbohydrate diet or routine care.', '4': 'Methods: Forty-six women aged (mean ± SEM) 33.3 ± 0.6 y and prepregnancy BMI 26.8 ± 0.9 kg/m2 were randomly assigned at 28.5 ± 0.4 wk to a modestly lower carbohydrate diet (MLC, ∼135 g/d carbohydrate) or routine care (RC, ∼200 g/d) for 6 wk.', '5': 'Blood ketones were ascertained by finger prick test strips and 3-d food diaries were collected at baseline and end of the intervention.', '6': 'Results: There were no detectable differences in blood ketones between completers in the MLC group compared with the RC group (0.1 ± 0.0 compared with 0.1 ± 0.0 mmol/L, n = 33, P = 0.31, respectively), even though carbohydrate and total energy intake were significantly lower in the intervention group (carbohydrate 165 ± 7 compared with 190 ± 9 g, P = 0.04; energy 7040 ± 240 compared with 8230 ± 320 kJ, P <0.01, respectively).', '7': 'Only 20% of participants in the MLC group met the target intake compared with 65% in the RC group (P <0.01).', '8': 'There were no differences in birth weight, rate of large-for-gestational-age infants, percent fat mass, or fat-free mass between groups.', '9': 'Conclusions: An intervention to reduce carbohydrate intake in GDM did not raise ketones to clinical significance, possibly because the target of 135 g/d was difficult to achieve in pregnancy.', '10': 'Feeding studies with food provision may be needed to assess the benefits and risks of low-carbohydrate diets.'}\n",
            "19: abstract: {'1': \"Objectives: Parkinson's disease (PD) features both motor and non-motor symptoms that substantially impact quality of life (QoL).\", '2': 'Levodopa-carbidopa intestinal gel (LCIG) reduces motor complications and improves some non-motor symptoms in advanced PD (APD).', '3': \"Change in patients' health-related quality of life (hrQoL) is a common endpoint in PD trials and has become an important factor in judging overall effect of LCIG.\", '4': 'However, hrQoL is considered to be only one dimension of QoL.', '5': 'The primary aim of this prospective observational study was to observe the effects of LCIG on individual quality of life (iQoL) in PD and caregivers.', '6': \"The secondary aim was to investigate its effects on patients' motor and non-motor symptoms as well as effects on caregiver burden.\", '7': 'Materials & methods: Utilizing the Schedule for the Evaluation of Individual Quality of Life-Questionnaire (SEIQoL-Q) and the Personal Wellbeing Index-Adult (PWI-A), twelve patients with advanced PD and their caregivers were followed for six months after initiation of LCIG treatment.', '8': 'Results: At the final follow-up, improvements of iQoL for patients (median SEIQoL index improvement 0.16, P < .05) and caregivers (median SEIQoL index improvement 0.20, P < .05) were seen together with improvements of motor and non-motor symptoms.', '9': 'There were no significant improvements of hrQoL.', '10': 'Conclusions: The study results indicate that LCIG improves iQoL in PD in addition to the improvement of motor and non-motor symptoms.', '11': 'Furthermore, this study signals that LCIG may also contribute to improvement of iQoL in caregivers.'}\n",
            "19: abstract: {'1': \"A vast advancement has been made in the treatment related to central nervous system disorders especially Parkinson's disease.\", '2': \"The development in therapeutics and a better understanding of the targets results in upsurge of many promising therapies for Parkinson's disease.\", '3': \"Parkinson's disease is defined by neuronal degeneration and neuroinflammation and it is reported that the presence of the neurofibrillary aggregates such as Lewy bodies is considered as the marker.\", '4': 'Along with this, it is also characterized by the presence of motor and non-motor symptoms, as seen in Parkinsonian patients.', '5': \"A lot of treatment options mainly focus on prophylactic measures or the symptomatic treatment of Parkinson's disease.\", '6': \"Neuroinflammation and neurodegeneration are the point of interest which can be exploited as a new target to emphasis on Parkinson's disease.\", '7': \"A thorough study of these targets helps in modifications of those molecules which are particularly involved in causing the neuronal degeneration and neuroinflammation in Parkinson's disease.\", '8': \"A lot of drug regimens are available for the treatment of Parkinson's disease, although levodopa remains the choice of drug for controlling the symptoms, yet is accompanied with significant snags.\", '9': 'It is always suggested to use other drug therapies concomitantly with levodopa.', '10': \"A number of significant causes and therapeutic targets for Parkinson's disease have been identified in the last decade, here an attempt was made to highlight the most significant of them.\", '11': 'It was also found that the treatment regimen and involvement of therapies are totally dependent on individuals and can be tailored to the needs of each individual patient.'}\n",
            "19: abstract: {'1': 'Objective: We tested the hypothesis that there are 2 distinct phenotypes of Parkinson tremor, based on interindividual differences in the response of resting tremor to dopaminergic medication.', '2': 'We also investigated whether this pattern is specific to tremor by comparing interindividual differences in the dopamine response of tremor to that of bradykinesia.', '3': 'Methods: In this exploratory study, we performed a levodopa challenge in 76 tremulous patients with Parkinson tremor.', '4': 'Clinical scores (Movement Disorders Society-sponsored version of the Unified Parkinson\\'s Disease Rating Scale part III) were collected \"off\" and \"on\" a standardized dopaminergic challenge (200/50 mg dispersible levodopa-benserazide).', '5': 'In both sessions, resting tremor intensity was quantified using accelerometry, both during rest and during cognitive coactivation.', '6': 'Bradykinesia was quantified using a speeded keyboard test.', '7': 'We calculated the distribution of dopamine-responsiveness for resting tremor and bradykinesia.', '8': 'In 41 patients, a double-blinded, placebo-controlled dopaminergic challenge was repeated after approximately 6 months.', '9': 'Results: The dopamine response of resting tremor, but not bradykinesia, significantly departed from a normal distribution.', '10': 'A cluster analysis on 3 clinical and electrophysiologic markers of tremor dopamine-responsiveness revealed 3 clusters: dopamine-responsive, intermediate, and dopamine-resistant tremor.', '11': 'A repeated levodopa challenge after 6 months confirmed this classification.', '12': 'Patients with dopamine-responsive tremor had greater disease severity and tended to have a higher prevalence of dyskinesia.', '13': 'Conclusion: Parkinson resting tremor can be divided into 3 partially overlapping phenotypes, based on the dopamine response.', '14': 'These tremor phenotypes may be associated with different underlying pathophysiologic mechanisms, requiring a different therapeutic approach.'}\n",
            "19: abstract: {'1': \"Parkinson's disease (PD) is diagnosed where bradykinesia occurs together with rigidity or tremor, in the presence of supporting features.\", '2': \"The diagnosis is clinical, and attention should be paid to exclusion criteria indicating an alternative diagnosis and to 'red flag' features.\", '3': 'There is no cure or disease-modifying treatment for PD, and the rate of progression is variable.', '4': 'The most effective symptomatic treatment remains levodopa, which has superior benefits for quality of life in early PD compared to other therapies.', '5': 'Motor fluctuations and dyskinesia later in the disease course can be improved with adjunctive treatments.', '6': 'Around 10% of patients per year with refractory motor fluctuations may be eligible for advanced therapies, including deep-brain stimulation surgery.', '7': 'There is emerging evidence for the management of non-motor symptoms in PD, and the importance of multidisciplinary care.', '8': 'In this article, the evidence base for optimal diagnosis and management of PD is discussed.'}\n",
            "19: abstract: {'1': \"Purpose: To investigate the comparative effectiveness of dopamine agonists and monoamine oxidase type-B (MAO-B) inhibitors available for treatment of Parkinson's disease.\", '2': \"Methods: We performed a systematic literature search identifying randomized controlled trials investigating 4 dopamine agonists (cabergoline, pramipexole, ropinirole, rotigotine) and 3 MAO-B inhibitors (selegiline, rasagiline, safinamide) for Parkinson's disease.\", '3': 'We extracted and pooled data from included clinical trials in a joint model allowing both direct and indirect comparison of the seven drugs.', '4': 'We considered dopamine agonists and MAO-B inhibitors given as monotherapy or in combination with levodopa.', '5': \"Selected endpoints were change in the Unified Parkinson's Disease Rating Scale (UPDRS) score, serious adverse events and withdrawals.\", '6': 'We estimated the relative effectiveness of each dopamine agonist and MAO-B inhibitor versus comparator drug.', '7': 'Results: Altogether, 79 publications were included in the analysis.', '8': 'We found all the investigated drugs to be effective compared with placebo when given as monotherapy except safinamide.', '9': 'When considering combination treatment, the estimated relative effects of selegiline, pramipexole, ropinirole, rotigotine, cabergoline, rasagiline and safinamide were 2.316 (1.819, 2.951), 2.091 (1.889, 2.317), 2.037 (1.804, 2.294), 1.912 (1.716, 2.129), 1.664 (1.113, 2.418), 1.584 (1.379, 1.820) and 1.179 (1.031, 1.352), respectively, compared with joint placebo and levodopa treatment.', '10': \"Conclusions: Dopamine agonists were found to be effective as treatment for Parkinson's disease, both when given as monotherapy and in combination with levodopa.\", '11': \"Selegiline and rasagiline were also found to be effective for treating Parkinson's disease, and selegiline was the best option in combination with levodopa among all the drugs investigated.\"}\n",
            "19: abstract: {'1': \"Parkinson's disease (PD), the second most frequent neurodegenerative disease, has been linked to increased central and peripheral inflammation.\", '2': 'Although the response of the immune system to dopaminergic treatment remains to be fully understood, dopaminergic agonists are known to exhibit immunoregulatory properties which may, at least in part, explain their therapeutic effect in PD.', '3': 'This highlights the need of analyzing immune parameters in longitudinal studies on PD patients receiving specific therapeutic regimes.', '4': 'In this work, PD patients were included in a two-year prospective study comparing the effect of levodopa alone and a levodopa/pramipexole combo therapy on several regulatory and pro-inflammatory immune cell populations.', '5': 'We demonstrated that PD patients show decreased circulating levels of several important regulatory subpopulations, as determined by flow cytometry.', '6': 'Notably, when administered alone, levodopa decreased the levels of functional Bregs and SLAMF1+ tolerogenic DCs and increased the levels of total and HLA-DR+ classical monocytes, while the pramipexole/levodopa combo may promote Treg- and tolerogenic DC-mediated regulatory responses.', '7': 'These results suggest that a regime based on levodopa alone may promote a pro-inflammatory-type response in PD patients, but when combined with pramipexole, it promotes a clinically beneficial regulatory-type environment.'}\n",
            "19: abstract: {'1': \"Introduction: Long-term treatment of Parkinson's disease (PD) with levodopa is hampered by motor complications related to the inability of residual nigrostriatal neurons to convert levodopa to dopamine (DA) and use it appropriately.\", '2': 'This generated a tendency to postpone levodopa, favoring the initial use of DA agonists, which directly stimulate striatal dopaminergic receptors.', '3': 'Use of DA agonists, however, is associated with multiple side effects and their efficacy is limited by suboptimal bioavailability.', '4': 'Areas covered: This paper reviewed the latest preclinical and clinical findings on the efficacy and adverse effects of non-ergot DA agonists, discussing the present and future of this class of compounds in PD therapy.', '5': 'Expert opinion: The latest findings confirm the effectiveness of DA agonists as initial treatment or adjunctive therapy to levodopa in advanced PD, but a more conservative approach to their use is emerging, due to the complexity and repercussions of their side effects.', '6': 'As various factors may increase the individual risk to side effects, assessing such risk and calibrating the use of DA agonists accordingly may become extremely important in the clinical management of PD, as well as the availability of new DA agonists with better profiles of safety and efficacy.'}\n",
            "19: abstract: {'1': \"Degradation of striatal dopamine in Parkinson's disease (PD) may initially be supplemented by increased cognitive control mediated by cholinergic mechanisms.\", '2': 'Shift to cognitive control of walking can be quantified by prefrontal cortex activation.', '3': 'Levodopa improves certain aspects of gait and worsens others, and cholinergic augmentation influence on gait and prefrontal cortex activity remains unclear.', '4': 'This study examined dopaminergic and cholinergic influence on gait and prefrontal cortex activity while walking in PD.', '5': 'A single-site, randomized, double-blind crossover trial examined effects of levodopa and donepezil in PD.', '6': 'Twenty PD participants were randomized, and 19 completed the trial.', '7': 'Participants were randomized to either levodopa + donepezil (5 mg) or levodopa + placebo treatments, with 2 weeks with treatment and a 2-week washout.', '8': 'The primary outcome was change in prefrontal cortex activity while walking, and secondary outcomes were change in gait and dual-task performance and attention.', '9': 'Levodopa decreased prefrontal cortex activity compared with off medication (effect size, -0.51), whereas the addition of donepezil reversed this decrease.', '10': 'Gait speed and stride length under single- and dual-task conditions improved with combined donepezil and levodopa compared with off medication (effect size, 1 for gait speed and 0.75 for stride length).', '11': 'Dual-task reaction time was quicker with levodopa compared with off medication (effect size, -0.87), and accuracy improved with combined donepezil and levodopa (effect size, 0.47).', '12': 'Cholinergic therapy, specifically donepezil 5 mg/day for 2 weeks, can alter prefrontal cortex activity when walking and improve secondary cognitive task accuracy and gait in PD.', '13': 'Further studies will investigate whether higher prefrontal cortex activity while walking is associated with gait changes.'}\n",
            "19: abstract: {'1': \"The natural pattern of progression of Parkinson's disease is largely unknown because patients are conventionally followed on treatment.\", '2': \"As Parkinson's disease progresses, the true magnitude of the long-duration response to levodopa remains unknown, because it can only be estimated indirectly in treated patients.\", '3': \"We aimed to describe the natural course of motor symptoms by assessing the natural OFF in consecutive Parkinson's disease patients never exposed to treatment (drug-naïve), and to investigate the effects of daily levodopa on the progression of motor disability in the OFF medication state over a 2-year period.\", '4': \"In this prospective naturalistic study in sub-Saharan Africa, 30 Parkinson's disease patients (age at onset 58 ± 14 years, disease duration 7 ± 4 years) began levodopa monotherapy and were prospectively assessed using the Unified Parkinson's disease Rating Scale (UPDRS).\", '5': 'Data were collected at baseline, at 1-year and 2-years follow-up.', '6': 'First-ever levodopa intake induced a significant improvement in motor symptoms (natural OFF versus ON state UPDRS-III 41.9 ± 15.9 versus 26.8 ± 15.1, respectively; P < 0.001).', '7': 'At 1-year follow-up, OFF state UPDRS-III score after overnight withdrawal of levodopa was considerably lower than natural OFF (26.5 ± 14.9; P < 0 .001).', '8': 'This effect was not modified by disease duration.', '9': 'At the 2-year follow-up, motor signs after overnight OFF (30.2 ± 14.2) were still 30% milder than natural OFF (P = 0.001).', '10': 'The ON state UPDRS-III at the first-ever levodopa challenge was similar to the overnight OFF score at 1-year follow-up and the two conditions were correlated (r = 0.72, P < 0.001).', '11': \"Compared to the natural progression of motor disability, levodopa treatment resulted in a 31% lower annual decline in UPDRS-III scores in the OFF state (3.33 versus 2.30 points/year) with a lower model's variance explained by disease duration (67% versus 36%).\", '12': 'Using the equation regressed on pretreatment data, we predicted the natural OFF at 1-year and 2-year follow-up visits and estimated that the magnitude of the long-duration response to levodopa ranged between 60% and 65% of total motor benefit provided by levodopa, independently of disease duration (P = 0.13).', '13': 'Although levodopa therapy was associated with motor fluctuations, overnight OFF disability during levodopa was invariably less severe than the natural course of the disease, independently of disease duration.', '14': 'The same applies to the yearly decline in UPDRS-III scores in the OFF state.', '15': \"Further research is needed to clarify the mechanisms underlying the long-duration response to levodopa in Parkinson's disease.\", '16': \"Understanding the natural course of Parkinson's disease and the long-duration response to levodopa may help to develop therapeutic strategies increasing its magnitude to improve patient quality of life and to better interpret the outcome of randomized clinical trials on disease-modifying therapies that still rely on the overnight OFF to define Parkinson's disease progression.\"}\n",
            "19: abstract: {'1': \"Background: No clinical trials have been specifically designed to compare medical treatments after surgery in Parkinson's disease (PD).\", '2': \"Objective: Study's objective was to compare the efficacy and safety of levodopa versus dopamine agonist monotherapy after deep brain stimulation (DBS) in PD.\", '3': 'Methods: Thirty-five surgical candidates were randomly assigned to receive postoperative monotherapy with either levodopa or dopamine agonist in a randomized, single-blind study.', '4': 'All patients were reevaluated in short- (3 months), mid- (6 months), and long-term (2.5 years) follow-up after surgery.', '5': 'The primary outcome measure was the change in the Non-Motor Symptoms Scale (NMSS) 3 months after surgery.', '6': 'Secondary outcome measures were the percentage of patients maintaining monotherapy, change in motor symptoms, and specific non-motor symptoms (NMS).', '7': 'Analysis was performed primarily in the intention-to-treat population.', '8': 'Results: Randomization did not significantly affect the primary outcome (difference in NMSS between treatment groups was 4.88 [95% confidence interval: -11.78-21.53, P = 0.566]).', '9': 'In short- and mid-term follow-up, monotherapy was safe and feasible in more than half of patients (60% in short- and 51.5% in mid-term follow-up), but it was more often possible for patients on levodopa.', '10': 'The ability to maintain dopamine agonist monotherapy was related to optimal contact location.', '11': 'In the long term, levodopa monotherapy was feasible only in a minority of patients (34.2%), whereas dopamine agonist monotherapy was not tolerated due to worsening of motor conditions or occurrence of impulse control disorders.', '12': 'Conclusions: This trial provides evidence for simplifying pharmacological treatment after functional neurosurgery for PD.', '13': 'The reduction in dopamine receptor agonists should be attempted while monitoring for occurrence of NMSs, such as apathy and sleep disturbances.'}\n",
            "20: abstract: {'1': 'Selective serotonin reuptake inhibitors (SSRIs) are a recently developed class of drugs with significantly greater antidepressant efficacy than placebo.', '2': \"Generally, in double-blind comparative trials, all SSRIs demonstrated antidepressant efficacy similar to that of the 'standard' tricyclic antidepressants amitriptyline and imipramine; a meta-analysis of controlled trials found the efficacy of the SSRIs to be equivalent to that of the 2 tricyclics.\", '3': 'Nevertheless, because of small patient numbers included in most studies that compare SSRIs with other antidepressants, no definitive statements about relative efficacy can be made.', '4': 'In these studies it is simply possible to state that no statistically significant differences were identified between SSRIs and the comparative antidepressants.', '5': 'Importantly, differences in clinical characteristics exist between the SSRIs-differences in elimination half-life (t1/2 beta) between fluoxetine and/or its metabolite (total t1/2 beta = 330 hours) and other SSRIs (t1/2 beta range = 15 to 30 hours), for example.', '6': 'This has implications in terms of potential drug interactions and must be considered when patients have to be switched to treatment with monoamine oxidase inhibitors.', '7': 'Studies with fluvoxamine have been conducted in both in- and outpatients, whereas trials with other SSRIs have been confined largely to outpatient populations.', '8': 'Fluvoxamine has been associated with a high incidence of nausea (37%), although this may have resulted from high initial dosages (rather than upward dose titration protocols) used in early trials.', '9': 'Of further interest, fluoxetine doses of 20mg may be sufficient to produce a satisfactory antidepressant response, and this SSRI may be particularly useful in patients with chronic retarded depression.', '10': 'More clinical data are required before the efficacy of sertraline and citalopram relative to standard antidepressants can be clearly defined.', '11': 'Preliminary data indicate that SSRIs are effective in the treatment of panic disorder, obsessive-compulsive disorder (OCD), eating (e.g. anorexia and bulimia) and personality disorders (e.g. anger, impulsiveness) and substance abuse (e.g. alcoholism); early results with fluvoxamine in the treatment of panic disorder and OCD, and with fluoxetine in the treatment of bulimia, personality disorders and alcohol abuse, have been encouraging.', '12': 'SSRIs have a more favourable tolerability profile than tricyclic antidepressants and, unlike the tricyclics, are not associated with anticholinergic adverse effects, sedation, cardiotoxicity or weight gain.', '13': 'SSRIs are associated with a relatively high incidence of nausea, particularly if high doses are used at the start of treatment.', '14': 'However, the incidence of nausea appears to decrease as treatment is continued.'}\n",
            "20: abstract: {'1': 'Twenty-five patients with a primary DSM-III-R diagnosis of panic disorder with or without agoraphobia were treated openly with the serotonin uptake inhibitor fluoxetine for up to 12 months.', '2': 'For most patients, treatment was initiated at 5 mg/day to minimize adverse effects previously reported with initiation at higher doses.', '3': 'Nineteen (76%) experienced moderate to marked improvement in panic attacks.', '4': 'Four (16%) were unable to tolerate fluoxetine due to adverse effects.', '5': 'Initiating treatment of panic disorder with low doses of fluoxetine may increase its acceptability and permit more patients to benefit from fluoxetine.'}\n",
            "20: abstract: {'1': 'Background: Although several studies have examined the long-term efficacy of antidepressants, relatively little attention has been paid to the management of relapses or recurrences during continued antidepressant treatment.', '2': 'This study examined whether depressed patients who had recovered and then relapsed on fluoxetine 20 mg/day would benefit from an increase in fluoxetine dose.', '3': 'Method: Eighteen patients who relapsed on fluoxetine 20 mg/day during long-term treatment with fluoxetine as part of a placebo-controlled study had their fluoxetine dose raised to 40 mg/day and were followed for at least 1 month (mean time = 4.7 months).', '4': 'Results: Twelve (67%) were full responders, 3 (17%) partial responders, and 3 (17%) dropped out because of side effects (e.g., insomnia and agitation).', '5': 'Of those patients who had either full or partial response (N = 15; 83%), 3 complete responders had a recurrence on 40 mg/day after a mean of 5.8 months and 1 partial responder had a recurrence 11 months later.', '6': 'Overall, 11 (61%) of 18 patients maintained their response during their follow-up while taking the higher dose of fluoxetine.', '7': 'Conclusion: An increase in dose of fluoxetine to 40 mg/day appears to be an effective strategy in the treatment of relapse among depressed patients who had initially responded to fluoxetine 20 mg/day.'}\n",
            "20: abstract: {'1': 'Fluoxetine (FLX) has a unique pharmacokinetic profile.', '2': \"Its major metabolite, norfluoxetine (NFLX), possesses FLX's antidepressant efficacy and a half-life of 7 to 15 days, suggesting the possibility of nonstandard dosing strategies.\", '3': 'This study examined the tolerability of a weekly dose and its equivalence to daily dosing of FLX for the continuation phase of treatment for major depressive disorder (MDD).', '4': 'One hundred fourteen subjects initially received open-label treatment with 20 mg of FLX daily for 7 weeks.', '5': 'Subsequently, 70 subjects with a score on the Hamilton Rating Scale for Depression (HAM-D) of 12 or less were randomly assigned in a double-blind design to one of three treatment groups: 20 mg FLX daily (N = 21), 60 mg FLX weekly (N = 28), or placebo (N = 21) and were followed for 7 weeks.', '6': 'HAM-D scores and blood levels of FLX and NFLX were analyzed using a repeated-measures analysis of variance.', '7': 'During the double-blind phase, blood levels for both FLX and NFLX differed across the treatment groups, yet no statistically significant difference in HAM-D scores was observed.', '8': 'There was no difference in the dropout rate across the groups.', '9': 'Subjects could not correctly identify the treatment group into which they were assigned.', '10': 'Weekly dosing of FLX seems to be well tolerated and possibly as effective as daily dosing in maintaining the therapeutic response in subjects with MDD.'}\n",
            "20: abstract: {'1': 'Objective: Although continuing antidepressant treatment after patients have responded to medication has been shown to greatly reduce the risk of relapse, this risk is not eliminated.', '2': 'A number of theories have been proposed to account for this apparent loss of efficacy.', '3': 'A common initial approach to managing relapse is to increase the dose of antidepressant.', '4': 'We prospectively evaluated the likelihood of response to increasing the fluoxetine doses in patients relapsing during a long-term efficacy study of two fluoxetine dosing regimens.', '5': 'Method: Patients meeting the DSM-IV criteria for major depressive disorder with modified HAMD17 scores > or =18 and CGI-severity scores > or =4 were treated for 13 weeks with open-label 20 mg/day fluoxetine in a multicenter US study.', '6': 'Responders (n = 501) were randomized to 20 mg fluoxetine daily, placebo, or 90 mg enteric-coated fluoxetine weekly for 25 weeks of double-blind continuation treatment.', '7': 'If the patients relapsed during the continuation phase, they were offered a 25-week optional rescue treatment phase during which the study medication dose was increased as follows: (1) patients on placebo had treatment with fluoxetine 20 mg/day reinitiated, (2) patients on fluoxetine 20 mg/day had their dose increased to 40 mg/day, and (3) patients on a 90-mg weekly dose had their dose increased to 90 mg twice a week.', '8': 'The results of the rescue phase for the latter two groups who relapsed while on continuation treatment with fluoxetine are reported.', '9': 'Response was defined as a 50% reduction in the modified HAMD17 score since time of relapse and a CGI-severity score < or =2.', '10': 'Additional efficacy analyses included HAMD and CGI-severity changes from baseline to endpoint.', '11': 'Safety measures included assessment of treatment-emergent adverse events, vital signs, and laboratory measures.', '12': 'Results: Overall, patients relapsing during the continuation treatment responded to an increased dose (57% of the 40-mg-daily group and 72% of the enteric-coated 90-mg-twice-weekly group).', '13': 'Mean modified HAMD17 scores decreased from a mean of approximately 20 to below 8 and were maintained for up to 6 months in the responders.', '14': 'Thirty-five percent of patients either did not respond or initially responded but again relapsed after augmentation of medication.', '15': 'Conclusions: The patients relapsing after initially responding to fluoxetine can benefit from an increase in fluoxetine dose.', '16': 'These results also generally support increasing dose as a first-line treatment strategy for a patient who has relapsed while taking a previously effective dose of an antidepressant.', '17': 'Increasing enteric-coated fluoxetine 90 mg once weekly to twice weekly appeared to be as well-tolerated and effective in restoring response as increasing a daily fluoxetine dose from 20 to 40 mg.'}\n",
            "20: abstract: {'1': 'Patients with major depressive disorder remain at risk for relapse following remission and often continue to experience subthreshold symptoms.', '2': 'This study examined whether depressed patients who had recovered and then relapsed on fluoxetine 20 mg/day would benefit from an increase in fluoxetine dose.', '3': 'A total of 132 outpatients with major depressive disorder who achieved remission with 8 weeks of treatment with fluoxetine 20 mg had the dose increased to 40 mg.', '4': 'They were randomized to receive cognitive therapy or medication management alone and were followed for up to 28 weeks for depressive relapse and change in depressive symptoms.', '5': 'A total of 47 (35.6%) out of 132 patients did not complete the 28-week continuation phase.', '6': 'Rates of discontinuation or relapse did not differ significantly between the groups.', '7': 'Change in residual symptoms or wellbeing as measured by Hamilton Depression Scale score or Symptom Questionnaire self-report also did not differ between groups.', '8': 'In this sample of outpatients in continuation phase treatment for major depressive disorder, the combination of cognitive therapy and fluoxetine 40 mg failed to yield any significant benefit in symptoms or relapse rates over fluoxetine 40 mg alone during 28 weeks of follow-up.'}\n",
            "20: abstract: {'1': 'Pediatric generalized anxiety disorder (GAD) is characterized by excessive and uncontrollable worry about a variety of events and is accompanied by physical symptoms such as headaches, tension, restlessness, gastrointestinal distress, and heart palpitations.', '2': 'Symptoms impose marked distress and interfere with social, emotional, and educational functioning.', '3': 'GAD occurs in over 10% of children and adolescents, has an average age of onset of 8.5 years, and is more often reported in girls.', '4': 'Common co-occurring conditions include separation anxiety disorder and social phobia.', '5': 'Assessment involves a multi-informant, multi-method approach involving the child, parents, and school teachers.', '6': 'A clinical interview should be conducted to assess for the three primary ways anxiety presents: behaviors, thoughts, and somatic symptoms.', '7': 'Several semi-structured diagnostic interviews are available, and the Anxiety Disorders Interview Schedule is increasingly used.', '8': 'Rating scales completed by the patient, caregivers, and teachers provide useful information for diagnosis and symptom monitoring.', '9': 'Several scales are available to assess patients for the Diagnostic and Statistical Manual of Mental Disorders (4th Edition) GAD diagnosis; however, instruments generally cannot distinguish children with GAD from children with similar anxiety disorders.', '10': 'Both cognitive-behavioral therapy (CBT) and selective serotonin reuptake inhibitors (SSRIs) have demonstrated efficacy for the treatment of pediatric anxiety disorders including GAD.', '11': 'Evidence suggests that the combination of CBT plus sertraline offers additional benefit compared with either treatment alone.', '12': 'With pharmacotherapy, systematic tracking of treatment-emergent adverse events such as headaches, stomach aches, behavioral activation, worsening symptoms, and emerging suicidal thoughts is important.', '13': 'Recommended starting doses are fluvoxamine 25 mg/day, fluoxetine 10 mg/day, and sertraline 25 mg/day, though lower starting doses are possible.', '14': 'Dosing can be adjusted as often as weekly with the goal of achieving a high-quality response, while minimizing side effects.', '15': 'Long-term treatment with medication has not been well studied; however, to achieve optimal long-term outcome extended use of medication may be required.', '16': 'It is recommended to continue medication for approximately 1 year following remission in symptoms, and when discontinuing medication to choose a stress-free time of the year.', '17': 'If symptoms return, medication re-initiation should be considered seriously.'}\n",
            "20: abstract: {'1': 'Background: Depression is the single largest contributor to non-fatal health loss worldwide.', '2': 'Second-generation antidepressants are the first-line option for pharmacological management of depression.', '3': 'Optimising their use is crucial in reducing the burden of depression; however, debate about their dose dependency and their optimal target dose is ongoing.', '4': 'We have aimed to summarise the currently available best evidence to inform this clinical question.', '5': 'Findings: 28 554 records were identified through our search (24 524 published and 4030 unpublished records).', '6': '561 published and 121 unpublished full-text records were assessed for eligibility, and 77 studies were included (19 364 participants; mean age 42·5 years, SD 11·0; 7156 [60·9%] of 11 749 reported were women).', '7': 'For SSRIs (99 treatment groups), the dose-efficacy curve showed a gradual increase up to doses between 20 mg and 40 mg fluoxetine equivalents, and a flat to decreasing trend through the higher licensed doses up to 80 mg fluoxetine equivalents.', '8': 'Dropouts due to adverse effects increased steeply through the examined range.', '9': 'The relationship between the dose and dropouts for any reason indicated optimal acceptability for the SSRIs in the lower licensed range between 20 mg and 40 mg fluoxetine equivalents.', '10': 'Venlafaxine (16 treatment groups) had an initially increasing dose-efficacy relationship up to around 75-150 mg, followed by a more modest increase, whereas for mirtazapine (11 treatment groups) efficacy increased up to a dose of about 30 mg and then decreased.', '11': 'Both venlafaxine and mirtazapine showed optimal acceptability in the lower range of their licensed dose.', '12': 'These results were robust to several sensitivity analyses.', '13': 'Interpretation: For the most commonly used second-generation antidepressants, the lower range of the licensed dose achieves the optimal balance between efficacy, tolerability, and acceptability in the acute treatment of major depression.'}\n",
            "20: abstract: {'1': 'Objective: Since several recent meta-analyses report a dose-response relationship for the antidepressant effect of the selective serotonin reuptake inhibitors (SSRIs), we investigated how these drugs are dosed in clinical practice.', '2': 'Methods: Through linkage of nation- or region-wide registers, we describe SSRI doses in 50,365 individuals residing in Region Västra Götaland, Sweden, with an incident diagnosis of depression and initiating SSRI treatment between 2007 and 2016.', '3': 'The primary question was to elucidate to what extent these individuals had been prescribed a daily dose that according to recent meta-analyses is required to elicit the maximum antidepressant effect, that is >20 mg citalopram, >10 mg escitalopram, >10 mg fluoxetine, >10 mg paroxetine or >50 mg sertraline.', '4': 'Results: In all, 21,049 (54%) out of 38,868 individuals <65 years of age, and 9,131 (79%) out of 11,497 individuals ≥65 years of age, never received an SSRI dose reported to exert maximum antidepressant effect.', '5': 'These prescribing practices were seen for citalopram, escitalopram and sertraline, but not for fluoxetine and paroxetine, and were frequent in both primary and secondary/tertiary care.', '6': 'Suggesting that doses here defined as maximum efficacy doses, when prescribed, are usually not intolerable, between 59% and 68% of individuals <65 years of age received such a dose also for the subsequent prescription, that is as frequently as in those prescribed a sub-maximum efficacy dose (52-69%).', '7': 'Conclusion: Most patients being prescribed an SSRI to treat their depression never receive the dose that according to recent meta-analyses is most likely to effectively combat their condition.', '8': 'The lack of consensus regarding effective dosing of SSRIs may have contributed to this state of affairs.'}\n",
            "20: abstract: {'1': 'Objective: A large number of people experience misophonia.', '2': 'In 2013, the Amsterdam Study Group recommended diagnostic criteria for misophonia.', '3': 'However, misophonia is not yet included in the Diagnostic and Statistical Manual of Mental Disorders.', '4': 'This report is the first report on drug use that directly affects misophonia and demonstrates a 14-year-old adolescent girl with misophonia successfully treated with fluoxetine.', '5': \"Methods: The patient's misophonia symptoms had been continuing for approximately 2 years, and her quality of life was significantly reduced.\", '6': 'Psychotherapy conditions could not be applied, and fluoxetine 10 mg/d was started and increased to 20 mg/d after a week.', '7': 'At the second-month follow-up, because of partial improvement, fluoxetine dose was increased to 30 mg/d.', '8': \"Results: At the fourth-month follow-up, there was a 40% decrease in Amsterdam Misophonia Scale score with a 70% decrease in the children's global assessment scale scores.\", '9': 'By the 16th week, the overall functionality level was good at the end.', '10': 'Conclusions: Fluoxetine may be used as an effective drug in the treatment of misophonia.'}\n",
            "21: abstract: {'1': 'Hiatus hernia refers to conditions in which elements of the abdominal cavity, most commonly the stomach, herniate through the oesophageal hiatus into the mediastinum.', '2': 'With the most common type (type I or sliding hiatus hernia) this is associated with laxity of the phrenooesophageal membrane and the gastric cardia herniates.', '3': 'Sliding hiatus hernia is readily diagnosed by barium swallow radiography, endoscopy, or manometry when greater than 2 cm in axial span.', '4': 'However, the mobility of the oesophagogastric junction precludes the reliable detection of more subtle disruption by endoscopy or radiography.', '5': 'Detecting lesser degrees of axial separation between the lower oesophageal sphincter and crural diaphragm can only be reliably accomplished with high-resolution manometry, a technique that permits real time localization of these oesophagogastric junction components without swallow or distention related artefact.'}\n",
            "21: abstract: {'1': 'A Spigelian hernia (or lateral ventral hernia) is a hernia through the spigelian fascia, which is the aponeurotic layer between the rectus abdominis muscle medially, and the semilunar line laterally.', '2': 'So far, about 1000 cases have been reported worldwide.', '3': 'These hernias are difficult to diagnose as they do not present with a subcutaneous swelling and have high risk of going for strangulation.', '4': 'We discuss the case of a 36 year old female who presented with history of pain and lumpiness in left lower abdomen, both of which decreased on lying down.', '5': 'She presented to emergency with an episode severe pain at same site which subsided spontaneously.', '6': 'Diagnosis was confirmed on CT scan, plication and onlay prolene mesh repair performed.', '7': 'Spigelian hernias are rare, interparietal type of hernias which have high risk undergoing strangulation.', '8': 'Knowledge of symptoms and signs is vital to diagnosis and treatment of these rare type of hernias.'}\n",
            "21: abstract: {'1': 'Purpose: Hiatal hernias are a common finding on radiographic or endoscopic studies.', '2': 'Hiatal hernias may become symptomatic or, less frequently, can incarcerate or become a volvulus leading to organ ischemia.', '3': 'This review examines latest evidence on the diagnostic workup and management of hiatal hernias.', '4': 'Methods: A literature review of contemporary and latest studies with highest quality of evidence was completed.', '5': 'This information was examined and compiled in review format.', '6': 'Results: Asymptomatic hiatal and paraesophageal hernias become symptomatic and necessitate repair at a rate of 1% per year.', '7': 'Watchful waiting is appropriate for asymptomatic hernias.', '8': 'Symptomatic hiatal hernias and those with confirmed reflux disease require operative repair with an anti-reflux procedure.', '9': 'Key operative steps include the following: reduction and excision of hernia sac, 3 cm of intraabdominal esophageal length, crural closure with mesh reinforcement, and an anti-reflux procedure.', '10': 'Repairs not amenable to key steps may undergo gastropexy and gastrostomy placement as an alternative procedure.', '11': 'Conclusions: Hiatal hernias are commonly incidental findings.', '12': 'When hernias become symptomatic or have reflux disease, an operative repair is required.', '13': 'A minimally invasive approach is safe and has improved outcomes.'}\n",
            "21: abstract: {'1': 'Inguinal hernia is the most frequently diagnosed hernia and during their lifetime one third of males are diagnosed with an inguinal hernia.', '2': 'The age distribution is bimodal with the highest incidence in childhood and after 50 years of age.', '3': 'Diagnosis is usually reached through clinical examination of a lump in the inguinal region although some patients can present with intestinal obstruction.', '4': 'Inguinal hernia repair is the only definitive treatment and is one of the most common surgical procedures performed.', '5': 'It is usually performed as an elective procedure in local, spinal or general anasthesia.', '6': 'The repair constitutes of reinforcing the posterior wall of the inguinal canal, often using a polypropylene mesh; either via an open anterior approach or posteriorly from within the abdomen with laparoscopy.', '7': 'The most common complications following a hernia repair are recurrent hernia and chronic -discomfort but recurrence rates have improved with the use of mesh and laparoscopic techniques.', '8': 'This evidence based review describes the -epidemiology and etiology of inguinal hernia together with the most common surgical procedures; focusing on recent innovations.'}\n",
            "21: abstract: {'1': 'Purpose: The aim of the study was to determine which diagnostic modality [Computerized Tomography (CT), Magnetic Resonance Imaging (MRI), or ultrasound (US)] is more precise in terms of sensitivity and specificity in diagnosing inguinal hernia and sub-type of inguinal hernia (direct or indirect).', '2': 'Results: Bubble charts depicting the size of each patient cohort and percentual range for both sensitivity and specificity showed that US was better than CT and MRI in diagnosing inguinal hernia.', '3': 'Bubble charts for US and CT depicted high values within the studies that reported sensitivity and specificity in diagnosing type of hernia.', '4': 'Conclusions: We found that US had the highest sensitivity and specificity.', '5': \"However, it must be taken into consideration that performance is highly dependent on the operator's level of expertise.\", '6': 'Based on this systematic review, ultrasound may be the preferred imaging modality when physical examination is inconclusive, given that local expertise in performing US examination for hernia disease is adequate.'}\n",
            "21: abstract: {'1': 'Groin hernias are caused by a defect of the abdominal wall in the groin area and comprise inguinal and femoral hernias.', '2': 'Inguinal hernias are more common in men.', '3': 'Although groin hernias are easily diagnosed on physical examination in men, ultrasonography is often needed in women.', '4': 'Ultrasonography is also helpful when a recurrent hernia, surgical complication after repair, or other cause of groin pain (e.g., groin mass, hydrocele) is suspected.', '5': 'Magnetic resonance imaging has higher sensitivity and specificity than ultrasonography and is useful for diagnosing occult hernias if clinical suspicion is high despite negative ultrasound findings.', '6': 'Herniography, which involves injecting contrast media into the hernial sac, may be used in selected patients.', '7': 'Becoming familiar with the common types of surgical interventions can help family physicians facilitate postoperative care and assess for complications, including recurrence.', '8': 'Laparoscopic repair is associated with shorter recovery time, earlier resumption of activities of daily living, less pain, and lower recurrence rates than open repair.', '9': 'Watchful waiting is a reasonable and safe option in men with asymptomatic or minimally symptomatic inguinal hernias.', '10': 'Watchful waiting is not recommended in patients with symptomatic hernias or in nonpregnant women.'}\n",
            "21: abstract: {'1': \"Introduction and importance: A Littre's hernia (LH) is defined by the presence of Meckel's diverticulum (MD) in any kind of hernia sac.\", '2': 'Preoperative diagnosis of LH is a challenge because of its rarity and the absence of specific radiological findings and clinical presentation.', '3': 'Surgery is the appropriate treatment of complicated LH that is an extremely rare condition with approximately 50 cases reported in the literature over the past 300 years.', '4': 'Case presentation: A 46-year-old Caucasian female was admitted to the Emergency Department with a two-day history of abdominal pain.', '5': 'Physical examination revealed an irreducible and painfull mass in umbilical region.', '6': 'Abdominal computed tomography scan showed the protrusion of greater omentum and small bowel loop through the umbilical ring.', '7': 'Laboratory tests were unremarkable.', '8': 'After diagnosis of strangulated umbilical hernia, the patient underwent exploratory laparotomy: the irreducible umbilical hernial sac was opened with presence of incarcerated and strangulated omentum and uncomplicated MD.', '9': 'Resection of incarcerated and ischemic greater omentum alone was performed.', '10': 'The postoperative course of patient was uneventful.', '11': \"Clinical discussion: Meckel's diverticulum (MD) is a vestigial remnant of the omphalomesenteric duct, representing the most common congenital malformation of the gastrointestinal tract.\", '12': 'Preoperative diagnosis of LH is very difficult and surgery represents the correct treatment of complicated LH.', '13': 'Conclusion: LH represents an extremely rare complication of MD difficult to diagnose and suspect because of the lack of specific radiological findings and clinical presentation.', '14': 'Surgery represents the appropriate treatment of abdominal wall hernias and complicated MD.'}\n",
            "21: abstract: {'1': 'Acute traumatic abdominal wall hernia (TAWH) is a rare type of hernia that occurs after a low or high velocity impact of the abdominal wall against a blunt object with few cases reported.', '2': 'Perforations of the hollow viscera commonly follow abdominal trauma and likely require surgery for hemorrhage and sepsis source control.', '3': 'We report a case where a high velocity impact of the abdominal wall against the stump of a felled tree caused a TAWH with concomitant gastric perforation in a 20-year-old male patient who required exploratory laparotomy with primary repair of the stomach and fascia.', '4': 'The physical examination findings without previous history of abdominal hernia and pneumoperitoneum in the chest X-ray made suspect our diagnosis and it was confirmed intraoperatively.', '5': 'At 3 months postoperatively the patient has a strong abdominal wall.', '6': 'It is imperative to emphasize the importance of the physical examination goal of not losing diagnosis of TAWH.'}\n",
            "21: abstract: {'1': 'Internal hernias are rare, and a delayed diagnosis can lead to dangerous complications.', '2': 'A 75-year-old male with no previous surgical history presented with right upper abdominal pain and vomiting.', '3': \"On examination, he had guarding in the right hypochondrium with a positive Murphy's sign.\", '4': 'However, ultrasonography of the gall bladder was normal with dilated bowel loops.', '5': 'Contrast-enhanced CT (CECT) revealed a falciform hernia with evidence of obstruction.', '6': 'Segmental resection of the gangrenous ileum was done with a double-barrel stoma.', '7': 'Later on, stoma reversal was also done with no complications.'}\n",
            "21: abstract: {'1': \"Richter's hernia, also called a partial enterocele, involves a protrusion of peritoneum with subsequent strangulation or incarceration of only part of the lumen of the anti-mesenteric portion of the small bowel through a fascial defect.\", '2': \"We report a rare presentation of incarcerated incisional Richter's hernia of the cecum in a 39-year-old female.\", '3': 'The patient presented with acute abdominal pain that gradually improved.', '4': 'Physical examination revealed right lower quadrant tenderness and nodularity just above an abdominoplasty scar.', '5': 'Subsequent computed tomography scan demonstrated a 1 cm by 1 cm hypovascular pocket arising from the cecum with protrusion into the anterior abdominal wall.', '6': 'The hernia was successfully repaired surgically with resolution of symptoms.', '7': \"It is essential for clinicians to be mindful of the diagnosis of Richter's hernia on the differential for abdominal pain as the risk of detrimental outcomes increases with delayed surgical intervention.\"}\n",
            "22: abstract: {'1': 'Birt-Hogg-Dubé syndrome (BHD) is an autosomal dominant condition characterised clinically by skin fibrofolliculomas, pulmonary cysts, spontaneous pneumothorax, and renal cancer.', '2': 'The condition is caused by germline mutations in the FLCN gene, which encodes folliculin; the function of this protein is largely unknown, although FLCN has been linked to the mTOR pathway.', '3': 'The availability of DNA-based diagnosis has allowed insight into the great variation in expression of FLCN, both within and between families.', '4': 'Patients can present with skin signs and also with pneumothorax or renal cancer.', '5': 'Preventive measures are aimed mainly at early diagnosis and treatment of renal cancer.', '6': 'This Review gives an overview of current diagnosis and management of BHD.'}\n",
            "22: abstract: {'1': 'Birt-Hogg-Dubé syndrome (BHD) is a rare, autosomal dominant disorder characterized by the development of hair follicle tumors, renal tumors and pulmonary cysts.', '2': 'BHD is caused by heterozygous, predominantly truncating mutations in the folliculin (FLCN) gene located on chromosome 17, which encodes a highly conserved tumor suppressor protein.', '3': 'Although management of renal tumors of low malignant potential is the primary focus of longitudinal care, pulmonary manifestations including cyst formation and spontaneous pneumothorax are among the most common manifestations in BHD.', '4': 'Due to the lack of awareness, there is commonly a delay in the pulmonary diagnosis of BHD and patients are frequently mislabeled as having chronic obstructive lung disease, emphysema or common bullae/blebs.', '5': 'A family history of pneumothorax is present in 35 % of patients with BHD.', '6': 'Certain imaging characteristics of the cysts, including size, basilar and peripheral predominance, perivascular and periseptal localization, and elliptical or lentiform shape can suggest the diagnosis of BHD based on inspection of the chest CT scan alone.', '7': 'Recurrent pneumothoraces are common and early pleurodesis is recommended.', '8': 'A better understanding of role of FLCN in pulmonary cyst formation and long term studies to define the natural history of the pulmonary manifestations of BHD are needed.'}\n",
            "22: abstract: {'1': 'Loss-of-function mutations in the folliculin gene (FLCN) on chromosome 17p cause Birt-Hogg-Dube syndrome (BHD), which is associated with cystic lung disease.', '2': 'The risk of lung collapse (pneumothorax) in BHD patients is 50-fold higher than in the general population.', '3': 'The cystic lung disease in BHD is distinctive because the cysts tend to be basilar, subpleural and lentiform, differentiating BHD from most other cystic lung diseases.', '4': 'Recently, major advances in elucidating the primary functions of the folliculin protein have been made, including roles in mTOR and AMPK signaling via the interaction of FLCN with FNIP1/2, and cell-cell adhesion via the physical interaction of FLCN with plakophilin 4 (PKP4), an armadillo-repeat containing protein that interacts with E-cadherin and is a component of the adherens junctions.', '5': 'In addition, in just the last three years, the pulmonary impact of FLCN deficiency has been examined for the first time.', '6': 'In mouse models, evidence has emerged that AMPK signaling and cell-cell adhesion are involved in alveolar enlargement.', '7': 'In addition, the pathologic features of human BHD cysts have been recently comprehensively characterized.', '8': 'The \"stretch hypothesis\" proposes that cysts in BHD arise because of fundamental defects in cell-cell adhesion, leading to repeated respiration-induced physical stretch-induced stress and, over time, expansion of alveolar spaces particularly in regions of the lung with larger changes in alveolar volume and at weaker \"anchor points\" to the pleura.', '9': 'This hypothesis ties together many of the new data from cellular and mouse models of BHD and from the human pathologic studies.', '10': 'Critical questions remain.', '11': 'These include whether the consequences of stretch-induced cyst formation arise through a destructive/inflammatory program or a proliferative program (or both), whether cyst initiation involves a \"second hit\" genetic event inactivating the remaining wild-type copy of FLCN (as is known to occur in BHD-associated renal cell carcinomas), and whether cyst initiation involves exclusively the epithelial compartment versus an interaction between the epithelium and mesenchyme.', '12': 'Ultimately, understanding the mechanisms of cystic lung disease in BHD may help to elucidate the pathogenesis of primary spontaneous pneumothorax, with more than 20,000 cases reported annually in the United States alone.'}\n",
            "22: abstract: {'1': 'Birt-Hogg-Dubé syndrome (BHD) is a rare autosomal dominant disorder caused by mutations in the Folliculin gene and is characterized by the formation of fibrofolliculomas, early onset renal cancers, pulmonary cysts, and spontaneous pneumothoraces.', '2': 'The exact pathogenesis of tumor and lung cyst formation in BHD remains unclear.', '3': 'There is great phenotypic variability in the clinical features of BHD, and patients can present with any combination of skin, pulmonary, or renal findings.', '4': 'More than 80% of adult patients with BHD have pulmonary cysts on high-resolution computed tomography scan of the chest.'}\n",
            "22: abstract: {'1': 'Germline mutations in the novel tumor suppressor gene FLCN are responsible for the autosomal dominant inherited disorder Birt-Hogg-Dubé (BHD) syndrome that predisposes to fibrofolliculomas, lung cysts and spontaneous pneumothorax, and an increased risk for developing kidney tumors.', '2': 'Although the encoded protein, folliculin (FLCN), has no sequence homology to known functional domains, x-ray crystallographic studies have shown that the C-terminus of FLCN has structural similarity to DENN (differentially expressed in normal cells and neoplasia) domain proteins that act as guanine nucleotide exchange factors (GEFs) for small Rab GTPases.', '3': \"FLCN forms a complex with folliculin interacting proteins 1 and 2 (FNIP1, FNIP2) and with 5' AMP-activated protein kinase (AMPK).\", '4': 'This review summarizes FLCN functional studies which support a role for FLCN in diverse metabolic pathways and cellular processes that include modulation of the mTOR pathway, regulation of PGC1α and mitochondrial biogenesis, cell-cell adhesion and RhoA signaling, control of TFE3/TFEB transcriptional activity, amino acid-dependent activation of mTORC1 on lysosomes through Rag GTPases, and regulation of autophagy.', '5': 'Ongoing research efforts are focused on clarifying the primary FLCN-associated pathway(s) that drives the development of fibrofolliculomas, lung cysts and kidney tumors in BHD patients carrying germline FLCN mutations.'}\n",
            "22: abstract: {'1': 'Objective: Birt-Hogg-Dubé (BHD) syndrome is an autosomal dominant inherited syndrome involving multiple organs.', '2': 'In young patients, renal neoplasms that are multiple, bilateral, or both, such as oncocytomas, chromophobe renal cell carcinoma (RCC), hybrid chromophobe RCC-oncocytomas, clear cell RCC, and papillary RCC, can suggest BHD syndrome.', '3': 'Extrarenal findings, including dermal lesions, pulmonary cysts, and spontaneous pneumothoraces, also aid in diagnosis.', '4': 'Conclusion: Radiologists may be one of the first medical specialists to suggest the diagnosis of BHD syndrome.', '5': 'Knowledge of pathogenesis and management, including the importance of the types of renal neoplasms in a given patient, is needed to properly recognize this rare condition.'}\n",
            "22: abstract: {'1': 'Birt-Hogg-Dubé (BHD) syndrome is an autosomal dominant disorder caused by germline loss-of-function mutations in Folliculin gene (FLCN).', '2': 'BHD is characterized by lower lobe-predominant pulmonary cysts with risk of pneumothorax, benign skin tumors (fibrofolliculomas), and renal cell carcinoma, often of an unusual chromophobe/oncocytic hybrid histology.', '3': \"The FLCN protein functions in multiple signaling and metabolic pathways including positive regulation of mechanistic target of rapamycin complex 1 (mTORC1) activity via FLCN's GTPase (GAP) activity for Rag C, positive regulation of Wnt signaling (in mesenchymal cells), and negative regulation of TFE3 nuclear localization.\", '4': 'Therefore, FLCN-deficient cells are predicted to have reduced mTORC1 and Wnt activity and enhanced TFE3 activity.', '5': \"Folliculin also has functions in autophagy, mitochondrial biogenesis, cell-cell adhesion, 5' AMP activated protein kinase activity, and other pathways.\", '6': 'The specific contributions of these pathways to the lung manifestations of BHD are largely unknown.', '7': 'This review is focused on the pulmonary manifestations of BHD, highlighting selected recent advances in elucidating the cellular functions of FLCN and current hypotheses related to the pathogenesis of cystic lung disease in BHD, including the \"stretch hypothesis.\"', '8': 'We also discuss important knowledge gaps in the field, including the genetic, cellular and physical mechanisms of cyst pathogenesis, and the timing of cyst initiation, which may occur during lung development.'}\n",
            "22: abstract: {'1': 'Birt-Hogg-Dubé syndrome (BHD) is an autosomal dominant genetic disorder characterised by pulmonary cysts, fibrofolliculomas and renal tumours.', '2': 'The pulmonary cysts may lead to pneumothorax, and in cases of primary, spontaneous pneumothorax the syndrome should be excluded.', '3': 'The renal tumours are frequently malignant, but slow-growing.', '4': 'Screening and family assessment enable discovery of renal cancer at an early stage.', '5': 'The syndrome is underdiagnosed and little known.'}\n",
            "22: abstract: {'1': 'Background and objective: The purpose of this study was to create a practical CT-based algorithm to differentiate Birt-Hogg-Dubé (BHD) syndrome from other diffuse cystic lung diseases (DCLD).', '2': 'Methods: The study was a retrospective review of the CT images of 33 patients with BHD syndrome, 33 patients with LAM, and 23 patients with NBNL (non-BHD and non-LAM) among DCLD patients.', '3': 'On the basis of the data collected, the CT images were reviewed again to evaluate the characteristics (size, number, distribution, and morphology) of pulmonary cysts.', '4': 'Results: Lower lung-predominant cysts were more likely to be found in patients with BHD syndrome than in patients with LAM or in the NBNL DCLD group.', '5': 'In the axial distribution, 18 of 33 patients in BHD group had cysts that were predominantly near the mediastinum, and all the patients in the LAM and NBNL DCLD groups had diffuse cysts.', '6': 'The appearance of fusiform cysts was more easily observed in patients in the BHD group.', '7': 'In total, 58% patients in the BHD group had less than 50 lung cysts, while all patients in the non-BHD group had more than 50 lung cysts.', '8': 'The biggest cyst was located in the lower lobe in 28 of 33 patients in the BHD group, while 11 of 33 patients in LAM group and 10 patients in the NBNL DCLD group had the biggest cyst in the lower lobe.', '9': 'Conclusion: The pulmonary cysts in patients with BHD tended to be fusiform, less numerous and located predominantly in the lower lobe and near the mediastinum.', '10': 'These radiologic pulmonary features could assist physicians in differentiating BHD from other DCLDs.'}\n",
            "22: abstract: {'1': 'Birt-Hogg-Dubé syndrome (BHD) is a rare inherited autosomal dominant disorder caused by germline mutations in the tumour suppressor gene FLCN, encoding the protein folliculin.', '2': 'Its clinical expression typically includes multiple pulmonary cysts, recurrent spontaneous pneumothoraces, cutaneous fibrofolliculomas and renal tumours of various histological types.', '3': 'BHD has no sex predilection and tends to manifest in the third or fourth decade of life.', '4': 'Multiple bilateral pulmonary cysts are found on chest computed tomography in >80% of patients and more than half experience one or more episodes of pneumothorax.', '5': 'A family history of pneumothorax is an important clue, which suggests the diagnosis of BHD.', '6': 'Unlike other cystic lung diseases such as lymphangioleiomyomatosis and pulmonary Langerhans cell histiocytosis, BHD does not lead to progressive loss of lung function and chronic respiratory insufficiency.', '7': 'Renal tumours affect about 30% of patients during their lifetime, and can be multiple and recurrent.', '8': 'The diagnosis of BHD is based on a combination of genetic, clinical and/or skin histopathological criteria.', '9': 'Management mainly consists of early pleurodesis in the case of pneumothorax, periodic renal imaging for tumour detection, and diagnostic work-up in search of BHD in relatives of the index patient.'}\n",
            "23: abstract: {'1': 'Phenylketonuria (PKU) is an autosomal recessive disorder caused by a large number of mutations at the phenylalanine hydroxylase (PAH) locus, most of which are strongly associated with specific RFLP or VNTR haplotypes.', '2': 'One of the major questions remaining in PKU research is why this apparently maladaptive disorder has been maintained at a frequency of approximately 1 in 10,000 among Caucasians.', '3': 'A growing number of studies have provided evidence that both the relatively high frequency of PKU and the strong mutation/haplotype associations might reflect the existence of multiple founding populations for PKU.', '4': 'Examples of putative founding populations for PKU in both Europe and Asia will be presented.', '5': 'Some PAH mutations are associated with multiple haplotypes, suggesting recurrence.', '6': 'Evidence for and against recurrence as the mechanism responsible for the association of the R408W mutation with RFLP haplotypes 1 and 2 will be discussed.'}\n",
            "23: abstract: {'1': '\"Inborn errors of metabolism,\" first recognized 100 years ago by Garrod, were seen as transforming evidence for chemical and biological individuality.', '2': 'Phenylketonuria (PKU), a Mendelian autosomal recessive phenotype, was identified in 1934 by Asbjörn Fölling.', '3': 'It is a disease with impaired postnatal cognitive development resulting from a neurotoxic effect of hyperphenylalaninemia (HPA).', '4': 'Its metabolic phenotype is accountable to multifactorial origins both in nurture, where the normal nutritional experience introduces L-phenylalanine, and in nature, where mutations (>500 alleles) occur in the phenylalanine hydroxylase gene (PAH) on chromosome 12q23.2 encoding the L-phenylalanine hydroxylase enzyme (EC 1.14.16.1).', '5': 'The PAH enzyme converts phenylalanine to tyrosine in the presence of molecular oxygen and catalytic amounts of tetrahydrobiopterin (BH4), its nonprotein cofactor.', '6': 'PKU is among the first of the human genetic diseases to enter, through newborn screening, the domain of public health, and to show a treatment effect.', '7': 'This effect caused a paradigm shift in attitudes about genetic disease.', '8': 'The PKU story contains many messages, including: a framework on which to appreciate the complexity of PKU in which phenotype reflects both locus-specific and genomic components; what the human PAH gene tells us about human population genetics and evolution of modern humans; and how our interest in PKU is served by a locus-specific mutation database (http://www.pahdb.mcgill.ca; last accessed 20 March 2007).', '9': 'The individual Mendelian PKU phenotype has no \"simple\" or single explanation; every patient has her/his own complex PKU phenotype and will be treated accordingly.', '10': 'Knowledge about PKU reveals genomic components of both disease and health.'}\n",
            "23: abstract: {'1': 'Phenylketonuria (PKU), a Mendelian autosomal recessive phenotype (OMIM 261600), is an inborn error of metabolism that can result in impaired postnatal cognitive development.', '2': 'The phenotypic outcome is multifactorial in origin, based both in nature, the mutations in the gene encoding the L-phenylalanine hydroxylase enzyme, and nurture, the nutritional experience introducing L-phenylalanine into the diet.', '3': 'The PKU story contains many messages including a framework to appreciate the complexity of this disease where phenotype reflects both locus-specific and genomic components.', '4': 'This knowledge is now being applied in the development of patient-specific therapies.'}\n",
            "23: abstract: {'1': 'Detection of individuals with phenylketonuria (PKU), an autosomal recessively inherited disorder in phenylalanine degradation, is straightforward and efficient due to newborn screening programs.', '2': 'A recent introduction of the pharmacological treatment option emerged rapid development of molecular testing.', '3': 'However, variants responsible for PKU do not all suppress enzyme activity to the same extent.', '4': 'A spectrum of over 850 variants, gives rise to a continuum of hyperphenylalaninemia from very mild, requiring no intervention, to severe classical PKU, requiring urgent intervention.', '5': 'Locus-specific and genotypes database are today an invaluable resource of information for more efficient classification and management of patients.', '6': \"The high-tech molecular methods allow patients' genotype to be obtained in a few days, especially if each laboratory develops a panel for the most frequent variants in the corresponding population.\"}\n",
            "23: abstract: {'1': 'Phenylketonuria (PKU) is an autosomal recessive inborn error of metabolism caused by a deficiency in the hepatic enzyme phenylalanine hydroxylase (PAH).', '2': 'If left untreated, the main clinical feature is intellectual disability.', '3': 'Treatment, which includes a low Phe diet supplemented with amino acid formulas, commences soon after diagnosis within the first weeks of life.', '4': 'Although dietary treatment has been successful in preventing intellectual disability in early treated PKU patients, there are major issues with dietary compliance due to palatability of the diet.', '5': 'Other potential issues associated with dietary therapy include nutritional deficiencies especially vitamin D and B12.', '6': 'Suboptimal outcomes in cognitive and executive functioning have been reported in patients who adhere poorly to dietary therapy.', '7': 'There have been continuous attempts at improving the quality of medical foods including their palatability.', '8': 'Advances in dietary therapy such as the use of large neutral amino acids (LNAA) and glycomacropeptides (GMP; found within the whey fraction of bovine milk) have been explored.', '9': 'Gene therapy and enzyme replacement or substitution therapy have yielded more promising data in the recent years.', '10': 'In this review the current and possible future treatments for PKU are discussed.'}\n",
            "23: abstract: {'1': 'Phenylketonuria (PKU) is an autosomal recessive inborn error of phenylalanine metabolism caused by deficiency in the enzyme phenylalanine hydroxylase that converts phenylalanine into tyrosine.', '2': 'If left untreated, PKU results in increased phenylalanine concentrations in blood and brain, which cause severe intellectual disability, epilepsy and behavioural problems.', '3': 'PKU management differs widely across Europe and therefore these guidelines have been developed aiming to optimize and standardize PKU care.'}\n",
            "23: abstract: {'1': 'Phenylketonuria (PKU) is an inborn error of metabolism (IEM) most often caused by missense mutations in the gene encoding phenylalanine hydroxylase (PAH) which catalyzes the hydroxylation of phenylalanine (Phe) generating tyrosine (Tyr).', '2': 'PKU belongs to a class of amino acid aminoacidopathies termed “toxic accumulation-IEMs” where the circulating toxin is an amino acid or its metabolites.', '3': 'Mutations in an enzyme, such as PAH, are recessive since one functioning enzyme with the wild-type allele is sufficient.', '4': 'Tetrahydrobiopterin (BH4) binds to the catalytic domain of PAH and is a cofactor for this reaction.', '5': 'PAH is primarily a hepatic enzyme.', '6': 'Elevated blood Phe levels and decreased Tyr levels characterize PKU.', '7': 'Newborns with PKU can appear normal at birth with the first signs appearing after several months.', '8': 'These signs can include musty odor from skin and urine, fair skin, eczema, seizures, tremors, and hyperactivity.'}\n",
            "23: abstract: {'1': 'Phenylketonuria (PKU) is considered to be a paradigm for a monogenic metabolic disorder but was never thought to be a primary application for human gene therapy due to established alternative treatment.', '2': 'However, somewhat unanticipated improvement in neuropsychiatric outcome upon long-term treatment of adults with PKU with enzyme substitution therapy might slowly change this assumption.', '3': 'In parallel, PKU was for a long time considered to be an excellent test system for experimental gene therapy of a Mendelian autosomal recessive defect of the liver due to an outstanding mouse model and the easy to analyze and well-defined therapeutic end point, that is, blood l-phenylalanine concentration.', '4': 'Lifelong treatment by targeting the mouse liver (or skeletal muscle) was achieved using different approaches, including (1) recombinant adeno-associated viral (rAAV) or nonviral naked DNA vector-based gene addition, (2) genome editing using base editors delivered by rAAV vectors, and (3) by delivering rAAVs for promoter-less insertion of the PAH-cDNA into the Pah locus.', '5': 'In this article we summarize the gene therapeutic attempts of correcting a mouse model for PKU and discuss the future implications for human gene therapy.'}\n",
            "23: abstract: {'1': 'Phenylketonuria (PKU), caused by variants in the phenylalanine hydroxylase (PAH) gene, is the most common autosomal-recessive Mendelian phenotype of amino acid metabolism.', '2': 'We estimated that globally 0.45 million individuals have PKU, with global prevalence 1:23,930 live births (range 1:4,500 [Italy]-1:125,000 [Japan]).', '3': 'Comparing genotypes and metabolic phenotypes from 16,092 affected subjects revealed differences in disease severity in 51 countries from 17 world regions, with the global phenotype distribution of 62% classic PKU, 22% mild PKU, and 16% mild hyperphenylalaninemia.', '4': 'A gradient in genotype and phenotype distribution exists across Europe, from classic PKU in the east to mild PKU in the southwest and mild hyperphenylalaninemia in the south.', '5': 'The c.1241A>G (p.Tyr414 Cys)-associated genotype can be traced from Northern to Western Europe, from Sweden via Norway, to Denmark, to the Netherlands.', '6': 'The frequency of classic PKU increases from Europe (56%) via Middle East (71%) to Australia (80%).', '7': 'Of 758 PAH variants, c.1222C> T (p.Arg408Trp) (22.2%), c.1066-11G>A (IVS10-11G>A) (6.4%), and c.782G> A (p.Arg261Gln) (5.5%) were most common and responsible for two prevalent genotypes: p.[Arg408Trp];[Arg408 Trp] (11.4%) and c.[1066-11G>A];[1066-11G>A] (2.6%).', '8': 'Most genotypes (73%) were compound heterozygous, 27% were homozygous, and 55% of 3,659 different genotypes occurred in only a single individual.', '9': 'PAH variants were scored using an allelic phenotype value and correlated with pre-treatment blood phenylalanine concentrations (n = 6,115) and tetrahydrobiopterin loading test results (n = 4,381), enabling prediction of both a genotype-based phenotype (88%) and tetrahydrobiopterin responsiveness (83%).', '10': 'This study shows that large genotype databases enable accurate phenotype prediction, allowing appropriate targeting of therapies to optimize clinical outcome.'}\n",
            "23: abstract: {'1': 'Phenylketonuria (PKU; also known as phenylalanine hydroxylase (PAH) deficiency) is an autosomal recessive disorder of phenylalanine metabolism, in which especially high phenylalanine concentrations cause brain dysfunction.', '2': 'If untreated, this brain dysfunction results in severe intellectual disability, epilepsy and behavioural problems.', '3': 'The prevalence varies worldwide, with an average of about 1:10,000 newborns.', '4': 'Early diagnosis is based on newborn screening, and if treatment is started early and continued, intelligence is within normal limits with, on average, some suboptimal neurocognitive function.', '5': 'Dietary restriction of phenylalanine has been the mainstay of treatment for over 60 years and has been highly successful, although outcomes are still suboptimal and patients can find the treatment difficult to adhere to.', '6': 'Pharmacological treatments are available, such as tetrahydrobiopterin, which is effective in only a minority of patients (usually those with milder PKU), and pegylated phenylalanine ammonia lyase, which requires daily subcutaneous injections and causes adverse immune responses.', '7': 'Given the drawbacks of these approaches, other treatments are in development, such as mRNA and gene therapy.', '8': 'Even though PAH deficiency is the most common defect of amino acid metabolism in humans, brain dysfunction in individuals with PKU is still not well understood and further research is needed to facilitate development of pathophysiology-driven treatments.'}\n",
            "24: abstract: {'1': 'Buspirone hydrochloride (HCl)1 is a new anxiolytic with a unique chemical structure.', '2': 'Its mechanism of action remains to be elucidated.', '3': \"Unlike the benzodiazepines, buspirone lacks hypnotic, anticonvulsant and muscle relaxant properties, and hence has been termed 'anxioselective'.\", '4': 'As evidenced by a few double-blind clinical trials, buspirone 15 to 30 mg/day improves symptoms of anxiety assessed by standard rating scales similarly to diazepam, clorazepate, alprazolam and lorazepam.', '5': 'Like diazepam, buspirone is effective in patients with mixed anxiety/depression, although the number of patients studied to date is small.', '6': \"In several studies, a 'lagtime' of 1 to 2 weeks to the onset of anxiolytic effect has been noted; hence motivation of patient compliance may be necessary.\", '7': 'Sedation occurs much less often after buspirone than after the benzodiazepines; other side effects are minor and infrequent.', '8': 'In healthy volunteers, buspirone does not impair psychomotor or cognitive function, and appears to have no additive effect with alcohol.', '9': 'Early evidence suggests that buspirone has limited potential for abuse and dependence.', '10': 'Thus, although only wider clinical use for longer periods of time will more clearly define some elements of its pharmacological profile, with its low incidence of sedation buspirone is a useful addition to the treatments available for generalised anxiety.', '11': 'It may well become the preferred therapy in patients in whom daytime alertness is particularly important.'}\n",
            "24: abstract: {'1': 'Forty-four patients with DSM-III-R generalized anxiety disorder participated in this double-blind, randomized study.', '2': 'Patients were on a benzodiazepine before the study and were stabilized on 3 to 5 mg/day lorazepam for 5 weeks (weeks 0 to 5).', '3': 'Thereafter, they were randomized to 15 mg/day buspirone or placebo for the following 6 weeks (weeks 6 to 11).', '4': 'During the first 2 weeks of double-blind, randomized treatment (weeks 6 to 7), lorazepam was tapered off.', '5': 'During weeks 12 to 13, patients received single-blind placebo.', '6': 'Assessment included the Hamilton Rating Scale for Anxiety, the State-Trait Anxiety Inventory, the Zung and Eddy Self-Rating Scale of Anxiety Symptoms, the Hamilton Rating Scale for Depression, and the Rome Depression Inventory, completed at weeks 0, 5, 6, 7, 8, 9, 11, and 13.', '7': 'Side effects were assessed through the Dosage Treatment Emergent Symptoms at the same times.', '8': 'The benzodiazepine-withdrawal syndrome was evaluated through a 27-symptom checklist (Clinical-Rated Benzodiazepine Withdrawal Symptom Schedule) at weeks 0, 5, 6, 7, 11, and 13.', '9': 'The results showed that buspirone was more effective than placebo and comparable to lorazepam.', '10': 'Buspirone-treated patients showed no rebound anxiety or benzodiazepine-withdrawal syndrome compared with placebo.', '11': 'Buspirone caused fewer side effects than lorazepam and was not different from placebo in this respect.', '12': 'Finally, buspirone maintained its anxiolytic effect for at least 2 weeks after the discontinuation of treatment.'}\n",
            "24: abstract: {'1': 'The respiratory and behavioral effects of the benzodiazepine receptor (BZR) inverse agonist ethyl-beta-carboline-3-carboxylate (beta-CCE) were determined alone and in combination with buspirone, lorazepam, flumazenil, and SR 95195 in rhesus monkeys.', '2': 'For the respiratory studies, one group of monkeys inhaled either air or 5% CO2 mixed in air according to a fixed alternating schedule; respiratory frequency and minute volume were monitored.', '3': 'For the behavioral studies, another group of monkeys responded under a fixed-ratio (FR 30) schedule of food presentation.', '4': 'The respiratory stimulant effects of beta-CCE in both air and 5% CO2 were enhanced by prior treatment with the 5-hydroxytryptamine1A (5-HT1A) partial agonist buspirone (0.03 and 0.3 mg/kg) and a weak BZR inverse agonist, SR 95195 (10.0 mg/kg).', '5': 'Coadministration of buspirone (0.1 and 0.3 mg/kg) also potentiated the rate-decreasing effects of beta-CCE under the FR schedule.', '6': 'The BZR agonist lorazepam (3.0 mg/kg) and BZR antagonist flumazenil (1.0 mg/kg) attenuated the effects of beta-CCE on respiratory frequency and minute volume particularly under the 5% CO2 condition, and lorazepam (0.1 and 0.3 mg/kg) and flumazenil (0.1 and 0.3 mg/kg) attenuated the effects of beta-CCE on FR responding.', '7': 'These latter results show that the respiratory and behavioral effects of beta-CCE in rhesus monkeys are at least in part due to effects at BZRs.', '8': 'Moreover, the findings suggest either that coactivation of benzodiazepine and 5-HT1A sites lead to a greater than additive effect or that beta-CCE and buspirone share a common mechanism of action that is unrelated to the receptor at which BZR inverse agonists act.'}\n",
            "24: abstract: {'1': '1. The purpose of this study was to compare the effects and abrupt discontinuation of buspirone 15 or 20 mg tid and lorazepam 3 or 4 mg tid following 8 weeks of treatment.', '2': 'A total of 43 outpatients with generalized anxiety disorder were included in the study and 39 entered the withdrawal phase.', '3': '2. Clinical assessments were performed at baseline, 2, 4, 6 and 8 weeks (active phase) and after 9 and 10 weeks (withdrawal phase).', '4': 'These included the Hamilton anxiety scale, the visual analogue scale, the CHESS 84 (a check list for the evaluation of somatic symptoms) and the Lader tranquilizer withdrawal scale (translated in french).', '5': '3. Results show similar efficacy for lorazepam and buspirone during the active phase with a higher significant difference for buspirone on the CHESS 84 in relation with neurovegetatives symptoms: lorazepam D0 :16.30 +/- 3.14 D56: 5.10 +/- 0.93 (p < or = 0.01) buspirone D0 :18.82 +/- 3.4 D56: 4.73 +/- 1.18 (p < or = 0.001).', '6': 'No withdrawal phenomena was observed for both drugs using HAM-A lorazepam D63 :12.59 +/- 2.26 D70: 12.0 +/- 1.75 (p = ns) buspirone D63 :10.05 +/- 1.28 D70: 10.32 +/- 1.82 (p = ns) and the same significant difference using Lader scale: lorazepam D63 :4.44 +/- 0.89 D70: 6.96 +/- 1.28 (p < or = 0.05) buspirone D63 :2.95 +/- 0.66 D70: 4.15 +/- 0.92 (p < or = 0.05)', '7': '4. This study confirmed that buspirone was as effective as lorazepam at D56 in monitored outpatients with generalized anxiety disorder.', '8': 'There are some evidences that these two drugs differed in efficacy against the various somatic symptoms encountered in generalized anxiety disorder.'}\n",
            "24: abstract: {'1': 'In this double-blind, placebo-controlled 10-week trial, the anxiolytic properties of the nonbenzodiazepine buspirone were compared with the benzodiazepine lorazepam and placebo in 125 outpatients with generalized anxiety disorder according to DSM-III.', '2': 'After a 3- to 7-day wash-out period, patients were allocated at random to receive orally 3 x 5 mg buspirone (n=58), 3 x 1 mg lorazepam (n=57), or placebo (n=10) over a 4-week period.', '3': 'The study also comprised a 2-week taper period and a 4-week placebo-control period to assess the stability of clinical improvement.', '4': \"The patient's clinical state was estimated on entry and at weekly intervals by general practitioners using the Hamilton Rating Scale for Anxiety (HAM-A) and Clinical Global Impression (CGI) assessment and by a self-rating scale (State Trait Anxiety Inventory X2=STAI-X2).\", '5': 'Lorazepam treatment resulted in descriptively, but not significantly, greater improvement on the Hamilton Rating Scale for Anxiety during the whole treatment (week 0-4) and taper period (week 5, 6) than did buspirone.', '6': 'After treatment with active drugs had been discontinued, the 4-week placebo control period showed buspirone-treated patients to display a stability of clinical improvement, while the symptoms of lorazepam-treated patients worsened at week 7-10.', '7': 'Both buspirone and lorazepam were more efficacious in reducing anxiety symptoms than placebo during the treatment and taper period; however, in contrast to the active drugs (buspirone, lorazepam), patients of the placebo group showed further clinical improvement during the control period, especially in the HAM-A score, so differences between placebo and active drugs became smaller at the end of the study.'}\n",
            "24: abstract: {'1': 'This multicentre study was conducted to evaluate the efficacy and consequences of progressive or abrupt withdrawal of clobazam in the treatment of Generalized Anxiety Disorder in a double blind study in comparison to lorazepam and buspirone.', '2': '128 outpatients suffering from Generalized Anxiety Disorder according to DMS III criteria were included in the study and treated for three weeks.', '3': 'They were randomly divided into 4 groups: group 1: 32 patients receiving clobazam, abruptly withdrawn and replaced by a placebo; group 2: 29 patients receiving clobazam with progressive withdrawal over 3 weeks, clobazam being replaced by a placebo; group 3: 33 patients receiving lorazepam with progressive withdrawal over 3 weeks, lorazepam being replaced by a placebo; group 4: 34 patients receiving buspirone, abruptly withdrawn and replaced by a placebo.', '4': 'The dosages were increased progressively during the first week of treatment.', '5': 'At the end of this time, the patients received either 30 mg clobazam or 30 mg buspirone or 3 mg lorazepam daily.', '6': 'After the first week, the Hamilton Anxiety Rating Scale (HARS) showed a significant improvement in clobazam and lorazepam groups but not in buspirone group.', '7': 'All the drugs were equally effective after three weeks of treatment.', '8': 'The anti-anxiety activity persisted after withdrawal of the studied drug in the 4 groups, without any signs of rebound anxiety or withdrawal syndrome.', '9': 'No clinically relevant differences were found between the 4 groups regarding safety.', '10': 'The side-effects reported were mainly drowsiness in clobazam and lorazepam groups, nausea and headache in buspirone group.', '11': 'In conclusion, clobazam like lorazepam improved anxiety more quickly than buspirone; after 3 weeks of therapy, efficacy was comparable with the 3 drugs and persisted after treatment discontinuation.'}\n",
            "24: abstract: {'1': 'Objective: Patients with generalized anxiety disorder (N=107) who had been long-term benzodiazepine users (average duration of use=8.5 years) were enrolled in a benzodiazepine discontinuation program that assessed the effectiveness of concomitant imipramine (180 mg/day) and buspirone (38 mg/day) compared to placebo in facilitating benzodiazepine discontinuation.', '2': 'Method: After a benzodiazepine stabilization period taking either diazepam, lorazepam, or alprazolam, patients were treated for 4 weeks with imipramine, buspirone, or placebo under double-blind conditions while benzodiazepine intake was kept stable (treatment phase).', '3': 'Patients then entered a 4-6 week benzodiazepine taper and a 5-week posttaper phase with imipramine, buspirone, and placebo treatment being continued until 3 weeks into the posttaper phase, at which time all patients were switched to placebo for 2 weeks.', '4': 'Benzodiazepine plasma levels were assayed weekly.', '5': 'Benzodiazepine-free status was assessed 3 and 12 months posttaper.', '6': 'Results: Study subjects were long-term benzodiazepine users with an average of three unsuccessful prior taper attempts.', '7': 'The success rate of the taper in this study was significantly higher for patients who received imipramine (82.6%), and nonsignificantly higher for patients who received buspirone (67.9%), than for patients who received placebo (37.5%).', '8': 'The imipramine effect remained highly significant even after the analysis adjusted for three other independent predictors of taper success: benzodiazepine dose, level of anxious symptoms at baseline, and duration of benzodiazepine therapy.', '9': 'Conclusions: Management of benzodiazepine discontinuation can be facilitated significantly by co-prescribing imipramine before and during the benzodiazepine taper.', '10': 'Daily benzodiazepine dose, severity of baseline symptoms of anxiety and depression, and duration of benzodiazepine use were additional significant predictors of successful taper outcome.'}\n",
            "24: abstract: {'1': 'A drug interaction refers to an event in which the usual pharmacological effect of a drug is modified by other factors, most frequently additional drugs.', '2': 'When two drugs are administered simultaneously, or within a short time of each other, an interaction can occur that may increase or decrease the intended magnitude or duration of the effect of one or both drugs.', '3': 'Drugs may interact on a pharmaceutical, pharmacokinetic or pharmacodynamic basis.', '4': 'Pharmacodynamic interactions arise when the alteration of the effects occurs at the site of action.', '5': 'This is a wide field where not only interactions between different drugs are considered but also drug and metabolites (midazolam/alpha-hydroxy-midazolam), enantiomers (ketamine), as well as phenomena such as tolerance (nordiazepam) and sensitization (diazepam).', '6': 'Pharmacodynamic interactions can result in antagonism or synergism and can originate at a receptor level (antagonism, partial agonism, down-regulation, up-regulation), at an intraneuronal level (transduction, uptake), or at an interneuronal level (physiological pathways).', '7': 'Alternatively, psychotropic drug interactions assessed through quantitative pharmaco-EEG can be viewed according to the broad underlying objective of the study: safety-oriented (ketoprofen/theophylline, lorazepam/diphenhydramine, granisetron/haloperidol), strictly pharmacologically-oriented (benzodiazepine receptors), or broadly neuro-physiologically-oriented (diazepam/buspirone).', '8': 'Methodological issues are stressed, particularly drug plasma concentrations, dose-response relationships and time-course of effects (fluoxetine/buspirone), and unsolved questions are addressed (yohimbine/caffeine, hydroxizyne/alcohol).'}\n",
            "24: abstract: {'1': 'Background: Several medications commonly used to treat generalized anxiety disorder (GAD) have been designated \"potentially inappropriate\" for use in patients aged > or =65 years because their risks may outweigh their potential benefits.', '2': 'The actual extent of use of these agents in clinical practice is unknown, however.', '3': 'Methods: Using a database with information from encounters with general practitioners (GP) in Germany, we identified all patients, aged > or =65 years, with any GP office visits or dispensed prescriptions with a diagnosis of GAD (ICD-10 diagnosis code F41.1) between 10/1/2003 and 9/30/2004 (\"GAD patients\").', '4': 'Among GAD-related medications (including benzodiazepines, tricyclic antidepressants [TCAs], selective serotonin reuptake inhibitors, venlafaxine, hydroxyzine, buspirone, pregabalin, and trifluoperazine), long-acting benzodiazepines, selected short-acting benzodiazepines at relatively high dosages, selected TCAs, and hydroxyzine were designated \"potentially inappropriate\" for use in patients aged > or = 65 years, based on published criteria.', '5': 'Results: A total of 975 elderly patients with GAD were identified.', '6': 'Mean age was 75 years, and 72% were women; 29% had diagnoses of comorbid depression.', '7': 'Forty percent of study subjects received potentially inappropriate agents - most commonly, bromazepam (10% of all subjects), diazepam (9%), doxepin (7%), amitriptyline (5%), and lorazepam (5%).', '8': 'Twenty-three percent of study subjects received long-acting benzodiazepines, 10% received short-acting benzodiazepines at relatively high doses, and 12% received TCAs designated as potentially inappropriate.', '9': 'Conclusion: GPs in Germany often prescribe medications that have been designated as potentially inappropriate to their elderly patients with GAD - especially those with comorbid depressive disorders.', '10': 'Further research is needed to ascertain whether there are specific subgoups of elderly patients with GAD for whom the benefits of these medications outweigh their risks.'}\n",
            "24: abstract: {'1': 'An 18 year-old woman presented to an outside hospital with seizure activity after a massive ingestion of lamotrigine, bupropion, trazodone, buspirone, and possibly isoretinoin.', '2': 'Her initial vital signs were remarkable for tachycardia (120 bpm).', '3': 'She was intubated for airway protection.', '4': 'For treatment of status epilepticus, she received a total of 12 mg of IV lorazepam along with a lorazepam infusion titrated to 15 mg/hr, a propofol infusion of unknown dosing, and phenobarbital 650 mg.', '5': 'She was transferred to a receiving hospital.', '6': 'Her initial ECG at the receiving hospital showed a QRS of 117 ms which narrowed with 50 mEq of sodium bicarbonate after approximately 6 hours.', '7': 'She required norepinephrine intermittently for blood pressure support for approximately 2 days.', '8': 'The patient had no dysrhythmias.', '9': 'EEG showed no epileptiform activity from approximately 11 hours-32 hours post ingestion.', '10': 'At the receiving hospital, her serum lamotrigine concentration was 109 mcg/mL (reference 3.0-14.0 mcg/mL) 7 hours after ingestion.', '11': 'Her bupropion concentration was 92 ng/mL (reference 50-100 ng/mL).', '12': 'She was extubated on hospital day 5 and discharged to a psychiatric facility on hospital day 13.'}\n",
            "25: abstract: {'1': 'Importance: The coronavirus disease 2019 (COVID-19) pandemic is threatening billions of people worldwide.', '2': 'Tocilizumab has shown promising results in retrospective studies in patients with COVID-19 pneumonia with a good safety profile.', '3': 'Objective: To evaluate the effect of early tocilizumab administration vs standard therapy in preventing clinical worsening in patients hospitalized with COVID-19 pneumonia.', '4': 'Design, setting, and participants: Prospective, open-label, randomized clinical trial that randomized patients hospitalized between March 31 and June 11, 2020, with COVID-19 pneumonia to receive tocilizumab or standard of care in 24 hospitals in Italy.', '5': 'Cases of COVID-19 were confirmed by polymerase chain reaction method with nasopharyngeal swab.', '6': 'Eligibility criteria included COVID-19 pneumonia documented by radiologic imaging, partial pressure of arterial oxygen to fraction of inspired oxygen (Pao2/Fio2) ratio between 200 and 300 mm Hg, and an inflammatory phenotype defined by fever and elevated C-reactive protein.', '7': 'Interventions: Patients in the experimental arm received intravenous tocilizumab within 8 hours from randomization (8 mg/kg up to a maximum of 800 mg), followed by a second dose after 12 hours.', '8': 'Patients in the control arm received supportive care following the protocols of each clinical center until clinical worsening and then could receive tocilizumab as a rescue therapy.', '9': 'Main outcome and measures: The primary composite outcome was defined as entry into the intensive care unit with invasive mechanical ventilation, death from all causes, or clinical aggravation documented by the finding of a Pao2/Fio2 ratio less than 150 mm Hg, whichever came first.', '10': 'Results: A total of 126 patients were randomized (60 to the tocilizumab group; 66 to the control group).', '11': 'The median (interquartile range) age was 60.0 (53.0-72.0) years, and the majority of patients were male (77 of 126, 61.1%).', '12': 'Three patients withdrew from the study, leaving 123 patients available for the intention-to-treat analyses.', '13': 'Seventeen patients of 60 (28.3%) in the tocilizumab arm and 17 of 63 (27.0%) in the standard care group showed clinical worsening within 14 days since randomization (rate ratio, 1.05; 95% CI, 0.59-1.86).', '14': 'Two patients in the experimental group and 1 in the control group died before 30 days from randomization, and 6 and 5 patients were intubated in the 2 groups, respectively.', '15': 'The trial was prematurely interrupted after an interim analysis for futility.', '16': 'Conclusions and relevance: In this randomized clinical trial of hospitalized adult patients with COVID-19 pneumonia and Pao2/Fio2 ratio between 200 and 300 mm Hg who received tocilizumab, no benefit on disease progression was observed compared with standard care.', '17': 'Further blinded, placebo-controlled randomized clinical trials are needed to confirm the results and to evaluate possible applications of tocilizumab in different stages of the disease.'}\n",
            "25: abstract: {'1': 'Hyperinflammation and cytokine storm has been noted as a poor prognostic factor in patients with severe pneumonia related to coronavirus disease 2019 (COVID-19).', '2': 'In COVID-19, pathogenic myeloid cell overactivation is found to be a vital mediator of damage to tissues, hypercoagulability, and the cytokine storm.', '3': 'These cytokines unselectively infiltrate various tissues, such as the lungs and heart, and nervous system.', '4': 'This cytokine storm can hence cause multi-organ dysfunction and life-threatening complications.', '5': 'Mavrilimumab is a monoclonal antibody (mAb) that may be helpful in some cases with COVID-19.', '6': 'During an inflammation, Granulocyte-macrophage colony-stimulating factor (GM-CSF) release is crucial to driving both innate and adaptive immune responses.', '7': 'The GM-CSF immune response is triggered when an antigen attaches to the host cell and induces the signaling pathway.', '8': 'Mavrilimumab antagonizes the action of GM-CSF and decreases the hyperinflammation associated with pneumonia in COVID-19, therefore strengthening the rationale that mavrilimumab when added to the standard protocol of treatment could improve the clinical outcomes in COVID-19 patients, specifically those patients with pneumonia.', '9': 'With this review paper, we aim to demonstrate the inhibitory effect of mavrilimumab on cytokine storms in patients with COVID-19 by reviewing published clinical trials and emphasize the importance of extensive future trials.'}\n",
            "25: abstract: {'1': 'Background: Monoclonal antibody therapy (MAT) is recommended in mild to moderate Coronavirus disease 2019 (COVID-19) patients who are at risk of progressing to severe disease.', '2': 'Due to limited data on its outcomes and the logistic challenges in administering the drug, MAT has not been widely used in the United States (US) despite of emergency use authorization (EUA) approval by the Food and Drug Administration (FDA).', '3': 'Aim: We aim to study the outcomes of MAT in patients predominantly from ethnic minority groups and the challenges we experienced in implementing the infusion therapy protocol in an inner-city safety-net-hospital in the South Bronx.', '4': 'Methods and results: We conducted a retrospective observational study of 49 patients who were offered MAT as per EUA protocol of FDA.', '5': 'Patient who met the criteria for MAT and received therapy were included in treatment group (n = 38) and the remaining (n = 11) who declined treatment were included in the control group.', '6': 'A majority of patients (76%) in the study group reported symptomatic improvement, the day after infusion.', '7': 'There was statistically significant reduction in COVID-19 related hospitalizations (7.8 vs 54.5%, P = < 0.001) mortality (0 vs 18.1%, P value = 0.008) in the treatment group.', '8': 'Conclusion: MAT reduced both hospitalization and mortality in this predominantly Hispanic patient population with mild to moderate COVID-19 with high risk factors for disease progression.'}\n",
            "25: abstract: {'1': 'Objectives: We aimed to evaluate the impact of neutralizing monoclonal antibodies (mAbs) treatment and to determine whether the mAbs selective pressure could facilitate the proliferation of virus variants with spike protein mutations that might attenuate mAb effectiveness.', '2': 'Patients and methods: We therefore evaluated the impact of mAbs on the nasopharyngeal (NP) viral load and virus quasispecies of mAb-treated patients using single molecule real time sequencing (Pacific Biosciences).', '3': 'The mAbs used were: Bamlanivimab alone (4 patients), Bamlanivimab/Etesevimab (23 patients), and Casirivimab/Imdevimab (5 patients).', '4': 'Results: The NP SARS-CoV-2 viral load of mAb-treated patients decreased from 8.2 log10 copies/ml before administration to 4.3 log10 copies/ml 7 days after administration.', '5': 'Five immunocompromised patients given Bamlanivimab/Etesevimab were found to have mAbs activity-reducing spike mutations.', '6': 'Two patients harbored SARS-CoV-2 variants with a Q493R spike mutation 7 days after administration, as did a third patient 14 days after administration.', '7': 'The fourth patient harbored a variant with a Q493K spike mutation 7 days post-treatment, and the fifth patient had a variant with a E484K spike mutation on day 21.', '8': 'The emergence of the spike mutation was accompanied by stabilization or rebound of the NP viral load in 3/5 patients.', '9': 'Conclusion: Two-m Ab therapy can drive the selection of resistant SARS-CoV-2 variants in immunocompromised patients.', '10': 'Patients given mAbs should be closely monitored and measures to limit virus spread reinforced.'}\n",
            "25: abstract: {'1': 'The ongoing pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its variants has posed a serious global public health emergency.', '2': 'Therapeutic interventions or vaccines are urgently needed to treat and prevent the further dissemination of this contagious virus.', '3': 'This study described the identification of neutralizing receptor-binding domain (RBD)-specific antibodies from mice through vaccination with a recombinant SARS-CoV-2 RBD.', '4': 'RBD-targeted monoclonal antibodies (mAbs) with distinct function and epitope recognition were selected to understand SARS-CoV-2 neutralization.', '5': 'High-affinity RBD-specific antibodies exhibited high potency in neutralizing both live and pseudotype SARS-CoV-2 viruses and the SARS-CoV-2 pseudovirus particle containing the spike protein S-RBDV367F mutant (SARS-CoV-2(V367F)).', '6': 'These results demonstrated that these antibodies recognize four distinct groups (I-IV) of epitopes on the RBD and that mAbs targeting group I epitope can be used in combination with mAbs recognizing groups II and/or IV epitope to make mAb cocktails against SARS-CoV-2 and its mutants.', '7': 'Moreover, structural characterization reveals that groups I, III, and IV epitopes are closely located to an RBD hotspot.', '8': 'The identification of RBD-specific antibodies and cocktails may provide an effective therapeutic and prophylactic intervention against SARS-CoV-2 and its isolates.'}\n",
            "25: abstract: {'1': 'Monoclonal antibodies (mAbs) with neutralizing activity against SARS-CoV-2 have demonstrated clinical benefit in cases of mild to moderate SARS-CoV-2 infection, substantially reducing the risk for hospitalization and severe disease 1-4.', '2': 'Treatment generally requires the administration of high doses of these mAbs with limited efficacy in preventing disease complications or mortality among hospitalized COVID-19 patients 5.', '3': 'Here we report the development and evaluation of Fc-optimized anti-SARS-CoV-2 mAbs with superior potency to prevent or treat COVID-19 disease.', '4': 'In several animal models of COVID-19 disease we demonstrate that selective engagement of activating FcγRs results in improved efficacy in both preventing and treating disease-induced weight loss and mortality, significantly reducing the dose required to confer full protection upon SARS-CoV-2 challenge and treatment of pre-infected animals.', '5': 'Our results highlight the importance of FcγR pathways in driving antibody-mediated antiviral immunity, while excluding any pathogenic or disease-enhancing effects of FcγR engagement of anti-SARS-CoV-2 antibodies upon infection.', '6': 'These findings have important implications for the development of Fc-engineered mAbs with optimal Fc effector function and improved clinical efficacy against COVID-19 disease.'}\n",
            "25: abstract: {'1': 'SARS-CoV-2 variants of concern show reduced neutralization by vaccine-induced and therapeutic monoclonal antibodies; therefore, treatment alternatives are needed.', '2': 'We tested therapeutic equine polyclonal antibodies (pAbs) that are being assessed in clinical trials in Costa Rica against five globally circulating variants of concern: alpha, beta, epsilon, gamma and delta, using plaque reduction neutralization assays.', '3': 'We show that equine pAbs efficiently neutralize the variants of concern, with inhibitory concentrations in the range of 0.146-1.078 μg/mL, which correspond to extremely low concentrations when compared to pAbs doses used in clinical trials.', '4': 'Equine pAbs are an effective, broad coverage, low-cost and a scalable COVID-19 treatment.'}\n",
            "25: abstract: {'1': 'Over 80 mAbs have been shown to block the interaction between the SARS-CoV-2 S1 glycoprotein and its cellular receptor, thus neutralizing virus infectivity in vitro.', '2': 'Some of those mAbs demonstrate therapeutic efficacy to curtail viral burden and lung inflammation in animal models.', '3': 'The neutralization mechanisms of mAbs against SARS-CoV-2 in vivo are not fully understood, but optimal protection correlates with Fc effector functions.', '4': 'Approximately 30 SARS-CoV-2 neutralizing m Abs are undergoing clinical trials in COVID-19 patients.', '5': 'Some were granted emergency authorization since they reduced viral load, disease severity, and hospitalization in randomized, controlled phase II clinical trials.', '6': 'However, mAbs are unaffordable for healthcare systems in many developing countries due to their high cost (> USD 1,500/vial), meaning that most infected people would not have access to them.', '7': 'Another obstacle for COVID-19 therapy with mAbs is the emergence of viral variants harboring changes in the receptor-binding domain (RBD) of the S1 glycoprotein.', '8': 'The variants of concern (VoC) exhibit enhanced transmissibility or virulence, circulate worldwide, and include those designated as alpha, beta, epsilon, gamma, and delta, first detected in the UK, South Africa, Brazil, USA, and India, respectively.', '9': 'Therapeutic mAbs, and antibodies in the plasma of vaccinated or convalescent individuals, fail to neutralize VoC efficiently.'}\n",
            "25: abstract: {'1': 'Introduction: Treatments for subjects with Covid-19 are required.', '2': 'One approach is neutralising monoclonal antibodies.', '3': 'Bamlanivimab and etesevimab are monoclonal antibodies to SARS-CoV-2.', '4': 'Areas covered: This evaluation is of the phase 3 BLAZE-1 clinical trial, which was of bamlanivimab plus etesevimab in adult ambulatory participants with a risk factor for, and mild to moderate, Covid-19 illness.', '5': 'The primary outcome was Covid 19 related hospitalisation of ≥ 24 hours or death from any cause by day 29, and this occurred in 2.1% subjects in the bamlanivimab/etesevimab group, compared to 7.0% in the placebo group.', '6': 'Expert opinion: In the pandemic, the attempts by the FDA to shorten approval processes for medicines and by journals to make information available in a timely manner are admirable.', '7': 'However, these shortened processes made negotiating the details of BLAZE-1 and producing accurate and critical appraisals difficult.', '8': 'It seems to me, that if there are any benefits of bamlanivimab alone in Covid-19, they are not clear-cut.', '9': 'Bamlanivimab has limited effects against the beta and gamma variants and is not effective against the delta variant.', '10': 'Thus, the benefits of bamlanivimab/etesevimab in the phase 3 of the BLAZE-1 may be solely due to etesevimab, and this needs to be tested.'}\n",
            "25: abstract: {'1': 'Objective: To evaluate the efficacy and safety of antiviral antibody therapies and blood products for the treatment of novel coronavirus disease 2019 (covid-19).', '2': 'Design: Living systematic review and network meta-analysis, with pairwise meta-analysis for outcomes with insufficient data.', '3': 'Data sources: WHO covid-19 database, a comprehensive multilingual source of global covid-19 literature, and six Chinese databases (up to 21 July 2021).', '4': 'Study selection: Trials randomising people with suspected, probable, or confirmed covid-19 to antiviral antibody therapies, blood products, or standard care or placebo.', '5': 'Paired reviewers determined eligibility of trials independently and in duplicate.', '6': 'Methods: After duplicate data abstraction, we performed random effects bayesian meta-analysis, including network meta-analysis for outcomes with sufficient data.', '7': 'We assessed risk of bias using a modification of the Cochrane risk of bias 2.0 tool.', '8': 'The certainty of the evidence was assessed using the grading of recommendations assessment, development, and evaluation (GRADE) approach.', '9': 'We meta-analysed interventions with ≥100 patients randomised or ≥20 events per treatment arm.', '10': 'Results: As of 21 July 2021, we identified 47 trials evaluating convalescent plasma (21 trials), intravenous immunoglobulin (IVIg) (5 trials), umbilical cord mesenchymal stem cells (5 trials), bamlanivimab (4 trials), casirivimab-imdevimab (4 trials), bamlanivimab-etesevimab (2 trials), control plasma (2 trials), peripheral blood non-haematopoietic enriched stem cells (2 trials), sotrovimab (1 trial), anti-SARS-CoV-2 IVIg (1 trial), therapeutic plasma exchange (1 trial), XAV-19 polyclonal antibody (1 trial), CT-P59 monoclonal antibody (1 trial) and INM005 polyclonal antibody (1 trial) for the treatment of covid-19.', '11': 'Patients with non-severe disease randomised to antiviral monoclonal antibodies had lower risk of hospitalisation than those who received placebo: casirivimab-imdevimab (odds ratio (OR) 0.29 (95% CI 0.17 to 0.47); risk difference (RD) -4.2%; moderate certainty), bamlanivimab (OR 0.24 (0.06 to 0.86); RD -4.1%; low certainty), bamlanivimab-etesevimab (OR 0.31 (0.11 to 0.81); RD -3.8%; low certainty), and sotrovimab (OR 0.17 (0.04 to 0.57); RD -4.8%; low certainty).', '12': 'They did not have an important impact on any other outcome.', '13': 'There was no notable difference between monoclonal antibodies.', '14': 'No other intervention had any meaningful effect on any outcome in patients with non-severe covid-19.', '15': 'No intervention, including antiviral antibodies, had an important impact on any outcome in patients with severe or critical covid-19, except casirivimab-imdevimab, which may reduce mortality in patients who are seronegative.', '16': 'Conclusion: In patients with non-severe covid-19, casirivimab-imdevimab probably reduces hospitalisation; bamlanivimab-etesevimab, bamlanivimab, and sotrovimab may reduce hospitalisation.', '17': 'Convalescent plasma, IVIg, and other antibody and cellular interventions may not confer any meaningful benefit.'}\n",
            "26: abstract: {'1': 'Background: A novel human coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was identified in China in December 2019.', '2': 'There is limited support for many of its key epidemiologic features, including the incubation period for clinical disease (coronavirus disease 2019 [COVID-19]), which has important implications for surveillance and control activities.', '3': 'Objective: To estimate the length of the incubation period of COVID-19 and describe its public health implications.', '4': 'Design: Pooled analysis of confirmed COVID-19 cases reported between 4 January 2020 and 24 February 2020.', '5': 'Setting: News reports and press releases from 50 provinces, regions, and countries outside Wuhan, Hubei province, China.', '6': 'Participants: Persons with confirmed SARS-CoV-2 infection outside Hubei province, China.', '7': 'Measurements: Patient demographic characteristics and dates and times of possible exposure, symptom onset, fever onset, and hospitalization.', '8': 'Results: There were 181 confirmed cases with identifiable exposure and symptom onset windows to estimate the incubation period of COVID-19.', '9': 'The median incubation period was estimated to be 5.1 days (95% CI, 4.5 to 5.8 days), and 97.5% of those who develop symptoms will do so within 11.5 days (CI, 8.2 to 15.6 days) of infection.', '10': 'These estimates imply that, under conservative assumptions, 101 out of every 10 000 cases (99th percentile, 482) will develop symptoms after 14 days of active monitoring or quarantine.', '11': 'Limitation: Publicly reported cases may overrepresent severe cases, the incubation period for which may differ from that of mild cases.', '12': 'Conclusion: This work provides additional evidence for a median incubation period for COVID-19 of approximately 5 days, similar to SARS.', '13': 'Our results support current proposals for the length of quarantine or active monitoring of persons potentially exposed to SARS-CoV-2, although longer monitoring periods might be justified in extreme cases.'}\n",
            "26: abstract: {'1': 'Recurrence of positive SARS CoV‐2 PCR has been described in patients discharged from hospital after 2 consecutive negative PCR.', '2': 'We discuss possible explanations including false negative, reactivation and re‐infection and propose different strategy to solve this issue.', '3': 'Prolonged SARS‐CoV‐2 RNA shedding and recurrence of viral RNA shedding in asymptomatic patients remain unknown.', '4': 'Transmission of SARS‐CoV‐2 by asymptomatic carriers had been documented.', '5': 'Considering the significance of this ongoing global public health emergency, it is necessary to carry out large studies to better understand the issue of potential SARS‐ CoV‐2 recurrence in COVID‐19 patients.'}\n",
            "26: abstract: {'1': 'Since December 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has infected over four million people worldwide.', '2': 'There are multiple reports of prolonged viral shedding in people infected with SARS-CoV-2 but the presence of viral RNA on a test does not necessarily correlate with infectivity.', '3': 'The duration of quarantine required after clinical recovery to definitively prevent transmission is therefore uncertain.', '4': 'In addition, asymptomatic and presymptomatic transmission may occur, and infectivity may be highest early after onset of symptoms, meaning that contact tracing, isolation of exposed individuals and social distancing are essential public health measures to prevent further spread.', '5': 'This review aimed to summarise the evidence around viral shedding vs infectivity of SARS-CoV-2.'}\n",
            "26: abstract: {'1': 'Background: Patients recovering from coronavirus disease 2019 (COVID-19) often continue to test positive for the causative virus by polymerase chain reaction (PCR) even after clinical recovery, thereby complicating return-to-work plans.', '2': 'The purpose of this study was to evaluate transmission potential of COVID-19 by examining viral load with respect to time.', '3': 'Methods: Health care personnel (HCP) at Cleveland Clinic diagnosed with COVID-19, who recovered without needing hospitalization, were identified.', '4': 'Threshold cycles (Ct) for positive PCR tests were obtained and viral loads calculated.', '5': 'The association of viral load with days since symptom onset was examined in a multivariable regression model, which was reduced by stepwise backward selection to only keep variables significant at a level of .05.', '6': 'Viral loads by day since symptom onset were predicted using the model and transmission potential evaluated by examination of a viral load-time curve.', '7': 'Results: Over 6 weeks, 230 HCP had 528 tests performed.', '8': 'Viral loads declined by orders of magnitude within a few days of symptom onset.', '9': 'The only variable significantly associated with viral load was time since onset of symptoms.', '10': 'Of the area under the curve (AUC) spanning symptom onset to 30 days, 96.9% lay within the first 7 days, and 99.7% within 10 days.', '11': 'Findings were very similar when validated using split-sample and 10-fold cross-validation.', '12': 'Conclusions: Among patients with nonsevere COVID-19, viral loads in upper respiratory specimens peak by 2 or 3 days from symptom onset and decrease rapidly thereafter.', '13': 'The vast majority of the viral load-time AUC lies within 10 days of symptom onset.'}\n",
            "26: abstract: {'1': 'Objectives: The distribution of the transmission onset of COVID-19 relative to the symptom onset is a key parameter for infection control.', '2': 'It is often not easy to study the transmission onset time, as it is difficult to know who infected whom exactly when.', '3': 'Methods: We inferred transmission onset time from 72 infector-infectee pairs in South Korea, either with known or inferred contact dates, utilizing the incubation period.', '4': \"Combining this data with known information of the infector's symptom onset, we could generate the transmission onset distribution of COVID-19, using Bayesian methods.\", '5': 'Serial interval distribution could be automatically estimated from our data.', '6': 'Results: We estimated the median transmission onset to be 1.31 days (standard deviation, 2.64 days) after symptom onset with a peak at 0.72 days before symptom onset.', '7': 'The pre-symptomatic transmission proportion was 37% (95% credible interval [CI], 16-52%).', '8': 'The median incubation period was estimated to be 2.87 days (95% CI, 2.33-3.50 days), and the median serial interval to be 3.56 days (95% CI, 2.72-4.44 days).', '9': 'Conclusions: Considering that the transmission onset distribution peaked with the symptom onset and the pre-symptomatic transmission proportion is substantial, the usual preventive measures might be too late to prevent SARS-CoV-2 transmission.'}\n",
            "26: abstract: {'1': 'Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the etiologic agent of coronavirus disease 2019 (COVID-19), has spread globally in a few short months.', '2': 'Substantial evidence now supports preliminary conclusions about transmission that can inform rational, evidence-based policies and reduce misinformation on this critical topic.', '3': 'This article presents a comprehensive review of the evidence on transmission of this virus.', '4': 'Although several experimental studies have cultured live virus from aerosols and surfaces hours after inoculation, the real-world studies that detect viral RNA in the environment report very low levels, and few have isolated viable virus.', '5': 'Strong evidence from case and cluster reports indicates that respiratory transmission is dominant, with proximity and ventilation being key determinants of transmission risk.', '6': 'In the few cases where direct contact or fomite transmission is presumed, respiratory transmission has not been completely excluded.', '7': 'Infectiousness peaks around a day before symptom onset and declines within a week of symptom onset, and no late linked transmissions (after a patient has had symptoms for about a week) have been documented.', '8': 'The virus has heterogeneous transmission dynamics: Most persons do not transmit virus, whereas some cause many secondary cases in transmission clusters called \"superspreading events.\"', '9': 'Evidence-based policies and practices should incorporate the accumulating knowledge about transmission of SARS-CoV-2 to help educate the public and slow the spread of this virus.'}\n",
            "26: abstract: {'1': 'Defining the duration of infectivity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has major implications for public health and infection control practice in healthcare facilities.', '2': 'Early in the pandemic, most hospitals required 2 negative RT-PCR tests before discontinuing isolation in patients with Covid-19.', '3': 'Many patients, however, have persistently positive RT-PCR tests for weeks to months following clinical recovery, and multiple studies now indicate that these generally do not reflect replication-competent virus.', '4': 'SARS-CoV-2 appears to be most contagious around the time of symptom onset, and infectivity rapidly decreases thereafter to near-zero after about 10 days in mild-moderately ill patients and 15 days in severely-critically ill and immunocompromised patients.', '5': 'The longest interval associated with replication-competent virus thus far is 20 days from symptom onset.', '6': 'This review summarizes evidence-to-date on the duration of infectivity of SARS-CoV-2, and how this has informed evolving public health recommendations on when it is safe to discontinue isolation precautions.'}\n",
            "26: abstract: {'1': 'Objectives: To summarise the evidence on the duration of infectiousness of individuals in whom SARS-CoV-2 ribonucleic acid is detected.', '2': 'Methods: A rapid review was undertaken in PubMed, Europe PubMed Central and EMBASE from 1 January 2020 to 26 August 2020.', '3': 'Results: We identified 15 relevant studies, including 13 virus culture studies and 2 contact tracing studies.', '4': 'For 5 virus culture studies, the last day on which SARS-CoV-2 was isolated occurred within 10 days of symptom onset.', '5': 'For another 5 studies, SARS-CoV-2 was isolated beyond day 10 for approximately 3% of included patients.', '6': 'The remaining 3 virus culture studies included patients with severe or critical disease; SARS-CoV-2 was isolated up to day 32 in one study.', '7': 'Two studies identified immunocompromised patients from whom SARS-CoV-2 was isolated for up to 20 days.', '8': 'Both contact tracing studies, when close contacts were first exposed greater than 5 days after symptom onset in the index case, found no evidence of laboratory-confirmed onward transmission of SARS-CoV-2.', '9': 'Conclusion: COVID-19 patients with mild-to-moderate illness are highly unlikely to be infectious beyond 10 days of symptoms.', '10': 'However, evidence from a limited number of studies indicates that patients with severe-to-critical illness or who are immunocompromised, may shed infectious virus for longer.'}\n",
            "26: abstract: {'1': 'Background: The efficacy of public health measures to control the transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has not been well studied in young adults.', '2': 'Methods: We investigated SARS-CoV-2 infections among U.S. Marine Corps recruits who underwent a 2-week quarantine at home followed by a second supervised 2-week quarantine at a closed college campus that involved mask wearing, social distancing, and daily temperature and symptom monitoring.', '3': 'Study volunteers were tested for SARS-CoV-2 by means of quantitative polymerase-chain-reaction (qPCR) assay of nares swab specimens obtained between the time of arrival and the second day of supervised quarantine and on days 7 and 14.', '4': 'Recruits who did not volunteer for the study underwent qPCR testing only on day 14, at the end of the quarantine period.', '5': 'We performed phylogenetic analysis of viral genomes obtained from infected study volunteers to identify clusters and to assess the epidemiologic features of infections.', '6': 'Results: A total of 1848 recruits volunteered to participate in the study; within 2 days after arrival on campus, 16 (0.9%) tested positive for SARS-CoV-2, 15 of whom were asymptomatic.', '7': 'An additional 35 participants (1.9%) tested positive on day 7 or on day 14.', '8': 'Five of the 51 participants (9.8%) who tested positive at any time had symptoms in the week before a positive qPCR test.', '9': 'Of the recruits who declined to participate in the study, 26 (1.7%) of the 1554 recruits with available qPCR results tested positive on day 14.', '10': 'No SARS-CoV-2 infections were identified through clinical qPCR testing performed as a result of daily symptom monitoring.', '11': 'Analysis of 36 SARS-CoV-2 genomes obtained from 32 participants revealed six transmission clusters among 18 participants.', '12': 'Epidemiologic analysis supported multiple local transmission events, including transmission between roommates and among recruits within the same platoon.', '13': 'Conclusions: Among Marine Corps recruits, approximately 2% who had previously had negative results for SARS-CoV-2 at the beginning of supervised quarantine, and less than 2% of recruits with unknown previous status, tested positive by day 14.', '14': 'Most recruits who tested positive were asymptomatic, and no infections were detected through daily symptom monitoring.', '15': 'Transmission clusters occurred within platoons.'}\n",
            "26: abstract: {'1': 'Background: As a highly contagious disease, coronavirus disease 2019 (COVID-19) is wreaking havoc around the world due to continuous spread among close contacts mainly via droplets, aerosols, contaminated hands or surfaces.', '2': 'Therefore, centralized isolation of close contacts and suspected patients is an important measure to prevent the transmission of COVID-19.', '3': 'At present, the quarantine duration in most countries is 14 d due to the fact that the incubation period of severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) is usually identified as 1-14 d with median estimate of 4-7.5 d.', '4': 'Since COVID-19 patients in the incubation period are also contagious, cases with an incubation period of more than 14 d need to be evaluated.', '5': 'Case summary: A 70-year-old male patient was admitted to the Department of Respiratory Medicine of The First Affiliated Hospital of Harbin Medical University on April 5 due to a cough with sputum and shortness of breath.', '6': 'On April 10, the patient was transferred to the Fever Clinic for further treatment due to close contact to one confirmed COVID-19 patient in the same room.', '7': 'During the period from April 10 to May 6, nucleic acid and antibodies to SARS-CoV-2 were tested 7 and 4 times, respectively, all of which were negative.', '8': 'On May 7, the patient developed fever with a maximum temperature of 39℃, and his respiratory difficulties had deteriorated.', '9': 'The results of nucleic acid and antibody detection of SARS-CoV-2 were positive.', '10': 'On May 8, the nucleic acid and antibody detection of SARS-CoV-2 by Heilongjiang Provincial Center for Disease Control were also positive, and the patient was diagnosed with COVID-19 and reported to the Chinese Center for Disease Control and Prevention.', '11': 'Conclusion: This case highlights the importance of the SARS-CoV-2 incubation period.', '12': 'Further epidemiological investigations and clinical observations are urgently needed to identify the optimal incubation period of SARS-CoV-2 and formulate rational and evidence-based quarantine policies for COVID-19 accordingly.'}\n",
            "27: abstract: {'1': 'Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in a worldwide pandemic.', '2': 'Safe and effective vaccines are needed urgently.', '3': 'Methods: In an ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial, we randomly assigned persons 16 years of age or older in a 1:1 ratio to receive two doses, 21 days apart, of either placebo or the BNT162b2 vaccine candidate (30 μg per dose).', '4': 'BNT162b2 is a lipid nanoparticle-formulated, nucleoside-modified RNA vaccine that encodes a prefusion stabilized, membrane-anchored SARS-CoV-2 full-length spike protein.', '5': 'The primary end points were efficacy of the vaccine against laboratory-confirmed Covid-19 and safety.', '6': 'Results: A total of 43,548 participants underwent randomization, of whom 43,448 received injections: 21,720 with BNT162b2 and 21,728 with placebo.', '7': 'There were 8 cases of Covid-19 with onset at least 7 days after the second dose among participants assigned to receive BNT162b2 and 162 cases among those assigned to placebo; BNT162b2 was 95% effective in preventing Covid-19 (95% credible interval, 90.3 to 97.6).', '8': 'Similar vaccine efficacy (generally 90 to 100%) was observed across subgroups defined by age, sex, race, ethnicity, baseline body-mass index, and the presence of coexisting conditions.', '9': 'Among 10 cases of severe Covid-19 with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient.', '10': 'The safety profile of BNT162b2 was characterized by short-term, mild-to-moderate pain at the injection site, fatigue, and headache.', '11': 'The incidence of serious adverse events was low and was similar in the vaccine and placebo groups.', '12': 'Conclusions: A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older.', '13': 'Safety over a median of 2 months was similar to that of other viral vaccines.', '14': '(Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04368728.).'}\n",
            "27: abstract: {'1': 'Background: Vaccines are needed to prevent coronavirus disease 2019 (Covid-19) and to protect persons who are at high risk for complications.', '2': 'The mRNA-1273 vaccine is a lipid nanoparticle-encapsulated mRNA-based vaccine that encodes the prefusion stabilized full-length spike protein of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes Covid-19.', '3': 'Methods: This phase 3 randomized, observer-blinded, placebo-controlled trial was conducted at 99 centers across the United States.', '4': 'Persons at high risk for SARS-CoV-2 infection or its complications were randomly assigned in a 1:1 ratio to receive two intramuscular injections of mRNA-1273 (100 μg) or placebo 28 days apart.', '5': 'The primary end point was prevention of Covid-19 illness with onset at least 14 days after the second injection in participants who had not previously been infected with SARS-CoV-2.', '6': 'Results: The trial enrolled 30,420 volunteers who were randomly assigned in a 1:1 ratio to receive either vaccine or placebo (15,210 participants in each group).', '7': 'More than 96% of participants received both injections, and 2.2% had evidence (serologic, virologic, or both) of SARS-CoV-2 infection at baseline.', '8': 'Symptomatic Covid-19 illness was confirmed in 185 participants in the placebo group (56.5 per 1000 person-years; 95% confidence interval [CI], 48.7 to 65.3) and in 11 participants in the mRNA-1273 group (3.3 per 1000 person-years; 95% CI, 1.7 to 6.0); vaccine efficacy was 94.1% (95% CI, 89.3 to 96.8%; P<0.001).', '9': 'Efficacy was similar across key secondary analyses, including assessment 14 days after the first dose, analyses that included participants who had evidence of SARS-CoV-2 infection at baseline, and analyses in participants 65 years of age or older.', '10': 'Severe Covid-19 occurred in 30 participants, with one fatality; all 30 were in the placebo group.', '11': 'Moderate, transient reactogenicity after vaccination occurred more frequently in the mRNA-1273 group.', '12': 'Serious adverse events were rare, and the incidence was similar in the two groups.', '13': 'Conclusions: The mRNA-1273 vaccine showed 94.1% efficacy at preventing Covid-19 illness, including severe disease.', '14': 'Aside from transient local and systemic reactions, no safety concerns were identified.', '15': '(Funded by the Biomedical Advanced Research and Development Authority and the National Institute of Allergy and Infectious Diseases; COVE ClinicalTrials.gov number, NCT04470427.).'}\n",
            "27: abstract: {'1': 'As of January 3, 2021, a total of 20,346,372 cases of coronavirus disease 2019 (COVID-19) and 349,246 associated deaths have been reported in the United States.', '2': 'Long-term sequalae of COVID-19 over the course of a lifetime currently are unknown; however, persistent symptoms and serious complications are being reported among COVID-19 survivors, including persons who initially experience a mild acute illness.*', '3': 'On December 11, 2020, the Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for Pfizer-BioNTech COVID-19 vaccine to prevent COVID-19, administered as 2 doses separated by 21 days.', '4': 'On December 12, 2020, the Advisory Committee on Immunization Practices (ACIP) issued an interim recommendation for use of Pfizer-BioNTech COVID-19 vaccine (1); initial doses were recommended for health care personnel and long-term care facility residents (2).', '5': 'As of December 23, 2020, a reported 1,893,360 first doses of Pfizer-BioNTech COVID-19 vaccine had been administered in the United States, and reports of 4,393 (0.2%) adverse events after receipt of Pfizer BioNTech COVID-19 vaccine had been submitted to the Vaccine Adverse Event Reporting System (VAERS).', '6': 'Among these, 175 case reports were identified for further review as possible cases of severe allergic reaction, including anaphylaxis.', '7': 'Anaphylaxis is a life-threatening allergic reaction that does occur rarely after vaccination, with onset typically within minutes to hours (3).', '8': 'Twenty-one cases were determined to be anaphylaxis (a rate of 11.1 per million doses administered), including 17 in persons with a documented history of allergies or allergic reactions, seven of whom had a history of anaphylaxis.', '9': 'The median interval from vaccine receipt to symptom onset was 13 minutes (range = 2-150 minutes).', '10': 'Among 20 persons with follow-up information available, all had recovered or been discharged home.', '11': 'Of the remaining case reports that were determined not to be anaphylaxis, 86 were judged to be nonanaphylaxis allergic reactions, and 61 were considered nonallergic adverse events.', '12': 'Seven case reports were still under investigation.', '13': 'This report summarizes the clinical and epidemiologic characteristics of case reports of allergic reactions, including anaphylaxis and nonanaphylaxis allergic reactions, after receipt of the first dose of Pfizer-BioNTech COVID-19 vaccine during December 14-23, 2020, in the United States.', '14': 'CDC has issued updated interim clinical considerations for use of mRNA COVID-19 vaccines currently authorized in the United States (4) and interim considerations for preparing for the potential management of anaphylaxis (5).', '15': 'In addition to screening for contraindications and precautions before administering COVID-19 vaccines, vaccine locations should have the necessary supplies available to manage anaphylaxis, should implement postvaccination observation periods, and should immediately treat persons experiencing anaphylaxis signs and symptoms with intramuscular injection of epinephrine (4,5).'}\n",
            "27: abstract: {'1': 'As of January 20, 2021, a total of 24,135,690 cases of coronavirus disease 2019 (COVID-19) and 400,306 associated deaths had been reported in the United States (https://covid.cdc.gov/covid-data-tracker/#cases_casesper100klast7days).', '2': 'On December 18, 2020, the Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for Moderna COVID-19 vaccine administered as 2 doses, 1 month apart to prevent COVID-19.', '3': 'On December 19, 2020, the Advisory Committee on Immunization Practices (ACIP) issued an interim recommendation for use of Moderna COVID-19 vaccine (1).', '4': 'As of January 10, 2021, a reported 4,041,396 first doses of Moderna COVID-19 vaccine had been administered in the United States, and reports of 1,266 (0.03%) adverse events after receipt of Moderna COVID-19 vaccine were submitted to the Vaccine Adverse Event Reporting System (VAERS).', '5': 'Among these, 108 case reports were identified for further review as possible cases of severe allergic reaction, including anaphylaxis.', '6': 'Anaphylaxis is a life-threatening allergic reaction that occurs rarely after vaccination, with onset typically within minutes to hours (2).', '7': 'Among these case reports, 10 cases were determined to be anaphylaxis (a rate of 2.5 anaphylaxis cases per million Moderna COVID-19 vaccine doses administered), including nine in persons with a documented history of allergies or allergic reactions, five of whom had a previous history of anaphylaxis.', '8': 'The median interval from vaccine receipt to symptom onset was 7.5 minutes (range = 1-45 minutes).', '9': 'Among eight persons with follow-up information available, all had recovered or been discharged home.', '10': 'Among the remaining case reports that were determined not to be anaphylaxis, 47 were assessed to be nonanaphylaxis allergic reactions, and 47 were considered nonallergic adverse events.', '11': 'For four case reports, investigators have been unable to obtain sufficient information to assess the likelihood of anaphylaxis.', '12': 'This report summarizes the clinical and epidemiologic characteristics of case reports of allergic reactions, including anaphylaxis and nonanaphylaxis allergic reactions, after receipt of the first dose of Moderna COVID-19 vaccine during December 21, 2020-January 10, 2021, in the United States.', '13': 'CDC has issued updated interim clinical considerations for use of mRNA COVID-19 vaccines currently authorized in the United States (3) and interim considerations for preparing for the potential management of anaphylaxis (4).'}\n",
            "27: abstract: {'1': 'Objective: The \"Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)\" disease has caused a worldwide challenging and threatening pandemic (COVID-19), with huge health and economic losses.', '2': 'The US Food and Drug Administration, (FDA) has granted emergency use authorization for treatment with the Pfizer/BioNTech and Moderna COVID-19 vaccines.', '3': 'Many people have a history of a significant allergic reaction to a specific food, medicine, or vaccine; hence, people all over the world have great concerns about these two authorized vaccines.', '4': 'This article compares the pharmacology, indications, contraindications, and adverse effects of the Pfizer/BioNTech and Moderna vaccines.', '5': 'Materials and methods: The required documents and information were collected from the relevant databases, including Web of Science (Clarivate Analytics), PubMed, EMBASE, World Health Organization (WHO), Food and Drug Authorities (FDA) USA, Local Ministries, Health Institutes, and Google Scholar.', '6': 'The key terms used were: Coronavirus, SARS-COV-2, COVID-19 pandemic, vaccines, Pfizer/BioN Tech vaccine, Moderna vaccine, pharmacology, benefits, allergic responses, indications, contraindications, and adverse effects.', '7': 'The descriptive information was recorded, and we eventually included 12 documents including research articles, clinical trials, and websites to record the required information.', '8': 'Results: Based on the currently available literature, both vaccines are beneficial to provide immunity against SARS-CoV-2 infection.', '9': 'Pfizer/BioN Tech Vaccine has been recommended to people 16 years of age and older, with a dose of 30 μg (0.3 m) at a cost of $19.50.', '10': 'It provides immunogenicity for at least 119 days after the first vaccination and is 95% effective in preventing the SARS-COV-2 infection.', '11': 'However, Moderna Vaccine has been recommended to people 18 years of age and older, with a dose of 50 μg (0.5 mL) at a cost of $32-37.', '12': 'It provides immunogenicity for at least 119 days after the first vaccination and is 94.5% effective in preventing the SARS-CoV-2 infection.', '13': 'However, some associated allergic symptoms have been reported for both vaccines.', '14': 'The COVID-19 vaccines can cause mild adverse effects after the first or second doses, including pain, redness or swelling at the site of vaccine shot, fever, fatigue, headache, muscle pain, nausea, vomiting, itching, chills, and joint pain, and can also rarely cause anaphylactic shock.', '15': 'The occurrence of adverse effects is reported to be lower in the Pfizer/BioNTech vaccine compared to the Moderna vaccine; however, the Moderna vaccine compared to the Pfizer vaccine is easier to transport and store because it is less temperature sensitive.', '16': 'Conclusions: The FDA has granted emergency use authorization for the Pfizer/BioNTech and Moderna COVID-19 vaccines.', '17': 'These vaccines can protect recipients from a SARS-CoV- 2 infection by formation of antibodies and provide immunity against a SARS-CoV-2 infection.', '18': 'Both vaccines can cause various adverse effects, but these reactions are reported to be less frequent in the Pfizer/BioNTech vaccine compared to the Moderna COVID-19 vaccine; however, the Moderna vaccine compared to the Pfizer vaccine is easier to transport and store because it is less temperature sensitive.'}\n",
            "27: abstract: {'1': 'In December 2020, the Food and Drug Administration (FDA) issued Emergency Use Authorizations (EUAs) for Pfizer-BioNTech and Moderna COVID-19 vaccines, and in February 2021, FDA issued an EUA for the Janssen (Johnson & Johnson) COVID-19 vaccine.', '2': 'After each EUA, the Advisory Committee on Immunization Practices (ACIP) issued interim recommendations for vaccine use; currently Pfizer-BioNTech is authorized and recommended for persons aged ≥12 years and Moderna and Janssen for persons aged ≥18 years (1-3).', '3': 'Both Pfizer-BioNTech and Moderna vaccines, administered as 2-dose series, are mRNA-based COVID-19 vaccines, whereas the Janssen COVID-19 vaccine, administered as a single dose, is a recombinant replication-incompetent adenovirus-vector vaccine.', '4': 'As of July 22, 2021, 187 million persons in the United States had received at least 1 dose of COVID-19 vaccine (4); close monitoring of safety surveillance has demonstrated that serious adverse events after COVID-19 vaccination are rare (5,6).', '5': 'Three medical conditions have been reported in temporal association with receipt of COVID-19 vaccines.', '6': 'Two of these (thrombosis with thrombocytopenia syndrome [TTS], a rare syndrome characterized by venous or arterial thrombosis and thrombocytopenia, and Guillain-Barré syndrome [GBS], a rare autoimmune neurologic disorder characterized by ascending weakness and paralysis) have been reported after Janssen COVID-19 vaccination.', '7': 'One (myocarditis, cardiac inflammation) has been reported after Pfizer-BioNTech COVID-19 vaccination or Moderna COVID-19 vaccination, particularly after the second dose; these were reviewed together and will hereafter be referred to as mRNA COVID-19 vaccination.', '8': 'ACIP has met three times to review the data associated with these reports of serious adverse events and has comprehensively assessed the benefits and risks associated with receipt of these vaccines.', '9': 'During the most recent meeting in July 2021, ACIP determined that, overall, the benefits of COVID-19 vaccination in preventing COVID-19 morbidity and mortality outweigh the risks for these rare serious adverse events in adults aged ≥18 years; this balance of benefits and risks varied by age and sex.', '10': 'ACIP continues to recommend COVID-19 vaccination in all persons aged ≥12 years.', '11': 'CDC and FDA continue to closely monitor reports of serious adverse events and will present any additional data to ACIP for consideration.', '12': 'Information regarding risks and how they vary by age and sex and type of vaccine should be disseminated to providers, vaccine recipients, and the public.'}\n",
            "27: abstract: {'1': 'There have been reports of myocarditis following COVID-19 vaccination.', '2': 'We surveyed all hospitalized military personnel in the Isareli Defense Forces during the period of the COVID-19 vaccination operation (12/28/2021-3/7/2021) for diagnosed myocarditis.', '3': 'We identified 7 cases of myocarditis with symptoms starting in the first week after the second dose of COVID-19 Pfizer-BioNTech vaccine.', '4': 'One case of myocarditis diagnosed 10 days after the second dose of the vaccine was not included.', '5': 'These 8 cases comprise of all events of myocarditis diagnosed in military personnel during this time period.', '6': 'All patients were young and generally healthy.', '7': 'All had mild disease with no sequalae.', '8': 'The incidence of myocarditis in the week following a second dose of the vaccine was 5.07/100,000 people vaccinated.', '9': 'Due to the nature of this report no causality could be established.', '10': 'Clinicians should be aware of the possibility of myocarditis following Pfizer-BioNTech vaccination.', '11': 'True incidence rates should be further investigated.'}\n",
            "27: abstract: {'1': 'The coronavirus disease 2019 (COVID-19) pandemic is a global crisis, with devastating health, business and social impacts.', '2': 'Vaccination is a safe, simple, and effective way of protecting a person against COVID-19.', '3': 'By the end of August 2021, only 24.6% of the world population has received two doses of a COVID-19 vaccine.', '4': 'Since the emergence of COVID-19, several COVID-19 vaccines have been developed and approved for emergency use.', '5': 'Current vaccines have shown efficacy with low risk of adverse effects.', '6': 'However, COVID-19 vaccines have been related to a relatively small number of cases of heart inflammation, anaphylaxis (allergic reactions), and blood clots formation.', '7': 'On the other hand, COVID-19 vaccination is not recommended for children less than 12 years of age.', '8': 'Furthermore, It has been proposed that some new variants (e.g., Lambda and Delta) are proficient in escaping from the antiviral immunity elicited by vaccination.', '9': 'Herein we present current considerations regarding the COVID-19 vaccines including: efficacy against new variants, challenges in distribution, disparities in availability, dosage gender and race difference, COVID-19 vaccine transport and storage, limitations in children and pregnant women.', '10': 'Long-time monitoring is essential in order to find vaccine efficacy and to rule out related side effects.'}\n",
            "27: abstract: {'1': 'Purpose: The COVID-19 pandemic has galvanized the development of new vaccines at an unprecedented pace.', '2': 'Since the widespread implementation of vaccination campaigns, reports of ocular adverse effects after COVID-19 vaccinations have emerged.', '3': 'This review summarizes ocular adverse effects possibly associated with COVID-19 vaccination, and discusses their clinical characteristics and management.', '4': \"Results: Ocular adverse effects of COVID-19 vaccinations include facial nerve palsy, abducens nerve palsy, acute macular neuroretinopathy, central serous retinopathy, thrombosis, uveitis, multiple evanescent white dot syndrome, Vogt-Koyanagi-Harada disease reactivation, and new-onset Graves' Disease.\", '5': 'Studies in current literature are primarily retrospective case series or isolated case reports - these are inherently weak in establishing association or causality.', '6': 'Nevertheless, the described presentations resemble the reported ocular manifestations of the COVID-19 disease itself.', '7': \"Hence, we hypothesize that the human body's immune response to COVID-19 vaccinations may be involved in the pathogenesis of the ocular adverse effects post-COVID-19 vaccination.\", '8': 'Conclusion: Ophthalmologists and generalists should be aware of the possible, albeit rare, ocular adverse effects after COVID-19 vaccination.'}\n",
            "27: abstract: {'1': 'Importance: Thrombosis with thrombocytopenia syndrome (TTS) has been reported after vaccination with the SARS-CoV-2 vaccines ChAdOx1 nCov-19 (Oxford-AstraZeneca) and Ad26.COV2.S (Janssen/Johnson & Johnson).', '2': 'Objective: To describe the clinical characteristics and outcome of patients with cerebral venous sinus thrombosis (CVST) after SARS-CoV-2 vaccination with and without TTS.', '3': 'Design, setting, and participants: This cohort study used data from an international registry of consecutive patients with CVST within 28 days of SARS-CoV-2 vaccination included between March 29 and June 18, 2021, from 81 hospitals in 19 countries.', '4': 'For reference, data from patients with CVST between 2015 and 2018 were derived from an existing international registry.', '5': 'Clinical characteristics and mortality rate were described for adults with (1) CVST in the setting of SARS-CoV-2 vaccine-induced immune thrombotic thrombocytopenia, (2) CVST after SARS-CoV-2 vaccination not fulling criteria for TTS, and (3) CVST unrelated to SARS-CoV-2 vaccination.', '6': 'Exposures: Patients were classified as having TTS if they had new-onset thrombocytopenia without recent exposure to heparin, in accordance with the Brighton Collaboration interim criteria.', '7': 'Main outcomes and measures: Clinical characteristics and mortality rate.', '8': 'Results: Of 116 patients with postvaccination CVST, 78 (67.2%) had TTS, of whom 76 had been vaccinated with ChAdOx1 nCov-19; 38 (32.8%) had no indication of TTS.', '9': 'The control group included 207 patients with CVST before the COVID-19 pandemic.', '10': 'A total of 63 of 78 (81%), 30 of 38 (79%), and 145 of 207 (70.0%) patients, respectively, were female, and the mean (SD) age was 45 (14), 55 (20), and 42 (16) years, respectively.', '11': 'Concomitant thromboembolism occurred in 25 of 70 patients (36%) in the TTS group, 2 of 35 (6%) in the no TTS group, and 10 of 206 (4.9%) in the control group, and in-hospital mortality rates were 47% (36 of 76; 95% CI, 37-58), 5% (2 of 37; 95% CI, 1-18), and 3.9% (8 of 207; 95% CI, 2.0-7.4), respectively.', '12': 'The mortality rate was 61% (14 of 23) among patients in the TTS group diagnosed before the condition garnered attention in the scientific community and 42% (22 of 53) among patients diagnosed later.', '13': 'Conclusions and relevance: In this cohort study of patients with CVST, a distinct clinical profile and high mortality rate was observed in patients meeting criteria for TTS after SARS-CoV-2 vaccination.'}\n",
            "28: abstract: {'1': 'Background: Inflammation-mediated lung injury is a major cause of health problems in many countries and has been the leading cause of morbidity/mortality in intensive care units.', '2': 'In the current COVID-19 pandemic, the majority of the patients experienced serious pneumonia resulting from inflammation (Acute respiratory distress syndrome/ARDS).', '3': 'Pathogenic infections cause cytokine release syndrome (CRS) by hyperactivation of immune cells, which in turn release excessive cytokines causing ARDS.', '4': 'Currently, there are no standard therapies for viral, bacterial or pathogen-mediated CRS.', '5': 'Purpose: This study aimed to investigate and validate the protective effects of Dehydrozingerone (DHZ) against LPS induced lung cell injury by in-vitro and in-vivo models and to gain insights into the molecular mechanisms that mediate these therapeutic effects.', '6': 'Methods:\\xa0The therapeutic activity of DHZ was determined in in-vitro models by pre-treating the cells with DHZ and exposed to LPS to stimulate the inflammatory cascade of events.', '7': 'We analysed the effect of DHZ on LPS induced inflammatory cytokines, chemokines and cell damage markers expression/levels using various cell lines.', '8': 'We performed gene expression, ELISA, and western blot analysis to elucidate the effect of DHZ on inflammation and its modulation of MAPK and NF-κB pathways.', '9': 'Further, the prophylactic and therapeutic effect of DHZ was evaluated against the LPS induced ARDS model in rats.', '10': 'Results: DHZ significantly (p < 0.01) attenuated the LPS induced ROS, inflammatory cytokine, chemokine gene expression and protein release in macrophages.', '11': 'Similarly, DHZ treatment protected the lung epithelial and endothelial cells by mitigating the LPS induced inflammatory events in a dose-dependent manner.', '12': 'In vivo analysis showed that DHZ treatment significantly (p < 0.001) mitigated the LPS induced ARDS pathophysiology of increase in the inflammatory cells in BALF, inflammatory cytokine and chemokines in lung tissues.', '13': 'LPS stimulated neutrophil-mediated events, apoptosis, alveolar wall thickening and alveolar inflammation were profoundly reduced by DHZ treatment in a rat model.', '14': 'Conclusion: This study demonstrates for the first time that DHZ has the potential to ameliorate LPS induced ARDS by inhibiting cytokine storm and oxidative through modulating the MAPK and NF-κB pathways.', '15': 'This data provides pre-clinical support to develop DHZ as a potential therapeutic agent against ARDS.'}\n",
            "28: abstract: {'1': 'Senescent cells, which arise due to damage-associated signals, are apoptosis-resistant and can express a pro-inflammatory, tissue-destructive senescence-associated secretory phenotype (SASP).', '2': 'We recently reported that a component of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) surface protein, S1, can amplify the SASP of senescent cultured human cells and that a related mouse β-coronavirus, mouse hepatitis virus (MHV), increases SASP factors and senescent cell burden in infected mice.', '3': 'Here, we show that SARS-CoV-2 induces senescence in human non-senescent cells and exacerbates the SASP in human senescent cells through Toll-like receptor-3 (TLR-3).', '4': 'TLR-3, which senses viral RNA, was increased in human senescent compared to non-senescent cells.', '5': 'Notably, genetically or pharmacologically inhibiting TLR-3 prevented senescence induction and SASP amplification by SARS-CoV-2 or Spike pseudotyped virus.', '6': 'While an artificial TLR-3 agonist alone was not sufficient to induce senescence, it amplified the SASP in senescent human cells.', '7': 'Consistent with these findings, lung p16INK4a+ senescent cell burden was higher in patients who died from acute SARS-CoV-2 infection than other causes.', '8': 'Our results suggest that induction of cellular senescence and SASP amplification through TLR-3 contribute to SARS-CoV-2 morbidity, indicating that clinical trials of senolytics and/or SASP/TLR-3 inhibitors for alleviating acute and long-term SARS-CoV-2 sequelae are warranted.'}\n",
            "28: abstract: {'1': 'Emerging evidence suggests that endothelial activation plays a central role in the pathogenesis of acute respiratory distress syndrome (ARDS) and multi-organ failure in patients with COVID-19.', '2': 'However, the molecular mechanisms underlying endothelial activation in COVID-19 patients remain unclear.', '3': 'In this study, the SARS-CoV-2 viral proteins that potently activate human endothelial cells were screened to elucidate the molecular mechanisms involved in endothelial activation.', '4': 'It was found that nucleocapsid protein (NP) of SARS-CoV-2 significantly activated human endothelial cells through TLR2/NF-κB and MAPK signaling pathways.', '5': 'Moreover, by screening a natural microbial compound library containing 154 natural compounds, simvastatin was identified as a potent inhibitor of NP-induced endothelial activation.', '6': 'Remarkablely, though the protein sequences of N proteins from coronaviruses are highly conserved, only NP from SARS-CoV-2 induced endothelial activation.', '7': 'The NPs from other coronaviruses such as SARS-CoV, MERS-CoV, HUB1-CoV and influenza virus H1N1 did not activate endothelial cells.', '8': 'These findings are well consistent with the results from clinical investigations showing broad endotheliitis and organ injury in severe COVID-19 patients.', '9': 'In conclusion, the study provides insights on SARS-CoV-2-induced vasculopathy and coagulopathy, and suggests that simvastatin, an FDA-approved lipid-lowering drug, may benefit to prevent the pathogenesis and improve the outcome of COVID-19 patients.', '10': 'IMPORTANCE Coronavirus disease 2019 (COVID-19), caused by the betacoronavirus SARS-CoV-2, is a worldwide challenge for health-care systems.', '11': 'The leading cause of mortality in patients with COVID-19 is hypoxic respiratory failure from acute respiratory distress syndrome (ARDS).', '12': 'To date, pulmonary endothelial cells (ECs) have been largely overlooked as a therapeutic target in COVID-19, yet emerging evidence suggests that these cells contribute to the initiation and propagation of ARDS by altering vessel barrier integrity, promoting a pro-coagulative state, inducing vascular inflammation and mediating inflammatory cell infiltration.', '13': 'Therefore, a better mechanistic understanding of the vasculature is of utmost importance.', '14': 'In this study, we screened the SARS-CoV-2 viral proteins that potently activate human endothelial cells and found that nucleocapsid protein (NP) significantly activated human endothelial cells through TLR2/NF-κB and MAPK signaling pathways.', '15': 'Moreover, by screening a natural microbial compound library containing 154 natural compounds, simvastatin was identified as a potent inhibitor of NP-induced endothelial activation.', '16': 'Our results provide insights on SARS-CoV-2-induced vasculopathy and coagulopathy, and suggests that simvastatin, an FDA-approved lipid-lowering drug, may benefit to prevent the pathogenesis and improve the outcome of COVID-19 patients.'}\n",
            "28: abstract: {'1': 'Some COVID-19 patients suffer complications from anti-viral immune responses which can lead to both a dangerous cytokine storm and development of blood-borne factors that render severe thrombotic events more likely.', '2': 'The precise immune response profile is likely, therefore, to determine and predict patient outcomes and also represents a target for intervention.', '3': 'Anti-viral T cell exhaustion in the early stages is associated with disease progression.', '4': 'Dysregulation of T cell functions, which precedes cytokine storm development and neutrophil expansion in alveolar tissues heralds damaging pathology.', '5': 'T cell function, cytokine production and factors that attract neutrophils to the lung can be modified through targeting molecules that can modulate T cell responses.', '6': 'Manipulating T cell responses by targeting the PI3K/Akt/mTOR pathway could provide the means to control the immune response in COVID-19 patients.', '7': 'During the initial anti-viral response, T cell effector function can be enhanced by delaying anti-viral exhaustion through inhibiting PI3K and Akt.', '8': 'Additionally, immune dysregulation can be addressed by enhancing immune suppressor functions by targeting downstream mTOR, an important intracellular modulator of cellular metabolism.', '9': 'Targeting this signalling pathway also has potential to prevent formation of thrombi due to its role in platelet activation.', '10': 'Furthermore, this signalling pathway is essential for SARS-cov-2 virus replication in host cells and its inhibition could, therefore, reduce viral load.', '11': 'The ultimate goal is to identify targets that can quickly control the immune response in COVID-19 patients to improve patient outcome.', '12': 'Targeting different levels of the PI3K/Akt/mTOR signalling pathway could potentially achieve this during each stage of the disease.'}\n",
            "28: abstract: {'1': 'The global pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its threat to humans have drawn worldwide attention.', '2': 'The acute and long-term effects of SARS-CoV-2 on the nervous system pose major public health challenges.', '3': 'Patients with SARS-CoV-2 present diverse symptoms of the central nervous system.', '4': 'Exploring the mechanism of coronavirus damage to the nervous system is essential for reducing the long-term neurological complications of COVID-19.', '5': 'Despite rapid progress in characterizing SARS-CoV-2, the long-term effects of COVID-19 on the brain remain unclear.', '6': 'The possible mechanisms of SARS-CoV-2 injury to the central nervous system include: 1) direct injury of nerve cells, 2) activation of the immune system and inflammatory cytokines caused by systemic infection, 3) a high affinity of the SARS-CoV-2 spike glycoprotein for the angiotensin-converting enzyme ACE2, 4) cerebrovascular disease caused by hypoxia and coagulation dysfunction, and 5) a systemic inflammatory response that promotes cognitive impairment and neurodegenerative diseases.', '7': 'Although we do not fully understand the mechanism by which SARS-CoV-2 causes nerve injury, we hope to provide a framework by reviewing the clinical manifestations, complications, and possible mechanisms of neurological damage caused by SARS-CoV-2.', '8': 'With hope, this will facilitate the early identification, diagnosis, and treatment of possible neurological sequelae, which could contribute toward improving patient prognosis and preventing transmission.'}\n",
            "28: abstract: {'1': 'Background and Objectives. The importance of mitochondria in inflammatory pathologies, besides providing energy, is associated with the release of mitochondrial damage products, such as mitochondrial DNA (mt-DNA), which may perpetuate inflammation.', '2': 'In this review, we aimed to show the importance of mitochondria, as organelles that produce energy and intervene in multiple pathologies, focusing mainly in COVID-19 and using multiple molecular mechanisms that allow for the replication and maintenance of the viral genome, leading to the exacerbation and spread of the inflammatory response.', '3': 'The evidence suggests that mitochondria are implicated in the replication of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which forms double-membrane vesicles and evades detection by the cell defense system.', '4': \"These mitochondrion-hijacking vesicles damage the integrity of the mitochondrion's membrane, releasing mt-DNA into circulation and triggering the activation of innate immunity, which may contribute to an exacerbation of the pro-inflammatory state.\", '5': 'Conclusions. While mitochondrial dysfunction in COVID-19 continues to be studied, the use of mt-DNA as an indicator of prognosis and severity is a potential area yet to be explored.'}\n",
            "28: abstract: {'1': 'SARS-CoV-2 infection has caused a global pandemic that has severely damaged both public health and the economy.', '2': 'The nucleocapsid protein of SARS-CoV-2 is multifunctional and plays an important role in ribonucleocapsid formation and viral genome replication.', '3': 'In order to elucidate its functions, interaction partners of the SARS-CoV-2 N protein in human cells were identified via affinity purification and mass spectrometry.', '4': 'We identified 160 cellular proteins as interaction partners of the SARS-CoV-2 N protein in HEK293T and/or Calu-3 cells.', '5': 'Functional analysis revealed strong enrichment for ribosome biogenesis and RNA-associated processes, including ribonucleoprotein complex biogenesis, ribosomal large and small subunits biogenesis, RNA binding, catalysis, translation and transcription.', '6': 'Proteins related to virus defence responses, including MOV10, EIF2AK2, TRIM25, G3BP1, ZC3HAV1 and ZCCHC3 were also identified in the N protein interactome.', '7': 'This study comprehensively profiled the viral-host interactome of the SARS-CoV-2 N protein in human cells, and the findings provide the basis for further studies on the pathogenesis and antiviral strategies for this emerging infection.'}\n",
            "28: abstract: {'1': 'Evidence is emerging that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can infect various organs of the body, including cardiomyocytes and cardiac endothelial cells in the heart.', '2': 'This review focuses on the effects of SARS-CoV-2 in the heart after direct infection that can lead to myocarditis and an outline of potential treatment options.', '3': 'The main points are: (1) Viral entry: SARS-CoV-2 uses specific receptors and proteases for docking and priming in cardiac cells.', '4': 'Thus, different receptors or protease inhibitors might be effective in SARS-CoV-2-infected cardiac cells.', '5': '(2) Viral replication: SARS-CoV-2 uses RNA-dependent RNA polymerase for replication.', '6': 'Drugs acting against ssRNA(+) viral replication for cardiac cells can be effective.', '7': '(3) Autophagy and double-membrane vesicles: SARS-CoV-2 manipulates autophagy to inhibit viral clearance and promote SARS-CoV-2 replication by creating double-membrane vesicles as replication sites.', '8': '(4) Immune response: Host immune response is manipulated to evade host cell attacks against SARS-CoV-2 and increased inflammation by dysregulating immune cells.', '9': 'Efficiency of immunosuppressive therapy must be elucidated.', '10': '(5) Programmed cell death: SARS-CoV-2 inhibits programmed cell death in early stages and induces apoptosis, necroptosis, and pyroptosis in later stages.', '11': '(6) Energy metabolism: SARS-CoV-2 infection leads to disturbed energy metabolism that in turn leads to a decrease in ATP production and ROS production.', '12': '(7) Viroporins: SARS-CoV-2 creates viroporins that lead to an imbalance of ion homeostasis.', '13': 'This causes apoptosis, altered action potential, and arrhythmia.'}\n",
            "28: abstract: {'1': 'The coronavirus disease 2019 (COVID-19) pandemic has raised concerns about the detrimental effects of antibodies.', '2': 'Antibody-dependent enhancement (ADE) of infection is one of the biggest concerns in terms of not only the antibody reaction to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) upon reinfection with the virus but also the reaction to COVID-19 vaccines.', '3': 'In this study, we evaluated ADE of infection by using COVID-19 convalescent-phase plasma and BHK cells expressing human Fcγ receptors (FcγRs).', '4': 'We found that FcγRIIA and FcγRIIIA mediated modest ADE of infection against SARS-CoV-2.', '5': 'Although ADE of infection was observed in monocyte-derived macrophages infected with SARS-CoV-2, including its variants, proinflammatory cytokine/chemokine expression was not upregulated in macrophages.', '6': 'SARS-CoV-2 infection thus produces antibodies that elicit ADE of infection, but these antibodies do not contribute to excess cytokine production by macrophages.', '7': 'IMPORTANCE Viruses infect cells mainly via specific receptors at the cell surface.', '8': 'Antibody-dependent enhancement (ADE) of infection is an alternative mechanism of infection for viruses to infect immune cells that is mediated by antibodies and IgG receptors (FcγRs).', '9': 'Because ADE of infection contributes to the pathogenesis of some viruses, such as dengue virus and feline coronavirus, it is important to evaluate the precise mechanism of ADE and its contribution to the pathogenesis of SARS-CoV-2.', '10': 'Here, using convalescent-phase plasma from COVID-19 patients, we found that two types of FcγRs, FcγRIIA and FcγRIIIA, mediate ADE of SARS-CoV-2 infection.', '11': 'Although ADE of infection was observed for SARS-CoV-2 and its recent variants, proinflammatory cytokine production in monocyte-derived macrophages was not upregulated.', '12': 'These observations suggest that SARS-CoV-2 infection produces antibodies that elicit ADE of infection, but these antibodies may not be involved in aberrant cytokine release by macrophages during SARS-CoV-2 infection.'}\n",
            "28: abstract: {'1': 'Some studies reported that genomic RNA of SARS-CoV-2 can absorb a few host miRNAs that regulate immune-related genes and then deprive their function.', '2': 'In this perspective, we conjecture that the absorption of the SARS-CoV-2 genome to host miRNAs is not a coincidence, which may be an indispensable approach leading to viral survival and development in host.', '3': 'In our study, we collected five datasets of miRNAs that were predicted to interact with the genome of SARS-CoV-2.', '4': 'The targets of these miRNAs in the five groups were consistently enriched immune-related pathways and virus-infectious diseases.', '5': 'Interestingly, the five datasets shared no one miRNA but their targets shared 168 genes.', '6': 'The signaling pathway enrichment of 168 shared targets implied an unbalanced immune response that the most of interleukin signaling pathways and none of the interferon signaling pathways were significantly different.', '7': 'Protein-protein interaction (PPI) network using the shared targets showed that PPI pairs, including IL6-IL6R, were related to the process of SARS-CoV-2 infection and pathogenesis.', '8': 'In addition, we found that SARS-CoV-2 absorption to host miRNA could benefit two popular mutant strains for more infectivity and pathogenicity.', '9': 'Conclusively, our results suggest that genomic RNA absorption to host miRNAs may be a vital approach by which SARS-CoV-2 disturbs the host immune system and infects host cells.'}\n",
            "29: abstract: {'1': 'Public health practices including handwashing and vaccinations help reduce the spread and impact of infections.', '2': 'Nevertheless, the global burden of infection is high, and additional measures are necessary.', '3': 'Acute respiratory tract infections, for example, were responsible for approximately 2.38 million deaths worldwide in 2016.', '4': 'The role nutrition plays in supporting the immune system is well-established.', '5': 'A wealth of mechanistic and clinical data show that vitamins, including vitamins A, B6, B12, C, D, E, and folate; trace elements, including zinc, iron, selenium, magnesium, and copper; and the omega-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid play important and complementary roles in supporting the immune system.', '6': 'Inadequate intake and status of these nutrients are widespread, leading to a decrease in resistance to infections and as a consequence an increase in disease burden.', '7': 'Against this background the following conclusions are made: (1) supplementation with the above micronutrients and omega-3 fatty acids is a safe, effective, and low-cost strategy to help support optimal immune function; (2) supplementation above the Recommended Dietary Allowance (RDA), but within recommended upper safety limits, for specific nutrients such as vitamins C and D is warranted; and (3) public health officials are encouraged to include nutritional strategies in their recommendations to improve public health.'}\n",
            "29: abstract: {'1': 'Objectives: The novel coronavirus infection (COVID-19) conveys a serious threat globally to health and economy because of a lack of vaccines and specific treatments.', '2': 'A common factor for conditions that predispose for serious progress is a low-grade inflammation, e.g., as seen in metabolic syndrome, diabetes, and heart failure, to which micronutrient deficiencies may contribute.', '3': 'The aim of the present article was to explore the usefulness of early micronutrient intervention, with focus on zinc, selenium, and vitamin D, to relieve escalation of COVID-19.', '4': 'Methods: We conducted an online search for articles published in the period 2010-2020 on zinc, selenium, and vitamin D, and corona and related virus infections.', '5': 'Results: There were a few studies providing direct evidence on associations between zinc, selenium, and vitamin D, and COVID-19.', '6': 'Adequate supply of zinc, selenium, and vitamin D is essential for resistance to other viral infections, immune function, and reduced inflammation.', '7': 'Hence, it is suggested that nutrition intervention securing an adequate status might protect against the novel coronavirus SARS-CoV-2 (Severe Acute Respiratory Syndrome - coronavirus-2) and mitigate the course of COVID-19.', '8': 'Conclusion: We recommended initiation of adequate supplementation in high-risk areas and/or soon after the time of suspected infection with SARS-CoV-2.', '9': 'Subjects in high-risk groups should have high priority as regards this nutritive adjuvant therapy, which should be started prior to administration of specific and supportive medical measures.'}\n",
            "29: abstract: {'1': 'This review focused on the use of plant based foods for enhancing the immunity of all aged groups against COVID-19.', '2': 'In humans, coronaviruses are included in the spectrum of viruses that cause the common cold and, recently, severe acute respiratory syndrome (SARS).', '3': 'Emerging infectious diseases, such as SARS present a major threat to public health.', '4': 'The novel coronavirus has spread rapidly to multiple countries and has been declared a pandemic by the World Health Organization.', '5': 'COVID-19 is usually caused a virus to which most probably the people with low immunity response are being effected.', '6': 'Plant based foods increased the intestinal beneficial bacteria which are helpful and makes up of 85% of the immune system.', '7': 'By the use of plenty of water, minerals like magnesium and Zinc, micronutrients, herbs, food rich in vitamins C, D & E and better life style one can promote the health and can overcome this infection.', '8': 'Various studies investigated that a powerful antioxidant Glutathione and a bioflavonoid Quercetin may prevent various infections including COVID-19.', '9': 'In conclusion, the plant based foods play a vital role to enhance the immunity of people to control of COVID-19.'}\n",
            "29: abstract: {'1': 'The pandemic caused by the new coronavirus has caused shock waves in many countries, producing a global health crisis worldwide.', '2': 'Lack of knowledge of the biological mechanisms of viruses, plus the absence of effective treatments against the disease (COVID-19) and/or vaccines have pulled factors that can compromise the proper functioning of the immune system to fight against infectious diseases into the spotlight.', '3': 'The optimal status of specific nutrients is considered crucial to keeping immune components within their normal activity, helping to avoid and overcome infections.', '4': 'Specifically, the European Food Safety Authority (EFSA) evaluated and deems six vitamins (D, A, C, Folate, B6, B12) and four minerals (zinc, iron, copper and selenium) to be essential for the normal functioning of the immune system, due to the scientific evidence collected so far.', '5': 'In this report, an update on the evidence of the contribution of nutritional factors as immune-enhancing aspects, factors that could reduce their bioavailability, and the role of the optimal status of these nutrients within the COVID-19 pandemic context was carried out.', '6': 'First, a non-systematic review of the current state of knowledge regarding the impact of an optimal nutritional status of these nutrients on the proper functioning of the immune system as well as their potential role in COVID-19 prevention/treatment was carried out by searching for available scientific evidence in PubMed and LitCovid databases.', '7': 'Second, a compilation from published sources and an analysis of nutritional data from 10 European countries was performed, and the relationship between country nutritional status and epidemiological COVID-19 data (available in the Worldometers database) was evaluated following an ecological study design.', '8': 'Furthermore, the potential effect of genetics was considered through the selection of genetic variants previously identified in Genome-Wide Association studies (GWAs) as influencing the nutritional status of these 10 considered nutrients.', '9': 'Therefore, access to genetic information in accessible databases (1000genomes, by Ensembl) of individuals from European populations enabled an approximation that countries might present a greater risk of suboptimal status of the nutrients studied.', '10': 'Results from the review approach show the importance of maintaining a correct nutritional status of these 10 nutrients analyzed for the health of the immune system, highlighting the importance of Vitamin D and iron in the context of COVID-19.', '11': 'Besides, the ecological study demonstrates that intake levels of relevant micronutrients-especially Vitamins D, C, B12, and iron-are inversely associated with higher COVID-19 incidence and/or mortality, particularly in populations genetically predisposed to show lower micronutrient status.', '12': 'In conclusion, nutrigenetic data provided by joint assessment of 10 essential nutrients for the functioning of the immune system and of the genetic factors that can limit their bioavailability can be a fundamental tool to help strengthen the immune system of individuals and prepare populations to fight against infectious diseases such as COVID-19.'}\n",
            "29: abstract: {'1': 'Viral infections are a leading cause of morbidity and mortality worldwide, and the importance of public health practices including handwashing and vaccinations in reducing their spread is well established.', '2': 'Furthermore, it is well known that proper nutrition can help support optimal immune function, reducing the impact of infections.', '3': 'Several vitamins and trace elements play an important role in supporting the cells of the immune system, thus increasing the resistance to infections.', '4': 'Other nutrients, such as omega-3 fatty acids, help sustain optimal function of the immune system.', '5': 'The main aim of this manuscript is to discuss of the potential role of micronutrients supplementation in supporting immunity, particularly against respiratory virus infections.', '6': 'Literature analysis showed that in vitro and observational studies, and clinical trials, highlight the important role of vitamins A, C, and D, omega-3 fatty acids, and zinc in modulating the immune response.', '7': 'Supplementation with vitamins, omega 3 fatty acids and zinc appears to be a safe and low-cost way to support optimal function of the immune system, with the potential to reduce the risk and consequences of infection, including viral respiratory infections.', '8': 'Supplementation should be in addition to a healthy diet and fall within recommended upper safety limits set by scientific expert bodies.', '9': 'Therefore, implementing an optimal nutrition, with micronutrients and omega-3 fatty acids supplementation, might be a cost-effective, underestimated strategy to help reduce the burden of infectious diseases worldwide, including coronavirus disease 2019 (COVID-19).'}\n",
            "29: abstract: {'1': 'The World Health Organization declared the novel coronavirus, named as SARS-CoV-2, as a global pandemic in early 2020 after the disease spread to more than 180 countries leading to tens of thousands of cases and many deaths within a couple of months.', '2': 'Consequently, this paper aims to summarize the evidence for the relationships between nutrition and the boosting of the immune system in the fight against the disease caused by SARS-CoV-2.', '3': \"This review, in particular, assesses the impact of vitamin and mineral supplements on the body's defence mechanisms against SARS-CoV-2.\", '4': 'The results revealed that there is a strong relationship between the ingestion of biological ingredients like vitamins C-E, and minerals such as zinc, and a reduction in the effects of coronavirus infection.', '5': 'These can be received from either nutrition rich food sources or from vitamin supplements.', '6': 'Furthermore, these macromolecules might have roles to play in boosting the immune response, in the healing process and the recovery time.', '7': 'Hence, we recommend that eating healthy foods rich in vitamins C-E with zinc and flavonoids could boost the immune system and consequently protect the body from serious infections.'}\n",
            "29: abstract: {'1': 'Previously, we reported that immunomodulatory lactobacilli, nasally administered, beneficially regulated the lung antiviral innate immune response induced by Toll-like receptor 3 (TLR3) activation and improved protection against the respiratory pathogens, influenza virus and respiratory syncytial virus in mice.', '2': 'Here, we assessed the immunomodulatory effects of viable and non-viable Lactiplantibacillus plantarum strains in human respiratory epithelial cells (Calu-3 cells) and the capacity of these immunobiotic lactobacilli to reduce their susceptibility to the acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.', '3': 'Immunobiotic L. plantarum MPL16 and CRL1506 differentially modulated IFN-β, IL-6, CXCL8, CCL5 and CXCL10 production and IFNAR2, DDX58, Mx1 and OAS1 expression in Calu-3 cells stimulated with the TLR3 agonist poly(I:C).', '4': 'Furthermore, the MPL16 and CRL1506 strains increased the resistance of Calu-3 cells to the challenge with SARS-CoV-2.', '5': 'L. plantarum MPL16 induced these beneficial effects more efficiently than the CRL1506 strain.', '6': 'Of note, neither non-viable MPL16 and CRL1506 strains nor the non-immunomodulatory strains L. plantarum CRL1905 and MPL18 could modify the resistance of Calu-3 cells to SARS-CoV-2 infection or the immune response to poly(I:C) challenge.', '7': 'To date, the potential beneficial effects of immunomodulatory probiotics on SARS-CoV-2 infection and COVID-19 outcome have been extrapolated from studies carried out in the context of other viral pathogens.', '8': 'To the best of our knowledge, this is the first demonstration of the ability of immunomodulatory lactobacilli to positively influence the replication of the new coronavirus.', '9': 'Further mechanistic studies and in vivo experiments in animal models of SARS-CoV-2 infection are necessary to identify specific strains of beneficial immunobiotic lactobacilli like L. plantarum MPL16 or CRL1506 for the prevention or treatment of the COVID-19.'}\n",
            "29: abstract: {'1': 'Dietary strategies aimed at preventing COVID-19 and dangerous pneumonia are continually being considered.', '2': 'Unfortunately, as in the case of drugs, studies in humans have not confirmed any specific food components to be effective in the case of COVID-19.', '3': 'We know that the immune system is the key to reducing the severity of COVID-19, and perhaps by modulating it in the right way we can save human lives with preventive measures.', '4': 'Numerous clinical studies have shown that nutraceuticals can beneficially stimulate the immune response in patients with various diseases, such as cancer or AIDS, and in healthy people at risk of viral infections.', '5': 'Natural compounds are commonly recognized as valuable agents in the fight against viruses due to their structural diversity and safety.', '6': 'Many products consumed by people and used in traditional medicine have been shown to contain substances with anti-inflammatory, antibacterial, and antiviral properties, e.g., vitamin C in the fruit or juice of raspberries or elderberries, hesperidin in St. John’s wort, kaempferol and methylglyoxal in honey, allicin in garlic and onion, gingerols in ginger, curcumin in turmeric, and piperine in black pepper.', '7': 'However, there is no strong scientific evidence, nor are there any systematic literature reviews with meta-analyses indicating that herbs, spices, health-promoting food ingredients, or dietary supplements prevent infection with SARS-CoV-2, mitigate COVID-19 symptoms, or can even be used to treat infections, including severe COVID pneumonia, acute lung failure, a cytokine storm, clotting disorders, or multiple organ failure.'}\n",
            "29: abstract: {'1': 'SARS-CoV-2 infection is associated with diverse clinical manifestations, immune dysfunction, and gut microbiota alterations.', '2': \"The nutritional and biochemical quality of one's diet can influence the intestinal microbiota, which may play a role in the defense mechanisms against potential pathogens, by promoting a wide variety of immune-host interactions.\", '3': 'In the COVID-19 pandemic, besides the development of pharmacological therapies, a healthy balanced diet, rich with food-derived antioxidants, may be a useful strategy.', '4': 'Many studies demonstrated that vitamins and probiotic therapies have positive effects on the treatment and prevention of oxidative stress and inflammation in COVID-19.', '5': 'The ecology of the gut microbiota in the digestive tract has been linked to the transport function of the host receptor known as angiotensin converting enzyme 2 (ACE2), suggesting that COVID-19 may be related to the gut microbiota.', '6': 'The angiotensin converting enzyme (ACE), and its receptor (ACE2), play central roles in modulating the renin-angiotensin system (RAS).', '7': 'In addition, ACE2 has functions that act independently of the RAS.', '8': 'ACE2 is the receptor for the SARS coronavirus, and ACE2 is essential for the expression of neutral amino acid transporters in the gut.', '9': 'In this context, ACE2 modulates innate immunity and influences the composition of the gut microbiota.', '10': 'Malnutrition is one of the leading underlying causes of morbidity and mortality worldwide and, including comorbidities, may be a major cause of worse outcomes and higher mortality among COVID-19 patients.', '11': \"This paper reviews the research on dietary components, with particular emphasis on vitamins, antioxidants, and probiotic therapies, and their impacts on the intestinal microbiota's diversity during the SARS-CoV-2 pandemic.\"}\n",
            "29: abstract: {'1': 'COVID-19 virus is a causative agent of viral pandemic in human beings which specifically targets respiratory system of humans and causes viral pneumonia.', '2': 'This unusual viral pneumonia is rapidly spreading to all parts of the world, currently affecting about 105 million people with 2.3 million deaths.', '3': 'Current review described history, genomic characteristics, replication, and pathogenesis of COVID-19 with special emphasis on Nigella sativum (N. sativum) as a treatment option.', '4': 'N. sativum seeds are historically and religiously used over the centuries, both for prevention and treatment of different diseases.', '5': 'This review summarizes the potential role of N. sativum seeds against COVID-19 infection at levels of in silico, cell lines and animal models.'}\n",
            "30: abstract: {'1': 'In the ongoing coronavirus disease 2019 (COVID-19) pandemic, one potential cause of concern is that some discharged COVID-19 patients are testing positive again for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA.', '2': 'To better understand what is happening and to provide public health policy planners and clinicians timely information, we have searched and reviewed published studies about discharged patients testing positive again for the SARS-CoV-2 RNA.', '3': 'Our search found 12 reports, all of which described patients in China.', '4': 'Our review of these reports indicates the presence of discharged patients who remain asymptomatic but test positive.', '5': 'However, it is unclear whether they are contagious because a positive reverse transcriptase - polymerase chain reaction (RT- PCR) test does not necessarily indicate the presence of replicating and transmissible virus.', '6': 'Our review suggests the need for timely, parallel testing of different samples, including, for example, fecal specimens, from COVID-19 patients before and after they are discharged from hospitals.'}\n",
            "30: abstract: {'1': 'Background: Nucleic acid persists after symptom resolution and infectivity for many viral infections via delayed clearance of nucleic acid fragments, non-infectious particles, or transmissible virus.', '2': 'For Coronavirus Disease 2019 (COVID-19), the relationship between nasopharyngeal (NP) swab positivity, the development of antibodies against COVID-19, and clinical history are unclear.', '3': 'Study design and methods: Individuals who recovered from COVID-19 and volunteered to donate convalescent plasma (CP) were screened by NP swab PCR, responded to a questionnaire, and were tested for anti-COVID-19 antibodies.', '4': 'Results: A proportion of 11.8% of individuals tested positive for SARS-CoV-2 by NP swab PCR greater than 14 days after the resolution of symptoms of active disease, including one donor who had asymptomatic disease and tested positive by NP swab 41 days after her initial diagnosis.', '5': 'Clinical history did not show a significant correlation with persistence of NP swab positivity.', '6': 'Also, NP swab positivity >14 days from symptom resolution did not correlate with anti-COVID-19 serology results.', '7': 'IgG anti-SARS-CoV-2 spike antibody strength correlated with hospitalization for COVID-19 using two different assays.', '8': 'Total anti-SARS-CoV-2 nucleocapsid antibody strength correlated with time from symptom resolution to sample collection and symptom duration.', '9': 'Conclusions: SARS-CoV-2 nucleic acid is detectable long after the resolution of symptoms in a significant percentage of previously diagnosed individuals, which is important to consider when interpreting PCR swab results.', '10': 'Persistence of PCR positivity does not correlate with antibody strength or symptoms of COVID-19.', '11': 'If anti-spike antibody is used to assess CP potency, individuals who suffered severe COVID-19 disease symptoms may represent better donors.'}\n",
            "30: abstract: {'1': 'Background: Coronavirus disease 2019 (COVID-19) convalescent plasma (CCP) collection began in two Brazilian hospitals for treatment of severe/critical patients.', '2': 'Methods and materials: Mild/moderate COVID-19 convalescents were selected as CCP donors after reverse transcription polymerase chain reaction (RT-PCR) confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and absence of symptoms for ≥14 days plus (a) age (18-60 years), body weight greater than 55 kg; (b) immunohematological studies; (c) no infectious markers of hepatitis B virus, hepatitis C virus, human immunodeficiency virus, human T-lymphotropic virus-1/2, Chagas and syphilis infection; (d) no HLA antibodies (multiparous); (e) second RT-PCR (nasopharyngeal swab and/or blood) negativity; (f) virus neutralization test (cytopathic effect-based virus neutralization test neutralizing antibody) and anti-nucleocapsid protein SARS-CoV-2 IgM, IgG, and IgA enzyme-linked immunosorbent assays.', '3': 'Results: Among 271 donors (41 females, 230 males), 250 presented with neutralizing antibodies.', '4': 'Final RT-PCR was negative on swab (77.0%) or blood (88.4%; P = .46).', '5': 'Final definition of RT-PCR was only defined at more than 28 days after full recovery in 59 of 174 (33.9%) RT-PCR -ve, and 25/69 RT-PCR +ve (36.2%; 13 between 35 and 48 days).', '6': 'Neutralizing antibody titers of 160 or greater were found in 63.6%.', '7': 'Correlation between IgG signal/cutoff of 5.0 or greater and neutralizing antibody of 160 or greater was 82.4%.', '8': 'Combination of final RT-PCR -ve with neutralizing antibody ≥160 was 41.3% (112/271).', '9': 'Serial plasma collection showed decline in neutralizing antibody titers and IgA levels (P < .05), probably denoting a \"golden period\" for CCP collection (≤28 days after joining the program); IgA might have an important role as neutralizing antibody.', '10': \"Donor's weight, days between disease onset and serial plasma collection, and IgG and IgM levels are important predictors for neutralizing antibody titer.\", '11': 'Conclusions: RT-PCR +ve cases are still detected in 36.2% within 28 to 48 days after recovery.', '12': 'High anti-nucleocapsid protein IgG levels may be used as a surrogate marker to neutralizing antibody.'}\n",
            "30: abstract: {'1': 'Many studies have shown that re-positive tests for SARS-CoV-2 by RT-PCR in recovered COVID-19 patients are very common.', '2': 'We aim to conduct this review to summarize the clinical and epidemiological characteristics of these patients and discuss the potential explanations for recurrences, the contagiousness of re-detectable positive SARS-CoV-2 virus, and the management of COVID-19 patients after discharge from hospital.', '3': 'The proportion of re-positive tests in discharged COVID-19 patients varied from 2.4 to 69.2% and persisted from 1 to 38 days after discharge, depending on population size, age of patients, and type of specimens.', '4': 'Currently, several causes of re-positive tests for SARS-CoV-2 in recovered COVID-19 patients are suggested, including false-negative, false-positive RT-PCR tests; reactivation; and re-infection with SARS-CoV-2, but the mechanism leading to these re-positive cases is still unclear.', '5': 'The prevention of re-positive testing in discharged patients is a fundamental measure to control the spread of the pandemic.', '6': 'In order to reduce the percentage of false-negative tests prior to discharge, we recommend performing more than two tests, according to the standard sampling and microbiological assay protocol.', '7': 'In addition, specimens should be collected from multiple body parts if possible, to identify SARS-CoV-2 viral RNA before discharge.', '8': 'Further studies should be conducted to develop novel assays that target a crucial region of the RNA genome in order to improve its sensitivity and specificity.'}\n",
            "30: abstract: {'1': 'Knowledge of the sensitivities of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody tests beyond 35 days after the clinical onset of COVID-19 is insufficient.', '2': 'We aimed to describe positivity rate of SARS-CoV-2 assays employing three different measurement principles over a prolonged period.', '3': 'Two hundred sixty-eight samples from 180 symptomatic patients with COVID-19 and a reverse transcription polymerase chain reaction (RT-PCR) test followed by serological investigation of SARS-CoV-2 antibodies were included.', '4': 'We conducted three chemiluminescence (including electrochemiluminescence assay (ECLIA)), four enzyme-linked immunosorbent assay (ELISA), and one lateral flow immunoassay (LFIA) test formats.', '5': 'Positivity rates, as well as positive (PPVs) and negative predictive values (NPVs), were calculated for each week after the first clinical presentation for COVID-19.', '6': 'Furthermore, combinations of tests were assessed within an orthogonal testing approach employing two independent assays and predictive values were calculated.', '7': 'Heat maps were constructed to graphically illustrate operational test characteristics.', '8': 'During a follow-up period of more than 9 weeks, chemiluminescence assays and one ELISA IgG test showed stable positivity rates after the third week.', '9': 'With the exception of ECLIA, the PPVs of the other chemiluminescence assays were ≥95% for COVID-19 only after the second week.', '10': 'ELISA and LFIA had somewhat lower PPVs.', '11': 'IgM exhibited insufficient predictive characteristics.', '12': 'An orthogonal testing approach provided PPVs ≥ 95% for patients with a moderate pretest probability (e.g., symptomatic patients), even for tests with a low single test performance.', '13': 'After the second week, NPVs of all but IgM assays were ≥95% for patients with low to moderate pretest probability.', '14': 'The confirmation of negative results using an orthogonal algorithm with another assay provided lower NPVs than the single assays.', '15': 'When interpreting results from SARS-CoV-2 tests, the pretest probability, time of blood draw, and assay characteristics must be carefully considered.', '16': 'An orthogonal testing approach increases the accuracy of positive, but not negative, predictions.'}\n",
            "30: abstract: {'1': 'Background: Reverse-transcription PCR (RT-PCR) assays are used to test for infection with the SARS-CoV-2 virus.', '2': 'RT-PCR tests are highly specific and the probability of false positives is low, but false negatives are possible depending on swab type and time since symptom onset.', '3': 'Aim: To determine how the probability of obtaining a false-negative test in infected patients is affected by time since symptom onset and swab type.', '4': 'Methods: We used generalised additive mixed models to analyse publicly available data from patients who received multiple RT-PCR tests and were identified as SARS-CoV-2 positive at least once.', '5': 'Results: The probability of a positive test decreased with time since symptom onset, with oropharyngeal (OP) samples less likely to yield a positive result than nasopharyngeal (NP) samples.', '6': 'The probability of incorrectly identifying an uninfected individual due to a false-negative test was considerably reduced if negative tests were repeated 24 hours later.', '7': 'For a small false-positive test probability (<0.5%), the true number of infected individuals was larger than the number of positive tests.', '8': 'For a higher false-positive test probability, the true number of infected individuals was smaller than the number of positive tests.', '9': 'Conclusion: NP samples are more sensitive than OP samples.', '10': 'The later an infected individual is tested after symptom onset, the less likely they are to test positive.', '11': 'This has implications for identifying infected patients, contact tracing and discharging convalescing patients who are potentially still infectious.'}\n",
            "30: abstract: {'1': 'Background: Coronavirus disease (COVID-19) has affected more than 100 countries worldwide and the discharge criteria of patients with COVID-19 vary across different countries.', '2': 'In China, patients with two negative respiratory viral RNA tests taken at least one day apart can be discharged with no further quarantine required.', '3': 'Currently, PCR testing of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in fecal sample is not routinely performed.', '4': 'Methods: We present a patient with COVID-19, whose respiratory swabs became negative but fecal sample remained positive for SARS-CoV-2 RNA.', '5': 'Results: Stool sample collected on 27th of February was still positive for SARS-CoV-2 RNA, 24 days after the first negative respiratory swab.', '6': 'Conclusions: Based on the experience from the 2003 SARS epidemic, we recommend that fecal RNA testing of SARS-CoV-2 should be incorporated into the discharge criteria to minimize the risk of transmission from the gastrointestinal tract.'}\n",
            "30: abstract: {'1': 'Diagnosis of severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) cases is based on the count of real-time reverse transcription-plymerase chain reaction (RT-PCR) positive people.', '2': 'Viral load by real-time RT-PCR has been suggested as a biomarker of the SARS-CoV-2 infection.', '3': 'However, the association of viral load and severity of the disease is not yet resolved.', '4': 'Nasopharyngeal samples from 458 patients were tested by RT-PCR for SARS-CoV-2 diagnosis.', '5': 'Relative quantitation was made by the comparative threshold cycle (ΔΔCt ) formula between ORF1ab viral and RNase P housekeeping genes.', '6': 'Absolute viral load was calculate using a reference positive control.', '7': 'Most prevalent clinical signs were cough (75.8%), myalgia (66.7%), and fever (48.5%).', '8': 'Hypertension (18.2%), neurological diseases (15.1%), and asthma and hypothyroidism (12.1%) were most frequent comorbidities.', '9': 'Fever, either as an exclusive symptom or combined with others, was associated with high viral loads ( 2−ΔΔCt range, 35.65-155.16; 4.25-4.89 log10 RNA copies/test]).', '10': 'During the first week after onset of symptoms in mild patients up to 60 years-old was detected the peak of viral load.', '11': 'Children under 10 years old have a high viral load (313.84; 2.50) in the first 2 days postinfection with a sharp decline thereafter.', '12': 'Cases between 10 and 49 years old mostly showed low and moderate viral load during the first 2 days postinfection (range, 0.03 to 17.24; -1.50 to 1.24).', '13': 'Patients over 60 years old have high viral load up to the second week after the onset of symptoms (range, 25.32-155.42; 1.40-2.19), indicating the longer presence of the virus in them.', '14': 'These findings suggest the viral load in nasopharyngeal swabs would help to monitor the SARS-CoV-2 infection in mild coronavirus disease 2019 cases.'}\n",
            "30: abstract: {'1': 'This study aimed to monitor severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral loads and specific serum-antibodies (immunoglobulin [Ig] G and M) among confirmed patients and asymptomatic carriers from returning healthy travelers.', '2': 'The throat swabs, sputum, and stool samples from 57 hospitalized coronavirus disease (COVID-19) patients and 8 asymptomatic carriers, among 170 returning healthy travelers were tested using reverse-transcription real-time polymerase chain reaction.', '3': 'SARS-CoV-2 IgM/IgG antibodies were detected via serum chemiluminescence assay.', '4': 'Sequential results showed higher viral RNA loads in the throat, sputum, and stool samples at 3-12 and 6-21 days after symptom onset among severely ill COVID-19 patients.', '5': 'Shorter viral habitation time (1-8 days) was observed in the oropharyngeal site and intestinal tract of asymptomatic carriers.', '6': 'The IgG and IgM response rates were 19/37 (51.4%) and 23/37 (62.6%) among the 29 confirmed patients and 8 asymptomatic carriers, respectively, within 66 days from symptom or detection onset.', '7': 'The median duration between symptom onset and positive IgG and IgM results was 30 (n=23; interquartile range [IQR]=20-66) and 23 (n=19; IQR=12-28) days, respectively.', '8': 'Of 170 returning healthy-travelers to China, 4.7% were asymptomatic carriers (8/170) within 2 weeks, and the IgG and IgM positivity rate was 12.8% (12/94).', '9': 'IgM/IgG-positivity confirmed 3 suspected SARS-CoV-2 cases, despite negative results for SARS-CoV-2 RNA.', '10': 'Compared with other respiratory viral infectious diseases, COVID-19 has fewer asymptomatic carriers, lower antibody response rates, and a longer antibody production duration in recovered patients and the contacted healthy population.', '11': 'This is an indication of the complexity of COVID-19 transmission.'}\n",
            "30: abstract: {'1': 'The number of serological assays for SARS-CoV-2 has skyrocketed in the past year.', '2': 'Concerns have been raised regarding their performance characteristics, depending on the disease severity and the time of the analysis post-symptom onset (PSO).', '3': 'Thus, independent validations using an unbiased sample selection are required for meaningful serology data interpretation.', '4': 'We aimed to assess the clinical performance of six commercially available assays, the seroconversion, and the dynamics of the humoral response to SARS-CoV-2 infection.', '5': 'The study included 528 serum samples from 156 patients with follow-up visits up to six months PSO and 161 serum samples from healthy people.', '6': 'The IgG/total antibodies positive percentage increased and remained above 95% after six months when chemiluminescent immunoassay (CLIA) IgG antiS1/S2 and electro-chemiluminescent assay (ECLIA) total antiNP were used.', '7': 'At early time points PSO, chemiluminescent microparticle immunoassay (CMIA) IgM antiS achieved the best sensitivity.', '8': 'IgM and IgG appear simultaneously in most circumstances, and when performed in parallel the sensitivity increases.', '9': 'The severe and the moderate clinical forms were significantly associated with higher seropositivity percentage and antibody levels.', '10': 'High specificity was found in all evaluated assays, but the sensitivity was variable depending on the time PSO, severity of disease, detection method and targeted antigen.'}\n",
            "31: abstract: {'1': 'Tardive dyskinesia (TD) is a disorder characterized by involuntary movements, typically of the orofacial muscles and also of the extremities and other muscle groups.', '2': 'The condition is associated with exposure to dopamine receptor blocking agents, including antipsychotics.', '3': 'Because the indications and off-label uses for these agents have expanded over the last 2 decades, a larger number of patients are receiving antipsychotic medications than in the past.', '4': 'While evidence suggests that patients being treated with second-generation antipsychotics have less risk for developing TD than those treated with first-generation antipsychotics, the decreased risk is not as great as was originally expected.', '5': 'In addition, patients with chronic psychiatric conditions often require long-term use of antipsychotics, putting them at risk for TD.', '6': 'This article addresses the prevalence, risk factors, and prevention of TD; assessment strategies including diagnostic criteria and rating scales; and evidence for TD treatments, including 2 newly approved medications: deutetrabenazine and valbenazine.'}\n",
            "31: abstract: {'1': 'Aim: The aim of this study was to summarize the characteristics, efficacy, and safety of vesicular monoamine transporter-2 (VMAT-2) inhibitors for treating tardive dyskinesia (TD).', '2': 'Materials and methods: We conducted a literature search in PubMed, Cochrane Database, and ClinicalTrials.gov, screening for systematic reviews, meta-analyses or double-blind, randomized, placebo-controlled trials (DBRPCTs) reporting efficacy or safety data of VMAT-2 inhibitors (tetrabenazine, deutetrabenazine, and valbenazine) in patients with TD.', '3': 'A random effects meta-analysis of efficacy and safety data from DBRPCTs was performed.', '4': 'Results: Two acute, 12-week DBRPCTs with deutetrabenazine 12-48 mg/day (n=413) and 4 acute, 4-6-week double-blind trials with valbenazine 12.5-100 mg/day (n=488) were meta-analyzable, without meta-analyzable, high-quality data for tetrabenazine.', '5': 'Regarding reduction in total Abnormal Involuntary Movement Scale (AIMS) scores (primary outcome), both deutetrabenazine (k=2, n=413, standardized mean difference [SMD] =-0.40, 95% confidence interval [CI] =-0.19, -0.62, p<0.001; weighted mean difference (WMD) =-1.44, 95% CI =-0.67, -2.19, p<0.001) and valbenazine (k=4, n=421, SMD =-0.58, 95% CI =-0.26, -0.91, p<0.001; WMD =-2.07, 95% CI =-1.08, -3.05, p<0.001) significantly outperformed placebo.', '6': 'Results were confirmed regarding responder rates (≥50% AIMS total score reduction; deutetrabenazine: risk ratio [RR] =2.13, 95% CI =1.10, 4.12, p=0.024, number-needed-to-treat [NNT] =7, 95% CI =3, 333, p=0.046; valbenazine: RR =3.05, 95% CI =1.81, 5.11, p<0.001, NNT =4, 95% CI =3, 6, p<0.001).', '7': 'Less consistent results emerged from patient-rated global impression-based response (p=0.15) and clinical global impression for deutetrabenazine (p=0.088), and for clinical global impression change for valbenazine (p=0.67).', '8': 'In an open-label extension (OLE) study of deutetrabenazine (≤54 weeks) and a dose-blinded valbenazine study (≤48 weeks), responder rates increased over time.', '9': 'With valbenazine, discontinuation effects were studied, showing TD symptom recurrence towards baseline severity levels within 4 weeks after valbenazine withdrawal.', '10': 'No increased cumulative or specific adverse (AEs) events versus placebo (acute trials) in extension versus acute trial data were observed.', '11': 'Conclusion: The 2 VMAT-2 inhibitors, valbenazine and deutetrabenazine, are effective in treating TD, both acutely and long-term, without concerns about increased risk of depression or suicide in the TD population.', '12': 'No head-to-head comparison among VMAT-2 inhibitors and no high-quality, meta-analyzable data are available for tetrabenazine in patients with TD.'}\n",
            "31: abstract: {'1': 'Tardive dyskinesias (TDs) are still common long-term sequelae of antipsychotic treatment.', '2': 'They are generally irreversible and associated with cognitive deficits, a decrease in quality of life and increased mortality.', '3': 'Furthermore, they potentially contribute to further stigmatization of the affected patients.', '4': 'However due to limited treatment options, antipsychotic drugs are still one of the cornerstones in treatment of most severe mental illnesses.', '5': 'Therefore, knowledge about risk factors and prevention of TDs is crucial.', '6': 'If TDs occur, the immediate optimization of the antipsychotic drug regimen is required.', '7': 'Targeted medical treatments such as VMAT - 2 inhibitors can be considered.', '8': 'The novel VMAT-2 inhibitors are not yet approved in Germany.', '9': 'Other drugs that are currently used to treat TDs include clonazepam and gingko biloba.', '10': 'This review summarizes the current evidence of treatment options of TDs and seeks to formulate clinical recommendations for the prevention and management of TDs.'}\n",
            "31: abstract: {'1': 'Tardive dyskinesia (TD) is a common, iatrogenic movement disorder affecting many individuals treated with dopamine-receptor blocking agents (DRBAs).', '2': 'Studying treatment of TD can be complex, as the symptoms can be affected by changes in either dosage or type of DRBA, as well as by the variable natural course of the disease.', '3': 'Historically many pharmacological therapies have been studied in TD, finding varying degrees of treatment success.', '4': 'Most recently, the VMAT2 inhibitors valbenazine and deutetrabenazine were rigorously studied in TD in large, phase III clinical trials, and were shown to be beneficial in this population.', '5': 'In this article, we will review various treatments of TD, including manipulation of the offending agent, VMAT2 inhibitors, other non-VMAT2-inhibiting medications, and non-pharmacological approaches.'}\n",
            "31: abstract: {'1': 'Background: Tardive dyskinesia is a movement disorder characterised by irregular, stereotyped, and choreiform movements associated with the use of antipsychotic medication.', '2': 'We aim to provide recommendations on the treatment of tardive dyskinesia.', '3': 'Results: Preventing tardive dyskinesia is of primary importance, and clinicians should follow best practice for prescribing antipsychotic medication, including limiting the prescription for specific indications, using the minimum effective dose, and minimising the duration of therapy.', '4': 'The first-line management of tardive dyskinesia is the withdrawal of antipsychotic medication if clinically feasible.', '5': 'Yet, for many patients with serious mental illness, the discontinuation of antipsychotics is not possible due to disease relapse.', '6': 'Switching from a first-generation to a second-generation antipsychotic with a lower D2 affinity, such as clozapine or quetiapine, may be effective in reducing tardive dyskinesia symptoms.', '7': 'The strongest evidence for a suitable co-intervention to treat tardive dyskinesia comes from tests with the new VMAT inhibitors, deutetrabenazine and valbenazine.', '8': 'These medications have not been approved for use in Canada.', '9': 'Conclusion: Data on tardive dyskinesia treatment are limited, and the best management strategy remains prevention.', '10': 'More long-term safety and efficacy data are needed for deutetrabenazine and valbenazine, and their routine availability to patients outside of the USA remains in question.'}\n",
            "31: abstract: {'1': 'Purpose of review: Tardive dyskinesia (TD) is caused by exposure to medications with dopamine antagonism, mainly antipsychotics.', '2': 'It often distresses individuals, physically and emotionally and affects their quality of life.', '3': 'We evaluated peer-reviewed recently published articles with a goal of providing a critically appraised update on the latest advancements in this field.', '4': 'Recent findings: In 2017, FDA approved VMAT2 inhibitors, deutetrabenazine and valbenazine.', '5': 'They have demonstrated efficacy in several class 1 studies.', '6': 'Also there have been update in the evidence-based guidelines for treatment for tardive dyskinesia.', '7': 'Various medication classes are being used for treatment of TD with VMAT2 inhibitors to be first FDA-approved medications.', '8': 'Their use should be tailored to the individual patient.', '9': 'Long-term studies will further guide us in how to optimize treatment, especially in the real-world setting.', '10': 'As clinicians, we need to take into consideration all aspects of symptomatology, etiology, potential side effects of the medications, to find the best possible \"match\" for our patients.'}\n",
            "31: abstract: {'1': 'Tardive dyskinesia (TD), a condition of potentially irreversible abnormal involuntary movements that is associated with dopamine receptor blocking agents (DRBAs), produces significant impairment of functioning and quality of life for patients.', '2': 'Contrary to expectations, TD has not vanished despite the introduction of SGAs.', '3': 'Instead, changing prescription practices and increased off-label prescription of DRBAs have placed more patients than ever at risk of this potentially dangerous and disabling condition.', '4': 'This activity provides an overview of treatment strategies for TD as part of an individualized management plan, including DRBA medication adjustment and antidyskinetic treatment.'}\n",
            "31: abstract: {'1': 'Tardive dyskinesia (TD) is an iatrogenic condition that encompasses a wide phenomenological spectrum of movement disorders caused by exposure to dopamine receptor blocking agents (DRBAs).', '2': 'TD may cause troublesome or disabling symptoms that impair quality of life.', '3': 'Due to frequent, often inappropriate, use of DRBAs, TD prevalence rates among patients exposed to DRBAs continue to be high.', '4': 'The judicious use of DRBAs is key to the prevention of TD, reduction of disease burden, and achieving lasting remission.', '5': 'Dopamine-depleting vesicular monoamine transporter type 2 inhibitors are considered the treatment of choice of TD.'}\n",
            "31: abstract: {'1': 'Objective: To examine the efficacy of pharmacologic treatments for tardive dyskinesia (TD).', '2': 'Data sources: PubMed was searched on December 12, 2017, for randomized, placebo-controlled trials examining the treatment of TD using the search terms (drug-induced dyskinesia OR tardive dyskinesia) AND (psychotic disorders OR schizophrenia).', '3': 'Study selection: Studies were included if they examined tardive dyskinesia treatment as the primary outcome and were randomized and placebo-controlled trials.', '4': 'Data extraction: The effect size (standard mean difference) of improvement (compared to placebo) stratified by medication class is reported for each of the trials included in this systematic review.', '5': 'A meta-analysis was conducted utilizing a fixed-effects model.', '6': 'Results: Vitamin E was associated with significantly greater reduction in TD symptoms compared to placebo (standardized mean difference [SMD] = 0.31 ± 0.08; 95% CI, 0.16 to 0.46; z = 4.1; P < .001).', '7': 'There was significant evidence of publication bias in vitamin E studies (Egger test: P = .02).', '8': 'Shorter duration of treatment and lower dose of vitamin E were significantly associated with greater measured treatment benefit.', '9': 'Vitamin B₆ was associated with significantly greater reduction in TD symptoms compared to placebo (SMD = 1.41 ± 0.22; 95% CI, 0.98 to 1.85; z = 6.4; P < .001) in 2 trials conducted by the same research group.', '10': 'Vesicular monoamine transporter 2 (VMAT2) inhibitors demonstrated significant benefit on tardive dyskinesia symptoms compared to placebo (SMD = 0.63 ± 0.11; 95% CI, 0.41 to 0.85; z = 5.58; P < .005).', '11': 'Amantadine was associated with significantly greater score reduction compared to placebo (SMD = 0.46 ± 0.21; 95% CI, 0.05 to 0.87; z = 2.20; P < .05).', '12': 'Calcium channel blockers were not associated with significantly greater score reduction compared to placebo (SMD = 0.31 ± 0.33; 95% CI, -0.34 to 0.96; z = 0.93; P = .35).', '13': 'Conclusions: Data from multiple trials suggests that VMAT2 inhibitors, vitamin E, vitamin B₆, and amantadine may be effective for the treatment of TD.', '14': 'Evidence of publication bias and a significant negative association of dose and duration of treatment with measured efficacy suggest that the benefits of vitamin E in TD may be overstated.', '15': 'Head-to-head trials are needed to compare the efficacy and cost-effectiveness of pharmacologic agents for TD.'}\n",
            "31: abstract: {'1': 'Tardive dyskinesia (TD) is a condition of potentially irreversible abnormal involuntary movements associated with dopamine receptor blocking agents, such as antipsychotics.', '2': 'While prevention is the best strategy, it is not always possible.', '3': 'This report outlines strategies to reduce TD symptoms, including the use of the FDA-approved treatment options (valbenazine and deutetrabenazine).'}\n",
            "32: abstract: {'1': 'Objectives: Elevated plasma homocysteine has been implicated as a risk factor for hypertension.', '2': 'C677T polymorphism in methylenetetrahydrofolate reductase gene (MTHFR) is a major determinant of hyperhomocysteinemia, which results in endothelial dysfunction.', '3': 'Angiotensin-converting enzyme (ACE) inhibitors appear to remedy the endothelial dysfunction and restore endothelium-dependent vasodilatation.', '4': 'The co-existence of genetic polymorphisms in drug metabolizing enzymes, targets, receptors, and transporters may influence the drug efficacy.', '5': 'The purpose of this study was to investigate whether short-term blood pressure control by benazepril, an ACE inhibitor, was modulated by C677T MTHFR gene polymorphism.', '6': 'Methods and results: A total of 444 hypertensive patients, aged 27 to 65 years, without any anti hypertensive therapy within 2 weeks were included.', '7': 'All of them were treated orally with benazepril at a single daily fixed dosage of 10 mg for 15 consecutive days.', '8': 'Blood pressures were measured at baseline and on the 16th day of treatment.', '9': 'Among them, the frequency of MTHFR C677T genotype CC, CT and TT was 24.3%, 51.8%, and 23.9%, respectively.', '10': 'In a recessive model (CC+CT versus TT genotype), both baseline diastolic blood pressure (DBP) and diastolic blood pressure response (DeltaDBP) were significantly higher in patients with the TT genotype than in those with the CT or CC genotype (P value=0.0076 for DBP, and P value=0.0005 for DeltaDBP).', '11': 'We further divided all patients into three groups based on the tertiles of the DeltaBP distribution.', '12': 'Compared to subjects in the lowest tertile of DeltaDBP, the adjusted relative odds of having the TT genotype among subjects in the highest tertile was 2.6 (95% CI, 1.4 to 4.9).', '13': 'However, baseline systolic blood pressure (SBP) and SBP response did not significantly associate with MTHFR C677T polymorphism.', '14': 'Conclusions: Our finding suggests that MTHFR C667T polymorphism modulated baseline DBP and DBP responsiveness by short-term treatment of ACE inhibitor in Chinese essential hypertensive patients.'}\n",
            "32: abstract: {'1': 'Recent studies have shown that antihypertensive drugs like diuretics increase plasma homocysteine (Hcy) levels.', '2': 'However, the effect of other antihypertensive drugs on plasma Hcy levels has not been tested extensively.', '3': 'The aim of present study was to investigate the effect of antihypertensive therapy (AHT) on Hcy levels in essential hypertensive subjects.', '4': 'A case-control study of 273 patients with essential hypertension (EH) and 103 normotensive controls was undertaken.', '5': 'Plasma Hcy levels were measured before and after 6 weeks of AHT.', '6': 'The genotyping of MTHFR C677T polymorphism was performed by polymerase chain reaction-restriction fragment length polymorphism.', '7': 'Angiotensin-converting enzyme (ACE) inhibitors and beta-blockers significantly decreased and hydrochlorothiazides significantly increased the plasma Hcy levels in hypertensive patients (P<0.05).', '8': 'No significant association between MTHFR C677T genotypes and changes in Hcy levels in response to antihypertensive was observed in EH patients.', '9': 'The decrease in Hcy induced by beta-blockers and ACE inhibitors observed in our study may be due to the improvement of endothelial function along with improved renal function.', '10': 'Thus, our results suggest that ACE inhibitors and beta-blockers may provide additional beneficial therapeutic effects to the EH patients by decreasing Hcy levels.'}\n",
            "32: abstract: {'1': 'Intervention with riboflavin was recently shown to produce genotype-specific lowering of blood pressure (BP) in patients with premature cardiovascular disease homozygous for the 677C→ T polymorphism (TT genotype) in the gene encoding the enzyme methylenetetrahydrofolate reductase (MTHFR).', '2': 'Whether this effect is confined to patients with high-risk cardiovascular disease is unknown.', '3': 'The aim of this randomized trial, therefore, was to investigate the responsiveness of BP to riboflavin supplementation in hypertensive individuals with the TT genotype but without overt cardiovascular disease.', '4': 'From an available sample of 1427 patients with hypertension, we identified 157 with the MTHFR 677TT genotype, 91 of whom agreed to participate in the trial.', '5': 'Participants were stratified by systolic BP and randomized to receive placebo or riboflavin (1.6 mg/d) for 16 weeks.', '6': 'At baseline, despite being prescribed multiple classes of antihypertensive drugs, >60% of participants with this genotype had failed to reach goal BP (≤140/90 mm Hg).', '7': 'A significant improvement in the biomarker status of riboflavin was observed in response to intervention (P<0.001).', '8': 'Correspondingly, an overall treatment effect of 5.6±2.6 mm Hg (P=0.033) in systolic BP was observed, with pre- and postintervention values of 141.8±2.9 and 137.1±3.0 mm Hg (treatment group) and 143.5±3.0 and 144.3±3.1 mm Hg (placebo group), whereas the treatment effect in diastolic BP was not significant (P=0.291).', '9': 'In conclusion, these results show that riboflavin supplementation targeted at hypertensive individuals with the MTHFR 677TT genotype can decrease BP more effectively than treatment with current antihypertensive drugs only and indicate the potential for a personalized approach to the management of hypertension in this genetically at-risk group.'}\n",
            "32: abstract: {'1': 'Methylenetetrahydrofolate reductase (MTHFR) is a critical folate-metabolising enzyme which requires riboflavin as its co-factor.', '2': 'A common polymorphism (677C→T) in the MTHFR gene results in reduced MTHFR activity in vivo which in turn leads to impaired folate metabolism and elevated homocysteine concentrations.', '3': 'Homozygosity for this polymorphism (TT genotype) is associated with an increased risk of a number of conditions including heart disease and stroke, but there is considerable variability in the extent of excess risk in various reports.', '4': 'The present review will explore the evidence which supports a role for this polymorphism as a risk factor for a number of adverse health outcomes, and the potential modulating roles for B-vitamins in alleviating disease risk.', '5': 'The evidence is convincing in the case which links this polymorphism with hypertension and hypertensive disorders of pregnancy, particularly preeclampsia.', '6': 'Furthermore, elevated blood pressure was found to be highly responsive to riboflavin intervention specifically in individuals with the MTHFR 677TT genotype.', '7': 'Future intervention studies targeted at these genetically predisposed individuals are required to further investigate this novel gene-nutrient interaction.', '8': 'This polymorphism has also been associated with an increased risk of neural tube defects (NTD) and other adverse pregnancy outcomes; however, the evidence in this area has been inconsistent.', '9': 'Preliminary evidence has suggested that there may be a much greater need for women with the MTHFR 677TT genotype to adhere to the specific recommendation of commencing folic acid prior to conception for the prevention of NTD, but this requires further investigation.'}\n",
            "32: abstract: {'1': \"Hypertension, a major risk factor for heart disease and stroke, is the world's leading cause of preventable, premature death.\", '2': 'A common polymorphism (677C→T) in the gene encoding the folate metabolizing enzyme methylenetetrahydrofolate reductase (MTHFR) is associated with increased blood pressure, and there is accumulating evidence demonstrating that this phenotype can be modulated, specifically in individuals with the MTHFR 677TT genotype, by the B-vitamin riboflavin, an essential co-factor for MTHFR.', '3': 'The underlying mechanism that links this polymorphism, and the related gene-nutrient interaction, with hypertension is currently unknown.', '4': 'Previous research has shown that 5-methyltetrahydrofolate, the product of the reaction catalysed by MTHFR, appears to be a positive allosteric modulator of endothelial nitric oxide synthase (eNOS) and may thus increase the production of nitric oxide, a potent vasodilator.', '5': \"Blood pressure follows a circadian pattern, peaking shortly after wakening and falling during the night, a phenomenon known as 'dipping'.\", '6': 'Any deviation from this pattern, which can only be identified using ambulatory blood pressure monitoring (ABPM), has been associated with increased cardiovascular disease (CVD) risk.', '7': 'This review will consider the evidence linking this polymorphism and novel gene-nutrient interaction with hypertension and the potential mechanisms that might be involved.', '8': 'The role of ABPM in B-vitamin research and in nutrition research generally will also be reviewed.'}\n",
            "32: abstract: {'1': 'Objective: This post hoc analysis of the CSPPT (China Stroke Primary Prevention Trial) assessed the individual variation in total homocysteine (tHcy)-lowering response after an average 4.5 years of 0.8 mg daily folic acid therapy in Chinese hypertensive adults and evaluated effect modification by methylenetetrahydrofolate reductase (MTHFR) C677T genotypes and serum folate levels.', '2': 'Approach and results: This analysis included 16 413 participants from the CSPPT, who were randomly assigned to 2 double-blind treatment groups: either 10-mg enalapril+0.8-mg folic acid or 10-mg enalapril, daily and had individual measurements of serum folate and tHcy levels at baseline and exit visits and MTHFR C677T genotypes.', '3': 'Mean baseline tHcy levels were comparable between the 2 treatment groups (14.5±8.5 versus 14.4±8.1 μmol/L; P=0.561).', '4': 'After 4.5 years of treatment, mean tHcy levels were reduced to 12.7±6.1 μmol/L in the enalapril+folic acid group, but almost stayed the same in the enalapril group (14.4±7.9 μmol/L, group difference: 1.61 μmol/L; 11% reduction).', '5': 'More importantly, tHcy lowering varied by MTHFR genotypes and serum folate levels.', '6': 'Compared with CC and CT genotypes, participants with the TT genotype had a more prominent L-shaped curve between tHcy and serum folate levels and required higher folate levels (at least 15 ng/mL) to eliminate the differences in tHcy by genotypes.', '7': 'Conclusions: Compared with CC or CT, tHcy in the TT group manifested a heightened L-shaped curve from low to high folate levels, but this difference in tHcy by genotype was eliminated when plasma folate levels reach ≈15 ng/mL or higher.', '8': 'Our data raised the prospect to tailor folic acid therapy according to individual MTHFR C677T genotype and folate status.'}\n",
            "32: abstract: {'1': 'Objective: In a subgroup analysis of the China Stroke Primary Prevention Trial, we aimed to explore the impact of folic acid supplementation on arterial stiffness and assess the modifying effect of the methylenetetrahydrofolate reductase (MTHFR) gene in Chinese patients with hypertension.', '2': 'Methods: This prospective study enrolled 2529 hypertensive Chinese patients.', '3': 'Participants were randomized to receive treatment with either a combination of enalapril and folic acid or enalapril.', '4': 'Brachial-ankle pulse wave velocity (PWV) was measured by trained medical staff using PWV instruments at both baseline and exit visits, approximately 5 years after enrollment.', '5': 'This trial was registered with clinicaltrials.gov (NCT00794885).', '6': 'Results: During the follow-up, change in folate was significantly and independently correlated with change in ba-PWV in study patients (β = -1.31, P < 0.001).', '7': 'Individuals with CC genotype had a significantly greater PWV response to folic acid supplementation than did carriers of the T allele (β = -2.79, P < 0.001 for CC homozygotes compared with β = -0.56, P = 0.464 for TT homozygotes).', '8': 'The positive effect of folic acid on improved PWV was modified by the MTHFR genotype (P for interaction = 0.034).', '9': 'Conclusion: In a subgroup of Chinese hypertensive patients who had received 5-year antihypertensive therapy, increases in folate status were associated with higher reductions in PWV, and individuals with the CC genotype showed greatest PWV response to folic acid supplementation.'}\n",
            "32: abstract: {'1': 'Objective: We evaluated the interaction of serum folate and vitamin B12 with methylenetetrahydrofolate reductase (MTHFR) C677T genotypes on the risk of first ischemic stroke and on the efficacy of folic acid treatment in prevention of first ischemic stroke.', '2': 'Methods: A total of 20,702 hypertensive adults were randomized to a double-blind treatment of daily enalapril 10 mg and folic acid 0.8 mg or enalapril 10 mg alone.', '3': 'Participants were followed up every 3 months.', '4': 'Results: Median values of folate and B12 concentrations at baseline were 8.1 ng/mL and 280.2 pmol/L, respectively.', '5': 'Over a median of 4.5 years, among those not receiving folic acid, participants with baseline serum B12 or serum folate above the median had a significantly lower risk of first ischemic stroke (hazard ratio [HR], 0.74; 95% confidence interval [CI], 0.57-0.96), especially in those with MTHFR 677 CC genotype (wild-type) (HR, 0.49; 95% CI, 0.31-0.78).', '6': 'Folic acid treatment significantly reduced the risk of first ischemic stroke in participants with both folate and B12 below the median (2.3% in enalapril-folic acid group vs 3.6% in enalapril-only group; HR, 0.62; 95% CI, 0.46-0.86), particularly in MTHFR 677 CC carriers (1.6% vs 4.9%; HR, 0.24; 95% CI, 0.11-0.55).', '7': 'However, TT homozygotes responded better with both folate and B12 levels above the median (HR, 0.28; 95% CI, 0.10-0.75).', '8': 'Conclusions: The risk of first ischemic stroke was significantly higher in hypertensive patients with low levels of both folate and B12.', '9': 'Effect of folic acid treatment was greatest in patients with low folate and B12 with the CC genotype, and with high folate and B12 with the TT genotype.'}\n",
            "32: abstract: {'1': 'Background: Hyperhomocysteinemia (HHCY) is a risk factor for cardiovascular and cerebrovascular diseases.', '2': 'The C677T 5, 10-methylenetetrahydrofolate reductase (MTHFR) gene polymorphism increases homocysteine (HCY) levels.', '3': 'This study analyzed the relationship between C677T MTHFR polymorphism and the therapeutic effect of lowering HCY in stroke patients with HHCY.', '4': 'Methods: Baseline data were collected from stroke patients with HHCY for this prospective cohort study.', '5': 'The C677T MTHFR genotype was detected by polymerase chain reaction-restriction fragment length polymorphism and the therapeutic effect to reduce HCY was compared.', '6': 'Results: Of 200 stroke patients 162 (81.0%) completed follow-up and were evaluated.', '7': 'Most of them responded well to treatment (103 cases, 63.5%), but 59 (36.4%) patients were in the poor efficacy group.', '8': 'There was a significant difference in terms of age (P < 0.001), hypertension (P = 0.041), hyperuricemia (P = 0.042), HCY after treatment (P < 0.001), and MTHFR genotype (P < 0.001) between the poor efficacy and effective groups, with increased frequency of the TT genotype in the poor efficacy group.', '9': 'Logistic regression showed that the T allele was associated with poor efficacy (OR = 0.733, 95%CI: 0.693, 0.862, P < 0.001).', '10': 'In the codominant model the TT genotype was associated with poor outcome (OR = 0.862, 95%CI: 0.767, 0.970, P = 0.017) and this was also the case in the recessive model (OR = 0.585, 95%CI: 0.462, 0.741, P < 0.001) but there was no association between CT and TT in the dominant model.', '11': 'Conclusions: The T allele and TT genotype of the MTHFR C677T polymorphism was associated with poor HCY reduction treatment efficacy in stroke patients with HHCY.'}\n",
            "32: abstract: {'1': 'Background: Genome-wide and clinical studies have linked the 677C→T polymorphism in the gene encoding methylenetetrahydrofolate reductase (MTHFR) with hypertension, whilst limited evidence shows that intervention with riboflavin (i.e. the MTHFR co-factor) can lower blood pressure (BP) in hypertensive patients with the variant MTHFR 677TT genotype.', '2': 'We investigated the impact of this common polymorphism on BP throughout adulthood and hypothesised that riboflavin status would modulate the genetic risk of hypertension.', '3': 'Methods: Observational data on 6076 adults of 18-102 years were drawn from the Joint Irish Nutrigenomics Organisation project, comprising the Trinity-Ulster Department of Agriculture (TUDA; volunteer sample) and the National Adult Nutrition Survey (NANS; population-based sample) cohorts.', '4': 'Participants were recruited from the Republic of Ireland and Northern Ireland (UK) in 2008-2012 using standardised methods.', '5': 'Results: The variant MTHFR 677TT genotype was identified in 12% of adults.', '6': 'From 18 to 70 years, this genotype was associated with an increased risk of hypertension (i.e. systolic BP ≥ 140 and/or a diastolic BP ≥ 90 mmHg): odds ratio (OR) 1.42, 95% confidence interval (CI) 1.07 to 1.90; P = 0.016, after adjustment for antihypertensive drug use and other significant factors, namely, age, male sex, BMI, alcohol and total cholesterol.', '7': 'Low or deficient biomarker status of riboflavin (observed in 30.2% and 30.0% of participants, respectively) exacerbated the genetic risk of hypertension, with a 3-fold increased risk for the TT genotype in combination with deficient riboflavin status (OR 3.00, 95% CI, 1.34-6.68; P = 0.007) relative to the CC genotype combined with normal riboflavin status.', '8': 'Up to 65 years, we observed poorer BP control rates on antihypertensive treatment in participants with the TT genotype (30%) compared to those without this variant, CT (37%) and CC (45%) genotypes (P < 0.027).', '9': 'Conclusions: The MTHFR 677TT genotype is associated with higher BP independently of homocysteine and predisposes adults to an increased risk of hypertension and poorer BP control with antihypertensive treatment, whilst better riboflavin status is associated with a reduced genetic risk.', '10': 'Riboflavin intervention may thus offer a personalised approach to prevent the onset of hypertension in adults with the TT genotype; however, this requires confirmation in a randomised trial in non-hypertensive adults.'}\n",
            "33: abstract: {'1': 'Gabapentin is an anticonvulsant drug, which in man is cleared solely by renal excretion and is not bound to plasma proteins.', '2': 'Because the clearance of gabapentin is dependent on renal function, the pharmacokinetics of gabapentin were investigated in anuric subjects maintained on hemodialysis.', '3': 'Plasma samples were obtained over an 8-day period after administration of single oral 400-mg doses of gabapentin.', '4': 'Pre- and post-dialyzer plasma samples and dialysate samples from quantitative collection of dialyzer effluent were obtained during hemodialysis sessions performed 2, 4, and 7 days after dosing.', '5': 'A mean (SD) maximum gabapentin plasma concentration of 6.0 (2.4) micrograms/mL was achieved at 4.7 (2.1) hours post-dose.', '6': 'The elimination half-life of gabapentin on non-hemodialysis days averaged 132 hours.', '7': 'Approximately 35% of the gabapentin dose was recovered in dialysate, and mean hemodialysis clearance of gabapentin was 142 (26) mL/min; approximately 93% of the dialyzer creatinine clearance.', '8': 'Gabapentin elimination half-life during hemodialysis was approximately 4 hours.', '9': 'Systemic plasma gabapentin concentrations increased approximately 30% during the first 2 hours after hemodialysis as a result of drug redistribution in the body.', '10': 'It is recommended that patients with end-stage renal disease maintained on hemodialysis receive an initial 300-mg to 400-mg gabapentin loading dose.', '11': 'Plasma gabapentin concentrations can be maintained by giving 200 to 300 mg of gabapentin after every 4 hours of hemodialysis.'}\n",
            "33: abstract: {'1': 'Gabapentin is a new antiepileptic drug (AED) with an attractive pharmacokinetic profile.', '2': 'It is absorbed by an active and saturable transport system, and has a high volume of distribution.', '3': 'Gabapentin is not bound to plasma proteins, does not induce hepatic enzymes and is not metabolized.', '4': 'At steady state, it has a half-life of 6-8 h, and is eliminated unchanged by renal route with a plasma clearance proportional to the creatinine clearance.', '5': 'It is devoid of significant drug-drug interactions when administered with the established AEDs or with oral contraceptives.', '6': 'Gabapentin used as an add-on AED significantly reduced the frequency of partial seizures and secondarily generalized tonic-clonic seizures in three large double-blind, placebo-controlled, parallel-group clinical trails.', '7': 'It is well tolerated, with transient somnolence and dizziness being the most frequent adverse effects.', '8': 'Although the mechanism of action of gabapentin is not fully established, there is strong evidence to suggest a novel mechanism of action.', '9': 'Gabapentin is a unique and promising drug that could improve the quality of life of patients with epilepsy and is a welcome addition to the armamentarium of currently available AEDs for the treatment of patients with seizures of partial onset.'}\n",
            "33: abstract: {'1': 'The amino acid antiepileptic drug (AED) gabapentin (GBP) is indicated for adjunctive use in the treatment of partial seizures with or without becoming secondarily generalized in individuals older than 12 years.', '2': 'GBP was about as potent as phenytoin in the maximal electroshock test, but had a different profile of efficacy than standard antiepileptics in a range of animal models.', '3': 'Possible mechanisms of action include biochemical effects enhancing the ratio of gamma-aminobutyric acid (GABA) to glutamate, ion-channel actions (direct or indirect), and/ or enhancement of nonsynaptic GABA release.', '4': 'The anticonvulsant effect appears to depend on concentration of gabapentin in neurons, presumably by the L-system amino acid transporter that has been implicated in absorption from the gut.', '5': 'Data from studies for U.S. Food and Drug Administration (FDA) approval suggested a direct relationship of clinical response to dose and efficacy did not plateau at the doses used.', '6': 'The maximally effective dose, relationship of efficacy to blood level, and maximum tolerable dose are not yet known conclusively.', '7': 'Lack of significant binding to plasma proteins and lack of liver metabolism contribute to the absence of known limiting drug-drug interactions, particularly with other AEDs.', '8': 'Excretion intact in the urine affords dose adjustment on the basis of creatinine clearance.', '9': 'A half-life of approximately 7 h necessitates multiple doses daily for many individuals.', '10': 'The medication is well tolerated, in general.', '11': 'Side effects tend to be mild to moderate in intensity, most frequently affect the central nervous system, and resolve with time in many individuals.', '12': 'GBP has been prescribed for approximately 70,000 individuals worldwide without untoward incidence of severe systemic toxicity to date.', '13': 'Safety data continue to accumulate.', '14': 'GBP has been labeled category C on the basis of effects on rodent fetuses.', '15': 'Experience with use in pregnant women is limited and human teratogenic effects have not been reported.', '16': 'Data from ongoing monotherapy trials will help to clarify the range of clinical utility of gabapentin.'}\n",
            "33: abstract: {'1': 'Purpose: This study was conducted to evaluate the effect of age, age-related changes in renal function, and gender on the single-dose pharmacokinetics of orally administered gabapentin (GBP).', '2': 'Methods: The pharmacokinetics of a single 400-mg oral dose of GBP were studied in 36 healthy subjects (18 men and 18 women) aged 20-78 years.', '3': 'Serial blood samples and total urine output were collected for 48 h after the dose.', '4': 'GBP concentrations in plasma and urine were measured by high-performance liquid chromatography, and pharmacokinetic parameters were calculated by noncompartmental methods.', '5': 'Results: All subjects tolerated the drug well, with only mild symptoms reported.', '6': 'No change in maximal GBP plasma concentration (Cmax), time at which Cmax occurred (tmax), or apparent volume of distribution (V/F) with age was noted.', '7': 'A significant linear decline in apparent oral clearance (CL/F), elimination-rate constant (lambda z), and renal clearance (CLR) with increasing age was observed (p < 0.005).', '8': 'Because total urinary recovery of unchanged drug (an estimate of F for GBP) did not change with age, the decline in CL/F and lambda z can be explained by the decline in CLR.', '9': 'The only pharmacokinetic parameter that was significantly different between genders was Cmax, which was approximately 25% higher for women than for men (p = 0.016), consistent with gender differences in body size.', '10': 'Conclusions: The results of this study suggest that changes in renal function are responsible for age-related changes in GBP pharmacokinetics.', '11': 'Reduction of GBP dosage may be required in elderly patients with reduced renal function.', '12': 'The pharmacokinetics of GBP are similar in men and women.'}\n",
            "33: abstract: {'1': 'Purpose: The pharmacokinetics of gabapentin in paediatric patients with uncontrolled seizures was studied.', '2': 'Methods: Thirteen paediatric patients (mean age: 9.4 years) with uncontrolled partial seizures were included.', '3': 'Patients received gabapentin orally until doses were individualized to 9.6-39.8 mg/kg/day.', '4': 'Blood samples were obtained just prior to the dose and over 8 h after gabapentin was administered in the fasting state.', '5': 'The plasma concentration of gabapentin was measured by a high-performance liquid chromatography assay.', '6': 'Pharmacokinetic parameters for gabapentin were determined by non-compartment methods using multivariate regression analysis.', '7': 'Results: Data from nine patients were suitable for pharmacokinetic analysis.', '8': 'The C(max) from 0.9 to 5.8 microg/mL (mean: 2.6 +/- 1.7 microg/mL) and T(max) from 0.5 to 2.0 h (mean: 1.6 +/- 1.0 h).', '9': 'The apparent clearance (Cl/F) ranged from 0.12 to 1.12 L/h/kg (mean: 0.50 +/- 0.29 L/h/kg), and the elimination half-life from 3.2 to 12.2 h (mean: 5.5 +/- 0.8 h).', '10': 'Five patients experienced moderate (n = 4) to severe (n = 1) aggressive behaviour and another gained weight on gabapentin.', '11': 'Conclusions: Our data suggests that gabapentin pharmacokinetics can vary substantially among paediatric patients.', '12': 'Gabapentin was well tolerated in patients with uncontrolled partial seizures up to 6 months of therapy.'}\n",
            "33: abstract: {'1': 'Pharmacokinetic data of gabapentin (GBP) in community-dwelling elderly patients show a significant effect of advanced age on GBP pharmacokinetics due to altered renal function.', '2': 'However, there are no data in elderly nursing home (NH) patients to evaluate gabapentin absorption and elimination.', '3': 'Our objective was to characterize the pharmacokinetics of GBP in elderly nursing home patients maintained on GBP therapy.', '4': 'This was a prospective pharmacokinetic study in elderly nursing home patients (≥60 years) receiving GBP for the management of chronic pain or epilepsy from seven nursing homes.', '5': 'Pharmacokinetic parameters were estimated by nonlinear mixed-effects modeling.', '6': 'A one-compartment model described the data and clearance (CL) was associated with estimated glomerular filtration rate (eGFR) (p < 0.0001).', '7': 'The GBP CL in elderly nursing home patients was 2.93 L/h.', '8': 'After adjusting for the effect of GFR, GBP CL was not affected by age, sex, body weight, or comorbidity scores.', '9': 'No significant effects of body size measures, age, and sex were detected on volume of distribution.', '10': 'Dose-dependent bioavailability of GBP was demonstrated, and the saturable absorption profile was described by a nonlinear hyperbolic function.', '11': 'Prediction-corrected visual predictive check (pc-VPC) suggests adequate fixed- and random-effects models that successfully simulated the mean trend and variability in gabapentin concentration-time profiles.', '12': 'In this analysis, the parameters of the hyperbolic nonlinearity appear to be similar between elderly and younger adults.'}\n",
            "33: abstract: {'1': 'Gabapentin is almost exclusively cleared by the kidney and thus presents challenges in patients with kidney failure.', '2': 'Gabapentin is known to be effectively cleared by hemodialysis, but the efficiency of clearance by peritoneal dialysis (PD) has not been previously described.', '3': 'We report a case of gabapentin toxicity in a patient on long-term PD who was treated with continuous automated cycling PD.', '4': 'We find that continuous PD provides significant clearance of gabapentin.', '5': 'With 2-L exchanges every 2 hours, we document an apparent elimination half-life of 41.33 hours, which is substantially shorter than the reported elimination half-life of 132 hours in the absence of kidney function.', '6': \"Further, our patient's symptoms of gabapentin toxicity gradually improved and had fully resolved after about 36 hours of dialysis.\", '7': 'Gabapentin clearance by PD was estimated at 94% of urea clearance.', '8': 'We conclude that intensive PD provides gabapentin clearance that approximates that of urea and is an effective but slow method to treat gabapentin overdose and toxicity.'}\n",
            "33: abstract: {'1': 'The objective of this study was to perform population pharmacokinetic (PK) analysis of gabapentin in healthy Korean subjects and to investigate the possible effect of genetic polymorphisms (1236C > T, 2677G > T/A, and 3435C > T) of ABCB1 gene on PK parameters of gabapentin.', '2': 'Data were collected from bioequivalence studies, in which 173 subjects orally received three different doses of gabapentin (300, 400, and 800 mg).', '3': 'Only data from reference formulation were used.', '4': 'Population pharmacokinetics (PKs) of gabapentin was estimated using a nonlinear mixed-effects model (NONMEM).', '5': 'Gabapentin showed considerable inter-individual variability (from 5.2- to 8.7-fold) in PK parameters.', '6': 'Serum concentration of gabapentin was well fitted by a one-compartment model with first-order absorption and lag time.', '7': 'An inhibitory Emax model was applied to describe the effect of dose on bioavailability.', '8': 'The oral clearance was estimated to be 11.1 L/h.', '9': 'The volume of distribution was characterized as 81.0 L.', '10': 'The absorption rate constant was estimated at 0.860 h-1, and the lag time was predicted at 0.311 h.', '11': 'Oral bioavailability was estimated to be 68.8% at dose of 300 mg, 62.7% at dose of 400 mg, and 47.1% at dose of 800 mg.', '12': 'The creatinine clearance significantly influenced on the oral clearance (P < 0.005) and ABCB1 2677G > T/A genotypes significantly influenced on the absorption rate constant (P < 0.05) of gabapentin.', '13': 'However, ABCB1 1236C > T and 3435C > T genotypes showed no significant effect on gabapentin PK parameters.', '14': 'The results of the present study indicate that the oral bioavailability of gabapentin is decreased when its dosage is increased.', '15': 'In addition, ABCB1 2677G > T/A polymorphism can explain the substantial inter-individual variability in the absorption of gabapentin.'}\n",
            "33: abstract: {'1': 'Gabapentin (GBP) is an organic cation mainly eliminated unchanged in urine, and active drug secretion has been suggested to contribute to its renal excretion.', '2': 'Our objective was to evaluate the potential drug-drug interaction between GBP and cetirizine (CTZ), an inhibitor of transporters for organic cations.', '3': 'An open-label, 2-period, crossover, nonrandomized clinical trial was conducted in patients with neuropathic pain to evaluate the effect of CTZ on GBP pharmacokinetics.', '4': 'Twelve participants were treated with a single dose of 300 mg GBP (treatment A) or with 20 mg/d of CTZ for 5 days and 300 mg GBP on the last day of CTZ treatment (treatment B).', '5': 'Blood sampling and pain intensity evaluation were performed up to 36 hours after GBP administration.', '6': 'The interaction of GBP and CTZ with transporters for organic cations was studied in human embryonic kidney (HEK) cells expressing the organic cation transporters (OCTs), multidrug and toxin extrusion proteins (MATEs), and OCTN1.', '7': 'CTZ treatment resulted in reduced area under the concentration-time curve and peak concentration compared with treatment A.', '8': 'In treatment B, the lower plasma concentrations of GBP resulted in reduced pain attenuation.', '9': 'GBP renal clearance was similar between treatments.', '10': 'GBP has low apparent affinity for OCT2 (concentration of an inhibitor where the response [or binding] is reduced by half [IC50 ] 237 µmol/L) and a high apparent affinity for hMATE1 (IC50 1.1 nmol/L), hMATE2-K (IC50 39 nmol/L), and hOCTN1 (IC50 2.1 nmol/L) in HEK cells.', '11': 'At therapeutic concentrations, CTZ interacts with hMATE1 and OCTN1.', '12': 'In summary, CTZ reduced the systemic exposure to GBP and its effect on neuropathic pain attenuation.', '13': 'However, CTZ × GBP interaction is not mediated by the renal transporters.'}\n",
            "33: abstract: {'1': 'Aims: Gabapentin (GBP) is widely used to treat neuropathic pain, including diabetic neuropathic pain.', '2': 'Our objective was to evaluate the role of diabetes and glycaemic control on GBP population pharmacokinetics.', '3': 'Methods: A clinical trial was conducted in patients with neuropathic pain (n = 29) due to type 2 diabetes (n = 19) or lumbar/cervical disc herniation (n = 10).', '4': 'All participants were treated with a single oral dose GBP.', '5': 'Blood was sampled up to 24 hours after GBP administration.', '6': 'Data were analysed with a population approach using the stochastic approximation expectation maximization algorithm.', '7': 'Weight, body mass index, sex, biomarkers of renal function and diabetes, and genotypes for the main genetic polymorphisms of SLC22A2 (rs316019) and SLC22A4 (rs1050152), the genes encoding the transporters for organic cations OCT2 and OCTN1, were tested as potential covariates.', '8': 'Results: GBP drug disposition was described by a 1-compartment model with lag-time, first-order absorption and linear elimination.', '9': 'The total clearance was dependent on estimated glomerular filtration rate.', '10': 'Population estimates (between-subject variability in percentage) for lag time, first-order absorption rate, apparent volume of distribution and total clearance were 0.316 h (10.6%), 1.12 h-1 (10.7%), 140 L (7.7%) and 14.7 L/h (6.97%), respectively.', '11': 'No significant association was observed with hyperglycaemia, glycated haemoglobin, diabetes diagnosis, age, sex, weight, body mass index, SLC22A2 or SLC22 A4 genotypes.', '12': 'Conclusion: This population pharmacokinetics model accurately estimated GBP concentrations in patients with neuropathic pain, using estimated glomerular filtrationrate as a covariate for total clearance.', '13': 'The distribution and excretion processes of GBP were not affected by hyperglycaemia or diabetes.'}\n",
            "34: abstract: {'1': 'Background: Methoxy polyethylene glycol-epoetin beta (PEG-EPO) is indicated for the treatment of anaemia due to chronic kidney disease.', '2': 'Its long half-life allows it to be administered once per month in maintenance therapy.', '3': 'Objective: To evaluate the use, effectiveness and cost of PEG-EPO in a group of pre-dialysis chronic renal failure patients.', '4': 'Method: Retrospective observational study in pre-dialysis patients who began treatment with PEG-EPO between May 2008 and February 2009.', '5': 'The following data were gathered: age, sex, haemoglobin levels (Hb) and erythropoiesis-stimulating agent (ESA) dose and frequency.', '6': 'The follow-up period was 12 months.', '7': 'Results: We included 198 patients.', '8': 'Mean Hb upon starting PEG-EPO in patients who had received no prior treatment was 10.8g/l, and 11.6g/l at 90 days (P<.0001).', '9': 'In patients previously treated with ESA, mean Hb before starting PEG-EPO treatment was 11.2g/l, and 11.4g/l at 12 months (P=.846).', '10': 'Hb values were higher than 12g/l (P<.0001) after 12 months of treatment in 25% of patients; of these, 45% had values above 13g/l.', '11': 'We observed doses 39% lower than those indicated on the drug leaflet, resulting in a reduction in the originally expected theoretical costs.', '12': 'Conclusions: The doses of PEG-EPO administered to patients with a prior history of ESA treatment were lower than those indicated by the drug leaflet, and Hb remained stable after 12 months of treatment.', '13': 'A large portion of the patients had levels above the 13g/l threshold.'}\n",
            "34: abstract: {'1': 'Protein-energy wasting (PEW), characterized by a decline in body protein mass and energy reserves, including muscle and fat wasting and visceral protein pool contraction, is an underappreciated condition in early to moderate stages of chronic kidney disease (CKD) and a strong predictor of adverse outcomes.', '2': 'The prevalence of PEW in early to moderate CKD is ≥20-25% and increases as CKD progresses, in part because of activation of proinflammatory cytokines combined with superimposed hypercatabolic states and declines in appetite.', '3': \"This anorexia leads to inadequate protein and energy intake, which may be reinforced by prescribed dietary restrictions and inadequate monitoring of the patient's nutritional status.\", '4': 'Worsening uremia also renders CKD patients vulnerable to potentially deleterious effects of uncontrolled diets, including higher phosphorus and potassium burden.', '5': 'Uremic metabolites, some of which are anorexigenic and many of which are products of protein metabolism, can exert harmful effects, ranging from oxidative stress to endothelial dysfunction, nitric oxide disarrays, renal interstitial fibrosis, sarcopenia, and worsening proteinuria and kidney function.', '6': \"Given such complex pathways, nutritional interventions in CKD, when applied in concert with nonnutritional therapeutic approaches, encompass an array of strategies (such as dietary restrictions and supplementations) aimed at optimizing both patients' biochemical variables and their clinical outcomes.\", '7': 'The applicability of many nutritional interventions and their effects on outcomes in patients with CKD with PEW has not been well studied.', '8': 'This article reviews the definitions and pathophysiology of PEW in patients with non-dialysis-dependent CKD, examines the current indications for various dietary modification strategies in patients with CKD (eg, manufactured protein-based supplements, amino acids and their keto acid or hydroxyacid analogues), discusses the rationale behind their potential use in patients with PEW, and highlights areas in need of further research.'}\n",
            "34: abstract: {'1': 'A panel of internists and nephrologists developed this practical approach for the Kidney Disease Outcomes Quality Initiative to guide assessment and care of chronic kidney disease (CKD) by primary care clinicians.', '2': 'Chronic kidney disease is defined as a glomerular filtration rate (GFR) <60 mL/min/1.73m  and/or markers of kidney damage for at least 3 months.', '3': 'In clinical practice the most common tests for CKD include GFR estimated from the serum creatinine concentration (eGFR) and albuminuria from the urinary albumin-to-creatinine ratio.', '4': 'Assessment of eGFR and albuminuria should be performed for persons with diabetes and/or hypertension but is not recommended for the general population.', '5': \"Management of CKD includes reducing the patient's risk of CKD progression and risk of associated complications, such as acute kidney injury and cardiovascular disease, anemia, and metabolic acidosis, as well as mineral and bone disorder.\", '6': 'Prevention of CKD progression requires blood pressure <140/90 mm Hg, use of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for patients with albuminuria and hypertension, hemoglobin A1c ≤7% for patients with diabetes, and correction of CKD-associated metabolic acidosis.', '7': 'To reduce patient safety hazards from medications, the level of eGFR should be considered when prescribing, and nephrotoxins should be avoided, such as nonsteroidal anti-inflammatory drugs.', '8': 'The main reasons to refer to nephrology specialists are eGFR <30 mL/min/1.73 m(2), severe albuminuria, and acute kidney injury.', '9': 'The ultimate goal of CKD management is to prevent disease progression, minimize complications, and promote quality of life.'}\n",
            "34: abstract: {'1': 'Background: Dietary changes are routinely recommended in people with chronic kidney disease (CKD) on the basis of randomised evidence in the general population and non-randomised studies in CKD that suggest certain healthy eating patterns may prevent cardiovascular events and lower mortality.', '2': 'People who have kidney disease have prioritised dietary modifications as an important treatment uncertainty.', '3': 'Objectives: This review evaluated the benefits and harms of dietary interventions among adults with CKD including people with end-stage kidney disease (ESKD) treated with dialysis or kidney transplantation.', '4': 'Main results: We included 17 studies involving 1639 people with CKD.', '5': 'Three studies enrolled 341 people treated with dialysis, four studies enrolled 168 kidney transplant recipients, and 10 studies enrolled 1130 people with CKD stages 1 to 5.', '6': 'Eleven studies (900 people) evaluated dietary counselling with or without lifestyle advice and six evaluated dietary patterns (739 people), including one study (191 people) of a carbohydrate-restricted low-iron, polyphenol enriched diet, two studies (181 people) of increased fruit and vegetable intake, two studies (355 people) of a Mediterranean diet and one study (12 people) of a high protein/low carbohydrate diet.', '7': 'Risks of bias in the included studies were generally high or unclear, lowering confidence in the results.', '8': 'Participants were followed up for a median of 12 months (range 1 to 46.8 months).', '9': 'Studies were not designed to examine all-cause mortality or cardiovascular events.', '10': 'In very-low quality evidence, dietary interventions had uncertain effects on all-cause mortality or ESKD.', '11': 'In absolute terms, dietary interventions may prevent one person in every 3000 treated for one year avoiding ESKD, although the certainty in this effect was very low.', '12': 'Across all 17 studies, outcome data for cardiovascular events were sparse.', '13': 'Dietary interventions in low quality evidence were associated with a higher health-related quality of life (2 studies, 119 people: MD in SF-36 score 11.46, 95% CI 7.73 to 15.18; I2 = 0%).', '14': 'Adverse events were generally not reported.', '15': 'Dietary interventions lowered systolic blood pressure (3 studies, 167 people: MD -9.26 mm Hg, 95% CI -13.48 to -5.04; I2 = 80%) and diastolic blood pressure (2 studies, 95 people: MD -8.95, 95% CI -10.69 to -7.21; I2 = 0%) compared to a control diet.', '16': 'Dietary interventions were associated with a higher estimated glomerular filtration rate (eGFR) (5 studies, 219 people: SMD 1.08; 95% CI 0.26 to 1.97; I2 = 88%) and serum albumin levels (6 studies, 541 people: MD 0.16 g/dL, 95% CI 0.07 to 0.24; I2 = 26%).', '17': 'A Mediterranean diet lowered serum LDL cholesterol levels (1 study, 40 people: MD -1.00 mmol/L, 95% CI -1.56 to -0.44).', '18': \"Authors' conclusions: Dietary interventions have uncertain effects on mortality, cardiovascular events and ESKD among people with CKD as these outcomes were rarely measured or reported.\", '19': 'Dietary interventions may increase health-related quality of life, eGFR, and serum albumin, and lower blood pressure and serum cholesterol levels.', '20': 'Based on stakeholder prioritisation of dietary research in the setting of CKD and preliminary evidence of beneficial effects on risks factors for clinical outcomes, large-scale pragmatic RCTs to test the effects of dietary interventions on patient outcomes are required.'}\n",
            "34: abstract: {'1': 'Importance: Chronic kidney disease (CKD) is the 16th leading cause of years of life lost worldwide.', '2': 'Appropriate screening, diagnosis, and management by primary care clinicians are necessary to prevent adverse CKD-associated outcomes, including cardiovascular disease, end-stage kidney disease, and death.', '3': 'Observations: Defined as a persistent abnormality in kidney structure or function (eg, glomerular filtration rate [GFR] <60 mL/min/1.73 m2 or albuminuria ≥30 mg per 24 hours) for more than 3 months, CKD affects 8% to 16% of the population worldwide.', '4': 'In developed countries, CKD is most commonly attributed to diabetes and hypertension.', '5': 'However, less than 5% of patients with early CKD report awareness of their disease.', '6': 'Among individuals diagnosed as having CKD, staging and new risk assessment tools that incorporate GFR and albuminuria can help guide treatment, monitoring, and referral strategies.', '7': 'Optimal management of CKD includes cardiovascular risk reduction (eg, statins and blood pressure management), treatment of albuminuria (eg, angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers), avoidance of potential nephrotoxins (eg, nonsteroidal anti-inflammatory drugs), and adjustments to drug dosing (eg, many antibiotics and oral hypoglycemic agents).', '8': 'Patients also require monitoring for complications of CKD, such as hyperkalemia, metabolic acidosis, hyperphosphatemia, vitamin D deficiency, secondary hyperparathyroidism, and anemia.', '9': 'Those at high risk of CKD progression (eg, estimated GFR <30 mL/min/1.73 m2, albuminuria ≥300 mg per 24 hours, or rapid decline in estimated GFR) should be promptly referred to a nephrologist.', '10': 'Conclusions and relevance: Diagnosis, staging, and appropriate referral of CKD by primary care clinicians are important in reducing the burden of CKD worldwide.'}\n",
            "34: abstract: {'1': 'Chronic kidney disease (CKD) is a prevalent worldwide public burden that increasingly compromises overall health as the disease progresses.', '2': 'Two of the most negatively affected tissues are bone and skeletal muscle, with CKD negatively impacting their structure, function and activity, impairing the quality of life of these patients and contributing to morbidity and mortality.', '3': 'Whereas skeletal health in this population has conventionally been associated with bone and mineral disorders, sarcopenia has been observed to impact skeletal muscle health in CKD.', '4': 'Indeed, bone and muscle tissues are linked anatomically and physiologically, and together regulate functional and metabolic mechanisms.', '5': 'With the initial crosstalk between the skeleton and muscle proposed to explain bone formation through muscle contraction, it is now understood that this communication occurs through the interaction of myokines and osteokines, with the skeletal muscle secretome playing a pivotal role in the regulation of bone activity.', '6': 'Regular exercise has been reported to be beneficial to overall health.', '7': 'Also, the positive regulatory effect that exercise has been proposed to have on bone and muscle anatomical, functional, and metabolic activity has led to the proposal of regular physical exercise as a therapeutic strategy for muscle and bone-related disorders.', '8': 'The detection of bone- and muscle-derived cytokine secretion following physical exercise has strengthened the idea of a cross communication between these organs.', '9': 'Hence, this review presents an overview of the impact of CKD in bone and skeletal muscle, and narrates how these tissues intrinsically communicate with each other, with focus on the potential effect of exercise in the modulation of this intercommunication.'}\n",
            "34: abstract: {'1': 'Background: Approximately 10% of adults in Germany have chronic kidney disease (CKD).', '2': 'The prevalence of CKD among patients being cared for by general practitioners is approximately 30%, and its prevalence in nursing homes is over 50%.', '3': 'An S3 guideline has been developed for the management of CKD in primary care.', '4': 'Methods: The guideline is based on publications retrieved by a systematic search of the literature for international guidelines published in the period 2013-2017, and additional searches on specific questions.', '5': 'It was created by the German College of General Practitioners and Family Physicians (Deutsche Gesellschaft für Allgemeinmedizin und Familienmedizin, DEGAM) and consented with the German Societies of Nephrology and Internal Medicine (DGfN, DGIM) and patient representation.', '6': \"Results: Upon the initial diagnosis of CKD (glomerular filtration rate [GFR] <60 mL/ min), the patient's blood pressure and urinary albumin-to-creatinine ratio (ACR) should be measured, and the urine should be examined for hematuria.\", '7': \"Monitoring intervals are determined on an individual basis depending on the stage of disease and the patient's general state of health and personal preferences.\", '8': 'Nephrological consultation should be obtained if the GFR is less than 30 mL/min, if CKD is initially diagnosed (GFR 30-59 mL/min) in the presence of persistent hematuria without any urological explanation or of albinuria in stage A2 or higher, if the patient has refractory hypertension requiring three or more antihypertensive drugs, or if the renal disease is rapidly progressive.', '9': 'The threshold for referring a patient should be kept low for persons under age 50; persons over age 70 should be referred only if warranted in consideration of their comorbidities and individual health goals.', '10': 'Conclusion: The main elements of the treatment of CKD are the treatment of hypertension and diabetes and the modification of lifestyle factors.', '11': \"An innovation from the primary care practioner's perspective is the assessment of albuminuria with the albumin-to-creatinine ratio.\"}\n",
            "34: abstract: {'1': 'Introduction: Secondary hyperparathyroidism (SHPT) represents a complication of chronic kidney disease (CKD).', '2': 'Vitamin D system is altered since early CKD, and vitamin D deficiency is an established trigger of SHPT.', '3': 'Although untreated SHPT may degenerate into tertiary hyperparathyroidism with detrimental consequences in advanced CKD, best treatments for counteracting SHPT from stage 3 CKD are still debated.', '4': 'Enthusiasm on prescription of vitamin D receptor activators (VDRA) in non-dialysis renal patients, has been mitigated by the risk of low bone turnover and positive calcium-phosphate balance.', '5': 'Nutritional vitamin D is now suggested as first-line therapy to treat SHPT with low 25(OH)D insufficiency.', '6': 'However, no high-grade evidence supports the best choice between ergocalciferol, cholecalciferol, and calcifediol (in its immediate or extended-release formulation).', '7': 'Areas covered: The review discusses available data on safety and efficacy of nutritional vitamin D, VDRA and nutritional therapy in replenishing 25(OH)D deficiency and counteracting SHPT in non-dialysis CKD patients.', '8': 'Expert opinion: Best treatment for low 25(OH)D and SHPT remains unknown, due to incomplete understanding of the best homeostatic, as mutable, adaptation of mineral metabolism to CKD progression.', '9': 'Nutritional vitamin D and nutritional therapy appear safest interventions, whenever contextualized with single-patient characteristics.', '10': 'VDRA should be restricted to uncontrolled SHPT by first-line therapy.'}\n",
            "34: abstract: {'1': 'Adherence to a Mediterranean lifestyle may be a useful primary and secondary prevention strategy for chronic kidney disease (CKD).', '2': 'This cross-sectional study aimed to explore adherence to a Mediterranean lifestyle and its association with cardiometabolic markers and kidney function in 99 people aged 73⋅2 ± 10⋅5 years with non-dialysis dependant CKD (stages 3-5) at a single Australian centre.', '3': 'Adherence was assessed using an a priori index, the Mediterranean Lifestyle (MEDLIFE) index.', '4': 'Cardiometabolic markers (total cholesterol, LDL-cholesterol, HbA1c and random blood glucose) and kidney function (estimated GFR) were sourced from medical records and blood pressure measured upon recruitment.', '5': 'Overall, adherence to a Mediterranean lifestyle was moderate to low with an average MEDLIFE index score of 11⋅33 ± 3⋅31.', '6': 'Adherence to a Mediterranean lifestyle was associated with employment (r 0⋅30, P = 0⋅004).', '7': 'Mediterranean dietary habits were associated with cardiometabolic markers, such as limiting sugar in beverages was associated with lower diastolic blood pressure (r 0⋅32, P = 0⋅002), eating in moderation with favourable random blood glucose (r 0⋅21, P = 0⋅043), having more than two snack foods per week with HbA1c (r 0⋅29, P = 0⋅037) and LDL-cholesterol (r 0⋅41, P = 0⋅002).', '8': 'Interestingly, eating in company was associated with a lower frequency of depression (χ 2 5⋅975, P = 0⋅015).', '9': 'To conclude, Mediterranean dietary habits were favourably associated with cardiometabolic markers and management of some comorbidities in this group of people with non-dialysis dependent CKD.'}\n",
            "34: abstract: {'1': 'Due to the unique role of the kidney in the metabolism of nutrients, patients with chronic kidney disease (CKD) lose the ability to excrete solutes and maintain homeostasis.', '2': 'Nutrient intake modifications and monitoring of nutritional status in this population becomes critical, since it can affect important health outcomes, including progression to kidney failure, quality of life, morbidity, and mortality.', '3': 'Although there are multiple hemodynamic and metabolic factors involved in the progression and prognosis of CKD, nutritional interventions are a central component of the care of patients with non-dialysis CKD (ND-CKD) and of the prevention of overweight and possible protein energy-wasting.', '4': 'Here, we review the reno-protective effects of diet in adults with ND-CKD stages 3-5, including transplant patients.'}\n",
            "35: abstract: {'1': 'Osteoporosis and its consequent increase in fracture risk is a major health concern for postmenopausal women and older men and has the potential to reach epidemic proportions.', '2': 'The \"gold standard\" for osteoporosis diagnosis is bone densitometry.', '3': 'However, economic issues or availability of the technology may prevent the possibility of mass screening.', '4': 'The goal of this study was to develop and validate a clinical scoring index designed as a prescreening tool to help clinicians identify which women are at increased risk of osteoporosis [bone mineral density (BMD) T-score -2.5 or less] and should therefore undergo further testing with bone densitometry.', '5': 'Records were analyzed for 1522 postmenopausal females over 50 years of age who had undergone testing with dual-energy X-ray absorptiometry (DXA).', '6': 'Osteoporosis risk index scores were compared to bone density T-scores.', '7': 'Hologic QDR 4500 technology was used to measure BMD at the femoral neck and lumbar spine (L1-L4).', '8': 'Participants who had a previous diagnosis of osteoporosis or were taking bone-active medication were excluded.', '9': 'Receiver-operating characteristic (ROC) analysis was used to identify the specific cutpoint value that would identify women at increased risk of low BMD.', '10': 'A simple algorithm based on age, weight, history of previous low impact fracture, early menopause, and corticosteroid therapy was developed.', '11': 'Validation of this five-item osteoporosis prescreening risk assessment (OPERA) index showed that the tool, at the recommended threshold (or cutoff value) of two, had a sensitivity that ranged from 88.1 [95% confidence interval (CI) for the mean: 86.2-91.9%] at the femoral neck to 90% (95% CI for the mean: 86.1-93.1%) at the lumbar spine area.', '12': 'Corresponding specificity values were 60.6 (95% CI for the mean: 57.9-63.3%) and 64.2% (95% CI for the mean: 61.4-66.9%), respectively.', '13': 'The positive predictive value (PPV) ranged from 29 at the femoral neck to 39.2% at the lumbar spine, while the corresponding negative predictive values (NPVs) reached 96.5 and 96.2%, respectively.', '14': 'Based on this cutoff value, the area under the ROC curve was 0.866 (95% CI for the mean: 0.847-0.882) for the lumbar spine and 0.814 (95% CI for the mean: 0.793-0.833) for the femoral neck.', '15': 'We conclude that the OPERA is a free and effective method for identifying Italian postmenopausal women at increased risk of osteoporosis.', '16': 'Its use could facilitate the appropriate and more cost-effective use of bone densitometry in developing countries.'}\n",
            "35: abstract: {'1': 'BACKGROUND: Although bone mineral density (BMD) testing to screen for osteoporosis (BMD T score, −2.50 or lower) is recommended for women 65 years of age or older, there are few data to guide decisions about the interval between BMD tests.', '2': 'METHODS: We studied 4957 women, 67 years of age or older, with normal BMD (T score at the femoral neck and total hip, −1.00 or higher) or osteopenia (T score, −1.01 to −2.49) and with no history of hip or clinical vertebral fracture or of treatment for osteoporosis, followed prospectively for up to 15 years.', '3': 'The BMD testing interval was defined as the estimated time for 10% of women to make the transition to osteoporosis before having a hip or clinical vertebral fracture, with adjustment for estrogen use and clinical risk factors.', '4': 'Transitions from normal BMD and from three subgroups of osteopenia (mild, moderate, and advanced) were analyzed with the use of parametric cumulative incidence models.', '5': 'Incident hip and clinical vertebral fractures and initiation of treatment with bisphosphonates, calcitonin, or raloxifene were treated as competing risks.', '6': 'RESULTS: The estimated BMD testing interval was 16.8 years (95% confidence interval [CI], 11.5 to 24.6) for women with normal BMD, 17.3 years (95% CI, 13.9 to 21.5) for women with mild osteopenia, 4.7 years (95% CI, 4.2 to 5.2) for women with moderate osteopenia, and 1.1 years (95% CI, 1.0 to 1.3) for women with advanced osteopenia.', '7': 'CONCLUSIONS: Our data indicate that osteoporosis would develop in less than 10% of older, post-menopausal women during rescreening intervals of approximately 15 years for women with normal bone density or mild osteopenia, 5 years for women with moderate osteopenia, and 1 year for women with advanced osteopenia.'}\n",
            "35: abstract: {'1': 'The US Preventive Services Task Force (USPSTF) guideline for osteoporosis screening concludes that there is a lack of evidence about optimal rescreening intervals and states that intervals >2 years may be necessary to better predict fracture risk.', '2': 'In addition, the USPSTF cites a prospective study showing that repeat measurement of BMD after 8 years added little predictive value compared with baseline DEXA scan results.', '3': 'Reconsider the intervals at which you recommend rescreening for osteoporosis; for post-menopausal women with a baseline of normal bone mineral density (BMD) or mild osteopenia, a 15-year interval is probably sufficient.'}\n",
            "35: abstract: {'1': 'We evaluated the prevalence and geographic variation of short-interval (repeated in under 2 years) dual-energy X-ray absorptiometry tests (DXAs) among Medicare beneficiaries.', '2': 'Short-interval DXA use varied across regions (coefficient of variation = 0.64), and unlike other DXAs, rates decreased with payment cuts.', '3': 'Introduction: The American College of Rheumatology, through the Choosing Wisely initiative, identified measuring bone density more often than every 2 years as care \"physicians and patients should question.\"', '4': 'We measured the prevalence and described the geographic variation of short-interval (repeated in under 2 years) DXAs among Medicare beneficiaries and estimated the cost of this testing and its responsiveness to payment change.', '5': 'Methods: Using 100 % Medicare claims data, 2006-2011, we identified DXAs and short-interval DXAs for female Medicare beneficiaries over age 66.', '6': 'We determined the population rate of DXAs and short-interval DXAs, as well as Medicare spending on short-interval DXAs, nationally and by hospital referral region (HRR).', '7': 'Results: DXA use was stable 2008-2011 (12.4 to 11.5 DXAs per 100 women).', '8': 'DXA use varied across HRRs: in 2011, overall DXA use ranged from 6.3 to 23.0 per 100 women (coefficient of variation = 0.18), and short-interval DXAs ranged from 0.3 to 8.0 per 100 women (coefficient of variation = 0.64).', '9': 'Short-interval DXA use fluctuated substantially with payment changes; other DXAs did not.', '10': 'Short-interval DXAs, which represented 10.1 % of all DXAs, cost Medicare approximately US$16 million in 2011.', '11': 'Conclusions: One out of ten DXAs was administered in a time frame shorter than recommended and at a substantial cost to Medicare.', '12': 'DXA use varied across regions.', '13': 'Short-interval DXA use was responsive to reimbursement changes, suggesting carefully designed policy and payment reform may reduce this care identified by rheumatologists as low value.'}\n",
            "35: abstract: {'1': 'Background: To develop an OSTAi tool and compare this with the National Osteoporosis Foundation recommendations in 2013 (NOF 2013) for bone mineral density (BMD) testing among Taiwan postmenopausal women.', '2': 'Methods: Taiwan Osteoporosis Association (TOA) conducted a nationwide BMD survey by a bus installed with a dual energy X-ray absorptiometry (DXA) between 2008 and 2011.', '3': 'All of the participants completed questionnaire, which included demographics and risk factors of osteoporotic fracture in FRAX tool.', '4': 'We used the database to analyze potential risk factors for osteoporosis and followed the model by Koh et al. to develop a risk index via multiple variable regression analysis and item reduction.', '5': 'We used the index values to set up a simple algorithm (namely OSTAi) to identify those who need BMD measurement.', '6': 'Receiver operating characteristic (ROC) curve and the area under the curve (AUC) was used to compare the sensitivity/specificity analysis of this model with that of recommendations by NOF 2013.', '7': 'Results: A total of 12,175 Taiwan postmenopausal women enrolled in this survey.', '8': 'The index value was derived by age and body weight of the participants according to weighted odds of each risk factor and the selected cutoff value was set at \"-1\".', '9': 'There are 6393 (52.5%) participants whose index value is below \"-1\" and whose risk of osteoporosis was 57.5% (3674/6393).', '10': 'The AUC for OSTAi and NOF 2013 were 0.739 (95% confidence interval (CI), 0.728-0.749, P<0.001) and 0.618 (95% CI, 0.606-0.630, P<0.001), respectively.', '11': 'The sensitivity and specificity of OSTAi, at the selected cutoff value of -1, and NOF 2013 to identify osteoporosis were 73.1%, 62.0% and 78.3%, 45.7%, respectively.', '12': 'Conclusions: As OSTA for Asian populations, OSTAi is an useful tool to identify Taiwan postmenopausal women with osteoporosis,', '13': 'In comparison with NOF 2013, OSTAi may be an easier and better tool for referral to BMD measurement by DXA in this area.'}\n",
            "35: abstract: {'1': 'Osteoporosis-related fractures affect approximately one in two white women and one in five white men in their lifetime.', '2': 'The impact of fractures includes loss of function, significant costs, and increased mortality.', '3': \"The U.S. Preventive Services Task Force recommends using dual energy x-ray absorptiometry to screen all women 65 years and older, and younger women who have an increased fracture risk as determined by the World Health Organization's FRAX Fracture Risk Assessment Tool.\", '4': 'Although guidelines are lacking for rescreening women who have normal bone mineral density on initial screening, intervals of at least four years appear safe.', '5': 'The U.S. Preventive Services Task Force found insufficient evidence to recommend screening for osteoporosis in men; other organizations recommend screening all men 70 years and older.', '6': 'In patients with newly diagnosed osteoporosis, suggested laboratory tests to identify secondary causes include serum 25-hydroxyvitamin D, calcium, creatinine, and thyroid-stimulating hormone.', '7': 'First-line treatment to prevent fractures consists of fall prevention, smoking cessation, moderation of alcohol intake, and bisphosphonate therapy.', '8': 'Clinicians should consider discontinuing bisphosphonate therapy after five years in women without a personal history of vertebral fractures.', '9': 'Raloxifene, teriparatide, and denosumab are alternative effective treatments for certain subsets of patients and for those who are unable to take or whose condition does not respond to bisphosphonates.', '10': 'The need for follow-up bone mineral density testing in patients receiving treatment for osteoporosis is uncertain.'}\n",
            "35: abstract: {'1': 'We investigated the value of routine laboratory testing for identifying underlying causes in older men diagnosed with osteoporosis.', '2': 'Most osteoporotic and nonosteoporotic men had ≥1 laboratory abnormality.', '3': 'Few individual laboratory abnormalities were more common in osteoporotic men.', '4': 'The benefit of routine laboratory testing in older osteoporotic men may be low.', '5': 'Introduction: To evaluate the utility of recommended laboratory testing to identify secondary causes in older men with osteoporosis, we examined prevalence of laboratory abnormalities in older men with and without osteoporosis.', '6': 'Methods: One thousand five hundred seventy-two men aged ≥65 years in the Osteoporotic Fractures in Men study completed bone mineral density (BMD) testing and a battery of laboratory measures, including serum calcium, phosphorus, alkaline phosphatase, parathyroid hormone (PTH), thyroid-stimulating hormone (TSH), 25-OH vitamin D, total testosterone, spot urine calcium/creatinine ratio, spot urine albumin/creatinine ratio, creatinine-derived estimated glomerular filtration rate, 24-h urine calcium, and 24-h urine free cortisol.', '7': 'Using cross-sectional analyses, we calculated prevalence ratios (PRs) and 95 % confidence intervals (CI) for the association of any and specific laboratory abnormalities with osteoporosis and the number of men with osteoporosis needed to test to identify one additional laboratory abnormality compared to testing men without osteoporosis.', '8': 'Results: Approximately 60 % of men had ≥1 laboratory abnormality in both men with and without osteoporosis.', '9': 'Among individual tests, only vitamin D insufficiency (PR, 1.13; 95 % CI, 1.05-1.22) and high alkaline phosphatase (PR, 3.05; 95 % CI, 1.52-6.11) were more likely in men with osteoporosis.', '10': 'Hypercortisolism and hyperthyroidism were uncommon and not significantly more frequent in men with osteoporosis.', '11': 'No osteoporotic men had hypercalciuria.', '12': 'Conclusions: Though most of these older men had ≥1 laboratory abnormality, few routinely recommended individual tests were more common in men with osteoporosis than in those without osteoporosis.', '13': 'Possibly excepting vitamin D and alkaline phosphatase, benefit of routine laboratory testing to identify possible secondary causes in older osteoporotic men appears low.', '14': 'Results may not be generalizable to younger men or to older men in whom history and exam findings raise clinical suspicion for a secondary cause of osteoporosis.'}\n",
            "35: abstract: {'1': 'Background: Clinical practice guidelines recommend use of fracture risk scores for screening and pharmacologic treatment decisions.', '2': 'The timing of occurrence of treatment-level (according to 2014 National Osteoporosis Foundation guidelines) or screening-level (according to 2011 US Preventive Services Task Force guidelines) fracture risk scores has not been estimated in postmenopausal women.', '3': 'Methods: We conducted a retrospective competing risk analysis of new occurrence of treatment-level and screening-level fracture risk scores in postmenopausal women aged 50 years and older, prior to receipt of pharmacologic treatment and prior to first hip or clinical vertebral fracture.', '4': 'Results: In 54,280 postmenopausal women aged 50 to 64 years without a bone mineral density test, the time for 10% to develop a treatment-level FRAX score could not be estimated accurately because of rare incidence of treatment-level scores.', '5': 'In 6096 women who had FRAX scores calculated with bone mineral density, the estimated unadjusted time to treatment-level FRAX ranged from 7.6 years (95% confidence interval [CI], 6.6-8.7) for those aged 65 to 69, to 5.1 years (95% CI, 3.5-7.5) for those aged 75 to 79 at baseline.', '6': 'Of 17,967 women aged 50 to 64 with a screening-level FRAX at baseline, 100 (0.6%) experienced a hip or clinical vertebral fracture by age 65 years.', '7': 'Conclusions: Postmenopausal women with sub-threshold fracture risk scores at baseline were unlikely to develop a treatment-level FRAX score between ages 50 and 64 years.', '8': 'After age 65, the increased incidence of treatment-level fracture risk scores, osteoporosis, and major osteoporotic fracture supports more frequent consideration of FRAX and bone mineral density testing.'}\n",
            "35: abstract: {'1': 'Background: Existing guidelines for repeat screening and treatment monitoring intervals regarding the use of dual-energy x-ray absorptiometry (DXA) scans are conflicting or lacking.', '2': 'The Choosing Wisely campaign recommends against repeating DXA scans within 2 years of initial screening.', '3': 'It is unclear how frequently physicians order repeat scans and what clinical factors contribute to their use.', '4': 'Objective: To estimate cumulative incidence and predictors of repeat DXA for screening or treatment monitoring in a regional health system.', '5': 'Design: Retrospective longitudinal cohort study', '6': 'PARTICIPANTS: A total of 5992 women aged 40-84 years who received initial DXA screening from 2006 to 2011 within a regional health system in Sacramento, CA.', '7': 'Main measures: Two- and five-year cumulative incidence and hazard rations (HR) of repeat DXA by initial screening result (classified into three groups: low or high risk of progression to osteoporosis, or osteoporosis) and whether women were prescribed osteoporosis drugs after initial DXA.', '8': 'Key results: Among women not treated after initial DXA, 2-year cumulative incidence for low-risk, high-risk, and osteoporotic women was 8.0%, 13.8%, and 19.6%, respectively, increasing to 42.9%, 60.4%, and 57.4% by 5 years after initial screening.', '9': 'For treated women, median time to repeat DXA was over 3 years for all groups.', '10': 'Relative to women with low-risk initial DXA, high-risk initial DXA significantly predicted repeat screening for untreated women [adjusted HR 1.67 (95% CI 1.40-2.00)] but not within the treated group [HR 1.09 (95% CI 0.91-1.30)].', '11': 'Conclusions: Repeat DXA screening was common in women both at low and high risk of progression to osteoporosis, with a substantial proportion of women receiving repeat scans within 2 years of initial screening.', '12': 'Conversely, only 60% of those at high-risk of progression to osteoporosis were re-screened within 5 years.', '13': 'Interventions are needed to help clinicians make higher-value decisions regarding repeat use of DXA scans.'}\n",
            "35: abstract: {'1': 'Importance: By 2020, approximately 12.3 million individuals in the United States older than 50 years are expected to have osteoporosis.', '2': 'Osteoporotic fractures, particularly hip fractures, are associated with limitations in ambulation, chronic pain and disability, loss of independence, and decreased quality of life, and 21% to 30% of patients who experience a hip fracture die within 1 year.', '3': 'The prevalence of primary osteoporosis (ie, osteoporosis without underlying disease) increases with age and differs by race/ethnicity.', '4': 'With the aging of the US population, the potential preventable burden is likely to increase in future years.', '5': 'Objective: To update the 2011 US Preventive Services Task Force (USPSTF) recommendation on screening for osteoporosis.', '6': 'Evidence review: The USPSTF reviewed the evidence on screening for and treatment of osteoporotic fractures in men and women, as well as risk assessment tools, screening intervals, and efficacy of screening and treatment in subgroups.', '7': 'The screening population was postmenopausal women and older men with no known previous osteoporotic fractures and no known comorbid conditions or medication use associated with secondary osteoporosis.', '8': 'Findings: The USPSTF found convincing evidence that bone measurement tests are accurate for detecting osteoporosis and predicting osteoporotic fractures in women and men.', '9': 'The USPSTF found adequate evidence that clinical risk assessment tools are moderately accurate in identifying risk of osteoporosis and osteoporotic fractures.', '10': 'The USPSTF found convincing evidence that drug therapies reduce subsequent fracture rates in postmenopausal women.', '11': 'The USPSTF found that the evidence is inadequate to assess the effectiveness of drug therapies in reducing subsequent fracture rates in men without previous fractures.', '12': 'Conclusions and recommendation: The USPSTF recommends screening for osteoporosis with bone measurement testing to prevent osteoporotic fractures in women 65 years and older.', '13': '(B recommendation) The USPSTF recommends screening for osteoporosis with bone measurement testing to prevent osteoporotic fractures in postmenopausal women younger than 65 years at increased risk of osteoporosis, as determined by a formal clinical risk assessment tool.', '14': '(B recommendation) The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of screening for osteoporosis to prevent osteoporotic fractures in men.', '15': '(I statement).'}\n",
            "36: abstract: {'1': 'Renal stones pose a significant burden on the health care system.', '2': 'The prevalence of renal stones has increased from 3.8% in 1970 to 8.8% in 2010 in the United States, with annual healthcare costs of USD 3.8 billion.', '3': 'It is estimated that more than half a million people a year visit the emergency room for kidney stone problems.', '4': 'The most common presenting symptoms include hematuria, pain in the flank, groin, or abdomen.', '5': 'There are many treatment modalities available for managing renal stones.', '6': 'They range from completely non-invasive outpatient procedures to invasive procedures requiring hospital admission and increased risks of complications.', '7': 'Extracorporeal shockwave lithotripsy (ESWL) is a truly non-invasive procedure as opposed to other surgical treatments used, such as retrograde intrarenal surgery (RIRS) and percutaneous nephrolithotomy (PCNL).', '8': 'The efficacy of ESWL lies in its ability to pulverize calculi in vivo into smaller segments, which are them expelled spontaneously by the boy.', '9': 'Shockwaves are generated and are then focused on a point within the body.', '10': 'The shockwaves propagate through the body with minimal dissipation of energy (and therefore damage) due to minimal difference in density of the soft tissues.', '11': 'At the stone fluid interface, a relatively significant difference in density, combined with a large concentration of multiple shockwaves in a small area, produces a significant dissipation of energy.', '12': 'Through the different mechanisms, this energy can overcome the tensile strength of the stone resulting in fragmentation.', '13': 'Repetition of this process leads to the pulverization of the stone into small fragments that the body then can pass painlessly and spontaneously.'}\n",
            "36: abstract: {'1': 'The landscape of managing ureteric stones has evolved over the last few decades and several treatment options exist depending on the stone size, location, and other patient and stone factors.', '2': 'While open surgery is now rarely performed, the use of medical expulsive therapy (MET) has been controversial and perhaps only recommended for large distal ureteric stones.', '3': 'The mainstay treatment balances between shockwave lithotripsy (SWL) and ureteroscopy (URS), with the latter usually recommended for larger stones.', '4': 'While the principles of ureteric stone management have remained largely unchanged, the modern era has generated new methods and means to deliver it.', '5': 'Advancements have occurred in all domains of endourology to try and refine treatment and balance it with cost, patient choice and quality of life.', '6': 'Dissemination of technologies and demonstration of their efficacy and safety will eventually result in new recommendations among international guidelines and evolution of new gold standards.'}\n",
            "36: abstract: {'1': 'The primary goals of medical expulsive therapy are to increase the rate of stone expulsion along the ureter to avoid ureteral obstruction and reduce ureteral colic and thus avoid the need for surgical and more invasive interventions.', '2': 'This review focussed on the findings from in vivo and in vitro animal and human studies that have investigated the pharmacological mechanisms controlling ureteral motility and their translation to current and potentially new clinically used drugs for increasing the rate of stone expulsion along the ureter.', '3': 'The complicated contractility profile of the ureter, which alters with age, tissue segment region, orientation and species contributes to the difficulty of interpreting studies on ureteral pharmacology, which translates to the complexity of discovering ideal drug targets for medical expulsive therapy.', '4': 'Nevertheless, the current drug classes clinically used for patients with stone lodgement include α1 -adrenoceptor antagonists, calcium channel blockers and NSAIDS, whilst there are promising targets for drug development that require further clinical investigations including the phosphodiesterase type 5 enzyme, β-adrenoceptors and 5-HT receptors.'}\n",
            "36: abstract: {'1': 'Background Percutaneous nephrolithotomy (PCNL) is the first choice treatment of renal stones larger than 2 cm.', '2': 'We aimed to evaluate if lasers perform as equal as non-laser devices in patients with kidney stones candidate to PCNL.', '3': 'Materials and methods A comprehensive literature search was performed in MEDLINE via PubMed, Scopus and Cochrane Central Register of Controlled Trials (CENTRAL) to assess the differences in the perioperative course, incidence of postoperative complications, and stone free-rate (SFR) in patients with kidney stones undergoing laser versus non-laser PCNL in randomized studies.', '4': 'The incidences of complications were pooled using the Cochran-Mantel-Haenszel Method with the random effect model and expressed as Risk Ratios (RR), 95% Confidence Intervals (CI), and p-values.', '5': 'Surgical time and length of stay were pooled using the inverse variance of the mean difference (MD) with a random effect, 95% CI, and p-values.', '6': 'Analyses were two-tailed, with a significance set at p ≤0.05.', '7': 'Results Six papers including 732 patients (311 patients undergoing holmium laser and 421 non-laser PCNL) were included in meta-analysis.', '8': 'Surgical time and postoperative stay were shorter in the non-laser group (MD:11.14, 95% CI:2.32-19.96, p=0.002; MD:-0.81, 95%CI:-2.18-0.57 p=0.25, respectively).', '9': 'SFR was significantly higher in the non-laser group (RR:1.08, 95% CI:1.01-1.15, p=0.03).', '10': 'Patients undergoing laser PCNL had a non-significant higher risk of postoperative fever >38°C (RR:0.64, 95%CI: .31-1.30, p=0.22).', '11': 'Transfusion rate did not differ between the two groups (RR:1.02, 95% CI:0.50-2.11 p=0.95).', '12': 'The need for stent positioning due to urine extravasation was higher risk in the laser group but the difference did not reach significance (RR:0.49, 95% CI:0.17-1.41 p=0.19).', '13': 'Conclusions Non-laser PCNL showed better perioperative outcomes and SFR as compared to holmium laser PCNL.'}\n",
            "36: abstract: {'1': 'Mini-Percutaneous Nephrolithotomy (M-PCNL) and Retrograde Intrarenal Surgery (RIRS) are commonly used methods in treatment of kidney stones.', '2': 'The aim of our study is to compare the efficacy and safety of M-PCNL and RIRS in kidney stone treatment over 50 years old patients.', '3': 'A total of 125 patients, 65 of whom had RIRS, and 60 of whom had M-PCNL, were included in the study.', '4': 'Age, gender, BMI (Body-Mass Index), ASA (American Society of Anesthesiology) scores of the patients; stone size, stone location, operation side, ESWL history, HU (Hounsfield Unit) values, hospital stay durations, SFR, complication rates according to Clavien modification system, postoperative hemoglobin loss, postoperative transfusion rates, and patients who needed a secondary operation were recorded.', '5': 'SFR values were calculated in the postoperative third and sixth months.', '6': 'The data between the two groups had similar characteristics in terms of age, gender, BMI, HU, stone size, operation side, stone location, ESWL history, operation time, postoperative transfusion rate, postoperative Clavien complications (p > 0.05).', '7': 'When the ASA categories were evaluated, the mean ASA scores, ASA I, and ASA II data had similar characteristics in both groups (p > 0.05).', '8': 'When the ASA 3 scores were evaluated, the number of ASA III patients in the RIRS group was statistically significantly higher (p < 0.05).', '9': 'When hospital stay duration and postoperative hemoglobin loss were examined, RIRS group was found to be advantageous (p < 0.05).', '10': 'Postoperative third month SFR and Postoperative sixth month values were statistically significantly higher in M-PCNL group (p < 0.05).', '11': 'M-PCNL and RIRS are methods that can be used safely and effectively over 50 years old patients in kidney stone surgery.', '12': 'M-PCNL has been found to be more advantageous in terms of SFR rates and as it requires less secondary intervention.', '13': 'RIRS is advantageous in terms of short hospital stay, postoperative hemoglobin loss, and applicability to patients who are not suitable for the prone position.'}\n",
            "36: abstract: {'1': 'Background: This study aimed to assess the efficacy and safety of minimally invasive percutaneous nephrolithotomy (MPCNL) versus standard percutaneous nephrolithotomy in patients with renal and upper ureteric stones.', '2': 'Methods: We conducted a pooled analysis on randomized controlled trials (RCTs).', '3': 'The eligible RCTs were selected from the following databases: MEDLINE, Embase, Web of Science, and the Cochrane Library.', '4': 'The reference lists of retrieved studies were also investigated.', '5': 'Results: Our analysis included 10 RCTs with 1612 patients.', '6': 'Pooled data from 10 RCTs revealed the following: stone-free rate (odds ratio = 1.46, 95% confidence interval (CI) [1.12,1.88], P = .004), operative time (mean difference [MD] = 4.10, 95% CI [-1.37,9.56], P = .14), length of hospital stay (MD = -15.31, 95% CI [-29.43,-1.19], P = .03), hemoglobin decrease (MD = -0.86, 95% CI [-1.19,-0.53], P < .00001), postoperative fever (MD = 0.83, 95% CI [0.49,1.40], P = .49), and urine leakage (MD = 0.59, 95% CI [0.25,1.37], P = .22).', '7': 'Besides, we performed sub-group analysis based on vacuum suction effect and multiple kidney stones.', '8': 'For vacuum suction effect, it revealed the following: stone-free rate in vacuum suction group (P = .007) and in non-vacuum suction group (P = .19).', '9': 'Operative time in vacuum suction group (P = .89), non-vacuum suction group (P = .16).', '10': 'Postoperative fever in vacuum suction group (P = .49), non-vacuum suction group (P = .85).', '11': 'Conclusion: This pooled analysis indicated that MPCNL was a safe and effective method for treating renal stones compared with standard percutaneous nephrolithotomy.', '12': 'Besides, the vacuum suction effect in MPCNL played a more important role.', '13': 'When it comes to multiple or staghorn stones, the longer operative time in MPCNL could not be ignored.'}\n",
            "36: abstract: {'1': 'The mini percutaneous nephrolithotomy (mini-PCNL) has become a versatile tool to remove kidney stones >2 cm, lower pole stones >1 cm, renal stones previously unresponsive to shockwave therapy or inaccessible by ureteroscopy (within a caliceal diverticulum), stones within complex urinary tracts (urinary diversions, transplanted kidney, and horseshoe kidneys), and large impacted proximal ureteral stones.', '2': 'After positioning in either the supine or prone position, a cystoscopy is performed to place an open-ended catheter, occlusion balloon, or Accordian device into the collecting system.', '3': 'A foley catheter is placed in the bladder.', '4': 'An ultrasound with a curvilinear probe is used to survey the kidney and guide access into the collecting system with an 18 g percutaneous needle.', '5': 'Once access is obtained, a small 0.5 cm skin incision is made and the percutaneous tract is dilated over a wire.', '6': 'A 16.5F metallic or self-dilating suctioning access sheath is positioned with fluoroscopic guidance.', '7': 'A 12F rigid mini-PCNL nephroscope is used to evaluate the collecting system.', '8': 'Once a calculus is observed, options for stone fragmentation include a lithotripter with ultrasonic and ballistic energy, or laser lithotripsy using holmium or thulium laser fibers.', '9': 'Flexible ureteroscopy can be considered to ensure clearance of the collecting system.', '10': 'A 6F ureteral stent can be placed in either a retrograde or antegrade approach for drainage.', '11': 'The tract is sealed using Surgiflo hemostatic matrix with thrombin.', '12': 'Guidelines for postoperative care and troubleshooting techniques for mini-PCNL are reviewed along with the surgical steps in the accompanying video (Supplementary Video S1).', '13': 'There are few randomized trials comparing mini-PCNL with standard PCNL and ureteroscopy.', '14': 'There is some evidence to suggest a difference in transfusion rates comparing mini- and standard PCNL, as well as differences in stone-free rates when comparing mini-PCNL with ureteroscopy for the treatment of lower pole stones.'}\n",
            "36: abstract: {'1': 'Introduction: Although spinal anesthesia (SA) may reduce postoperative morbidity, most urologists perform flexible ureterorenoscopy (fURS) under general anesthesia (GA).', '2': \"The objective of our study is to provide technical details, results, complications, and patients' satisfaction with fURS performed under exclusive SA.\", '3': 'Methods: We analyzed all consecutive fURS performed under SA to treat renal stones from March 2011 to February 2017.', '4': \"Details of technique, operative time, outcomes, need for further treatments, complications, and patients' satisfaction were evaluated.\", '5': 'Results: Two hundred thirty-four fURS under SA were considered.', '6': 'SA was performed through L2-L3 vertebral interspace in 64.1%.', '7': 'Patients were discharged the same day of surgery.', '8': 'Mean stone burden was 13.5 ± 6.6 mm and mean operative time 76.9 ± 34.6 min.', '9': 'Single-procedure SFR was 69.7%.', '10': 'Further treatments were performed in 22.8%. 96.6% had no anesthesia-related complications.', '11': 'No Clavien-Dindo grade ≥ IIIb complications were noticed.', '12': '99.6% of patients were satisfied with SA.', '13': 'No cases of conversion from SA to GA occurred.', '14': 'Conclusion: fURS can be performed safely and efficiently under SA, taking into account a few details of the technique.', '15': \"Patients' satisfaction with SA is very high, and complications are rare.\", '16': 'Although SA is usually adopted in unfit patients for GA, it may be considered as a viable alternative in fit patients.'}\n",
            "36: abstract: {'1': 'Introduction: We determine the effect of patient characteristics (age, sex, and body mass index BMI) and stone characteristics (density, location, and size) by non-contrast computed tomography of the kidneys, ureters, and bladder (CT-KUB) in predicting the success of extracorporeal shock wave lithotripsy (ESWL) in the treatment of kidney and ureteric stones.', '2': 'We present this study to further enrich the knowledge of physicians towards the effect of different patient characteristics upon predicting extra-corporal shock wave lithotripsy success rates.', '3': 'Methods: We evaluated 155 patients who received ESWL for renal and ureteric stone measuring 3-20 mm (mm), over a 3-month period.', '4': 'The stone size in millimeters, density in Hounsfield units (HU) and its location was determined on pre-treatment CT-KUB.', '5': 'ESWL was successful if post-treatment residual renal stone fragments were ≤3 mm and for ureteric stones should be totally cleared.', '6': 'Results: The overall success of ESWL treatment was observed in 65.8% of the 155 patients.', '7': 'There was no significant difference seen when the effect of patients age, sex and BMI were studied with ESWL outcome with P values were 0.155, 0.101 and 0.415 respectively.', '8': 'Also, stone location either in the kidney or ureter has no statistically significant effect on ESWL response rate.', '9': 'while stone density and size determined on CT KUB have statistically significant effect on the success rate of ESWL with a P-value of 0.002 and 0.000 respectively.', '10': 'Conclusions: This study shows that determination of stone density and stone size on CT KUB pre ESWL can help to predict the outcome of ESWL.', '11': 'We propose that stone density <500 HU and stone size < 5 mm are highly likely to result in successful ESWL.'}\n",
            "36: abstract: {'1': 'The introduction of technologically advanced methods of lithotripsy into medical practice changes the nature of postoperative complications.', '2': 'Among them, the main complications are inflammatory infections.', '3': 'This largely determines the search for new, improved methods of stone fragmentation avoiding small stone fragments and dissemination of the pelvicalyceal system of the kidney with stone-associated infection.', '4': 'The authors have developed a method for controlled stone fragmentation using a continuous-wave diode laser with a hot-spot effect at the optical fiber end.', '5': 'The aim of the study was to evaluate the efficacy of controlled urinary stone fragmentation using a continuous-wave diode laser with a highly heated distal end of the optical fiber light guide as a method of preventing inflammatory infections in clinical practice.', '6': 'Materials and methods: We analyzed 1666 case histories of urolithiasis patients who underwent percutaneous nephrolithotripsy/ nephrolithoextraction and contact ureterolithotripsy/ureteroextraction, we also performed a prospective analysis of complications based on the Clavien-Dindo classification in 90 patients who underwent fine fragmentation of stones with various lithotripters: ultrasonic, pneumatic, and holmium laser.', '7': 'The method of controlled stone fragmentation by a diode laser with a hot-spot effect was tested on postoperative samples of 26 renal calculi.', '8': 'For the first time in clinical practice, this method was tested in the bladder cavity (n=10).', '9': 'Results: In the percutaneous nephrolithotripsy group, postoperative infectious and inflammatory complications occurred in 34.1% of cases, in the percutaneous nephrolithoextraction group - in 24.6%, in the contact ureterolithotripsy group - in 7.8%, in the ureterolithoextraction group - in 2.5%.', '10': 'The analysis made it possible to identify factors promoting the development of infectious and inflammatory complications.', '11': 'For the first time in clinical practice, there were successfully performed ten operations of stone fragmentation using a continuous-wave diode laser with a hot-spot effect.', '12': 'Controlled coarse fragmentation of stones providing the possibility to reduce the number of infectious and inflammatory complications was performed in the bladder as a model for testing the method.', '13': 'Conclusion: The method of laser-induced controlled coarse fragmentation of stones with a hot-spot effect, developed and tested in clinical practice, is promising for the prevention of infectious and inflammatory complications in patients with potentially infected stones since their fine fragmentation and, consequently, spread of stone-associated toxins and microflora within the urinary system is avoided.'}\n",
            "37: abstract: {'1': 'Background: Antiepileptic drugs (AEDs) can be associated with neurotoxic side effects including cognitive dysfunction, a problem of considerable importance given the usual long-term course of treatment.', '2': 'Pregabalin is a relatively new AED widely used for the treatment of seizures and some types of chronic pain including fibromyalgia.', '3': 'We measured the cognitive effects of 12 weeks of pregabalin in healthy volunteers.', '4': 'Methods: Thirty-two healthy volunteers were randomized in a double-blind parallel study to receive pregabalin or placebo (1:1).', '5': 'Pregabalin was titrated over 8 weeks to 600 mg/d.', '6': 'At baseline, and after 12 weeks of treatment, all subjects underwent cognitive testing.', '7': 'Test-retest changes in all cognitive and subjective measures were Z scored against test-retest regressions previously developed from 90 healthy volunteers.', '8': 'Z scores from the placebo and pregabalin groups were compared using Wilcoxon tests.', '9': 'Results: Thirty subjects completed the study (94%).', '10': 'Three of 6 target cognitive measures (Digit Symbol, Stroop, Controlled Oral Word Association) revealed significant test-retest differences between the pregabalin and placebo groups, all showing negative effects with pregabalin (p < 0.05).', '11': 'These cognitive effects were paralleled by complaints on the Portland Neurotoxicity Scale, a subjective measure of neurotoxicity (p < 0.01).', '12': 'Conclusion: At conventional doses and titration, pregabalin induced mild negative cognitive effects and neurotoxicity complaints in healthy volunteers.', '13': 'These effects are one factor to be considered in the selection and monitoring of chronic AED therapy.', '14': 'Class of Evidence: This study provides Class I evidence that pregabalin 300 mg BID negatively impacts cognition on some tasks in healthy volunteers.'}\n",
            "37: abstract: {'1': 'Objective: Long-term benzodiazepine (BDZ) use and dependence affect cognitive functioning adversely and partly irreversibly.', '2': 'Emerging evidence suggests that pregabalin (PGB) might be a safe and efficacious treatment of long-term BDZ use.', '3': 'The aim of the present study was to investigate the changes in several core cognitive functions after successful treatment of long-term BDZ use and dependence with PGB.', '4': 'Methods: Fourteen patients with long-term BDZ use (mean duration >15 years) underwent neuropsychological assessment with the mini-mental state examination and four tests from the Cambridge Neuropsychological Test Automated Battery (CANTAB) battery before the initiation of PGB treatment and at a two months follow-up after the cessation of BDZs.', '5': \"Patients' CANTAB percentile score distributions were compared with normative CANTAB data.\", '6': 'Results: Patients improved on cognitive measures of global cognitive functioning, time orientation, psychomotor speed, and visuospatial memory and learning with strong effect sizes.', '7': 'By contrast, they failed to improve on measures of attentional flexibility.', '8': \"Despite their significant improvement, patients' scores on most tests remained still at the lower percentiles of CANTAB normative scores.\", '9': 'Conclusions: Although preliminary, our findings suggest that successful treatment of long-term BDZ use with PGB is associated with a substantial, though only partial, recovery of BDZ-compromised neuropsychological functioning, at least at a 2-month follow-up.'}\n",
            "37: abstract: {'1': 'A 74-year-old man with peripheral neuropathy due to diabetes presented with deliberate ingestion of 450 mg of pregabalin (PBG) over a period of 8 hours followed by altered mental status.', '2': 'A bedside electroencephalogram was performed to rule out nonconvulsive status epilepticus, which showed continuous triphasic waves (TWs) with slow background activity.', '3': 'He recovered after 48 hours of stopping PBG, and his repeat electroencephalogram after 72 hours did not show any TWs.', '4': 'We present a rare case of PBG-induced TWs thereby highlighting the extent of the etiologic spectrum of TWs and discussing the literature related to this association.'}\n",
            "37: abstract: {'1': 'Aim: Randomized Phase I study examining the effects of gabapentinoids gabapentin, pregabalin and gastroretentive gabapentin on simulated driving performance, sedation and cognitive function in healthy volunteers (n = 32).', '2': 'Methods: Driving attentiveness, sleepiness and cognition were evaluated prior to subjects receiving study doses.', '3': 'Blood samples were collected during each treatment.', '4': 'Results: Subjects receiving gastroretentive gabapentin showed less change in variation in lateral lane position (p = 0.0275), less tremor (p = 0.0304) and fewer vision disturbances compared with gabapentin (p = 0.0177).', '5': 'Statistically significant decrease in One Card Learning Test performance was observed after treatment with gastroretentive gabapentin.', '6': 'Conclusion: Gastroretentive gabapentin demonstrated reduced driving impairment and lower scores on key neurotoxicity measures.', '7': 'Further studies in patients with postherpetic neuralgia are needed.'}\n",
            "37: abstract: {'1': 'We aimed to investigate the terms used to refer to cognitive and fatigue related side effects and their prevalence in phase III add-on clinical trials of anti-epileptic drugs (AEDs).', '2': 'We extracted data from publicly available FDA documents as well as the published literature.', '3': 'Target drug doses were then calculated as drug loads and divided into three categories (low, average, high).', '4': 'The odds ratio of developing the side effects was calculated for each drug load, and the presence of a dose-response effect was also assessed.', '5': 'We found that the cognitive terms used across trials were very variable, and data on discontinuation rates were limited.', '6': 'Placebo rates for cognitive side effects ranged from 0 to 10.6% while those for fatigue ranged from 2.5 to 37.7%.', '7': 'Keeping in mind the variable placebo rates and terminology, the majority of AEDs exhibited a clear dose response effect and significant odds ratios at high doses except brivaracetam and zonisamide for the cognitive side effects and tiagabine, topiramate, and zonisamide for the fatigue side effects.', '8': 'Due to their clinical relevance and impact on quality of life, new trials should make data related to the prevalence and discontinuation rates of these side effects publicly available.', '9': 'Given the clear dose response effect, physicians should consider aiming for lower drug loads and adjusting doses to improve tolerability.'}\n",
            "37: abstract: {'1': 'Background: Pregabalin has shown opioid sparing and analgesic effects in the early postoperative period; however, perioperative effects on cognition have not been studied.', '2': 'A randomized, parallel group, placebo-controlled investigation in 80 donor nephrectomy patients was previously performed that evaluated the analgesic, opioid-sparing, and antihyperalgesic effects of pregabalin.', '3': 'This article describes a secondary exploratory analysis that tested the hypothesis that pregabalin would impair cognitive function compared to placebo.', '4': 'Methods: Eighty patients scheduled for donor nephrectomy participated in this randomized, placebo-controlled study.', '5': 'Pregabalin (150 mg twice daily, n = 40) or placebo (n = 40) was administered on the day of surgery and the first postoperative day, in addition to a pain regimen consisting of opioids, steroids, local anesthetics, and acetaminophen.', '6': 'Specific cognitive tests measuring inhibition, sustained attention, psychomotor speed, visual memory, and strategy were performed at baseline, 24 h, and 3 to 5 days after surgery, using tests from the Cambridge Neuropsychological Test Automated Battery.', '7': 'Results: In the spatial working memory within errors test, the number of errors increased with pregabalin compared to placebo 24 h after surgery; median (25th, 75th percentile) values were 1 (0, 6) versus 0 (0, 1; rate ratio [95% CI], 3.20 [1.55 to 6.62]; P = 0.002).', '8': 'Furthermore, pregabalin significantly increased the number of errors in the stop-signal task stop-go test compared with placebo; median (25th, 75th percentile) values were 3 (1, 6) versus 1 (0, 2; rate ratio, 2.14 [1.13 to 4.07]; P = 0.020).', '9': 'There were no significant differences between groups in the paired associated learning, reaction time, rapid visual processing, or spatial working memory strategy tests.', '10': 'Conclusions: Perioperative pregabalin significantly negatively affected subdomains of executive functioning, including inhibition, and working memory compared to placebo, whereas psychomotor speed was not changed.'}\n",
            "37: abstract: {'1': 'Pregabalin abuse has become an emerging concern; thus, the current study has been designed to study the neurotoxic hazards of prolonged high-dose of pregabalin (akin to that abused by addicts) and to evaluate the effect of alpha tocopherol as a possible ameliorating agent.', '2': 'The current study evaluated the brain neurotransmitters; dopamine, glutamate, and norepinephrine.', '3': 'The study also assessed the expression of the apoptosis-related markers Bax, Bcl2, and caspase 3.', '4': 'Western-blotted analysis of the three major mitogen-activated protein kinases (MAPKs), the c-JUN N-terminal kinase (JNK), the p38 MAPK, and the extracellular signal-regulated kinase (ERK), has also been performed.', '5': 'The study also evaluated oxidative stress via assessment of the cortical tissue levels of reduced glutathione and malondialdehyde and the activity of superoxide dismutase.', '6': 'Histopathological examination and histomorphometric evaluation of the darkly degenerated cortical neurons have also been performed.', '7': 'Pregabalin in high doses (150 mg/kg/day and 300 mg/kg/day) disrupted the ERK/JNK/p38-MAPK signaling, reversed the bax/bcl2 ratio, and induced oxidative stress.', '8': 'It also diminished the release of dopamine, glutamate, and norepinephrine and increased the count of degenerated neurons.', '9': 'Alpha tocopherol treatment significantly attenuated the deleterious effects induced by pregabalin.', '10': 'The role of alpha tocopherol in ameliorating the oxidative stress injury, and apoptosis induced by pregabalin, along with its role in normalizing neurotransmitters, modulating the ERK/JNK/p38-MAPK signaling pathways and improving the histopathological cortical changes, offers alpha tocopherol as a promising adjunctive therapy in patients undergoing prolonged pregabalin therapy as those suffering from prolonged seizures and neuropathies.'}\n",
            "37: abstract: {'1': 'Herpes zoster is an acute, painful, herpes skin disease caused by varicella-zoster virus, which may cause viral meningitis.', '2': 'Pregabalin has been shown to be efficacious in the treatment of pain in patients with herpes zoster.', '3': 'However, it has the side effects of neurotoxicity.', '4': 'We describe a 68-year-old female patient with herpes zoster, and she was treated with pregabalin.', '5': 'The patient presented with stuttering and frequent blepharospasm after 3 days of pregabalin treatment.', '6': 'Pregabalin was discontinued, the symptoms of stuttering and frequent blepharospasm completely resolved without any special treatment after one week.', '7': 'In this case, the etiology of stuttering and frequent blepharospasm may be related to pregabalin.', '8': 'Clinicians should be alert to the rare symptoms associated with the use of pregabalin.'}\n",
            "37: abstract: {'1': 'Central nervous system adverse effects are commonly reported with pregabalin (PGB).', '2': 'On the other hand, movement disorders (MDs) associated with this drug were rarely described.', '3': 'However, their occurrence could significantly affect the quality of life of PGB users.', '4': 'This literature review aims to evaluate the clinical epidemiological profile, pathological mechanisms, and management of PGB-associated MDs.', '5': 'Relevant reports in six databases were identified and assessed by two reviewers without language restriction.', '6': 'A total of 46 reports containing 305 cases from 17 countries were assessed.', '7': 'The MDs encountered were as follows: 184 individuals with ataxia, 61 with tremors, 39 with myoclonus, 8 with parkinsonism, 1 with restless legs syndrome, 1 with dystonia, 1 with dyskinesia, and 1 with akathisia.', '8': 'The mean age was 62 years (range: 23-94).', '9': 'The male sex was slightly predominant with 54.34%.', '10': 'The mean PGB dose when the MD occurred was 238 mg, and neuropathic pain was the most common indication of PGB.', '11': 'The time from PGB start to MD was < 1 month at 75%.', '12': 'The time from PGB withdrawal to recovery was < 1 week at 77%.', '13': 'All the individuals where the follow-up was reported had a full recovery.', '14': 'The most common management was PGB withdrawal.', '15': 'In the literature, the majority of the cases did not report information about timeline events, neurological examination details, or electrodiagnostic studies.', '16': 'The best management for all MDs is probably PGB withdrawal.', '17': 'If the patient is on dialysis program, perhaps an increased number of sessions will decrease recovery time.', '18': 'Furthermore, the addition of a benzodiazepine could accelerate recovery.'}\n",
            "37: abstract: {'1': 'Pregabalin (PGB) is an analog of the inhibitory neurotransmitter gamma-aminobutyric acid.', '2': 'The currently available evidence favors the misuse and abuse potential of PGB.', '3': 'However, its neurotoxicity remains unclear.', '4': 'Therefore, this study assessed the toxic effects of chronic pregabalin dependence as well as withdrawal on the cortical neurons of the frontal lobe.', '5': 'This study included eighty adult male albino rats which were divided into three groups.', '6': 'Group I (Control) included 40 rats and was further subdivided into two equal subgroups (IA and IB) as negative and positive controls.', '7': 'Group II (PGB-dependent) included 20 rats which received PGB starting with the therapeutic dose (300 mg/day), then the doses were gradually increased until they reached the dependent dose (3400 mg/day) by the end of the first month.', '8': 'Further, the dependent dose was given daily for another 2 months.', '9': 'Group III (PGB withdrawal) included 20 rats which received PGB as described in group II.', '10': 'After that, administration of PGB was stopped and the rats were kept for another one month.', '11': 'By the end of the experiment, all animals were sacrificed by cervical decapitation.', '12': 'The specimens were taken from the frontal cortex for histologic and immunohistochemical staining as well as morphometric analysis.', '13': 'Sections of the frontal cortex of group II showed changes in the form of disturbed architectural pattern of cortical layers, apoptotic cells, weak immunoexpression of Bcl-2 and VEGF as well as moderate-strong immunoexpression of iNOS and nestin.', '14': 'These expressions were significantly different from the control groups, but they were non-significant in comparison with group III.', '15': 'These findings indicate that chronic PGB dependence induces neurotoxic effects mainly in the form of neuronal apoptosis, gliosis, and oxidative stress injury of the frontal cortex.', '16': 'The PGB- induced neurotoxic effects persisted after withdrawal.', '17': 'The influence of these neurotoxic effects and their relevance to the cognitive or neurologic disorders in PGB-dependent individuals warrants further research.', '18': 'Furthermore, it is recommended to quantify the behavioral changes related to PGB dependence as well as withdrawal in future studies.'}\n",
            "38: abstract: {'1': 'Pressure ulcers are a common and serious problem predominately among elderly persons who are confined to bed or chair.', '2': 'Additional factors associated with pressure ulcer development include cerebrovascular accident, impaired nutritional intake, urinary or fecal incontinence, hypoalbuminemia, and previous fracture.', '3': 'Implementation of preventive measures, such as an in-depth assessment for mobility, a pressure-relieving device combined with adequate repositioning, and thorough evaluation for nutritional status and urinary incontinence, significantly reduce pressure ulcer incidence.', '4': 'If the pressure ulcer is a partial thickness (stage II) wound, the causative factors are probably friction or moisture.', '5': 'If the ulcer is full thickness (stage III and IV), it is secondary to pressure or shearing forces.', '6': 'The development of wound infection is the most common complication in the management approach.', '7': 'Osteomyelitis is not an uncommon occurrence and must be initially ruled out in all full thickness pressure ulcers.', '8': 'Surgical debridement of necrotic tissue is necessary prior to further treatment and assessments.', '9': 'Antibiotic therapy is indicated only upon evidence of infection (cellulitis, osteomyelitis, leukocytosis, bandemia, or fever).', '10': 'Topical pharmacologic agents may be used to prevent or treat infection but must be carefully controlled to avoid such adverse effects as toxicity to the wound, allergic reaction, and development of resistant pathogens.', '11': 'Proper use of occlusive dressings increase patient comfort, enhance healing, decrease the possibility of infection, save time, and reduce costs.', '12': 'A patient presenting an ulcer that fails to improve or, because of its size, will take a great deal of time to heal should be evaluated for surgical closure.'}\n",
            "38: abstract: {'1': 'The use of wound dressings that are based on the principles of moist wound healing has recently changed the management of pressure ulcers.', '2': 'These products may improve healing rates but also offer improved comfort to the patient, reduced dressing time and improved cosmesis.', '3': 'However, healing is unlikely to be achieved unless the factors that contribute to ulcer formation are addressed.', '4': 'Principles of management include the elimination or reduction of pressure and other contributing factors, treatment of infection, appropriate wound management, involvement and education of the patient and caregivers, and maintenance of healed tissue.', '5': 'It is estimated that 95 percent of all pressure ulcers are preventable.', '6': 'Prevention rather than mere treatment of established ulcers remains a top priority in the effort to reduce the incidence of this common, complex and difficult problem.', '7': 'Use of assessment tools that quantify the primary risk factors for the development of pressure ulcers is helpful in predicting and preventing compromise of tissue.'}\n",
            "38: abstract: {'1': 'Pressure ulcers represent complex wounds that are difficult to prevent or manage.', '2': 'Guidelines for prevention include identifying patients at risk, reducing the effect of pressure, friction, shear forces, and assessing co-morbidities such as nutritional status.', '3': 'Management should follow eight treatment strategies including accurately assessing the ulcer, relieving pressure, assessing pain and nutritional status, maintaining a moist wound environment, encouraging granulation and epithelial tissue formation, evaluating the need for debridement, and controlling infection.'}\n",
            "38: abstract: {'1': 'A pressure ulcer is a localized injury to the skin or underlying tissue, usually over a bony prominence, as a result of unrelieved pressure.', '2': 'Predisposing factors are classified as intrinsic (e.g., limited mobility, poor nutrition, comorbidities, aging skin) or extrinsic (e.g., pressure, friction, shear, moisture).', '3': 'Prevention includes identifying at-risk persons and implementing specific prevention measures, such as following a patient repositioning schedule; keeping the head of the bed at the lowest safe elevation to prevent shear; using pressure-reducing surfaces; and assessing nutrition and providing supplementation, if needed.', '4': 'When an ulcer occurs, documentation of each ulcer (i.e., size, location, eschar and granulation tissue, exudate, odor, sinus tracts, undermining, and infection) and appropriate staging (I through IV) are essential to the wound assessment.', '5': 'Treatment involves management of local and distant infections, removal of necrotic tissue, maintenance of a moist environment for wound healing, and possibly surgery.', '6': 'Debridement is indicated when necrotic tissue is present.', '7': 'Urgent sharp debridement should be performed if advancing cellulitis or sepsis occurs.', '8': 'Mechanical, enzymatic, and autolytic debridement methods are nonurgent treatments.', '9': 'Wound cleansing, preferably with normal saline and appropriate dressings, is a mainstay of treatment for clean ulcers and after debridement.', '10': 'Bacterial load can be managed with cleansing.', '11': 'Topical antibiotics should be considered if there is no improvement in healing after 14 days.', '12': 'Systemic antibiotics are used in patients with advancing cellulitis, osteomyelitis, or systemic infection.'}\n",
            "38: abstract: {'1': 'Background: Pressure ulcers, also known as bed sores, pressure sores or decubitus ulcers develop as a result of a localised injury to the skin or underlying tissue, or both.', '2': 'The ulcers usually arise over a bony prominence, and are recognised as a common medical problem affecting people confined to a bed or wheelchair for long periods of time.', '3': 'Anabolic steroids are used as off-label drugs (drugs which are used without regulatory approval) and have been used as adjuvants to usual treatment with dressings, debridement, nutritional supplements, systemic antibiotics and antiseptics, which are considered to be supportive in healing of pressure ulcers.', '4': 'Anabolic steroids are considered because of their ability to stimulate protein synthesis and build muscle mass.', '5': 'Comprehensive evidence is required to facilitate decision making, regarding the benefits and harms of using anabolic steroids.', '6': 'Objectives: To assess the effects of anabolic steroids for treating pressure ulcers.', '7': 'Main results: The review contains only one trial with a total of 212 participants, all with spinal cord injury and open pressure ulcers classed as stage III and IV.', '8': 'The participants were mainly male (98.2%, 106/108) with a mean age of 58.4 (standard deviation 10.4) years in the oxandrolone group and were all male (100%, 104/104) with a mean age of 57.3 (standard deviation 11.6) years in the placebo group.', '9': 'This trial compared oxandrolone (20 mg/day, administered orally) with a dose of placebo (an inactive substance consisting of 98% starch and 2% magnesium stearate) and reported data on complete healing of ulcers and adverse events.', '10': 'There was very low-certainty evidence on the relative effect of oxandrolone on complete ulcer healing at the end of a 24-week treatment period (risk ratio RR) 0.81, 95% confidence interval (CI) 0.52 to 1.26) (downgraded twice for imprecision due to an extremely wide 95% CI, which spanned both benefit and harm, and once for indirectness, as the participants were mostly male spinal cord injury patients).', '11': 'Thus, we are uncertain whether oxandrolone improves or reduces the complete healing of pressure ulcers, as we assessed the certainty of the evidence as very low.', '12': 'There was low-certainty evidence on the risk of non-serious adverse events reported in participants treated with oxandrolone compared with placebo (RR 3.85, 95% CI 1.12 to 13.26) (downgraded once for imprecision and once for indirectness, as the participants were mostly male spinal cord injury patients).', '13': 'Thus, the treatment with oxandrolone may increase the risk of non-serious adverse events reported in participants.', '14': 'There was very low-certainty evidence on the risk of serious adverse events reported in participants treated with oxandrolone compared with placebo (RR 0.54, 95% CI 0.25 to 1.17) (downgraded twice for imprecision due to an extremely wide 95% CI, which spanned both benefit and harm, and once for indirectness, as the participants were mostly male spinal cord injury patients).', '15': 'Of the five serious adverse events reported in the oxandrolone-treated group, none were classed by the trial teams as being related to treatment.', '16': 'We are uncertain whether oxandrolone increases or decreases the risk of serious adverse events as we assessed the certainty of the evidence as very low.', '17': 'Secondary outcomes such as pain, length of hospital stay, change in wound size or wound surface area, incidence of different type of infection, cost of treatment and quality of life were not reported in the included trial.', '18': 'Overall the evidence in this study was of very low quality (downgraded for imprecision and indirectness).', '19': 'This trial stopped early when the futility analysis (interim analysis) in the opinion of the study authors showed that oxandrolone had no benefit over placebo for improving ulcer healing.', '20': \"Authors' conclusions: There is no high quality evidence to support the use of anabolic steroids in treating pressure ulcers.\", '21': 'Further well-designed, multicenter trials, at low risk of bias, are necessary to assess the effect of anabolic steroids on treating pressure ulcers, but careful consideration of the current trial and its early termination are required when planning future research.'}\n",
            "38: abstract: {'1': 'Background: Pressure ulcers, also known as pressure injuries and bed sores, are localised areas of injury to the skin or underlying tissues, or both.', '2': 'Dressings made from a variety of materials, including foam, are used to treat pressure ulcers.', '3': 'An evidence-based overview of dressings for pressure ulcers is needed to enable informed decision-making on dressing use.', '4': 'This review is part of a suite of Cochrane Reviews investigating the use of dressings in the treatment of pressure ulcers.', '5': 'Each review will focus on a particular dressing type.', '6': 'Objectives: To assess the clinical and cost effectiveness of foam wound dressings for healing pressure ulcers in people with an existing pressure ulcer in any care setting.', '7': 'Main results: We included nine trials with a total of 483 participants, all of whom were adults (59 years or older) with an existing pressure ulcer Category/Stage II or above.', '8': 'All trials had two arms, which compared foam dressings with other dressings for treating pressure ulcers.', '9': 'The certainty of evidence ranged from low to very low due to various combinations of selection, performance, attrition, detection and reporting bias, and imprecision due to small sample sizes and wide confidence intervals.', '10': 'We had very little confidence in the estimate of effect of included studies.', '11': \"Where a foam dressing was compared with another foam dressing, we established that the true effect was likely to be substantially less than the study's estimated effect.\", '12': 'We present data for four comparisons.', '13': 'One trial compared a silicone foam dressing with another (hydropolymer) foam dressing (38 participants), with an eight-week (short-term) follow-up.', '14': 'It was uncertain whether alternate types of foam dressing affected the incidence of healed pressure ulcers (RR 0.89, 95% CI 0.45 to 1.75) or adverse events (RR 0.37, 95% CI 0.04 to 3.25), as the certainty of evidence was very low, downgraded for serious limitations in study design and very serious imprecision.', '15': 'Four trials with a median sample size of 20 participants (230 participants), compared foam dressings with hydrocolloid dressings for eight weeks or less (short-term).', '16': 'It was uncertain whether foam dressings affected the probability of healing in comparison to hydrocolloid dressings over a short follow-up period in three trials (RR 0.85, 95% CI 0.54 to 1.34), very low-certainty evidence, downgraded for very serious study limitations and serious imprecision.', '17': 'It was uncertain if there was a difference in risk of adverse events between groups (RR 0.88, 95% CI 0.37 to 2.11), very low-certainty evidence, downgraded for serious study limitations and very serious imprecision.', '18': 'Reduction in ulcer size, patient satisfaction/acceptability, pain and cost effectiveness data were also reported but we assessed the evidence as being of very low certainty.', '19': 'One trial (34 participants), compared foam and hydrogel dressings over an eight-week (short-term) follow-up.', '20': 'It was uncertain if the foam dressing affected the probability of healing (RR 1.00, 95% CI 0.78 to 1.28), time to complete healing (MD 5.67 days 95% CI -4.03 to 15.37), adverse events (RR 0.33, 95% CI 0.01 to 7.65) or reduction in ulcer size (MD 0.30 cm2 per day, 95% CI -0.15 to 0.75), as the certainty of the evidence was very low, downgraded for serious study limitations and very serious imprecision.', '21': 'The remaining three trials (181 participants) compared foam with basic wound contact dressings.', '22': 'Follow-up times ranged from short-term (8 weeks or less) to medium-term (8 to 24 weeks).', '23': 'It was uncertain whether foam dressings affected the probability of healing compared with basic wound contact dressings, in the short term (RR 1.33, 95% CI 0.62 to 2.88) or medium term (RR 1.17, 95% CI 0.79 to 1.72), or affected time to complete healing in the medium term (MD -35.80 days, 95% CI -56.77 to -14.83), or adverse events in the medium term (RR 0.58, 95% CI 0.33 to 1.05).', '24': 'This was due to the very low-certainty evidence, downgraded for serious to very serious study limitations and imprecision.', '25': 'Reduction in ulcer size, patient satisfaction/acceptability, pain and cost effectiveness data were also reported but again, we assessed the evidence as being of very low certainty.', '26': 'None of the included trials reported quality of life or pressure ulcer recurrence.', '27': \"Authors' conclusions: It is uncertain whether foam dressings are more clinically effective, more acceptable to users, or more cost effective compared to alternative dressings in treating pressure ulcers.\", '28': 'It was difficult to make accurate comparisons between foam dressings and other dressings due to the lack of data on reduction of wound size, complete wound healing, treatment costs, or insufficient time-frames.', '29': 'Quality of life and patient (or carer) acceptability/satisfaction associated with foam dressings were not systematically measured in any of the included studies.', '30': 'We assessed the certainty of the evidence in the included trials as low to very low.', '31': 'Clinicians need to carefully consider the lack of robust evidence in relation to the clinical and cost-effectiveness of foam dressings for treating pressure ulcers when making treatment decisions, particularly when considering the wound management properties that may be offered by each dressing type and the care context.'}\n",
            "38: abstract: {'1': 'Wound pressure injuries have been given various names over the last several years.', '2': 'In the past, they were referred to as pressure ulcers, decubitus ulcers, or bed sores; and now they are most commonly termed \"pressure injuries.\"', '3': 'Pressure injuries are defined as the breakdown of skin integrity due to some types of unrelieved pressure.', '4': 'This can be from a bony area on the body coming into contact with an external surface which leads to pressure injury.', '5': 'These wounds represent the destruction of normal structure and function of the skin and soft tissue through a variety of mechanisms and etiologies.', '6': 'The wound healing process is affected by various factors including infection, the presence of chronic diseases like diabetes, aging, nutritional deficiency like vitamin C, medications like steroids, and low perfusion of oxygen and blood flow to the wound in cases of hypoxia and cold temperature.', '7': 'Pressure ulcers result from long periods of repeated pressure applied to the skin, soft tissue, muscle, and bone.', '8': 'In pressure ulcers, the external pressure exceeds capillary closing pressure.'}\n",
            "38: abstract: {'1': 'Background: The biodegradable and biocompatible nature of pectin-based films is of particular interest in wound dressing applications, due to its non-toxicity, pH-sensitivity and gelling activity.', '2': 'An approach to improve the mechanical properties, the release profile of bioactive compounds as well as the performance in wet environments of pectin-based films is mixing with other biopolymers.', '3': 'Objective: To prepare hydrocolloid films based on crosslinked pectin / starch blend loaded with bioactive extracts from leaves of G. tinctoria and U. molinae with controlled release of bioactive compounds and healing property.', '4': 'Methods: The hydrocolloid films were characterized by FTIR, SEM, and TGA-FTIR techniques and their tensile properties, water uptake, and polyphenolic release profile in aqueous media were evaluated.', '5': 'The dermal anti inflammatory activity of the hydrocolloid films was assessed by the mouse ear inflammation test.', '6': 'The wound healing property of the loaded hydrocolloid films was explored in a rat model and in a clinical trial (sacrum pressure ulcer).', '7': 'Results: The films showed an adequate water-uptake capacity between 100-160%.', '8': 'The release of active compounds from the hydrocolloid films followed the Korsmeyer-Peppas equation.', '9': 'The mechanical properties of hydrocolloid films were not affected by the plant extracts within the concentration range used.', '10': 'The incorporation of the bioactive extracts in the polysaccharide films inhibited the topical edematous response by about 50%.', '11': 'The topical application of the loaded hydrocolloid film on the pressure ulcer is completely closed after 17 days without showing any adverse reaction.', '12': 'Conclusion: A novel hydrocolloid matrix was produced from crosslinked starch-pectin, which exhibited suitable chemical-physical properties to be used as a carrier of plant extracts with wound healing properties.'}\n",
            "38: abstract: {'1': 'Mask wearing is now ubiquitous because of the COVID-19 pandemic and has given rise to medical device-related pressure injuries in persons at risk of skin breakdown.', '2': 'The ear has unique anatomy that is particularly susceptible to injury from pressure.', '3': 'In this time of mandatory personal protective equipment requirements in healthcare facilities, protection and assessment of skin in the vulnerable postauricular area are needed.', '4': 'This article presents a case report of a pressure injury on the ear, reviews the anatomy of the ear, and provides strategies for assessment and treatment of pressure injuries in this often overlooked anatomic region.', '5': 'Treating Mask-Related Pressure Injury: Begin by removing the offending device.', '6': 'If the patient continues to require a mask, provide a mask or “ear saver” mask strap that secures around the head or back of the neck rather than the ear, although again, this does not remove the need for continued skin assessment to areas subjected to pressure and friction.', '7': 'Infection should be considered and ruled out.', '8': 'Local cellulitis is characterized by warmth, redness, pain, and swelling.', '9': 'Presence of purulent discharge might indicate deeper infection and/or abscess.', '10': 'If infection is present, treatment should be initiated with topical and/or systemic antibiotics, depending on culture and severity.', '11': 'Removing hair in the area may be helpful, because it eliminates foreign body intrusion into the wound base, as well as a source of contamination, consistent with the principles of wound bed preparation.', '12': 'It is important to note that a healed wound may not have the same physical strength as normal tissue and may be prone to recurrence, also known as recidivism.'}\n",
            "38: abstract: {'1': 'Pressure injury (PI) corresponds to a skin damage of ischemic aetiology that affects the integrity of the skin and is produced by prolonged pressure or friction between a hard internal and external surface.', '2': 'Treatment can be challenging when there is no resolution with usual care.', '3': 'The use of autologous platelet-rich plasma (APRP) gel arises as a therapeutic possibility in the presence of chronic pressure injuries.', '4': 'The case of a patient with chronic PI who has been treated with APRP is presented, achieving resolution of the lesion.'}\n",
            "39: abstract: {'1': 'Background: Primary progressive aphasia (PPA) is associated with amyloid-β (Aβ) pathology.', '2': 'However, clinical feature of PPA based on Aβ positivity remains unclear.', '3': 'Objective: We aimed to assess the prevalence of Aβ positivity in patients with PPA and compare the clinical characteristics of patients with Aβ-positive (A+) and Aβ-negative (A-) PPA.', '4': 'Further, we applied Aβ and tau classification system (AT system) in patients with PPA for whom additional information of in vivo tau biomarker was available.', '5': 'Methods: We recruited 110 patients with PPA (41 semantic [svPPA], 27 non-fluent [nfvPPA], 32 logopenic [lvPPA], and 10 unclassified [ucPPA]) who underwent Aβ-PET imaging at multi centers.', '6': 'The extent of language impairment and cortical atrophy were compared between the A+ and A-PPA subgroups using general linear models.', '7': 'Results: The prevalence of Aβ positivity was highest in patients with lvPPA (81.3%), followed by ucPPA (60.0%), nfvPPA (18.5%), and svPPA (9.8%).', '8': 'The A+ PPA subgroup manifested cortical atrophy mainly in the left superior temporal/inferior parietal regions and had lower repetition scores compared to the A-PPA subgroup.', '9': 'Further, we observed that more than 90%(13/14) of the patients with A+ PPA had tau deposition.', '10': 'Conclusion: Our findings will help clinicians understand the patterns of language impairment and cortical atrophy in patients with PPA based on Aβ deposition.', '11': \"Considering that most of the A+ PPA patents are tau positive, understanding the influence of Alzheimer's disease biomarkers on PPA might provide an opportunity for these patients to participate in clinical trials aimed for treating atypical Alzheimer's disease.\"}\n",
            "39: abstract: {'1': 'The detection of chemical compounds in exhaled human breath presents an opportunity to determine physiological state, diagnose disease or assess environmental exposure.', '2': 'Recent advancements in metabolomics research have led to improved capabilities to explore human metabolic profiles in breath.', '3': 'Despite some notable challenges in sampling and analysis, exhaled breath represents a desirable medium for metabolomics applications, foremost due to its non-invasive, convenient and practically limitless availability.', '4': 'Several breath-based tests that target either endogenous or exogenous gas-phase compounds are currently established and are in practical and/or clinical use.', '5': 'This review outlines the concept of breath analysis in the context of these unique tests and their applications.', '6': 'The respective breath biomarkers targeted in each test are discussed in relation to their physiological production in the human body and the development and implementation of the associated tests.', '7': 'The paper concludes with a brief insight into prospective tests and an outlook of the future direction of breath research.'}\n",
            "39: abstract: {'1': 'Recent studies have shown that nitric oxide (NO) is a central mediator in diseases occurring with thoracic aortic aneurysm (TAA), such as Marfan syndrome (MFS).', '2': 'The progressive dilation of the aorta in TAA ultimately leads to aortic dissection.', '3': 'Unfortunately, current medical treatments neither halt aortic enlargement nor prevent rupture, leaving surgical repair as the only effective treatment.', '4': 'There is therefore a pressing need for effective therapies to delay or even avoid the need for surgical repair in TAA patients.', '5': 'Here, we summarize the mechanisms through which NO signalling dysregulation causes TAA, particularly in MFS and discuss recent advances based on the identification of new MFS mediators related to pathway overactivation that represent potential disease biomarkers.', '6': 'Likewise, we propose iNOS, sGC, and PRKG1, whose pharmacological inhibition reverses aortopathy in MFS mice, as targets for therapeutic intervention in TAA and candidates for clinical trials.'}\n",
            "39: abstract: {'1': 'Background: Circular RNAs (circRNAs) have attracted increasing attention in recent years for their potential application as disease biomarkers due to their high abundance and stability.', '2': 'In this study, we attempted to screen circRNAs that can be used to predict postoperative recurrence and survival in patients with gastric cancer (GC).', '3': 'Methods: High-throughput RNA sequencing was used to identify differentially expressed circRNAs in GC patients with different prognoses.', '4': 'The expression level of circRNAs in the training set (n = 136) and validation set (n = 167) was detected by quantitative real-time PCR (qRT-PCR).', '5': 'Kaplan-Meier estimator, receiver operating characteristic (ROC) curve and cox regression analysis were used to evaluate the prognostic value of circRNAs on recurrence-free survival (RFS) and overall survival (OS) in GC patients.', '6': 'CeRNA network prediction, gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses were performed for the circRNAs with prognostic significance.', '7': 'Results: A total of 259 differentially expressed circRNAs were identified in GC patients with different RFS.', '8': 'We found two circRNAs (hsa_circ_0005092 and hsa_circ_0002647) that highly expressed in GC patients with good prognoses, and subsequently established a predictive model for postoperative recurrence and prognosis evaluation, named circPanel.', '9': 'Patients with circPanellow might have shorter recurrence-free survival (RFS) and overall survival (OS).', '10': 'We also performed circRNA-miRNA-mRNA network prediction and functional analysis for hsa_circ_0005092 and hsa_circ_0002647.', '11': 'Conclusions: CircPanel has the potential to be a prognostic biomarker in GC patients with greater accuracy than a single circRNA and certain traditional tumor markers (e.g., CEA, CA19-9 and CA724).'}\n",
            "39: abstract: {'1': \"Elevated expression of β-amyloid (Aβ1-42) and tau are considered risk-factors for Alzheimer's disease in healthy older adults.\", '2': 'We investigated the effect of aging and cerebrospinal fluid levels of Aβ1-42 and tau on 1) frontal metabolites measured with proton magnetic resonance spectroscopy (MRS) and 2) cognition in cognitively normal older adults (n = 144; age range 50-85).', '3': 'Levels of frontal gamma aminobutyric acid (GABA+) and myo-inositol relative to creatine (mI/tCr) were predicted by age.', '4': 'Levels of GABA+ predicted cognitive performance better than mI/tCr.', '5': 'Additionally, we found that frontal levels of n-acetylaspartate relative to creatine (tNAA/tCr) were predicted by levels of t-tau.', '6': 'In cognitively normal older adults, levels of frontal GABA+ and mI/t Cr are predicted by aging, with levels of GABA+ decreasing with age and the opposite for mI/tCr.', '7': \"These results suggest that age- and biomarker-related changes in brain metabolites are not only located in the posterior cortex as suggested by previous studies and further demonstrate that MRS is a viable tool in the study of aging and biomarkers associated with pathological aging and Alzheimer's disease.\"}\n",
            "39: abstract: {'1': 'Multiple sclerosis (MS) is a complex disease of the central nervous system (CNS) that involves an intricate and aberrant interaction of immune cells leading to inflammation, demyelination, and neurodegeneration.', '2': 'Due to the heterogeneity of clinical subtypes, their diagnosis becomes challenging and the best treatment cannot be easily provided to patients.', '3': 'Biomarkers have been used to simplify the diagnosis and prognosis of MS, as well as to evaluate the results of clinical treatments.', '4': 'In recent years, research on biomarkers has advanced rapidly due to their ability to be easily and promptly measured, their specificity, and their reproducibility.', '5': 'Biomarkers are classified into several categories depending on whether they address personal or predictive susceptibility, diagnosis, prognosis, disease activity, or response to treatment in different clinical courses of MS.', '6': 'The identified members indicate a variety of pathological processes of MS, such as neuroaxonal damage, gliosis, demyelination, progression of disability, and remyelination, among others.', '7': 'The present review analyzes biomarkers in cerebrospinal fluid (CSF) and blood serum, the most promising imaging biomarkers used in clinical practice.', '8': 'Furthermore, it aims to shed light on the criteria and challenges that a biomarker must face to be considered as a standard in daily clinical practice.'}\n",
            "39: abstract: {'1': 'Extracellular vesicles (EVs) are found in all biological fluids, providing potential for the identification of disease biomarkers such as colorectal cancer (CRC).', '2': 'EVs are heavily glycosylated with specific glycoconjugates such as tetraspanins, integrins, and mucins, reflecting the characteristics of the original cell offering valuable targets for detection of CRC.', '3': 'We report here on europium-nanoparticle (EuNP)-based assay to detect and characterize different surface glycoconjugates of EVs without extensive purification steps from five different CRC and the HEK 293 cell lines.', '4': 'The promising EVs candidates from cell culture were clinically evaluated on small panel of serum samples including early-stage (n = 11) and late-stage (n = 11) CRC patients, benign condition (n = 11), and healthy control (n = 10).', '5': 'The majority of CRC cell lines expressed tetraspanin sub-population and glycovariants of integrins and conventional tumor markers.', '6': 'The subpopulation of CD151 having CD63 expression (CD151CD63) was significantly (p = 0.001) elevated in early-stage CRC (8 out of 11) without detecting any benign and late-stage samples, while conventional CEA detected mostly late-stage CRC (p = 0.045) and with only four early-stage cases.', '7': 'The other glycovariant assays such as CEACon-A, CA125WGA, CA 19.9Ma696, and CA 19.9Con-A further provided some complementation to the CD151CD63 assay.', '8': 'These results indicate the potential application of CD151CD63 assay for early detection of CRC patients in human serum.'}\n",
            "39: abstract: {'1': 'Lung cancer accounts for more than half of the new cancers diagnosed world-wide with poor survival rates.', '2': 'Despite the development of chemical, radiological, and immunotherapies, many patients do not benefit from these therapies, as recurrence is common.', '3': 'We performed single-cell RNA-sequencing (scRNA-seq) analysis using Fluidigm C1 systems to characterize human lung cancer transcriptomes at single-cell resolution.', '4': 'Validation of scRNA-seq differentially expressed genes (DEGs) through quantitative real time-polymerase chain reaction (qRT-PCR) found a positive correlation in fold-change values between C-X-C motif chemokine ligand 1 (CXCL1) and 2 (CXCL2) compared with bulk-cell level in 34 primary lung adenocarcinomas (LUADs) from Stage I patients.', '5': 'Furthermore, we discovered an inverse correlation between chemokine mRNAs, miR-532-5p, and miR-1266-3p in early-stage primary LUADs.', '6': 'Specially, miR-532-5p was quantifiable in plasma from the corresponding LUADs.', '7': 'Collectively, we identified markers of early-stage lung cancer that were validated in primary lung tumors and circulating blood.'}\n",
            "39: abstract: {'1': 'Among the many complications associated with pregnancy, hypertensive disorders of pregnancy (HDP) constitute one of the most important.', '2': 'Since the pathophysiology of HDP is complex, new disease biomarkers (DBMs) are needed to serve as indicators of disease activity.', '3': 'However, in the current status of laboratory medicine, despite the fact that blood pressure measurement has been used for a long time, not many DBMs contribute adequately to the subsequent diagnosis and treatment.', '4': 'In this article, we discuss studies focusing on peptide fragments in blood identified by comprehensive quantitative methods, among the currently proposed DBM candidates.', '5': 'Furthermore, we describe the basic techniques of peptidomics, especially quantitative proteomics, and outline the current status and challenges of measuring peptides in blood as DBM for HDP.'}\n",
            "39: abstract: {'1': 'This literature review focuses on the role of disease biomarkers in the management of patients with diabetic retinopathy (DR) investigating in detail the problem of retinal neurodegeneration in such patients.', '2': 'Identification and assessment of the significance of qualitative and quantitative biomarkers of DR and neurodegeneration can complement screening examination, as well as help predict the course of the disease and the response to therapy.', '3': 'A comprehensive analysis of these factors allows for effective treatment and prevention of complications in patients with DR based on prognostic models and dynamic monitoring of these indicators.'}\n",
            "40: abstract: {'1': 'Venous (gravitational) leg ulcers are unsightly, sometimes painful and often difficult to heal.', '2': 'They are associated with incompetence of valves in the deep leg veins and venous hypertension.', '3': \"The main approaches in the management of venous leg ulcers have been to reduce the 'back pressure' in the veins by surgical removal of any varicose veins, postural drainage (elevation of the legs when the patient is lying or seated), and use of compression therapy with bandages, hosiery or intermittent pneumatic compression.\", '4': 'In this article, we review the efficacy and discuss correct use of compression therapy.'}\n",
            "40: abstract: {'1': 'Background: Up to 1% of adults will suffer from leg ulceration at some time.', '2': 'The majority of leg ulcers are venous in origin and are caused by high pressure in the veins due to blockage or weakness of the valves in the veins of the leg.', '3': 'Prevention and treatment of venous ulcers is aimed at reducing the pressure either by removing / repairing the veins, or by applying compression bandages / stockings to reduce the pressure in the veins.', '4': 'The vast majority of venous ulcers are healed using compression bandages.', '5': 'Once healed they often recur and so it is customary to continue applying compression in the form of bandages, tights, stockings or socks in order to prevent recurrence.', '6': 'Compression bandages or hosiery (tights, stockings, socks) are often applied for ulcer prevention.', '7': 'Objectives: To assess the effects of compression hosiery (socks, stockings, tights) or bandages in preventing the recurrence of venous ulcers.', '8': 'To determine whether there is an optimum pressure/type of compression to prevent recurrence of venous ulcers.', '9': 'Main results: No trials compared recurrence rates with and without compression.', '10': 'One trial (300 patients) compared high (UK Class 3) compression hosiery with moderate (UK Class 2) compression hosiery.', '11': 'A intention to treat analysis found no significant reduction in recurrence at five years follow up associated with high compression hosiery compared with moderate compression hosiery (relative risk of recurrence 0.82, 95% confidence interval 0.61 to 1.12).', '12': 'This analysis would tend to underestimate the effectiveness of the high compression hosiery because a significant proportion of people changed from high compression to medium compression hosiery.', '13': 'Compliance rates were significantly higher with medium compression than with high compression hosiery.', '14': 'One trial (166 patients) found no difference in recurrence between two types of medium (UK Class 2) compression hosiery (relative risk of recurrence with Medi was 0.74, 95% confidence interval 0.45 to 1.2).', '15': 'Both trials reported that not wearing compression hosiery was strongly associated with ulcer recurrence and this is circumstantial evidence that compression reduces ulcer recurrence.', '16': 'No trials were found which evaluated compression bandages for preventing ulcer recurrence.', '17': \"Reviewer's conclusions: No trials compared compression with vs no compression for prevention of ulcer recurrence.\", '18': 'Not wearing compression was associated with recurrence in both studies identified in this review.', '19': 'This is circumstantial evidence of the benefit of compression in reducing recurrence.', '20': 'Recurrence rates may be lower in high compression hosiery than in medium compression hosiery and therefore patients should be offered the strongest compression with which they can comply.', '21': 'Further trials are needed to determine the effectiveness of hosiery prescribed in other settings, i.e. in the UK community, in countries other than the UK.'}\n",
            "40: abstract: {'1': 'Chronic venous insufficiency (CVI) has a significant socioeconomic impact.', '2': 'The existent venous hypertension and the subsequent capillary hypertension result in trophic skin damage culminating in an ulcer.', '3': 'Venous ulcers affect 1-3% of the adult population.', '4': 'Compression therapy provides the basis for noninvasive treatment of CVI.', '5': 'It can be applied alone or in combination with invasive strategies.', '6': 'A variety of materials are available for phlebological compression therapy in the form of compression bandages and compression hosiery.', '7': \"Knowledge of the different qualities of the compression materials and their mode of action is important in choosing the correct means of compression with regard to clinical findings and the patient's needs.\", '8': 'As far as possible, the compression method applied should be monitored for any loss of effectivity during regular follow-up examinations of the patients.', '9': 'The following article deals with this topic.', '10': 'A new option for compression therapy of crural ulcers is presented and the possibility for checking the effectiveness of the compression stockings during outpatient'}\n",
            "40: abstract: {'1': 'Background: A too high resting pressure of compression devices is poorly tolerated and may cause skin defects, especially in patients with concomitant arterial occlusive disease.', '2': 'Aim: To investigate whether low compression pressure will improve venous pumping function in patients with venous incompetence.', '3': 'Material and methods: Venous pumping function was assessed in 20 patients with severe reflux in the great saphenous vein by measuring ejection fraction (EF) using strain-gauge plethysmography.', '4': 'Measurements were repeated after application of knee-high medical compression stockings and of inelastic bandages applied with a pressure of 20, 40 and 60 mmHg in the supine position.', '5': 'Results: EF was significantly reduced compared with healthy controls.', '6': 'Compression stockings exerting a median pressure of 27 mmHg (interquartile range [IQR] 25-29) in the supine and 30.5 mmHg (IQR 28.25-34.25) in the standing position produced a moderate, non-significant improvement of EF of 17%.', '7': 'Inelastic bandages with a resting pressure of 20.5 mmHg (IQR 20-22) in the supine position resulting in a standing pressure of 36 mmHg (IQR 33-40.75) led to a significant increase of EF of 61.5% (P < 0.01).', '8': 'A further increase of the resting pressure to 40 and 60 mmHg achieved an increase of the EF of 91% and 98%, respectively (P < 0.001).', '9': 'Conclusions: In patients with venous pumping failure, inelastic bandages produce a significant pressure-dependent increase of EF.', '10': 'A significant improvement in venous pumping function was achieved with inelastic bandages even at a resting pressure of 20 mmHg.'}\n",
            "40: abstract: {'1': 'Although compression therapy was initially described over 2,000 years ago (Felty and Rooke Semin Vasc Surg Mar 18:36-40, 1), several patients with edema do not receive appropriate compression therapy.', '2': 'Instead, most patients with edema are treated primarily with diuretics.', '3': 'Compression therapy is the cornerstone of treatment of venous edema and lymphatic disorders.', '4': 'Compression therapy decreases the foot and leg volume and reduces venous reflux and venous hypertension.', '5': 'Compression can be achieved by multiple different modalities, such as inelastic bandages; multilayered wraps; short, medium, and long stretch bandages; graduated compression stockings; and pneumatic compression devices.', '6': 'The major criticism of compression therapy is poor patient compliance.', '7': 'Compliance can be improved by selecting appropriate compression therapy tailored to the needs of the individual patient and by providing adequate patient education.'}\n",
            "40: abstract: {'1': 'Objectives: This study was conducted to define bandage pressures that are safe and effective in treating leg ulcers of mixed arterial-venous etiology.', '2': 'Methods: In 25 patients with mixed-etiology leg ulcers who received inelastic bandages applied with pressures from 20 to 30, 31 to 40, and 41 to 50 mm Hg, the following measurements were performed before and after bandage application to ensure patient safety throughout the investigation: laser Doppler fluxmetry (LDF) close to the ulcer under the bandage and at the great toe, transcutaneous oxygen pressure (TcPo(2)) on the dorsum of the foot, and toe pressure.', '3': 'Ejection fraction (EF) of the venous pump was performed to assess efficacy on venous hemodynamics.', '4': 'Results: LDF values under the bandages increased by 33% (95% confidence interval [CI], 17-48; P < .01), 28% (95% CI, 12-45; P < .05), and 10% (95% CI, -7 to 28), respectively, under the three pressure ranges applied.', '5': 'At toe level, a significant decrease in flux of -20% (95% CI, -48 to 9; P < .05) was seen when bandage pressure >41 mm Hg.', '6': 'Toe pressure values and TcPo(2) showed a moderate increase, excluding a restriction to arterial perfusion induced by the bandages.', '7': 'Inelastic bandages were highly efficient in improving venous pumping function, increasing the reduced ejection fraction by 72% (95% CI, 50%-95%; P < .001) under pressure of 21 to 30 mm Hg and by 103% (95% CI, 70%-128%; P < .001) at 31 to 40 mm Hg.', '8': 'Conclusions: In patients with mixed ulceration, an ankle-brachial pressure index >0.5 and an absolute ankle pressure of >60 mm Hg, inelastic compression of up to 40 mm Hg does not impede arterial perfusion but may lead to a normalization of the highly reduced venous pumping function.', '9': 'Such bandages are therefore recommended in combination with walking exercises as the basic conservative management for patients with mixed leg ulcers.'}\n",
            "40: abstract: {'1': 'Aim: A review is given on the different tools of compression therapy and their mode of action.', '2': 'Methods: Interface pressure and stiffness of compression devices, alone or in combination can be measured in vivo.', '3': 'Hemodynamic effects have been demonstrated by measuring venous volume and flow velocity using MRI, Duplex and radioisotopes, venous reflux and venous pumping function using plethysmography and phlebodynamometry.', '4': 'Oedema reduction can be measured by limb volumetry.', '5': 'Results: Compression stockings exerting a pressure of ~20 mm Hg on the distal leg are able to increase venous blood flow velocity in the supine position and to prevent leg swelling after prolonged sitting and standing.', '6': 'In the upright position, an interface pressure of more than 50 mmHg is needed for intermittent occlusion of incompetent veins and for a reduction of ambulatory venous hypertension during walking.', '7': 'Such high intermittent interface pressure peaks exerting a \"massaging effect\" may rather be achieved by short stretch multilayer bandages than by elastic stockings.', '8': 'Conclusion: Compression is a cornerstone in the management of venous and lymphatic insufficiency.', '9': 'However, this treatment modality is still underestimated and deserves better understanding and improved educational programs, both for patients and medical staff.'}\n",
            "40: abstract: {'1': 'Compression therapy is the basic therapy in phlebology and lymphology.', '2': 'The pressure under the bandages has to exceed the intravenous pressure especially in standing position.', '3': 'Different compression materials such as short stretch systems, long stretch bandages and compression garments work differently on ambulatory venous hypertension, speed of reducing edema and arterial flow.', '4': 'Compression with high stiffness, inelastic materials is more effective than compression with low stiffness, elastic materials.', '5': 'These materials have to be placed correctly.', '6': 'Inelastic systems should be applied with high initial pressure because the pressure will loose at some time after walking.', '7': 'Even after one week of wearing, inelastic bandages keep higher resting and working pressure during walking than elastic bandages.', '8': 'However, more important is that they have lower resting pressure than elastic materials.', '9': 'Long stretch bandages and compression garments with great extensibility ensure low working pressure and higher resting pressure than short stretch systems.'}\n",
            "40: abstract: {'1': 'Objectives: This study was conducted to determine hemodynamic and clinical tolerance under short-stretch compression therapy in elderly patients suffering from mixed-etiology leg ulcers.', '2': 'Design: Transversal observational study conducted in 25 hospitalized patients with a moderate peripheral arterial occlusive disease defined as an ankle-brachial pressure index>0.5, an ankle pressure of> 70mm Hg and a toe cuff pressure (TP)> 50mm Hg.', '3': 'Material and methods: Short-stretch bandages were applied daily with pressures from 20 to 30mm Hg.', '4': 'Ankle-brachial pressure, great toe laser Doppler flowmetry (LDF) and transcutaneous oxygen pressure (TcPO2) on dorsum of the foot were measured at baseline and after its removal at 24hours.', '5': 'Great toe LDF was also measured at 10minutes after bandage application.', '6': 'Compression pressure (CP) was measured with a sub-bandage device at baseline, at 10minutes and before bandage removal at 24hours.', '7': \"Clinical tolerance was evaluated taking into account the patient's pain and skin tolerance.\", '8': 'Results: Mean age of patients was 80±15 years.', '9': 'Median duration of ulcers was 18 months.', '10': 'Hypertension was highly prevalent.', '11': 'One third of patients had diabetes.', '12': 'Toe pressure index and TcPO2 values did not significantly change under compression therapy (P=0.51 and P=0.09, respectively) whereas CP decreased significantly during 24hours.', '13': 'The loss of CP was significant 10minutes after bandage application (P<0.001).', '14': 'Nearly all ulcers were painful prior to placement of compression therapy and required level 1 analgesics.', '15': 'One patient required level 2 analgesic for pain relief.', '16': 'No increase in pain and no ischemic skin damage occurred under compression therapy.', '17': 'Conclusions: In elderly patients with mixed leg ulcers and with an absolute TP>50mm Hg, short-stretch compression of up to 30mm Hg does not adversely affect arterial flow and appears clinically well tolerated.', '18': 'Such bandages with appropriate levels of compression may aid ulcer healing by treating the venous part of the disease.'}\n",
            "40: abstract: {'1': 'The presence of chronic heart failure (CHF) results in a significant risk of leg oedema.', '2': 'Medical compression (MC) treatment is one of the basic methods of leg oedema elimination in patients with chronic venous disease and lymphedema, but it is not routinely considered in subjects with CHF-related swelling.', '3': 'In the study, an overview of the current knowledge related to the benefits and risk of using MC in the supportive treatment of leg oedema in CHF patients is presented.', '4': 'The available studies dedicated the comprehensive management of leg swelling using MC in CHF patients published in the English language literature till December 2019 were evaluated in term of the treatment efficacy and safety.', '5': 'In studies performed on CHF populations, manual lymphatic drainage, MC stocking, multilayer bandaged, as well as intermittent pneumatic compression or electric calf stimulations were used.', '6': 'The current evidence is based on non-randomized studies, small study cohorts, as well as very heterogenous populations.', '7': 'The use of the intermittent pneumatic compression in CHF patients significantly increases the right auricular pressure and mean pulmonary artery pressures as well as decreases systemic vascular resistance in most patients without the clinical worsening.', '8': 'The transient and rapid increase in the human atrial natriuretic peptide, after an application of the MC stocking in New York Heart Association (NYHA) class II patients was observed without clinical exacerbation.', '9': 'An application of the multilayer bandages in NYHA classes III and IV patients lead a significant increase in the right arterial pressure and lead to transient deterioration of the right and the left ventricular functions.', '10': 'In the manual lymphatic drainage study, aside from expected leg circumference reduction, no clinical worsening was observed.', '11': 'In a pilot study performed in a small cohort of CHF patients, electrical calf stimulation use resulted in a reduction in the lean mass of the legs without cardiac function worsening.', '12': 'The use of local leg compression can be considered stable CHF patients without decompensated heart function for both CHF-related oedema treatment and for treatment of the concomitant diseases leading to leg swelling occurrence.', '13': 'The use of MC in more severe classes of CHF (NYHA III and IV) should be the subject of future clinical studies to select the safest and most efficient compression method as well as to select the patients who benefit most from this kind of treatment.'}\n",
            "41: abstract: {'1': 'Autosomal dominant polycystic kidney disease is an important cause of end-stage renal disease, for which there is no proven therapy.', '2': 'Mutations in PKD1 (the gene encoding polycystin-1) are the principal cause of this disease.', '3': 'The disease begins in utero and is slowly progressive, but it is not known whether cystogenesis is an ongoing process during adult life.', '4': 'We now show that inactivation of Pkd1 in mice before postnatal day 13 results in severely cystic kidneys within 3 weeks, whereas inactivation at day 14 and later results in cysts only after 5 months.', '5': 'We found that cellular proliferation was not appreciably higher in cystic specimens than in age-matched controls, but the abrupt change in response to Pkd1 inactivation corresponded to a previously unrecognized brake point during renal growth and significant changes in gene expression.', '6': 'These findings suggest that the effects of Pkd1 inactivation are defined by a developmental switch that signals the end of the terminal renal maturation process.', '7': \"Our studies show that Pkd1 regulates tubular morphology in both developing and adult kidney, but the pathologic consequences of inactivation are defined by the organ's developmental status.\", '8': 'These results have important implications for clinical understanding of the disease and therapeutic approaches.'}\n",
            "41: abstract: {'1': 'In patients with von Hippel-Lindau (VHL) disease, renal cysts and clear cell renal cell carcinoma (ccRCC) arise from renal tubular epithelial cells containing biallelic inactivation of the VHL tumour suppressor gene.', '2': 'However, it is presumed that formation of renal cysts and their conversion to ccRCC involve additional genetic changes at other loci.', '3': 'Here, we show that cystic lesions in the kidneys of patients with VHL disease also demonstrate activation of the phosphatidylinositol-3-kinase (PI3K) pathway.', '4': 'Strikingly, combined conditional inactivation of Vhlh and the Pten tumour suppressor gene, which normally antagonises PI3K signalling, in the mouse kidney, elicits cyst formation after short latency, whereas inactivation of either tumour suppressor gene alone failed to produce such a phenotype.', '5': 'Interestingly, cells lining these cysts frequently lack a primary cilium, a microtubule-based cellular antenna important for suppression of uncontrolled kidney epithelial cell proliferation and cyst formation.', '6': 'Our results support a model in which the PTEN tumour suppressor protein cooperates with pVHL to suppress cyst development in the kidney.'}\n",
            "41: abstract: {'1': 'Autosomal dominant polycystic kidney disease (ADPKD) is the leading genetic cause of renal failure.', '2': 'We have recently shown that inhibiting miR-17~92 is a potential novel therapeutic approach for ADPKD.', '3': 'However, miR-17~92 is a polycistronic cluster that encodes microRNAs (miRNAs) belonging to the miR-17, miR-18, miR-19 and miR-25 families, and the relative pathogenic contribution of these miRNA families to ADPKD progression is unknown.', '4': 'Here we performed an in vivo anti-miR screen to identify the miRNA drug targets within the miR-17~92 miRNA cluster.', '5': 'We designed anti-miRs to individually inhibit miR-17, miR-18, miR-19 or miR-25 families in an orthologous ADPKD model.', '6': 'Treatment with anti-miRs against the miR-17 family reduced cyst proliferation, kidney-weight-to-body-weight ratio and cyst index.', '7': 'In contrast, treatment with anti-miRs against the miR-18, 19, or 25 families did not affect cyst growth.', '8': 'Anti-miR-17 treatment recapitulated the gene expression pattern observed after miR-17~92 genetic deletion and was associated with upregulation of mitochondrial metabolism, suppression of the mTOR pathway, and inhibition of cyst-associated inflammation.', '9': 'Our results argue against functional cooperation between the various miR-17~92 cluster families in promoting cyst growth, and instead point to miR-17 family as the primary therapeutic target for ADPKD.'}\n",
            "41: abstract: {'1': 'This consensus-based guideline was developed by all relevant German pediatric medical societies.', '2': 'Ultrasound is the standard imaging modality for pre- and postnatal kidney cysts and should also exclude extrarenal manifestations in the abdomen and internal genital organs.', '3': 'MRI has selected indications.', '4': 'Suspicion of a cystic kidney disease should prompt consultation of a pediatric nephrologist.', '5': 'Prenatal management must be tailored to very different degrees of disease severity.', '6': 'After renal oligohydramnios, we recommend delivery in a perinatal center.', '7': 'Neonates should not be denied renal replacement therapy solely because of their age.', '8': 'Children with unilateral multicystic dysplastic kidney do not require routine further imaging or nephrectomy, but long-term nephrology follow-up (as do children with uni- or bilateral kidney hypo-/dysplasia with cysts).', '9': 'ARPKD (autosomal recessive polycystic kidney disease), nephronophthisis, Bardet-Biedl syndrome and HNF1B mutations cause relevant extrarenal disease and genetic testing is advisable.', '10': 'Children with tuberous sclerosis complex, tumor predisposition (e. g. von Hippel Lindau syndrome) or high risk of acquired kidney cysts should have regular ultrasounds.', '11': 'Even asymptomatic children of parents with ADPKD (autosomal dominant PKD) should be monitored for hypertension and proteinuria.', '12': 'Presymptomatic diagnostic ultrasound or genetic examination for ADPKD in minors should only be done after thorough counselling.', '13': 'Simple cysts are very rare in children and ADPKD in a parent should be excluded.', '14': 'Complex renal cysts require further investigation.'}\n",
            "41: abstract: {'1': 'Tuberous sclerosis complex (TSC) is caused by mutations in either TSC1 or TSC2 genes and affects multiple organs, including kidney, lung, and brain.', '2': 'In the kidney, TSC presents with the enlargement of benign tumors (angiomyolipomata) and cysts, which eventually leads to kidney failure.', '3': 'The factors promoting cyst formation and tumor growth in TSC are incompletely understood.', '4': 'Here, we report that mice with principal cell-specific inactivation of Tsc1 develop numerous cortical cysts, which are overwhelmingly composed of hyperproliferating A-intercalated (A-IC) cells.', '5': 'RNA sequencing and confirmatory expression studies demonstrated robust expression of Forkhead Transcription Factor 1 (Foxi1) and its downstream targets, apical H+-ATPase and cytoplasmic carbonic anhydrase 2 (CAII), in cyst epithelia in Tsc1 knockout (KO) mice but not in Pkd1 mutant mice.', '6': 'In addition, the electrogenic 2Cl-/H+ exchanger (CLC-5) is significantly up-regulated and shows remarkable colocalization with H+-ATPase on the apical membrane of cyst epithelia in Tsc1 KO mice.', '7': 'Deletion of Foxi1, which is vital to intercalated cells viability and H+-ATPase expression, completely abrogated the cyst burden in Tsc1 KO mice, as indicated by MRI images and histological analysis in kidneys of Foxi1/Tsc1 double-knockout (dKO) mice.', '8': 'Deletion of CAII, which is critical to H+-ATPase activation, caused significant reduction in cyst burden and increased life expectancy in CAII/Tsc1 dKO mice vs. Tsc1 KO mice.', '9': 'We propose that intercalated cells and their acid/base/electrolyte transport machinery (H+-ATPase/CAII/CLC-5) are critical to cystogenesis, and their inhibition or inactivation is associated with significant protection against cyst generation and/or enlargement in TSC.'}\n",
            "41: abstract: {'1': 'DNA damage and alterations in DNA damage response (DDR) signaling could be one of the molecular mechanisms mediating focal kidney cyst formation in autosomal dominant polycystic kidney disease (ADPKD).', '2': 'The aim of this study was to test the hypothesis that markers of DNA damage and DDR signaling are increased in human and experimental ADPKD.', '3': 'In the human ADPKD transcriptome, the number of up-regulated DDR-related genes was increased by 16.6-fold compared with that in normal kidney, and by 2.5-fold in cystic compared with that in minimally cystic tissue (P < 0.0001).', '4': 'In end-stage human ADPKD tissue, γ-H2A histone family member X (H2AX), phosphorylated ataxia telangiectasia and radiation-sensitive mutant 3 (Rad3)-related (pATR), and phosphorylated ataxia telangiectasia mutated (pATM) localized to cystic kidney epithelial cells.', '5': 'In vitro, pATR and pATM were also constitutively increased in human ADPKD tubular cells (WT 9-7 and 9-12) compared with control (HK-2).', '6': 'In addition, extrinsic oxidative DNA damage by hydrogen peroxide augmented γ-H2AX and cell survival in human ADPKD cells, and exacerbated cyst growth in the three-dimensional Madin-Darby canine kidney cyst model.', '7': 'In contrast, DDR-related gene expression was only transiently increased on postnatal day 0 in Pkd1RC/RC mice, and not altered at later time points up to 12 months of age.', '8': 'In conclusion, DDR signaling is dysregulated in human ADPKD and during the early phases of murine ADPKD.', '9': 'The constitutive expression of the DDR pathway in ADPKD may promote survival of PKD1-mutated cells and contribute to kidney cyst growth.'}\n",
            "41: abstract: {'1': 'Polycystic kidney disease (PKD) is a genetic disorder characterized by aberrant renal epithelial cell proliferation and formation and progressive growth of numerous fluid-filled cysts within the kidneys.', '2': 'Previously, we showed that there is elevated Notch signaling compared to normal renal epithelial cells and that Notch signaling contributes to the proliferation of cystic cells.', '3': 'Quinomycin A, a bis-intercalator peptide, has previously been shown to target the Notch signaling pathway and inhibit tumor growth in cancer.', '4': 'Here, we show that Quinomycin A decreased cell proliferation and cyst growth of human ADPKD cyst epithelial cells cultured within a 3D collagen gel.', '5': 'Treatment with Quinomycin A reduced kidney weight to body weight ratio and decreased renal cystic area and fibrosis in Pkd1RC/RC ; Pkd2+/- mice, an orthologous PKD mouse model.', '6': 'This was accompanied by reduced expression of Notch pathway proteins, RBPjk and HeyL and cell proliferation in kidneys of PKD mice.', '7': 'Quinomycin A treatments also normalized cilia length of cyst epithelial cells derived from the collecting ducts.', '8': 'This is the first study to demonstrate that Quinomycin A effectively inhibits PKD progression and suggests that Quinomycin A has potential therapeutic value for PKD patients.'}\n",
            "41: abstract: {'1': 'Background: In autosomal dominant polycystic kidney disease (ADPKD), cyst development and enlargement lead to ESKD.', '2': 'Macrophage recruitment and interstitial inflammation promote cyst growth.', '3': 'TWEAK is a TNF superfamily (TNFSF) cytokine that regulates inflammatory responses, cell proliferation, and cell death, and its receptor Fn14 (TNFRSF12a) is expressed in macrophage and nephron epithelia.', '4': 'Methods: To evaluate the role of the TWEAK signaling pathway in cystic disease, we evaluated Fn14 expression in human and in an orthologous murine model of ADPKD.', '5': 'We also explored the cystic response to TWEAK signaling pathway activation and inhibition by peritoneal injection.', '6': 'Results: Meta-analysis of published animal-model data of cystic disease reveals mRNA upregulation of several components of the TWEAK signaling pathway.', '7': 'We also observed that TWEAK and Fn14 were overexpressed in mouse ADPKD kidney cysts, and TWEAK was significantly high in urine and cystic fluid from patients with ADPKD.', '8': 'TWEAK administration induced cystogenesis and increased cystic growth, worsening the phenotype in a murine ADPKD model.', '9': 'Anti-TWEAK antibodies significantly slowed the progression of ADPKD, preserved renal function, and improved survival.', '10': 'Furthermore, the anti-TWEAK cystogenesis reduction is related to decreased cell proliferation-related MAPK signaling, decreased NF-κB pathway activation, a slight reduction of fibrosis and apoptosis, and an indirect decrease in macrophage recruitment.', '11': 'Conclusions: This study identifies the TWEAK signaling pathway as a new disease mechanism involved in cystogenesis and cystic growth and may lead to a new therapeutic approach in ADPKD.'}\n",
            "41: abstract: {'1': 'Autosomal dominant polycystic kidney disease is a common inherited renal disorder that results from mutations in either PKD1 or PKD2, encoding polycystin-1 (PC1) and polycystin-2 (PC2), respectively.', '2': 'Downregulation or overexpression of PKD1 or PKD2 in mouse models results in renal cyst formation, suggesting that the quantity of PC1 and PC2 needs to be maintained within a tight functional window to prevent cystogenesis.', '3': 'Here we show that enhanced PC2 expression is a common feature of PKD1 mutant tissues, in part due to an increase in Pkd2 mRNA.', '4': 'However, our data also suggest that more effective protein folding contributes to the augmented levels of PC2.', '5': 'We demonstrate that the unfolded protein response is activated in Pkd1 knockout kidneys and in Pkd1 mutant cells and that this is coupled with increased levels of GRP94, an endoplasmic reticulum protein that is a member of the HSP90 family of chaperones.', '6': 'GRP94 was found to physically interact with PC2 and depletion or chemical inhibition of GRP94 led to a decrease in PC2, suggesting that GRP94 serves as its chaperone.', '7': 'Moreover, GRP94 is acetylated and binds to histone deacetylase 6 (HDAC6), a known deacetylase and activator of HSP90 proteins.', '8': 'Inhibition of HDAC6 decreased PC2 suggesting that HDAC6 and GRP94 work together to regulate PC2 levels.', '9': 'Lastly, we showed that inhibition of GRP94 prevents cAMP-induced cyst formation in vitro.', '10': 'Taken together our data uncovered a novel HDAC6-GRP94-related axis that likely participates in maintaining elevated PC2 levels in Pkd1 mutant cells.'}\n",
            "41: abstract: {'1': 'Cystic Echinococcosis or Hydatid disease is caused by the infection with the larval stage of long tapeworm, Echinococcus granulosus.', '2': 'This condition often remains asymptomatic for years before the cyst grows large enough to cause symptoms in affected organs.', '3': 'The most common organs involved are liver and lungs although the heart, brain, bone, central nervous system, and kidney may also be involved.', '4': 'This case is about a young woman who presented with left flank pain and urinary tract infection who was later diagnosed as having left renal hydatid cyst.', '5': 'The cyst was approximately 7.8×6.6×8cm with internal multiple septations at the lower pole cortex of the left kidney.', '6': 'Laparoscopic pericystectomy was performed and with no postoperative complications, she was discharged on albendazole and other supportive medication.', '7': 'With timely management using combination therapy, this condition is curable and the patient can live a healthy life with normal kidney function.'}\n",
            "42: abstract: {'1': 'The linker histones (H1, H1 zero, H5, etc.) and a group of abundant non-histone chromosomal proteins (HMG1/2) bind to linker DNA in chromatin and exhibit both generalized and specific effects on gene transcription.', '2': 'The two classes of proteins share many features of DNA binding behaviour, although they are structurally unrelated.', '3': 'While the linker histones and HMG1/2 exhibit direct competition in binding to such structures as four-way junction DNA, whether they compete for binding to the nucleosome has not been investigated.', '4': 'The possibility for either opposite or synergistic effects on gene regulation must be considered at this point.'}\n",
            "42: abstract: {'1': 'Histones are known for their ability to bind to and regulate expression of DNA.', '2': 'However, histones are also present in cytoplasm and extracellular fluids where they serve host defense functions and promote inflammatory responses.', '3': 'Histones are a major component of neutrophil extracellular traps that contribute to bacterial killing but also to inflammatory injury.', '4': 'Histones can act as antimicrobial peptides and directly kill bacteria, fungi, parasites and viruses, in vitro and in a variety of animal hosts.', '5': 'In addition, histones can trigger inflammatory responses in some cases acting through Toll-like receptors or inflammasome pathways.', '6': 'Extracellular histones mediate organ injury (lung, liver), sepsis physiology, thrombocytopenia and thrombin generation and some proteins can bind histones and reduce these potentially harmful effects'}\n",
            "42: abstract: {'1': 'Eight types of short-chain Lys acylations have recently been identified on histones: propionylation, butyrylation, 2-hydroxyisobutyrylation, succinylation, malonylation, glutarylation, crotonylation and β-hydroxybutyrylation.', '2': 'Emerging evidence suggests that these histone modifications affect gene expression and are structurally and functionally different from the widely studied histone Lys acetylation.', '3': \"In this Review, we discuss the regulation of non-acetyl histone acylation by enzymatic and metabolic mechanisms, the acylation 'reader' proteins that mediate the effects of different acylations and their physiological functions, which include signal-dependent gene activation, spermatogenesis, tissue injury and metabolic stress.\", '4': 'We propose a model to explain our present understanding of how differential histone acylation is regulated by the metabolism of the different acyl-CoA forms, which in turn modulates the regulation of gene expression.'}\n",
            "42: abstract: {'1': 'Background: While the genomes of eukaryotes and Archaea both encode the histone-fold domain, only eukaryotes encode the core histone paralogs H2A, H2B, H3, and H4.', '2': 'With DNA, these core histones assemble into the nucleosomal octamer underlying eukaryotic chromatin.', '3': 'Importantly, core histones for H2A and H3 are maintained as neofunctionalized paralogs adapted for general bulk chromatin (canonical H2 and H3) or specialized chromatin (H2A.', '4': 'Z enriched at gene promoters and cenH3s enriched at centromeres).', '5': 'In this context, the identification of core histone-like \"doublets\" in the cytoplasmic replication factories of the Marseilleviridae (MV) is a novel finding with possible relevance to understanding the origin of eukaryotic chromatin.', '6': 'Here, we analyze and compare the core histone doublet genes from all known MV genomes as well as other MV genes relevant to the origin of the eukaryotic replisome.', '7': 'Results: Using different phylogenetic approaches, we show that MV histone domains encode obligate H2B-H2A and H4-H3 dimers of possible proto-eukaryotic origin.', '8': 'MV core histone moieties form sister clades to each of the four eukaryotic clades of canonical and variant core histones.', '9': 'This suggests that MV core histone moieties diverged prior to eukaryotic neofunctionalizations associated with paired linear chromosomes and variant histone octamer assembly.', '10': 'We also show that MV genomes encode a proto-eukaryotic DNA topoisomerase II enzyme that forms a sister clade to eukaryotes.', '11': 'This is a relevant finding given that DNA topo II influences histone deposition and chromatin compaction and is the second most abundant nuclear protein after histones.', '12': 'Conclusions: The combined domain architecture and phylogenomic analyses presented here suggest that a primitive origin for MV histone genes is a more parsimonious explanation than horizontal gene transfers + gene fusions + sufficient divergence to eliminate relatedness to eukaryotic neofunctionalizations within the H2A and H3 clades without loss of relatedness to each of the four core histone clades.', '13': 'We thus suggest MV histone doublet genes and their DNA topo II gene possibly were acquired from an organism with a chromatinized replisome that diverged prior to the origin of eukaryotic core histone variants for H2/H2A.Z and H3/cen H3.', '14': 'These results also imply that core histones were utilized ancestrally in viral DNA compaction and/or protection from host endonucleases.'}\n",
            "42: abstract: {'1': 'Linker histones are major players in chromatin organization and per se are essential players in genome homeostasis.', '2': 'As the fifth class of histone proteins the linker histones not only interact with DNA and core histones but also with other chromatin proteins.', '3': 'These interactions prove to be essential for the higher levels of chromatin organization like chromatin loops, transcription factories and chromosome territories.', '4': 'Our recent results have proved that Saccharomyces cerevisiae linker histone - Hho1p, physically interacts with the actin-related protein 4 (Arp4) and that the abrogation of this interaction through the deletion of the gene for the linker histone in arp4 mutant cells leads to global changes in chromatin compaction.', '5': 'Here, we show that the healthy interaction between the yeast linker histone and Arp4p is critical for maintaining genome stability and for controlling cellular sensitivity to different types of stress.', '6': 'The abolished interaction between the linker histone and Arp4p leads the mutant yeast cells to premature ageing phenotypes.', '7': 'Cells die young and are more sensitive to stress.', '8': 'These results unambiguously prove the role of linker histones and chromatin remodelling in ageing by their cooperation in pertaining higher-order chromatin compaction and thus maintaining genome stability.'}\n",
            "42: abstract: {'1': 'cHistone posttranslational modifications (PTMs) are essential for regulating chromatin and maintaining gene expression throughout cell differentiation.', '2': 'Despite the deep level of understanding of immunophenotypic differentiation pathways in hematopoietic cells, few studies have investigated global levels of histone PTMs required for differentiation and maintenance of these distinct cell types.', '3': 'Here, we describe an approach to couple fluorescence-activated cell sorting (FACS) with targeted mass spectrometry to define global \"epi-proteomic\" signatures for primary leukocytes.', '4': 'FACS was used to sort closely and distantly related leukocytes from normal human peripheral blood for quantitation of histone PTMs with a multiple reaction monitoring LC-MS/MS method measuring histone PTMs on histones H3 and H4.', '5': 'We validate cell sorting directly into H2SO4 for immediate histone extraction to decrease time and number of steps after FACS to analyze histone PTMs.', '6': 'Relative histone PTM levels vary in T cells across healthy donors, and the majority of PTMs remain stable up to 2 days following initial blood draw.', '7': 'Large differences in the levels of histone PTMs are observed across the mature lymphoid and myeloid lineages, as well as between different types within the same lineage, though no differences are observed in closely related T cell subtypes.', '8': 'The results show a streamlined approach for quantifying global changes in histone PTMs in cell types separated by FACS that is poised for clinical deployment.'}\n",
            "42: abstract: {'1': 'Extracellular histones released from injured or dying cells following trauma and other severe insults can act as potent damage-associated molecular patterns.', '2': 'In fact, elevated levels of histones are present in human circulation in hyperinflammatory states such as acute respiratory distress syndrome and sepsis.', '3': 'The molecular mechanisms owing to histone-induced pathologies are at the very beginning of elucidating.', '4': 'However, neutralization of histones with antibodies, histone-binding or histone-degrading proteins, and heparan sulfates have shown promising therapeutic effects in pre-clinical acute respiratory distress syndrome and sepsis models.', '5': 'Various cell types undergoing necrosis and apoptosis or activated neutrophils forming neutrophil extracellular traps have been implicated in excessive release of histones which further augments tissue injury and may culminate in multiple organ failure.', '6': 'At the molecular level, an uncontrolled inflammatory cascade has been considered as the major event; however, histone-activated coagulation and thrombosis represent additional pathologic events reflecting coagulopathy.', '7': 'Furthermore, epigenetic regulation and chemical modifications of circulating histones appear to be critically important in their biological functions as evidenced by increased cytotoxicity associated with citrullinated histone.', '8': 'Herein, we will briefly review the current knowledge on the role of histones in acute respiratory distress syndrome and sepsis, and discuss the future potential of anti-histone therapy for treatment of these life-threatening disorders.'}\n",
            "42: abstract: {'1': 'Background: The oncogenic role of histone mutations is one of the most relevant discovery in cancer epigenetics.', '2': 'Recurrent mutations targeting histone genes have been described in pediatric brain tumors, chondroblastoma, giant cell tumor of bone and other tumor types.', '3': 'The demonstration that mutant histones can be oncogenic and drive the tumorigenesis in pediatric tumors, led to the coining of the term \"oncohistones.\" The first identified histone mutations were localized at or near residues normally targeted by post-translational modifications (PTMs) in the histone N-terminal tails and suggested a possible interference with histone PTMs regulation and reading.', '4': 'Main body: In this review, we describe the peculiar organization of the multiple genes that encode histone proteins, and the latter advances in both the identification and the biological role of histone mutations in cancer.', '5': 'Recent works show that recurrent somatic mutations target both N-terminal tails and globular histone fold domain in diverse tumor types.', '6': 'Oncohistones are often dominant-negative and occur at higher frequencies in tumors affecting children and adolescents.', '7': 'Notably, in many cases the mutations target selectively only some of the genes coding the same histone protein and are frequently associated with specific tumor types or, as documented for histone variant H3.3 in pediatric glioma, with peculiar tumors arising from specific anatomic locations.', '8': 'Conclusion: The overview of the most recent advances suggests that the oncogenic potential of histone mutations can be exerted, together with the alteration of histone PTMs, through the destabilization of nucleosome and DNA-nucleosome interactions, as well as through the disruption of higher-order chromatin structure.', '9': 'However, further studies are necessary to fully elucidate the mechanism of action of oncohistones, as well as to evaluate their possible application to cancer classification, prognosis and to the identification of new therapies.'}\n",
            "42: abstract: {'1': 'Over time, the knowledge on the role of histones has significantly changed.', '2': 'Initially, histones were only known as DNA packaging proteins but later, it was discovered that they act extracellularly as powerful antimicrobial agents and also as potentially self-detrimental agents.', '3': 'Indeed, histones were found to be the most abundant proteins within neutrophil extracellular traps what ultimately highlighted their microbicidal function.', '4': 'In addition, extracellular histones proved to be involved in triggering exacerbated inflammatory and coagulation responses, depending on the cell type affected.', '5': 'Consequently, several investigations were conducted towards studying the potential of histones and their derivatives as either biomarkers or therapeutic target candidates in different diseases in which inflammation and thrombosis have a key pathophysiological role, such as sepsis, thrombosis and different types of cancer.', '6': 'The main objective of this review is to summarize and discuss the current state of the art with regard to both beneficial and harmful roles of histones and also their possible use as biomarkers and therapeutic targets.'}\n",
            "42: abstract: {'1': 'Histones constitute the chief protein component of DNA.', '2': 'They help to maintain chromatin structure and regulate gene expression.', '3': 'The long double-stranded DNA molecule winds around histone octamers to form nucleosomes which serve the purpose of compacting DNA within the confines of the nuclear membrane.', '4': 'There are five major types of histones, namely H1/H5, H2, H3 and H4.', '5': 'H3.3 is a subtype of H3 histone and can be encoded either by the H3F3A or H3F3B genes independently.', '6': 'Amino acids such as lysine and arginine found in the histone tails are sites of post-translational modifications (PTMs) such as methylation and acetylation.', '7': 'These PTMs in histones are involved in the regulation of gene expression by chromatin remodelling and by controlling DNA methylation patterns.', '8': 'Mutations in histone genes can affect sites of PTMs causing changes in local and global DNA methylation status.', '9': 'These effects are directly linked to neoplastic transformation by altered gene expression.', '10': 'Recurrent H3.3 histone mutations are increasingly identified in several malignancies and developmental disorders.', '11': 'The following review attempts to shed light on the diseases associated with H3.3 histone mutations.'}\n",
            "43: abstract: {'1': 'The first cardiac implantable electronic device (CIED), the electronic pacemaker, maintains cardiac contraction during bradycardia.', '2': 'The implantable cardioverter-defibrillator (ICD) manages ventricular tachycardia (VT) or fibrillation (VF) and saves lives primarily through the use of high-energy shocks.', '3': 'The cardiac resynchronization therapy (CRT) device restores interventricular and intraventricular dyssynchrony in patients with heart failure (HF).', '4': 'Despite >50 years of pacing and 40 years of ICD therapy, the lead remains the weakest link between the device and the patient.'}\n",
            "43: abstract: {'1': \"A pacemaking system consists of an impulse generator and lead or leads to carry the electrical impulse to the patient's heart.\", '2': 'Pacemaker and implantable cardioverter defibrillator codes were made to describe the type of pacemaker or implantable cardioverter defibrillator implanted.', '3': 'Indications for pacing and implantable cardioverter defibrillator implantation were given by the American College of Cardiologists.', '4': 'Certain pacemakers have magnet-operated reed switches incorporated; however, magnet application can have serious adverse effects; hence, devices should be considered programmable unless known otherwise.', '5': 'When a device patient undergoes any procedure (with or without anesthesia), special precautions have to be observed including a focused history/physical examination, interrogation of pacemaker before and after the procedure, emergency drugs/temporary pacing and defibrillation, reprogramming of pacemaker and disabling certain pacemaker functions if required, monitoring of electrolyte and metabolic disturbance and avoiding certain drugs and equipments that can interfere with pacemaker function.', '6': 'If unanticipated device interactions are found, consider discontinuation of the procedure until the source of interference can be eliminated or managed and all corrective measures should be taken to ensure proper pacemaker function should be done.', '7': 'Post procedure, the cardiac rate and rhythm should be monitored continuously and emergency drugs and equipments should be kept ready and consultation with a cardiologist or a pacemaker-implantable cardioverter defibrillator service may be necessary.'}\n",
            "43: abstract: {'1': 'There have been significant advances in pacing and implantable defibrillator technology over the past decade.', '2': 'The relationships between ventricular activation sequence and cardiac mechanical performance are now better appreciated, and will become more completely understood.', '3': 'Even in the setting of infra-His block and bundle branch block, ventricular activation over the Purkinje system can now be achieved in many patients with direct pacing of the His bundle, providing a more physiologic alternative to RV pacing that should avoid pacing induced ventricular dysfunction, as well as provide an alternative to left ventricular pacing for CRT.', '4': 'Advances in the lead technology will increase ease and use of this form of pacing.', '5': 'When activation of the ventricles from the His Purkinje system is not feasible, LV pacing for cardiac resynchronization therapy (CRT) will continue to be important for patients with depressed ventricular function associated with left bundle branch block.', '6': 'Surprisingly, CRT is often beneficial even though present implementation is limited to the few LV pacing sites accessible through the coronary venous system.', '7': 'The advent of pacing leads with multiple electrodes for placement in the coronary venous system is a notable advance, that in contrast to traditional bipolar leads, provides multiple LV pacing configurations from which to select the optimal site for LV pacing without compromising lead stability.', '8': 'This option also addresses problems of phrenic nerve stimulation and high pacing thresholds that often limit delivery of LV pacing.', '9': 'These leads will also allow performance of simultaneous pacing from multiple LV sites, which may improve mechanical performance in situations other than left bundle branch block.'}\n",
            "43: abstract: {'1': 'Pacemakers are electronic devices that stimulate the heart with electrical impulses to maintain or restore a normal heartbeat.', '2': 'In 1952, Zoll described an effective means of supporting the patients with intrinsic cardiac pacemaker activity and/or conducting tissue by an artificial, electric, external pacemaker.', '3': 'The pacing of the heart was accomplished by subcutaneous electrodes but could be maintained only for a short period.', '4': 'In 1957, complete heart block was treated using electrodes directly attached to the heart.', '5': 'These early observations instilled the idea that cardiac electrical failure can be controlled.', '6': 'It ultimately led to the development of totally implantable pacemaker by Chardack, Gage, and Greatbatch.', '7': 'Since then, there have been several advancements in the pacemakers, and the modern-day permanent pacemaker is subcutaneously placed device.', '8': 'There are 3 types of artificial pacemakers: Implantable pulse generators with endocardial or myocardial electrodes;  External, miniaturized, patient portable, battery-powered, pulse generators with exteriorized electrodes for temporary transvenous endocardial or transthoracic myocardial pacing; Console battery or AC-powered cardioverters or monitors with high-current external transcutaneous or low-current endocardial or myocardial circuits for temporary pacing in asynchronous or demand modes, with manual or triggered initiation of pacing.', '9': 'All cardiac pacemakers consist of 2 components: a pulse generator which provides the electrical impulse for myocardial stimulation and 1 or more electrodes or leads which deliver the electrical impulse from the generator to the myocardium.'}\n",
            "43: abstract: {'1': 'Pacemakers are adjustable artificial electrical pulse generators, frequently emitting a pulse with a duration between 0.5 and 25 milliseconds with an output of 0.1 to 15 volts, at a frequency up to 300 times per minute.', '2': 'The cardiologist or pacemaker technologist will be able to interrogate and control the pacing rate, the pulse width, and the voltage, whether the device is temporary or permanent.', '3': 'Pacemakers are typically categorized as external or internal.', '4': 'The external variety is almost always placed for temporary stabilization of the patient or to facilitate some type of surgical procedure.', '5': 'The implantable type is usually permanent and often, significantly more complex than the temporary, external variety.', '6': 'Pacemakers are one type of cardiac implantable electronic devices (known as CIED).', '7': 'This broad category also includes implantable cardioverter-defibrillators (ICDs).', '8': 'Collectively, this group of devices was first introduced in the 1950s, shortly after the advent of the transistor.', '9': 'As technology has improved, so has the pacemaker device.', '10': 'The first implantable ICD was developed in 1980, and since that time, it has become more difficult to differentiate between pacemakers and ICDs.', '11': 'This is because every ICD currently implanted has an anti-bradycardia pacing function.', '12': 'It is critical for the patient and any health care provider to understand which device has been implanted to prevent unnecessary ICD therapy.', '13': 'This is most likely to occur with any electromagnetic interference (EMI) and could lead to activation of the device (if it is an ICD).', '14': 'Most types of CIED use several insulated lead wires with non-insulated tips that are implanted in the heart, either by percutaneous vein insertion or directly by a cardiac surgeon.', '15': 'Cardiac pacemakers are made up of two parts: the pulse generator and the leads or electrodes.'}\n",
            "43: abstract: {'1': 'Cardiac implantable electronic devices (CIEDs) provide lifesaving therapy for the treatment of bradyarrhythmias, ventricular tachyarrhythmias, and advanced systolic heart failure.', '2': 'All pacemakers have 2 basic functions: (1) to pace and (2) to sense intrinsic electrical activity of the heart.', '3': 'Most pacemakers are programmed to inhibit pacing when they sense native electrical activity and only pace in the absence of intrinsic electrical activity.', '4': 'More specifically, pacemakers can be programmed to set which chamber or chambers will pace, which chamber or chambers will sense intrinsic electrical activity, how the pacemaker will respond to sensed electrical activity (ie, inhibit pacing), and if rate-adaptive pacing will be used.'}\n",
            "43: abstract: {'1': 'The human heart is a pivotal organ in the circulatory system, and it beats more than 2 billion times during normal life.', '2': 'This functioning of the heart depends on the cardiac conduction system, which includes impulse generators (e.g., sino-atrial node) and the impulse propagating (His-Purkinje) system.', '3': 'The sinoatrial node acts as the natural pacemaker of the heart.', '4': 'The cells present in the sinus node have innate automaticity, which starts the electrical activity in the heart.', '5': 'This innate electrical potential moves from the sinoatrial node to the atrioventricular node and finally into the His-Purkinje system.', '6': \"This movement of electric potential in an orderly manner controls the rhythmic contraction of the heart's chambers.\", '7': 'The failure of this intrinsic electrical conduction in the heart can result in different arrhythmic problems.', '8': 'Several diseases and conditions affect the conduction system by involving impulse generation, impulse propagation, or both.', '9': 'Acquired conditions such as myocardial infarction, age-related degeneration, procedural complications, and drug toxicity are the major causes of the native conduction system malfunction.', '10': 'The current standard of care for symptomatic bradyarrhythmias due to conduction system diseases is the implantation of a cardiac implantable electronic device.', '11': 'These pacing devices provide an external electrical stimulus that leads to depolarization of myocytes and helps maintain the electrical excitability of the heart tissue.', '12': 'This process leads to excitation-contraction coupling resulting in the contraction of myocardial tissue.'}\n",
            "43: abstract: {'1': 'This article provides an overview of current cardiac device management, complications, and future areas for development.', '2': 'The last 70 years have seen huge advances in the field of implantable cardiac devices, from diagnostic tools to electrical therapies for bradycardia, ventricular arrhythmia and cardiac resynchronisation.', '3': 'While out-of-hours specialist cardiology cover and regional arrhythmia pathways are increasingly established, they are not universal, and the management of arrhythmia remains an important facet of clinical medicine for the general physician.', '4': 'This article discusses core recommendations from international guidelines with respect to heart rhythm diagnostics, pacing for bradycardia, cardiac resynchronisation and implantable cardioverter defibrillators, along with common complications.', '5': 'Finally, future innovations such as the diagnostic potential of portable technologies, antibiotic envelopes for cardiac devices and the increasing use of leadless pacemakers are described.'}\n",
            "43: abstract: {'1': 'Introduction: Cardiac stimulation evolved from life-saving devices to prevent asystole to the treatment of heart rhythm disorders and heart failure, capable of remote patient and disease-progression monitoring.', '2': 'Cardiac stimulation nowadays aims to correct the electrophysiologic roots of mechanical inefficiency in different structural heart diseases.', '3': 'Areas covered: Clinical experience, as per available literature, has led to awareness of the concealed risks of customary cardiac pacing, that can inadvertently cause atrio-ventricular and inter/intra-ventricular dyssynchrony.', '4': \"New pacing modalities have emerged, leading to a new concept of what truly represents 'physiologic pacing' beyond maintenance of atrio-ventricular coupling.\", '5': 'In this article we will analyze the emerging evidence in favor of the available strategies to achieve an individualized physiologic setting in bradycardia pacing, and the hints of future developments.', '6': \"Expert opinion: 'physiologic stimulation' technologies should evolve to enable an effective and widespread adoption.\", '7': 'In one way new guiding catheters and the adoption of electrophysiologic guidance and non-fluoroscopic lead implantation are needed to make His-Purkinje pacing successful and effective at long term in a shorter procedure time; in the other way leadless stimulation needs to upgrade to a superior physiologic setting to mimic customary DDD pacing and possibly His-Purkinje pacing.'}\n",
            "43: abstract: {'1': 'Leadless pacemakers (LPs) have revolutionized the field of pacing by miniaturizing pacemakers and rendering them completelty intracardiac, hence reducing complications related to pacemaker pockets and transvenous leads.', '2': 'However, first generation LPs appear to be associated with a higher rate of myocardial perforation as compared to transvenous pacemakers (TV-PPM).', '3': 'Currently, LPs are predominantly designed to pace the right ventricle with no LPs that provide atrial or biventricular pacing.', '4': 'In this article, we review the available data on LPs while advocating for the need for a randomized controlled trial comparing LPs to TV-PPMs.', '5': 'In addition, we review the future directions of leadless devices.'}\n",
            "44: abstract: {'1': 'This review addresses the pathophysiology and treatment of hemorrhagic shock - a condition produced by rapid and significant loss of intravascular volume, which may lead sequentially to hemodynamic instability, decreases in oxygen delivery, decreased tissue perfusion, cellular hypoxia, organ damage, and death.', '2': 'Hemorrhagic shock can be rapidly fatal.', '3': 'The primary goals are to stop the bleeding and to restore circulating blood volume.', '4': 'Resuscitation may well depend on the estimated severity of hemorrhage.', '5': 'It now appears that patients with moderate hypotension from bleeding may benefit by delaying massive fluid resuscitation until they reach a definitive care facility.', '6': 'On the other hand, the use of intravenous fluids, crystalloids or colloids, and blood products can be life saving in those patients who are in severe hemorrhagic shock.', '7': 'The optimal method of resuscitation has not been clearly established.', '8': 'A hemoglobin level of 7-8 g/dl appears to be an appropriate threshold for transfusion in critically ill patients with no evidence of tissue hypoxia.', '9': 'However, maintaining a higher hemoglobin level of 10 g/dl is a reasonable goal in actively bleeding patients, the elderly, or individuals who are at risk for myocardial infarction.', '10': 'Moreover, hemoglobin concentration should not be the only therapeutic guide in actively bleeding patients.', '11': 'Instead, therapy should be aimed at restoring intravascular volume and adequate hemodynamic parameters.'}\n",
            "44: abstract: {'1': 'Uncontrolled bleeding is the leading cause of shock in trauma patients and delays in recognition and treatment have been linked to adverse outcomes.', '2': 'For prompt detection and management of hypovolaemic shock, ATLS(®) suggests four shock classes based upon vital signs and an estimated blood loss in percent.', '3': 'Although this classification has been widely implemented over the past decades, there is still no clear prospective evidence to fully support this classification.', '4': 'In contrast, it has recently been shown that this classification may be associated with substantial deficits.', '5': 'A retrospective analysis of data derived from the TraumaRegister DGU(®) indicated that only 9.3% of all trauma patients could be allocated into one of the ATLS(®) shock classes when a combination of the three vital signs heart rate, systolic blood pressure and Glasgow Coma Scale was assessed.', '6': 'Consequently, more than 90% of all trauma patients could not be classified according to the ATLS(®) classification of hypovolaemic shock.', '7': 'Further analyses including also data from the UK-based TARN registry suggested that ATLS(®) may overestimate the degree of tachycardia associated with hypotension and underestimate mental disability in the presence of hypovolaemic shock.', '8': 'This finding was independent from pre-hospital treatment as well as from the presence or absence of a severe traumatic brain injury.', '9': 'Interestingly, even the underlying trauma mechanism (blunt or penetrating) had no influence on the number of patients who could be allocated adequately.', '10': 'Considering these potential deficits associated with the ATLS(®) classification of hypovolaemic shock, an online survey among 383 European ATLS(®) course instructors and directors was performed to assess the actual appreciation and confidence in this tool during daily clinical trauma care.', '11': 'Interestingly, less than half (48%) of all respondents declared that they would assess a potential circulatory depletion within the primary survey according to the ATLS(®) classification of hypovolaemic shock.', '12': 'Based on these observations, a critical reappraisal of the current ATLS(®) classification of hypovolaemic seems warranted.'}\n",
            "44: abstract: {'1': 'Current monitoring technologies are unable to detect early, compensatory changes that are associated with significant blood loss.', '2': 'We previously introduced a novel algorithm to calculate the Compensatory Reserve Index (CRI) based on the analysis of arterial waveform features obtained from photoplethysmogram recordings.', '3': 'In the present study, we hypothesized that the CRI would provide greater sensitivity and specificity to detect blood loss compared with traditional vital signs and other hemodynamic measures.', '4': 'Continuous noninvasive vital sign waveform data, including CRI, photoplethysmogram, heart rate, blood pressures, SpO2, cardiac output, and stroke volume, were analyzed from 20 subjects before, during, and after an average controlled voluntary hemorrhage of ∼1.2 L of blood.', '5': 'Compensatory Reserve Index decreased by 33% in a linear fashion across progressive blood volume loss, with no clinically significant alterations in vital signs.', '6': 'The receiver operating characteristic area under the curve for the CRI was 0.90, with a sensitivity of 0.80 and specificity of 0.76.', '7': 'In comparison, blood pressures, heart rate, SpO2, cardiac output, and stroke volume had significantly lower receiver operating characteristic area under the curve values and specificities for detecting the same volume of blood loss.', '8': 'Consistent with our hypothesis, CRI detected blood loss and restoration with significantly greater specificity than did other traditional physiologic measures.', '9': 'Single measurement of CRI may enable more accurate triage, whereas CRI monitoring may allow for earlier detection of casualty deterioration.'}\n",
            "44: abstract: {'1': 'Development of a human model of hemorrhage has provided a unique opportunity to investigate the underlying physiology that defines the individual capacity to avoid the life-threatening clinical condition of inadequate tissue oxygenation known as “shock.”', '2': 'The experimental approach of progressively reducing central blood volume to the point of hemodynamic decompensation with the use of lower body negative pressure has revealed stark distinctions in the physiological compensatory responses between individuals with high compared with low tolerances to blood loss.', '3': 'High tolerance to hemorrhage is defined by a capacity to maintain systemic perfusion pressure and reduce the rate of cerebral hypoperfusion by: (1) protecting cardiac output with greater elevations in heart rate associated with greater cardiac vagal withdrawal and sympathetically mediated adrenergic stimulation; (2) greater increases in systemic peripheral vascular resistance associated with higher sympathetic nerve activation and levels of circulating vasopressor endocrine responses; (3) alternating blood flow between the brain and peripheral tissue with greater sympathetically mediated oscillatory patterns of systemic pressure and flow; and (4) enhancing cardiac filling and cerebral perfusion pressure gradient by optimizing the respiratory pump.', '4': 'When the capacity for these compensatory responses is exhausted, an active vasodilation drops resistance to blood flow allowing for increased perfusion of peripheral tissue.', '5': 'When cardiac filling is no longer adequate to maintain systemic pressure and flow, a reflex-mediated pronounced bradycardia leads to the initiation of decompensatory shock.'}\n",
            "44: abstract: {'1': 'Etiology: Though most commonly thought of in the setting of trauma, there are numerous causes of hemorrhagic shock that span many systems.', '2': 'Blunt or penetrating trauma is the most common cause, followed by upper and lower gastrointestinal sources.', '3': 'Obstetrical, vascular, iatrogenic, and even urological sources have all been described.', '4': 'Bleeding may be either external or internal.', '5': 'A substantial amount of blood loss to the point of hemodynamic compromise may occur in the chest, abdomen, or retroperitoneum.', '6': 'The thigh itself can hold up to 1 L to 2 L of blood.', '7': 'Pathophysiology: Hemorrhagic shock is due to the depletion of intravascular volume through blood loss to the point of being unable to match the tissues demand for oxygen.', '8': 'As a result, mitochondria are no longer able to sustain aerobic metabolism for the production of oxygen and switch to the less efficient anaerobic metabolism to meet the cellular demand for adenosine triphosphate.', '9': 'In the latter process, pyruvate is produced and converted to lactic acid to regenerate nicotinamide adenine dinucleotide (NAD+) to maintain some degree of cellular respiration in the absence of oxygen.', '10': 'The body compensates for volume loss by increasing heart rate and contractility, followed by baroreceptor activation resulting in sympathetic nervous system activation and peripheral vasoconstriction.', '11': 'Typically, there is a slight increase in the diastolic blood pressure with narrowing of the pulse pressure.', '12': 'As diastolic ventricular filling continues to decline and cardiac output decreases, systolic blood pressure drops.', '13': 'Due to sympathetic nervous system activation, blood is diverted away from noncritical organs and tissues to preserve blood supply to vital organs such as the heart and brain.', '14': 'While prolonging heart and brain function, this also leads to other tissues being further deprived of oxygen causing more lactic acid production and worsening acidosis.', '15': 'This worsening acidosis along with hypoxemia, if left uncorrected, eventually causes the loss of peripheral vasoconstriction, worsening hemodynamic compromise, and death.', '16': 'The body’s compensation varies by cardiopulmonary comorbidities, age, and vasoactive medications.', '17': 'Due to these factors, heart rate and blood pressure responses are extremely variable and, therefore, cannot be relied upon as the sole means of diagnosis.'}\n",
            "44: abstract: {'1': 'Background: We endeavored to develop clinically translatable nonhuman primate (NHP) models of severe polytraumatic hemorrhagic shock.', '2': 'Methods: NHPs were randomized into five severe pressure-targeted hemorrhagic shock (PTHS) ± additional injuries scenarios: 30-min PTHS (PTHS-30), 60-min PTHS (PTHS-60), PTHS-60 + soft tissue injury (PTHS-60+ST), PTHS-60+ ST + femur fracture (PTHS-60+ST+FF), and decompensated PTHS+ST+FF (PTHS-D).', '3': 'Physiologic parameters were recorded and blood samples collected at five time points with animal observation through T = 24 h.', '4': \"Results presented as mean ± SEM; statistics: log transformation followed by two-way ANOVA with Bonferroni multiple comparisons, Wilcoxon nonparametric test for comparisons, and the Friedmans' one-way ANOVA; significance: P < 0.05.\", '5': 'Results: Percent blood loss was 40% ± 2, 59% ± 3, 52% ± 3, 49% ± 2, and 54% ± 2 for PTHS-30, PTHS-60, PTHS-60+ST, PTHS-60+ST+FF, and PTHS-D, respectively.', '6': 'All animals survived to T = 24 h except one in each of the PTHS-60 and PTHS-60+ST+FF groups and seven in the PTHS-D group.', '7': 'Physiologic, coagulation, and inflammatory parameters demonstrated increasing derangements with increasing model severity.', '8': 'Conclusion: NHPs exhibit a high degree of resilience to hemorrhagic shock and polytrauma as evidenced by moderate perturbations in metabolic, coagulation, and immunologic outcomes with up to 60 min of profound hypotension regardless of injury pattern.', '9': 'Extending the duration of PTHS to the point of decompensation in combination with polytraumatic injury, evoked derangements consistent with those observed in severely injured trauma patients which would require ICU care.', '10': 'Thus, we have successfully established a clinically translatable NHP trauma model for use in testing therapeutic interventions to trauma.'}\n",
            "44: abstract: {'1': 'The term \"shock\" refers to a life-threatening circulatory failure caused by an imbalance between the supply and demand of cellular oxygen.', '2': 'Hypovolemic shock is characterized by a reduction of intravascular volume and a subsequent reduction in preload.', '3': 'The body compensates the loss of volume by increasing the stroke volume, heart frequency, oxygen extraction rate, and later by an increased concentration of 2,3-diphosphoglycerate with a rightward shift of the oxygen dissociation curve.', '4': 'Hypovolemic hemorrhagic shock impairs the macrocirculation and microcirculation and therefore affects many organ systems (e.g. kidneys, endocrine system and endothelium).', '5': 'For further identification of a state of shock caused by bleeding, vital functions, coagulation tests and hematopoietic procedures are implemented.', '6': 'Every hospital should be in possession of a specific protocol for massive transfusions.', '7': 'The differentiated systemic treatment of bleeding consists of maintenance of an adequate homeostasis and the administration of blood products and coagulation factors.'}\n",
            "44: abstract: {'1': 'Hypovolemic shock exists as a spectrum, with its early stages characterized by subtle pathophysiologic tissue insults and its late stages defined by multi-system organ dysfunction.', '2': 'The importance of timely detection of shock is well known, as early interventions improve mortality, while delays render these same interventions ineffective.', '3': 'However, detection is limited by the monitors, parameters, and vital signs that are traditionally used in the intensive care unit (ICU).', '4': 'Many parameters change minimally during the early stages, and when they finally become abnormal, hypovolemic shock has already occurred.', '5': 'The compensatory reserve (CR) is a parameter that represents a new paradigm for assessing physiologic status, as it comprises the sum total of compensatory mechanisms that maintain adequate perfusion to vital organs during hypovolemia.', '6': 'When these mechanisms are overwhelmed, hemodynamic instability and circulatory collapse will follow.', '7': 'Previous studies involving CR measurements demonstrated their utility in detecting central blood volume loss before hemodynamic parameters and vital signs changed.', '8': 'Measurements of the CR have also been used in clinical studies involving patients with traumatic injuries or bleeding, and the results from these studies have been promising.', '9': 'Moreover, these measurements can be made at the bedside, and they provide a real-time assessment of hemodynamic stability.', '10': 'Given the need for rapid diagnostics when treating critically ill patients, CR measurements would complement parameters that are currently being used.', '11': 'Consequently, the purpose of this article is to introduce a conceptual framework where the CR represents a new approach to monitoring critically ill patients.', '12': 'Within this framework, we present evidence to support the notion that the use of the CR could potentially improve the outcomes of ICU patients by alerting intensivists to impending hypovolemic shock before its onset.'}\n",
            "44: abstract: {'1': 'Background: A severe mismatch between the supply and demand of oxygen is the common feature of all types of shock.', '2': 'We present a newly developed, clinically oriented classification of the various types of shock and their therapeutic implications.', '3': 'Results: There are only four major categories of shock, each of which is mainly related to one of four organ systems.', '4': 'Hypovolemic shock relates to the blood and fluids compartment while distributive shock relates to the vascular system; cardiogenic shock arises from primary cardiac dysfunction; and obstructive shock arises from a blockage of the circulation.', '5': 'Hypovolemic shock is due to intravascular volume loss and is treated by fluid replacement with balanced crystalloids.', '6': 'Distributive shock, on the other hand, is a state of relative hypovolemia resulting from pathological redistribution of the absolute intravascular volume and is treated with a combination of vasoconstrictors and fluid replacement.', '7': 'Cardiogenic shock is due to inadequate function of the heart, which shall be treated, depending on the situation, with drugs, surgery, or other interventional procedures.', '8': 'In obstructive shock, hypoperfusion due to elevated resistance shall be treated with an immediate life-saving intervention.', '9': 'Pathogenesis and pathophysiology: The characteristic feature of both, hemorrhagic and traumatic hemorrhagic shock is bleeding.', '10': 'However, differences exist between the two subcategories in terms of the extent of soft tissue damage.', '11': 'Clinically the most significant cause of hemorrhagic shock is acute bleeding from an isolated injury to a large blood vessel, gastrointestinal bleeding, nontraumatic vascular rupture (e.g., aortic aneurysm), obstetric hemorrhage (e.g., uterine atony), and hemorrhage in the region of the ear, nose, and throat (vascular erosion).', '12': 'The shock is triggered by the critical drop in circulating blood volume; massive loss of red blood cells intensifies the tissue hypoxia.'}\n",
            "44: abstract: {'1': 'Introduction: Hemorrhage is the leading cause of preventable death in combat, although early recognition of hemorrhage is still challenging on the battlefield.', '2': 'Hypothesis/Problem: The objective of this study was to describe the shock index (SI) in a healthy military population, and to measure its variation during a controlled blood loss, simulated by blood donation.', '3': 'Methods: A prospective observational study that enrolled military subjects, volunteers for blood donation, was conducted.', '4': 'Demographic and clinical information, concerning both the patient and the blood collection, were recorded.', '5': 'Baseline vital signs were measured, before and after donation, in a 45° supine position.', '6': 'Statistical analysis was performed after calculation of SI.', '7': 'Results: A total of 483 participants were included in the study.', '8': 'The mean blood donation volume was 473mL (SD = 44mL).', '9': 'The median pre- and post-blood donation SI were significantly different: 0.54 (IQR = 0.48-0.63) and 0.57 (IQR = 0.49-0.66), respectively (P = .002).', '10': 'Changes in pre-/post-donation blood pressure (BP) and heart rate (HR) also reached statistical difference but represented a clinically poor relevance.', '11': 'The multivariate analysis showed no significant associations between SI variations and age, sex, body mass index (BMI), sport activities, blood donation volume, and enteral volume replacement (EVR).', '12': 'Conclusion: In this model of mild hemorrhage, SI exhibited significant variations but failed to reach clinical relevance.', '13': 'Further studies are needed to prove the benefit of SI calculation as a possible parameter for early recognition of hemorrhage in combat casualties at the point of injury.'}\n",
            "45: abstract: {'1': 'Background: Pressure ulcers, also known as bedsores, decubitus ulcers and pressure injuries, are localised areas of injury to the skin or the underlying tissue, or both.', '2': 'Dressings are widely used to treat pressure ulcers and promote healing, and there are many options to choose from including alginate, hydrocolloid and protease-modulating dressings.', '3': 'Topical agents have also been used as alternatives to dressings in order to promote healing.', '4': 'A clear and current overview of all the evidence is required to facilitate decision-making regarding the use of dressings or topical agents for the treatment of pressure ulcers.', '5': 'Such a review would ideally help people with pressure ulcers and health professionals assess the best treatment options.', '6': 'This review is a network meta-analysis (NMA) which assesses the probability of complete ulcer healing associated with alternative dressings and topical agents.', '7': 'Main results: We included 51 studies (2947 participants) in this review and carried out NMA in a network of linked interventions for the sole outcome of probability of complete healing.', '8': 'The network included 21 different interventions (13 dressings, 6 topical agents and 2 supplementary linking interventions) and was informed by 39 studies in 2127 participants, of whom 783 had completely healed wounds.', '9': 'We judged the network to be sparse: overall, there were relatively few participants, with few events, both for the number of interventions and the number of mixed treatment contrasts; most studies were small or very small.', '10': 'The consequence of this sparseness is high imprecision in the evidence, and this, coupled with the (mainly) high risk of bias in the studies informing the network, means that we judged the vast majority of the evidence to be of low or very low certainty.', '11': 'We have no confidence in the findings regarding the rank order of interventions in this review (very low-certainty evidence), but we report here a summary of results for some comparisons of interventions compared with saline gauze.', '12': 'We present here only the findings from evidence which we did not consider to be very low certainty, but these reported results should still be interpreted in the context of the very low certainty of the network as a whole.', '13': 'It is not clear whether regimens involving protease-modulating dressings increase the probability of pressure ulcer healing compared with saline gauze (risk ratio (RR) 1.65, 95% confidence interval (CI) 0.92 to 2.94) (moderate-certainty evidence: low risk of bias, downgraded for imprecision).', '14': 'This risk ratio of 1.65 corresponds to an absolute difference of 102 more people healed with protease modulating dressings per 1000 people treated than with saline gauze alone (95% CI 13 fewer to 302 more).', '15': 'It is unclear whether the following interventions increase the probability of healing compared with saline gauze (low-certainty evidence): collagenase ointment (RR 2.12, 95% CI 1.06 to 4.22); foam dressings (RR 1.52, 95% CI 1.03 to 2.26); basic wound contact dressings (RR 1.30, 95% CI 0.65 to 2.58) and polyvinylpyrrolidone plus zinc oxide (RR 1.31, 95% CI 0.37 to 4.62); the latter two interventions both had confidence intervals consistent with both a clinically important benefit and a clinically important harm, and the former two interventions each had high risk of bias as well as imprecision.', '16': \"Authors' conclusions: A network meta-analysis (NMA) of data from 39 studies (evaluating 21 dressings and topical agents for pressure ulcers) is sparse and the evidence is of low or very low certainty (due mainly to risk of bias and imprecision).\", '17': 'Consequently we are unable to determine which dressings or topical agents are the most likely to heal pressure ulcers, and it is generally unclear whether the treatments examined are more effective than saline gauze.', '18': 'More research is needed to determine whether particular dressings or topical agents improve the probability of healing of pressure ulcers.', '19': 'The NMA is uninformative regarding which interventions might best be included in a large trial, and it may be that research is directed towards prevention, leaving clinicians to decide which treatment to use on the basis of wound symptoms, clinical experience, patient preference and cost.'}\n",
            "45: abstract: {'1': 'Background: Pressure ulcers often seriously affect the quality of life of patients.', '2': 'Moist Exposed Burn Ointment (MEBO) has been developed to treat patients with pressure ulcers.', '3': 'The present study aimed to evaluate the efficacy and safety of MEBO in the treatment of pressure ulcers in Chinese patients.', '4': 'Methods: Seventy-two patients with pressure ulcers were randomly assigned to 2 groups who received a placebo or MEBO for 2 months.', '5': 'The primary outcomes included the wound surface area (WSA) and pressure ulcer scale for healing (PUSH) tool.', '6': 'The secondary outcomes included a visual analog scale (VAS), questionnaire of ulcer status, and adverse effects.', '7': 'Results: Sixty-seven patients completed the study.', '8': 'After 2 months of treatment, the difference of mean change from the baseline was greater for MEBO (vs placebo) for WSA mean (SD) -6.0 (-8.8, -3.3), PUSH Tool -2.6 (-4.7, -1.5), and VAS score -2.9 (-4.4, -1.7).', '9': 'On the basis of the questionnaire, the pressure ulcers were \"completely healed\" (50.0% vs 16.7%) (P < .05) in patients after 2 months of treatment with MEBO versus placebo.', '10': 'No major adverse effects were found in the 2 groups.', '11': 'Conclusion: We showed that MEBO is effective and well tolerated for improving wound healing in Chinese patients with pressure ulcers.'}\n",
            "45: abstract: {'1': 'Aims: To describe the utilization of clostridial collagenase ointment (CCO) and medicinal honey debridement methods in real-world inpatient and outpatient hospital settings among pressure ulcer (PU) patients and compare the frequency of healthcare re-encounters between CCO- and medicinal honey-treated patients.', '2': 'Materials and methods: De-identified hospital discharge records for patients receiving CCO or medicinal honey methods of debridement and having an ICD-9 code for PU were extracted from the US Premier Healthcare Database.', '3': 'Multivariable analysis was used to compare the frequency of inpatient and outpatient revisits up to 6 months after an index encounter for CCO- vs medicinal honey-treated PUs.', '4': 'Results: The study identified 48,267 inpatients and 2,599 outpatients with PUs treated with CCO or medicinal honeys.', '5': 'Among study inpatients, n = 44,725 (93%) were treated with CCO, and n = 3,542 (7%) with medicinal honeys.', '6': 'CCO and medicinal honeys accounted for 1,826 (70%) and 773 (30%), respectively, of study outpatients.', '7': 'In adjusted models, those treated with CCO had lower odds for inpatient readmissions (OR = 0.86, 95% CI = 0.80-0.94) after inpatient index visits, and outpatient re-encounters both after inpatient (OR = 0.73, 95% CI = 0.67-0.79) and outpatient (OR = 0.78, 95% CI = 0.64-0.95) index visits in 6 months of follow-up.', '8': 'Limitations: The study was observational in nature, and did not adjust for reasons why patients were hospitalized initially, or why they returned to the facility.', '9': 'Although the study adjusted for differences in a variety of demographic, clinical, and hospital characteristics between the treatments, we are not able to rule out selection bias.', '10': 'Conclusion: Patients with CCO-treated PUs returned to inpatient and outpatient hospital settings less often compared with medicinal honey-treated PUs.', '11': 'These results from real-world administrative data help to gain a better understanding of the clinical characteristics of patients with PUs treated with these two debridement methods and the economic implications of debridement choice in the acute care setting.'}\n",
            "45: abstract: {'1': 'Objective: To evaluate the effectiveness of topical pentoxifylline (PTX) on pressure ulcer (PU) healing in critically ill patients.', '2': 'Method: In this randomised, double blind, placebo-controlled clinical trial, patients with category I or II PUs were randomly assigned to receive either topical PTX 5% or a placebo twice daily for 14 days.', '3': 'Changes in PU characteristics (category and size) were assessed.', '4': 'The category of the PU was determined by the Stirling Pressure Ulcer Severity Scale (two-digit) at baseline (day zero), day seven and day 14 of treatment.', '5': 'PU length and width was measured with a disposable ruler and expressed as cm2.', '6': 'Results: A total of 112 adult patients were enrolled in the study.', '7': 'Median PU size and score at day zero were 32 (10.00-69.33)cm2 and 1(1.00-2.00) respectively.', '8': 'In the PTX group, the mean differences (95% confidence interval, CI) of all PU scores and sizes decreased significantly across the intervals (day seven versus day zero, day 14 versus day zero, and day 14 versus day seven), compared with the placebo group', '9': 'Conclusion: The severity and size of PUs improved significantly in patients who received topical PTX 5% ointment twice a day for 14 days compared with those in the placebo group.', '10': 'Topical PTX may be considered as a potential option in the treatment of categories I and II PUs in critically ill patients.'}\n",
            "45: abstract: {'1': 'Products that provide a protective skin barrier play a vital role in defending the skin against the corrosive effect of bodily fluids, including wound exudate, urine, liquid faeces, stoma output and sweat.', '2': 'There are many products to choose from, which can be broadly categorised by ingredients.', '3': 'This article describes the differences in mechanisms of action between barrier products comprising petrolatum and/or zinc oxide, silicone film-forming polymers and cyanoacrylates, and compares the evidence on them.', '4': 'The literature indicates that all types of barrier product are clinically effective, with little comparative evidence indicating that any one ingredient is more efficacious than another, although film-forming polymers and cyanoacrylates have been found to be easier to apply and more cost-effective.', '5': 'However, laboratory evidence, albeit limited, indicates that a concentrated cyanoacrylate produced a more substantial and adherent layer on a porcine explant when compared with a diluted cyanoacrylate and was more effective at protecting skin from abrasion and repeated exposure to moisture than a film-forming polymer.', '6': 'Finally, a silicone-based cream containing micronutrients was found to significantly reduce the incidence of pressure ulceration when used as part of a comprehensive prevention strategy.'}\n",
            "45: abstract: {'1': 'Chronic wounds unresponsive to existing treatments constitute a serious disease burden.', '2': 'Factors that contribute to the pathogenesis of chronic ulcers include oxidative stress, comorbid microbial infections, and the type of immune system response.', '3': 'Preclinically, and in a case study, a formulation containing a Ceratothoa oestroides olive oil extract promoted wound healing.', '4': 'Patients with chronic venous and pressure ulcers, clinically assessed as being unresponsive to healing agents, were treated for 3 months with an ointment containing the C oestroides extract combined with antibiotic and/or antiseptic agents chosen according to the type of bacterial infection.', '5': 'Treatment evaluation was performed using the Bates-Jensen criteria with +WoundDesk and MOWA cell phone applications.', '6': 'After 3 months of treatment, C oestroides resulted in an average decrease of 36% in the Bates-Jensen score of ulcers (P < .000), with the decrease being significant from the first month (P < .007).', '7': 'The combined use of topically applied antibiotics and antiseptics efficiently controlled microbial ulcer infection and facilitated wound healing.', '8': 'In relation to other factors such as initial wound size, chronicity appeared to be an important prognostic factor regarding the extent of wound healing.', '9': 'Future clinical investigations assessing the wound healing efficacy of the C oestroides olive oil extract are warranted.'}\n",
            "45: abstract: {'1': 'Background: Effect of nifedipine on pressure ulcer (PU) healing has not been evaluated in the human subjects yet.', '2': 'Study question: In this study, the effect of topical application of nifedipine 3% ointment on PU healing in critically ill patients was investigated.', '3': 'Study design: This was a randomized, double-blind, placebo-controlled clinical.', '4': 'Measures and outcomes: In this study, 200 patients with stage I or II PU according to 2-digit Stirling Pressure Ulcer Severity Scale were randomized to receive topical nifedipine 3% ointment or placebo twice daily for 14 days.', '5': 'Changes in the size and stage of the ulcers were considered as primary outcome of the study.', '6': 'The stage of the ulcers at baseline and on day 7 and day 14 of study was determined by using 2-digit stirling scale.', '7': 'In addition, the surface area of the wounds was estimated by multiplying width by length.', '8': 'Results: In total, 83 patients in each group completed the study.', '9': 'The groups were matched for the baseline stage and size of PUs.', '10': 'Mean decrease in the stage of PU in the nifedipine group was significantly higher than the placebo group on day 7 (-1.71 vs. -0.16, respectively, P < 0.001) and day 14 (-0.78 vs. -0.09, respectively, P < 0.001).', '11': 'Furthermore, the mean decrease in the surface area of PU was significantly higher in the nifedipine group compared with the placebo group on day 7 (-1.44 vs. -0.32, respectively, P < 0.001) and day 14 (-2.51 vs. -0.24, respectively, P < 0.001) of study.', '12': 'Conclusions: Topical application of nifedipine 3% ointment for 14 days significantly improved the healing process of stage I or II PUs in critically ill patients.'}\n",
            "45: abstract: {'1': 'Introduction: Treatment of decubitus ulcers is a grave medical problem.', '2': 'In many cases, it is difficult to cure a pressure ulcer, especially when it is deep and extensive, and prognosis is usually unfavourable.', '3': 'Treatment of decubitus ulcers requires new specialist dressings, which play an important role in the healing process.', '4': 'Aim: To evaluate therapeutic efficacy of active specialist medical dressings in the treatment of decubitus.', '5': 'Material and methods: Research involved 40 patients - 18 (45%) women and 22 (55%) men, suffering from decubitus ulcers of different size and depth, localized in the sacral region, lasting from 1.5 to 30 months.', '6': 'Patients were randomly assigned to two research groups (20 people each), were treated for 4 weeks with 2 different specialist dressings.', '7': 'ATRAUMAN Ag, which contains silver ions, was used in the first group, while paraffin gauze of BACTIGRAS type was used in the second group.', '8': \"An assessment of pressure ulcers' healing progress was done with a planimetric method, which evaluates the wound surface area.\", '9': 'Results: The analysis results showed a significant statistical decrease in an average decubitus ulcer surface area in both research groups: in the first group by 60.2% (p = 0.001), and in the second group by 32.95% (p < 0.001), which speaks in favour of dressings with silver ions as having better therapeutic effectiveness.', '10': 'Conclusions: Using specialist dressings results in a significant decrease in the decubitus ulcer surface area, depending on the type of dressing and active substances contained within, while silver ions support curative effectiveness of the dressing used.'}\n",
            "45: abstract: {'1': 'Objective: The aim of this study was to investigate the effect of Ma Yinglong Shexiang Hemorrhoids Cream combined with pearl powder on pain and complications in patients with severe pressure ulcers.', '2': 'Methods: One hundred seventeen patients with severe pressure ulcers hospitalized and treated in our hospital (January 2019--December 2019) were divided into Ma Yinglong Musk Hemorrhoid Cream Group (MY Group), Pearl Powder Group (PP Group), and combination with Ma Yinglong Musk Hemorrhoid Cream and Pearl Powder Group (MP group), 39 patients in each group.', '3': 'There was no significant difference in the general data of patients in MY group, PP group, and MP group.', '4': 'By analyzing the differences in clinical efficacy, secondary effects, scar incidence, pain, and clinical indicators of patients in the MY group, PP group, and MP group, the effects of Mayinglong Shexiang Hemorrhoid Cream combined with pearl powder in the treatment of pain and complications in patients with severe pressure ulcers were explored.', '5': 'Results: After treatment, compared with the MY group and the PP group, the MP group had a higher clinical efficacy than the MY group and the PP group.', '6': 'Compared with MY group and PP group, the healing time, dressing change times, and dressing change time of MP group were better than MY group (P < .05).', '7': 'After treatment, the VAS score and incidence of secondary effects of the MP group was significantly lower than that of the MY group and PP group (P < .05).', '8': 'The incidence and area of scar formation in the MP group were lower than those in the MY group and the PP group (P < .05).', '9': 'Conclusion: Compared with Ma Yinglong Musk Hemorrhoid Cream or Pearl Powder, combination of Ma Yinglong Musk Hemorrhoid Cream and Pearl Powder are more effective in treating severe pressure ulcer patients, and can significantly reduce the pain in the affected area and reduce the occurrence of complications.'}\n",
            "45: abstract: {'1': 'Pressure ulcer (PU) is a worldwide problem that is hard to heal because of its prolonged inflammatory response and impaired ECM deposition caused by local hypoxia and repeated ischemia/reperfusion.', '2': 'Our previous study discovered that the non-fouling zwitterionic sulfated poly (sulfobetaine methacrylate) (SBMA) hydrogel can improve PU healing with rapid ECM rebuilding.', '3': 'However, the mechanism of the SBMA hydrogel in promoting ECM rebuilding is unclear.', '4': 'Therefore, in this work, the impact of the SBMA hydrogel on ECM reconstruction is comprehensively studied, and the underlying mechanism is intensively investigated in a rat PU model.', '5': 'The in vivo data demonstrate that compared to the PEG hydrogel, the SBMA hydrogel enhances the ECM remolding by the upregulation of fibronectin and laminin expression as well as the inhibition of MMP-2.', '6': 'Further investigation reveals that the decreased MMP-2 expression of zwitterionic SBMA hydrogel treatment is due to the activation of autophagy through the inhibited PI3K/Akt/mTOR signaling pathway and reduced inflammation.', '7': 'The association of autophagy with ECM remodeling may provide a way in guiding the design of biomaterial-based wound dressing for chronic wound repair.'}\n",
            "46: abstract: {'1': 'Background/aims: The CFTR-Associated Ligand (CAL), a PDZ domain containing protein with two coiled-coil domains, reduces cell surface WT CFTR through degradation in the lysosome by a well-characterized mechanism.', '2': \"However, CAL's regulatory effect on ΔF508 CFTR has remained almost entirely uninvestigated.\", '3': 'Methods: In this study, we describe a previously unknown pathway for CAL by which it regulates the membrane expression of ΔF508 CFTR through arrest of ΔF508 CFTR trafficking in the endoplasmic reticulum (ER) using a combination of cell biology, biochemistry and electrophysiology.', '4': 'Results: We demonstrate that CAL is an ER localized protein that binds to ΔF508 CFTR and is degraded in the 26S proteasome.', '5': 'When CAL is inhibited, ΔF508 CFTR retention in the ER decreases and cell surface expression of mature functional ΔF508 CFTR is observed alongside of enhanced expression of plasma membrane scaffolding protein NHERF1.', '6': 'Chaperone proteins regulate this novel process, and ΔF508 CFTR binding to HSP40, HSP90, HSP70, VCP, and Aha1 changes to improve ΔF508 CFTR cell surface trafficking.', '7': 'Conclusion: Our results reveal a pathway in which CAL regulates the cell surface availability and intracellular retention of ΔF508 CFTR.'}\n",
            "46: abstract: {'1': 'The cystic fibrosis transmembrane conductance regulator (CFTR) is a Cl- channel that apparently has evolved from an ancestral active transporter.', '2': 'Key to the CFTR\\'s switch from pump to channel function may have been the appearance of one or more \"lateral portals.\"', '3': 'Such portals connect the cytoplasm to the transmembrane channel pore, allowing a continuous pathway for the electrodiffusional movement of Cl- ions.', '4': 'However, these portals remain the least well-characterized part of the Cl- transport pathway; even the number of functional portals is uncertain, and if multiple portals do exist, their relative functional contributions are unknown.', '5': \"Here, we used patch-clamp recording to identify the contributions of positively charged amino acid side chains located in CFTR's cytoplasmic transmembrane extensions to portal function.\", '6': 'Mutagenesis-mediated neutralization of several charged side chains reduced single-channel Cl- conductance.', '7': 'However, these same mutations differentially affected channel blockade by cytoplasmic suramin and Pt(NO2)42- anions.', '8': 'We considered and tested several models by which the contribution of these positively charged side chains to one or more independent or non-independent portals to the pore could affect Cl- conductance and interactions with blockers.', '9': 'Overall, our results suggest the existence of a single portal that is lined by several positively charged side chains that interact electrostatically with both Cl- and blocking anions.', '10': 'We further propose that mutations at other sites indirectly alter the function of this single portal.', '11': 'Comparison of our functional results with recent structural information on CFTR completes our picture of the overall molecular architecture of the Cl- permeation pathway.'}\n",
            "46: abstract: {'1': 'Cystic fibrosis (CF) is caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene and remains the most common life-shortening diseases affecting the exocrine organs.', '2': 'The absence of this channel results in an imbalance of ion concentrations across the cell membrane and results in more abnormal secretion and mucus plugging in the gastrointestinal tract and in the lungs of CF patients.', '3': 'The direct introduction of fully functional CFTR by gene therapy has long been pursued as a therapeutical option to restore CFTR function independent of the specific CFTR mutation, but the different clinical trials failed to propose persuasive evidence of this strategy.', '4': 'The last ten years has led to the development of new pharmacotherapies which can activate CFTR function in a mutation-specific manner.', '5': 'Although approximately 2,000 different disease-associated mutations have been identified, a single codon deletion, F508del, is by far the most common and is present on at least one allele in approximately 70% of the patients in CF populations.', '6': 'This strategy is limited by chemistry, the knowledge on CFTR and the heterogenicity of the patients.', '7': 'New research efforts in CF aim to develop other therapeutical approaches to combine different strategies.', '8': 'Targeting RNA appears as a new and an important opportunity to modulate dysregulated biological processes.', '9': 'Abnormal miRNA activity has been linked to numerous diseases, and over the last decade, the critical role of miRNA in regulating biological processes has fostered interest in how miRNA binds to and interacts explicitly with the target protein.', '10': 'Herein, this review describes the different strategies to identify dysregulated miRNA opens up a new concept and new opportunities to correct CFTR deficiency.', '11': 'This review describes therapeutic applications of antisense techniques currently under investigation in CF.'}\n",
            "46: abstract: {'1': 'Background and purpose: Cystic fibrosis (CF) is a lethal autosomal recessive genetic disease that originates from the defective function of the CF transmembrane conductance regulator (CFTR) protein, a cAMP-dependent anion channel involved in fluid transport across epithelium.', '2': 'Because small synthetic transmembrane anion transporters (anionophores) can replace the biological anion transport mechanisms, independent of genetic mutations in the CFTR, such anionophores are candidates as new potential treatments for CF.', '3': 'Experimental approach: In order to assess their effects on cell physiology, we have analysed the transport properties of five anionophore compounds, three prodigiosines and two tambjamines.', '4': 'Chloride efflux was measured in large uni-lamellar vesicles and in HEK293 cells with chloride-sensitive electrodes.', '5': 'Iodide influx was evaluated in FRT cells transfected with iodide-sensitive YFP.', '6': 'Transport of bicarbonate was assessed by changes of pH after a NH4 + pre-pulse using the BCECF fluorescent probe.', '7': 'Assays were also carried out in FRT cells permanently transfected with wild type and mutant human CFTR.', '8': 'Key results: All studied compounds are capable of transporting halides and bicarbonate across the cell membrane, with a higher transport capacity at acidic pH.', '9': 'Interestingly, the presence of these anionophores did not interfere with the activation of CFTR and did not modify the action of lumacaftor (a CFTR corrector) or ivacaftor (a CFTR potentiator).', '10': 'Conclusion and implications: These anionophores, at low concentrations, transported chloride and bicarbonate across cell membranes, without affecting CFTR function.', '11': 'They therefore provide promising starting points for the development of novel treatments for CF.'}\n",
            "46: abstract: {'1': 'Cystic fibrosis (CF) is an autosomal recessive disease caused by the loss of function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein which primarily acts as a chloride channel.', '2': 'CFTR has mainly been studied in epithelial cells although it is also functional and expressed in other cell types including endothelial cells.', '3': 'The present review summarizes current knowledge on the role of the endothelium in CF.', '4': 'More specifically, this review highlights the role of endothelial cells in CF in acting as a semipermeable barrier, as a key regulator of angiogenesis, coagulation, the vascular tone and the inflammatory responses.', '5': 'It could contribute to different aspects of the disease including cardiovascular symptoms, excessive blood vessel formation, pulmonary and portal hypertension and CF-related diabetes.', '6': 'Despite the important role of vascular endothelium in many biological processes, it has largely been under investigated in CF.'}\n",
            "46: abstract: {'1': 'Cystic fibrosis patients display multi-organ system dysfunction (e.g. pancreas, gastrointestinal tract, and lung) with pathogenesis linked to a failure of Cl- secretion from the epithelial surfaces of these organs.', '2': 'If unmanaged, organ dysfunction starts early and patients experience chronic respiratory infection with reduced lung function and a failure to thrive due to gastrointestinal malabsorption.', '3': 'Early mortality is typically caused by respiratory failure.', '4': 'In the past 40 years of newborn screening and improved disease management have driven the median survival up from the mid-teens to 43-53, with most of that improvement coming from earlier and more aggressive management of the symptoms.', '5': 'In the last decade, promising pharmacotherapies have been developed for the correction of the underlying epithelial dysfunction, namely, Cl- secretion.', '6': 'A new generation of systemic drugs target the mutated Cl- channels in cystic fibrosis patients and allow trafficking of the immature mutated protein to the cell membrane (correctors), restore function to the channel once in situ (potentiators), or increase protein levels in the cells (amplifiers).', '7': 'Restoration of channel function prior to symptom development has the potential to significantly change the trajectory of disease progression and their evidence suggests that a modest restoration of Cl- secretion may delay disease progression by decades.', '8': 'In this article, we review epithelial vectorial ion and fluid transport, its quantification and measurement as a marker for cystic fibrosis ion transport dysfunction, and highlight some of the recent therapies targeted at the dysfunctional ion transport of cystic fibrosis.'}\n",
            "46: abstract: {'1': 'Human primary bronchial epithelial cells differentiated in vitro represent a valuable tool to study lung diseases such as cystic fibrosis (CF), an inherited disorder caused by mutations in the gene coding for the Cystic Fibrosis Transmembrane Conductance Regulator.', '2': 'In CF, sphingolipids, a ubiquitous class of bioactive lipids mainly associated with the outer layer of the plasma membrane, seem to play a crucial role in the establishment of the severe lung complications.', '3': 'Nevertheless, no information on the involvement of sphingolipids and their metabolism in the differentiation of primary bronchial epithelial cells are available so far.', '4': 'Here we show that ceramide and globotriaosylceramide increased during cell differentiation, whereas glucosylceramide and gangliosides content decreased.', '5': 'In addition, we found that apical plasma membrane of differentiated bronchial cells is characterized by a higher content of sphingolipids in comparison to the other cell membranes and that activity of sphingolipids catabolic enzymes associated with this membrane results altered with respect to the total cell activities.', '6': 'In particular, the apical membrane of CF cells was characterized by high levels of ceramide and glucosylceramide, known to have proinflammatory activity.', '7': 'On this basis, our data further support the role of sphingolipids in the onset of CF lung pathology.'}\n",
            "46: abstract: {'1': 'Cystic Fibrosis (CF) is an autosomal recessive disease caused by mutations in the CF transmembrane regulator (CFTR) gene, which encodes a chloride channel located at the apical surface of epithelial cells.', '2': 'Unsaturated Fatty Acid (UFA) deficiency has been a persistent observation in tissues from patients with CF.', '3': 'However, the impacts of such deficiencies on the etiology of the disease have been the object of intense debates.', '4': 'The aim of the present review is first to highlight the general consensus on fatty acid dysregulations that emerges from, sometimes apparently contradictory, studies.', '5': 'In a second step, a unifying mechanism for the potential impacts of these fatty acid dysregulations in CF cells, based on alterations of membrane biophysical properties (known as lipointoxication), is proposed.', '6': 'Finally, the contribution of lipointoxication to the progression of the CF disease and how it could affect the efficacy of current treatments is also discussed.'}\n",
            "46: abstract: {'1': 'Background: Cystic fibrosis (CF) is a common life-shortening genetic condition caused by a variant in the cystic fibrosis transmembrane conductance regulator (CFTR) protein.', '2': 'A class II CFTR variant F508del (found in up to 90% of people with CF (pwCF)) is the commonest CF-causing variant.', '3': 'The faulty protein is degraded before reaching the cell membrane, where it needs to be to effect transepithelial salt transport.', '4': 'The F508del variant lacks meaningful CFTR function and corrective therapy could benefit many pwCF.', '5': 'Therapies in this review include single correctors and any combination of correctors and potentiators.'}\n",
            "46: abstract: {'1': 'Cystic fibrosis is a monogenic, autosomal, recessive disease characterized by an alteration of chloride transport caused by mutations in the CFTR (Cystic Fibrosis Transmembrane Conductance Regulator) gene.', '2': 'The loss of Phe residue in position 508 (ΔF508-CFTR) causes an incorrect folding of the protein causing its degradation and electrolyte imbalance.', '3': 'CF patients are extremely predisposed to the development of a chronic inflammatory process of the bronchopulmonary system.', '4': 'When the cells of a tissue are damaged, the immune cells are activated and trigger the production of free radicals, provoking an inflammatory process.', '5': 'In addition to routine therapies, today drugs called correctors are available for mutations such as ΔF508-CFTR as well as for others less frequent ones.', '6': 'These active molecules are supposed to facilitate the maturation of the mutant CFTR protein, allowing it to reach the apical membrane of the epithelial cell.', '7': 'Matrine induces ΔF508-CFTR release from the endoplasmic reticulum to cell cytosol and its localization on the cell membrane.', '8': 'We now have evidence that Matrine and Lumacaftor not only restore the transport of mutant CFTR protein, but probably also counteract the inflammatory process by improving the course of the disease.'}\n",
            "47: abstract: {'1': 'Background: Low serum levels of alkaline phosphatase (ALP) are a hallmark of hypophosphatasia.', '2': 'However, the clinical significance and the underlying genetics of low ALP in unselected populations are unclear.', '3': 'Methods: In order to clarify this issue, we performed a clinical, biochemical and genetic study of 42 individuals (age range 20-77yr) with unexplained low ALP levels.', '4': 'Results: Nine had mild hyperphosphatemia and three had mild hypercalcemia.', '5': 'ALP levels were inversely correlated with serum calcium (r=-0.38, p=0.012), pyridoxal phosphate (PLP; r=-0.51, p=0.001) and urine phosphoethanolamine (PEA; r=-0.49, p=0.001).', '6': 'Although many subjects experienced minor complaints, such as mild musculoskeletal pain, none had major health problems.', '7': 'Mutations in ALPL were found in 21 subjects (50%), including six novel mutations.', '8': 'All but one, were heterozygous mutations.', '9': 'Missense mutations were the most common (present in 18 subjects; 86%) and the majority were predicted to have a damaging effect on protein activity.', '10': 'The presence of a mutated allele was associated with tooth loss (48% versus 12%; p=0.04), slightly lower levels of serum ALP (p=0.002), higher levels of PLP (p<0.0001) and PEA (p<0.0001), as well as mildly increased serum phosphate (p=0.03).', '11': 'Ten individuals (24%) had PLP levels above the reference range; all carried a mutated allele.', '12': 'Conclusion: One-half of adult individuals with unexplained low serum ALP carried an ALPL mutation.', '13': 'Although the associated clinical manifestations are usually mild, in approximately 50% of the cases, enzyme activity is low enough to cause substrate accumulation and may predispose to defects in calcified tissues.'}\n",
            "47: abstract: {'1': 'Hypophosphatasia is the inborn error of metabolism characterized by low serum alkaline phosphatase activity (hypophosphatasaemia).', '2': 'This biochemical hallmark reflects loss-of-function mutations within the gene that encodes the tissue-nonspecific isoenzyme of alkaline phosphatase (TNSALP).', '3': 'TNSALP is a cell-surface homodimeric phosphohydrolase that is richly expressed in the skeleton, liver, kidney and developing teeth.', '4': 'In hypophosphatasia, extracellular accumulation of TNSALP natural substrates includes inorganic pyrophosphate, an inhibitor of mineralization, which explains the dento-osseous and arthritic complications featuring tooth loss, rickets or osteomalacia, and calcific arthopathies.', '5': \"Severely affected infants sometimes also have hypercalcaemia and hyperphosphataemia due to the blocked entry of minerals into the skeleton, and pyridoxine-dependent seizures from insufficient extracellular hydrolysis of pyridoxal 5'-phosphate, the major circulating form of vitamin B6, required for neurotransmitter synthesis.\", '6': 'Autosomal recessive or dominant inheritance from ~300 predominantly missense ALPL (also known as TNSALP) mutations largely accounts for the remarkably broad-ranging expressivity of hypophosphatasia.', '7': \"High serum concentrations of pyridoxal 5'-phosphate represent a sensitive and specific biochemical marker for hypophosphatasia.\", '8': 'Also, phosphoethanolamine levels are usually elevated in serum and urine, though less reliably for diagnosis.', '9': 'TNSALP mutation detection is important for recurrence risk assessment and prenatal diagnosis.', '10': 'Diagnosing paediatric hypophosphatasia is aided by pathognomic radiographic changes when the skeletal disease is severe.', '11': 'Hypophosphatasia was the last type of rickets or osteomalacia to await a medical treatment.', '12': 'Now, significant successes for severely affected paediatric patients are recognized using asfotase alfa, a bone-targeted recombinant TNSALP.'}\n",
            "47: abstract: {'1': 'Hypophosphatasia (HPP) is the inborn-error-of-metabolism that features low serum alkaline phosphatase (ALP) activity (hypophosphatasemia) caused by loss-of-function mutation(s) of the gene that encodes the tissue-nonspecific isoenzyme of ALP (TNSALP).', '2': \"Autosomal recessive or autosomal dominant inheritance from among >300 TNSALP (ALPL) mutations largely explains HPP's remarkably broad-ranging severity.\", '3': 'TNSALP is a cell-surface homodimeric phosphohydrolase richly expressed in the skeleton, liver, kidney, and developing teeth.', '4': 'In HPP, TNSALP substrates accumulate extracellularly.', '5': 'Among them is inorganic pyrophosphate (PPi), a potent inhibitor of mineralization.', '6': 'Superabundance of extracellular PPi explains the hard tissue complications of HPP that feature premature loss of deciduous teeth and often rickets or osteomalacia as well as calcific arthropathies in some affected adults.', '7': \"In infants with severe HPP, blocked entry of minerals into the skeleton can cause hypercalcemia, and insufficient hydrolysis of pyridoxal 5'-phosphate (PLP), the major circulating form of vitamin B6, can cause pyridoxine-dependent seizures.\", '8': 'Elevated circulating PLP is a sensitive and specific biochemical marker for HPP.', '9': 'Also, the TNSALP substrate phosphoethanolamine (PEA) is usually elevated in serum and urine in HPP, though less reliably for diagnosis.', '10': 'Pathognomonic radiographic changes occur in pediatric HPP when the skeletal disease is severe.', '11': 'TNSALP mutation analysis is essential for recurrence risk assessment for HPP in future pregnancies and for prenatal diagnosis.', '12': 'HPP was the final rickets/osteomalacia to have a medical treatment.', '13': 'Now, significant successes using asfotase alfa, a mineral-targeted recombinant TNSALP, are published concerning severely affected newborns, infants, and children.', '14': 'Asfotase alfa was approved by regulatory agencies multinationally in 2015 typically for pediatric-onset HPP.'}\n",
            "47: abstract: {'1': 'A majority of adults with persistently low serum alkaline phosphatase values carry a pathogenic or likely pathogenic variant in the ALPL gene and also have elevated alkaline phosphatase substrate values in serum and urine.', '2': 'These adults may fall within the spectrum of the adult form of hypophosphatasia.', '3': 'Introduction: The primary objective of this study was to determine what proportion of adults with persistently low serum alkaline phosphatase values (hypophosphatasemia) harbor mutations in the ALPL gene or have elevated alkaline phosphatase (ALP) substrates.', '4': 'Some adults with persistent hypophosphatasemia share clinical and radiographic features with the adult form of hypophosphatasia (HPP).', '5': 'In HPP, ALPL mutations result in persistent hypophosphatasemia and ALP substrate accumulation in plasma (pyridoxal-5-phosphate (PLP)) and urine (phosphoethanolamine (PEA)).', '6': 'Methods: Biochemical analyses, including serum ALP activity, bone-specific ALP, plasma PLP, and urine PEA, were performed in adults with persistent hypophosphatasemia.', '7': 'Mutational analyses were performed using PCR and Sanger sequencing methods.', '8': 'Gene variants were classified as pathogenic (P), likely pathogenic (LP), variants of uncertain significance (VUS), likely benign (LB), and benign (B).', '9': 'P and LP variants were further grouped as \"Positive ALPL variants\" and LB and B grouped as \"Negative ALPL variants.\"', '10': 'Results: Fifty subjects completed all mutational and biochemical analyses.', '11': 'Sixteen percent carried only Negative ALPL variants.', '12': 'Of the remaining 42 subjects, 67% were heterozygous for a P variant, 19% for an LP variant, and 14% for a VUS.', '13': 'Biochemical results were highly inter-correlated and consistent with the expected inverse relationship between ALP and its substrates.', '14': 'Subjects harboring Positive ALPL variants showed lower ALP and BSAP and higher PLP and PEA values compared with subjects harboring only Negative ALPL variants.', '15': 'Approximately half of all subjects harboring Positive ALPL variants or ALPL VUS showed elevations in plasma PLP, and three quarters showed elevations in urine PEA.', '16': 'Conclusion: Adults with persistent hypophosphatasemia frequently harbor ALPL mutations and have elevated ALP substrates.', '17': 'These adults may fall within the spectrum of the adult form of hypophosphatasia.', '18': 'Clinicians should take note of persistent hypophosphatasemia in their patients and be cautious in prescribing bisphosphonates when present.'}\n",
            "47: abstract: {'1': 'Purpose: The study aimed to define the clinical, biochemical and genetic features of adult patients with osteopenia/osteoporosis and/or bone fragility and low serum alkaline phosphatase (sALP).', '2': 'Methods: Twenty-two patients with at least two sALP values below the reference range were retrospectively enrolled after exclusion of secondary causes.', '3': \"Data about clinical features, mineral and bone markers, serum pyridoxal-5'-phosphate (PLP), urine phosphoethanolamine (PEA), lumbar and femur bone densitometry, and column X-ray were collected.\", '4': 'Peripheral blood DNA of each participant was analyzed to detect ALPL gene anomalies.', '5': 'Results: Pathogenic ALPL variants (pALPL) occurred in 23% and benign variants in 36% of patients (bALPL), while nine patients harbored wild-type alleles (wtALPL).', '6': 'Fragility fractures and dental anomalies were more frequent in patients harboring pALPL and bALPL than in wtALPL patients.', '7': 'Of note, wtALPL patients comprised women treated with tamoxifen for hormone-sensitive breast cancer.', '8': 'Mineral and bone markers were similar in the three groups.', '9': 'Mean urine PEA levels were significantly higher in patients harboring pALPL than those detected in patients harboring bALPL and wtALPL; by contrast, serum PLP levels were similar in the three groups.', '10': 'A 6-points score, considering clinical and biochemical features, was predictive of pALPL detection [P = 0.060, OR 1.92 (95% CI 0.972, 3.794)], and more significantly of pALPL or bALPL [P = 0.025, OR 14.33 (95% CI 1.401, 14.605)].', '11': 'Conclusion: In osteopenic/osteoporotic patients, single clinical or biochemical factors did not distinguish hypophosphatasemic patients harboring pALPL or bALPL from those harboring wtALPL.', '12': 'Occurrence of multiple clinical and biochemical features is predictive of ALPL anomalies, and, therefore, they should be carefully identified.', '13': 'Tamoxifen emerged as a hypophosphatasemic drug.'}\n",
            "47: abstract: {'1': 'Background: Severe hypercalcemia is rare in newborns; even though often asymptomatic, it may have important sequelae.', '2': 'Hypophosphatemia can occur in infants experiencing intrauterine malnutrition, sepsis and early high-energy parenteral nutrition (PN) and can cause severe hypercalcemia through an unknown mechanism.', '3': 'Monitoring and supplementation of phosphate (PO4) and calcium (Ca) in the first week of life in preterm infants are still debated.', '4': \"Case presentation: We report on a female baby born at 29 weeks' gestation with intrauterine growth retardation (IUGR) experiencing sustained severe hypercalcemia (up to 24 mg/dl corrected Ca) due to hypophosphatemia while on phosphorus-free PN.\", '5': 'Hypercalcemia did not improve after hyperhydration and furosemide but responded to infusion of PO4.', '6': 'Eventually, the infant experienced symptomatic hypocalcaemia (ionized Ca 3.4 mg/dl), likely exacerbated by contemporary infusion of albumin.', '7': 'Subsequently, a normalization of both parathyroid hormone (PTH) and alkaline phosphatase (ALP) was observed.', '8': 'Conclusions: Although severe hypercalcemia is extremely rare in neonates, clinicians should be aware of the possible occurrence of this life-threatening condition in infants with or at risk to develop hypophosphatemia.', '9': 'Hypophosphatemic hypercalcemia can only be managed with infusion of PO4, with strict monitoring of Ca and PO4 concentrations.'}\n",
            "47: abstract: {'1': 'Background: Hypophosphatasia (HPP) is an inborn disease caused by pathogenic variants in ALPL.', '2': 'Low levels of alkaline phosphatase (ALP) are a biochemical hallmark of the disease.', '3': 'Scarce knowledge about the prevalence of HPP in Scandinavia exists, and the variable clinical presentations make diagnostics challenging.', '4': 'The aim of this study was to investigate the prevalence of ALPL variants as well as the clinical and biochemical features among adults with endocrinological diagnoses and persistent hypophosphatasaemia.', '5': 'Methods: A biochemical database containing ALP measurements of 26,121 individuals was reviewed to identify adults above 18 years of age with persistently low levels of ALP beneath range (≤ 35 ± 2.7 U/L).', '6': 'ALPL genetic testing, biochemical evaluations and assessment of clinical features by a systematic questionnaire among included patients, were performed.', '7': 'Results: Among 24 participants, thirteen subjects (54.2%) revealed a disease-causing variant in ALPL and reported mild clinical features of HPP, of which musculoskeletal pain was the most frequently reported (n = 9).', '8': 'The variant c. 571G > A; p.(Glu191 Lys) was identified in six subjects, and an unreported missense variant (c.1019A > C; p.(His340Pro)) as well as a deletion of exon 2 were detected by genetic screening.', '9': \"Biochemical analyses showed no significant differences in ALP (p = 0.059), the bone specific alkaline phosphatase (BALP) (p = 0.056) and pyridoxal-5'-phosphate (PLP) (p = 0.085) between patients with an ALPL variant and negative genetic screening.\", '10': 'Patients with a variant in ALPL had significantly higher PLP levels than healthy controls (p = 0.002).', '11': 'We observed normal ALP activity in some patients classified as mild HPP, and slightly increased levels of PLP in two subjects with normal genetic screening and four healthy controls.', '12': 'Among 51 patients with persistent hypophosphatasaemia, fifteen subjects (29.4%) received antiresorptive treatment.', '13': 'Two patients with unrecognized HPP were treated with bisphosphonates and did not show complications due to the treatment.', '14': 'Conclusions: Pathogenic variants in ALPL are common among patients with endocrinological diagnoses and low ALP.', '15': 'Regarding diagnostics, genetic testing is necessary to identify mild HPP due to fluctuating biochemical findings.', '16': 'Antiresorptive treatment is a frequent reason for hypophosphatasaemia and effects of these agents in adults with a variant in ALPL and osteoporosis remain unclear and require further studies.'}\n",
            "47: abstract: {'1': 'Summary: Hypophosphatasia (HPP) is a rare and under-recognised genetic defect in bone mineralisation.', '2': 'Patients presenting with fragility fractures may be mistakenly diagnosed as having osteoporosis and prescribed antiresorptive therapy, a treatment which may increase fracture risk.', '3': 'Adult-onset HPPhypophosphatasia was identified in a 40-year-old woman who presented with bilateral atypical femoral fractures after 4 years of denosumab therapy.', '4': 'A low serum alkaline phosphatase (ALP) and increased serum vitamin B6 level signalled the diagnosis, which was later confirmed by identification of two recessive mutations of the ALPL gene.', '5': 'The patient was treated with teriparatide given the unavailability of ALP enzyme-replacement therapy (asfotase alfa).', '6': 'Fracture healing occurred, but impaired mobility persisted.', '7': 'HPP predisposes to atypical femoral fracture (AFF) during antiresorptive therapy; hence, bisphosphonates and denosumab are contraindicated in this condition.', '8': \"Screening patients with fracture or 'osteoporosis' to identify a low ALP level is recommended.\", '9': 'Learning points: Hypophosphatasia (HPP) is a rare and under-recognised cause of bone fragility produced by impaired matrix mineralisation that can be misdiagnosed as a fragility fracture due to age-related bone loss.', '10': 'Antiresorptive therapy is contraindicated in HPP.', '11': 'Low serum alkaline phosphatase (ALP) provides a clue to the diagnosis.', '12': 'Elevated serum vitamin B6 (an ALP substrate) is indicative of HPP, while identification of a mutation in the ALPL gene is confirmatory.', '13': 'Enzyme therapy with recombinant ALP (asfotase alfa) is currently prohibitively costly.', '14': 'Treatment with anabolic bone agents such as teriparatide has been reported, but whether normally mineralized bone is formed requires further study.'}\n",
            "47: abstract: {'1': 'Hypophosphatasia (HPP) is the heritable dento-osseous disease caused by loss-of-function mutation(s) of the gene ALPL that encodes the tissue-nonspecific isoenzyme of alkaline phosphatase (TNSALP).', '2': 'TNSALP is a cell-surface homodimeric phosphomonoester phosphohydrolase expressed in healthy people especially in the skeleton, liver, kidneys, and developing teeth.', '3': \"In HPP, diminished TNSALP activity leads to extracellular accumulation of its natural substrates including inorganic pyrophosphate (PPi), an inhibitor of mineralization, and pyridoxal 5'-phosphate (PLP), the principal circulating form of vitamin B6 (B6).\", '4': 'Autosomal dominant and autosomal recessive inheritance involving >450 usually missense defects scattered throughout ALPL largely explains the remarkably broad-ranging severity of this inborn-error-of-metabolism.', '5': 'In 1985 when we identified elevated plasma PLP as a biochemical hallmark of HPP, all 14 investigated affected children and adults had markedly increased PLP levels.', '6': 'However, pyridoxal (PL), the dephosphorylated form of PLP that enters cells to cofactor many enzymatic reactions, was not low but often inexplicably elevated.', '7': 'Levels of pyridoxic acid (PA), the B6 degradation product quantified to assess B6 sufficiency, were unremarkable.', '8': 'Canonical signs or symptoms of B6 deficiency or toxicity were absent.', '9': 'B6-dependent seizures in infants with life-threatening HPP were later explained by their profound deficiency of TNSALP activity blocking PLP dephosphorylation to PL and diminishing gamma-aminobutyric acid synthesis in the brain.', '10': 'Now, there is speculation that altered B6 metabolism causes further clinical complications in HPP.', '11': 'Herein, we assessed the plasma PL and PA levels accompanying previously reported elevated plasma PLP concentrations in 150 children and adolescents with HPP.', '12': 'Their mean (SD) plasma PL level was nearly double the mean for our healthy pediatric controls: 66.7 (59.0) nM versus 37.1 (22.2) nM (P < 0.0001), respectively.', '13': 'Their PA levels were broader than our pediatric control range, but their mean value was normal; 40.2 (25.1) nM versus 39.3 (9.9) nM (P = 0.7793), respectively.', '14': 'In contrast, adults with HPP often had plasma PL and PA levels suggestive of dietary B6 insufficiency.', '15': 'We discuss why the B6 levels of our pediatric patients with HPP would not cause B6 toxicity or deficiency, whereas in affected adults dietary B6 insufficiency can develop.'}\n",
            "47: abstract: {'1': 'Background: Tissue-nonspecific alkaline phosphatase (TNSALP) encoded by the ALPL gene is of particular importance for bone mineralization.', '2': 'Mutation in the ALPL gene can lead to persistent low ALP activity resulting in the rare disease Hypophosphatasia (HPP) that is characterized by disturbed bone and dental mineralization.', '3': 'While severe forms are extremely rare with an estimated prevalence of 1/100.000, recent studies suggest that moderate form caused by heterozygous mutations are much more frequent with an estimated prevalence of 1/508.', '4': 'The purpose of this study was to estimate the prevalence of low AP levels in the population based on laboratory measurements.', '5': 'Methods: In this study, the prevalence of low AP activity and elevated pyridoxal-5-phosphate (PLP) levels was analyzed in 6.918.126 measurements from 2011 to 2016 at a single laboratory in northern Germany.', '6': 'Only laboratory values of subjects older than 18 years of age were included.', '7': 'Only the first measurement was included, all repeated values were excluded.', '8': 'Results: In total, 8.46% of the measurements of a total of 6.918.126 values showed a value < 30 U/L. 0.59% of the subjects with an ALP activity below 30 U/L had an additional PLP measurement.', '9': 'Here, 6.09% showed elevated pyridoxal-5-phosphate (PLP) levels.', '10': 'This suggest that 0.52% (1:194) of subjects show laboratory signs of HPP.', '11': 'Conclusion: These data support the genetic estimation that the prevalence of moderate forms of HPP may be significantly higher than expected.', '12': 'Based on these data, we recommend automatically measurement of PLP in the case of low ALP activity and a notification to the ordering physician that HPP should be included in the differential diagnosis and further exploration is recommended.'}\n",
            "48: abstract: {'1': 'Objectives: To characterize the relationship of anifrolumab pharmacokinetics with efficacy and safety in patients with moderate to severe SLE despite standard therapy, using pooled data from 2 phase 3 trials.', '2': 'Methods: TULIP-1 and TULIP-2 were randomized, placebo-controlled, 52-week trials of intravenous anifrolumab (every 4 weeks for 48 weeks).', '3': 'For the exposure-response analysis, BILAG-based Composite Lupus Assessment (BICLA) or SLE Responder Index (SRI[4]) response rates at week 52 in each quartile/tertile of average anifrolumab serum concentration (Cave) were compared for anifrolumab and placebo in all-comers, patients who completed treatment, and interferon gene signature (IFNGS)-high patients who completed treatment, using average marginal effect logistic regression.', '4': 'Relationships between exposure and key safety events were assessed graphically.', '5': 'Results: Of patients in TULIP-1/TULIP-2 who received anifrolumab (150 mg [n = 91], 300 mg [n = 356]) or placebo (n = 366), 574 completed treatment, of whom 470 were IFNGS high.', '6': 'In the exposure-efficacy analyses, BICLA and SRI(4) treatment differences favoring anifrolumab 300 mg vs placebo were observed across Cave subgroups and all analysis populations.', '7': 'Logistic regression identified Cave as a significant covariate for predicted BICLA response, as higher anifrolumab Cave predicted greater efficacy.', '8': 'There was no evidence of exposure-driven incidence of key safety events through week 52 in patients receiving anifrolumab 150 or 300 mg.', '9': 'Conclusion: While higher Cave predicted greater efficacy, consistent positive benefit favouring anifrolumab 300 mg vs placebo was observed in BICLA and SRI(4) responses across Cave subgroups in the TULIP trials.', '10': 'There was no evidence of exposure-driven safety events.'}\n",
            "48: abstract: {'1': 'Lupus nephritis (LN) is the most frequent severe organ manifestation of systemic lupus erythematosus (SLE).', '2': 'About 30% of patients are refractory to treatment.', '3': 'The authors report a case of treatment of LN with interleukin-17-targeted therapy, demonstrating its possible benefit, after reports of T helper 17 cell involvement in SLE pathogenesis.', '4': 'We present the case of a childbearing age woman with SLE, who developed refractory LN despite all the indicated therapeutic options.', '5': 'During follow up, infection with human papillomavirus was detected, a possible trigger, and the following management was based on this discovery.', '6': 'We currently know that cytokines play a major role in tissue damage and interleukin-17 (IL-17) seems to be a fundamental key in SLE and LN, having shown its expression in renal glomeruli and urinary sediment.', '7': 'Thus, it was decided to start treatment with an anti-IL-17A antibody, secukinumab.', '8': 'After starting secukinumab, clinical and biological features improved and complete renal response was achieved.'}\n",
            "48: abstract: {'1': 'Systemic lupus erythematosus (SLE) is a common autoimmune connective tissue disease with unclear etiology and pathogenesis.', '2': 'Mesenchymal stem cell (MSC) and MSC derived extracellular vesicles (EVs) play important roles in regulating innate and adaptive immunity, which are involved in many physiological and pathological processes and contribute to the immune homeostasis in SLE.', '3': 'The effects of MSCs and EVs on SLE have been drawing more and more attention during the past few years.', '4': 'This article reviews the immunomodulatory effects and underlying mechanisms of MSC/MSC-EVs in SLE, which provides novel insight into understanding SLE pathogenesis and guiding the biological therapy.'}\n",
            "48: abstract: {'1': 'Objective: To determine the relative effectiveness and safety of belimumab and anifrolumab in patients with active systemic lupus erythematosus (SLE).', '2': 'Materials and methods: A Bayesian network meta-analysis was performed from randomized controlled trials (RCTs) on the effectiveness and safety of belimumab 10 mg, anifrolumab 300 mg, and a placebo in patients with active SLE.', '3': 'Results: Six RCTs (2,757 patients) were included in this study.', '4': 'The response rate based on the SLE 4 Responder Index (SRI4) at 52 weeks was substantially higher in the belimumab 10-mg and anifrolumab 300-mg groups than that in the placebo group (OR 2.90, % credible intervals (CrIs) 2.37 - 3.56; OR 1.60, % CrI 1.22 - 2.08).', '5': 'The SRI4 response rate for belimumab 10 mg was significantly higher than that for anifrolumab 300 mg (OR 1.82, 95% CrI 1.30 - 2.53).', '6': 'Ranking probability based on surface under the cumulative ranking curve (SUCRA) indicated that belimumab 10 mg was most likely the best treatment for SRI4 response (SUCRA = 0.999), followed by anifrolumab 300 mg (SUCRA = 0.500) and placebo (SUCRA = 0.001).', '7': 'The number of serious adverse events (SAEs) did not differ significantly among the 4 treatment groups.', '8': 'Conclusion: Based on the SRI4 response rate, belimumab 10 mg had the best response efficacy, followed by anifrolumab 10 mg.', '9': 'However, there was no difference in the number of SAEs among the treatment options.'}\n",
            "48: abstract: {'1': 'Objective: Randomised trials of type I anti-CD20 antibodies rituximab and ocrelizumab failed to show benefit in proliferative lupus nephritis (LN).', '2': 'We compared obinutuzumab, a humanised type II anti-CD20 monoclonal antibody that induces potent B-cell depletion, with placebo for the treatment of LN in combination with standard therapies.', '3': 'Methods: Patients with LN receiving mycophenolate and corticosteroids were randomised to obinutuzumab 1000 mg or placebo on day 1 and weeks 2, 24 and 26, and followed through week 104.', '4': 'The primary endpoint was complete renal response (CRR) at week 52.', '5': 'Exploratory analyses through week 104 were conducted.', '6': 'The prespecified alpha level was 0.2. Results: A total of 125 patients were randomised and received blinded infusions.', '7': 'Achievement of CRR was greater with obinutuzumab at week 52 (primary endpoint, 22 (35%) vs 14 (23%) with placebo; percentage difference, 12% (95% CI -3.4% to 28%), p=0.115) and at week 104 (26 (41%) vs 14 (23%); percentage difference, 19% (95% CI 2.7% to 35%), p=0.026).', '8': 'Improvements in other renal response measures, serologies, estimated glomerular filtration rate and proteinuria were greater with obinutuzumab.', '9': 'Obinutuzumab was not associated with increases in serious adverse events, serious infections or deaths.', '10': 'Non-serious infusion-related reactions occurred more frequently with obinutuzumab.', '11': 'Conclusions: Improved renal responses through week 104 were observed in patients with LN who received obinutuzumab plus standard therapies compared with standard therapies alone.', '12': 'Obinutuzumab was well tolerated and no new safety signals were identified.'}\n",
            "48: abstract: {'1': 'Introduction: Low-dose interleukin-2 (IL-2) selectively restores disturbances of regulatory T cells (Treg) and conventional T cells, resulting in the induction of remission in patients with systemic lupus erythematosus.', '2': 'However, to date no research has been carried out on the efficacy of low-dose IL-2 in the treatment of refractory lupus nephritis (LN).', '3': 'The aim of the study reported here was to investigate the renal response to low-dose IL-2 in patients with refractory LN.', '4': 'Methods: The study population comprised ten patients with refractory LN who failed to achieve complete response or who had relapsed while being treated with at least two conventional immunosuppressive agents.', '5': 'One treatment cycle consisted of IL-2 at a dose of 1 million IU administered subcutaneously every other day for 2 weeks followed by a 2-week break.', '6': 'All patients received three cycles of IL-2 and were then followed up for another 12 weeks without any increase in the dose of previous immunosuppressive agents and steroids.', '7': 'Results: Of the ten patients enrolled in the study, seven (70%) achieved ≥ 50% improvement in proteinuria at 12 weeks after initiating treatment with IL-2.', '8': 'Median proteinuria was significantly reduced by 50.3% at week 12, from 1.83 (interquartile range [IQR] 1.23-3.21) g/24 h at baseline to 0.91 (IQR 0.52-1.60) g/24 h at 12 weeks (P = 0.005).', '9': 'This was accompanied by a 71% reduction in urine erythrocytes, from 64/µl (IQR 24-102/µl) at baseline to 18/µl (IQR 2-20/µl) at 12 weeks (P = 0.018).', '10': 'Anti-ds DNA was decreased from 27.9 (IQR 7.6-40.28) IU/ml at baseline to 14.1 (IQR 7.3-20.12) IU/ml (P = 0.021) at week 12, while complements C3 and C4 were slightly increased (P = 0.445, P = 0.241, respectively).', '11': 'A significant expansion of Treg cells, from 9.3% at baseline to 16.6% at 12 weeks, was also found (P < 0.05).', '12': 'No serious adverse events occurred during the treatment period.', '13': 'Conclusions: Low-dose IL-2 therapy may have a promising role in the treatment of refractory LN as an alternative and safe therapeutic approach.', '14': 'It may be used as multi-target combination therapy in clinical practice.'}\n",
            "48: abstract: {'1': 'Significance: Metformin has been proposed as a treatment for systemic lupus erythematosus (SLE).', '2': 'The primary target of metformin, the electron transport chain complex I in the mitochondria, is associated with redox homeostasis in immune cells, which plays a critical role in the pathogenesis of autoimmune diseases.', '3': 'This review addresses the evidence and knowledge gaps on whether a beneficial effect of metformin in lupus may be due to a restoration of a balanced redox state.', '4': 'Recent Advances: Clinical trials in SLE patients with mild to moderate disease activity and preclinical studies in mice have provided encouraging results for metformin.', '5': 'The mechanism by which this therapeutic effect was achieved is largely unknown.', '6': 'Metformin regulates redox homeostasis in a context-specific manner.', '7': 'Multiple cell types contribute to SLE, with evidence of increased mitochondrial oxidative stress in T cells and neutrophils.', '8': 'Critical issues: The major knowledge gaps are whether the efficacy of metformin is linked to a restored redox homeostasis in the immune system, and if it does, in which cell types it occurs?', '9': 'We also need to know which patients may have a better response to metformin, and whether it corresponds to a specific mechanism?', '10': 'Finally, the identification of biomarkers to predict treatment outcomes would be of great value.'}\n",
            "48: abstract: {'1': 'Systemic lupus erythematosus (SLE) is a chronic autoimmune disease.', '2': 'Although previous studies have demonstrated that SLE is related to the imbalance of cells in the immune system, including B cells, T cells, and dendritic cells, etc., the mechanisms underlying SLE pathogenesis remain unclear.', '3': 'Therefore, effective and low side-effect therapies for SLE are lacking.', '4': 'Recently, mesenchymal stem cell (MSC) therapy for autoimmune diseases, particularly SLE, has gained increasing attention.', '5': 'This therapy can improve the signs and symptoms of refractory SLE by promoting the proliferation of Th2 and Treg cells and inhibiting the activity of Th1, Th17, and B cells, etc.', '6': 'However, MSC therapy is also reported ineffective in some patients with SLE, which may be related to MSC- or patient-derived factors.', '7': 'Therefore, the therapeutic effects of MSCs should be further confirmed.', '8': 'This review summarizes the status of MSC therapy in refractory SLE treatment and potential reasons for the ineffectiveness of MSC therapy from three perspectives.', '9': 'We propose various MSC modification methods that may be beneficial in enhancing the immunosuppression of MSCs in SLE.', '10': 'However, their safety and protective effects in patients with SLE still need to be confirmed by further experimental and clinical evidence.'}\n",
            "48: abstract: {'1': 'As treatment options in advanced systematic lupus erythematosus (SLE) are limited, there is an urgent need for new and effective therapeutic alternatives for selected cases with severe disease.', '2': 'Bortezomib (BTZ) is a specific, reversible, inhibitor of the 20S subunit of the proteasome.', '3': 'Herein, we report clinical experience regarding efficacy and safety from all patients receiving BTZ as therapy for SLE in Sweden during the years 2014-2020.', '4': '8 females and 4 males were included with a mean disease duration at BTZ initiation of 8.8 years (range 0.7-20 years).', '5': 'Renal involvement was the main target for BTZ.', '6': 'Reduction of global disease activity was recorded by decreasing SLEDAI-2K scores over time and remained significantly reduced at the 6-month (p=0.007) and the 12-month (p=0.008) follow-up visits.', '7': 'From BTZ initiation, complement protein 3 (C3) levels increased significantly after the 2nd treatment cycle (p=0.05), the 6-month (p=0.03) and the 12-month (p=0.04) follow-up visits.', '8': 'The urine albumin/creatinine ratio declined over time and reached significance at the 6-month (p=0.008) and the 12-month follow-up visits (p=0.004).', '9': 'Seroconversion of anti-dsDNA (27%), anti-C1q (50%) and anti-Sm (67%) was observed.', '10': '6 of 12 patients experienced at least one side-effect during follow-up, whereof the most common adverse events were infections.', '11': 'Safety parameters (C-reactive protein, blood cell counts) mainly remained stable over time.', '12': 'To conclude, we report favorable therapeutic effects of BTZ used in combination with corticosteroids in a majority of patients with severe SLE manifestations irresponsive to conventional immunosuppressive agents.', '13': 'Reduction of proteinuria was observed over time as well as seroconversion of some autoantibody specificities.', '14': 'In most patients, tolerance was acceptable but mild adverse events was not uncommon.', '15': 'Special attention should be paid to infections and hypogammaglobinemia.'}\n",
            "48: abstract: {'1': 'Therapeutic success in treating patients with systemic lupus erythematosus (SLE) is limited by the multivariate disease etiology, multi-organ presentation, systemic involvement, and complex immunopathogenesis.', '2': 'Agents targeting B-cell differentiation and survival are not efficacious for all patients, indicating a need to target other inflammatory mediators.', '3': 'One such target is the type I interferon pathway.', '4': 'Type I interferons upregulate interferon gene signatures and mediate critical antiviral responses.', '5': 'Dysregulated type I interferon signaling is detectable in many patients with SLE and other autoimmune diseases, and the extent of this dysregulation is associated with disease severity, making type I interferons therapeutically tangible targets.', '6': 'The recent approval of the type I interferon-blocking antibody, anifrolumab, by the US Food and Drug Administration for the treatment of patients with SLE demonstrates the value of targeting this pathway.', '7': 'Nevertheless, the interferon pathway has pleiotropic biology, with multiple cellular targets and signaling components that are incompletely understood.', '8': 'Deconvoluting the complexity of the type I interferon pathway and its intersection with lupus disease pathology will be valuable for further development of targeted SLE therapeutics.', '9': 'This review summarizes the immune mediators of the interferon pathway, its association with disease pathogenesis, and therapeutic modalities targeting the dysregulated interferon pathway.'}\n",
            "49: abstract: {'1': 'Edema is an accumulation of fluid in the interstitial space that occurs as the capillary filtration exceeds the limits of lymphatic drainage, producing noticeable clinical signs and symptoms.', '2': 'The rapid development of generalized pitting edema associated with systemic disease requires timely diagnosis and management.', '3': 'The chronic accumulation of edema in one or both lower extremities often indicates venous insufficiency, especially in the presence of dependent edema and hemosiderin deposition.', '4': 'Skin care is crucial in preventing skin breakdown and venous ulcers.', '5': 'Eczematous (stasis) dermatitis can be managed with emollients and topical steroid creams.', '6': 'Patients who have had deep venous thrombosis should wear compression stockings to prevent postthrombotic syndrome.', '7': 'If clinical suspicion for deep venous thrombosis remains high after negative results are noted on duplex ultrasonography, further investigation may include magnetic resonance venography to rule out pelvic or thigh proximal venous thrombosis or compression.', '8': 'Obstructive sleep apnea may cause bilateral leg edema even in the absence of pulmonary hypertension.', '9': 'Brawny, nonpitting skin with edema characterizes lymphedema, which can present in one or both lower extremities.', '10': 'Possible secondary causes of lymphedema include tumor, trauma, previous pelvic surgery, inguinal lymphadenectomy, and previous radiation therapy.', '11': 'Use of pneumatic compression devices or compression stockings may be helpful in these cases.'}\n",
            "49: abstract: {'1': 'Aim: Leg edema, observed on comprehensive geriatric assessment (CGA) of 142 elderly outpatients with a variety of chronic diseases, was studied clinically to clarify its incidence and its associated risk factors.', '2': 'Methods: The severity of pitting edema was assessed at 3 points, namely, the pretibial edge, medial malleolus, and the dorsum of the foot.', '3': 'On palpation, edema was graded as 0 to 3 for each point on one leg, the sum of which was used as the edema score.', '4': 'According to the edema score, subjects were divided into 3 groups; the moderate to severe (MS) group, the slight to mild (SM) group, and the group without pitting edema.', '5': 'The MS group was defined as having an edema score of 4 or more or edema of grade 2 or more, while the SM group was defined as having an edema score of 2 to 3 points without edema of grade 2 or more.', '6': 'The status of underlying disease, vascular risks, varicose veins, medications, daily activity, nutrition, total protein (TP), albumin, brain natriuretic peptide (BNP), and the estimated glomerular filtration rate (eGFR) were compared among the 3 groups.', '7': 'Results: There were 36 subjects in the MS group and 19 subjects in the SM group.', '8': 'Diabetes, atrial fibrillation, varicose veins, and polypharmacy were more frequent in the MS group than in the control group.', '9': 'Sedentary life style, house-bound, and gait trouble were significantly more frequent in the MS and SM groups.', '10': 'There were no significant differences in the scores of the Mini-Nutritional Assessment Short Form among the groups, although both the body weight and calf circumference in the MS group were significantly greater than those in the group without pitting edema.', '11': 'Low serum TP, albumin and eGFR were seen in the MS group as well as high BNP levels.', '12': 'Multiple regression analysis revealed diabetes, varicose veins, sedentarism, and hypoalbuminemia as risk factors associated with leg edema (R(2)=0.365, p<0.0001).', '13': 'Conclusion: Leg edema was frequent in the elderly outpatients and was associated strongly with diabetes, varicose veins, sedentarism, and hypoalbuminemia.', '14': 'These findings suggest that advising against a sedentary life style could help the resolution of edema, and also indicates the clinical usefulness of CGA.', '15': 'Furthermore, leg edema should be seriously considered along with nutritional assessment because edema could influence various anthropometric parameters.'}\n",
            "49: abstract: {'1': 'Symmetrical leg swelling formed in the course of the years is a common and in most cases benign phenomenon that is mostly encountered in the aged population, especially in women.', '2': 'Venous insufficiency of the lower limbs is the most common cause of symmetrical leg swelling among those over 50 years of age.', '3': 'Diseases of the essential organs such as the heart, the liver and the kidneys are excluded during the initial stage.', '4': 'Pitting edema occurs both in venous insufficiency and in right-sided heart failure.', '5': 'Basic tests and drug history are usually sufficient to exclude a host of general causes of the edema.'}\n",
            "49: abstract: {'1': 'Rheumatologists are increasingly aware of the entity synovitis with pitting edema.', '2': \"The remitting seronegative symmetrical synovitis with pitting edema (RS3PE) syndrome has been reported with an array of conditions that include polymyalgia rheumatica, rheumatoid arthritis, Sjögren's syndrome and psoriatic arthropathy.\", '3': 'Synovitis with pitting edema is now being increasingly recognized with systemic lupus erythematosus (SLE).', '4': 'We report a patient who presented with edema of hands and feet and was diagnosed eventually with definite SLE.', '5': 'With magnetic resonance imaging, joint effusions and tenosynovitis were confirmed to be associated with the otherwise-unexplained extremity edema.'}\n",
            "49: abstract: {'1': '46 year old male with past medical history of schizoaffective disorder and chronic lower back pain, was admitted for management of worsening depression and anxiety.', '2': 'He was started on gabapentin, 300mg twice daily for his back pain and anxiety symptoms.', '3': 'His only other medication was hydrocodone.', '4': 'Over next few days, he started developing worsening bilateral lower extremity edema.', '5': 'He did not have any cardiovascular related symptoms.', '6': 'Physical exam was only significant for 3+ pitting edema with all laboratory values and imaging being unremarkable.', '7': 'Gabapentin was discontinued and his lower extremity swelling improved over subsequent days.', '8': 'Incidence of pedal edema with gabapentin use is approximately 7 to 7.5% with all studies being in elderly patients receiving doses above 1200 mg/day.', '9': 'This case illustrates that lower doses of gabapentin can also cause this adverse effect.', '10': 'It is important to recognize this adverse effect because gabapentin is used in conditions like diabetic neuropathy, which is associated with multiple co-morbidities that can give rise to bilateral leg swelling.', '11': 'Presence of gabapentin induced leg swelling can thus confound the clinical picture.'}\n",
            "49: abstract: {'1': 'Background: Leg edema is a common adverse effect of dihydropyridine Calcium Channel Blockers (CCB) that may need dose reduction or drug withdrawal, adversely affecting the antihypertensive efficacy.', '2': 'Leg edema is reported to occur less often with (S)-amlodipine compared to conventional racemic amlodipine.', '3': 'We aimed to find the incidence of leg edema as a primary outcome and antihypertensive efficacy with (S)-amlodipine compared to conventional amlodipine.', '4': 'Methods: This prospective, double-blind, controlled clinical trial randomized 172 hypertensive patients, not controlled on beta-blockers (BB) and angiotensin converting enzyme inhibitors/angiotensin receptor blockers (ACEI/ARB), to either conventional amlodipine (5-10 mg; n = 86) or (S)-amlodipine (2.5-5 mg; n = 86), while continuing their previous anti-hypertensive medications.', '5': 'Sample was sufficient to find a difference in edema between the interventions with 80 % power at 5 % significance level.', '6': 'Intension to treat analysis (ITT) for safety data and per protocol analysis for efficacy data was performed.', '7': \"Fischer's exact test was applied to observe difference between responder rates and proportions of subjects having peripheral edema in the two groups.\", '8': 'Pitting edema test scores were compared using Mann-Whitney test.', '9': 'Results: Altogether 146 patients (amlodipine, n = 76 and (S)-amlodipine, n = 70) completed 120 days treatment.', '10': 'Demographic variables and treatment adherence were comparable in the two groups.', '11': 'Incidence of new edema after randomization was 31.40 % in test group and 46.51 % in control group [p = 0.03; absolute risk reduction (ARR) = 15.1 %; Number Needed to Treat (NNT) = 7, ITT analysis].', '12': 'Pitting edema score and patient rated edema score increased significantly in the control compared to test group (p = 0.038 and 0.036 respectively) after treatment period.', '13': 'Edema scores increased significantly in the control group from baseline (p < 0.0001).', '14': 'Responders in blood pressure were 98.57 % in test and 98.68 % in control group.', '15': 'Most common adverse events (AE) were pitting edema and increased urinary frequency.', '16': 'Incidence of all AEs other than edema was similar in both groups.', '17': 'Two serious AEs occurred unrelated to therapy.', '18': 'Biochemical and ECG parameters in the two groups were comparable.', '19': 'Conclusions: In hypertensive patients not controlled on prior BB and ACEI/ARB therapy, addition of (S)-amlodipine besylate at half the dose of conventional amlodipine provides better tolerability with reduced incidence of peripheral edema, and equal antihypertensive efficacy compared to amlodipine given at usual doses.'}\n",
            "49: abstract: {'1': 'We encountered an elderly male patient who after cardiac surgery for mitral stenosis had refractory pitting edema in both legs involving painful leg joints after a 1-month history of waxing and waning arthralgia.', '2': 'His family doctor had prescribed a combination of diuretics, 40 mg furosemide and 25 mg spironolactone; however, pitting edema in his lower legs persisted.', '3': 'He was diagnosed with worsening of congestive heart failure because of a previous cardiac surgery and was transferred to our hospital.', '4': \"On admission, we closely observed the patient's condition and noticed that his body temperature increased to 38.0 °C every evening.\", '5': 'Furthermore, his ankle joints felt feverish and were swollen.', '6': 'Therefore, we suspected polyarthritis as an etiology, although we initially suspected rheumatoid arthritis (RA).', '7': 'Antibody testing did not support RA diagnosis; therefore we concluded the association of remitting seronegative symmetrical synovitis with pitting edema (RS3PE) syndrome with his condition.', '8': 'After daily treatment with 15 mg prednisolone, the refractory edema symptom dramatically improved.', '9': 'The concept of RS3PE syndrome could explain such as an impressive clinical course.', '10': '<Learning objective: Physicians encounter patients with pitting edema of unknown etiology in daily clinical practice.', '11': 'In particular, cardiologists usually tend to prescribe diuretics for patients with pitting edema in their legs.', '12': 'Cardiologists should consider RS3PE syndrome as a differential diagnosis, for patients with localized pitting edema in their extremities.', '13': 'This report cautions regarding arbitrarily prescribing diuretics for localized pitting edema.>.'}\n",
            "49: abstract: {'1': 'May-Thurner syndrome (MTS) is a clinical condition characterized by the compression of the left iliac vein by the right iliac artery.', '2': 'This condition predisposes the patient to deep venous thrombosis (DVT).', '3': 'We present the case of a 30-year\\ufeff-old female who arrived at the emergency department of our facility with progressive left leg swelling for four weeks, with low-risk probability for DVT.', '4': 'Examination revealed left leg swelling with pitting edema extending up to the knee.', '5': 'Her calf muscle was tender to palpation.', '6': 'Dorsalis pedis, anterior tibial, and posterior tibial pulsations were fairly palpable due to the edema; however, the rest of her pulsations were appropriately felt.', '7': 'Therefore, the provisional diagnosis of possible DVT was made, and further investigations were requested.', '8': 'We present this case intending to highlight the clinical presentation of May-Thurner syndrome, its diagnosis, and treatment.'}\n",
            "49: abstract: {'1': 'BACKGROUND In lymphedema, an imbalance in the formation and absorption of lymph causes accumulation of protein-rich fluid in the interstitium of the most gravity-dependent parts of the body.', '2': 'Diagnosis is usually made based on patient medical history and a physical examination showing a typical appearance of the affected body part.', '3': 'Differential diagnosis is confirmed by imaging.', '4': 'CASE REPORT Primary lymphedema is inherited in through an autosomal dominant pattern.', '5': 'Congestive cardiac failure and non-filarial infections predispose patients to the secondary form of lymphedema, elephantiasis nostras verrucosa (ENV).', '6': 'We present the case of a 65-year-old man with lymphedema praecox complicated by congestive cardiac failure.', '7': 'The patient was experiencing worsening left leg swelling and had a prior history of unilateral leg swelling at puberty.', '8': 'The condition was inherited through an autosomal dominant pattern, as his father, elder brother, and nephew were diagnosed with the same disease.', '9': 'The left leg showed non-pitting edema with indurated, woody skin and lichenification.', '10': 'The right leg had mild pitting edema.', '11': 'There were numerous verrucous folds and cobblestone-like nodules, and plaques and a painless ulcer on the left leg.', '12': 'Laboratory evaluation demonstrated an elevated B-type natriuretic peptide.', '13': 'He was treated with compression stockings and inelastic multi-layer bandaging and was administered limb decongestive treatment.', '14': 'After 1 week of therapy, his swelling had somewhat improved.', '15': 'CONCLUSIONS Various conditions can cause ENV and it can superimpose on any form of hereditary lymphedema.', '16': 'The most effective strategy for this condition seems to be a thorough workup of the underlying cause of the ENV and early intervention.'}\n",
            "49: abstract: {'1': 'BACKGROUND Lipedema is a common condition that presents as excessive fat deposition in the extremities, initially sparing the trunk, ankles, and feet, and is found mainly in women, usually occurring after puberty or pregnancy.', '2': 'Lipedema can progress to include lipo-lymphedema of the ankles and feet.', '3': 'This report is of a 41-year old woman with Stage 3 lipedema and lipo-lymphedema with excessive fat of the lower body since puberty, with progression to swollen ankles and feet despite dietary caloric restriction.', '4': 'CASE REPORT A 41-year-old woman noticed increased fat in her legs since age 12.', '5': 'Her weight and leg size increased until age 21, when she reached a maximum weight of 165 kg, and underwent a Roux-En-Y gastric bypass.', '6': 'Over 12 months, she lost 74.8 kg.', '7': 'Her trunk significantly reduced in weight, but her legs did not.', '8': 'Fifteen years later, during recovery from hysterectomy surgery, she became progressively weaker and swollen over her entire body.', '9': 'Laboratory test results showed hypoalbuminemia (2.0 g/dL), lymphopenia, and hypolipoproteinemia.', '10': 'She was diagnosed with protein and calorie malnutrition with marked gut edema requiring prolonged parenteral nutrition.', '11': 'After restoration of normal protein, her health returned and her pitting edema resolved, but her extremities remained enlarged.', '12': 'She was subsequently diagnosed with lipedema.', '13': 'CONCLUSIONS This report demonstrates that early and correct diagnosis of lipedema is important, as women who believe the condition is due to obesity may suffer the consequences of calorie or protein-calorie deficiency in an attempt to lose weight.'}\n",
            "50: abstract: {'1': 'Sarcoidosis is characterized by granuloma formation, the macrophage being the most important building block.', '2': 'The activated macrophage in sarcoidosis produces interleukin-1 (II-1).', '3': 'It is well known that interleukin-1, among other functions, stimulates the hepatic production of C-reactive protein.', '4': 'We therefore prospectively measured the serum C-reactive protein in 17 patients with active pulmonary sarcoidosis, 10 patients with other chronic interstitial lung diseases of unknown etiology, 11 patients with active lung tuberculosis, and 10 healthy volunteers.', '5': 'Serum C-reactive protein was assayed by enzymoimmunodiffusion test.', '6': 'The serum C-reactive protein was negative in 13 patients suffering from active sarcoidosis and positive in four.', '7': 'Patients with other interstitial lung diseases had negative results in 7 and positive in 3 cases.', '8': 'The analyses of C-reactive protein in patients with sputum positive lung tuberculosis were positive in 10 cases.', '9': 'All the healthy controls had negative C-reactive protein measurements.', '10': 'The difference between the groups was statistically significant when sarcoidosis and tuberculosis serum C-reactive protein measurements were compared (p less than 0.01), as well as the difference between the group of other interstitial lung diseases and tuberculosis (p less than 0.01).', '11': 'In this respect, the measurements of serum C-reactive protein are valuable in the differentiation of sarcoidosis and other chronic interstitial lung diseases of unknown etiology from tuberculosis and other diseases which are known to induce an acute phase response.'}\n",
            "50: abstract: {'1': 'We analyzed the short-term and long-term outcome of 42 patients with distal type aortic dissection.', '2': 'Twenty-eight patients underwent intensive medical therapy within two weeks after the onset of pain (acute dissection).', '3': 'The remaining 14 patients had chronic dissection.', '4': 'The goals of medical treatment were to control blood pressure and to attain a negative C-reactive protein test result.', '5': 'Hospital survival rate in the patients with acute dissection was 96% (27/28).', '6': 'In-hospital complications included changes in mental status, renal dysfunction, bradycardia, orthostatic hypotension, and liver dysfunction, all of which were managed medically.', '7': 'Three of these patients underwent surgical therapy in the chronic phase and were discharged uneventfully.', '8': 'Fifteen (62.5%) of the 24 medically treated patients were discharged with negative C-reactive protein tests.', '9': 'Spontaneous resolution of a dissection was demonstrated by radiological examinations in 8 cases.', '10': 'Five-year survival rates in 24 medically treated patients was 93%.', '11': 'Hospital survival rate in the patients with chronic dissection was 100% (14/14).', '12': 'The rigorous control of blood pressure in the acute phase, and subsequent meticulous evaluation of the dissection by radiological tests and C-reactive protein test provides acceptable short-term and long-term outcomes of patients with acute distal dissection without the need for emergency surgical intervention.'}\n",
            "50: abstract: {'1': 'The role of subclinical intrauterine infection in preterm labor was evaluated prospectively in 40 patients and appropriate control subjects.', '2': 'The 24 preterm labor patients (60%) with a negative C-reactive protein value responded to tocolysis 95.8% of the time, with a mean delay of delivery of 35.5 days and a mean gestational age of 36.9 weeks.', '3': 'The 16 patients (40%) with a positive C-reactive protein value responded to tocolysis only 37.5% of the time, with a mean delay of delivery of 14.4 days and a mean gestational age of 33.2 weeks.', '4': 'Pathologic evidence of chorioamnionitis was present in 32.9% of 310 preterm deliveries as compared to only 22.3% of 1631 term deliveries.', '5': 'The presence of subclinical infection must be considered in cases of preterm labor, especially among patients for whom tocolytic therapy is unsuccessful.'}\n",
            "50: abstract: {'1': 'Purpose: To evaluate the practical value of initial C-reactive protein (CRP) in the diagnosis of bacterial infection in children.', '2': 'Methods: The subjects comprised 11 children, six boys and five girls, aged 3 months through to 3 years (median age 16 months), whose initial CRP levels were < 1.0 mg/dL despite bacterial infection.', '3': 'C-reactive protein was quantitated at the first medical examination by nephelometry.', '4': 'Results: The diagnosis was urinary tract infection (n = 4), bacterial meningitis (n = 2), sepsis (n = 2), pneumonia (n = 2) and arthritis of the hip joint (n = 1).', '5': 'The CRP levels were significantly elevated during the course of infection, ranging from 7.6 to 28.5 mg/dL.', '6': 'The bacterial etiology was non-specific.', '7': 'Eight patients were examined within 12 h of onset, three exhibited negative CRP values despite the duration of the insult over 12 h.', '8': 'Six patients were tentatively diagnosed as having a bacterial infection, but the other five were not.', '9': 'Each patient was treated, leading to a favorable outcome without any serious complications.', '10': 'Conclusions: Low levels of CRP do not rule out the possibility of bacterial infection in children.', '11': 'The initial value of CRP may be negative, even in patients with severe bacterial infection or even after 12 h from onset.', '12': 'The data suggest that pediatricians should consistently be aware of the possibility of bacterial infection even if the initial CRP test result is negative and that serial CRP measurements appear to be practical.'}\n",
            "50: abstract: {'1': 'C-reactive protein (CRP) is a phylogenetically highly conserved plasma protein, with homologs in vertebrates and many invertebrates, that participates in the systemic response to inflammation.', '2': 'Its plasma concentration increases during inflammatory states, a characteristic that has long been employed for clinical purposes.', '3': 'CRP is a pattern recognition molecule, binding to specific molecular configurations that are typically exposed during cell death or found on the surfaces of pathogens.', '4': 'Its rapid increase in synthesis within hours after tissue injury or infection suggests that it contributes to host defense and that it is part of the innate immune response.', '5': 'Recently, an association between minor CRP elevation and future major cardiovascular events has been recognized, leading to the recommendation by the Centers for Disease Control and the American Heart Association that patients at intermediate risk of coronary heart disease might benefit from measurement of CRP.', '6': 'This review will largely focus on our current understanding of the structure of CRP, its ligands, the effector molecules with which it interacts, and its apparent functions.'}\n",
            "50: abstract: {'1': 'Objective: To compare the accuracy of procalcitonin and C-reactive protein as diagnostic markers of bacterial infection in critically ill children at the onset of systemic inflammatory response syndrome (SIRS).', '2': 'Design: Prospective cohort study.', '3': 'Setting: Tertiary care, university-affiliated pediatric intensive care unit (PICU).', '4': 'Patients: Consecutive patients with SIRS.', '5': 'Interventions: From June to December 2002, all PICU patients were screened daily to include cases of SIRS.', '6': 'At inclusion (onset of SIRS), procalcitonin and C-reactive protein levels as well as an array of cultures were obtained.', '7': 'Diagnosis of bacterial infection was made a posteriori by an adjudicating process (consensus of experts unaware of the results of procalcitonin and C-reactive protein).', '8': 'Baseline and daily data on severity of illness, organ dysfunction, and outcome were collected.', '9': 'Measurements and main results: Sixty-four patients were included in the study and were a posteriori divided into the following groups: bacterial SIRS (n = 25) and nonbacterial SIRS (n = 39).', '10': 'Procalcitonin levels were significantly higher in patients with bacterial infection compared with patients without bacterial infection (p = .01).', '11': 'The area under the receiver operating characteristic curve for procalcitonin was greater than that for C-reactive protein (0.71 vs. 0.65, respectively).', '12': 'A positive procalcitonin level (>or=2.5 ng/mL), when added to bedside clinical judgment, increased the likelihood of bacterial infection from 39% to 92%, while a negative C-reactive protein level (<40 mg/L) decreased the probability of bacterial infection from 39% to 2%.', '13': 'Conclusions: Procalcitonin is better than C-reactive protein for differentiating bacterial from nonbacterial SIRS in critically ill children, although the accuracy of both tests is moderate.', '14': 'Diagnostic accuracy could be enhanced by combining these tests with bedside clinical judgment.'}\n",
            "50: abstract: {'1': 'Fever after cardiac surgery in children may be due to bacterial infection or noninfectious origin like systemic inflammatory response syndrome (SIRS) secondary to bypass procedure.', '2': 'A marker to distinguish bacterial from nonbacterial fever in these conditions is clinically important.', '3': 'The purpose of our study was to evaluate, in the early postcardiac surgery period, whether serial measurement of C-reactive protein (CRP) and its change over time (CRP velocity) can assist in detecting bacterial infection.', '4': 'A series of consecutive children who underwent cardiac surgery with bypass were tested for serum levels of CRP at several points up to 5 days postoperatively and during febrile episodes (>38.0°C).', '5': 'Findings were compared among febrile patients with proven bacterial infection (FWI group; sepsis, pneumonia, urinary tract infection, deep wound infection), febrile patients without bacterial infection (FNI group), and patients without fever (NF group).', '6': 'In all, 121 children were enrolled in the study, 31 in the FWI group, 42 in the FNI group, and 48 patients in the NF group.', '7': 'Ages ranged from 4 days to 17.8 years (median 19.0, mean 46 ± 56 months).', '8': 'There was no significant difference among the groups in mean CRP level before surgery, 1 hour, and 18 hours after.', '9': 'A highly significant interaction was found in the change in CRP over time by FWI group compared with FNI group (P < .001).', '10': 'Mean CRP velocity ([fCRP - 18hCRP]/[fever time (days) - 0.75 day]) was significantly higher in the infectious group (4.0 ± 4.2 mg/dL per d) than in the fever-only group (0.60 ± 1.6 mg/dL per d; P < .001).', '11': 'A CRP velocity of 4 mg/dL per d had a positive predictive value (PPV) of 85.7% for bacterial infection with 95.2% specificity.', '12': 'Serial measurements of CRP/CRP velocity after cardiac surgery in children may assist clinicians in differentiating postoperative fever due to bacterial infection from fever due to noninfectious origin.'}\n",
            "50: abstract: {'1': 'Background: There is no agreeing if rescue therapy can avoid short-term colectomy in patients treated for severe steroid-refractory ulcerative colitis.', '2': 'Aims: The aim of our study was to identify predictors of response to infliximab and cyclosporine A.', '3': 'Methods: In this cross-sectional study, 49 patients with severe ulcerative colitis were included.', '4': 'Response to therapy was defined as three or more point reductions in Mayo score after 6 months of treatment and avoidance of colectomy after 1 year.', '5': 'The predictors analysed were gender, age, time from ulcerative colitis diagnosis, months of steroid or/and azathioprine therapy before onset of the severe phase, smoking habits, extension of the disease, laboratory analyses and Mayo score.', '6': 'Results: Patients treated with infliximab showed a statistically significant higher response rate in case of moderate Mayo score (P = 0.04).', '7': 'Ex-smokers had very low chance of response to infliximab (P = 0.03).', '8': 'In the group treated with cyclosporine A, patients with C-reactive protein >3 mg/L had a response rate significantly higher than those with C-reactive protein <3 mg/L (P = 0.03); those with negative C-reactive protein and moderate Mayo score did not responded to therapy, while in the ones with elevated C-reactive protein and/or severe Mayo score, 15 versus 4 responded (P = 0.008).', '9': 'Conclusions: Our data suggest that cyclosporine A is advisable in ex-smokers.', '10': 'In never smokers or active smokers, infliximab can be prescribed in case of Mayo score ≤10 and/or negative CRP, while cyclosporine A is indicated in case of Mayo score >10 and positive CRP.'}\n",
            "50: abstract: {'1': 'We evaluated the impact of tumor shrinkage (TS) induced by molecular targeted therapy as the first-line systemic therapy on the survival of patients with metastatic renal cell carcinoma (mRCC).', '2': 'A total of 67 patients with mRCC who received first-line molecular targeted therapy were included in this study.', '3': 'Sixty patients were evaluable by response evaluation criteria in solid tumors.', '4': 'Patients underwent the first evaluation at 8-12 weeks after the start of the therapy.', '5': 'Twenty patients had TS ≧30%, 32 from 30% to -20%, and 8 ≦-20%.', '6': 'The median overall survival periods of patients who achieved TS ≧30%, from 30% to -20%, and ≦-20% at first evaluation were 41.0, 35.0, and 11.5 months, respectively.', '7': 'Univariate and multivariate analyses showed that TS of≧0%, in addition to negative C-reactive protein and the absence of bone metastasis were good predictors of overall survival.', '8': 'The patients who achieved 0% or more at the initial evaluation had longer survival than those who had no tumor reduction (40.0 months vs 12.0 months, p<0. 001).', '9': 'These findings suggest that early TS affects overall survival in real practice.', '10': 'We should consider alternative therapies for patients who have not achieved tumor reduction at the initial evaluation.'}\n",
            "50: abstract: {'1': 'Background: Corona virus disease 2019 has become a global health issue.', '2': 'The goal of this study was to investigate the characteristics and outcomes of patients with corona virus disease 2019 undergoing invasive mechanical ventilation and identify factors associated with mortality.', '3': 'Methods: Ninety four consecutive critically ill patients with confirmed corona virus disease 2019 undergoing invasive mechanical ventilation were included in this retrospective, single-center, observational study.', '4': 'The outcome variable was mortality of patients undergoing invasive mechanical ventilation and factors associated with it during intensive care unit stay.', '5': \"Results: Seventy nine (84%) out of 94 patients with confirmed corona virus disease 2019 who underwent invasive mechanical ventilation didn't survive.\", '6': \"Ninety four percent of patients who had Type 2 Diabetes Mellitus did not survive in comparison to 72 percent of patients who didn't have Type 2 Diabetes Mellitus.\", '7': \"Similarly, 48 (94.1%) out of 51 patients with a positive C-reactive protein value didn't survive in comparison to 31 (72%) out of 43 patients with a negative C-reactive protein.\", '8': 'Conclusions: The presence of Type 2 Diabetes Mellitus and a positive C-reactive protein value were strongly associated with mortality.', '9': \"Patients with a Sequential organ failure assessment score of more than eight at intensive care unit admission and peak D-dimer level of more than or equal to two during intensive care unit stay didn't show significant association with mortality.\", '10': 'These findings need further exploration through larger prospective studies.'}\n",
            "51: abstract: {'1': 'Pancreatic islet-cell antibodies (I.C.Ab) were detected in 31 patients with organ-specific autoimmune disorders, 4 first-degree relatives of I.C.Ab-positive diabetics, and 1 apparently normal subject, none of whom had clinical evidence of diabetes.', '2': '10 of these 36 subjects were found to have diabetic glucose-tolerance tests (G.T.T.S), 4 had lag storage, and 22 had normal G.T.T.S.2 had latent diabetes, as evidenced by diabetic G.T.T.S during pregnancy and thyrotoxicosis; another 2 subsequently developed insulin-dependent diabetes (I.D.D.)', '3': 'Serum from 26 subjects had been stored for 1-11 yr before the G.T.T.S were done.', '4': 'The titres in some were shown to rise and fall over the years, while in others they remained remarkably constant.', '5': 'There was no correlation between the titre, change in titre or the duration of I.C.Ab or the presence of HLA-B8, BW15, or CW3 and the result of the G.T.T.', '6': 'In addition to acting as a marker for asymptomatic and latent diabetes and prediabetes, it seems that the presence of I.C.Ab in the serum may define a new group of potential diabetics with normal G.T.T.S.', '7': 'Many such subjects have one or more organ-specific autoimmune disorders (irrespective of diabetic family history), but some are first-degree relatives of I.C.Ab-positive subjects (mainly I.D.D.).', '8': 'About 0-5% of the general population also have I.C.Ab in their serum.'}\n",
            "51: abstract: {'1': 'Basal insulin secretion was compared in nine islet-cell antibody positive, non-diabetic first-degree relatives of children with Type 1 (insulin-dependent) diabetes mellitus and nine normal control subjects matched for age, sex and weight.', '2': 'Acute insulin responses to a 25 g intravenous glucose tolerance test were similar in the two groups (243 (198-229) vs 329 (285-380) mU.l-1 x 10 min-1, mean (+/- SE), p = 0.25).', '3': 'Fasting plasma insulin was assayed in venous samples taken at one min intervals for 2 h.', '4': 'Time series analysis was used to demonstrate oscillatory patterns in plasma insulin.', '5': 'Autocorrelation showed that regular oscillatory activity was generally absent in the islet-cell antibody-positive group, whereas a regular 13 min cycle was shown in control subjects (p less than 0.0001).', '6': 'Fourier transformation did, however, show a 13 min spectral peak in the islet-cell antibody positive group, consistent with intermittent pulsatility.', '7': 'We conclude that overall oscillatory patterns of basal insulin secretion are altered in islet-cell antibody positive subjects even when the acute insulin response is within the normal range.'}\n",
            "51: abstract: {'1': 'It has been suggested that screening all patients with diabetes diagnosed in later life for islet cell antibodies (ICA) would help predict insulin dependence.', '2': 'We have surveyed the case notes of 55 patients (22 male; ages 37-88 years) who were found to be ICA positive over a 9-year screening period to assess what contribution knowledge of ICA status made to their management.', '3': 'Forty-two patients had been put on insulin (half within 6 months of diagnosis and the rest after up to 6 years).', '4': 'Of the 13 patients not on insulin, six were on diet alone and seven on oral hypoglycaemic agents after a median follow-up of 3 years.', '5': 'In 37 of the 42 patients, insulin treatment was started for clinical rather than immunological reasons (diabetic ketoacidosis, ketonuria, weight loss and/or severe symptoms).', '6': 'Five patients were started on insulin because of ICA status when there was no compelling reason on clinical grounds.', '7': 'Knowledge that seven non-insulin-treated patients were ICA positive made doctors reluctant to discharge them from clinic.', '8': 'The data suggest that routine ICA estimation in this age group is unnecessary, as the decision to treat with insulin is best made on clinical grounds, and ICA estimation can lead to unwarranted insulin treatment, or anxiety in patients and doctors who are aware of a positive result.'}\n",
            "51: abstract: {'1': 'A monoclonal islet cell antibody, HISL-19, reactive with human, bovine, and porcine pancreatic islets has been used to identify and characterize a novel group of islet cell proteins (p120, p69, p67, and p56).', '2': 'Besides the islets, HISL-19-reactive antigenic determinants are also expressed on selected cell types, namely, gut endocrine cells, thyroid parafollicular cells (p120), anterior pituitary cells (p40 and p24), specific hypothalamic neuroendocrine cells, and a single layer of large pyramidal cells of the cerebral cortex, thus defining a new family of neuroendocrine molecules.'}\n",
            "51: abstract: {'1': 'Islet cell antibodies (ICA; proteins made against insulin-producing cells) are a marker of insulin-dependent diabetes mellitus (IDDM).', '2': 'ICA are detected in 60-80% of the patients with IDDM at the onset of the disease.', '3': 'The presence of ICA in patients with non-insulin-dependent diabetes mellitus (NIDDM) indicates that the patients are likely to develop IDDM.', '4': 'However, as ICA are measured by the indirect immunofluorescent method, the reliability of the ICA assay is not high in some institutes.', '5': 'Use of the pancreas tissue having high antigenicity is recommended as one solution for a reliable assay.', '6': 'Standardization of the ICA assay is under way with the use of an ICA positive standard sera as 80 JDF units.', '7': 'Anti-glutamate decarboxylase (GAD) antibody assays using a radioimmunoassay (RIA) or enzyme-linked immunosorbent assay (ELISA) have recently been developed.', '8': 'The significance of anti-GAD antibodies is comparable to that of ICA.', '9': 'Since the anti-GAD assay is reproducible and easy to perform, it should be used widely in parallel with the ICA assay.'}\n",
            "51: abstract: {'1': 'Insulin-dependent diabetes mellitus (IDDM) is associated with the formation of autoantibodies against different antigens in the islets of Langerhans, so-called islet cell antibodies (ICA).', '2': 'The expression of a major autoantigen, the beta-cell specific enzyme glutamic acid decarboxylase (GAD), is glucose-dependent in vitro and correlated to insulin release in vitro.', '3': 'In this study the expression of islet autoantigens was examined in vivo and the relationship between beta-cell function and islet cell surface antibody (ICSA) reactivity was tested.', '4': 'Rats were fed for 10 days with glipizide or diazoxide, in order to stimulate or inhibit insulin release, respectively.', '5': 'Frozen sections of pancreata were incubated with ten ICA-positive IDDM sera and analyzed by indirect immunofluorescence.', '6': 'Two sera with a \"beta-cell restricted\" staining, five with an \"all-islet cell\" staining and three with a \"mixed\" pattern were employed.', '7': 'In all three groups, the highest end-point titres were obtained when pancreata of rats treated with glipizide were used.', '8': 'Intermediate titres were seen in control animals and the lowest titres were observed on pancreata from diazoxide-treated rats, regardless of the serum used.', '9': 'In contrast to these observations, no correlation between ICSA reactivity and islet cell activity could be demonstrated.', '10': 'Conflicting results concerning ICSA in previous reports and our failure to show a glucose regulation of ICSA reactivity, indicate that ICSA is a phenomenon with a low degree of specificity.'}\n",
            "51: abstract: {'1': 'Measurement of beta-cell function is an important marker of progression to diabetes in individuals at risk for the disease.', '2': 'Although the peak incidence for the disease occurs before 17 years of age, normal values for insulin secretion were not available in this age group.', '3': 'We performed a simplified intravenous glucose tolerance test in 167 normal children, and in 98 islet cell antibody (ICA)-negative and 12 ICA-positive siblings of diabetic patients.', '4': 'Their age range was 1-16 yr.', '5': 'The first phase of insulin secretion, evaluated as the sum of plasma insulin concentrations at 1 and 3 min, increased with age and was significantly lower in ICA-negative siblings (86 +/- 6 microU/ml, P < 0.002) than in normal controls (115 +/- 6 microU/ml).', '6': 'This difference was not apparent before 8 yr of age.', '7': 'None of the ICA-negative siblings developed diabetes after an average of 4.5 yr.', '8': 'ICA-positive siblings at first study had a first phase insulin response similar to that of ICA negative siblings, but significantly lower than that of the normal controls (74 +/- 13 microU/ml, P < 0.02).', '9': 'The reason for the decreased insulin secretion in ICA-negative siblings is unknown, but could involve a defect in the growth of beta-cell mass or insulin secretion that could be part of the multifactorial pathogenesis of type 1 diabetes.'}\n",
            "51: abstract: {'1': 'We studied the effect of severe reduction of beta-cell mass by 90% pancreatectomy on the immune tolerance to the endocrine pancreas.', '2': 'Four months after subtotal pancreatectomy all LEW.Han rats had developed mononuclear infiltration of islets and 9 of 14 rats were positive for islet-cell antibodies.', '3': 'Electron microscopy revealed lymphocytic invasion of endocrine tissue, lysis of beta cells and phagocytotic macrophages.', '4': 'None of these changes were seen 2 weeks after 90% pancreatectomy or 4 months after 10% pancreatectomy.', '5': 'Weekly substitution of islet antigens in the form of a homogenate of 100 islets into 90% pancreatectomized LEW.Han rats almost completely prevented the development of insulitis and autoantibodies.', '6': 'The dependence of insulitis on T cells was shown when 90% pancreatectomy in LEW.rnu rats (i.e., the congenic athymic nude strain), did not result in islet infiltration.', '7': 'The exocrine tissue remained normal in all experimental groups.', '8': 'During the observation period insulitis was not associated with overt diabetes but was accompanied by substantial enlargement of islets and of beta-cell mass, as shown by morphometry.', '9': 'Suppression of islet inflammation by injection of islet antigens abolished beta-cell regeneration, despite continuing metabolic stress in rats with 90% pancreatectomy.', '10': 'The findings indicate induction of islet autoimmunity in response to 90% but not to 10% pancreatectomy.', '11': 'We conclude that severe reduction of the islet-antigen mass allows the development of T-cell-dependent islet autoimmunity which indicates a loss of immune tolerance.', '12': 'In addition, the data suggest the existence of islet-antigen autoreactive immune cells in rats not genetically predisposed to autoimmune diabetes.', '13': 'Finally, we conclude that selective beta-cell regeneration occurs in association with insulitis.'}\n",
            "51: abstract: {'1': 'Islet cell antibodies (ICA) continue to serve as the basis of the principal serological test for definition of active autoimmunity of beta-cells.', '2': 'Its disadvantages are the need for human pancreatic tissue and difficulty in obtaining quantitative results.', '3': 'In the past decade biochemically-defined beta-cell toxins were described, leading to the development of sensitive and specific autoantibody assays, to predict insulin-dependent diabetes mellitus (IDDM).', '4': 'We examined the value of combined biochemically-based serological assays, such as autoantibodies to insulin (IAA), glutamic acid decarboxylase (GADA) and ICA512 (ICA512A) to replace the traditional ICA assay.', '5': 'Blood samples of 114 newly diagnosed IDDM patients, aged 12 +/- 5 yrs (range 2 months-29 years) were tested for ICA (indirect immunofluorescence), IAA, GADA and ICA512A (radiobinding assay).', '6': 'The latter 2 assays were performed using recombinant human [35S]-labeled antigen produced by in vitro transcription/translation.', '7': 'We found that fewer sera scored positive for ICA and/or IAA (80.7%, 92/114) than for 1 or more of IAA, GAD, or ICA512 (88.6%, 101/114).', '8': 'We conclude that combined testing for IAA, GAD and ICA512 can replace the traditional ICA/IAA test to predict IDDM and is helpful in the differential diagnosis of insulin-dependent and noninsulin-dependent diabetes.'}\n",
            "51: abstract: {'1': 'Objective: Obese youth clinically diagnosed with type 2 diabetes mellitus (T2DM) frequently have evidence of islet cell autoimmunity (proteins made against insulin-producing cells).', '2': 'We investigated the clinical and biochemical differences, and therapeutic modalities among autoantibody positive (Ab+) vs. autoantibody negative (Ab-) youth at the time of diagnosis and over time in a multi-provider clinical setting.', '3': 'Study design: Chart review of 145 obese youth diagnosed with T2DM from January 2003 to July 2012.', '4': 'Of these, 70 patients were Ab+ and 75 Ab-.', '5': 'The two groups were compared with respect to clinical presentation, physical characteristics, laboratory data, and therapeutic modalities at diagnosis and during follow up to assess the changes in these parameters associated with disease progression.', '6': 'Results: At presentation, Ab+ youth with a clinical diagnosis of T2DM were younger, had higher rates of ketosis, higher hemoglobin A1c (HbA1c) and glucose levels, and lower insulin and c-peptide concentrations compared with the Ab- group.', '7': 'The Ab- group had a higher body mass index (BMI) z-score and cardiometabolic risk factors at diagnosis and such difference remained over time.', '8': 'Univariate analysis revealed that treatment modality had no effect on BMI in either group.', '9': 'Generalized estimating equations for longitudinal data analysis revealed that (i) BMI z-score and diastolic blood pressure (DBP) were significantly affected by duration of diabetes; (ii) systolic blood pressure (SBP) and ALT were affected by changes in BMI z-score; and (iii) changes in HbA1c had an effect on lipid profile and cardiometabolic risk factors regardless of antibody status.', '10': 'Conclusions: Irrespective of antibody status and treatment modality, youth who present with obesity and diabetes, show no improvement in obesity status over time, with the deterioration in BMI z-score affecting blood pressure (BP) and ALT, but the lipid profile being mostly impacted by HbA1c and glycemic control.', '11': 'Effective control of BMI and glycemia are needed to lessen the future macrovascular complications irrespective of antibody status.'}\n",
            "52: abstract: {'1': 'Turner syndrome is a sex chromosome aneuploidy with characteristic malformations.', '2': 'Amniotic fluid, a complex biological material, could contribute to the understanding of Turner syndrome pathogenesis.', '3': 'In this pilot study, global gene expression analysis of cell-free RNA in amniotic fluid supernatant was utilized to identify specific genes/organ systems that may play a role in Turner syndrome pathophysiology.', '4': 'Cell-free RNA from amniotic fluid of five mid-trimester Turner syndrome fetuses and five euploid female fetuses matched for gestational age was extracted, amplified, and hybridized onto Affymetrix(®) U133 Plus 2.0 arrays.', '5': 'Significantly differentially regulated genes were identified using paired t tests.', '6': 'Biological interpretation was performed using Ingenuity Pathway Analysis and BioGPS gene expression atlas.', '7': 'There were 470 statistically significantly differentially expressed genes identified.', '8': 'They were widely distributed across the genome.', '9': 'XIST was significantly down-regulated (p < 0.0001); SHOX was not differentially expressed.', '10': 'One of the most highly represented organ systems was the hematologic/immune system, distinguishing the Turner syndrome transcriptome from other aneuploidies we previously studied.', '11': 'Manual curation of the differentially expressed gene list identified genes of possible pathologic significance, including NFATC3, IGFBP5, and LDLR.', '12': 'Transcriptomic differences in the amniotic fluid of Turner syndrome fetuses are due to genome-wide dysregulation.', '13': 'The hematologic/immune system differences may play a role in early-onset autoimmune dysfunction.', '14': 'Other genes identified with possible pathologic significance are associated with cardiac and skeletal systems, which are known to be affected in females with Turner syndrome.', '15': 'The discovery-driven approach described here may be useful in elucidating novel mechanisms of disease in Turner syndrome.'}\n",
            "52: abstract: {'1': 'Turner syndrome is a chromosomal abnormality characterized by the absence of whole or part of the X chromosome in females.', '2': 'This X aneuploidy condition is associated with a diverse set of clinical phenotypes such as gonadal dysfunction, short stature, osteoporosis and Type II diabetes mellitus, among others.', '3': 'These phenotypes differ in their severity and penetrance among the affected individuals.', '4': 'Haploinsufficiency for a few X linked genes has been associated with some of these disease phenotypes.', '5': 'RNA sequencing can provide valuable insights to understand molecular mechanism of disease process.', '6': 'In the current study, we have analysed the transcriptome profiles of human untransformed 45,X and 46,XX fibroblast cells and identified differential expression of genes in these two karyotypes.', '7': 'Functional analysis revealed that these differentially expressing genes are associated with bone differentiation, glucose metabolism and gonadal development pathways.', '8': 'We also report differential expression of lincRNAs in X monosomic cells.', '9': 'Our observations provide a basis for evaluation of cellular and molecular mechanism(s) in the establishment of Turner syndrome phenotypes.'}\n",
            "52: abstract: {'1': 'Turner Syndrome (TS) is an unfavorable genetic condition with a prevalence of 1:2500 in newborn girls.', '2': 'Prompt and effective diagnosis is very important to appropriately monitor the comorbidities.', '3': 'The aim of the present study was to propose a feasible and practical molecular diagnostic tool for newborn screening by quantifying the gene dosage of the SHOX, VAMP7, XIST, UBA1, and SRY genes by quantitative polymerase chain reaction (qPCR) in individuals with a diagnosis of complete X monosomy, as well as those with TS variants, and then compare the results to controls without chromosomal abnormalities.', '4': 'According to our results, the most useful markers for these chromosomal variants were the genes found in the pseudoautosomic regions 1 and 2 (PAR1 and PAR2), because differences in gene dosage (relative quantification) between groups were more evident in SHOX and VAMP7 gene expression.', '5': 'Therefore, we conclude that these markers are useful for early detection in aneuploidies involving sex chromosomes.'}\n",
            "52: abstract: {'1': 'Turner syndrome (TS) is one of the most common sexual chromosome abnormalities and is clearly associated with an increased risk of autoimmune diseases, particularly thyroid disease and coeliac disease (CD).', '2': 'Single-nucleotide polymorphism analyses have been shown to provide correlative evidence that specific genes are associated with autoimmune disease.', '3': 'Our aim was to study the functional polymorphic variants of PTPN22 and ZFAT in relation to thyroid disease and those of MYO9B in relation to CD.', '4': 'A cross-sectional comparative analysis was performed on Mexican mestizo patients with TS and age-matched healthy females.', '5': 'Our data showed that PTPN22 C1858T (considered a risk variant) is not associated with TS (X2 = 3.50, p = .61, and OR = 0.33 [95% CI = 0.10-1.10]).', '6': 'Also, ZFAT was not associated with TS (X2 = 1.2, p = .28, and OR = 1.22 [95% CI = 0.84-1.79]).', '7': 'However, for the first time, rs2305767 MYO9B was revealed to have a strong association with TS (X2 = 58.6, p = .0001, and OR = 10.44 [95% C = 5.51-19.80]), supporting a high level of predisposition to CD among TS patients.', '8': 'This report addresses additional data regarding the polymorphic variants associated with autoimmune disease, one of the most common complications in TS.'}\n",
            "52: abstract: {'1': 'Turner Syndrome (TS) is a condition where several genes are affected but the molecular mechanism remains unknown.', '2': 'Identifying the genes that regulate the TS network is one of the main challenges in understanding its aetiology.', '3': 'Here, we studied the regulatory network from manually curated genes reported in the literature and identified essential proteins involved in TS.', '4': 'The power-law distribution analysis showed that TS network carries scale-free hierarchical fractal attributes.', '5': 'This organization of the network maintained the self-ruled constitution of nodes at various levels without having centrality-lethality control systems.', '6': 'Out of twenty-seven genes culminating into leading hubs in the network, we identified two key regulators (KRs) i.e. KDM6A and BDNF.', '7': 'These KRs serve as the backbone for all the network activities.', '8': 'Removal of KRs does not cause its breakdown, rather a change in the topological properties was observed.', '9': 'Since essential proteins are evolutionarily conserved, the orthologs of selected interacting proteins in C. elegans, cat and macaque monkey (lower to higher level organisms) were identified.', '10': 'We deciphered three important interologs i.e. KDM6A-WDR5, KDM6A-ASH2L and WDR5-ASH2L that form a triangular motif.', '11': 'In conclusion, these KRs and identified interologs are expected to regulate the TS network signifying their biological importance.'}\n",
            "52: abstract: {'1': 'X-chromosome inactivation generally results in dosage equivalence for expression of X-linked genes between 46,XY males and 46,XX females.', '2': 'The 20-30% of genes that escape silencing are thus candidates for having a role in the phenotype of Turner syndrome.', '3': 'Understanding which genes escape from silencing, and how they avoid this chromosome-wide inactivation is therefore an important step toward understanding Turner Syndrome.', '4': 'We have examined the mechanism of escape using a previously reported knock-in of a BAC containing the human escape gene RPS4X in mouse.', '5': 'We now demonstrate that escape from inactivation for RPS4X is already established by embryonic Day 9.5, and that both silencing and escape are faithfully maintained across the lifespan.', '6': 'No overt abnormalities were observed for transgenic mice up to 1 year of age despite robust transcription of the human RPS4X gene with no detectable downregulation of the mouse homolog.', '7': 'However, there was no significant increase in protein levels, suggesting translational compensation in the mouse.', '8': 'Finally, while many of the protein-coding genes have been assessed for their inactivation status, less is known about the X-linked RNA genes, and we propose that for many microRNA genes their inactivation status can be predicted as they are intronic to genes for which the inactivation status is known.'}\n",
            "52: abstract: {'1': 'The pathogenesis of Turner syndrome (TS) and the genotype-phenotype relationship has been thoroughly investigated during the last decade.', '2': 'It has become evident that the phenotype seen in TS does not only depend on simple gene dosage as a result of X chromosome monosomy.', '3': 'The origin of TS specific comorbidities such as infertility, cardiac malformations, bone dysgenesis, and autoimmune diseases may depend on a complex relationship between genes as well as transcriptional and epigenetic factors affecting gene expression across the genome.', '4': 'Furthermore, two individuals with TS with the exact same karyotype may exhibit completely different traits, suggesting that no conventional genotype-phenotype relationship exists.', '5': 'Here, we review the different genetic mechanisms behind differential gene expression, and highlight potential key-genes essential to the comorbidities seen in TS and other X chromosome aneuploidy syndromes.', '6': 'KDM6A, important for germ cell development, has shown to be differentially expressed and methylated in Turner and Klinefelter syndrome across studies.', '7': 'Furthermore, TIMP1/TIMP3 genes seem to affect the prevalence of bicuspid aortic valve.', '8': 'KDM5 C could play a role in the neurocognitive development of Turner and Klinefelter syndrome.', '9': 'However, further research is needed to elucidate the genetic mechanism behind the phenotypic variability and the different phenotypic traits seen in TS.'}\n",
            "52: abstract: {'1': 'Background: Turner syndrome (TS) is a sex chromosome aneuploidy with a variable spectrum of symptoms including short stature, ovarian failure and skeletal abnormalities.', '2': 'The etiology of TS is complex, and the mechanisms driving its pathogenesis remain unclear.', '3': 'Methods: In our study, we used the online Gene Expression Omnibus (GEO) microarray expression profiling dataset GSE46687 to identify differentially expressed genes (DEGs) between monosomy X TS patients and normal female individuals.', '4': 'The relevant data on 26 subjects with TS (45,XO) and 10 subjects with the normal karyotype (46,XX) was investigated.', '5': 'Then, tissue-specific gene expression, functional enrichment, and protein-protein interaction (PPI) network analyses were performed, and the key modules were identified.', '6': 'Results: In total, 25 upregulated and 60 downregulated genes were identified in the differential expression analysis.', '7': 'The tissue-specific gene expression analysis of the DEGs revealed that the system with the most highly enriched tissue-specific gene expression was the hematologic/immune system, followed by the skin/skeletal muscle and neurologic systems.', '8': 'The PPI network analysis, construction of key modules and manual screening of tissue-specific gene expression resulted in the identification of the following five genes of interest: CD99, CSF2RA, MYL9, MYLPF, and IGFBP2.', '9': 'CD99 and CSF2RA are involved in the hematologic/immune system, MYL9 and MYLPF are related to the circulatory system, and IGFBP2 is related to skeletal abnormalities.', '10': 'In addition, several genes of interest with possible roles in the pathogenesis of TS were identified as being associated with the hematologic/immune system or metabolism.', '11': 'Conclusion: This discovery-driven analysis may be a useful method for elucidating novel mechanisms underlying TS.', '12': 'However, more experiments are needed to further explore the relationships between these genes and TS in the future.'}\n",
            "52: abstract: {'1': '47,XXX (triple X) and Turner syndrome (45,X) are sex chromosomal abnormalities with detrimental effects on health with increased mortality and morbidity.', '2': 'In karyotypical normal females, X-chromosome inactivation balances gene expression between sexes and upregulation of the X chromosome in both sexes maintain stoichiometry with the autosomes.', '3': 'In 47,XXX and Turner syndrome a gene dosage imbalance may ensue from increased or decreased expression from the genes that escape X inactivation, as well as from incomplete X chromosome inactivation in 47,XXX.', '4': 'We aim to study genome-wide DNA-methylation and RNA-expression changes can explain phenotypic traits in 47,XXX syndrome.', '5': 'We compare DNA-methylation and RNA-expression data derived from white blood cells of seven women with 47,XXX syndrome, with data from seven female controls, as well as with seven women with Turner syndrome (45,X).', '6': 'To address these questions, we explored genome-wide DNA-methylation and transcriptome data in blood from seven females with 47,XXX syndrome, seven females with Turner syndrome, and seven karyotypically normal females (46,XX).', '7': 'Based on promoter methylation, we describe a demethylation of six X-chromosomal genes (AMOT, HTR2C, IL1RAPL2, STAG2, TCEANC, ZNF673), increased methylation for GEMIN8, and four differentially methylated autosomal regions related to four genes (SPEG, MUC4, SP6, and ZNF492).', '8': 'We illustrate how these changes seem compensated at the transcriptome level although several genes show differential exon usage.', '9': 'In conclusion, our results suggest an impact of the supernumerary X chromosome in 47,XXX syndrome on the methylation status of selected genes despite an overall comparable expression profile.'}\n",
            "53: abstract: {'1': 'The objective of this study was to evaluate whether first-degree relatives (FDRs) of patients with type 2 diabetes had abnormal circadian insulin secretion and, if so, whether this abnormality affected their glucose metabolism.', '2': 'Six African-American FDRs with normal glucose tolerance and 12 matched normal control subjects (who had no family history of diabetes) were exposed to 48 h of hyperglycemic clamping (approximately 12 mmol/l).', '3': 'Insulin secretion rates (ISRs) were determined by deconvolution of plasma C-peptide levels using individual C-peptide kinetic parameters.', '4': 'Detrending and smoothing of data (z-scores) and computation of autocorrelation functions were used to identify ISR cycles.', '5': 'During the initial hours after start of glucose infusions, ISRs were approximately 60% higher in FDRs than in control subjects (585 vs. 366 nmol/16 h, P < 0.05), while rates of glucose uptake were the same (5.6 mmol x kg(-1) x h(-1)), indicating that the FDRs were insulin resistant.', '6': 'Control subjects had well-defined circadian (24 h) cycles of ISR and plasma insulin that rose in the early morning, peaked in the afternoon, and declined during the night.', '7': 'In contrast, FDRs had several shorter ISR cycles of smaller amplitude that lacked true periodicity.', '8': 'This suggested that the lack of a normal circadian ISR increase had made it impossible for the FDRs to maintain their compensatory insulin hypersecretion beyond 18 h of hyperglycemia.', '9': 'As a result, ISR decreased to the level found in control subjects, and glucose uptake fell below the level of control subjects (61 vs. 117 micromol x kg(-1) x min(-1), P < 0.05).', '10': 'In summary, we found that FDRs with normal glucose tolerance had defects in insulin action and secretion.', '11': 'The newly recognized insulin secretory defect consisted of disruption of the normal circadian ISR cycle, which resulted in reduced insulin secretion (and glucose uptake) during the ascending part of the 24 h ISR cycle.'}\n",
            "53: abstract: {'1': 'Background: In diabetic patients, postprandial glucose levels, which have a major impact on metabolic control, are determined by the rate of nutrient delivery into the intestine, absorption of nutrients from the small intestine, and the metabolism of the absorbed nutrients by the liver.', '2': 'The present study addresses whether Type 1 diabetic patients have increased intestinal permeability and intestinal permeability predicts postprandial glucose variability.', '3': 'Material and methods: Thirty Type 1 diabetic patients together with 15 sex- and age-matched healthy controls were enrolled in the study.', '4': 'After an overnight fasting all patients and controls received 100 micro Ci 51 Cr of EDTA as a radioactive tracer and the percentage of the isotope excreted in a 24-h urinary specimen was the permeability measure.', '5': 'Instant blood glucose was measured just before the test, and the patients performed and recorded self-monitoring of fasting and 2nd-hour postprandial blood glucose levels during the following week.', '6': 'Results: We found that intestinal permeability is increased in Type 1 diabetic patients compared with age- and sex-matched healthy controls.', '7': 'Increased intestinal permeability is related at least in part to the instant blood glucose level and the presence of diabetic autonomic neuropathy.', '8': 'Conclusion: Increased intestinal permeability leads to higher variation in postprandial blood glucose levels, thereby worsening metabolic control.'}\n",
            "53: abstract: {'1': 'Aims: Individuals with Type 1 diabetes mellitus are susceptible to hypoglycaemia during and after continuous moderate-intensity exercise, but hyperglycaemia during intermittent high-intensity exercise.', '2': 'The combination of both forms of exercise may have a moderating effect on glycaemia in recovery.', '3': 'The aims of this study were to compare the physiological responses and associated glycaemic changes to continuous moderate-intensity exercise vs. continuous moderate-intensity exercise + intermittent high-intensity exercise in athletes with Type 1 diabetes.', '4': 'Methods: Interstitial glucose levels were measured in a blinded fashion in 11 trained athletes with Type 1 diabetes during two sedentary days and during 2 days in which 45 min of afternoon continuous moderate-intensity exercise occurred either with or without intermittent high-intensity exercise.', '5': 'The total amount of work performed and the duration of exercise was identical between sessions.', '6': 'Results: During exercise, heart rate, respiratory exchange ratio, oxygen utilization, ventilation and blood lactate levels were higher during continuous moderate-intensity + intermittent high-intensity exercise vs. continuous moderate-intensity exercise (all P < 0.05).', '7': 'Despite these marked cardiorespiratory differences between trials, there was no difference in the reduction of interstitial glucose or plasma glucose levels between the exercise trials.', '8': 'Nocturnal glucose levels were higher in continuous moderate-intensity + intermittent high-intensity exercise and in sedentary vs. continuous moderate-intensity exercise (P < 0.05).', '9': 'Compared with continuous moderate-intensity exercise alone, continuous moderate-intensity + intermittent high-intensity exercise was associated with less post-exercise hypoglycaemia (5.2 vs. 1.5% of the time spent with glucose < 4.0 mmol/l) and more post-exercise hyperglycaemia (33.8 vs. 20.4% of time > 11.0 mmol/l).', '10': 'Conclusions: Although the decreases in glucose level during continuous moderate-intensity exercise and continuous moderate-intensity + intermittent high-intensity exercise are similar, the latter form of exercise protects against nocturnal hypoglycaemia in athletes with Type 1 diabetes.'}\n",
            "53: abstract: {'1': \"Context: Endogenous glucocorticoid excess (Cushing's syndrome) predominantly increases postprandial glucose concentration.\", '2': 'The pattern of hyperglycemia induced by prednisolone has not been well characterized.', '3': 'Objective: Our objective was to define the circadian effect of prednisolone on glucose concentration to optimize management of prednisolone-induced hyperglycemia.', '4': 'Design and setting: This was a cross-sectional study in a teaching hospital.', '5': 'Participants: Participants included 60 consecutive consenting subjects with chronic obstructive pulmonary disease admitted to hospital: 13 without known diabetes admitted for other indications and not treated with glucocorticoids (group 1), 40 without known diabetes admitted with an exacerbation of chronic obstructive pulmonary disease and treated with prednisolone (group 2, prednisolone = 30 ± 6 mg/d), and seven with known diabetes treated with prednisolone (group 3, prednisolone = 26 ± 9 mg/d).', '6': 'Main outcome measure: Interstitial glucose concentration was assessed during continuous glucose monitoring.', '7': 'Results: Significantly more subjects in group 2 [21 of 40 (53%), P = 0.02] and group 3 [seven of seven (100%), P = 0.003] recorded a glucose of at least 200 mg/dl (≥11.1 mmol/liter) during continuous glucose monitoring than in group 1 [one of 13 (8%)].', '8': 'The mean glucose concentration between 2400-1200 h for group 3 (142 ± 36 mg/dl) was significantly greater than in the other two groups (P < 0.005), whereas mean glucose concentrations between 2400-1200 h in group 1 (108 ± 16 mg/dl) and group 2 (112 ± 22 mg/dl) were not significantly different.', '9': 'In contrast, the mean glucose concentrations between 1200-2400 h for group 2 (142 ± 25 mg/dl) and group 3 (189 ± 32 mg/dl) were both significantly greater than group 1 (117 ± 14 mg/dl, P < 0.05 for both comparisons).', '10': 'Conclusions: Prednisolone predominantly causes hyperglycemia in the afternoon and evening.', '11': 'Treatment of prednisolone-induced hyperglycemia should be targeted at this time period.'}\n",
            "53: abstract: {'1': 'Objectives: Afternoon napping is a common habit in China.', '2': 'We used data obtained from the Dongfeng-Tongji cohort to examine if duration of habitual afternoon napping was associated with risks for impaired fasting plasma glucose (IFG) and diabetes mellitus (DM) in a Chinese elderly population.', '3': 'Methods: A total of 27,009 participants underwent a physical examination, laboratory tests, and face-to-face interview.', '4': 'They were categorized into four groups according to nap duration (no napping, <30, 30 to <60, 60 to <90, and > or =90 min).', '5': 'Logistic regression models were used to examine the odds ratios (ORs) of napping duration with IFG and DM.', '6': 'Results: Of the participants, 18,515 (68.6%) reported regularly taking afternoon naps.', '7': 'Those with longer nap duration had considerably higher prevalence of IFG and DM.', '8': 'Napping duration was associated in a dose-dependent manner with IFG and DM (P<.001).', '9': 'After adjusting for possible confounders, longer nap duration (>60 min; all P<.05) was still significantly associated with increased risk for IFG, and longer nap duration (>30 min) was associated with increased risk for DM; however, this finding was not significant in the group with a nap duration of 60-90 min.', '10': 'Conclusions: Longer habitual afternoon napping was associated with a moderate increase for DM risk, independent of several covariates.', '11': 'This finding suggests that longer nap duration may represent a novel risk factor for DM and higher blood glucose levels.'}\n",
            "53: abstract: {'1': 'Background: Although physical exercise (PE) is recommended for individuals with type 1 diabetes (DM1), participation in exercise is challenging because it increases the risk of severe hypoglycemia and the available therapeutic options to prevent it frequently result in hyperglycemia.', '2': 'There is no clear recommendation about the best timing for exercise.', '3': 'The aim of this study was to compare the risk of hypoglycemia after morning or afternoon exercise sessions up to 36 hours postworkout.', '4': 'Methods: This randomized crossover study enrolled subjects with DM1, older than 18 years of age, on sensor-augmented insulin pump (SAP) therapy.', '5': 'Participants underwent 2 moderate-intensity exercise sessions; 1 in the morning and 1 in the afternoon, separated by a 7 to 14 day wash-out period.', '6': 'Continuous glucose monitoring (CGM) data were collected 24 hours before, during and 36 hours after each session.', '7': 'Results: Thirty-five subjects (mean age 30.31 ± 12.66 years) participated in the study.', '8': 'The rate of hypoglycemia was significantly lower following morning versus afternoon exercise sessions (5.6 vs 10.7 events per patient, incidence rate ratio, 0.52; 95% CI, 0.43-0.63; P < .0001).', '9': 'Most hypoglycemic events occurred 15-24 hours after the session.', '10': 'On days following morning exercise sessions, there were 20% more CGM readings in near-euglycemic range (70-200 mg/dL) than on days prior to morning exercise (P = .003).', '11': 'Conclusions: Morning exercise confers a lower risk of late-onset hypoglycemia than afternoon exercise and improves metabolic control on the subsequent day.'}\n",
            "53: abstract: {'1': 'Time-restricted feeding (TRF) is a form of intermittent fasting that involves having a longer daily fasting period.', '2': 'Preliminary studies report that TRF improves cardiometabolic health in rodents and humans.', '3': 'Here, we performed the first study to determine how TRF affects gene expression, circulating hormones, and diurnal patterns in cardiometabolic risk factors in humans.', '4': 'Eleven overweight adults participated in a 4-day randomized crossover study where they ate between 8 am and 2 pm (early TRF (eTRF)) and between 8 am and 8 pm (control schedule).', '5': 'Participants underwent continuous glucose monitoring, and blood was drawn to assess cardiometabolic risk factors, hormones, and gene expression in whole blood cells.', '6': 'Relative to the control schedule, eTRF decreased mean 24-hour glucose levels by 4 ± 1 mg/dl (p = 0.0003) and glycemic excursions by 12 ± 3 mg/dl (p = 0.001).', '7': 'In the morning before breakfast, eTRF increased ketones, cholesterol, and the expression of the stress response and aging gene SIRT1 and the autophagy gene LC3A (all p < 0.04), while in the evening, it tended to increase brain-derived neurotropic factor (BNDF; p = 0.10) and also increased the expression of MTOR (p = 0.007), a major nutrient-sensing protein that regulates cell growth.', '8': 'eTRF also altered the diurnal patterns in cortisol and the expression of several circadian clock genes (p < 0.05).', '9': 'eTRF improves 24-hour glucose levels, alters lipid metabolism and circadian clock gene expression, and may also increase autophagy and have anti-aging effects in humans.'}\n",
            "53: abstract: {'1': 'Objective: To determine the effect of morning exercise in the fasting condition vs afternoon exercise on blood glucose responses to resistance exercise (RE).', '2': \"Research design and methods: For this randomized crossover design, 12 participants with type 1 diabetes mellitus [nine females; aged 31 ± 8.9 years; diabetes duration, 19.1 ± 8.3 years; HbA1c, 7.4% ± 0.8% (57.4 ± 8.5 mmol/mol)] performed ∼40 minutes of RE (three sets of eight repetitions, seven exercises, at the individual's predetermined eight repetition maximum) at either 7 am (fasting) or 5 pm.\", '3': 'Sessions were performed at least 48 hours apart.', '4': 'Venous blood samples were collected immediately preexercise, immediately postexercise, and 60 minutes postexercise.', '5': 'Interstitial glucose was monitored overnight postexercise by continuous glucose monitoring (CGM).', '6': 'Results: Data are presented as mean ± SD.', '7': 'Blood glucose rose during fasting morning exercise (9.5 ± 3.0 to 10.4 ± 3.0 mmol/L), whereas it declined with afternoon exercise (8.2 ± 2.5 to 7.4 ± 2.6 mmol/L; P = 0.031 for time-by-treatment interaction).', '8': 'Sixty minutes postexercise, blood glucose concentration was significantly higher after fasting morning exercise than after afternoon exercise (10.9 ± 3.2 vs 7.9 ± 2.9 mmol/L; P = 0.019).', '9': 'CGM data indicated more glucose variability (2.7 ± 1.1 vs 2.0 ± 0.7 mmol/L; P = 0.019) and more frequent hyperglycemia (12 events vs five events; P = 0.025) after morning RE than after afternoon RE.', '10': 'Conclusions: Compared with afternoon RE, morning (fasting) RE was associated with distinctly different blood glucose responses and postexercise profiles.'}\n",
            "53: abstract: {'1': 'To date, nutritional studies have focused on the total intake of dietary fiber rather than intake timing.', '2': 'In this study, we examined the effect of the timing of daily Helianthus tuberosus ingestion on postprandial and 24 h glucose levels, as well as on intestinal microbiota in older adults.', '3': 'In total, 37 healthy older adults (age = 74.9 ± 0.8 years) were recruited.', '4': 'The participants were randomly assigned to either a morning group (MG, n = 18) or an evening group (EG, n = 17).', '5': 'The MG and EG groups were instructed to take Helianthus tuberosus powder (5 g/day) just before breakfast or dinner, respectively, for 1 week after the 1-week control period.', '6': 'The glucose levels of all participants were monitored using a continuous glucose monitoring system throughout the 2 weeks.', '7': 'The intestinal microbiota was analyzed by sequencing 16S rRNA genes from feces before and after the intervention.', '8': 'There were no significant differences in the physical characteristics or energy intake between groups.', '9': 'Helianthus tuberosus intake led to decreases in tissue glucose levels throughout the day in both groups (p < 0.01, respectively).', '10': 'As a result of examining the fluctuations in tissue glucose levels up to 4 hours after each meal, significant decreases in the areas under the curves (AUCs) were observed for all three meals after intervention, but only in the MG (breakfast: p = 0.012, lunch: p = 0.002, dinner: p = 0.005).', '11': 'On the other hand, in the EG, there was a strong decrease in the AUC after dinner, but only slight decreases after breakfast and lunch (breakfast: p = 0.017, lunch: p = 0.427, dinner: p = 0.002).', '12': 'Moreover, the rate of change in the peak tissue glucose level at breakfast was significantly decreased in the MG compared to the EG (p = 0.027).', '13': 'A greater decrease was observed in the change in the blood glucose level after the ingestion of Helianthus tuberosus in the MG than in the EG.', '14': 'Furthermore, the relative abundance of Ruminococcus in the MG at the genus level was significantly higher at baseline than in the EG (p = 0.016) and it was also significantly lower after the intervention (p = 0.013).', '15': 'Our findings indicate that Helianthus tuberosus intake in the morning might have relatively stronger effects on the intestinal microbiota and suppress postprandial glucose levels to a greater extent than when taken in the evening.'}\n",
            "53: abstract: {'1': 'Aim: To examine whether mild early time-restricted eating (eating dinner at 18:00 vs. at 21:00) improves 24-h blood glucose levels and postprandial lipid metabolism in healthy adults.', '2': 'Methods: Twelve participants (2 males and 10 females) were included in the study.', '3': 'In this 3-day (until the morning of day 3) randomized crossover study, two different conditions were tested: eating a late dinner (at 21:00) or an early dinner (at 18:00).', '4': 'During the experimental period, blood glucose levels were evaluated by each participant wearing a continuous blood glucose measuring device.', '5': 'Metabolic measurements were performed using the indirect calorimetry method on the morning of day 3.', '6': \"The study was conducted over three days; day 1 was excluded from the analysis to adjust for the effects of the previous day's meal, and only data from the mornings of days 2 and 3 were used for the analysis.\", '7': 'Results: Significant differences were observed in mean 24-h blood glucose levels on day 2 between the two groups (p = 0.034).', '8': 'There was a significant decrease in the postprandial respiratory quotient 30 min and 60 min after breakfast on day 3 in the early dinner group compared with the late dinner group (p < 0.05).', '9': 'Conclusion: Despite a difference of only 3 h, eating dinner early (at 18:00) has a positive effect on blood glucose level fluctuation and substrate oxidation compared with eating dinner late (at 21:00).'}\n",
            "54: abstract: {'1': 'Family physicians often use quantitative human chorionic gonadotropin (HCG) testing to assess first-trimester bleeding.', '2': 'While we anticipate a range of normal results for any given week in the first trimester, we predict an approximate doubling over 48 hours in a normal pregnancy during the first trimester.', '3': 'Human chorionic gonadotropin tends to peak at about 10 weeks’ gestation before declining and stabilizing.', '4': 'When HCG levels plateau prematurely or fail to rise as expected, we consider that the pregnancy might not be viable.'}\n",
            "54: abstract: {'1': 'Objective: The aim of this study was to investigate whether subfertility, measured as longer time-to-pregnancy (TTP) in spontaneously conceived pregnancies, affects the first trimester levels of pregnancy-associated plasma protein-A (PAPP-A) and free beta-human chorionic gonadotrophin (β-hCG) and hence the risk estimates in Down syndrome screening.', '2': 'Methods: The study included a cohort of 10 469 singleton pregnant women who underwent first trimester combined screening and responded to a questionnaire regarding TTP.', '3': 'PAPP-A and free β-hCG levels were measured between gestational week 8 + 0 and 13 + 6 and were related to TTP.', '4': 'Results: The median PAPP-A and free β-hCG MoMs were significantly lower in women with a TTP ≥24 months compared with the reference group with a TTP <6 months (PAPP-A: 0.96 vs 1.06 MoM, p = 0.003; free β-hCG: 1.04 vs 1.12 MoM, p = 0.03).', '5': 'This led to an increased odds for trisomy 21 risk ≥1 : 300 for TTP ≥24 months compared with TTP <6 months, but when adjusting for potential confounders, the odds ratio (OR) lost significance (OR 1.4, 95% confidence interval; 0.8-2.4).', '6': 'Conclusion: Time-to-pregnancy ≥24 months in spontaneously conceived pregnancies is associated with decreased levels of PAPP-A and free β-hCG.'}\n",
            "54: abstract: {'1': 'The first trimester screening programme offers a noninvasive option for the early detection of aneuploidy pregnancies.', '2': 'This screening is done by a combination of two biochemical markers i.e. serum free β-human chorionic gonadotrophin (free β-hCG) and pregnancy associated plasma protein A (PAPP-A), maternal age and fetal nuchal translucency (NT) thickness at 11 + 0-13 + 6 weeks of gestation.', '3': 'A beneficial consequence of screening is the early diagnosis or trisomies 21, 18 and 13.', '4': 'At 11 + 0-13 + 6 weeks, the relative prevalence of trisomies 18 and 13 to trisomy 21 are found to be one to three and one to seven, respectively.', '5': 'All three trisomies are associated with increased maternal age, increased fetal NT and decreased PAPP-A, but in trisomy 21 serum free β-hCG is increased whereas in trisomies 18 and 13 free β-hCG is decreased.'}\n",
            "54: abstract: {'1': 'Human chorionic gonadotropin (hCG) is generally quantified in serum, but spot urine samples are also used to assess hCG levels in Japan.', '2': 'The purpose of the present study was to elucidate whether urinary hCG can be used clinically as a substitute for serum hCG.', '3': 'A total of 189 samples of serum and spot urine were collected from patients, including cases of normal pregnancy (NP) -13, abortion (AB) -21, extrauterine pregnancy (EP) 25, and hydatidiform mole (MOL) -7, during medical treatment and comparisons were made concerning serum and urinary hCG levels.', '4': 'The histogram of relative urinary/serum hCG(U-hCG.act/S-hCG) of the samples showed a wide distribution of values, but tended to converge to a narrow distribution by creatinine correction (U-hCG.cor/S-hCG).', '5': 'U-hCG.cor/S-hCG of the AB, EP, and MOL groups decreased 1 day to 14 days or was no earlier than 15 days postoperatively compared to preoperatively.', '6': 'The alteration of serum Intact/Total tended to be similar to that of U-hCG.cor/S-hCG in clinical course.', '7': 'The presented case indicated that U-hCG.act/S-hCG did not correspond to serum hCG levels.', '8': 'Because urinary hCG levels are inconsistent depending on whether spot urine is concentrated or diluted, the levels of hCG in spot urine do not always correlate with serum levels of hCG.', '9': 'Therefore, the data of urinary hCG should be interpreted after creatinine correction.', '10': 'Overall, it is recommended to determine serum hCG levels rather than creatinine corrected urinary hCG levels, considering that the relative urinary/serum hCG was not constant postoperatively.'}\n",
            "54: abstract: {'1': 'Human chorionic gonadotropin (hCG) is a pregnancy hormone secreted by the placental synctiotrophoblast cell layer that has been linked to fetal growth and various placental, uterine and fetal functions.', '2': 'In order to investigate the effects of hCG on clinical endpoints, knowledge on reference range (RR) methodology and determinants of gestational hCG levels is crucial.', '3': 'Moreover, a better understanding of gestational hCG physiology can improve current screening programs and future clinical management.', '4': 'Serum total hCG levels were determined in 8195 women participating in the Generation R Study.', '5': \"Gestational age specific RRs using 'ultrasound derived gestational age' (US RRs) were calculated and compared with 'last menstrual period derived gestational age' (LMP RRs) and a model-based RR.\", '6': 'We also investigated which pregnancy characteristics were associated with hCG levels.', '7': 'Compared to the US RRs, the LMP RRs were lower, most notably for the median and lower limit levels.', '8': 'No considerable differences were found between RRs calculated in the general population or in uncomplicated pregnancies only.', '9': 'Maternal smoking, BMI, parity, ethnicity, fetal gender, placental weight and hyperemesis gravidarum symptoms were associated with total hCG.', '10': 'We provide gestational RRs for total hCG and show that total hCG values and RR cut-offs during pregnancy vary depending on pregnancy dating methodology.', '11': 'This is likely due to the influence of hCG on embryonic growth, suggesting that ultrasound based pregnancy dating might be less reliable in women with high/low hCG levels.', '12': 'Furthermore, we identify different pregnancy characteristics that influence total hCG levels considerably and should therefore be accounted for in clinical studies.'}\n",
            "54: abstract: {'1': 'The objective was to determine the strength of relationship between maternal free beta human chorionic gonadotropin (β-hCG) concentrations and rates of adverse pregnancy outcomes.', '2': 'Consecutive records of the database of our Down screening project were assessed for free β-hCG levels and pregnancy outcomes.', '3': 'Pregnancies with foetal chromosomal or structural anomalies and those with underlying disease were excluded.', '4': 'Free β-hCG levels of < 0.5, > 0.5 and < 2.0, and ≥ 2.0 MoM were categorised as low, normal and high, respectively.', '5': 'Of 17,082 screened women, 13,620 were available for analysis.', '6': 'In the first trimester (n = 8150), low β-hCG levels significantly increased risk for intrauterine growth restriction (IUGR), preterm birth, low birth weight (LBW) and low Apgar score with relative risk of 1.66, 1.43, 1.83 and 2.89; whereas high β-hCG group had a significant decreased risk of preterm birth and GDM with relative risk of 0.73 and 0.62.', '7': 'In the second trimester (n = 5470), both low and high β-hCG groups had significant increased risks of the most common adverse outcomes, i.e. spontaneous abortion, IUGR and preterm birth.', '8': 'In conclusion, abnormally low (< 0.5MoM) or high (> 2.0 MoM) free β-hCG levels are generally associated with an increased risk of adverse pregnancy outcomes.', '9': 'Nevertheless, high free β-hCG levels in the first trimester may possibly decrease risk of preterm delivery and GDM.'}\n",
            "54: abstract: {'1': 'Introduction: The presentation of Ectopic Pregnancy (EP) can be highly variable and serum Beta hCG estimation plays an important role in early diagnosis.', '2': 'Aim: Aim of the study was to determine the trends of hCG levels in EP and to explore the role of hCG in decisions related to management and follow-up of EPs.', '3': 'Materials and methods: A retrospective study of women who had EPs from January 2006 to December 2012 at an advanced tertiary care centre in southern India was carried out.', '4': 'These women had undergone treatment based on the hospital protocol.', '5': 'Results: The study identified 337 women with EP.', '6': 'Thirty one surgically confirmed cases were diagnosed below the discriminatory zone of 1500 mIU/ml.', '7': 'Among women who had Beta hCG estimations 48 hours apart, plateauing was observed in 22.5% while decrease >15% was noted in 26.8%.', '8': 'Almost half (47.9%) of the cases had an increase >15% and a few (2.8%) demonstrated an initial fall followed by a rise in titres.', '9': 'In 23.9% of these women, there was a rise >53% similar to intrauterine pregnancy.', '10': 'The average pre-treatment Beta hCG was 429.8, 3866.2 and 12961.5 mIU/ml for those who received expectant, medical and direct surgical treatment respectively.', '11': '43 women with relative contraindications received medical management and 39 were lost to follow-up after medical and expectant management.', '12': 'Excluding them, the success rate of these two modalities was 76.6% and 85.0% respectively.', '13': 'Conclusion: No single level of Beta hCG is diagnostic of EP and serial levels can demonstrate atypical trends in some cases.', '14': 'Hence, interpretation of these results should be done in conjunction with clinical and sonographic findings to arrive at a correct diagnosis.'}\n",
            "54: abstract: {'1': 'Human chorionic gonadotropin (hCG) is a chemical created by trophoblast tissue, tissue typically found in early embryos and which will eventually be part of the placenta.', '2': 'Measuring hCG levels can be helpful in identifying a normal pregnancy, pathologic pregnancy, and can also be useful following an aborted pregnancy.', '3': 'There is also a benefit in measuring hCG in a variety of cancers including choriocarcinoma and extra-uterine malignancies.'}\n",
            "54: abstract: {'1': 'Objective: To examine patients after embryo transfer for predictive influence of the human chorionic gonadotropin (hCG) level on the probability of finishing pregnancy with delivery.', '2': 'Methods: 490 patients pregnant after IVF + ET treatment placed in the study.', '3': 'The influence of other factors: age (patients 20-50), number of transferred embryos (one, two and more) and the length of cultivation on the probability of finishing pregnancy with delivery or loss and the possibility to predict multiple pregnancy was also related to the known hCG value.', '4': 'The transferred embryos were divided into two groups - early (cultivation 48 and 72 hrs) and prolonged cultivation (PC 96 and 120 hrs).', '5': 'The answer here, therefore, is a multinomial variable with four levels.', '6': 'For that reason the data was analysed through a multinomial logistic model vs. multinomial distribution of a mistake and generalised logistic link function.', '7': 'Results: The hCG level grows exponentially in the course of the 9th to 17th day after an embryo transfer (ET).', '8': 'The probability of one child delivery after the transfer of one embryo overdue after prolonged cultivation (96 or 120 hrs) grows with the average and above-average hCG values on the day of the draw.', '9': 'The hCG value was 678 (564-815) IU/l1 on the 14th day after ET in pregnancy ended in delivery, 321 (216-477) IU/l on average in abortion, 82 (51-132) IU/l in biochemical pregnancy and 1070 (737-1554) IU/l in multiple pregnancy.', '10': 'The probability of multiple pregnancy increased with hCG values greatly above the average and on the other hand, below-average values indicated abortion or biochemical pregnancy.', '11': 'The patients age was not proven to be of significant influence, the hCG level slightly decreased with higher age.', '12': 'On the contrary, an increasing frequency of abortions depending on the increasing age of the mother was once again confirmed.', '13': 'Conclusion: The measured hCG values are considerably different depending on the pregnancy result, which is why this value is considered a quality predictive factor of the pregnancy result.'}\n",
            "54: abstract: {'1': 'Objectives: Level of βhCG and the presence of any uterine mass of hydatidiform mole need a careful review or monitoring in order to prevent metastasis, provide an early treatment and avoid unnecessary chemotherapy.', '2': 'Case presentation: A 36-year old fifth gravida patient who had a missed abortion was diagnosed as having a molar pregnancy with beta human chorionic gonadotrophin (βhCG) level of 509,921 IU/L.', '3': 'Her lung field was clear and she underwent suction and curettage (S & C) procedure.', '4': 'However, after six weeks, AA presented to the emergency department with a massive bleeding, although her βhCG level had decreased to 65,770 IU/L.', '5': 'A trans-abdominal ultrasound indicated the presence of an intra-uterine mass (3.0 × 4.4 cm).', '6': 'Nevertheless, her βhCG continued to show a declining trend (8,426 IU/L).', '7': 'AA was advised to undergo a chemotherapy but she refused, citing preference for alternative medicine like herbs instead.', '8': 'She opted for an \"at own risk\" (AOR) discharge with scheduled follow up.', '9': 'Subsequently, her condition improved with her βhCG showing a downward trend.', '10': 'Surprisingly, at six months post S & C, her βhCG ameliorated to 0 IU/L with no mass detected by ultrasound.', '11': 'Conclusions: Brucea javanica fruits, Pereskia bleo and Annona muricata leaves can potentially be useful alternatives to chemotherapy and need further studies.'}\n",
            "55: abstract: {'1': 'Sixty-three adults with the diagnosis of the postviral fatigue syndrome were enrolled in a double-blind, placebo-controlled study of essential fatty acid therapy.', '2': 'The patients had been ill for from one to three years after an apparently viral infection, suffering from severe fatigue, myalgia and a variety of psychiatric symptoms.', '3': 'The preparation given contained linoleic, gamma-linolenic, eicosapentaenoic and docosahexaenoic acids and either it, or the placebo, was given as 8 x 500 mg capsules per day over a 3-month period.', '4': 'The trial was parallel in design and patients were evaluated at entry, one month and three months.', '5': 'In consultation with the patient the doctors assessed overall condition, fatigue, myalgia, dizziness, poor concentration and depression on a 3-point scale.', '6': 'The essential fatty acid composition of their red cell membrane phospholipids was analysed at the first and last visits.', '7': 'At 1 month, 74% of patients on active treatment and 23% of those on placebo assessed themselves as improved over the baseline, with the improvement being much greater in the former.', '8': 'At 3 months the corresponding figures were 85% and 17% (p less than 0.0001) since the placebo group had reverted towards the baseline state while those in the active group showed continued improvement.', '9': 'The essential fatty acid levels were abnormal at the baseline and corrected by active treatment.', '10': 'There were no adverse events.', '11': 'We conclude that essential fatty acids provide a rational, safe and effective treatment for patients with the post-viral fatigue syndrome.'}\n",
            "55: abstract: {'1': 'Abnormalities of Essential Fatty Acid (EFA) incorporation into phospholipid are found in chronic diseases.', '2': 'More recently changes in circulating EFA metabolites (EFAM) together with EFAM hypo-responsiveness of immune cells and EFAM production from cells have been found associated with disease.', '3': 'We hypothesize that changes in ratio of EFAMs are the normal physiological responses to stressors, but when stressors are excessive or prolonged, EFAM systems may become unpredictably hypo-responsive owing to factors such as receptor down regulation and substrate depletion.', '4': 'In time, many homeostatic system become deranged and held in that state by minor stressors.', '5': 'Literature review of chronic fatigue syndrome (CFS) shows hyper and hypo-responsiveness in immune function, several Hypothalamo-Pituitary (HP) axes and sympathetic nervous system, all relatable to dysfunctional changes in EFA metabolism.', '6': 'For the first time, we explain chronic immune system activation and hypo-responsive immune function in CFS; through EFAMs.', '7': 'Dietary EFA modulation (DEFA) can alter ratios of both membrane EFAs and produced EFAMs, and if maintained can restore hypo-responsive function.', '8': 'We discuss dietary strategies and relevance in CFS, and a case series of CFS patients applying DEFA with other titrated published managements which saw 90% gaining improvement within 3 months and more than 2/3 fit for full time duties.', '9': 'This hypothesis and DEFA may have relevance in other chronic conditions.'}\n",
            "55: abstract: {'1': 'Evidence is put forward to suggest that myalgic encephalomyelitis, also known as chronic fatigue syndrome, may be associated with persistent viral infection.', '2': 'In turn, such infections are likely to impair the ability of the body to biosynthesise n-3 and n-6 long-chain polyunsaturated fatty acids by inhibiting the delta-6 desaturation of the precursor essential fatty acids--namely, alpha-linolenic acid and linoleic acid.', '3': 'This would, in turn, impair the proper functioning of cell membranes, including cell signalling, and have an adverse effect on the biosynthesis of eicosanoids from the long-chain polyunsaturated fatty acids dihomo-gamma-linolenic acid, arachidonic acid and eicosapentaenoic acid.', '4': 'These actions might offer an explanation for some of the symptoms and signs of myalgic encephalomyelitis.', '5': 'A potential therapeutic avenue could be offered by bypassing the inhibition of the enzyme delta-6-desaturase by treatment with virgin cold-pressed non-raffinated evening primrose oil, which would supply gamma-linolenic acid and lipophilic pentacyclic triterpenes, and with eicosapentaenoic acid.', '6': 'The gamma-linolenic acid can readily be converted into dihomo-gamma-linolenic acid and thence arachidonic acid, while triterpenes have important free radical scavenging, cyclo-oxygenase and neutrophil elastase inhibitory activities.', '7': 'Furthermore, both arachidonic acid and eicosapentaenoic acid are, at relatively low concentrations, directly virucidal.'}\n",
            "55: abstract: {'1': 'Background: Phosphatidylserine (PS) may have beneficial effects on cognitive functions.', '2': 'We evaluated the efficacy of a novel preparation of PS containing omega-3 long-chain polyunsaturated fatty acids attached to its backbone (PS-DHA) in non-demented elderly with memory complaints.', '3': 'Methods: 157 participants were randomized to receive either PS-DHA or placebo for 15 weeks.', '4': 'Efficacy measures, assessed at baseline and endpoint, included the Rey Auditory Verbal Learning Test, Rey Complex Figure Test, and a computerized cognitive battery.', '5': \"Clinicians' Global Impression of Change was assessed following 7 and 15 weeks of treatment.\", '6': 'Results: 131 participants completed the study although 9 were excluded from the efficacy analysis due to protocol violation.', '7': 'At endpoint, verbal immediate recall was significantly improved in the PS-DHA group compared to the placebo group.', '8': 'Post-hoc analysis revealed that a subset of participants with relatively good cognitive performance at baseline had significant treatment-associated improvements in immediate and delayed verbal recall, learning abilities, and time to copy complex figure.', '9': 'These favorable results were further supported by responder analysis.', '10': 'Conclusions: The results indicate that PS-DHA may improve cognitive performance in non-demented elderly with memory complaints.', '11': 'Post-hoc analysis of subgroups suggests that participants with higher baseline cognitive status were most likely to respond to PS-DHA.', '12': 'The results of this exploratory study should be followed up by additional studies aimed at confirming the present tentative conclusions.'}\n",
            "55: abstract: {'1': 'Background: Attention-deficit hyperactivity disorder (ADHD) is the most commonly diagnosed behavioural disorder of childhood, affecting 3-5% of school-age children.', '2': 'The present study investigated whether the supplementation of soy-derived phosphatidylserine (PS), a naturally occurring phospholipid, improves ADHD symptoms in children.', '3': 'Methods: Thirty six children, aged 4-14 years, who had not previously received any drug treatment related to ADHD, received placebo (n = 17) or 200 mg day(-1) PS (n = 19) for 2 months in a randomised, double-blind manner.', '4': 'Main outcome measures included: (i) ADHD symptoms based on DSM-IV-TR; (ii) short-term auditory memory and working memory using the Digit Span Test of the Wechsler Intelligence Scale for Children; and (iii) mental performance to visual stimuli (GO/NO GO task).', '5': 'Results: PS supplementation resulted in significant improvements in: (i) ADHD (P < 0.01), AD (P < 0.01) and HD (P < 0.01); (ii) short-term auditory memory (P < 0.05); and (iii) inattention (differentiation and reverse differentiation, P < 0.05) and inattention and impulsivity (P < 0.05).', '6': 'No significant differences were observed in other measurements and in the placebo group.', '7': 'PS was well-tolerated and showed no adverse effects.', '8': 'Conclusions: PS significantly improved ADHD symptoms and short-term auditory memory in children.', '9': 'PS supplementation might be a safe and natural nutritional strategy for improving mental performance in young children suffering from ADHD.'}\n",
            "55: abstract: {'1': 'Loss of function in mitochondria, the key organelle responsible for cellular energy production, can result in the excess fatigue and other symptoms that are common complaints in almost every chronic disease.', '2': 'At the molecular level, a reduction in mitochondrial function occurs as a result of the following changes: (1) a loss of maintenance of the electrical and chemical transmembrane potential of the inner mitochondrial membrane, (2) alterations in the function of the electron transport chain, or (3) a reduction in the transport of critical metabolites into mitochondria.', '3': \"In turn, these changes result in a reduced efficiency of oxidative phosphorylation and a reduction in production of adenosine-5'-triphosphate (ATP).\", '4': 'Several components of this system require routine replacement, and this need can be facilitated with natural supplements.', '5': 'Clinical trials have shown the utility of using oral replacement supplements, such as L-carnitine, alpha-lipoic acid (α-lipoic acid [1,2-dithiolane-3-pentanoic acid]), coenzyme Q10 (CoQ10 [ubiquinone]), reduced nicotinamide adenine dinucleotide (NADH), membrane phospholipids, and other supplements.', '6': 'Combinations of these supplements can reduce significantly the fatigue and other symptoms associated with chronic disease and can naturally restore mitochondrial function, even in long-term patients with intractable fatigue.'}\n",
            "55: abstract: {'1': 'More than 2 million people in the United States have myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS).', '2': 'We performed targeted, broad-spectrum metabolomics to gain insights into the biology of CFS.', '3': 'We studied a total of 84 subjects using these methods.', '4': 'Forty-five subjects (n = 22 men and 23 women) met diagnostic criteria for ME/CFS by Institute of Medicine, Canadian, and Fukuda criteria.', '5': 'Thirty-nine subjects (n = 18 men and 21 women) were age- and sex-matched normal controls.', '6': 'Males with CFS were 53 (±2.8) y old (mean ± SEM; range, 21-67 y).', '7': 'Females were 52 (±2.5) y old (range, 20-67 y).', '8': 'The Karnofsky performance scores were 62 (±3.2) for males and 54 (±3.3) for females.', '9': 'We targeted 612 metabolites in plasma from 63 biochemical pathways by hydrophilic interaction liquid chromatography, electrospray ionization, and tandem mass spectrometry in a single-injection method.', '10': 'Patients with CFS showed abnormalities in 20 metabolic pathways.', '11': 'Eighty percent of the diagnostic metabolites were decreased, consistent with a hypometabolic syndrome.', '12': 'Pathway abnormalities included sphingolipid, phospholipid, purine, cholesterol, microbiome, pyrroline-5-carboxylate, riboflavin, branch chain amino acid, peroxisomal, and mitochondrial metabolism.', '13': 'Area under the receiver operator characteristic curve analysis showed diagnostic accuracies of 94% [95% confidence interval (CI), 84-100%] in males using eight metabolites and 96% (95% CI, 86-100%) in females using 13 metabolites.', '14': 'Our data show that despite the heterogeneity of factors leading to CFS, the cellular metabolic response in patients was homogeneous, statistically robust, and chemically similar to the evolutionarily conserved persistence response to environmental stress known as dauer.'}\n",
            "55: abstract: {'1': 'Background: Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is characterized by unexplained persistent fatigue, commonly accompanied by cognitive dysfunction, sleeping disturbances, orthostatic intolerance, fever, lymphadenopathy, and irritable bowel syndrome (IBS).', '2': 'The extent to which the gastrointestinal microbiome and peripheral inflammation are associated with ME/CFS remains unclear.', '3': 'We pursued rigorous clinical characterization, fecal bacterial metagenomics, and plasma immune molecule analyses in 50 ME/CFS patients and 50 healthy controls frequency-matched for age, sex, race/ethnicity, geographic site, and season of sampling.', '4': 'Results: Topological analysis revealed associations between IBS co-morbidity, body mass index, fecal bacterial composition, and bacterial metabolic pathways but not plasma immune molecules.', '5': 'IBS co-morbidity was the strongest driving factor in the separation of topological networks based on bacterial profiles and metabolic pathways.', '6': 'Predictive selection models based on bacterial profiles supported findings from topological analyses indicating that ME/CFS subgroups, defined by IBS status, could be distinguished from control subjects with high predictive accuracy.', '7': 'Bacterial taxa predictive of ME/CFS patients with IBS were distinct from taxa associated with ME/CFS patients without IBS.', '8': 'Increased abundance of unclassified Alistipes and decreased Faecalibacterium emerged as the top biomarkers of ME/CFS with IBS; while increased unclassified Bacteroides abundance and decreased Bacteroides vulgatus were the top biomarkers of ME/CFS without IBS.', '9': 'Despite findings of differences in bacterial taxa and metabolic pathways defining ME/CFS subgroups, decreased metabolic pathways associated with unsaturated fatty acid biosynthesis and increased atrazine degradation pathways were independent of IBS co-morbidity.', '10': 'Increased vitamin B6 biosynthesis/salvage and pyrimidine ribonucleoside degradation were the top metabolic pathways in ME/CFS without IBS as well as in the total ME/CFS cohort.', '11': 'In ME/CFS subgroups, symptom severity measures including pain, fatigue, and reduced motivation were correlated with the abundance of distinct bacterial taxa and metabolic pathways.', '12': 'Conclusions: Independent of IBS, ME/CFS is associated with dysbiosis and distinct bacterial metabolic disturbances that may influence disease severity.', '13': 'However, our findings indicate that dysbiotic features that are uniquely ME/CFS-associated may be masked by disturbances arising from the high prevalence of IBS co-morbidity in ME/CFS.', '14': 'These insights may enable more accurate diagnosis and lead to insights that inform the development of specific therapeutic strategies in ME/CFS subgroups.'}\n",
            "55: abstract: {'1': 'Membrane Lipid Replacement is the use of functional oral supplements containing cell membrane glycerolphospholipids and antioxidants to safely replace damaged membrane lipids that accumulate during aging and in various chronic and acute diseases.', '2': 'Most if not all clinical conditions and aging are characterized by membrane phospholipid oxidative damage, resulting in loss of membrane and cellular function.', '3': 'Clinical trials have shown the benefits of Membrane Lipid Replacement supplements in replenishing damaged membrane lipids and restoring mitochondrial function, resulting in reductions in fatigue in aged subjects and patients with a variety of clinical diagnoses.', '4': \"Recent observations have indicated that Membrane Lipid Replacement can be a useful natural supplement strategy in a variety of conditions: chronic fatigue, such as found in many diseases and disorders; fatiguing illnesses (fibromyalgia and chronic fatigue syndrome); chronic infections (Lyme disease and mycoplasmal infections); cardiovascular diseases; obesity, metabolic syndrome and diabetes; neurodegenerative diseases (Alzheimer's disease); neurobehavioral diseases (autism spectrum disorders); fertility diseases; chemical contamination (Gulf War illnesses); and cancers (breast, colorectal and other cancers).\", '5': 'Membrane Lipid Replacement provides general membrane nutritional support during aging and illness to improve membrane function and overall health without risk of adverse effects.'}\n",
            "55: abstract: {'1': 'This is a comprehensive literature review of chronic fatigue syndrome (CFS).', '2': 'We provide a description of the background, etiology, pathogenesis, diagnosis, and management regarding CFS.', '3': 'CFS is a multifaceted illness that has many symptoms and a wide array of clinical presentations.', '4': 'As of recent, CFS has been merged with myalgic encephalomyelitis (ME).', '5': 'Much of the difficulty in its management has stemmed from a lack of a concrete understanding of its etiology and pathogenesis.', '6': 'There is a potential association between dysfunction of the autoimmune, neuroendocrine, or autonomic nervous systems and the development of CFS.', '7': 'Possible triggering events, such as infections followed by an immune dysregulation resulting have also been proposed.', '8': 'In fact, ME/CFS was first described following Epstein Barr virus (EBV) infections, but it was later determined that it was not always preceded by EBV infection.', '9': 'Patient diagnosed with CFS have shown a noticeably earlier activation of anaerobic metabolism as a source of energy, which is suggestive of impaired oxygen consumption.', '10': 'The differential diagnoses range from tick-borne illnesses to psychiatric disorders to thyroid gland dysfunction.', '11': 'Given the many overlapping symptoms of CFS with other illnesses makes diagnosing it far from an easy task.', '12': 'The Centers for Disease Control and Prevention (CDC) considers it a diagnosing of exclusion, stating that self-reported fatigue for at minimum of six months and four of the following symptoms are necessary for a proper diagnosis: memory problems, sore throat, post-exertion malaise, tender cervical or axillary lymph nodes, myalgia, multi-joint pain, headaches, and troubled sleep.', '13': 'In turn, management of CFS is just as difficult.', '14': 'Treatment ranges from conservative, such as cognitive behavioral therapy (CBT) and antidepressants, to minimally invasive management.', '15': 'Minimally invasive management involving ranscutaneous electrical acupoint stimulation of target points has demonstrated significant improvement in fatigue and associated symptoms in a 2017 randomized controlled study.', '16': 'The understanding of CFS is evolving before us as we continue to learn more about it.', '17': 'As further reliable studies are conducted, providing a better grasp of what the syndrome encompasses, we will be able to improve our diagnosis and management of it.'}\n",
            "56: abstract: {'1': 'We report on three infants with hand anomalies and congenital hypopituitarism.', '2': 'In two of the cases, a hypothalamic tumor was found; the third infant died without postmortem brain studies.', '3': \"Family history in the first case suggested possible familial recurrence; the mother's sister had died at 17 hr of age with polydactyly, microglossia, and flat nasal bridge (no autopsy done).\", '4': 'Our second case was born by cesarean section after a pregnancy complicated by extremely low maternal estriols.', '5': 'At birth, hypopituitarism was diagnosed, a cranial CT scan was read as normal, and hormonal replacement was begun with thyroxine, hydrocortisone, and growth hormone.', '6': 'At 11.5 mo of age she developed seizures; and a repeat CT scan showed a mass extending beneath the hypothalamus.', '7': 'This tumor was removed surgically at 12 mo, the first successful treatment of this disorder.', '8': 'Our third possible case had a bifid epiglottis, hypopituitarism, and hand anomalies.', '9': 'A CT scan at birth failed to reveal a mass in the hypothalamus.', '10': 'This child died from complications of untreated hypopituitarism, and no neuropathology studies were done.', '11': 'These three cases were conceived between March 10th and April 17th in three different years in three geographically contiguous counties of Vermont.', '12': 'Clustering in time and space and possible familial recurrence, in one of these cases, suggest a possible gene/environment interaction.'}\n",
            "56: abstract: {'1': 'Pallister-Hall syndrome (PHS, M146510) was first described in 1980 in six newborns.', '2': 'It is a pleiotropic disorder of human development that comprises hypothalamic hamartoma, central polydactyly, and other malformations.', '3': 'This disorder is inherited as an autosomal dominant trait and has been mapped to 7p13 (S. Kang et al.Autosomal dominant Pallister-Hall syndrome maps to 7p13. Am. J. Hum. Genet. 59, A81 (1996)), co-localizing the PHS locus and the GLI3 zinc finger transcription factor gene.', '4': 'Large deletions or translocations resulting in haploinsufficiency of the GLI3 gene have been associated with Greig cephalopolysyndactyly syndrome (GCPS; M175700) although no mutations have been identified in GCPS patients with normal karyotypes.', '5': 'Both PHS and GCPS have polysyndactyly, abnormal craniofacial features and are inherited in an autosomal dominant pattern, but they are clinically distinct.', '6': 'The polydactyly of GCPS is commonly preaxial and that of PHS is typically central or postaxial.', '7': 'No reported cases of GCPS have hypothalamic hamartoma and PHS does not cause hypertelorism or broadening of the nasal root or forehead.', '8': 'The co-localization of the loci for PHS and GCPS led us to investigate GLI3 as a candidate gene for PHS.', '9': \"Herein we report two PHS families with frameshift mutations in GLI3 that are 3' of the zinc finger-encoding domains, including one family with a de novo mutation.\", '10': 'These data implicate mutations in GLI3 as the cause of autosomal dominant PHS, and suggest that frameshift mutations of the GLI3 transcription factor gene can alter the development of multiple organ systems in vertebrates.'}\n",
            "56: abstract: {'1': 'Pallister-Hall syndrome (PHS) is a rare, single-gene, malformation syndrome that includes central polydactyly, hypothalamic hamartoma, bifid epiglottis, endocrine dysfunction, and other anomalies.', '2': 'The syndrome has variable clinical manifestations and is inherited in an autosomal dominant pattern.', '3': 'We sought to determine whether psychiatric disorders and/or neuropsychological impairment were characteristic of PHS.', '4': 'We prospectively conducted systematic neuropsychiatric evaluations with 19 PHS subjects ranging in age from 7 to 75 years.', '5': 'The evaluation included detailed clinical interviews, clinician-rated and self-report instruments, and a battery of neuropsychological tests.', '6': 'Seven of 14 adult PHS subjects met diagnostic criteria for at least one DSM-IV Axis I disorder.', '7': 'Three additional subjects demonstrated developmental delays and/or neuropsychological deficits on formal neuropsychological testing.', '8': 'However, we found no characteristic psychiatric phenotype associated with PHS, and the frequency of each of the diagnoses observed in these subjects was not different from that expected in this size sample.', '9': 'The overall frequency of psychiatric findings among all patients with PHS cannot be compared to point prevalence estimates of psychiatric disease in the general population because of biased ascertainment. ', '10': 'This limitation is inherent to the study of behavioral phenotypes in rare disorders. ', '11': 'The general issue of psychiatric evaluation of rare genetic syndromes is discussed in light of this negative result.'}\n",
            "56: abstract: {'1': 'Clinical characteristics: Pallister-Hall syndrome (referred to as PHS in this entry) is characterized by a spectrum of anomalies ranging from polydactyly, asymptomatic bifid epiglottis, and hypothalamic hamartoma at the mild end to laryngotracheal cleft with neonatal lethality at the severe end.', '2': 'Individuals with mild PHS may be incorrectly diagnosed as having isolated postaxial polydactyly type A.', '3': 'Individuals with PHS can have pituitary insufficiency and may die as neonates from undiagnosed and untreated adrenal insufficiency.', '4': 'Diagnosis/testing: The diagnosis of Pallister-Hall syndrome can be established in a proband with both hypothalamic hamartoma and mesoaxial polydactyly.', '5': 'Identification of a heterozygous pathogenic variant in GLI3 confirms the diagnosis.', '6': 'Management: Treatment of manifestations: Urgent treatment for endocrine abnormalities, especially cortisol deficiency; management of epiglottic abnormalities depending on the abnormality and the extent of respiratory compromise.', '7': 'Bifid epiglottis, the most common abnormality, typically does not need treatment.', '8': 'Standard treatment of anal atresia or stenosis; symptomatic treatment of seizures; elective repair of polydactyly; developmental intervention or special education for developmental delays.', '9': 'Prevention of secondary complications: Biopsy or resection of hypothalamic hamartoma may result in complications and lifelong need for hormone replacement; seizures may begin or worsen with use of stimulants for attention deficit disorder.', '10': 'Surveillance: During childhood, annual developmental assessment and annual medical evaluation to assess growth and monitor for signs of precocious puberty.', '11': 'Genetic counseling: Pallister-Hall syndrome is inherited in an autosomal dominant manner. ', '12': 'Individuals with PHS may have an affected parent or may have the disorder as the result of a de novo pathogenic variant.', '13': 'About 25% of individuals have a de novo pathogenic variant.', '14': 'Persons with a de novo pathogenic variant are generally more severely affected than those with a family history of PHS.', '15': 'The risk to offspring of an affected individual is 50%.', '16': 'Prenatal testing for pregnancies at increased risk is possible if the pathogenic variant in the family is known.', '17': 'The reliability of ultrasound examination for prenatal diagnosis is unknown.'}\n",
            "56: abstract: {'1': 'Pallister-Hall syndrome (PHS) is a rare disorder caused by mutations in GLI3 that produce a transcriptional repressor (GLI3R).', '2': 'Individuals with PHS present with a variably penetrant variety of urogenital system malformations, including renal aplasia or hypoplasia, hydroureter, hydronephrosis or a common urogenital sinus.', '3': 'The embryologic mechanisms controlled by GLI3R that result in these pathologic phenotypes are undefined.', '4': 'We demonstrate that germline expression of GLI3R causes renal hypoplasia, associated with decreased nephron number, and hydroureter and hydronephrosis, caused by blind-ending ureters.', '5': 'Mice with obligate GLI3R expression also displayed duplication of the ureters that was caused by aberrant common nephric duct patterning and ureteric stalk outgrowth.', '6': 'These developmental abnormalities are associated with suppressed Hedgehog signaling activity in the cloaca and adjacent vesicular mesenchyme.', '7': 'Mice with conditional expression of GLI3R were utilized to identify lineage-specific effects of GLI3R.', '8': 'In the ureteric bud, GLI3R expression decreased branching morphogenesis.', '9': 'In Six2-positive nephrogenic progenitors, GLI3R decreased progenitor cell proliferation reducing the number of nephrogenic precursor structures.', '10': 'Using mutant mice with Gli3R and Gli3 null alleles, we demonstrate that urogenital system patterning and development is controlled by the levels of GLI3R and not by an absence of full-length GLI3.', '11': 'We conclude that the urogenital system phenotypes observed in PHS are caused by GLI3R-dependent perturbations in nephric duct patterning, renal branching morphogenesis and nephrogenic progenitor self-renewal.'}\n",
            "56: abstract: {'1': 'Pallister-Hall syndrome was initially recognized under fairly unique circumstances involving exhumation of the very first case.', '2': 'The first two cases had dramatic and unusual features including a hypothalamic hamartoblastoma, imperforate anus, an unusual type of polydactyly with the extra digit being central, hypopituitarism with secondary hypoadrenalism, and lethality after birth (probably due to hypoadrenalism).', '3': 'Within a short time frame, four additional cases were identified. ', '4': 'As the full spectrum and variability of anomalies was recognized, it became clear that it was not such a rare disorder.', '5': 'Shortly after familial cases were recognized, the responsible gene was identified at GLI3.', '6': 'However, since other different conditions also involved GLI3, elaborating the domains of the gene and the types of mutations needed to be defined in order to have a clear correlation of the genotype-phenotype relations.'}\n",
            "56: abstract: {'1': 'Pallister Hall syndrome is autosomal dominant disorder usually diagnosed in infants and children.', '2': 'Current diagnostic criteria include presence of hypothalamic hamartoma, post axial polydactyly and positive family history, but the disease has variable manifestations.', '3': 'Herein we report Pallister Hall syndrome diagnosed in a family where both patients were adults.', '4': 'A 59 year old man developed seizures 4 years prior to our evaluation of him, at which time imaging showed a hypothalamic hamartoma.', '5': 'The seizures were controlled medically.', '6': 'He did well until he had visual changes after a traumatic head injury.', '7': 'Repeat MRI showed slight expansion of the mass with formal visual field testing demonstrating bitemporal hemianopsia.', '8': 'There was no evidence of pituitary dysfunction except for large urine volume.', '9': 'He underwent surgery to debulk the hamartoma and the visual field defects improved.', '10': 'There was no hypopituitarism post-operatively, and the polydyspia resolved.', '11': 'His 29 year old daughter also had seizures and hypothalamic hamartoma.', '12': 'Both patients had had polydactyly with prior surgical correction in childhood.', '13': 'The daughter underwent genetic testing, which revealed a previously undescribed heterozygous single base pair deletion in exon 13 of the GLI3 gene causing a frameshift mutation.', '14': 'Further investigation into family history revealed multiple members in previous generations with polydactyly and/or seizures.', '15': 'Pallister-Hall syndrome is caused by an inherited autosomal dominant or de novo mutation in GLI3 gene.', '16': 'This rare syndrome has not had prevalence defined, however.', '17': 'Generally, diagnoses are made in the pediatric population.', '18': 'Our report adds to the few cases detected in adulthood.'}\n",
            "56: abstract: {'1': 'Polydactyly is a relatively common abnormality in infants.', '2': 'However, it can be a marker of a wide variety of neurological and systemic abnormality.', '3': 'Hence, it is important for pediatrician and physician to have insight into the various association of this apparently innocuous anomaly.', '4': 'In this write-up, we report an extremely rare syndrome associated with polydactyly that is Pallister-Hall syndrome.', '5': 'A 10-month-old male child born by lower segment cesarean section presented with global delay associated with microcephaly, frontal bossing, hypertelorism, flat nose, short philtrum, incomplete cleft in the upper lip and hard palate, polydactyly, and syndactyly.', '6': 'The child presented with repeated vomiting and crying episodes.', '7': 'The patient was investigated which revealed a hypothalamic hamartomas.', '8': 'Pallister-Hall syndrome is a very rare autosomal dominant genetic disorder due to mutation in GLI3 gene in the short arm of chromosome 7 with variable penetrance and expressivity.'}\n",
            "56: abstract: {'1': 'Pallister-Hall syndrome (PHS) is an extremely rare syndrome of unknown prevalence with autosomal dominant inheritance due to GLI3 gene mutations classically characterized by the presence of a hypothalamic hamartoma and polydactyly.', '2': 'Additional diagnostic criteria include bifid epiglottis, imperforate anus, small nails, hypopituitarism, growth hormone deficiency, and genital hypoplasia.', '3': 'It is typically diagnosed in infancy and early childhood, presenting with seizures and/or precocious puberty due to the hypothalamic hamartoma, and with limb anomalies due to central polydactyly.', '4': 'Our patient had presented with polysyndactyly at birth.', '5': 'However, as this is not uncommon in infants and is usually as part of the sporadic, isolated form of polydactyly, no further work up was done.', '6': 'He then presented at age 16 years with a headache and subjective visual changes, with brain imaging revealing a hypothalamic hamartoma.', '7': 'He did not have a history of seizures or central precocious puberty.', '8': 'Genotyping revealed a pathogenic variant affecting the GLI3 gene.', '9': 'We encourage all clinicians to consider PHS or an associated syndrome with a clinical finding of polydactyly.', '10': \"Further, as the natural history continues to reveal itself, this patient's presentation provides important new data to the broad phenotypic spectrum of PHS.\"}\n",
            "56: abstract: {'1': 'Introduction: Pallister-Hall syndrome (PHS) is a rare autosomal dominant syndrome characterized by polydactyly, bifid or shortened epiglottis, visceral anomalies, hypothalamic hamartoma often combined with hypopituitarism.', '2': 'PHS is characterized by significant variability in the expression of clinical symptoms.', '3': 'The clinical course ranges from mild with a good prognosis to severe and which can lead to death during the neonatal period.', '4': 'Case report: Two-years-old girl with facial dysmorphia, skeletal malformations of hand and feet and growth hormone deficiency.', '5': 'PHS was diagnosed on the basis of the presented symptoms and genetic tests.', '6': 'Summary: Skeletal malformations, such as polydactyly or oligodactyly, are a markers which can be associated with endocrinological disorders.', '7': \"Quick and correct diagnosis would help in planning treatment during childhood and giving family counseling, including prenatal advice regarding the next pregnancy of the child's mother.\"}\n",
            "57: abstract: {'1': 'Traumatic injury to the peripheral nerves often results in persistent discomfort.', '2': 'Substance P has been implicated as a mediator of pain, and depletion of this neurotransmitter has been shown to reduce pain.', '3': 'Subjects suffering from traumatic dysesthesia of the trigeminal nerve were treated with capsaicin, a substance P depleter with significant long-term effects.', '4': 'This form of therapy may be used individually or in combination with other pharmacologic interventions in the treatment of traumatic trigeminal dysesthesia.'}\n",
            "57: abstract: {'1': 'Objective: To report a novel wireless neuromodulation system for treatment of refractory craniofacial pain.', '2': 'Background: Previous studies utilizing peripheral nerve stimulation (PNS) of the occipital and trigeminal nerves reported positive outcomes for alleviating neuropathic pain localized to the craniofacial and occipital areas.', '3': 'However several technological limitations and cosmetic concerns inhibited a more widespread acceptance and use of neuromodulation.', '4': 'Also, a relatively high incidence of adverse events like electrode erosions, dislocation, wire fracture and/or infection at the surgical site mandates a change in our approach to neuromodulation technology and implant techniques in the craniofacial region.', '5': 'Methods: We report a novel approach for the management of craniofacial pain with a wirelessly powered, minimally invasive PNS system.', '6': 'The system is percutaneously implanted and placed subcutaneously adjacent to affected facial nerves via visual guidance by the clinician.', '7': 'In this feasibility study, pilot evidence was gathered in a cohort of ten subjects suffering from a combination of chronic headaches, facial pain for at least 15 days per month and for at least 4h/day.', '8': 'Results: At four weeks post-implant follow up, all patients reported sustained pain relief of the primary pain area.', '9': 'Electrode location and total number of electrodes used per subject varied across the cohort.', '10': 'The average pain reduction using the visual analog scale was ≥82%.', '11': 'The procedure had no adverse events or side effects.', '12': 'Conclusion: Percutaneous placement of a wireless neurostimulation device directly adjacent to affected craniofacial nerve(s) is a minimally invasive and reversible method of pain control in patients with craniofacial pain refractory to conventional medical managements.', '13': 'Preliminary results are encouraging and further larger scale studies are required for improved applications.'}\n",
            "57: abstract: {'1': 'Trigeminal neuralgia is caused by compression of trigeminal nerve root and it leads to demyelination gradually.', '2': 'It was almost idiopathic and occurred unexpected.', '3': 'The upper cervical spinal cord contains the spinal trigeminal tract and nucleus.', '4': 'Fibers with cell bodies in the trigeminal ganglion enter in the upper pons and descend caudally to C2 level.', '5': 'We experienced a rare patient with facial pain, which was paroxysmal attack with severe pain after a clear event, cervical spinal injury (C2).', '6': 'So, this case reminds us of a possible cause of trigeminal neuralgia after a trauma of the head and neck.'}\n",
            "57: abstract: {'1': 'Orofacial pain syndromes encompass several clinically defined and classified entities.', '2': 'The focus here is on the role of clinical neurophysiologic and psychophysical tests in the diagnosis, differential diagnosis, and pathophysiological mechanisms of definite trigeminal neuropathic pain and other chronic orofacial pain conditions (excluding headache and temporomandibular disorders).', '3': 'The International Classification of Headache Disorders 2018 classifies these facial pain disorders under the heading Painful cranial neuropathies and other facial pains.', '4': 'In addition to unambiguous painful posttraumatic or postherpetic trigeminal neuropathies, burning mouth syndrome, persistent idiopathic facial and dental pain, and trigeminal neuralgia have also been identified with neurophysiologic and quantitative sensory testing to involve the nervous system.', '5': 'Despite normal clinical examination, these all include clusters of patients with evidence for either peripheral or central nervous system pathology compatible with the subclinical end of a continuum of trigeminal neuropathic pain conditions.', '6': 'Useful tests in the diagnostic process include electroneuromyography with specific needle, neurography techniques for the inferior alveolar and infraorbital nerves, brain stem reflex recordings (blink reflex with stimulation of the supraorbital, infraorbital, mental, and lingual nerves; jaw jerk; masseter silent period), evoked potential recordings, and quantitative sensory testing.', '7': 'Habituation of the blink reflex and evoked potential responses to repeated stimuli evaluate top-down inhibition, and navigated transcranial magnetic stimulation allows the mapping of reorganization within the motor cortex in chronic neuropathic pain.', '8': 'With systematic use of neurophysiologic and quantitative sensory testing, many of the current ambiguities in the diagnosis, classification, and understanding of chronic orofacial syndromes can be clarified for clinical practice and future research.'}\n",
            "57: abstract: {'1': 'Introduction: Trigeminal neuralgia is an exemplary neuropathic pain condition characterized by paroxysmal electric-shock-like pain.', '2': 'However, up to 50% of patients also experiences concomitant continuous pain.', '3': 'In this neuroimaging study, we aimed to identify the specific anatomical features of trigeminal nerve root in patients with concomitant continuous pain.', '4': 'Methods: We enrolled 73 patients with a definitive diagnosis of classical and idiopathic trigeminal neuralgia and 40 healthy participants.', '5': 'The diagnosis of trigeminal neuralgia was independently confirmed by two clinicians.', '6': 'Patients were grouped as patients with purely paroxysmal pain (45 patients) and patients also with concomitant continuous pain (28 patients).', '7': 'All participants underwent a structured clinical examination and a 3T MRI with sequences dedicated to the anatomical study of the trigeminal nerve root, including volumetric study.', '8': 'Images analysis was independently performed by two investigators, blinded to any clinical data.', '9': 'Results: In most patients with concomitant continuous pain, this type of pain, described as burning, throbbing or aching, manifested at the disease onset.', '10': 'Demographic and clinical variables did not differ between the two groups of patients; the frequency of neurovascular compression and nerve dislocation were similar.', '11': 'Conversely, trigeminal nerve root atrophy was more severe in patients with concomitant continuous pain than in those with purely paroxysmal pain (p = 0.006).', '12': 'Conclusions: Our clinical and neuroimaging study found that in patients with trigeminal neuralgia, concomitant continuous pain was associated with trigeminal nerve root atrophy, therefore suggesting that this type of pain is likely related to axonal loss and abnormal activity in denervated trigeminal second-order neurons.'}\n",
            "57: abstract: {'1': 'Introduction: The complex nature of facial pain conditions creates a diagnostic challenge which may necessitate specialist referral.', '2': 'Aim: To identify the case mix presenting to a specialist tertiary care facial pain clinic. ', '3': 'Methods: A retrospective review of 112 patient records was undertaken.', '4': 'Trends in provisional diagnoses from referrers and the correlation to diagnoses made following specialist consultation were reviewed.', '5': 'Results: The most common provisional diagnoses recorded in referral letters were painful temporomandibular disorders, trigeminal neuralgia and persistent idiopathic facial pain (PIFP).', '6': 'Over a quarter of referrals did not include a provisional diagnosis.', '7': 'Following assessment, only one case was not given a definitive diagnosis and no patients were diagnosed with PIFP.', '8': 'A causative factor was identified in all the initially queried PIFP cases, and painful post-traumatic trigeminal neuropathic pain was found in multiple patients.', '9': 'Conclusions: Painful post-traumatic trigeminal neuropathic pain should be considered if pain onset coincides with dental treatment or other traumatic events.', '10': 'PIFP is a rare facial pain diagnosis and may be over-diagnosed by dental and medical practitioners.', '11': 'It is important to systematically exclude other causes before reaching this diagnosis.', '12': 'This will facilitate effective treatment, manage patient expectations and potentially reduce unnecessary referrals.'}\n",
            "57: abstract: {'1': 'Background: Neuropathic facial pain occurs due to pathologic dysfunctions of a nerve responsible for mediating sensory fibers to the head.', '2': 'Surgical interventions, in cases of failed medical therapy, include microvascular decompression, radiofrequency (RF) ablation, percutaneous balloon decompression, and stereotactic radiosurgery.', '3': 'In this review, we focused on RF ablation as a treatment for chronic facial pain.', '4': 'Objectives: The objective of this review was to summarize available evidence behind RF ablation for facial pain, including pain outcome measures, secondary outcomes, and complications.', '5': 'Study design: Systematic review.', '6': 'Setting: This systematic review examined studies that applied the use of RF ablation for management of facial pain.', '7': 'Methods: This systematic review was reported following the guidelines outlined in the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA).', '8': 'Two reviewers independently scored the methodological quality of the selected studies.', '9': 'Due to heterogeneity of studies, a best-evidence synthesis of the available prognostic factors was provided.', '10': 'Results: We reviewed 44 studies and assessed their short- and long-term pain relief measurements, as well as secondary outcomes including patient satisfaction, quality of life improvements, decrease in oral medication use, and recurrence rates.', '11': 'Maximal pain relief was achieved in treatment groups using combined continuous radiofrequency (CRF) and pulsed radiofrequency (PRF) therapies, followed by CRF therapy alone and finally PRF therapy alone.', '12': 'All treatment regimens improved secondary outcomes.', '13': 'Common complications of treatment included facial numbness, masseter weakness, cheek hematomas, diminished corneal reflex, and dry eyes.', '14': 'Limitations: A large variability in definitions of trigeminal neuralgia, RF technique, and patient selection bias was observed in our selected cohort of studies.', '15': 'In addition, there was a paucity of strong longitudinal randomized controlled trials and prospective studies.', '16': 'Conclusions: This systematic review found evidence that RF ablation is efficient in treating patients with facial pain, as well as in improving quality of life and reducing oral medication use.', '17': 'Maximal pain control is achieved using combined CRF and PRF therapy.', '18': 'Complications are uncommon and include facial numbness, masseter weakness, cheek hematomas, diminished corneal reflex, and dry eyes.'}\n",
            "57: abstract: {'1': 'Introduction: Facial pain (FP) is a type of neuropathic pain which recognizes both central and peripheral causes.', '2': 'It can be difficult to treat because it can often become resistant to pharmacological treatments.', '3': 'Motor Cortex Stimulation (MCS) has been used in selected cases, but the correct indications of MCS in FP have not been fully established.', '4': 'Here we systematically reviewed the literature regarding MCS in FP analysing the results of this technique and studying the possible role of different factors in the prognosis of these patients.', '5': 'Methods: A literature search was performed through different databases (PubMed, Scopus, and Embase) according to PRISMA guidelines using the following terms in any possible combination: \"facial pain\" or \"trigeminal\" or \"anaesthesia dolorosa\" and \"motor cortex stimulation.\"', '6': 'Results: 111 articles were reviewed, and 12 studies were included in the present analysis for a total of 108 patients.', '7': 'Overall, at latest follow-up (FU), 70.83% of patients responded to MCS.', '8': 'The preoperative VAS significantly decreased at the latest FU (8.83 ± 1.17 and 4.31 ± 2.05, respectively; p < 0.0001).', '9': 'Younger age (p = 0.0478) and a peripheral FP syndrome (p = 0.0006) positively affected the definitive implantation rate on univariate analysis.', '10': 'Younger age emerged as a factor strongly associated to a higher probability to go to a definitive MCS implant on multivariate analysis (p = 0.0415).', '11': 'Conclusion: Our results evidenced the effectiveness of MCS in treating FP.', '12': 'Moreover, the younger age emerged as a positive prognostic factor for definitive implantation.', '13': 'Further studies with longer FU are needed to better evaluate the long-term results of MCS.'}\n",
            "57: abstract: {'1': 'Post-traumatic trigeminal neuralgia (PTTN), also known as anesthesia dolorosa, is at times a debilitating affliction, but remains a condition with minimal research and without definitive treatment, specifically in the periorbital and malar regions.', '2': 'Below we present a case of PTTN in a patient with historic facial trauma who has successfully achieved resolution of pain.', '3': 'We describe diagnostic and therapeutic anesthesia blocks and ablative procedures targeting the zygomaticofacial and zygomaticotemporal nerves.', '4': 'We promote awareness for the procedures and the potential large impact on the oral and maxillofacial surgery community when treating those suffering from facial pain.', '5': 'Finally, we present an algorithm that can aid surgeons in diagnosing and treating patients with PTTN.'}\n",
            "57: abstract: {'1': 'The current understanding of ON is that it causes neuropathic pain in the distribution of the greater occipital nerve, the lesser occipital nerve, the third occipital nerve or a combination of the 3.', '2': 'It is currently a subset of headaches although there is some debate if ON should be its own condition.', '3': 'Occipital neuralgia causes chronic, sharp, stabbing pain in the upper neck, back of the head, and behind the ears that can radiate to the front of the head.', '4': 'Diagnosis is typically clinical and patients present with intermittent, painful episodes associated with the occipital region and the nerves described above.', '5': 'Most cases are unilateral pain, however bilateral pain can be present and the pain can radiate to the frontal region and face.', '6': 'Physical examination is the first step in management of this disease and patients may demonstrate tenderness over the greater occipital and lesser occipital nerves.', '7': 'Anesthetics like 1% to 2% lidocaine or 0.25% to 0.5% bupivacaine can be used to block these nerves and anti-inflammatory drugs like corticosteroids can be used in combination to prevent compressive symptoms.', '8': 'Other treatments like botulinum toxin and radiofrequency ablation have shown promise and require more research.', '9': 'Surgical decompression through resection of the obliquus capitis inferior is the definitive treatment however there are significant risks associated with this procedure.'}\n",
            "58: abstract: {'1': 'The timing of the development of specific adaptive immunity after natural SARS-CoV-2 infection, and its relevance in clinical outcome, has not been characterized in depth.', '2': 'Description of the long-term maintenance of both cellular and humoral responses elicited by real-world anti-SARS-CoV-2 vaccination is still scarce.', '3': 'Here we aimed to understand the development of optimal protective responses after SARS-CoV-2 infection and vaccination.', '4': 'We performed an early, longitudinal study of S1-, M- and N-specific IFN-Î³ and IL-2 T cell immunity and anti-S total and neutralizing antibodies in 88 mild, moderate or severe acute COVID-19 patients.', '5': 'Moreover, SARS-CoV-2-specific adaptive immunity was also analysed in 234 COVID-19 recovered subjects, 28 uninfected BNT162b2-vaccinees and 30 uninfected healthy controls.', '6': 'Upon natural infection, cellular and humoral responses were early and coordinated in mild patients, while weak and inconsistent in severe patients.', '7': 'The S1-specific cellular response measured at hospital arrival was an independent predictive factor against severity.', '8': 'In COVID-19 recovered patients, four to seven months post-infection, cellular immunity was maintained but antibodies and neutralization capacity declined.', '9': 'Finally, a robust Th1-driven immune response was developed in uninfected BNT162b2-vaccinees.', '10': 'Three months post-vaccination, the cellular response was comparable, while the humoral response was consistently stronger, to that measured in COVID-19 recovered patients.', '11': 'Thus, measurement of both humoral and cellular responses provides information on prognosis and protection from infection, which may add value for individual and public health recommendations.'}\n",
            "58: abstract: {'1': 'Introduction: Coronavirus disease 2019 (COVID-19) vaccines are nothing short of a miracle story halting the pandemic across the globe.', '2': 'Nearly half of the global population has received at least one dose.', '3': 'Nevertheless, antibody levels in vaccinated people have shown waning, and breakthrough infections have occurred.', '4': 'Our study aims to measure antibody kinetics following AZD1222 (ChAdOx1) vaccination six months after the second dose and the factors affecting the kinetics.', '5': 'Materials and methods: We conducted a prospective longitudinal study monitoring for six months after the second of two AZD1222 (ChAdOx1) vaccine doses in healthcare professionals and healthcare facility employees at Veer Surendra Sai Institute of Medical Sciences and Research (included doctors, nurses, paramedical staff, security and sanitary workers, and students).', '6': 'Two 0.5-mL doses of the vaccine were administered intramuscularly, containing 5 x 1010 viral particles 28 to 30 days between doses.', '7': 'We collected blood samples one month after the first dose (Round 1), one month after the second dose (Round 2), and six months after the second dose (Round 3).', '8': 'We tested for immunoglobulin G (IgG) levels against the receptor-binding domain of the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by chemiluminescence microparticle immunoassay.', '9': 'We conducted a linear mixed model analysis to study the antibody kinetics and influencing factors.', '10': 'Results: Our study included 122 participants (mean age, 41.5 years; 66 men, 56 women).', '11': 'The geometric mean IgG titers were 138.01 binding antibody units (BAU)/mL in Round 1, 176.48 BAU/mL in Round 2, and 112.95 BAU/mL in Round 3.', '12': 'Seven participants showed seroreversion, and 11 had breakthrough infections.', '13': 'Eighty-six participants showed a substantial decline in antibody titer from Rounds 2 to 3.', '14': 'Persons aged 45 or older had higher mean titer than people aged younger than 45 years.', '15': 'Overweight and obese (BMI â‰¥ 25 kg/m2) had a higher mean titer than average or underweight persons.', '16': 'The only significant predictor of IgG titers at six months was SARS-CoV-2 infection on mixed model analysis.', '17': 'Conclusion: We found a substantial decline in antibody levels leading to seven cases of seroreversion in healthcare professionals who received the ChAdOx1 vaccine.', '18': 'History of prior COVID-19 was the only significant factor in antibody levels at six months.', '19': 'Seroreversion and breakthrough infection warrant further research into the optimal timing and potential benefits of booster doses of the AZD1222 (ChAdOx1) COVID-19 vaccine.'}\n",
            "58: abstract: {'1': 'Estimates of COVID-19 mRNA vaccine effectiveness (VE) have declined in recent months because of waning vaccine induced immunity over time, possible increased immune evasion by SARS-CoV-2 variants, or a combination of these and other factors.', '2': 'CDC recommends that all persons aged â‰¥12 years receive a third dose (booster) of an mRNA vaccine â‰¥5 months after receipt of the second mRNA vaccine dose and that immunocompromised individuals receive a third primary dose.', '3': 'A third dose of BNT162b2 (Pfizer-BioNTech) COVID-19 vaccine increases neutralizing antibody levels, and three recent studies from Israel have shown improved effectiveness of a third dose in preventing COVID-19 associated with infections with the SARS-CoV-2 B.1.617.2 (Delta) variant.', '4': 'Yet, data are limited on the real-world effectiveness of third doses of COVID-19 mRNA vaccine in the United States, especially since the SARS-CoV-2 B.1.1.529 (Omicron) variant became predominant in mid-December 2021.', '5': 'The VISION Network examined VE by analyzing 222,772 encounters from 383 emergency departments (EDs) and urgent care (UC) clinics and 87,904 hospitalizations from 259 hospitals among adults aged â‰¥18 years across 10 states from August 26, 2021 to January 5, 2022.', '6': 'Analyses were stratified by the period before and after the Omicron variant became the predominant strain (>50% of sequenced viruses) at each study site.', '7': 'During the period of Delta predominance across study sites in the United States (August-mid-December 2021), VE against laboratory-confirmed COVID-19-associated ED and UC encounters was 86% 14-179 days after dose 2, 76% â‰¥180 days after dose 2, and 94% â‰¥14 days after dose 3.', '8': 'Estimates of VE for the same intervals after vaccination during Omicron variant predominance were 52%, 38%, and 82%, respectively.', '9': 'During the period of Delta variant predominance, VE against laboratory-confirmed COVID-19-associated hospitalizations was 90% 14-179 days after dose 2, 81% â‰¥180 days after dose 2, and 94% â‰¥14 days after dose 3.', '10': 'During Omicron variant predominance, VE estimates for the same intervals after vaccination were 81%, 57%, and 90%, respectively.', '11': 'The highest estimates of VE against COVID-19-associated ED and UC encounters or hospitalizations during both Delta- and Omicron-predominant periods were among adults who received a third dose of mRNA vaccine.', '12': 'All unvaccinated persons should get vaccinated as soon as possible.', '13': 'All adults who have received mRNA vaccines during their primary COVID-19 vaccination series should receive a third dose when eligible, and eligible persons should stay up to date with COVID-19 vaccinations.'}\n",
            "58: abstract: {'1': 'The BNT162b2 vaccine is highly effective against COVID-19 infection and was delivered with a 3-week time interval in registration studies 1.', '2': 'However, many countries extended this interval to accelerate population coverage with a single vaccine.', '3': 'It is not known how immune responses are influenced by delaying the second dose.', '4': 'We provide the assessment of immune responses in the first 14 weeks after standard or extended-interval BNT162b2 vaccination and show that delaying the second dose strongly boosts the peak antibody response by 3.5-fold in older people.', '5': 'This enhanced antibody response may offer a longer period of clinical protection and delay the need for booster vaccination.', '6': 'In contrast, peak cellular-specific responses were the strongest in those vaccinated on a standard 3-week vaccine interval.', '7': 'As such, the timing of the second dose has a marked influence on the kinetics and magnitude of the adaptive immune response after mRNA vaccination in older people.'}\n",
            "58: abstract: {'1': 'Objectives: To determine the status of immune responses after primary and booster immunization for coronavirus disease 2019 (COVID-19) variants and evaluate the differences in disease-resistance based upon titers of neutralizing antibodies (NAbs) against the variants.', '2': 'Methods: Participants aged 18 - 59 y received two doses of inactivated COVID-19 vaccine, 14 days apart, and a booster dose after 12 m.', '3': 'Blood samples were collected before vaccination (baseline), 1 and 6 m after primary immunization, and at multiple instances within 21 d of booster dose.', '4': 'NAbs against the spike protein of Wuhan-Hu-1 and three variants were measured using pseudovirus neutralization assays.', '5': 'Results: Out of 400 enrolled participants, 387 completed visits scheduled within 6 m of the second dose, and 346 participated received the booster dose in the follow-up research.', '6': 'After 1 m of primary immunization, geometric mean titers (GMTs) of NAbs peaked for Wuhan-Hu-1, while GMTs of other variants were < 30.', '7': 'After 6 m of primary immunization, GMTs of NAbs against all strains were < 30.', '8': 'After 3 d of booster immunization, GMTs were unaltered, seroconversion rates reached approximately 50% after 7 d, and GMTs of NAbs against all strains peaked at 14 d.', '9': 'Conclusion: Two-dose of inactivated COVID-19 vaccine induced the formation of NAbs and memory-associated immune responses, and high titers of NAbs against the variants obtained after booster immunization may further improve the effectiveness of the vaccine.'}\n",
            "58: abstract: {'1': 'Background: Vaccine effectiveness against COVID-19 beyond 6 months remains incompletely understood.', '2': 'We aimed to investigate the effectiveness of COVID-19 vaccination against the risk of infection, hospitalisation, and death during the first 9 months after vaccination for the total population of Sweden.', '3': 'Methods: This retrospective, total population cohort study was done using data from Swedish nationwide registers.', '4': 'The cohort comprised all individuals vaccinated with two doses of ChAdOx1 nCoV-19, mRNA-1273, or BNT162b2, and matched unvaccinated individuals, with data on vaccinations and infections updated until Oct 4, 2021.', '5': 'Two outcomes were evaluated.', '6': 'The first was SARS-CoV-2 infection of any severity from Jan 12 to Oct 4, 2021.', '7': 'The second was severe COVID-19, defined as hospitalisation for COVID-19 or all-cause 30-day mortality after confirmed infection, from March 15 to Sept 28, 2021.', '8': 'Findings: Between Dec 28, 2020, and Oct 4, 2021, 842 974 individuals were fully vaccinated (two doses), and were matched (1:1) to an equal number of unvaccinated individuals (total study cohort n=1 685 948).', '9': 'For the outcome SARS-CoV-2 infection of any severity, the vaccine effectiveness of BNT162b2 waned progressively over time, from 92% (95% CI 92 to 93; p<0Â·001) at 15-30 days, to 47% (39 to 55; p<0Â·001) at 121-180 days, and to 23% (-2 to 41; p=0Â·07) from day 211 onwards.', '10': 'Waning was slightly slower for mRNA-1273, with a vaccine effectiveness of 96% (94 to 97; p<0Â·001) at 15-30 days and 59% (18 to 79; p=0Â·012) from day 181 onwards.', '11': 'Waning was also slightly slower for heterologous ChAdOx1 nCoV-19 plus an mRNA vaccine, for which vaccine effectiveness was 89% (79 to 94; p<0Â·001) at 15-30 days and 66% (41 to 80; p<0Â·001) from day 121 onwards.', '12': 'By contrast, vaccine effectiveness for homologous ChAdOx1 nCoV-19 vaccine was 68% (52 to 79; p<0Â·001) at 15-30 days, with no detectable effectiveness from day 121 onwards (-19% [-98 to 28]; p=0Â·49).', '13': 'For the outcome of severe COVID-19, vaccine effectiveness waned from 89% (82 to 93; p<0Â·001) at 15-30 days to 64% (44 to 77; p<0Â·001) from day 121 onwards.', '14': 'Overall, there was some evidence for lower vaccine effectiveness in men than in women and in older individuals than in younger individuals.', '15': 'Interpretation: We found progressively waning vaccine effectiveness against SARS-CoV-2 infection of any severity across all subgroups, but the rate of waning differed according to vaccine type.', '16': 'With respect to severe COVID-19, vaccine effectiveness seemed to be better maintained, although some waning became evident after 4 months.', '17': 'The results strengthen the evidence-based rationale for administration of a third vaccine dose as a booster.'}\n",
            "58: abstract: {'1': 'Recognizing that anti-SARS-CoV-2 antibody levels wane over time following the 2-dose SARS-CoV-2 mRNA series, the FDA approved a booster dose for people greater than 12 years old.', '2': 'Limited data exist on whether a booster dose of the mRNA vaccine results in greater antibody protection than the primary series.', '3': 'We examined total and neutralizing antibodies to the spike protein of SARS-CoV-2, and neutralizing antibodies against Washington-1 (WA-1) and variants of concern (VOC) including Beta, Delta and Omicron in a longitudinal cohort.', '4': 'Healthcare workers (HWs) were included in the analysis if serum was collected 1) within 14-44 days post-dose2 of an mRNA SARS-CoV-2 vaccine (Timepoint 1, TP1), or 2) at least 8 months post-dose2 (Timepoint 2, TP2), or 3) within 14-44 days following mRNA booster (Timepoint 3, TP3).', '5': 'HWs with prior covid-positive PCR were excluded.', '6': 'We found that there is little to no neutralizing capability following a 2-dose mRNA vaccine series against the omicron variant, and neutralizing capacity to any variant strain tested has been lost by 8-months post two-dose vaccination series.', '7': 'However, the mRNA booster series eliminates the immune escape observed by the omicron variant with the two-dose series.', '8': 'Neutralizing titers were significantly higher for all variants post-boost compared to the titers post two-dose series.', '9': 'The longitudinal nature of our cohort facilitated the analysis of paired samples pre and post boost, showing a greater than 15-fold increase in neutralization against omicron post-boost in these paired samples.', '10': 'An mRNA booster dose provides greater quantity and quality of antibodies compared to a two-dose regimen and is critical to provide any protection against the omicron variant.'}\n",
            "58: abstract: {'1': 'Background: Immunization against SARS-CoV-2, the causative agent of coronavirus disease-19 (COVID-19) occurs via natural infection or vaccination.', '2': 'However, it is currently unknown how long infection- or vaccination-induced immunological memory will last.', '3': 'Methods: We performed a longitudinal evaluation of immunological memory to SARS-CoV-2 up to one year post infection and following mRNA vaccination in naÃ¯ve and COVID-19 recovered individuals.', '4': 'Results: We found that memory cells are still detectable 8 months after vaccination, while antibody levels decline significantly especially in naÃ¯ve subjects.', '5': 'We also found that a booster injection is efficacious in reactivating immunological memory to spike protein in naÃ¯ve subjects, while it results ineffective in previously SARS-CoV-2 infected individuals.', '6': 'Finally, we observed a similar kinetics of decay of humoral and cellular immunity to SARS-CoV-2 up to one year following natural infection in a cohort of unvaccinated individuals.', '7': 'Conclusion: Short-term persistence of humoral immunity, together with the reduced neutralization capacity versus the currently prevailing SARS-CoV-2 variants, may account for reinfections and breakthrough infections.', '8': 'Long-lived memory B and CD4+ T cells may protect from severe disease development.', '9': 'A booster dose restores optimal anti-spike immunity in naÃ¯ve subjects, while the need for vaccinated COVID-19 recovered subjects has yet to be defined.'}\n",
            "58: abstract: {'1': 'There is considerable interest in the waning of effectiveness of coronavirus disease 2019 (COVID-19) vaccines and vaccine effectiveness (VE) of booster doses.', '2': 'Using linked national Brazilian databases, we undertook a test-negative design study involving almost 14 million people (~16 million tests) to estimate VE of Corona Vac over time and VE of BNT162b2 booster vaccination against RT-PCR-confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and severe COVID-19 outcomes (hospitalization or death).', '3': 'Compared with unvaccinated individuals, CoronaVac VE at 14-30 d after the second dose was 55.0% (95% confidence interval (CI): 54.3-55.7) against confirmed infection and 82.1% (95% CI: 81.4-82.8) against severe outcomes.', '4': 'VE decreased to 34.7% (95% CI: 33.1-36.2) against infection and 72.5% (95% CI: 70.9-74.0) against severe outcomes over 180 d after the second dose.', '5': 'A BNT162b2 booster, 6 months after the second dose of CoronaVac, improved VE against infection to 92.7% (95% CI: 91.0-94.0) and VE against severe outcomes to 97.3% (95% CI: 96.1-98.1) 14-30 d after the booster.', '6': 'Compared with younger age groups, individuals 80 years of age or older had lower protection after the second dose but similar protection after the booster.', '7': 'Our findings support a BNT162b2 booster vaccine dose after two doses of CoronaVac, particularly for the elderly.'}\n",
            "58: abstract: {'1': 'Objectives: To estimate the effectiveness of mRNA vaccines against SARS-CoV-2 infection and severe covid-19 at different time after vaccination.', '2': 'Design: Retrospective cohort study.', '3': 'Setting: Italy, 27 December 2020 to 7 November 2021.', '4': 'Participants: 33 250 344 people aged â‰¥16 years who received a first dose of BNT162b2 (Pfizer-BioNTech) or mRNA-1273 (Moderna) vaccine and did not have a previous diagnosis of SARS-CoV-2 infection.', '5': 'Main outcome measures: SARS-CoV-2 infection and severe covid-19 (admission to hospital or death).', '6': 'Data were divided by weekly time intervals after vaccination.', '7': 'Incidence rate ratios at different time intervals were estimated by multilevel negative binomial models with robust variance estimator.', '8': 'Sex, age group, brand of vaccine, priority risk category, and regional weekly incidence in the general population were included as covariates.', '9': 'Geographic region was included as a random effect.', '10': 'Adjusted vaccine effectiveness was calculated as (1-IRR)Ã—100, where IRR=incidence rate ratio, with the time interval 0-14 days after the first dose of vaccine as the reference.', '11': 'Results: During the epidemic phase when the delta variant was the predominant strain of the SARS-CoV-2 virus, vaccine effectiveness against SARS-CoV-2 infection significantly decreased (P<0.001) from 82% (95% confidence interval 80% to 84%) at 3-4 weeks after the second dose of vaccine to 33% (27% to 39%) at 27-30 weeks after the second dose.', '12': 'In the same time intervals, vaccine effectiveness against severe covid-19 also decreased (P<0.001), although to a lesser extent, from 96% (95% to 97%) to 80% (76% to 83%).', '13': 'High risk people (vaccine effectiveness -6%, -28% to 12%), those aged â‰¥80 years (11%, -15% to 31%), and those aged 60-79 years (2%, -11% to 14%) did not seem to be protected against infection at 27-30 weeks after the second dose of vaccine.', '14': 'Conclusions: The results support the vaccination campaigns targeting high risk people, those aged â‰¥60 years, and healthcare workers to receive a booster dose of vaccine six months after the primary vaccination cycle.', '15': 'The results also suggest that timing the booster dose earlier than six months after the primary vaccination cycle and extending the offer of the booster dose to the wider eligible population might be warranted.'}\n",
            "59: abstract: {'1': 'Background: Use of heterologous prime-boost COVID-19 vaccine schedules could facilitate mass COVID-19 immunisation.', '2': 'However, we have previously reported that heterologous schedules incorporating an adenoviral vectored vaccine (ChAdOx1 nCoV-19, AstraZeneca; hereafter referred to as ChAd) and an mRNA vaccine (BNT162b2, Pfizer-BioNTech; hereafter referred to as BNT) at a 4-week interval are more reactogenic than homologous schedules.', '3': 'Here, we report the safety and immunogenicity of heterologous schedules with the ChAd and BNT vaccines.', '4': 'Methods: Com-COV is a participant-blinded, randomised, non-inferiority trial evaluating vaccine safety, reactogenicity, and immunogenicity.', '5': 'Adults aged 50 years and older with no or well controlled comorbidities and no previous SARS-CoV-2 infection by laboratory confirmation were eligible and were recruited at eight sites across the UK.', '6': 'The majority of eligible participants were enrolled into the general cohort (28-day or 84-day prime-boost intervals), who were randomly assigned (1:1:1:1:1:1:1:1) to receive ChAd/ChAd, ChAd/BNT, BNT/BNT, or BNT/ChAd, administered at either 28-day or 84-day prime-boost intervals.', '7': 'A small subset of eligible participants (n=100) were enrolled into an immunology cohort, who had additional blood tests to evaluate immune responses; these participants were randomly assigned (1:1:1:1) to the four schedules (28-day interval only).', '8': 'Participants were masked to the vaccine received but not to the prime-boost interval.', '9': 'The primary endpoint was the geometric mean ratio (GMR) of serum SARS-CoV-2 anti-spike IgG concentration (measured by ELISA) at 28 days after boost, when comparing ChAd/BNT with ChAd/ChAd, and BNT/ChAd with BNT/BNT.', '10': 'The heterologous schedules were considered non-inferior to the approved homologous schedules if the lower limit of the one-sided 97·5% CI of the GMR of these comparisons was greater than 0·63.', '11': 'The primary analysis was done in the per-protocol population, who were seronegative at baseline.', '12': 'Safety analyses were done among participants receiving at least one dose of a study vaccine.', '13': 'The trial is registered with ISRCTN, 69254139.', '14': 'Findings: Between Feb 11 and Feb 26, 2021, 830 participants were enrolled and randomised, including 463 participants with a 28-day prime-boost interval, for whom results are reported here.', '15': 'The mean age of participants was 57·8 years (SD 4·7), with 212 (46%) female participants and 117 (25%) from ethnic minorities.', '16': 'At day 28 post boost, the geometric mean concentration of SARS-CoV-2 anti-spike IgG in ChAd/BNT recipients (12 906 ELU/mL) was non-inferior to that in ChAd/ChAd recipients (1392 ELU/mL), with a GMR of 9·2 (one-sided 97·5% CI 7·5 to ∞).', '17': 'In participants primed with BNT, we did not show non-inferiority of the heterologous schedule (BNT/ChAd, 7133 ELU/mL) against the homologous schedule (BNT/BNT, 14 080 ELU/mL), with a GMR of 0·51 (one-sided 97·5% CI 0·43 to ∞).', '18': 'Four serious adverse events occurred across all groups, none of which were considered to be related to immunisation.', '19': 'Interpretation: Despite the BNT/ChAd regimen not meeting non-inferiority criteria, the SARS-CoV-2 anti-spike IgG concentrations of both heterologous schedules were higher than that of a licensed vaccine schedule (ChAd/ChAd) with proven efficacy against COVID-19 disease and hospitalisation.', '20': 'Along with the higher immunogenicity of ChAd/BNT compared with ChAD/ChAd, these data support flexibility in the use of heterologous prime-boost vaccination using ChAd and BNT COVID-19 vaccines.'}\n",
            "59: abstract: {'1': 'Background: While Coronavirus disease 2019 (Covid-19) vaccines are highly effective, breakthrough infections are occurring.', '2': 'Booster vaccinations have recently received emergency use authorization (EUA) for certain populations but are restricted to homologous mRNA vaccines.', '3': 'We evaluated homologous and heterologous booster vaccination in persons who had received an EUA Covid-19 vaccine regimen.', '4': 'Methods: In this phase 1/2 open-label clinical trial conducted at ten U.S. sites, adults who received one of three EUA Covid-19 vaccines at least 12 weeks prior to enrollment and had no reported history of SARS-CoV-2 infection received a booster injection with one of three vaccines (Moderna mRNA-1273 100-μg, Janssen Ad26.COV2.S 5×10 10 virus particles, or Pfizer-BioNTech BNT162b2 30-μg; nine combinations).', '5': 'The primary outcomes were safety, reactogenicity, and humoral immunogenicity on study days 15 and 29.', '6': 'Results: 458 individuals were enrolled: 154 received mRNA-1273, 150 received Ad26.CoV2.S, and 153 received BNT162b2 booster vaccines.', '7': 'Reactogenicity was similar to that reported for the primary series.', '8': 'Injection site pain, malaise, headache, and myalgia occurred in more than half the participants.', '9': 'Booster vaccines increased the neutralizing activity against a D614G pseudovirus (4.2-76-fold) and binding antibody titers (4.6-56-fold) for all combinations; homologous boost increased neutralizing antibody titers 4.2-20-fold whereas heterologous boost increased titers 6.2-76-fold.', '10': 'Day 15 neutralizing and binding antibody titers varied by 28.7-fold and 20.9-fold, respectively, across the nine prime-boost combinations.', '11': 'Conclusion: Homologous and heterologous booster vaccinations were well-tolerated and immunogenic in adults who completed a primary Covid-19 vaccine regimen at least 12 weeks earlier.'}\n",
            "59: abstract: {'1': 'Background: Given the importance of flexible use of different COVID-19 vaccines within the same schedule to facilitate rapid deployment, we studied mixed priming schedules incorporating an adenoviral-vectored vaccine (ChAdOx1 nCoV-19 [ChAd], AstraZeneca), two mRNA vaccines (BNT162b2 [BNT], Pfizer-BioNTech, and mRNA-1273 [m1273], Moderna) and a nanoparticle vaccine containing SARS-CoV-2 spike glycoprotein and Matrix-M adjuvant (NVX-CoV2373 [NVX], Novavax).', '2': 'Methods: Com-COV2 is a single-blind, randomised, non-inferiority trial in which adults aged 50 years and older, previously immunised with a single dose of ChAd or BNT in the community, were randomly assigned (in random blocks of three and six) within these cohorts in a 1:1:1 ratio to receive a second dose intramuscularly (8-12 weeks after the first dose) with the homologous vaccine, m1273, or NVX.', '3': 'The primary endpoint was the geometric mean ratio (GMR) of serum SARS-CoV-2 anti-spike IgG concentrations measured by ELISA in heterologous versus homologous schedules at 28 days after the second dose, with a non-inferiority criterion of the GMR above 0·63 for the one-sided 98·75% CI.', '4': 'The primary analysis was on the per-protocol population, who were seronegative at baseline.', '5': 'Safety analyses were done for all participants who received a dose of study vaccine.', '6': 'The trial is registered with ISRCTN, number 27841311.', '7': 'Findings: Between April 19 and May 14, 2021, 1072 participants were enrolled at a median of 9·4 weeks after receipt of a single dose of ChAd (n=540, 47% female) or BNT (n=532, 40% female).', '8': 'In ChAd-primed participants, geometric mean concentration (GMC) 28 days after a boost of SARS-CoV-2 anti-spike IgG in recipients of ChAd/m1273 (20 114 ELISA laboratory units [ELU]/mL [95% CI 18 160 to 22 279]) and ChAd/NVX (5597 ELU/mL [4756 to 6586]) was non-inferior to that of ChAd/ChAd recipients (1971 ELU/mL [1718 to 2262]) with a GMR of 10·2 (one-sided 98·75% CI 8·4 to ∞) for ChAd/m1273 and 2·8 (2·2 to ∞) for ChAd/NVX, compared with ChAd/ChAd.', '9': 'In BNT-primed participants, non-inferiority was shown for BNT/m1273 (GMC 22 978 ELU/mL [95% CI 20 597 to 25 636]) but not for BNT/NVX (8874 ELU/mL [7391 to 10 654]), compared with BNT/BNT (16 929 ELU/mL [15 025 to 19 075]) with a GMR of 1·3 (one-sided 98·75% CI 1·1 to ∞) for BNT/m1273 and 0·5 (0·4 to ∞) for BNT/NVX, compared with BNT/BNT; however, NVX still induced an 18-fold rise in GMC 28 days after vaccination.', '10': 'There were 15 serious adverse events, none considered related to immunisation.', '11': 'Interpretation: Heterologous second dosing with m1273, but not NVX, increased transient systemic reactogenicity compared with homologous schedules.', '12': 'Multiple vaccines are appropriate to complete primary immunisation following priming with BNT or ChAd, facilitating rapid vaccine deployment globally and supporting recognition of such schedules for vaccine certification.'}\n",
            "59: abstract: {'1': \"Rationale for review: Heterologous prime-boost doses of COVID-19 vaccines ('mix-and-match' approach) are being studied to test for the effectiveness of Oxford (AZD1222), Pfizer (BNT162b2), Moderna (mRNA-1273) and Novavax (NVX-CoV2373) vaccines for COVID in 'Com-Cov2 trial' in UK, and that of Oxford and Pfizer vaccines in 'CombivacS trial' in Spain.\", '2': 'Later, other heterologous combinatios of CoronaVac (DB15806), Janssen (JNJ-78436735), CanSino (AD5-nCOV), and other were also being trialed to explore their effectiveness.', '3': 'Previously, such a strategy was deployed for HIV, Ebola virus, malaria, tuberculosis, influenza, and hepatitis B to develop the artificial acquired active immunity.', '4': 'The present review explores the science behind such an approach for candidate COVID-19 vaccines developed using eleven different platforms approved by the World Health Organization.', '5': \"Key findings: The candidate vaccines' pharmaceutical parameters (e.g. platforms, number needed to vaccinate and intervals, adjuvanted status, excipients and preservatives added, efficacy and effectiveness, vaccine adverse events, and boosters), and clinical aspects must be analysed for the mix-and-match approach.\", '6': 'Heterologous prime-boost trials showed safety, effectiveness, higher systemic reactogenicity, well tolerability with improved immunogenicity, and flexibility profiles for future vaccinations, especially during acute and global shortages, compared to the homologous counterparts.', '7': 'Conclusions/recommendations. Still, large controlled trials are warranted to address challenging variants of concerns including Omicron and other, and to generalize the effectiveness of the approach in regular as well as emergency use during vaccine scarcity.'}\n",
            "59: abstract: {'1': 'Background: The humoral immune response after primary immunisation with a SARS-CoV-2 vector vaccine (AstraZeneca AZD1222, ChAdOx1 nCoV-19, Vaxzevria) followed by an mRNA vaccine boost (Pfizer/BioNTech, BNT162b2; Moderna, m-1273) was examined and compared with the antibody response after homologous vaccination schemes (AZD1222/AZD1222 or BNT162b2/BNT162b2).', '2': 'Methods: Sera from 59 vaccinees were tested for anti-SARS-CoV-2 immunoglobulin G (IgG) and virus-neutralising antibodies (VNA) with three IgG assays based on (parts of) the SARS-CoV-2 spike (S)-protein as antigen, an IgG immunoblot (additionally contains the SARS-CoV-2 nucleoprotein (NP) as an antigen), a surrogate neutralisation test (sVNT), and a Vero-cell-based virus-neutralisation test (cVNT) with the B.1.1.7 variant of concern (VOC; alpha) as antigen.', '3': 'Investigation was done before and after heterologous (n = 30 and 42) or homologous booster vaccination (AZD1222/AZD1222, n = 8/9; BNT162b2/BNT162b2, n = 8/8).', '4': 'After the second immunisation, a subgroup of 26 age- and gender-matched sera (AZD1222/mRNA, n = 9; AZD1222/AZD1222, n = 9; BNT162b2/BNT162b2, n = 8) was also tested for VNA against VOC B.1.617.2 (delta) in the cVNT.', '5': 'The strength of IgG binding to separate SARS-CoV-2 antigens was measured by avidity.', '6': 'Results: After the first vaccination, the prevalence of IgG directed against the (trimeric) SARS-CoV-2 S-protein and its receptor binding domain (RBD) varied from 55-95% (AZD1222) to 100% (BNT162b2), depending on the vaccine regimen and the SARS-CoV-2 antigen used.', '7': 'The booster vaccination resulted in 100% seroconversion and the occurrence of highly avid IgG, which is directed against the S-protein subunit 1 and the RBD, as well as VNA against VOC B.1.1.7, while anti-NP IgGs were not detected.', '8': 'The results of the three anti-SARS-CoV-2 IgG tests showed an excellent correlation to the VNA titres against this VOC.', '9': 'The agreement of cVNT and sVNT results was good.', '10': 'However, the sVNT seems to overestimate non- and weak B.1.1.7-neutralising titres.', '11': 'The anti-SARS-CoV-2 IgG concentrations and the B.1.1.7-neutralising titres were significantly higher after heterologous vaccination compared to the homologous AZD1222 scheme.', '12': 'If VOC B.1.617.2 was used as antigen, significantly lower VNA titres were measured in the cVNT, and three (33.3%) vector vaccine recipients had a VNA titre < 1:10.', '13': 'Conclusions: Heterologous SARS-CoV-2 vaccination leads to a strong antibody response with anti-SARS-CoV-2 IgG concentrations and VNA titres at a level comparable to that of a homologous BNT162b2 vaccination scheme.', '14': 'Irrespective of the chosen immunisation regime, highly avid IgG antibodies can be detected just 2 weeks after the second vaccine dose indicating the development of a robust humoral immunity.', '15': 'The reduction in the VNA titre against VOC B.1.617.2 observed in the subgroup of 26 individuals is remarkable and confirms the immune escape of the delta variant.'}\n",
            "59: abstract: {'1': 'Background: Although the three vaccines against coronavirus disease 2019 (Covid-19) that have received emergency use authorization in the United States are highly effective, breakthrough infections are occurring.', '2': 'Data are needed on the serial use of homologous boosters (same as the primary vaccine) and heterologous boosters (different from the primary vaccine) in fully vaccinated recipients.', '3': 'Methods: In this phase 1-2, open-label clinical trial conducted at 10 sites in the United States, adults who had completed a Covid-19 vaccine regimen at least 12 weeks earlier and had no reported history of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection received a booster injection with one of three vaccines: mRNA-1273 (Moderna) at a dose of 100 μg, Ad26.COV2.S (Johnson & Johnson-Janssen) at a dose of 5×1010 virus particles, or BNT162b2 (Pfizer-BioNTech) at a dose of 30 μg.', '4': 'The primary end points were safety, reactogenicity, and humoral immunogenicity on trial days 15 and 29.', '5': 'Results: Of the 458 participants who were enrolled in the trial, 154 received mRNA-1273, 150 received Ad26.COV2.S, and 153 received BNT162b2 as booster vaccines; 1 participant did not receive the assigned vaccine.', '6': 'Reactogenicity was similar to that reported for the primary series.', '7': 'More than half the recipients reported having injection-site pain, malaise, headache, or myalgia.', '8': 'For all combinations, antibody neutralizing titers against a SARS-CoV-2 D614 G pseudovirus increased by a factor of 4 to 73, and binding titers increased by a factor of 5 to 55.', '9': 'Homologous boosters increased neutralizing antibody titers by a factor of 4 to 20, whereas heterologous boosters increased titers by a factor of 6 to 73.', '10': 'Spike-specific T-cell responses increased in all but the homologous Ad26.COV2.S-boosted subgroup.', '11': 'CD8+ T-cell levels were more durable in the Ad26.COV2.S-primed recipients, and heterologous boosting with the Ad26.COV2.S vaccine substantially increased spike-specific CD8+ T cells in the mRNA vaccine recipients.', '12': 'Conclusions: Homologous and heterologous booster vaccines had an acceptable safety profile and were immunogenic in adults who had completed a primary Covid-19 vaccine regimen at least 12 weeks earlier.'}\n",
            "59: abstract: {'1': 'Introduction: The vital renal replacement therapy makes it impossible for dialysis patients to distance themselves socially.', '2': 'This results in a high risk of SARS-CoV-2 infection and developing COVID-19 with excess mortality due to disease burden and immunosuppression.', '3': 'We determined the efficacy of a 100 µg booster of mRNA-1273 (Moderna, Inc., Cambridge, Massachusetts, USA) 6 months after two doses of BNT162b2 (BioNTech/Pfizer, Mainz, Germany/New York, NY, USA) in 194 SARS-CoV-2 naïve dialysis patients.', '4': 'Methods: Anti-SARS-CoV-2-spike antibodies were measured with the Elecsys® Anti-SARS-CoV-2 S assay (Roche Diagnostics GmbH, Germany) 4 and 10-12 weeks after two doses of BNT162b2 as well as 4 weeks after the mRNA-1273 booster.', '5': 'The presence of neutralizing antibodies was measured by the SARS-CoV-2 Surrogate Virus Neutralization Test (GenScript Biotech, USA).', '6': \"Two different cut-offs for positivity were used, one according to the manufacturer's specifications and one correlating with positivity in a plaque reduction neutralization test (PRNT).\", '7': 'ROC analyses were performed to match the anti-SARS-CoV-2-spike antibody cut-offs with the cut-offs in the surrogate neutralization assay accordingly.', '8': 'Results: Any level of immunoreactivity determined by anti-SARS-CoV-2-spike antibody assay was found in 87.3% (n = 144/165) and 90.6% (n = 164/181) 4 and 10-12 weeks after two doses of BNT162b2.', '9': 'This was reduced to 68.5% or 60.6% 4 weeks and 51.7% or 35.4% 10-12 weeks, respectively, when using the ROC revealed cut-offs for neutralizing antibodies in the surrogate neutralization test (manufacturer given cut-off ≥ 103 U/ml and cut-off correlating with PRNT ≥ 196 U/ml).', '10': 'Four weeks after the mRNA-1273 booster, the concentration of anti-SARS-CoV-2-spike antibodies increased to 23 119.9 U/ml and consecutively to 97.3% for both cut-offs of neutralizing antibodies.', '11': 'Conclusion: Two doses of BNT162b2 followed by one dose of mRNA-1273 within 6 months in patients receiving maintenance dialysis resulted in significant titers of SARS-CoV-2-S-Ab.', '12': 'While two doses of mRNA vaccine only achieved adequate humoral immunity in a minority, the third vaccination boosts the development of virus-neutralizing quantities of SARS-CoV-2 spike antibodies (against wild type SARS-CoV-2) in almost all patients.'}\n",
            "59: abstract: {'1': 'Background: Heterologous vaccinations against SARS-CoV-2 with ChAdOx1 nCoV-19 and a second dose of an mRNA-based vaccine have been shown to be more immunogenic than homologous ChAdOx1 nCoV-19.', '2': 'In the current study, we examined the kinetics of the antibody response to the second dose of three different vaccination regimens (homologous ChAdOx1 nCoV-19 vs. ChAdOx1 nCoV-19 + BNT162b2 or mRNA-1273) against SARS-CoV-2 in a longitudinal manner; whether there are differences in latency or amplitude of the early response and which markers are most suitable to detect these responses.', '3': 'Methods: We performed assays for anti-S1 IgG and IgA, anti-NCP IgG and a surrogate neutralization assay on serum samples collected from 57 participants on the day of the second vaccination as well as the following seven days.', '4': 'Results: All examined vaccination regimens induced detectable antibody responses within the examined time frame.', '5': 'Both heterologous regimens induced responses earlier and with a higher amplitude than homologous ChAdOx1 nCoV-19.', '6': 'Between the heterologous regimens, amplitudes were somewhat higher for ChAdOx1 nCoV-19 + mRNA-1273.', '7': 'There was no difference in latency between the IgG and IgA responses.', '8': 'Increases in the surrogate neutralization assay were the first changes to be detectable for all regimens and the only significant change seen for homologous ChAdOx1 nCoV-19.', '9': 'Discussion: Both examined heterologous vaccination regimens are superior in immunogenicity, including the latency of the response, to homologous ChAdOx1 nCoV-19.', '10': 'While the IgA response has a shorter latency than the IgG response after the first dose, no such difference was found after the second dose, implying that both responses are driven by separate plasma cell populations.', '11': 'Early and steep increases in surrogate neutralization levels suggest that this might be a more sensitive marker for antibody responses after vaccination against SARS-CoV-2 than absolute levels of anti-S1 IgG.'}\n",
            "59: abstract: {'1': 'In Spain, 1.5 million essential < 60-year-old workers were vaccinated with a first AstraZeneca vaccine dose.', '2': 'After assessing the cases of thrombosis with thrombocytopenia associated to this vaccine, the European Medicines Agency (EMA) supported the administration of 2 doses of the AstraZeneca vaccine with no age restrictions.', '3': 'Nevertheless, Spain decided not to administer the second dose of this vaccine to < 60-year-olds.', '4': 'The government sponsored a clinical trial (CombiVacS) to assess the immunogenicity response to a Pfizer/BioNTech vaccine dose in adults primed with the AstraZeneca vaccine.', '5': 'The positive results backed the Public Health Commission and the Spanish Ministry of Health to offer the Pfizer/BioNTech vaccine as the booster.', '6': \"Nevertheless, regional public health authorities-responsible for administering vaccines-believed that, following the EMA's decision, an AstraZeneca booster dose should be given.\", '7': 'The public confrontation of these 2 positions forced the Spanish Health Ministry to request the signature of an informed consent form to those individuals willing to receive the AstraZeneca vaccine booster and rejecting the Pfizer/BioNTech vaccine dose.', '8': 'Eventually, it was decided that these essential workers could choose the vaccine but signing an informed consent form.', '9': \"All relevant information was posted on the Ministry of Health and regional health authorities' websites and provided to potential vaccine recipients at vaccination sites.\", '10': 'Most individuals (≥ 75%) chose the AstraZeneca vaccine: perhaps because they likely trusted the EMA more than the CombiVacS results.', '11': 'This unprecedented and massive exercise of individual autonomy about the choice of COVID-19 vaccines from 2 different platforms has shown that adequately informed persons can autonomously weigh their options, regardless of government decisions.', '12': 'Exercising individual autonomy may contribute to the success of future COVID-19 booster vaccination campaigns.'}\n",
            "59: abstract: {'1': 'Reports of waning antibody levels and breakthrough infections among vaccinated individuals1 have prompted the recommendation for vaccine boosters to prevent SARS-CoV-2 infections.', '2': 'Despite more than 80% of the population in Singapore having received 2 doses of a COVID-19 vaccine, cases surged in September 2021 with the relaxation of social distancing and quarantine measures.', '3': 'In response, adults 60 years and older who completed their primary vaccination series at least 6 months prior were invited to receive a booster injection and given a choice of either 30-μg BNT162b2 (Pfizer-BioNTech) or 50-μg mRNA-1273 (Moderna).', '4': 'We estimated SARS-CoV-2 infections and disease severity with the receipt of a booster and by type of booster.', '5': 'Methods: This study was carried out under the Infectious Diseases Act for policy decision-making and exempted from ethical review and informed consent by the Singapore Ministry of Health.', '6': 'Rates and severity of SARS-CoV-2 infections between September 15 and October 31, 2021, among those eligible to receive vaccine boosters between September 15 and October 15, 2021, were analyzed based on official data reported to the Singapore Ministry of Health.', '7': 'Cases were identified through testing of symptomatic individuals and nonsymptomatic high-risk workers and close contacts.', '8': 'Outcomes included polymerase chain reaction–confirmed infections and severe disease (requiring oxygen supplementation, intensive care admission, or death due to COVID-19).', '9': 'Individuals were classified under the booster group 12 days after receiving a vaccine booster and under the nonbooster group otherwise to account for time required for antibody levels to rise.', '10': 'Person-days at risk were reported because individuals could contribute observations to both the nonbooster and booster groups.', '11': 'Using a Poisson regression, we estimated the incidence rate ratio (IRR) of confirmed infections and severe disease between booster and nonbooster groups by type of vaccine received for the primary series (BNT162b2 or mRNA-1273).', '12': 'Covariates included sex, race (4 official racial categories reported in Singapore are Chinese, Malay, Indian, and others and registered at birth according to the child’s parents’ race), housing type as a marker of socioeconomic status, age group, date of second vaccine dose to account for possible waning of immunity, and individual dummy variables for calendar date to adjust for the varying force of infection over the study period (eMethods in the Supplement).', '13': 'We obtained IRRs for individuals receiving the same vaccine as a booster (homologous boosted) and those receiving a different vaccine (heterologous boosted).', '14': 'Data analysis was carried out in Stata version 17.0 (StataCorp LLC) and a 2-sided P value less than .05 was considered statistically significant.', '15': 'Results: Among 703\\u202f209 eligible individuals during the study period, 576\\u202f132 received boosters.', '16': 'The study included 22\\u202f643\\u202f521 and 9\\u202f339\\u202f981 person-days among the nonbooster and booster groups, respectively.', '17': 'By person-days, 59% were 60 to 69 years, 29% were 70 to 79 years, and 11% were aged 80 years and older, with 53% being female.', '18': 'Among individuals who received BNT162b2 for their primary series, the incidences (per million person-days) of confirmed and severe infections were 227.9 and 1.4 for the homologous boosted compared with 600.4 and 20.5 for the nonboosted.', '19': 'The IRRs were 0.272 (95% CI, 0.258-0.286) for the confirmed cases among the homologous-boosted individuals and 0.047 (95% CI, 0.026-0.084) for severe cases (Table).', '20': 'For the heterologous-boosted individuals, the incidences of confirmed and severe infections were 147.9 and 2.3 cases per million person-days, respectively, with IRRs of 0.177 (95% CI, 0.138-0.227) and 0.078 (95% CI, 0.011-0.560).', '21': 'For individuals who received mRNA-1273 for their primary series, the incidence of confirmed infections for the homologous boosted was 133.9 cases per million person-years (IRR, 0.198 [95% CI, 0.144-0.271]).', '22': 'For heterologous-boosted individuals, the incidence of confirmed infections was 100.6 per million person-days (IRR, 0.140 [95% CI, 0.052-0.376]).', '23': 'The number of severe infections among individuals receiving mRNA-1273 for their primary series was too small to assess IRRs.', '24': 'Discussion: Heterologous boosting was associated with lower SARS-CoV-2 incidence rates than homologous boosting.', '25': 'Severe infections were lower among those receiving a booster after BNT162b2 as the primary series compared with the nonboosted individuals, regardless of the type of booster.', '26': 'Limitations of the study include potential confounding from unobservable individual characteristics that may influence individuals’ choice of booster, a short follow-up period, small numbers of infections after mRNA-1273 administration, and lack of data from younger age groups.', '27': 'The study results support recommendations for vaccine boosters and suggest that heterologous boosting may provide greater protection against COVID-19.'}\n",
            "60: abstract: {'1': 'We experienced a 72-year-old man who developed laboratory-confirmed human coronavirus HKU1 pneumonia.', '2': 'PCR testing for SARS-CoV-2 from a nasopharyngeal specimen was negative twice, and rapid immunochromatographic antibody test (RIAT) using a commercially available kit for IgM and IgG against SARS-CoV-2 showed him turning positive for IgG against SARS-CoV-2.', '3': 'We then performed RIAT in stored serum samples from other patients who suffered laboratory-confirmed human common cold coronaviruses (n = 6) and viruses other than coronavirus (influenza virus, n = 3; rhinovirus, n = 3; metapneumovirus, n = 1; adenovirus, n = 1) admitted until January 2019.', '4': 'Including the present case, four of 7 (57%) showed false-positive RIAT results due to human common cold coronaviruses infection.', '5': 'Two of the 4 patients showed initial negative to subsequent positive RIAT results, indicating seroconversion.', '6': 'RIAT was positive for IgG and IgM in viruses other than coronavirus in 2 (25.0%) and 1 (12.5%) patient.', '7': 'Because of high incidence of false positive RIAT results, cross antigenicity between human common cold coronaviruses and SARS-CoV-2 can be considered.', '8': 'Results of RIAT should be interpreted in light of epidemics of human common cold coronaviruses infection.', '9': 'Prevalence of past SARS-CoV-2 infection may be overestimated due to high incidence of false-positive RIAT results.'}\n",
            "60: abstract: {'1': 'Background: Combating the COVID-19 pandemic is a major challenge for health systems, citizens and policy makers worldwide.', '2': 'Early detection of affected patients within the large and heterogeneous group of patients with common cold symptoms is an important element of this effort, but often hindered by limited testing resources, false-negative test results and the lack of pathognomonic symptoms in COVID-19.', '3': 'Therefore, we aimed to identify anamnestic items with an increased/decreased odds ratio for a positive SARS-CoV-2 PCR (CovPCR) result in a primary care setting.', '4': 'Methods: We performed a multi-center cross-sectional cohort study on predictive clinical characteristics for a positive CovPCR over a period of 4 weeks in primary care patients in Germany.', '5': 'Results: In total, 374 patients in 14 primary care centers received CovPCR and were included in this analysis.', '6': 'The median age was 44.0 (IQR: 31.0-59.0) and a fraction of 10.7% (n = 40) tested positive for COVID-19.', '7': 'Patients who reported anosmia had a higher odds ratio (OR: 4.54; 95%-CI: 1.51-13.67) for a positive test result while patients with a sore throat had a lower OR (OR: 0.33; 95%-CI: 0.11-0.97).', '8': 'Furthermore, patients who had a first grade contact with an infected persons and showed symptoms themselves also had an increased OR for positive testing (OR: 5.16; 95% CI: 1.72-15.51).', '9': 'This correlation was also present when they themselves were still asymptomatic (OR: 12.55; 95% CI: 3.97-39.67).', '10': 'Conclusions: Several anamnestic criteria may be helpful to assess pre-test probability of COVID-19 in patients with common cold symptoms.'}\n",
            "60: abstract: {'1': 'Antigen-detecting rapid diagnostic tests (Ag-RDTs) can complement molecular diagnostics for COVID-19.', '2': 'The recommended temperature for storage of SARS-CoV-2 Ag-RDTs ranges between 2-30 °C.', '3': 'In the global South, mean temperatures can exceed 30 °C.', '4': 'In the global North, Ag-RDTs are often used in external testing facilities at low ambient temperatures.', '5': 'We assessed analytical sensitivity and specificity of eleven commercially-available SARS-CoV-2 Ag-RDTs using different storage and operational temperatures, including short- or long-term storage and operation at recommended temperatures or at either 2-4 °C or at 37 °C.', '6': 'The limits of detection of SARS-CoV-2 Ag-RDTs under recommended conditions ranged from 1.0×106- 5.5×107 genome copies/mL of infectious SARS-CoV-2 cell culture supernatant.', '7': 'Despite long-term storage at recommended conditions, 10 min pre-incubation of Ag-RDTs and testing at 37 °C resulted in about ten-fold reduced sensitivity for five out of 11 SARS-CoV-2 Ag-RDTs, including both Ag-RDTs currently listed for emergency use by the World Health Organization.', '8': 'After 3 weeks of storage at 37 °C, eight of the 11 SARS-CoV-2 Ag-RDTs exhibited about ten-fold reduced sensitivity.', '9': 'Specificity of SARS-CoV-2 Ag-RDTs using cell culture supernatant from common respiratory viruses was not affected by storage and testing at 37 °C, whereas false-positive results occurred at outside temperatures of 2-4 °C for two out of six tested Ag-RDTs, again including an Ag-RDT recommended by the WHO.', '10': 'In summary, elevated temperatures impair sensitivity, whereas low temperatures impair specificity of SARS-CoV-2 Ag-RDTs.', '11': 'Consequences may include false-negative test results at clinically relevant virus concentrations compatible with transmission and false-positive results entailing unwarranted quarantine assignments.', '12': 'Storage and operation of SARS-CoV-2 Ag-RDTs at recommended conditions is essential for successful usage during the pandemic.'}\n",
            "60: abstract: {'1': 'Prompt and accurate detection of SARS-CoV-2, the virus that causes COVID-19, has been important during public health responses for containing the spread of COVID-19, including in hospital settings (1-3).', '2': 'In vitro diagnostic nucleic acid amplification tests (NAAT), such as real-time reverse transcription-polymerase chain reaction (RT-PCR) can be expensive, have relatively long turnaround times, and require experienced laboratory personnel.*', '3': 'Antigen detection tests can be rapidly and more easily performed and are less expensive.', '4': 'The performance† of antigen detection tests, compared with that of NAATs, is an area of interest for the rapid diagnosis of SARS-CoV-2 infection.', '5': 'The Quidel Sofia 2 SARS Antigen Fluorescent Immunoassay (FIA) (Quidel Corporation) received Food and Drug Administration Emergency Use Authorization for use in symptomatic patients within 5 days of symptom onset (4).', '6': 'The reported test positive percentage agreement§ between this test and an RT-PCR test result is 96.7% (95% confidence interval [CI] = 83.3%-99.4%), and the negative percentage agreement is 100.0% (95% CI = 97.9%-100.0%) in symptomatic patients.¶', '7': 'However, performance in asymptomatic persons in a university setting has shown lower sensitivity (5); assessment of performance in a clinical setting is ongoing.', '8': 'Data collected during June 30-August 31, 2020, were analyzed to compare antigen test performance with that of RT-PCR in a hospital setting.', '9': 'Among 1,732 paired samples from asymptomatic patients, the antigen test sensitivity was 60.5%, and specificity was 99.5% when compared with RT-PCR.', '10': 'Among 307 symptomatic persons, sensitivity and specificity were 72.1% and 98.7%, respectively.', '12': 'Health care providers must remain aware of the lower sensitivity of this test among asymptomatic and symptomatic persons and consider confirmatory NAAT testing in high-prevalence settings because a false-negative result might lead to failures in infection control and prevention practices and cause delays in diagnosis, isolation, and treatment.'}\n",
            "60: abstract: {'1': 'Positive retests of COVID-19 represent a public health concern because of the increased risk of transmission.', '2': 'This study explored whether factors other than the nucleic acid amplification test (NAAT) contribute to positive retest results.', '3': 'Patients with COVID-19 admitted to the Guanggu district of the Hubei Maternal and Child Health Hospital between February 17 and March 28, 2020, were retrospectively included.', '4': 'The patients were grouped into the negative (n = 133) and positive (n = 51) retest groups.', '5': 'The results showed that the proportion of patients presenting with cough was higher (P < 0.001) and the proportion of patients with dyspnea was lower (P = 0.018) in the positive than in the negative retest group.', '6': 'The positive retest group showed shorter durations between symptom onset and hospitalization (P < 0.001) and symptom onset and the first positive NAAT (P = 0.033).', '7': 'The positive retest group had higher basophil counts (P = 0.023) and direct bilirubin (P = 0.032) and chlorine concentrations (P = 0.023) but lower potassium concentrations (P = 0.001) than the negative retest group.', '8': 'Multivariable regression analysis showed that coughing (OR = 7.59, 95% CI 2.28-25.32, P = 0.001) and serum chloride concentrations (OR = 1.38, 95% CI 1.08-1.77, P = 0.010) were independently associated with a positive retest result.', '9': 'Coughing and serum chloride concentrations were independent risk factors for positive NAAT retest results.', '10': 'Patients with a hospital stay of < 2 weeks or a short incubation period should stay in isolation and be monitored to reduce transmission.', '11': 'These results could help identify patients who require closer surveillance.'}\n",
            "60: abstract: {'1': 'Antigen-based rapid diagnostics tests (Ag-RDTs) are useful tools for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) detection.', '2': 'However, misleading demonstrations of the Abbott Panbio coronavirus disease 2019 (COVID-19) Ag-RDT on social media claimed that SARS-CoV-2 antigen could be detected in municipal water and food products.', '3': 'To offer a scientific rebuttal to pandemic misinformation and disinformation, this study explored the impact of using the Panbio SARS-CoV-2 assay with conditions falling outside manufacturer recommendations.', '4': 'Using Panbio, various water and food products, laboratory buffers, and SARS-CoV-2-negative clinical specimens were tested with and without manufacturer buffer.', '5': 'Additional experiments were conducted to assess the role of each Panbio buffer component (tricine, NaCl, pH, and Tween 20) as well as the impact of temperature (4°C, 20°C, and 45°C) and humidity (90%) on assay performance.', '6': 'Direct sample testing (without the kit buffer) resulted in false-positive signals resembling those obtained with SARS-CoV-2 positive controls tested under proper conditions.', '7': 'The likely explanation of these artifacts is nonspecific interactions between the SARS-CoV-2-specific conjugated and capture antibodies, as proteinase K treatment abrogated this phenomenon, and thermal shift assays showed pH-induced conformational changes under conditions promoting artifact formation.', '8': 'Omitting, altering, and reverse engineering the kit buffer all supported the importance of maintaining buffering capacity, ionic strength, and pH for accurate kit function.', '9': 'Interestingly, the Panbio assay could tolerate some extremes of temperature and humidity outside manufacturer claims.', '10': 'Our data support strict adherence to manufacturer instructions to avoid false-positive SARS-CoV-2 Ag-RDT reactions, otherwise resulting in anxiety, overuse of public health resources, and dissemination of misinformation.', '11': 'IMPORTANCE: With the Panbio severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antigen test being deployed in over 120 countries worldwide, understanding conditions required for its ideal performance is critical.', '12': 'Recently on social media, this kit was shown to generate false positives when manufacturer recommendations were not followed.', '13': 'While erroneous results from improper use of a test may not be surprising to some health care professionals, understanding why false positives occur can help reduce the propagation of misinformation and provide a scientific rebuttal for these aberrant findings.', '14': \"This study demonstrated that the kit buffer's pH, ionic strength, and buffering capacity were critical components to ensure proper kit function and avoid generation of false-positive results.\", '15': 'Typically, false positives arise from cross-reacting or interfering substances; however, this study demonstrated a mechanism where false positives were generated under conditions favoring nonspecific interactions between the two antibodies designed for SARS-CoV-2 antigen detection.', '16': 'Following the manufacturer instructions is critical for accurate test results.'}\n",
            "60: abstract: {'1': 'The aim was to determine the accuracy of anterior nasal swab in rapid antigen (Ag) tests in a low SARS-CoV-2 prevalence and massive screened community.', '2': 'Individuals, aged 18 years or older, who self-booked an appointment for real-time reverse transcriptase-polymerase chain reaction (RT-PCR) test in March 2021 at a public test center in Copenhagen, Denmark were included.', '3': 'An oropharyngeal swab was collected for RT-PCR testing, followed by a swab from the anterior parts of the nose examined by Ag test (SD Biosensor).', '4': 'Accuracy of the Ag test was calculated with RT-PCR as reference.', '5': 'We included 7074 paired conclusive tests (n = 3461, female: 50.7%).', '6': 'The median age was 48 years (IQR: 36-57 years).', '7': 'The prevalence was 0.9%, that is, 66 tests were positive on RT-PCR.', '8': 'Thirty-two had a paired positive Ag test.', '9': 'The sensitivity was 48.5% and the specificity was 100%.', '10': 'This study conducted in a low prevalence setting in a massive screening set-up showed that the Ag test had a sensitivity of 48.5% and a specificity of 100%, that is, no false positive tests.', '11': 'The lower sensitivity is a challenge especially if Ag testing is not repeated frequently allowing this scalable test to be a robust supplement to RT-PCR testing in an ambitious public SARS-CoV-2 screening.'}\n",
            "60: abstract: {'1': 'At the start of the COVID-19 pandemic, the Centers for Disease Control and Prevention (CDC) designed, manufactured, and distributed the CDC 2019-Novel Coronavirus (2019-nCoV) Real-Time RT-PCR Diagnostic Panel for SARS-CoV-2 detection.', '2': 'The diagnostic panel targeted three viral nucleocapsid gene loci (N1, N2, and N3 primers and probes) to maximize sensitivity and to provide redundancy for virus detection if mutations occurred.', '3': 'After the first distribution of the diagnostic panel, state public health laboratories reported fluorescent signal in the absence of viral template (false-positive reactivity) for the N3 component and to a lesser extent for N1.', '4': 'This report describes the findings of an internal investigation conducted by the CDC to identify the cause(s) of the N1 and N3 false-positive reactivity.', '5': 'For N1, results demonstrate that contamination with a synthetic template, that occurred while the \"bulk\" manufactured materials were located in a research lab for quality assessment, was the cause of false reactivity in the first lot.', '6': \"Base pairing between the 3' end of the N3 probe and the 3' end of the N3 reverse primer led to amplification of duplex and larger molecules resulting in false reactivity in the N3 assay component.\", '7': 'We conclude that flaws in both assay design and handling of the \"bulk\" material, caused the problems with the first lot of the 2019-nCoV Real-Time RT-PCR Diagnostic Panel.', '8': 'In addition, within this study, we found that the age of the examined diagnostic panel reagents increases the frequency of false positive results for N3.', '9': 'We discuss these findings in the context of improvements to quality control, quality assurance, and assay validation practices that have since been improved at the CDC.'}\n",
            "60: abstract: {'1': 'To investigate endogenous interference factors of the detection results of novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) IgM/IgG.', '2': 'Enzyme-linked immunosorbent assay (ELISA) was used to detect SARS-CoV-2 IgM/IgG in sera of 200 patients without COVID-19 infection, including rheumatoid factor (RF) positive group, antinuclear antibody (ANA) positive group, pregnant women group, and normal senior group, with 50 in each group and 100 normal controls.', '3': 'The level of SARS-CoV-2 IgG in pregnant women was significantly higher than that in the normal control group (p = 0.000), but there was no significant difference between other groups.', '4': 'The levels of SARS-CoV-2 IgM in the pregnant women group, normal senior group, ANA positive group, and RF positive group were significantly higher than that in the normal control group (p < 0.05), with significant higher false-positive rates in these groups (p = 0.036, p = 0.004, p = 0.000, vs. normal control group).', '5': 'Serum RF caused SARS-CoV-2 IgM false-positive in a concentration-dependent manner, especially when its concentration was higher than 110.25 IU/L, and the urea dissociation test can turn the false positive to negative.', '6': 'ANA, normal seniors, pregnant women, and RF can lead to false-positive reactivity of SARS-CoV-2 IgM and/or IgG detected using ELISA.', '7': 'These factors should be considered when SARS-CoV-2 IgM or IgG detection is positive, false positive samples caused by RF positive can be used for urea dissociation test.'}\n",
            "60: abstract: {'1': 'Background: COVID-19 is an ongoing public health pandemic regardless of the countless efforts made by various actors.', '2': 'Quality diagnostic tests are important for early detection and control.', '3': 'Notably, several commercially available one step RT-PCR based assays have been recommended by the WHO.', '4': 'Yet, their analytic and diagnostic performances have not been well documented in resource-limited settings.', '5': 'Hence, this study aimed to evaluate the diagnostic sensitivities and specificities of three commercially available one step reverse transcriptase-polymerase chain reaction (RT-PCR) assays in Ethiopia in clinical setting.', '6': 'Methods: A cross-sectional study was conducted from April to June, 2021 on 279 respiratory swabs originating from community surveillance, contact cases and suspect cases.', '7': 'RNA was extracted using manual extraction method.', '8': 'Master-mix preparation, amplification and result interpretation was done as per the respective manufacturer.', '9': 'Agreements between RT-PCRs were analyzed using kappa values.', '10': 'Bayesian latent class models (BLCM) were fitted to obtain reliable estimates of diagnostic sensitivities, specificities of the three assays and prevalence in the absence of a true gold standard.', '11': 'Results: Among the 279 respiratory samples, 50(18%), 59(21.2%), and 69(24.7%) were tested positive by TIB, Da An, and BGI assays, respectively.', '12': 'Moderate to substantial level of agreement was reported among the three assays with kappa value between 0 .55 and 0.72.', '13': 'Based on the BLCM relatively high specificities (95% CI) of 0.991(0.973-1.000), 0.961(0.930-0.991) and 0.916(0.875-0.952) and considerably lower sensitivities with 0.813(0.658-0.938), 0.836(0.712-0.940) and 0.810(0.687-0.920) for TIB MOLBIOL, Da An and BGI respectively were found.', '14': 'Conclusions: While all the three RT-PCR assays displayed comparable sensitivities, the specificities of TIB MOLBIOL and Da An were considerably higher than BGI.', '15': 'These results help adjust the apparent prevalence determined by the three RT-PCRs and thus support public health decisions in resource limited settings and consider alternatives as per their prioritization matrix.'}\n",
            "61: abstract: {'1': 'The comparative absorption of zinc after oral administration of three different complexed forms was studied in 15 healthy human volunteers in a double-blind four-period crossover trial.', '2': 'The individuals were randomly divided into four groups.', '3': 'Each group rotated for four week periods through a random sequence of oral supplementation including: zinc picolinate, zinc citrate, and zinc gluconate (equivalent to 50 mg elemental zinc per day) and placebo.', '4': 'Zinc was measured in hair, urine, erythrocyte and serum before and after each period.', '5': 'At the end of four weeks hair, urine and erythrocyte zinc levels rose significantly (p less than 0.005, p less than 0.001, and p less than 0.001) during zinc picolinate administration.', '6': 'There was no significant change in any of these parameters from zinc gluconate, zinc citrate or placebo administration.', '7': 'There was a small, insignificant rise in serum zinc during zinc picolinate, zinc citrate and placebo supplementation.', '8': 'The results of this study suggest that zinc absorption in humans can be improved by complexing zinc with picolinic acid.'}\n",
            "61: abstract: {'1': 'The anti-VSC (volatile sulphur compounds) effect of zinc is known to be associated with free zinc ions.', '2': 'Objective: To examine whether zinc salts with low stability constants were more suitable as sources of zinc in zinc lozenges than zinc salts with high stability constants.', '3': 'The former provide free zinc ions upon dissolution in water, whereas the latter provide few such ions.', '4': 'Design and participants: Identical lozenges were produced which contained either zinc acetate, zinc gluconate (low stability constants), zinc citrate or amino-acid chelated zinc (extremely high stability constants).', '5': 'All the lozenges contained 0.1 per cent of zinc.', '6': 'A test panel of 10 volunteers used the different lozenges randomly.', '7': 'VSC were measured by GC.', '8': 'Results and conclusion: The lozenge with the highest stability constant was as effective as those with very low stability constants.', '9': 'The anti-VSC effect was thus not related to this constant.', '10': 'These findings may be explained by the possibility that alternative ligands with stronger affinity for zinc than the original ligands in the lozenges may be present in the oral cavity.', '11': 'An in vitro experiment indicated that the sulphide ion (S2-) may be such a ligand.'}\n",
            "61: abstract: {'1': 'Objective: Zinc supplementation is beneficial in some clinical conditions such as age-related macula degeneration (AMD).', '2': 'It has been suggested that zinc absorption is influenced by the form in which zinc is ingested.', '3': 'Therefore, the pharmacokinetics of zinc gluconate (organic) were compared with those of zinc oxide (inorganic).', '4': 'Methods: 12 healthy male subjects aged between 21 and 31 years (24 years median) orally received daily doses of 20 mg metal zinc as zinc gluconate and 17.4 mg metal zinc as zinc oxide under randomized crossover conditions for 14 days each with at least 14 days as a washout.', '5': 'Zinc plasma concentrations were measured by means of inductively coupled plasma-atomic emission spectroscopy.', '6': 'Results: C(max) was found 18.3% (10.3 - 26.3%) higher following multiple-dose administration of zinc gluconate as compared to zinc oxide (mean; 0.95% confidence interval of the relative differences between both treatment conditions; p < 0.05).', '7': 'AUC(0-24h) was noted 8.1% (1.9 - 14.3%) higher after zinc was given as zinc gluconate when compared to zinc oxide (p < 0.05) whereas t(max) did not differ between both treatment conditions.', '8': 'Conclusions: Zinc absorption in humans could be improved by zinc complexation with gluconate.'}\n",
            "61: abstract: {'1': 'Zinc (Zn)-enriched yeast and gluconate are considered two of the more biologically available supplements.', '2': 'However, there have been few reports comparing the bioavailability of these supplements.', '3': 'The objective of this study was to demonstrate whether Zn was absorbed better by healthy male volunteers when given supplements where the mineral is found organically bound in yeast or as a salt gluconate form.', '4': 'The trial used a randomized, two-way crossover design.', '5': 'Urine, blood, and fecal samples were collected and analyzed over a 48-h period after a single dose of supplement.', '6': 'The net Zn balance and the relative bioavailability were calculated.', '7': 'No differences were observed in urine excretion of the two supplements.', '8': 'Zinc gluconate gave higher Zn concentrations in the blood in the first 6 h but also showed greater losses in the feces.', '9': 'Zinc yeast also increased in blood with time but showed significantly less loss in the feces.', '10': 'Thus, the net Zn balance after 48 h for Zn yeast was 9.46 but for Zn gluconate it was -2.00, indicating that Zn gluconate supplementation contributed to a net loss of Zn.', '11': 'It was concluded that organic Zn yeast supplements are more biologically available than Zn gluconate salts.'}\n",
            "61: abstract: {'1': 'Currently much attention has been given to the neurotoxicity of zinc, yet little is known about the influence of the counterions present.', '2': 'Therefore, we investigated the influence of different Zn(2+)-salts (concentrations range 0.05-0.3 mM) on cell viability, ATP and glutathione concentration and caspase activation in differentiated PC12 cells as a model for neuronal cells.', '3': 'Generally, at concentrations of 0.05 mM most Zn(2+)-salts were not cytotoxic except for zinc-citrate.', '4': 'At concentrations between 0.1 and 0.3 mM Zn(2+) a significant decrease in GSH and ATP levels preceded cell death induced by all salts, except of zinc-histidinate.', '5': 'Zinc-citrate and zinc-sulphate turned out to be the most toxic salts particularly at low concentrations.', '6': 'Analyses of caspase 3/7 activity showed that dependent on the concentration and the type of the salt used cell death may show more or less signs of both, necrosis and apoptosis.', '7': 'Interestingly, the uptake of Zn(2+) from zinc-sulphate and zinc-citrate was significantly higher than that of other salts, implicating a correlation between uptake and toxicity.', '8': 'In conclusion, Zn(2+)-salts could be divided into three categories with high (zinc-citrate, zinc-sulphate), moderate (zinc-orotate, zinc-acetate, zinc-chloride(,) zinc-gluconate) and low cytotoxicity (zinc-histidinate).'}\n",
            "61: abstract: {'1': 'Zinc has earned recognition recently as a micronutrient of outstanding and diverse biological, clinical, and global public health importance.', '2': 'Regulation of absorption by zinc transporters in the enterocyte, together with saturation kinetics of the absorption process into and across the enterocyte, are the principal means by which whole-body zinc homeostasis is maintained.', '3': 'Several physiologic factors, most notably the quantity of zinc ingested, determine the quantity of zinc absorbed and the efficiency of absorption.', '4': 'Other factors are age and the time over which zinc is ingested.', '5': 'Zinc from supplements has not been shown to be absorbed differently from that taken with meals that lack inhibitors of zinc absorption.', '6': 'The principal dietary factor known to impair zinc bioavailability is inositol hexa- (and penta-) phosphate or phytate.', '7': 'Modeling of zinc absorption as a function of dietary zinc and phytate accounts for >80% of the variability in the quantity of zinc absorbed.', '8': 'Fitting the model to new data has resulted in continual improvement in parameter estimates, which currently indicate a maximal absorption in adults of approximately 6 mg Zn/d and that the average estimated dietary requirement doubles with 1000 mg dietary phytate/d.', '9': 'Intestinal excretion of endogenous zinc is regulated in response to recent absorption and to zinc status.', '10': 'The quantitative relation of intestinal excretion of endogenous zinc to zinc absorption is currently considered to be of major importance in the determination of zinc requirements.', '11': 'The effects of phytate on intestinal losses of endogenous zinc merit further investigation but are probably not of the same magnitude as its inhibitory effects on absorption of exogenous zinc.'}\n",
            "61: abstract: {'1': 'Unlike iron, zinc absorption is influenced by dietary zinc intake, not zinc status.', '2': 'As dietary zinc increases, the total amount of absorbed zinc increases while the percent absorbed declines.', '3': 'The gastrointestinal tract maintains whole-body zinc homeostasis by adjusting endogenous zinc losses to the amount absorbed.', '4': 'At intakes below about 9 mg/day, zinc absorption occurs primarily by a saturable (carrier) process involving ZIP4, ZnT1, and other transporters.', '5': 'There is no evidence that past zinc intakes, or status, influences zinc absorption.', '6': 'Instead, current zinc intake is the chief determinant of zinc absorption.', '7': 'Supplemental zinc taken with water in the post-absorptive state initially is absorbed more efficiently than food zinc, but absorption efficiency declines within 24 hours presumably due to down-regulation of the zinc transporters.', '8': 'More research is needed to understand the effect of physiological state on zinc absorption.'}\n",
            "61: abstract: {'1': 'The water-soluble zinc salts gluconate, sulfate, and acetate are commonly used as supplements in tablet or syrup form to prevent zinc deficiency and to treat diarrhea in children in combination with oral rehydration.', '2': 'Zinc citrate is an alternative compound with high zinc content, slightly soluble in water, which has better sensory properties in syrups but no absorption data in humans.', '3': 'We used the double-isotope tracer method with (67) Zn and (70) Zn to measure zinc absorption from zinc citrate given as supplements containing 10 mg of zinc to 15 healthy adults without food and compared absorption with that from zinc gluconate and zinc oxide (insoluble in water) using a randomized, double-masked, 3-way crossover design.', '4': 'Median (IQR) fractional absorption of zinc from zinc citrate was 61.3% (56.6-71.0) and was not different from that from zinc gluconate with 60.9% (50.6-71.7).', '5': 'Absorption from zinc oxide at 49.9% (40.9-57.7) was significantly lower than from both other supplements (P < 0.01).', '6': 'Three participants had little or no absorption from zinc oxide.', '7': 'We conclude that zinc citrate, given as a supplement without food, is as well absorbed by healthy adults as zinc gluconate and may thus be a useful alternative for preventing zinc deficiency and treating diarrhea.', '8': 'The more insoluble zinc oxide is less well absorbed when given as a supplement without food and may be minimally absorbed by some individuals.'}\n",
            "61: abstract: {'1': 'The normal human prostate accumulates the highest levels of zinc (Zn) of any soft tissue in the body.', '2': 'The pool of zinc available to the body is known to significantly decrease with age.', '3': 'It is suggested that dietary Zn supplementation protects against oxidative damage and reduces the risk of cancer.', '4': 'Zinc sulfate and zinc gluconate were the most frequently mentioned in per os administration in studies on Zn supplementation.', '5': 'The major aim of the study was to compare the bioavailability of different Zn compounds (sulfate, gluconate and citrate) in the prostate after their daily administration to male rats at three different doses (3.0; 15.0; and 50.0 mg Zn/kg b.w.) for 30 days.', '6': 'The results show that bioavailability in the prostate differs significantly between individual zinc preparations.', '7': 'A significantly elevated Zn concentration in the dorso-lateral lobe of the prostate, compared to controls, was found in the rats supplemented with two compounds only: zinc gluconate and zinc citrate.', '8': 'However, after administration of zinc gluconate, this effect occurred even at the lowest dose.', '9': 'The lowest zinc bioavailability in the prostate was found in the rats administered zinc sulfate: no significant Zn increase was seen in particular zones of the prostate.', '10': 'To sum up, the use of zinc gluconate is worth considering as a possible means of zinc supplementation in men.'}\n",
            "61: abstract: {'1': 'Background: There is a clinical need for new therapeutic products against Herpes simplex virus (HSV).', '2': 'The pomegranate, fruit of the tree Punica granatum L, has since ancient times been linked to activity against infection.', '3': 'This work probed the activity of pomegranate rind extract (PRE) and co-administered zinc (II) ions.', '4': 'Materials and methods: PRE was used in conjunction with zinc (II) salts to challenge HSV-1 and aciclovir-resistant HSV in terms of virucidal plaque assay reduction and antiviral activities in epithelial Vero host cells.', '5': 'Cytotoxicity was determined by the MTS assay using a commercial kit.', '6': 'Results: Zinc sulphate, zinc citrate, zinc stearate and zinc gluconate demonstrated similar potentiated virucidal activity with PRE against HSV-1 by up to 4-fold.', '7': 'A generally parabolic relationship was observed when HSV-1 was challenged with PRE and varying concentrations of ZnSO4, with a maximum potentiation factor of 5.5.', '8': 'Punicalagin had 8-fold greater virucidal activity than an equivalent mass of PRE.', '9': 'However, antiviral data showed that punicalagin had significantly lower antiviral activity compared to the activity of PRE (EC50 = 0.56 μg mL-1) a value comparable to aciclovir (EC50 = 0.18 μg mL-1); however, PRE also demonstrated potency against aciclovir-resistant HSV (EC50 = 0.02 μg mL-1), whereas aciclovir showed no activity.', '10': 'Antiviral action of PRE was not influenced by ZnSO4.', '11': 'No cytotoxicity was detected with any test solution.', '12': 'Conclusions: The potentiated virucidal activity of PRE by coadministered zinc (II) has potential as a multi-action novel topical therapeutic agent against HSV infections, such as coldsores.'}\n",
            "62: abstract: {'1': 'A double-blind crossover study of inhibition of histamine-induced pruritus by three commonly prescribed antihistamines was conducted on 28 normal subjects.', '2': 'Drugs used included diphenhydramine HCl (Benadryl), cyproheptadine (Periactin), hydroxyzine HCl (Atarax), and a lactose placebo in identical capsules.', '3': 'Intradermal histamine dose-response thresholds of pruritus were obtained before and after pretreatment with the three antihistamines and placebo in each subject.', '4': 'Analysis of data revealed a fivefold increase above baseline of the histamine dose required to produce pruritus following both cyproheptadine and placebo.', '5': 'This compared to a tenfold increase following diphenhydramine and a 750-fold increase following hydroxyzine HCl.', '6': 'The most common side effect was drowsiness, which occurred with all three drugs.'}\n",
            "62: abstract: {'1': 'First-generation antihistamines have potency, pharmacokinetic, and cost advantages compared with nonsedating second-generation antihistamines.', '2': 'Bedtime dosing of hydroxyzine was investigated as a dosing strategy to minimize reaction time degradation and adverse subjective symptoms previously documented for hydroxyzine in divided doses.', '3': 'Hydroxyzine, 50 mg qhs, was compared with terfenadine, 60 mg bid, in this double-blind, placebo-controlled crossover study of 15 healthy, asymptomatic adults.', '4': 'Computer-based eye-hand reaction time tests of simple reaction time (SRT) and choice reaction time (CRT) were not statistically different among the three drugs.', '5': 'Drowsiness, dry mouth, and irritability were significant for hydroxyzine (P = .0001, .001 and .02, respectively) compared with terfenadine or placebo, but less than seen in a previous study of hydroxyzine, 25 mg bid.', '6': 'Symptom scores with terfenadine were comparable to placebo.', '7': 'Histamine skin test wheal and flare were both significantly and comparably suppressed by hydroxyzine and terfenadine (P = .0001).', '8': 'While wheal suppression by hydroxyzine was universal, four of the 15 subjects showed little or no suppression with terfenadine (P = .03).', '9': 'Although bedtime dosing of hydroxyzine did not eliminate subjective symptoms, it maintained skin H1-receptor antagonism the following morning and alleviated the prolongation of reaction times previously reported with hydroxyzine in divided doses.', '10': 'The significant adverse subjective symptoms and psychomotor performance degradations caused by first-generation antihistamines can be mitigated by creative dosing schedules.'}\n",
            "62: abstract: {'1': 'This article reviews clinical pharmacokinetic data on the H1-receptor antagonists, commonly referred to as the antihistamines.', '2': 'Despite their widespread use over an extended period, relatively little pharmacokinetic data are available for many of these drugs.', '3': 'A number of H1-receptor antagonists have been assayed mainly using radioimmunoassay methods.', '4': 'These have also generally measured metabolites to greater or lesser extents.', '5': 'Thus, the interpretation of such data is complex.', '6': 'After oral administration of H1-receptor antagonists as syrup or tablet formulations, peak plasma concentrations are usually observed after 2 to 3 hours.', '7': 'Bioavailability has not been extensively studied, but is about 0.34 for chlorpheniramine, 0.40 to 0.60 for diphenhydramine, and about 0.25 for promethazine.', '8': 'Most of these drugs are metabolised in the liver, this being very extensive in some instances (e.g. cyproheptadine and terfenadine).', '9': 'Total body clearance in adults is generally in the range of 5 to 12 ml/min/kg (for astemizole, brompheniramine, chlorpheniramine, diphenhydramine, hydroxyzine, promethazine and triprolidine), while their elimination half-lives range from about 3 hours to about 18 days [cinnarizine about 3 hours; diphenhydramine about 4 hours; promethazine 10 to 14 hours; chlorpheniramine 14 to 25 hours; hydroxyzine about 20 hours; brompheniramine about 25 hours; astemizole and its active metabolites about 7 to 20 days (after long term administration); flunarizine about 18 to 20 days].', '10': 'They also have relatively large apparent volumes of distribution in excess of 4 L/kg.', '11': 'In children, the elimination half-lives of chlorpheniramine and hydroxyzine are shorter than in adults.', '12': 'In patients with alcohol-related liver disease, the elimination half-life of diphenhydramine was increased from 9 to 15 hours, while in patients with chronic renal disease that of chlorpheniramine was very greatly prolonged.', '13': 'Little, if any, published information is available on the pharmacokinetics of these drugs in neonates, pregnancy or during lactation.', '14': 'The relatively long half-lives of a number of the older H1-receptor antagonists such as brompheniramine, chlorpheniramine and hydroxyzine suggest that they can be administered to adults once daily.'}\n",
            "62: abstract: {'1': 'Study objective: To evaluate the efficacy of a 4-day \"burst\" course of prednisone added to standard treatment with H1 antihistamines for the management of acute urticaria in outpatients.', '2': 'Design: Prospective, randomized, double-blinded, clinical trial.', '3': 'Setting: Emergency department of an urban tertiary care teaching hospital.', '4': \"Participants: Adult patients with urticarial rash of no more than 24 hours' duration, regardless of cause.\", '5': 'Patients were excluded if they manifested wheezing, stridor, or angioedema or if they had taken antihistamines or glucocorticoids within 5 days of arrival at the ED.', '6': 'Patients also were excluded if there was a history of diabetes or active peptic ulcer disease.', '7': 'Interventions: All patients were asked to evaluate the severity of pruritus (\"itch score\") on a 10-cm visual analog scale.', '8': 'Patients were then given diphenhydramine, 50 mg intramuscularly, and discharged home on a regimen of hydroxyzine, 25 mg orally, every 4 to 8 hours for pruritus, plus either prednisone, 20 mg, or placebo orally every 12 hours for 4 days.', '9': \"Patients' conditions were reassessed clinically, with itch score calculated again 2 days later, and again at 5 days by telephone.\", '10': 'Results: Forty-three patients were enrolled; 24 received prednisone and 19 received placebo.', '11': 'The two groups had similar itch scores at enrollment (prednisone, 8.1 +/- 1.7; placebo, 7.4 +/- 2.1, P = .25 [ANOVA]), but at 2- and 5-day follow-up the prednisone group had significantly lower itch scores (1.3 +/- 1.3 and .0 +/- .0 versus 4.4 +/- 2.2 and 1.6 +/- 1.0, respectively; P < .0001 [ANCOVA] at each interval) and greater clinical improvement in rash.', '12': 'Response did not correlate with age, sex, or identification of an allergen.', '13': 'No adverse effects were noted in either group.', '14': 'Conclusion: The addition of a prednisone burst improves the symptomatic and clinical response of acute urticaria to antihistamines.', '15': \"Patients' conditions improved more quickly and more completely when prednisone was administered, without any apparent adverse effects.\"}\n",
            "62: abstract: {'1': 'First-generation histamine H1-receptor antagonists, such as diphenhydramine, triprolidine, hydroxyzine or chlorpheniramine (chlorphenamine), frequently cause somnolence or other CNS adverse effects.', '2': 'Second-generation H1-antagonists, such as terfenadine, astemizole, loratadine and cetirizine, represent a true advance in therapeutics.', '3': \"In manufacturers' recommended doses, they have a more favourable benefit/risk ratio than their predecessors with regard to lack of CNS effects, and do not exacerbate the adverse CNS effects of alcohol or other CNS-active chemicals.\", '4': 'Rarely, some of the newer H1-antagonists may cause cardiac dysrhythmias after overdose or under other specific conditions.', '5': 'The concept of a risk-free H1-antagonist is proving to be an oversimplification.', '6': 'An H1-antagonist absolutely free from adverse effects under all circumstances is not yet available for use.', '7': 'The magnitude of the beneficial effects of each H1-antagonist should be related to the magnitude of the unwanted effects, especially in the CNS and cardiovascular system, and a benefit-risk ratio or therapeutic index should be developed for each medication in this class.'}\n",
            "62: abstract: {'1': 'Although older, potentially sedating, \"first-generation\" antihistamines (H1-receptor antagonists) are commonly used in childhood, their central nervous system (CNS) effects have not been well-documented in young subjects.', '2': 'We hypothesized that diphenhydramine and hydroxyzine would affect CNS function adversely in this population.', '3': 'Our objective was to evaluate the effects of these medications on central and peripheral histamine H1-receptors in children.', '4': 'Fifteen subjects with allergic rhinitis were tested before and 2-2.5 h after administration of diphenhydramine, hydroxyzine, or placebo in a double-blind, single-dose, three-way crossover study.', '5': 'Impairment of cognitive processing was assessed objectively by the latency of the P300 event-related potential (P300).', '6': 'Somnolence was assessed subjectively by a visual analog scale.', '7': 'Peripheral H1-blockade was assessed by suppression of the histamine-induced wheals and flares.', '8': 'At the central (Cz) and frontal (Fz) electrodes, diphenhydramine and hydroxyzine increased the P300 latency significantly (P < 0.05) compared to baseline.', '9': 'Hydroxyzine increased somnolence, as recorded on the visual analog scale, significantly compared to baseline (P < 0.05), with a similar trend for diphenhydramine (P = 0.07).', '10': 'Both antihistamines reduced histamine-induced wheals and flares significantly compared to baseline and compared to placebo.', '11': 'In children, diphenhydramine and hydroxyzine are effective H1-receptor antagonists, but both these medications cause CNS dysfunction, as evidenced by increased P300 latency, a measure of cognitive function, and by increased subjective somnolence.'}\n",
            "62: abstract: {'1': 'Objectives: To determine the national rate and trend of inappropriate medication administration to elderly emergency department (ED) patients.', '2': 'Secondary objectives were to identify risk factors for receiving an inappropriate medication and to determine whether administration is sometimes justified based on diagnosis.', '3': 'Design: Retrospective analysis of ED visits in the 1992-2000 National Hospital Ambulatory Medical Care Survey.', '4': \"Inappropriate medications identified using Beers' 1997 explicit criteria.\", '5': 'Setting: EDs of U.S. noninstitutionalized general and short-stay hospitals.', '6': 'Participants: ED survey patients aged 65 and older.', '7': 'Measurements: Magnitude and rate of administration of 36 medications.', '8': 'Results: Inappropriate medications were administered in an estimated 16.1 million (95% confidence interval (CI)=14.9-17.3 million) or 12.6% (95% CI=11.6-13.5%) of elderly ED visits from 1992 to 2000.', '9': 'The rate of inappropriate administration was unchanged throughout the study period (P=.40).', '10': 'Six drugs accounted for 70.8% of inappropriate administration: promethazine (22.2%), meperidine (18.0%), propoxyphene (17.2%), hydroxyzine (10.3%), diphenhydramine (7.1%), and diazepam (6.0%).', '11': 'In multivariate analysis, number of ED medications was the strongest predictor, with an odds ratio for two to three medications of 6.0 (95% CI=5.3-6.7) and for four to six medications of 8.1 (95% CI=7.2-9.2).', '12': 'Diagnoses indicating potentially appropriate uses of these medications were rarely present.', '13': 'For example, only 42.4% of patients receiving diphenhydramine and 7.4% receiving hydroxyzine were diagnosed with an allergic process.', '14': 'Conclusion: Elderly ED patients are frequently administered inappropriate medications.', '15': 'Potentially appropriate uses of generally inappropriate drugs cannot account for such administrations.', '16': 'Inappropriate administration rates remain unchanged despite the 1997 publication of explicit criteria.'}\n",
            "62: abstract: {'1': 'Several noncardiac drugs have been linked to cardiac safety concerns, highlighting the importance of post-marketing surveillance and continued evaluation of the benefit-risk of long-established drugs.', '2': 'Here, we examine the risk of QT prolongation and/or torsade de pointes (TdP) associated with the use of hydroxyzine, a first generation sedating antihistamine.', '3': 'We have used a combined methodological approach to re-evaluate the cardiac safety profile of hydroxyzine, including: (1) a full review of the sponsor pharmacovigilance safety database to examine real-world data on the risk of QT prolongation and/or TdP associated with hydroxyzine use and (2) nonclinical electrophysiological studies to examine concentration-dependent effects of hydroxyzine on a range of human cardiac ion channels.', '4': 'Based on a review of pharmacovigilance data between 14th December 1955 and 1st August 2016, we identified 59 reports of QT prolongation and/or TdP potentially linked to hydroxyzine use.', '5': 'Aside from intentional overdose, all cases involved underlying medical conditions or concomitant medications that constituted at least 1 additional risk factor for such events.', '6': 'The combination of cardiovascular disorders plus concomitant treatment of drugs known to induce arrhythmia was identified as the greatest combined risk factor.', '7': 'Parallel patch-clamp studies demonstrated hydroxyzine concentration-dependent inhibition of several human cardiac ion channels, including the ether-a-go-go-related gene (hERG) potassium ion channels.', '8': 'Results from this analysis support the listing of hydroxyzine as a drug with \"conditional risk of TdP\" and are in line with recommendations to limit hydroxyzine use in patients with known underlying risk factors for QT prolongation and/or TdP.'}\n",
            "62: abstract: {'1': 'Objective: Antihistamines often have sedative side effects.', '2': 'This was the first study to measure regional cerebral glucose (energy) consumption and hemodynamic responses in young adults during cognitive tests after antihistamine administration.', '3': 'Methods: In this double-blind, placebo-controlled, three-way crossover study, 18 healthy young Japanese men received single doses of levocetirizine 5 mg and diphenhydramine 50 mg at intervals of at least six days.', '4': 'Subjective feeling, task performances, and brain activity were evaluated during three cognitive tests (word fluency, two-back, and Stroop).', '5': 'Regional cerebral glucose consumption changes were measured using positron emission tomography with [18 F]fluorodeoxyglucose.', '6': 'Regional hemodynamic responses were measured using near-infrared spectroscopy.', '7': 'Results: Energy consumption in prefrontal regions was significantly increased after antihistamine administration, especially diphenhydramine, whereas prefrontal hemodynamic responses, evaluated with oxygenated hemoglobin levels, were significantly lower with diphenhydramine treatment.', '8': 'Stroop test accuracy was significantly impaired by diphenhydramine, but not by levocetirizine.', '9': 'There was no significant difference in subjective sleepiness.', '10': 'Conclusions: Physiological \"coupling\" between metabolism and perfusion in the healthy human brain may not be maintained under pharmacological influence due to antihistamines.', '11': 'This uncoupling may be caused by a combination of increased energy demands in the prefrontal regions and suppression of vascular permeability in brain capillaries after antihistamine treatment.', '12': 'Further research is needed to validate this hypothesis.'}\n",
            "62: abstract: {'1': 'Background: This study aimed to measure the association of various H1-antihistamines (H1A) with Torsade de Pointes (TdP), and present a comprehensive overview of H1A-induced TdP cases reported to the Food and Drug Administration Adverse Event Reporting System (FAERS).', '2': \"Methods: All H1A-induced TdP cases (n = 406) were retrieved from the FAERS database using the preferred term 'Torsade de Pointes' of MedDRA version-22 from 1990 to 2019.\", '3': 'Four data-mining algorithms were used for disproportionality analysis: Reporting Odds Ratio (ROR); Proportional Reporting Ratio (PRR), Empirical Bayes Geometric Mean (EBGM), and Information Content (IC).', '4': 'H1A with >3 TdP cases were included.', '5': 'Results: A total of 12 signals (Astemizole, cetirizine, chlorpheniramine, clemastine, desloratadine, diphenhydramine, hydroxyzine, loratadine, meclizine, promethazine, terfenadine, and trimeprazine) were identified including six new signals (cetirizine, chlorpheniramine, clemastine, desloratadine, loratadine, and meclizine).', '6': 'The number of risk factors (p = 0.031) and concomitant QT-prolonging drugs (p = <0.001) were significantly lower among new signals vs old signals.', '7': 'Moreover, new signals were strongly associated with QT-prolongation, cardiac reactions, and electrolyte abnormalities as compared with old signals.', '8': 'Conclusions: Our study found the increased torsadogenic potential of new signals compared with previously known old signals, hence necessitating clinical studies to determine the actual torsadogenic potential of newly identified signals.'}\n",
            "63: abstract: {'1': 'Purpose: Increased epidermal growth factor receptor (EGFR) expression may promote breast cancer resistance to endocrine therapy.', '2': 'We have therefore investigated whether neoadjuvant gefitinib, an EGFR inhibitor, might overcome biologic and clinical resistance to neoadjuvant anastrozole in a phase II placebo-controlled trial.', '3': 'Patients and methods: Postmenopausal women with stage I to IIIB hormone receptor-positive early breast cancer received anastrozole 1 mg daily for 16 weeks and were randomly assigned at a ratio of 2:5:5 to receive, in addition, gefitinib 250 mg/d orally for 16 weeks: placebo 1 tablet/d orally for 2 weeks and then gefitinib for 14 weeks or placebo for 16 weeks.', '4': 'The primary end point was biologic change in proliferation as measured by Ki67 at 2 and 16 weeks; the main secondary end point was overall objective response (OR).', '5': 'Results: Two hundred six women were randomly assigned.', '6': 'Mean changes in Ki67 with anastrozole and gefitinib versus anastrozole alone were -77.4% and -83.6%, respectively, between baseline and 16 weeks (geometric mean ratio = 1.37; 95% CI, 0.79 to 2.39; P = .26), -80.1% and -71.3% between baseline and 2 weeks (geometric mean ratio = 0.70; 95% CI, 0.39 to 1.25; P = .22) and -19.3% and -43% (geometric mean ratio = 1.42; 95% CI, 0.86 to 2.35; P = .16) between 2 and 16 weeks.', '7': 'ORs in the combination and anastrozole alone groups were 48% and 61% (estimated difference = -13.1%; 95% CI, -27.3% to 1.2%), respectively, with a nonsignificant trend against the combination (P = .08) and 48% versus 72% (estimated difference = -24.1%; 95% CI, -45.3% to -2.9%) in the progesterone-receptor-positive subgroup, which was significant (P = .03) and consistent with Ki67 changes.', '8': 'Common treatment-related adverse events included diarrhea, rash, alopecia, dry skin, and nausea.', '9': 'There was no evidence of a pharmacokinetic interaction.', '10': 'Conclusion: Addition of gefitinib to neoadjuvant anastrozole had no additional clinical or biologic effect, failing to support our original hypothesis.'}\n",
            "63: abstract: {'1': 'Previous studies have demonstrated that both anastrozole and letrozole are well tolerated.', '2': 'Letrozole suppresses estrogen to a greater degree than anastrozole in the serum and breast tumor.', '3': \"Concerns have been raised that greater potency may adversely affect patients' quality of life (QOL).\", '4': 'One hundred eighty-one postmenopausal women with invasive estrogen receptor-positive breast cancers were randomized to receive either 12 weeks of letrozole followed by 12 weeks of anastrozole or the reverse sequence.', '5': 'One hundred and six received immediate adjuvant aromatase inhibitors (AIs) following surgery, and 75 received extended adjuvant therapy.', '6': 'The Functional Assessment of Cancer Therapy Endocrine Subscale (FACT-B-ES) QOL questionnaires were completed to assess QOL on each drug.', '7': 'Additional side-effect profiles were collected.', '8': 'Each patient completed a patient preference form.', '9': 'Twenty-one patients withdrew before study end, 10/179 (5.6%) while taking letrozole and 4/173 (2.3%) while taking anastrozole (P = 0.12).', '10': 'Tamoxifen-naïve patients had a higher mean ES (endocrine symptoms subscale) score at entry versus those having extended therapy (66.0 vs. 61.9; P = 0.001).', '11': 'There was no significant change in FACT-B-ES (overall) scores or ES scores while patients were taking anastrozole or letrozole and no significant differences between drugs.', '12': 'Nearly 80% of patients reported one or more side effects with either agent.', '13': 'No differences in frequency, grade, or range of side effects were seen between drugs.', '14': \"Of 160 patients, 49 (30.6%) preferred letrozole, 57 (35.6%) preferred anastrozole, and 54 (33.8%) had no preference (P = 0.26, Pearson's Chi-squared test).\", '15': 'In conclusion, both AIs are equally well tolerated.', '16': 'There were no significant differences in QOL scores between the two drugs.'}\n",
            "63: abstract: {'1': 'Background: Whereas the frequency of alopecia to cytotoxic chemotherapies has been well described, the incidence of alopecia during endocrine therapies (i.e., anti-estrogens, aromatase inhibitors) has not been investigated.', '2': 'Endocrine agents are widely used in the treatment and prevention of many solid tumors, principally those of the breast and prostate.', '3': 'Adherence to these therapies is suboptimal, in part because of toxicities.', '4': 'We performed a systematic analysis of the literature to ascertain the incidence and risk for alopecia in patients receiving endocrine therapies.', '5': 'Results: Data from 19,430 patients in 35 clinical trials were available for analysis.', '6': 'Of these, 13,415 patients had received endocrine treatments and 6,015 patients served as controls.', '7': 'The incidence of all-grade alopecia ranged from 0% to 25%, with an overall incidence of 4.4% (95% confidence interval: 3.3%-5.9%).', '8': 'The highest incidence of all-grade alopecia was observed in patients treated with tamoxifen in a phase II trial (25.4%); similarly, the overall incidence of grade 2 alopecia by meta-analysis was highest with tamoxifen (6.4%).', '9': 'The overall relative risk of alopecia in comparison with placebo was 12.88 (p < .001), with selective estrogen receptor modulators having the highest risk.', '10': 'Conclusion: Alopecia is a common yet underreported adverse event of endocrine-based cancer therapies.', '11': \"Their long-term use heightens the importance of this condition on patients' quality of life.\", '12': 'These findings are critical for pretherapy counseling, the identification of risk factors, and the development of interventions that could enhance adherence and mitigate this psychosocially difficult event.'}\n",
            "63: abstract: {'1': 'The objective of this study was to examine the associations between aromatase inhibitor therapy and hair loss or hair thinning among female breast cancer survivors.', '2': 'Data were analyzed from 851 female breast cancer survivors who responded to a hospital registry-based survey.', '3': 'Data on hair loss, hair thinning, demographic characteristics, and health habits were based on self-report; data on aromatase inhibitor therapy were collected on the survey and verified using medical record review.', '4': 'Logistic regression was used to estimate the odds ratios (ORs) and 95 % confidence intervals (CIs) for the associations between aromatase inhibitor therapy and the hair outcome variables adjusted for potential confounders, including age and chemotherapy treatment.', '5': 'The results showed that 22.4 % of the breast cancer survivors reported hair loss and 31.8 % reported hair thinning.', '6': 'In the confounder-adjusted analyses, breast cancer survivors who were within 2 years of starting aromatase inhibitor treatment at the time of survey completion were approximately two and a half times more likely to report reporting hair loss (OR 2.55; 95 % CI 1.19-5.45) or hair thinning (OR 2.33; 95 % CI 1.10-4.93) within the past 4 weeks compared to those who were never treated with an aromatase inhibitor.', '7': 'Current aromatase inhibitor use for two or more years at the time of the survey and prior use were significantly associated with hair thinning (current users, ≥2 years: OR 1.86; prior users: OR 1.62), but not hair loss.', '8': 'Findings from this study suggest that aromatase inhibitor use is associated with an increased risk of hair loss and hair thinning independent of chemotherapy and age; these side effects are likely due to the substantial decrease in estrogen concentrations resulting from treatment with this drug.', '9': 'Future research should focus on examining these associations in a prospective manner using more detailed and objective measures of hair loss and thinning.'}\n",
            "63: abstract: {'1': 'We report five cases of pattern alopecia in female patients who are undergoing hormonal anticancer therapy for the prevention of recurrence of breast cancer after surgery.', '2': 'Three patients demonstrated male pattern alopecia with receding frontal hairlines, and two patients demonstrated female pattern alopecia without receding hairlines.', '3': 'The detailed clinical history showed that the pattern alopecia of the patients developed after the full recovery of global hair loss of the entire scalp due to previous cytotoxic chemotherapy.', '4': 'All of the adjuvant hormonal anticancer drugs that were used in the patients are antiestrogenic agents, either aromatase inhibitors or selective estrogen receptor modulators.', '5': 'Considering androgen effect on the hair follicles of the fronto-parietal scalp, the androgen-estrogen imbalance caused by the drugs was thought to be the reason for the onset of pattern alopecia in the patients.', '6': 'In general, alopecia that develops during cytotoxic chemotherapy is well known to both physicians and patients; however, the diagnosis of pattern alopecia during hormonal anticancer therapy in breast cancer patients seems to be overlooked.'}\n",
            "63: abstract: {'1': 'Background: Aromatase inhibitors (AIs) are standard hormone therapy (HT) for the adjuvant treatment of postmenopausal endocrine-sensitive early breast cancer.', '2': 'Treatment discontinuation due to toxicity is an important issue that may help clinicians identify effective clinical interventions to allow adequate treatment duration.', '3': 'We reviewed the main reasons for interruption of AIs at our institution from 2006 to 2009.', '4': 'Methods: 236 patients treated with adjuvant AIs were eligible for analysis.', '5': 'Median age was 64 years (35-89), median follow-up 53 months (6-60).', '6': 'Prior adjuvant chemotherapy was taxane based in 47 patients and anthracycline based in 43 patients.', '7': '118 patients had received letrozole, 101 anastrozole, and 17 exemestane.', '8': 'Results: Twenty-four patients (10%) needed discontinuation of the first AI assigned as a result of toxicity.', '9': 'Grade 2/3 arthralgia was the main reason for discontinuation in 13/24 patients.', '10': 'No differences in the incidence of arthralgia were noted in patients who had received taxanes or anthracyclines.', '11': 'Headache, alopecia, itching, diffuse skin reaction, allergic reaction with hypertensive crisis, xerostomia and xerophthalmia, insomnia and somnolence were the other reasons for discontinuation.', '12': 'In multivariate logistic regression analysis, age (65 years) and HT were independent factors associated with the onset of arthralgia (p = 0.006 and p = 0.008, respectively; OR 2.65, 95% CI 1.32-5.31).', '13': 'Alternative HT (AI or tamoxifen) was offered to patients who wanted or needed to permanently interrupt the ongoing drug.', '14': 'Conclusions: In our analysis, 10% of patients discontinued the first AI assigned because of toxicity.', '15': 'Median time course of all adverse events leading to HT discontinuation was 155 days and 135 days for arthralgia.', '16': 'A switch to alternative HT with toxicity monitoring is a recommended option for avoiding premature and permanent interruption of an effective treatment.'}\n",
            "63: abstract: {'1': 'Endocrine therapy-induced hair loss (ETIHL) associated with aromatase inhibitors and tamoxifen treatment is currently mostly reported but remained an unresolved therapeutic issue in patients with breast cancer (BC) since the number of studies regarding the management is limited in literature.', '2': 'Herein we investigated the possible causes of this clinical problem and its relation with endocrine therapies widely used for BC survivors and made some modest practical recommendations in light of the literature review in order to provide an optimal management.', '3': 'On the basis of literature findings, common causes of hair loss apart from endocrine therapies should be investigated with an initial evaluation workup and then should be corrected, if observed.', '4': 'Treatment with topical 5-alpha reductase inhibitors and supplementation of Vitamin C and omega-3 fatty acids are likely appeared to be the most appropriate treatment agents for ETIHL without causing an adverse effect on BC prognosis.', '5': 'However, more prospective, randomised, placebo-controlled studied are required in order to confirm our results and also identify the clinical effects of this problem on patients with BC.'}\n",
            "63: abstract: {'1': 'Importance: Endocrine therapy-induced alopecia (EIA) has been anecdotally reported but not systematically described.', '2': 'Objective: To characterize EIA in patients with breast cancer.', '3': 'Design, setting, and participants: Retrospective cohort study of 112 patients with breast cancer, diagnosed with EIA from January 1, 2009, to December 31, 2016, the patients were examined at the dermatology service in a large tertiary care hospital and comprehensive cancer center.', '4': 'Main outcomes and measures: The clinical features, alopecia-related quality of life (QoL), and response to minoxidil of EIA in patients with breast cancer were assessed.', '5': 'Data from the Hairdex Questionnaire was used to assess the impact of the alopecia on patients QoL. ', '6': 'Higher score indicates lower QoL (0-100 score).', '7': 'Efficacy of minoxidil was measured at 3 or 6 months by a single-blinded investigator through standardized clinical photographs of the scalp.', '8': 'Results: A total of 112 female patients with breast cancer were included (median [range] age, 60 [34-90] years).', '9': 'A total of 104 patients (93%) had standardized clinical photographs; of these, 59 patients (53%) had trichoscopy images available at baseline, and 46 patients (41%) were assessed for response to minoxidil.', '10': 'Alopecia was attributed to aromatase inhibitors in 75 patients (67%) and tamoxifen in 37 (33%).', '11': 'Severity was grade 1 in 96 of 104 patients (92%), and the pattern was similar to androgenetic alopecia.', '12': 'The predominant trichoscopic feature at baseline was the presence of vellus hairs and intermediate- and thick-diameter terminal hair shafts.', '13': 'A negative impact on QoL was reported, with a higher effect in the emotion domain according to the Hairdex score (mean [SD], 41.8 [21.3]; P < .001).', '14': 'After treatment with topical minoxidil, moderate or significant improvement in alopecia was observed in 37 of 46 patients (80%).', '15': 'Conclusions and relevance: Endocrine therapies are associated with a pattern alopecia similar to androgenetic-type, consistent with the mechanism of action of causal agents.', '16': 'A significant negative impact on QoL was reported by patients, despite mostly mild alopecia severity.'}\n",
            "63: abstract: {'1': 'Background and objective: Anastrozole is a well-established active pharmaceutical ingredient (API) used for the treatment of hormone-sensitive breast cancer (BC) in postmenopausal women.', '2': 'However, treatment with the only available oral formulation is often associated with concentration-dependent serious side effects such as hot flashes, fatigue, muscle and joint pain, nausea, diarrhea, headache, and others.', '3': 'In contrast, a sustained-release system for the local application of anastrozole should minimize these serious adverse drug reactions.', '4': 'Methods: Anastrozole-in-adhesive transdermal drug delivery systems (TDDS) were developed offering efficient loading, avoidance of inhomogeneity or crystallization of the drug, the desired controlled release kinetics, storage stability, easy handling, mechanical stability, and sufficient stickiness on the skin.', '5': 'In vitro continuous anastrozole release profiles were studied in Franz diffusion cells.', '6': 'In vivo, consecutive drug plasma kinetics from the final anastrozole transdermal system was tested in beagle dogs.', '7': 'For drug analysis, a specific validated liquid chromatography- mass spectrometry method using fragment ion detection was developed and validated.', '8': 'Results: After efficient drug loading, a linear and sustained 65% drug release from the TDDS over 48 h was obtained.', '9': 'In vivo data showed a favorable anastrozole plasma concentration-time course, avoiding side effect-associated peak concentrations as obtained after oral administration but matching therapeutic plasma levels up to 72 h.', '10': 'Conclusion: These results provide the basis for establishing the transdermal application of anastrozole with improved pharmacokinetics and drug safety as novel therapeutic approach and promising option to treat human BC by decreasing the high burden of unwanted side effects.'}\n",
            "63: abstract: {'1': 'Hair loss and thinning are possible complications in those undergoing endocrine therapies with aromatase inhibitors.', '2': 'Alopecia in pediatric patients undergoing endocrine therapy has not been previously reported.', '3': 'We describe two adolescents, 14 and 16 years of age, who developed androgenetic alopecia following treatment with anastrozole for idiopathic short stature.', '4': 'Accordingly, the possible adverse event of alopecia should be considered in the pediatric population undergoing treatment with aromatase inhibitors.'}\n",
            "64: abstract: {'1': 'Purpose: The vast majority of mutations responsible for epilepsy syndromes such as genetic epilepsy with febrile seizures plus (GEFS+) and Dravet syndrome (DS) occur in the gene encoding the type 1 alpha subunit of neuronal voltage-gated sodium channel (SCN1A).', '2': 'Methods: 63 individuals presenting with either DS or GEFS + syndrome phenotype were screened for SCN1A gene mutation using Sanger sequencing and multiplex ligation-dependent probe amplification (MLPA).', '3': 'Results: Our research study identified 15 novel pathogen mutations in the SCN1A gene of which 12 appeared to be missense mutations with addition of two frameshift-deletions and one in-frame deletion.', '4': 'The distribution of clinical phenotypes in patients carrying SCN1A mutations was as follows: twelve patients had classical DS, three patients had GEFS + syndrome and two relatives of DS patients were suffering from febrile seizures.', '5': 'Conclusions: Our study highlights the phenotypic and genotypic heterogeneities of DS and GEFS + with the important aim of gaining a deeper understanding of SCN1A-related disorders.', '6': 'This study also represents the first genetic analysis of the SCN1A gene in a Hungarian cohort with the DS and GEFS + syndrome phenotype.'}\n",
            "64: abstract: {'1': 'Background: SCN1 A is one of the most important epilepsy-related genes, with pathogenic variants leading to a range of phenotypes with varying disease severity.', '2': 'Different modifying factors have been hypothesized to influence SCN1A-related phenotypes.', '3': 'We investigate the presence of rare and more common variants in epilepsy-related genes as potential modifiers of SCN1A-related disease severity.', '4': 'Methods: 87 patients with SCN1A-related epilepsy were investigated.', '5': 'Whole-exome sequencing was performed by the Beijing Genomics Institute (BGI).', '6': 'Functional variants in 422 genes associated with epilepsy and/or neuronal excitability were investigated.', '7': 'Differences in proportions of variants between the epilepsy genes and four control gene sets were calculated, and compared to the proportions of variants in the same genes in the ExAC database.', '8': 'Results: Statistically significant excesses of variants in epilepsy genes were observed in the complete cohort and in the combined group of mildly and severely affected patients, particularly for variants with minor allele frequencies of <0.05.', '9': 'Patients with extreme phenotypes showed much greater excesses of epilepsy gene variants than patients with intermediate phenotypes.', '10': 'Conclusion: Our results indicate that relatively common variants in epilepsy genes, which would not necessarily be classified as pathogenic, may play a large role in modulating SCN1A phenotypes.', '11': 'They may modify the phenotypes of both severely and mildly affected patients.', '12': 'Our results may be a first step toward meaningful testing of modifier gene variants in regular diagnostics for individual patients, to provide a better estimation of disease severity for newly diagnosed patients.'}\n",
            "64: abstract: {'1': 'Objective: To describe the spectrum of being detected gene mutations in patients with epilepsy in clinical practice of neurologists specializing in epilepsy with an analysis of diagnosed epileptic syndromes, the characteristics of seizures, the timing of a genetic diagnosis, options and treatment effectiveness.', '2': 'Patients and methods: The study included 100 patients (40 boys, 60 girls) with epilepsy and/or epileptic encephalopathy and a gene mutation identified.', '3': 'The average age was 6.9Â±5.1 years.', '4': 'Through remote access, epilepsy specialists filled out a specially designed unified table containing information from outpatient case history.', '5': 'Results and discussion: There are patients with a wide range of gene mutations, the leading of which is a mutation in the SCN1A gene (15%).', '6': 'The main method (85%) of detection remains the sequencing of the last generation in the Â«Hereditary EpilepsyÂ» panel.', '7': 'Years pass from the onset of the disease to the genetic diagnosis (Me - 3 years).', '8': 'In most cases, patients with severe (52% have epileptic encephalopathy, 88% have developmental disorders) and pharmacoresistant (mean amount of anti-epileptic drugs - 3.8Â±2.2, multitherapy - 70%) syndromes have undergone genetic testing.', '9': 'In the treatment of these patients epileptologists are increasingly (52%) use alternative methods: steroids, ketogenic diet and others.', '10': 'The absence of seizures was observed only in 46% of patients.', '11': 'Conclusion: Thus, in the outpatient practice of epileptologists, patients with a wide range of gene mutations are found.', '12': 'As a rule, these are patients with severe, therapy-resistant epileptic syndromes.'}\n",
            "64: abstract: {'1': 'Background: Arthrogryposis multiplex congenita (AMC) is characterised by congenital joint contractures in two or more body areas.', '2': 'AMC exhibits wide phenotypic and genetic heterogeneity.', '3': 'Our goals were to improve the genetic diagnosis rates of AMC, to evaluate the added value of whole exome sequencing (WES) compared with targeted exome sequencing (TES) and to identify new genes in 315 unrelated undiagnosed AMC families.', '4': 'Methods: Several genomic approaches were used including genetic mapping of disease loci in multiplex or consanguineous families, TES then WES.', '5': 'Sanger sequencing was performed to identify or validate variants.', '6': 'Results: We achieved disease gene identification in 52.7% of AMC index patients including nine recently identified genes (CNTNAP1, MAGEL2, ADGRG6, ADCY6, GLDN, LGI4, LMOD3, UNC50 and SCN1A).', '7': 'Moreover, we identified pathogenic variants in ASXL3 and STAC3 expanding the phenotypes associated with these genes.', '8': 'The most frequent cause of AMC was a primary involvement of skeletal muscle (40%) followed by brain (22%).', '9': 'The most frequent mode of inheritance is autosomal recessive (66.3% of patients).', '10': 'In sporadic patients born to non-consanguineous parents (n=60), de novo dominant autosomal or X linked variants were observed in 30 of them (50%).', '11': 'Conclusion: New genes recently identified in AMC represent 21% of causing genes in our cohort.', '12': 'A high proportion of de novo variants were observed indicating that this mechanism plays a prominent part in this developmental disease.', '13': 'Our data showed the added value of WES when compared with TES due to the larger clinical spectrum of some disease genes than initially described and the identification of novel genes.'}\n",
            "64: abstract: {'1': 'Neurodevelopmental diseases are increasingly recognized to be caused by \"de novo\" variants with the expanding use of next-generation sequencing.', '2': 'The apparent de novo variants may actually be low-level hereditary parental mosaic variants, which could increase the recurrence risk of disease by >50% and is thought to be an underappreciated cause of neurodevelopmental diseases.', '3': 'Our study aimed to investigate the frequency of parental mosaicism in \"de novo\" neurodevelopmental diseases.', '4': 'A total of 237 patients (and parents) with neurodevelopmental diseases carrying apparent de novo pathogenic or likely pathogenic variants were recruited consecutively.', '5': 'Deep next-generation sequencing was performed on parental samples to identify parental mosaicism.', '6': 'Fourteen parental disease-causing mosaicism variants (3.0%) in 11 genes were detected with alternate allele frequency (AAF) 0.22%-34%.', '7': 'Three parents showed milder clinical phenotypes than their offspring with relatively high AAF (23.33%, 25%, 34% separately).', '8': 'One recurrent variant was identified prenatally.', '9': 'A review of cohort study on parental mosaicism in neurodevelopmental diseases was performed.', '10': 'Our study highlights that identifying the parental mosaic disease-causing variants especially the low-level mosaicism will contribute to improving the accuracy of genetic counseling and prenatal diagnosis for reproductive risks.'}\n",
            "64: abstract: {'1': 'Background: Glucose-transporter-1 deficiency syndrome (GLUT1-DS), due to SLC2A1 gene mutation, is characterized by early-onset seizures, which are often drug-resistant, developmental delay, and hypotonia.', '2': 'Hemiplegic migraine (HM) is a rare form of migraine, defined by headache associated with transient hemiplegia, and can be caused by mutations in either CACNA1A, ATP1A2, or SCN1A.', '3': 'Paroxysmal movements, other transient neurological disorders, or hemiplegic events can occur in GLUT1-DS patients with a mild phenotype.', '4': 'Case: We report on a girl with GLUT1-DS, due to SLC2A1 mutation, with a mild phenotype.', '5': 'In early childhood, she developed epilepsy and mild cognitive impairment, balance disorders, and clumsiness.', '6': 'At the age of 9, the patient reported a first hemiplegic episode, which regressed spontaneously.', '7': 'Over the next 3 years, two similar episodes occurred, accompanied by headache.', '8': 'Therefore, in the hypothesis of HM, genetic testing was performed and CACNA1A mutation was identified.', '9': 'The treatment with Lamotrigine avoided the recurrence of HM episodes.', '10': 'Discussion: To our knowledge, among the several cases of GLUT1-DS with HM symptoms described in the literature, genetic testing was only performed in two of them, which eventually proved to be negative.', '11': 'In all other cases, no other genes except for SLC2A1 were examined.', '12': 'Consequently, our patient would be the first description of GLUT1-DS with HM due to CACNA1A mutation.', '13': 'We would emphasize the importance of performing specific genetic testing in patients with GLUT1-DS with symptoms evocative of HM, which may allow clinicians to use specific pharmacotherapy.'}\n",
            "64: abstract: {'1': 'Background and purpose: In childhood epilepsy, genetic etiology is increasingly recognized in recent years with the advent of next generation sequencing.', '2': 'This has broadened the scope of precision medicine in intractable epilepsy, particularly epileptic encephalopathy (EE).', '3': 'Developmental disorder (DD) is an integral part of childhood uncontrolled epilepsy.', '4': 'This study was performed to investigate the genetic etiology of childhood epilepsy and DD.', '5': 'Methods: In this study, 40 children with epilepsy and DD with positive genetic mutation were included retrospectively.', '6': 'It was done in a tertiary care referral hospital of Bangladesh from January 2019 to December 2020.', '7': 'Genetic study was done by next generation sequencing.', '8': 'In all cases electroencephalography, neuroimaging was done and reviewed.', '9': 'Results: In total, 40 children were enrolled and the average age was 41.4Â±35.850 months with a male predominance (67.5%).', '10': 'Generalized seizure was the predominant type of seizure.', '11': 'Regarding the association, intellectual disability and attention deficit hyperactivity disorder was common.', '12': 'Seventeen cases had genetically identified early infantile EE and common mutations observed were SCN1A (3), SCN8A (2), SLC1A2 (2), KCNT1 (2), and etc.', '13': 'Five patients of progressive myoclonic epilepsy were diagnosed and the mutations identified were in KCTD7, MFSD8, and CLN6 genes.', '14': 'Three cases had mitochondrial gene mutation (MT-ND5, MT-CYB).', '15': 'Some rare syndromes like Gibbs syndrome, KohlschÃ¼tter-TÃ¶nz syndrome, Cockayne syndrome, Pitt-Hopkins syndrome and cerebral creatine deficiency were diagnosed.', '16': 'Conclusions: This is the first study from Bangladesh on genetics of epilepsy and DD.', '17': 'This will help to improve the understanding of genetics epilepsy of this region as well as contribute in administering precision medicine in these patients.'}\n",
            "64: abstract: {'1': 'Pathogenic variants in the voltage-gated sodium channel gene (SCN1A) are amongst the most common genetic causes of childhood epilepsies.', '2': 'There is considerable heterogeneity in both the types of causative variants and associated phenotypes; a recent expansion of the phenotypic spectrum of SCN1A associated epilepsies now includes an early onset severe developmental and epileptic encephalopathy with regression and a hyperkinetic movement disorder.', '3': 'Herein, we report a female with a developmental and degenerative epileptic-dyskinetic encephalopathy, distinct and more severe than classic Dravet syndrome.', '4': 'Clinical diagnostics indicated a paternally inherited c.5053G>T; p. A1685S variant of uncertain significance in SCN1A.', '5': 'Whole-exome sequencing detected a second de novo mosaic (18%) c.2345G>A; p. T782 I likely pathogenic variant in SCN1A (maternal allele).', '6': 'Biophysical characterization of both mutant channels in a heterologous expression system identified gain-of-function effects in both, with a milder shift in fast inactivation of the p. A1685S channels; and a more severe persistent sodium current in the p. T782I.', '7': 'Using computational models, we show that large persistent sodium currents induce hyper-excitability in individual cortical neurons, thus relating the severe phenotype to the empirically quantified sodium channel dysfunction.', '8': 'These findings further broaden the phenotypic spectrum of SCN1A associated epilepsies and highlight the importance of testing for mosaicism in epileptic encephalopathies.', '9': 'Detailed biophysical evaluation and computational modelling further highlight the role of gain-of-function variants in the pathophysiology of the most severe phenotypes associated with SCN1A.'}\n",
            "64: abstract: {'1': 'Background and objectives: Pathogenic variants in the neuronal sodium-channel Î±1-subunit gene (SCN1A) are the most frequent monogenic cause of epilepsy.', '2': 'Phenotypes comprise a wide clinical spectrum including the severe childhood epilepsy, Dravet syndrome, characterized by drug-resistant seizures, intellectual disability and high mortality, and the milder genetic epilepsy with febrile seizures plus (GEFS+), characterized by normal cognition.', '3': \"Early recognition of a child's risk for developing Dravet syndrome versus GEFS+ is key for implementing disease-modifying therapies when available before cognitive impairment emerges.\", '4': 'Our objective was to develop and validate a prediction model using clinical and genetic biomarkers for early diagnosis of SCN1A-related epilepsies.', '5': 'Methods: Retrospective multicenter cohort study comprising data from SCN1A-positive Dravet syndrome and GEFS+ patients consecutively referred for genetic testing (March 2001-June 2020) including age of seizure onset and a newly-developed SCN1A genetic score.', '6': 'A training cohort was used to develop multiple prediction models that were validated using two independent blinded cohorts.', '7': 'Primary outcome was the discriminative accuracy of the model predicting Dravet syndrome versus other GEFS+ phenotypes.', '8': 'Results: 1018 participants were included.', '9': 'The frequency of Dravet syndrome was 616/743 (83%) in the training cohort, 147/203 (72%) in validation cohort 1 and 60/72 (83%) in validation cohort 2.', '10': 'A high SCN1A genetic score 133.4 (SD, 78.5) versus 52.0 (SD, 57.5; p < 0.001) and young age of onset 6.0 (SD, 3.0) months versus 14.8 (SD, 11.8; p < 0.001) months, were each associated with Dravet syndrome versus GEFS+.', '11': \"A combined 'SCN1A genetic score and seizure onset' model separated Dravet syndrome from GEFS+ more effectively (area under the curve [AUC], 0.89 [95% CI, 0.86-0.92]) and outperformed all other models (AUC, 0.79-0.85; p < 0.001).\", '12': 'Model performance was replicated in both validation cohorts 1 (AUC, 0.94 [95% CI, 0.91-0.97]) and 2 (AUC, 0.92 [95% CI, 0.82-1.00]).', '13': 'Discussion: The prediction model allows objective estimation at disease onset whether a child will develop Dravet syndrome versus GEFS+, assisting clinicians with prognostic counseling and decisions on early institution of precision therapies (http://scn1a-prediction-model.broadinstitute.org/).', '14': \"Classification of evidence: This study provides Class II evidence that a combined 'SCN1A genetic score and seizure onset' model distinguishes Dravet syndrome from other GEFS+ phenotypes.\"}\n",
            "64: abstract: {'1': 'Background: The EPIGENE network was created in 2014 by four multidisciplinary teams composed of geneticists, pediatric neurologists and neurologists specialized in epileptology and neurophysiology.', '2': 'The ambition of the network was to harmonize and improve the diagnostic strategy of Mendelian epileptic disorders using next-generation sequencing, in France.', '3': 'Over the years, five additional centers have joined EPIGENE and the network has been working in close collaboration, since 2018, with the French reference center for rare epilepsies (CRÃ©ER).', '4': 'Results: Since 2014, biannual meetings have led to the design of four successive versions of a monogenic epilepsy gene panel (PAGEM), increasing from 68 to 144 genes.', '5': 'A total of 4035 index cases with epileptic disorders have been analyzed with a diagnostic yield of 31% (n = 1265/4035).', '6': 'The top 10 genes, SCN1A, KCNQ2, STXBP1, SCN2A, SCN8A, PRRT2, PCDH19, KCNT1, SYNGAP1, and GRIN2A, account for one-sixth of patients and half of the diagnoses provided by the PAGEM.', '7': 'Conclusion: These results suggest that a gene-panel approach is an efficient first-tier test for the genetic diagnosis of Mendelian epileptic disorders.', '8': 'In a near future, French patients with \"drug-resistant epilepsies with seizure-onset in the first two-years of life\" can benefit from whole-genome sequencing (WGS), as a second line genetic screening with the implementation of the 2025 French Genomic Medicine Plan.', '9': 'The EPIGENE network has also promoted scientific collaborations on genetic epilepsies within CRÃ©ER.'}\n",
            "65: abstract: {'1': 'There is evidence that alteration in plasma fatty acid composition may play a role in certain neurological disorders.', '2': 'This case control study was conducted to evaluate the association between plasma fatty acid levels and mental retardation in Korean children.', '3': 'Plasma phospholipid fatty acids, plasma lipids, dietary fatty acids and selected nutrients were measured in 31 mentally retarded boys (mean age 9.93 +/-1.5 yrs) and matched controls.', '4': 'Total plasma omega-3 fatty acids (Sigmaw3), docosahexaenoic acid (DHA) and high density lipoprotein (HDL) concentrations were significantly lower and the Sigmaomega-6/Sigmaomega-3 ratio was significantly higher in cases than in controls.', '5': 'The odds in favor of mental retardation increased by 69 % for each unit increase in the Sigmaomega-6/ Sigmaomega-3 ratio (adjusted odds ratio = 1.69, 95% CI = 1.25-2.29).', '6': 'Significant variation in plasma Sigmaomega-3 and the Sigmaomega-6/ Sigmaomega-3 ratio was explained by mental retardation and plasma HDL concentrations (45% and 37 % respectively).', '7': 'There was a significant inverse association between plasma DHA and mental retardation.', '8': 'For each unit increase in plasma DHA, odds of mental retardation decreased by 74 %.', '9': 'There was no significant difference in either total dietary fat or fatty acids intakes between cases and controls.', '10': 'The energy intake of cases was significantly higher than the controls.', '11': 'These results suggest that proportion of plasma Sigmaomega-3 fatty acids, particularly, DHA, and the Sigmaomega-6/ Sigmaomega-3 ratio are associated with mental retardation in children in this study.'}\n",
            "65: abstract: {'1': 'Background: The ω-6 (n-6) to ω-3 (n-3) fatty acid (FA) ratio (n-6:n-3 ratio) was previously shown to be a predictor of executive function performance in children aged 7-9 y.', '2': 'Objective: We aimed to replicate and extend previous findings by exploring the role of the n-6:n-3 ratio in executive function performance.', '3': 'We hypothesized that there would be an interaction between n-3 and the n-6:n-3 ratio, with children with low n-3 performing best with a low ratio, and those with high n-3 performing best with a high ratio.', '4': 'Design: Children were recruited on the basis of their consumption of n-6 and n-3 FAs.', '5': 'The executive function performance of 78 children aged 7-12 y was tested with the use of the Cambridge Neuropsychological Test Automated Battery and a planning task.', '6': 'Participants provided blood for plasma FA quantification, and the caregiver completed demographic and activity questionnaires.', '7': 'We investigated the role of the n-6:n-3 ratio in the entire sample and separately in children aged 7-9 y (n = 41) and 10-12 y (n = 37).', '8': 'Results: Dietary and plasma n-6:n-3 ratio and n-3 predicted performance on working memory and planning tasks in children 7-12 y old.', '9': 'The interaction between dietary n-6:n-3 ratio and n-3 predicted the number of moves required to solve the most difficult planning problems in children aged 7-9 y and those aged 10-12 y, similar to results from the previous study.', '10': 'There was also an interaction between the plasma n-6:n-3 ratio and n-3 predicting time spent thinking through the difficult 5-move planning problems.', '11': 'The n-6:n-3 ratio and n-3 predicted executive function performance differently in children aged 7-9 y and in those aged 10-12 y, indicating different optimal FA balances across development.', '12': 'Conclusions: The n-6:n-3 ratio is an important consideration in the role of FAs in cognitive function, and the optimal balance of n-6 and n-3 FAs depends on the cognitive function and developmental period studied.'}\n",
            "65: abstract: {'1': 'Background: Attention deficit hyperactivity disorder (ADHD) is a debilitating behavioural disorder affecting daily ability to function, learn, and interact with peers.', '2': 'This publication assesses the role of omega-3/6 fatty acids in the treatment and management of ADHD.', '3': 'Methods: A systematic review of 16 randomised controlled trials was undertaken.', '4': 'Trials included a total of 1,514 children and young people with ADHD who were allocated to take an omega-3/6 intervention, or a placebo.', '5': 'Results: Of the studies identified, 13 reported favourable benefits on ADHD symptoms including improvements in hyperactivity, impulsivity, attention, visual learning, word reading, and working/short-term memory.', '6': 'Four studies used supplements containing a 9 : 3 : 1 ratio of eicosapentaenoic acid : docosahexaenoic acid : gamma linolenic acid which appeared effective at improving erythrocyte levels.', '7': 'Supplementation with this ratio of fatty acids also showed promise as an adjunctive therapy to traditional medications, lowering the dose and improving the compliance with medications such as methylphenidate.', '8': 'Conclusion: ADHD is a frequent and debilitating childhood condition.', '9': 'Given disparaging feelings towards psychostimulant medications, omega-3/6 fatty acids offer great promise as a suitable adjunctive therapy for ADHD.'}\n",
            "65: abstract: {'1': 'Maternal obesity is associated with adverse offspring outcomes.', '2': 'Inflammation and deficiency of anti-inflammatory nutrients like omega(n)-3 polyunsaturated fatty acids (PUFA) may contribute to these associations.', '3': 'Fetal supply of n-3 PUFA is dependent on maternal levels and studies have suggested that improved offspring outcomes are associated with higher maternal intake.', '4': 'However, little is known about how maternal obesity affects the response to n-3 supplementation during pregnancy.', '5': 'We sought to determine (1) the associations of obesity with PUFA concentrations and (2) if the systemic response to n-3 supplementation differs by body mass index (BMI).', '6': 'This was a secondary analysis of 556 participants (46% lean, 28% obese) in the Maternal-Fetal Medicine Units Network trial of n-3 (Docosahexaenoic acid (DHA) + Eicosapentaenoic acid (EPA)) supplementation, in which participants had 2g/day of n-3 (n = 278) or placebo (n = 278) from 19 to 22 weeks until delivery.', '7': 'At baseline, obese women had higher plasma n-6 arachidonic acid concentrations (β: 0.96% total fatty acids; 95% Confidence Interval (CI): 0.13, 1.79) and n-6/n-3 ratio (β: 0.26 unit; 95% CI: 0.05, 0.48) compared to lean women.', '8': 'In the adjusted analysis, women in all BMI groups had higher n-3 concentrations following supplementation, although obese women had attenuated changes (β = -2.04%, CI: -3.19, -0.90, interaction p = 0.000) compared to lean women, resulting in a 50% difference in the effect size.', '9': 'Similarly, obese women also had an attenuated reduction (β = 0.94 units, CI: 0.40, 1.47, interaction p = 0.046) in the n-6/n-3 ratio (marker of inflammatory status), which was 65% lower compared to lean women.', '10': 'Obesity is associated with higher inflammation and with an attenuated response to n-3 supplementation in pregnancy.'}\n",
            "65: abstract: {'1': 'Evidence for a relationship between omega-6/omega-3 (n-6/n-3) polyunsaturated fatty acid (PUFA) ratio and obesity in humans is inconsistent, perhaps due to differences in dietary intake or metabolism of PUFAs between different subsets of the population.', '2': 'Since chronic inflammation is central to obesity and inflammatory pathways are regulated by PUFAs, the objective of this study was to examine whether variants in the NFKB1 gene, an upstream regulator of the inflammatory response, modify the association between the n-6/n-3 ratio (from diet and plasma) and anthropometric traits in a multiethnic/multiracial population of young adults.', '3': \"Participants' (n = 898) dietary PUFA intake was assessed using a food frequency questionnaire and plasma PUFA concentrations by gas chromatography.\", '4': 'Nine tag single nucleotide polymorphisms (SNP) in NFKB1 were genotyped.', '5': 'Significant interactions were found between racial/ethnic groups and plasma n-6/n-3 ratio for body mass index (BMI) (p = 0.02) and waist circumference (WC) (p = 0.007).', '6': 'Significant interactions were also observed between racial/ethnic groups and three NFKB1 genotypes (rs11722146, rs1609798, and rs230511) for BMI and WC (all p ≤ 0.04).', '7': 'Significant interactions were found between two NFKB1 genotypes and plasma n-6/n-3 ratio for BMI and WC (rs4648090 p = 0.02 and 0.03; rs4648022 p = 0.06 and 0.04, respectively).', '8': 'Our findings suggest that anthropometric traits may be influenced by a unique combination of n-6/n-3 ratio, racial/ethnic background, and NFKB1 genotypes.'}\n",
            "65: abstract: {'1': 'Background: Atopic dermatitis is a common childhood disease, potentially influenced by prenatal nutritional exposures such as polyunsaturated fatty acids (PUFAs).', '2': 'Objective: In a racially diverse cohort, we hypothesized that childhood atopic dermatitis would be associated with higher prenatal omega-6 (n-6) and lower omega-3 (n-3) PUFAs.', '3': 'Methods: We included mother-child dyads, births 2006 to 2011, enrolled in the University of Tennessee Health Sciences Center Conditions Affecting Neurocognitive Development in Early Childhood cohort.', '4': 'Primary exposures included second trimester plasma n-3 and n-6 PUFA status and the ratio of the two (n-6:n-3).', '5': 'We assessed child current atopic dermatitis symptoms in the previous 12 months at age approximately 4 to 6 years.', '6': 'We investigated the association between PUFA exposures and atopic dermatitis using multivariable logistic regression, adjusting for potential confounders.', '7': 'We assessed for effect modification by maternal prenatal smoking, atopic disease history, and child sex.', '8': 'Results: Among 1131 women, 67% were African American and 42% had an atopic disease history; 17% of children had atopic dermatitis.', '9': 'Higher prenatal n-6 PUFAs were associated with increased relative odds of child atopic dermatitis (adjusted odds ratio: 1.25; confidence interval: 1.01-1.54 per interquartile range difference), and interaction models demonstrated that this association was seen in dyads in which the women had a history of atopic disease.', '10': 'Neither prenatal n-3 PUFAs nor n-6:n-3 were associated with child atopic dermatitis.', '11': 'Conclusion: In this racially diverse cohort, higher second trimester n-6 PUFAs were associated with atopic dermatitis in children of women with atopy.', '12': 'PUFAs may represent a modifiable risk factor for atopic dermatitis, particularly in individuals with a familial predisposition.'}\n",
            "65: abstract: {'1': 'Background/aim: Breast cancer is the most common type of cancer among women around the world and the leading cause of cancer-related death among women.', '2': 'The knowledge about modifiable risk factors, such as diet, can be an acceptable, cheap and non-pharmacological prevention tool.', '3': 'The aim of this study was to investigate the association between dietary fat, dietary fatty acids, fish intake, and breast cancer in women.', '4': 'Patients and methods: A case-control study was designed.', '5': 'A total of 201 consecutive, newly diagnosed, polish female cancer patients (mean age: 58 years) and 201 one-to-one age-matched controls were enrolled.', '6': 'A standardized questionnaire assessing various socio-demographic, clinical, lifestyle, and dietary characteristics was applied via face-to-face interviews.', '7': 'Detailed dietary intake information was assessed using a validated Food Frequency Questionnaire.', '8': 'Odds ratios (OR) and 95% confidence intervals (95%CI) were obtained using multiple unconditional logistic regression models controlling for non-dietary and dietary potential confounders.', '9': 'Results: Consumption of polyunsaturated fats (PUFA) over 10% of total energy intake was associated with a significantly lower risk of breast cancer compared to low intake of PUFA (OR=0.4, 95%CI=0.19-0.85).', '10': 'Low (<0.2) omega-3/ omega-6 ratio (OR=2.04, 95%CI=0.996-4.17), fish consumption less than once every six months (OR=3.37, 95%CI=1.57-7.23) and being overweight (OR=2.07, 95%CI=1.3-3.3) were associated with increased risk of breast cancer.', '11': 'Residents of rural areas had a significantly higher risk compared to women from urban areas (OR=1.8, 95%CI=1.06-3.03).', '12': 'Conclusion: High intake of PUFA can decrease the risk of breast cancer, while the low omega-3/omega-6 ratio increases the risk.', '13': 'In addition, overweight state, eliminating fish from the diet and living in rural areas can also increase the risk of breast cancer.'}\n",
            "65: abstract: {'1': 'Sickle cell disease (SCD) is a hematologic disorder with complex pathophysiology that includes chronic hemolysis, vaso-occlusion and inflammation.', '2': 'Increased leukocyte-erythrocyte-endothelial interactions, due to upregulated expression of adhesion molecules and activated endothelium, are thought to play a primary role in initiation and progression of SCD vaso-occlusive crisis and end-organ damage.', '3': 'Several new pathophysiology-based therapeutic options for SCD are being developed, chiefly targeting the inflammatory pathways.', '4': 'Omega-3 fatty acids are polyunsaturated fatty acids that are known to have effects on diverse physiological processes.', '5': 'Eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) are the principal biologically active omega-3 fatty acids.', '6': 'The therapeutic effects of DHA and EPA on chronic inflammatory disorders and cardiovascular diseases are well recognized.', '7': 'The therapeutic effects of omega-3 fatty acids are attributed to their anti-inflammatory and anti-thrombotic eicosanoids, and the novel class of EPA and DHA derived lipid mediators: resolvins, protectins and maresins.', '8': 'Blood cell membranes of patients with SCD have abnormal fatty acids composition characterized by high ratio of pro-inflammatory arachidonic acid (AA) to anti-inflammatory DHA and EPA (high omega-6/omega-3 ratio).', '9': 'In addition, experimental and clinical studies provide evidence that treatment with DHA does confer improvement in rheological properties of sickle RBC, inflammation and hemolysis.', '10': 'The clinical studies have shown improvements in VOC rate, markers of inflammation, adhesion, and hemolysis.', '11': 'In toto, the results of studies on the therapeutic effects of omega-3 fatty acids in SCD provide good body of evidence that omega-3 fatty acids could be a safe and effective treatment for SCD.'}\n",
            "65: abstract: {'1': 'Polyunsaturated fatty acids (PUFAs) are involved both in immune system regulation and inflammation.', '2': 'In particular, within the PUFAs category, omega-3 (ω-3) may reduce inflammation, whereas omega-6 (ω-6) PUFAs are generally considered to have a proinflammatory effect.', '3': 'Recent evidence highlights an imbalance in the ω-3:ω-6 ratio with an increased intake of ω-6, as a consequence of the shift towards a westernized diet.', '4': 'In critical age groups such as infants, toddlers and young children, as well as pregnant and lactating women or fish allergic patients, ω-3 intake may be inadequate.', '5': 'This review aims to discuss the potential beneficial effects of PUFAs on pediatric food allergy prevention and treatment, both at prenatal and postnatal ages.', '6': 'Data from preclinical studies with PUFAs supplementation show encouraging effects in suppressing allergic response.', '7': 'Clinical studies results are still conflicting about the best timing and dosages of supplementation and which individuals are most likely to benefit; therefore, it is still not possible to draw firm conclusions.', '8': 'With regard to food-allergic children, it is still debated whether PUFAs could slow disease progression or not, since consistent data are lacking.', '9': 'In conclusion, more data on the effects of ω-3 PUFAs supplementation alone or in combination with other nutrients are warranted, both in the general and food allergic population.'}\n",
            "65: abstract: {'1': 'Elevated inflammatory cytokines and chronic pain are associated with shorter leukocyte telomere length (LTL), a measure of cellular aging.', '2': 'Micronutrients, such as 25-hydroxyvitamin D (vitamin D) and omega 3, have anti-inflammatory properties.', '3': 'Little is known regarding the relationships between vitamin D, omega 6:3 ratio, LTL, inflammation, and chronic pain.', '4': 'We investigate associations between vitamin D, omega 6:3 ratio, LTL, and C-reactive protein (CRP) in people living with/without chronic pain overall and stratified by chronic pain status.', '5': 'A cross-sectional analysis of 402 individuals (63% women, 79.5% with chronic pain) was completed.', '6': 'Demographic and health information was collected.', '7': 'Chronic pain was assessed as pain experienced for at least three months.', '8': 'LTL was measured in genomic DNA isolated from blood leukocytes, and micronutrients and CRP were measured in serum samples.', '9': 'Data were analyzed with general linear regression.', '10': 'Although an association between the continuous micronutrients and LTL was not observed, a positive association between omega 6:3 ratio and CRP was detected.', '11': 'In individuals with chronic pain, based on clinical categories, significant associations between vitamin D, omega 6:3 ratio, and CRP were observed.', '12': 'Findings highlight the complex relationships between anti-inflammatory micronutrients, inflammation, cellular aging, and chronic pain.'}\n",
            "66: abstract: {'1': 'Nephrotic syndrome (NS) is one of the most common glomerular diseases that affect children.', '2': 'Renal histology reveals the presence of minimal change nephrotic syndrome (MCNS) in more than 80% of these patients.', '3': 'Most patients with MCNS have favorable outcomes without complications.', '4': 'However, a few of these children have lesions of focal segmental glomerulosclerosis, suffer from severe and prolonged proteinuria, and are at high risk for complications.', '5': 'Complications of NS are divided into two categories: disease-associated and drug-related complications.', '6': 'Disease-associated complications include infections (e.g., peritonitis, sepsis, cellulitis, and chicken pox), thromboembolism (e.g., venous thromboembolism and pulmonary embolism), hypovolemic crisis (e.g., abdominal pain, tachycardia, and hypotension), cardiovascular problems (e.g., hyperlipidemia), acute renal failure, anemia, and others (e.g., hypothyroidism, hypocalcemia, bone disease, and intussusception).', '7': 'The main pathomechanism of disease-associated complications originates from the large loss of plasma proteins in the urine of nephrotic children.', '8': 'The majority of children with MCNS who respond to treatment with corticosteroids or cytotoxic agents have smaller and milder complications than those with steroid-resistant NS.', '9': 'Corticosteroids, alkylating agents, cyclosporin A, and mycophenolate mofetil have often been used to treat NS, and these drugs have treatment-related complications.', '10': 'Early detection and appropriate treatment of these complications will improve outcomes for patients with NS.'}\n",
            "66: abstract: {'1': 'Background and objectives: There are very little data available regarding nephrotic syndrome (NS) in elderly (aged ≥65 years) Japanese.', '2': 'The aim of this study was to examine the causes and outcomes of NS in elderly patients who underwent renal biopsies between 2007 and 2010.', '3': 'Design, setting, participants, and measurements: From July 2007 to June 2010, all of the elderly (aged ≥65 years) Japanese primary NS patients who underwent native renal biopsies and were registered in the Japan renal biopsy registry (J-RBR; 438 patients including 226 males and 212 females) were identified.', '4': 'From this cohort, 61 patients [28 males and 33 females including 29, 19, 6, 4, and 3 patients with membranous nephropathy (MN), minimal change nephrotic syndrome (MCNS), focal segmental glomerulosclerosis (FSGS), membranoproliferative glomerulonephritis (MPGN), and other conditions, respectively] were registered from the representative multi-centers over all districts of Japan, and analyzed retrospectively.', '5': 'The treatment outcome was assessed using proteinuria-based criteria; i.e., complete remission (CR) was defined as urinary protein level of <0.3 g/day or g/g Cr, and incomplete remission type I (ICR-I) was defined as urinary protein level of <1.0-0.3 g/day or g/g Cr, and renal dysfunction was defined as a serum creatinine (Cr) level of 1.5 times the baseline level.', '6': 'Results: In this elderly primary NS cohort, MN was the most common histological type of NS (54.8 %), followed by MCNS (19.4 %), FSGS (17.4 %), and MPGN (8.4 %).', '7': 'Of the patients with MN, MCNS, or FSGS, immunosuppressive therapy involving oral prednisolone was performed in 25 MN patients (86.2 %), 18 MCNS patients (94.7 %), and all 6 FSGS patients (100 %).', '8': 'CR was achieved in all 19 (100 %) MCNS patients.', '9': 'In addition, CR and ICR-I were achieved in 16 (55.2 %) and 18 (62.1 %) MN patients and 4 (66.7 %) and 5 (83.3 %) FSGS patients, respectively.', '10': 'There were significant differences in the median time to CR among the MCNS, FSGS, and MN patients (median: 26 vs. 271 vs. 461 days, respectively, p < 0.001), and between the elderly (65-74 years, n = 7) and very elderly (aged ≥75 years, n = 12) MCNS patients (7 vs. 22 days, p = 0.037).', '11': 'Relapse occurred in two (6.9 %) of the MN and nine (47.4 %) of the MCNS patients.', '12': 'Renal dysfunction was observed in five (7.2 %) of the MN patients.', '13': 'Serious complications developed in eight (14.8 %) patients, i.e., two (3.7 %) patients died, four (7.4 %, including three MCNS patients) were hospitalized due to infectious disease, and two (3.7 %) developed malignancies.', '14': 'The initiation of diabetic therapy was necessary in 14 of the 61 patients (23.0 %) with much higher initial steroid dosage.', '15': 'Conclusion: Renal biopsy is a valuable diagnostic tool for elderly Japanese NS patients.', '16': 'In this study, most of elderly primary NS patients respond to immunosuppressive therapy with favorable clinical outcomes.', '17': 'On the other hand, infectious disease is a harmful complication among elderly NS patients, especially those with MCNS.', '18': 'In future, modified clinical guidelines for elderly NS patients should be developed.'}\n",
            "66: abstract: {'1': 'Background: Few studies have examined the treatment and outcome of adult-onset minimal change nephrotic syndrome (MCNS).', '2': 'We retrospectively studied 125 patients who had MCNS with onset in either adulthood or late adolescence.', '3': 'Presenting characteristics, duration of initial treatment and response to treatment, relapse patterns, complications, and long-term outcome were studied.', '4': 'Study design: Case series.', '5': 'Setting & participants: Patients with new-onset nephrotic syndrome 16 years or older and a histologic diagnosis of MCNS in 1985 to 2011 were identified from pathology records of 10 participating centers.', '6': 'Outcomes: Partial and complete remission, treatment resistance, relapse, complications, renal survival.', '7': 'Results: Corticosteroids were given as initial treatment in 105 (84%) patients.', '8': 'After 16 weeks of corticosteroid treatment, 92 (88%) of these patients had reached remission.', '9': 'Median time to remission was 4 (IQR, 2-7) weeks.', '10': '7 (6%) patients initially received cyclophosphamide with or without corticosteroids, and all attained remission after a median of 4 (IQR, 3-11) weeks.', '11': '13 (10%) patients reached remission without immunosuppressive treatment.', '12': 'One or more relapses were observed in 57 (54%) patients who received initial corticosteroid treatment.', '13': 'Second-line cyclophosphamide resulted in stable remission in 57% of patients with relapsing MCNS.', '14': 'Acute kidney injury was observed in 50 (40%) patients.', '15': 'Recovery of kidney function occurred almost without exception.', '16': 'Arterial or venous thrombosis occurred in 11 (9%) patients.', '17': 'At the last follow-up, 113 (90%) patients were in remission and had preserved kidney function.', '18': '3 patients with steroid-resistant MCNS progressed to end-stage renal disease, which was associated with focal segmental glomerulosclerosis lesions on repeat biopsy.', '19': 'Limitations: Retrospective design, variable treatment protocols.', '20': 'Conclusions: The large majority of patients who had MCNS with onset in adulthood or late adolescence were treated with corticosteroids and reached remission, but many had relapses.', '21': 'Cyclophosphamide resulted in stable remission in many patients with relapses.', '22': 'Significant morbidity was observed due to acute kidney injury and other complications.', '23': 'Progression to end-stage renal disease occurred in a few patients and was explained by focal segmental glomerulosclerosis.'}\n",
            "66: abstract: {'1': 'Background: Despite recent advances in immunosuppressive therapy for patients with primary nephrotic syndrome, its effectiveness and safety have not been fully studied in recent nationwide real-world clinical data in Japan.', '2': 'Methods: A 5-year cohort study, the Japan Nephrotic Syndrome Cohort Study, enrolled 374 patients with primary nephrotic syndrome in 55 hospitals in Japan, including 155, 148, 38, and 33 patients with minimal change disease (MCD), membranous nephropathy (MN), focal segmental glomerulosclerosis (FSGS), and other glomerulonephritides, respectively.', '3': 'The incidence rates of remission and relapse of proteinuria, 50% and 100% increases in serum creatinine, end-stage kidney disease (ESKD), all-cause mortality, and other major adverse outcomes were compared among glomerulonephritides using the Log-rank test.', '4': 'Incidence of hospitalization for infection, the most common cause of mortality, was compared using a multivariable-adjusted Cox proportional hazard model.', '5': 'Results: Immunosuppressive therapy was administered in 339 (90.6%) patients.', '6': 'The cumulative probabilities of complete remission within 3 years of the baseline visit was ≥ 0.75 in patients with MCD, MN, and FSGS (0.95, 0.77, and 0.79, respectively).', '7': 'Diabetes was the most common adverse events associated with immunosuppressive therapy (incidence rate, 71.0 per 1000 person-years).', '8': 'All-cause mortality (15.6 per 1000 person-years), mainly infection-related mortality (47.8%), was more common than ESKD (8.9 per 1000 person-years), especially in patients with MCD and MN.', '9': 'MCD was significantly associated with hospitalization for infection than MN.', '10': 'Conclusions: Patients with MCD and MN had a higher mortality, especially infection-related mortality, than ESKD.', '11': 'Nephrologists should pay more attention to infections in patients with primary nephrotic syndrome.'}\n",
            "66: abstract: {'1': 'Background: Little population-based data exist about adults with primary nephrotic syndrome.', '2': 'Methods: To evaluate kidney, cardiovascular, and mortality outcomes in adults with primary nephrotic syndrome, we identified adults within an integrated health care delivery system (Kaiser Permanente Northern California) with nephrotic-range proteinuria or diagnosed nephrotic syndrome between 1996 and 2012.', '3': 'Nephrologists reviewed medical records for clinical presentation, laboratory findings, and biopsy results to confirm primary nephrotic syndrome and assigned etiology.', '4': 'We identified a 1:100 time-matched cohort of adults without diabetes, diagnosed nephrotic syndrome, or proteinuria as controls to compare rates of ESKD, cardiovascular outcomes, and death through 2014, using multivariable Cox regression.', '5': 'Results: We confirmed 907 patients with primary nephrotic syndrome (655 definite and 252 presumed patients with FSGS [40%], membranous nephropathy [40%], and minimal change disease [20%]).', '6': 'Mean age was 49 years; 43% were women.', '7': 'Adults with primary nephrotic syndrome had higher adjusted rates of ESKD (adjusted hazard ratio [aHR], 19.63; 95% confidence interval [95% CI], 12.76 to 30.20), acute coronary syndrome (aHR, 2.58; 95% CI, 1.89 to 3.52), heart failure (aHR, 3.01; 95% CI, 2.16 to 4.19), ischemic stroke (aHR, 1.80; 95% CI, 1.06 to 3.05), venous thromboembolism (aHR, 2.56; 95% CI, 1.35 to 4.85), and death (aHR, 1.34; 95% CI, 1.09 to 1.64) versus controls.', '8': 'Excess ESKD risk was significantly higher for FSGS and membranous nephropathy than for presumed minimal change disease.', '9': 'The three etiologies of primary nephrotic syndrome did not differ significantly in terms of cardiovascular outcomes and death.', '10': 'Conclusions: Adults with primary nephrotic syndrome experience higher adjusted rates of ESKD, cardiovascular outcomes, and death, with significant variation by underlying etiology in the risk for developing ESKD.'}\n",
            "66: abstract: {'1': 'Chylothorax is an uncommon and serious clinical condition, typically induced by trauma, either postsurgical or accidental injury, but the mechanism of chylothorax caused by nephrotic syndrome is still unclear.', '2': 'Here, we report a case of primary nephrotic syndrome with membranous nephropathy (MN) in a 66-year-old man who presented with severe chylothorax.', '3': 'The chylothorax was managed by intercostal chest tube drainage, subcutaneous injection of enoxaparin, and treatment with anti-inflammatory agents and diuretics.', '4': \"After treatment, the patient's pleural effusion decreased, and the chyle gradually became clear.\", '5': 'We discuss the causes of MN with chylothorax.', '6': 'We considered that the hypoproteinemia changed the permeability of mucous membranes and lymphatic vessels, leading to leakage of chylous particles and chylous pleural effusion formation.', '7': 'Chylothorax may also have been caused by severe tissue edema, edema of the lymphatic walls, and increased pressure, resulting in increased permeability or rupture of the lymphatic wall, and leakage of chylous fluid into the thoracic cavity.', '8': \"Because of its rarity, we hope this case report will improve clinicians' understanding of MN complications in primary nephrotic syndrome and provide suitable treatment options for future clinical reference.\"}\n",
            "66: abstract: {'1': 'Background: Steroid resistant nephrotic syndrome (SRNS), while uncommon in children, is associated with significant morbidity.', '2': 'Calcineurin inhibitors (CNIs) remain the first line recommended therapy for children with non-genetic forms of SRNS, but some children fail to respond to them.', '3': 'Intravenous (IV) cyclophosphamide (CTX) has been shown to be effective in Asian-Indian children with difficult to treat SRNS (SRNS-DTT).', '4': 'Our study evaluated the outcome of IV CTX treatment in North American children with SRNS-DTT.', '5': 'Methods: Retrospective review of the medical records of children with SRNS-DTT treated with IV CTX from January 2000 to July 2019 at our center.', '6': 'Data abstracted included demographics, histopathology on renal biopsy, prior and concomitant use of other immunosuppressive agents and serial clinical/laboratory data.', '7': 'Primary outcome measure was attainment of complete remission (CR).', '8': 'Results: Eight children with SRNS-DTT received monthly doses (median 6; range 4-6) of IV CTX.', '9': 'Four (50%) went into CR, 1 achieved partial remission and 3 did not respond.', '10': 'Three of the 4 responders had minimal change disease (MCD).', '11': 'Excluding the 1 child who responded after the 4th infusion, the median time to CR was 6.5 (range 0.5-8) months after completion of IV CTX infusions.', '12': 'Three remain in CR at a median of 8.5 years (range: 3.7-10.5 years) after completion of CTX; one child relapsed and became steroid-dependent.', '13': 'No infections or life-threatening complications related to IV CTX were observed.', '14': 'Conclusions: IV CXT can induce long term remission in North-American children with MCD who have SRNS-DTT.'}\n",
            "66: abstract: {'1': 'Background: Although venous thromboembolism is a well-known complication of nephrotic syndrome, the long-term absolute and relative risks of arterial thromboembolism, venous thromboembolism, and bleeding in adults with nephrotic syndrome remain unclarified.', '2': 'Methods: In this matched cohort study, we identified every adult with first-time recorded nephrotic syndrome from admissions, outpatient clinics, or emergency department visits in Denmark during 1995-2018.', '3': 'Each patient was matched by age and sex with 10 individuals from the general population.', '4': 'We estimated the 10-year cumulative risks of recorded arterial thromboembolism, venous thromboembolism, and bleeding accounting for the competing risk of death.', '5': 'Using Cox models, we computed crude and adjusted hazard ratios (HRs) of the outcomes in patients with nephrotic syndrome versus comparators.', '6': 'Results: Among 3967 adults with first-time nephrotic syndrome, the 1-year risk of arterial thromboembolism was 4.2% (95% confidence interval [CI] 3.6-4.8), of venous thromboembolism was 2.8% (95% CI 2.3-3.3), and of bleeding was 5.2% (95% CI 4.5-5.9).', '7': 'The 10-year risk of arterial thromboembolism was 14.0% (95% CI 12.8-15.2), of venous thromboembolism 7.7% (95% CI 6.8-8.6), and of bleeding 17.0% (95% CI 15.7-18.3), with highest risks of ischemic stroke (8.1%), myocardial infarction (6.0%), and gastrointestinal bleeding (8.2%).', '8': 'During the first year, patients with nephrotic syndrome had increased rates of both arterial thromboembolism (adjusted HR [HRadj] = 3.11 [95% CI 2.60-3.73]), venous thromboembolism (HRadj = 7.11 [5.49-9.19]), and bleeding (HRadj = 4.02 [3.40-4.75]) compared with the general population comparators after adjusting for confounders.', '9': 'Conclusion: Adults with nephrotic syndrome have a high risk of arterial thromboembolism, venous thromboembolism, and bleeding compared with the general population.', '10': 'The mechanisms and consequences of this needs to be clarified.'}\n",
            "66: abstract: {'1': 'Children with nephrotic syndrome (NS) have a number of potential risk factors for the development of acute kidney injury (AKI) including intravascular volume depletion, infection, exposure to nephrotoxic medication, and renal interstitial edema.', '2': 'This study was aimed to determine the incidence of AKI in children hospitalized with a relapse of NS and its short-term outcome.', '3': 'This prospective observational study was conducted from February 2017 to January 2018 at a tertiary care teaching hospital.', '4': 'A total of 54 children and adolescents (1-18 years) hospitalized with a diagnosis of NS and relapse with/or without other complications were enrolled.', '5': 'Clinical data and examination were recorded.', '6': 'AKI was defined using the Kidney Disease Improving Global Outcomes (KDIGO) serum creatinine criteria and Pediatric Risk, Injury, Failure, Loss, End-Stage Renal Disease (p-RIFLE) classification.', '7': 'Children who developed AKI during the first two weeks of hospitalization were followed up till recovery or six weeks whichever was earlier to determine the outcome and factors predisposing to AKI.', '8': 'The mean age of the study population was 59.5 months and 35 (64.8%) patients were male.', '9': 'Of the 54 patients hospitalized, 42 (77.8%) were admitted with infection-associated relapses while 22.2% of children had relapse alone.', '10': 'Diarrhea and spontaneous bacterial peritonitis were the most common infections (26.1% each) followed by urinary tract infections in 19% and pneumonia in 14.3%.', '11': 'Twenty-three (42.6%) children developed AKI according to the KDIGO definition and 27 (50%) using the pRIFLE classification.', '12': 'Fourteen (60.9%) had stage 2 AKI while 21.7% had stage 3 AKI.', '13': 'Infections [odds ratio (OR) 1.24] and use of angiotensin-converting enzyme inhibitors (ACEI) (OR 2.3) were the most common predisposing factors for AKI.', '14': 'The mean recovery time for AKI was 7.34 days.', '15': 'Development of AKI was associated with prolonged hospital stay (12.57 vs.8.55 days P <0.01) and delayed recovery.', '16': 'At the end of follow-up all children recovered from AKI.', '17': 'The incidence of AKI in children hospitalized with complications of NS is high.', '18': 'While the occurrence of these AKI episodes may appear transient, a recurrence of such episodes may be detrimental to the long-term outcome of children with NS.', '19': 'Infections and the use of ACEI during relapses are risk factor for the occurrence of AKI.'}\n",
            "66: abstract: {'1': 'Nephrotic syndrome (NS) encompasses a variety of disease processes leading to heavy proteinuria and edema.', '2': 'Minimal change disease (MCD) remains the most common primary cause of NS, as well as the most responsive to pharmacologic treatment with often minimal to no chronic kidney disease.', '3': 'Other causes of NS include focal segmental glomerulosclerosis, which follows MCD, and secondary causes, including extrarenal or systemic diseases, infections, and drugs.', '4': 'Although initial diagnosis relies on clinical findings as well as urine and blood chemistries, renal biopsy and genetic testing are important diagnostic tools, especially when considering non-MCD NS.', '5': 'Moreover, biomarkers in urine and serum have become important areas for research in this disease.', '6': 'NS progression and prognosis are variable and depend on etiology, with corticosteroids being the mainstay of treatment.', '7': 'Other alternative therapies found to be successful in inducing and maintaining remission include calcineurin inhibitors and rituximab.', '8': 'Disease course can range from recurrent disease relapse with or without acute kidney injury to end-stage renal disease in some cases.', '9': 'Given the complex pathogenesis of NS, which remains incompletely understood, complications are numerous and diverse and include infections, electrolyte abnormalities, acute kidney injury, and thrombosis.', '10': 'Pediatricians must be aware of the presentation, complications, and overall long-term implications of NS and its treatment.'}\n",
            "67: abstract: {'1': 'Objective: The objective of this health technology policy analysis was to determine, where, how, and when physiotherapy services are best delivered to optimize functional outcomes for patients after they undergo primary (first-time) total hip replacement or total knee replacement, and to determine the Ontario-specific economic impact of the best delivery strategy.', '2': 'The objectives of the systematic review were as follows: To determine the effectiveness of inpatient physiotherapy after discharge from an acute care hospital compared with outpatient physiotherapy delivered in either a clinic-based or home-based setting for primary total joint replacement patients.', '3': 'To determine the effectiveness of outpatient physiotherapy delivered by a physiotherapist in either a clinic-based or home-based setting in addition to a home exercise program compared with a home exercise program alone for primary total joint replacement patients.', '4': 'To determine the effectiveness of preoperative exercise for people who are scheduled to receive primary total knee or hip replacement surgery.', '5': 'Conclusions: Based on the evidence, the Medical Advisory Secretariat reached the following conclusions with respect to physiotherapy rehabilitation and physical functioning 1 year after primary TKR or THR surgery: There is high-quality evidence from 1 large RCT to support the use of home-based physiotherapy instead of inpatient physiotherapy after primary THR or TKR surgery.', '6': 'There is low-to-moderate quality evidence from 1 large RCT to support the conclusion that receiving a monitoring phone call from a physiotherapist and practicing home exercises is comparable to receiving clinic-based physiotherapy and practicing home exercises for people who have had primary TKR surgery.', '7': 'However, results may not be generalizable to those who have had THR surgery.', '8': 'There is moderate evidence to suggest that an exercise program beginning 4 to 6 weeks before primary TKR surgery is not effective.'}\n",
            "67: abstract: {'1': 'Total knee arthroplasty (TKA) is the gold standard treatment for end-stage knee osteoarthritis.', '2': 'Most patients report successful long-term outcomes and reduced pain after TKA, but recovery is variable and the majority of patients continue to demonstrate lower extremity muscle weakness and functional deficits compared to age-matched control subjects.', '3': 'Given the potential positive influence of postoperative rehabilitation and the lack of established standards for prescribing exercise paradigms after TKA, the purpose of this study was to systematically review randomized, controlled studies to determine the effectiveness of postoperative outpatient care on short- and long-term functional recovery.', '4': 'Nineteen studies were identified as highly relevant for the review and four categories of postoperative intervention were discussed: 1) strengthening exercises; 2) aquatic therapy; 3) balance training; and 4) clinical environment.', '5': 'Optimal outpatient physical therapy protocols should include: strengthening and intensive functional exercises given through land-based or aquatic programs, the intensity of which is increased based on patient progress.', '6': 'Due to the highly individualized characteristics of these types of exercises, outpatient physical therapy performed in a clinic under the supervision of a trained physical therapist may provide the best long-term outcomes after the surgery.', '7': 'Supervised or remotely supervised therapy may be effective at reducing some of the impairments following TKA, but several studies without direct oversight produced poor results.', '8': 'Most studies did not accurately describe the \"usual care\" or control groups and information about the dose, frequency, intensity and duration of the rehabilitation protocols were lacking from several studies.'}\n",
            "67: abstract: {'1': 'Background: Rehabilitation, with an emphasis on physiotherapy and exercise, is widely promoted after total knee replacement.', '2': 'However, provision of services varies in content and duration.', '3': 'The aim of this study is to update the review of Minns Lowe and colleagues 2007 using systematic review and meta-analysis to evaluate the effectiveness of post-discharge physiotherapy exercise in patients with primary total knee replacement.', '4': 'Methods: We searched MEDLINE, Embase, PsycInfo, CINAHL and Cochrane CENTRAL to October 4(th) 2013 for randomised evaluations of physiotherapy exercise in adults with recent primary knee replacement.', '5': 'Outcomes were: patient-reported pain and function, knee range of motion, and functional performance.', '6': 'Authors were contacted for missing data and outcomes.', '7': 'Risk of bias and heterogeneity were assessed.', '8': 'Data was combined using random effects meta-analysis and reported as standardised mean differences (SMD) or mean differences (MD).', '9': 'Results: Searches identified 18 randomised trials including 1,739 patients with total knee replacement.', '10': 'Interventions compared: physiotherapy exercise and no provision; home and outpatient provision; pool and gym-based provision; walking skills and more general physiotherapy; and general physiotherapy exercise with and without additional balance exercises or ergometer cycling.', '11': 'Compared with controls receiving minimal physiotherapy, patients receiving physiotherapy exercise had improved physical function at 3-4 months, SMD -0.37 (95% CI -0.62, -0.12), and pain, SMD -0.45 (95% CI -0.85, -0.06).', '12': 'Benefit up to 6 months was apparent when considering only higher quality studies.', '13': 'There were no differences for outpatient physiotherapy exercise compared with home-based provision in physical function or pain outcomes.', '14': 'There was a short-term benefit favouring home-based physiotherapy exercise for range of motion flexion.', '15': 'There were no differences in outcomes when the comparator was hydrotherapy, or when additional balancing or cycling components were included.', '16': 'In one study, a walking skills intervention was associated with a long-term improvement in walking performance.', '17': 'However, for all these evaluations studies were under-powered individually and in combination.', '18': 'Conclusion: After recent primary total knee replacement, interventions including physiotherapy and exercise show short-term improvements in physical function.', '19': 'However this conclusion is based on meta-analysis of a few small studies and no long-term benefits of physiotherapy exercise interventions were identified.', '20': 'Future research should target improvements to long-term function, pain and performance outcomes in appropriately powered trials.'}\n",
            "67: abstract: {'1': 'Purpose: The aim of the present study was to evaluate the efficacy and safety of non-supervised home-based exercise versus individualized and supervised programs delivered in clinic-based settings for the functional recovery immediately after discharge from a primary TKA.', '2': 'Methods: Medline, Embase, Cochrane, and PEDro databases were screened, from inception to April 2015, in search for randomized clinical trials (RCT) of home-based exercise interventions versus individualized and supervised outpatient physical therapy after primary TKA.', '3': 'Target outcomes were: knee range of motion (ROM), patient-reported pain and function, functional performance, and safety.', '4': 'Risk of bias was assessed with the PEDro scale.', '5': 'After assessing homogeneity, data were combined using random effects meta-analysis and reported as standardized mean differences or mean differences.', '6': 'We set a non-inferiority margin of four points in mean differences.', '7': 'Results: The search and selection process identified 11 RCT of moderate quality and small sample sizes.', '8': 'ROM active extension data suitable for meta-analysis was available from seven studies with 707 patients, and ROM active flexion from nine studies with 983 patients.', '9': 'Most studies showed no difference between groups.', '10': 'Pooled differences were within the non-inferiority margin.', '11': 'Most meta-analyses showed significant statistical heterogeneity.', '12': 'Conclusion: Short-term improvements in physical function and knee ROM do not clearly differ between outpatient physiotherapy and home-based exercise regimes in patients after primary TKA; however, this conclusion is based on a meta-analysis with high heterogeneity.'}\n",
            "67: abstract: {'1': 'Background: Total knee arthroplasty (TKA) alleviates pain, but muscle strength and function is reduced for a long period postoperatively.', '2': 'Aim: To investigate whether maximal strength training (MST) is more effective in improving muscle strength than standard rehabilitation (SR) after TKA.', '3': 'Design: A randomized, controlled study.', '4': 'Setting: Community physical therapy centers and University hospital research department.', '5': 'Population: Forty-one adults <75 years with primary, unilateral osteoarthritis of the knee scheduled for TKA.', '6': 'Methods: Participants were randomized to supervised MST of the lower extremities 3 times/week for 8 weeks and physiotherapy session1/week (N.=21) or to SR, including physiotherapy sessions/telephone contact 1/week and writing home exercise logs (N.=20).', '7': 'Maximal strength in leg press and knee extension, 6-minute walk test, patient-reported functional outcome score and pain were assessed preoperatively, 7 days, 10 weeks and 12 months postoperatively.', '8': \"Results: The MST group exceeded preoperative levels of muscle strength in leg press and knee extension by 37% and 43%, respectively at 10 weeks' follow-up, and the increase was higher than in the SR group (P≤0.001).\", '9': 'Strength differences persisted up to 12-months follow-up.', '10': 'At 12 months, both groups recovered to normative levels in the 6-Minute Walk Test, with no statistically significantly difference between the groups.', '11': 'Conclusions: Participants undergoing MST experienced superior increases in leg press and knee extension muscle strength compared with those managed with SR from 7-day to 10-week follow-up.', '12': 'The difference in muscle strength was maintained at 12-month follow-up.', '13': 'No differences in functional performance were found at any time-point.', '14': 'Clinical rehabilitation impact: Exercises after TKA should be performed with high intensity and target the operated leg specifically.'}\n",
            "67: abstract: {'1': 'This study evaluated the use of telerehabilitation during the postoperative period for patients who underwent total knee arthroplasty (TKA) or unicompartmental knee arthroplasty (UKA).', '2': 'Specifically, this study evaluated the following: (1) patient compliance and adherence to the program, (2) time spent performing physical therapy exercises, (3) the usability of the virtual rehabilitation platform, and (4) clinical outcome scores in a selected primary knee arthroplasty cohort.', '3': 'A total of 157 consecutive patients underwent TKA (n = 18) or UKA (n = 139).', '4': 'These patients used a telerehabilitation system with an instructional avatar, three-dimensional motion measurement and analysis software, and real-time televisit capability designed for arthroplasty patients.', '5': 'Compliance was determined by how many times the patients followed prescribed repetitions of exercises.', '6': 'The total time spent performing exercises for each patient was collected.', '7': \"The usability of the virtual rehabilitation platform (on the patient's end) was evaluated using the system usability scale (SUS) questionnaire.\", '8': 'The number of in-person and televisits was recorded for each patient.', '9': 'Patient-reported outcomes were collected through the patient and clinician interfaces and included the Knee Society Score (KSS) for pain and functions, the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) score, and Boston University Activity Measure for Post-Acute Care (AM-PAC) score.', '10': 'Patients spent an average of 29.5 days partaking in the therapy.', '11': 'TKA and UKA patients had a mean of 3.5 and 3.2 outpatient follow-up visits, each, for in-office therapy with a physical therapist, respectively.', '12': 'This figure exceeded the mean number of real-time virtual patient-clinician visits by 0.8 visits per patient in the TKA cohort and by 1 visit per patient in the UKA cohort.', '13': 'Patients spent on average 26.5 minutes per day conducting an average of 13.5 exercises.', '14': 'By the end of rehabilitation, patients had spent an average of 10.8 hours performing exercises, and of all the exercises performed, approximately 21 exercises were uniquely designed.', '15': 'Mean SUS score in the cohort was 93 points, which was interpreted as being above the 50th percentile point of the scale.', '16': 'Following therapy, KSS pain and function scores improved markedly and the improvements were measured at 368% for TKA and 350% for UKA (pain) and 27% for UKA and 33% for TKA (function).', '17': 'In addition, WOMAC scores improved by 57% and 66% for UKA and TKA patients while the improvement in AM-PAC scores was at 22% and 24%.', '18': 'This telerehabilitation platform encouraged clinician-patient interaction beyond the hospital setting and offers the advantage of cost savings, convenience, at-home monitoring, and coordination of care, all of which are geared to improve adherence and overall patient satisfaction.', '19': 'Additionally, the biometric data can be used to develop custom physical therapy regimens to assure proper rehabilitation, which is lacking in other telerehabilitation applications that use noninteractive videos that can be watched on mobile devices and tablets.'}\n",
            "67: abstract: {'1': 'Objective: Although total knee replacement (TKR) surgery is highly prevalent and generally successful, functional outcomes post-TKR vary widely.', '2': 'Most patients receive some physical therapy (PT) following TKR, but PT practice is variable and associations between specific content and dose of PT interventions and functional outcomes are unknown.', '3': 'Research has identified exercise interventions associated with better outcomes but studies have not assessed whether such evidence has been translated into clinical practice.', '4': \"We characterized the content, dose, and progression of usual post-acute PT services following TKR, and examined associations of specific details of post-acute PT with patients' 6-month functional outcomes.\", '5': 'Methods: Post-acute PT data were collected from patients who were undergoing primary unilateral TKR and participating in a clinical trial of a phone-based coaching intervention.', '6': 'PT records from the terminal episode of care were reviewed and utilization and exercise content data were extracted.', '7': 'Descriptive statistics and linear regression models characterized PT treatment factors and identified associations with 6-month outcomes.', '8': 'Results: We analyzed 112 records from 30 PT sites.', '9': 'Content and dose of specific exercises and incidence of progression varied widely.', '10': 'Open chain exercises were utilized more frequently than closed chain (median 21 [interquartile range (IQR) 4-49] versus median 13 [IQR 4-28.5]).', '11': 'Median (IQR) occurrence of progression of closed and open chain exercise was 0 (0-2) and 1 (0-3), respectively.', '12': 'Shorter timed stair climb was associated with greater total number of PT interventions and use and progression of closed chain exercises.', '13': 'Discussion: Data suggest that evidence-based interventions are underutilized and dose may be insufficient to obtain optimal outcomes.'}\n",
            "67: abstract: {'1': 'Background: Early ambulation with physical therapy (PT) following total knee arthroplasty (TKA) has demonstrated benefits in the literature.', '2': 'However, the impact of early PT on rehabilitation performance and opioid consumption has not been elucidated.', '3': 'We evaluate the effect of same-day PT on inhospital functional outcomes and opioid consumption.', '4': 'Methods: We retrospectively identified 2 cohorts of primary TKA patients from July 2016 to December 2017: PT0 (n = 295) received PT on the day of surgery, and PT1 (n = 392) received PT on postoperative day (POD) 1.', '5': 'Outcomes studied included number of feet walked on POD0-3, visual analog scale pain scores, morphine equivalents (ME) consumed, length of stay, and discharge disposition.', '6': 'Analysis was conducted using the Student t-test and Fisher exact test.', '7': 'Results: In comparison to the PT1 group, the PT0 group walked significantly more steps on POD1 (347.6 vs 167.4 ft, P < .0001), POD2 (342.1 vs 203.5 ft, P < .0001), and POD3 (190.3 vs 128.9 ft, P = .00028).', '8': 'There was no difference between the 2 groups for visual analog scale.', '9': 'The PT0 group also consumed significantly fewer total ME when compared to the PT1 group (149.0 vs 200.3 mg, P = .0002).', '10': 'The PT0 group had a significantly shorter length of stay when compared to the PT1 group (2.7 vs 3.2 days, P = .00075).', '11': 'More patients were discharged home in the PT0 group (81.7% vs 54.8%, P < .0001).', '12': 'Conclusion: We observed that initiation of PT on POD0 led to better PT performance, reduced ME during hospitalization, and more patients discharged home.'}\n",
            "67: abstract: {'1': 'Total knee arthroplasty (TKA) is among the most common elective procedures performed worldwide.', '2': 'Recent efforts have been made to significantly improve patient outcomes, specifically with postoperative rehabilitation.', '3': 'Despite the many rehabilitation modalities available, the optimal rehabilitation strategy has yet to be determined.', '4': 'Therefore, this systematic review focuses on evaluating existing postoperative rehabilitation protocols.', '5': 'Specifically, this review analyses the study designs, rehabilitation methods, and outcome measures of postoperative rehabilitation protocols for TKA recipients in the past five years.', '6': 'The PubMed, EMBASE, and Cochrane Library databases were queried for studies evaluating rehabilitation protocols following primary TKA.', '7': 'Of the 11,013 studies identified within the last five years, 70 met the inclusion and exclusion criteria.', '8': 'After assessing for relevance and removing duplicates, a final count of 20 studies remained for analysis.', '9': 'Level-of-evidence was determined by the American Academy of Orthopaedic Surgeons (AAOS) classification system.', '10': 'Our findings demonstrated that continuous passive motion and inpatient rehabilitation may not provide additional benefit to the patient or healthcare system.', '11': 'However, early rehabilitation, telerehabilitation, outpatient therapy, high intensity, and high velocity exercise may be successful forms of rehabilitation.', '12': 'Additionally, weight-bearing biofeedback, neuromuscular electrical stimulation, and balance control appear to be beneficial adjuncts to conventional rehabilitation.', '13': 'Postoperative rehabilitation following TKA facilitates patient recovery and improves quality of life.', '14': 'This systematic review analyzed the existing rehabilitation protocols from the past five years.', '15': 'Some studies did not accurately describe the conventional rehabilitation protocols, the duration of therapy sessions, and the timing of these sessions.', '16': 'As such, future studies should explicitly describe their methodology.', '17': 'This will allow high-quality assessments and the conception of standardized protocols.'}\n",
            "67: abstract: {'1': 'Physical therapy is routinely delivered to patients after discharge from the hospital following knee arthroplasty.', '2': 'Posthospitalization physical therapy is thought to be beneficial, particularly for those patients most at risk of poor outcome, the subgroup with persistent function-limiting pain, despite an apparently successful surgery.', '3': 'Research teams have undertaken 3 large-scale multicenter Phase 3 randomized clinical trials designed specifically for patients at risk of poor outcome following knee arthroplasty.', '4': 'All 3 trials screened for poor outcome risk using different methods and investigated different physical therapist interventions delivered in different ways.', '5': 'Despite the variety of types of physical therapy and mode of delivery, all trials found no effects of the enhanced treatment compared with usual care.', '6': 'In all cases, usual care required a lower dosage of physical therapy compared with the enhanced interventions.', '7': 'This Perspective compares and contrasts the 3 trials, speculates on factors that could explain the no-effect findings, and proposes areas for future study designed to benefit the poor outcome phenotype.'}\n",
            "68: abstract: {'1': 'SARS-CoV-2 infection is characterized by a protean clinical picture that can range from asymptomatic patients to life-threatening conditions.', '2': 'Severe COVID-19 patients often display a severe pulmonary involvement and develop neutrophilia, lymphopenia, and strikingly elevated levels of IL-6.', '3': 'There is an over-exuberant cytokine release with hyperferritinemia leading to the idea that COVID-19 is part of the hyperferritinemic syndrome spectrum.', '4': \"Indeed, very high levels of ferritin can occur in other diseases including hemophagocytic lymphohistiocytosis, macrophage activation syndrome, adult-onset Still's disease, catastrophic antiphospholipid syndrome and septic shock.\", '5': 'Numerous studies have demonstrated the immunomodulatory effects of ferritin and its association with mortality and sustained inflammatory process.', '6': 'High levels of free iron are harmful in tissues, especially through the redox damage that can lead to fibrosis.', '7': 'Iron chelation represents a pillar in the treatment of iron overload.', '8': 'In addition, it was proven to have an anti-viral and anti-fibrotic activity.', '9': 'Herein, we analyse the pathogenic role of ferritin and iron during SARS-CoV-2 infection and propose iron depletion therapy as a novel therapeutic approach in the COVID-19 pandemic.'}\n",
            "68: abstract: {'1': 'Background and aims: Iron is an essential trace element to almost all organism, and the delicate balance between host defend system and viral proliferation plays an important role in infective conditions.', '2': 'While the association of the iron metabolism with the prognosis of COVID-19 remains poorly understood.', '3': 'We aimed to estimate the associations of systemic iron metabolism parameters with the severity and risks of adverse outcomes in COVID-19.', '4': 'Methods: In this retrospective cohort study, we included 158 confirmed COVID-19 patients in Tongji Hospital, Wuhan, China (27 January to 5 April, 2020).', '5': 'Demographic data, comorbidities, laboratory examinations, treatments, and clinical outcomes were all collected.', '6': 'Multivariable Poisson regression was used to estimate the association of iron parameter levels with the severity and risks of adverse outcomes in COVID-19 patients.', '7': 'Results: We identified 60 (38%) severe cases in 158 COVID-19 patients.', '8': 'The median age was 63 years (interquartile range [IQR]: 54-73) and the median length of hospital stay was 28 days (IQR: 17-40).', '9': 'After adjusting for age, sex, IL-6, and pre-existing comorbidities, all iron parameters were associated with the severity of COVID-19 with adjusted risk ratio of 0.42 [95% CI: 0.22-0.83], 4.38 [95% CI: 1.86-10.33], 0.19 [95% CI: 0.08-0.48], and 0.25 [95% CI: 0.10-0.58] for serum iron, ferritin, transferrin, and total iron-binding capacity, respectively.', '10': 'These iron indices were also related to the risk of ARDS, coagulopathy, acute cardiac injury, acute liver injury, and acute kidney injury in COVID-19 patients and high cytokine concentrations.', '11': 'Conclusions: Patients with low serum iron status likely suffered from severe condition and multiple-organ injury in COVID-19.', '12': 'The iron metabolism parameters might be risk factors and clinical biomarkers for COVID-19 prognosis.'}\n",
            "68: abstract: {'1': 'This report provides perspectives concerning dual roles of serum ferritin as a measure of both iron status and inflammation.', '2': 'We suggest benefits of a lower range of serum ferritin as has occurred for total serum cholesterol and fasting blood glucose levels.', '3': 'Observations during a prospective randomized study using phlebotomy in patients with peripheral arterial disease offered unique insights into dual roles of serum ferritin both as an iron status marker and acute phase reactant.', '4': 'Robust positive associations between serum ferritin, interleukin 6 [IL-6], tissue necrosis factor-alpha, and high sensitivity C-reactive protein were discovered.', '5': 'Elevated serum ferritin and IL-6 levels associated with increased mortality and with reduced mortality at ferritin levels <100 ng mL-1.', '6': 'Epidemiologic studies demonstrate similar outcomes.', '7': 'Extremely elevated ferritin and IL-6 levels also occur in individuals with high mortality due to SARS-CoV-2 infection.', '8': 'Disordered iron metabolism reflected by a high range of serum ferritin level signals disease severity and outcomes.', '9': 'Based upon experimental and epidemiologic data, we suggest testing the hypotheses that optimal ferritin levels for cardiovascular mortality reduction range from 20 to 100 ng mL-1 with % transferrin levels from 20 to 50%, to ensure adequate iron status and that ferritin levels above 194 ng mL-1 associate with all-cause mortality in population cohorts.'}\n",
            "68: abstract: {'1': 'Iron is a micronutrient essential for a wide range of metabolic processes in virtually all living organisms.', '2': 'During infections, a battle for iron takes place between the human host and the invading pathogens.', '3': 'The liver peptide hepcidin, which is phylogenetically and structurally linked to defensins (antimicrobial peptides of the innate immunity), plays a pivotal role by subtracting iron to pathogens through its sequestration into host cells, mainly macrophages.', '4': 'While this phenomenon is well studied in certain bacterial infections, much less is known regarding viral infections.', '5': 'Iron metabolism also has implications on the functionality of cells of the immune system.', '6': 'Once primed by the contact with antigen presenting cells, lymphocytes need iron to sustain the metabolic burst required for mounting an effective cellular and humoral response.', '7': 'The COVID-19 pandemic has boosted an amount of clinical and translational research over the possible influences of nutrients on SARS-CoV-2 infection, in terms of either susceptibility or clinical course.', '8': 'Here we review the intersections between iron metabolism and COVID-19, belonging to the wider domain of the so-called \"nutritional immunity\".', '9': 'A better understanding of such connections has potential broad implications, either from a mechanistic standpoint, or for the development of more effective strategies for managing COVID-19 and possible future pandemics.'}\n",
            "68: abstract: {'1': 'While it took decades to arrive to a conclusion that ferritin is more than an indicator of iron storage level, it took a short period of time through the COVID-19 pandemic to wonder what the reason behind high levels of ferritin in patients with severe COVID-19 might be.', '2': 'Unsurprisingly, acute phase reactant was not a satisfactory explanation.', '3': 'Moreover, the behavior of ferritin in patients with severe COVID-19 and the subsequent high mortality rates in patients with high ferritin levels necessitated further investigations to understand the role of ferritin in the diseases.', '4': 'Ferritin was initially described to accompany various acute infections, both viral and bacterial, indicating an acute response to inflammation.', '5': \"However, with the introduction of the hyperferritinemic syndrome connecting four severe pathological conditions such as adult-onset Still's disease, macrophage activation syndrome, catastrophic antiphospholipid syndrome, and septic shock added another aspect of ferritin where it could have a pathogenetic role rather than an extremely elevated protein only.\", '6': 'In fact, suggesting that COVID-19 is a new member in the spectrum of hyperferritinemic syndrome besides the four mentioned conditions could hopefully direct further search on the pathogenetic role of ferritin.', '7': 'Doubtlessly, improving our understanding of those aspects of ferritin would enormously contribute to better coping with severe diseases in terms of treatment and prevention of complications.', '8': 'The origin, history, importance, and the advances of searching the role of ferritin in various pathological and clinical processes are presented hereby in our article.', '9': 'In addition, the implications of ferritin in COVID-19 are addressed.'}\n",
            "68: abstract: {'1': \"Ferritin, which includes twenty-four light and heavy chains in varying proportions in different tissues, is primarily responsible for maintaining the body's iron metabolism.\", '2': 'Its normal value is between 10 and 200 ngmL-1 in men and between 30-300 ngmL-1 in women.', '3': 'Iron is delivered to the tissue via them, and they act as immunomodulators, signaling molecules, and inflammatory markers.', '4': 'When ferritin level exceeds 1000 µgL-1, the patient is categorized as having hyperferritinemia.', '5': 'Iron chelators such as deferiprone, deferirox, and deferoxamine are currently FDA approved to treat iron overload.', '6': 'The inflammation cascade and poor prognosis of COVID-19 may be attributed to high ferritin levels.', '7': 'Critically ill patients can benefit from deferasirox, an iron chelator administered orally at 20-40 mgkg-1 once daily, as well as intravenous deferoxamine at 1000 mg initially followed by 500 mg every 4 to 12 hours.', '8': 'It can be combined with monoclonal antibodies, antioxidants, corticosteroids, and lactoferrin to make iron chelation therapy effective for COVID-19 victims.', '9': 'In this article, we analyze the antiviral and antifibrotic activity of iron chelators, thereby promoting iron depletion therapy as a potentially innovative treatment strategy for COVID-19.'}\n",
            "68: abstract: {'1': \"Large variability in COVID-19 clinical progression urges the need to find the most relevant biomarkers to predict patients' outcomes.\", '2': 'We evaluated iron metabolism and immune response in 303 patients admitted to the main hospital of the northern region of Portugal with variable clinical pictures, from September to November 2020.', '3': 'One hundred and twenty-seven tested positive for SARS-CoV-2 and 176 tested negative.', '4': 'Iron-related laboratory parameters and cytokines were determined in blood samples collected soon after admission.', '5': 'Demographic data, comorbidities and clinical outcomes were recorded.', '6': 'Patients were assigned into five groups according to severity.', '7': 'Serum iron and transferrin levels at admission were lower in COVID-19-positive than in COVID-19-negative patients.', '8': 'The levels of interleukin (IL)-6 and monocyte chemoattractant protein 1 (MCP-1) were increased in COVID-19-positive patients.', '9': 'The lowest serum iron and transferrin levels at diagnosis were associated with the worst outcomes.', '10': 'Iron levels negatively correlated with IL-6 and higher levels of this cytokine were associated with a worse prognosis.', '11': 'Serum ferritin levels at diagnosis were higher in COVID-19-positive than in COVID-19-negative patients.', '12': 'Serum iron is the simplest laboratory test to be implemented as a predictor of disease progression in COVID-19-positive patients.'}\n",
            "68: abstract: {'1': 'During infections, the host redistributes iron in order to starve pathogens from this nutrient.', '2': 'Several proteins are involved in iron absorption, transport, and storage.', '3': 'Ferritin is the most important iron storage protein.', '4': 'It is composed of variable proportions of two peptides, the L- and H-ferritins (FTL and FTH).', '5': 'We previously showed that macrophages increase their expression of FTH1 when they are infected in vitro with Mycobacterium avium, without a significant increase in FTL.', '6': 'In this work, we investigated the role of macrophage FTH1 in M. avium infection in vivo.', '7': 'We found that mice deficient in FTH1 in myeloid cells are more resistant to M. avium infection, presenting lower bacterial loads and lower levels of proinflammatory cytokines than wild-type littermates, due to the lower levels of available iron in the tissues.', '8': 'Importantly, we also found that FTH1 produced by myeloid cells in response to infection may be found in circulation and that it plays a key role in iron redistribution.', '9': 'Specifically, in the absence of FTH1 in myeloid cells, increased expression of ferroportin is observed in liver granulomas and increased iron accumulation occurs in hepatocytes.', '10': 'These results highlight the importance of FTH1 expression in myeloid cells for iron redistribution during infection.'}\n",
            "68: abstract: {'1': 'The importance of ferritin as an inflammatory marker is well recognized.', '2': 'However, it is unknown whether this differs between Covid-19 and non-Covid-19 patients.', '3': 'The blood levels of ferritin, white blood cells (WBC), C-reactive protein (CRP), and lactate dehydrogenase may all be measured to check whether there is a difference.', '4': 'The researchers want to see if the inflammatory process changes between these two kinds (LDH).', '5': 'Methodology: Blood samples were collected from 119 COVID-19 patients in the hospital and 50 healthy persons.', '6': 'Corona virus was discovered when a nasopharyngeal swab was collected and tested using the RT-PCR technique.', '7': 'Ferritin, LDH, WBC, and CRP were also tested using Min Vidus, AccEnT 200, Ruby system, and Latx in that sequence.', '8': 'The study revealed that COVID-19 patients had higher levels of ferritin, WBC, CRP, and LDH in their blood than healthy people, with values of 539,08 ng/mL, 44.7109/L, 22.95 mg/L, and 403.95 U/L for COVID-19 patients versus 77.103 ng/mL, 4.9.4109/L, 6.53 mg/L, and 171.56 U/L for healthy people.', '9': 'According to the existing data, males are more likely to be infected with COVID-19 (81%) than females (32%), and females had greater ferritin, CRP, WBC, and LDH levels than males.', '10': 'Because they are related to an optimum test for predicting COVID-19 infection, the recommended cut-off values for ferritin, WBC, CRP, and LDH are 109.8 ng/mL, 14.9109/L, 10.15 mg/L, and 229.33 U/L, respectively.', '11': 'Finally, an increase in ferritin levels in the inflammatory response to COVID-19 is linked to an increase in inflammatory markers including CRP, WBC, and LDH, which may assist in the diagnosis of COVID-19 infection.'}\n",
            "68: abstract: {'1': 'Background: Several studies have suggested that COVID-19 is a systemic disease that can affect several organs, including the brain.', '2': 'In the brain, specifically, viral infection can cause dyshomeostasis of some trace elements that promote complex biochemical reactions in specialized neurological functions.', '3': 'Objective: Understand the neurovirulence of SARS-CoV-2 and the relationship between trace elements and neurological disorders after infection, and provide new insights on the drug development for the treatment of SARS-CoV-2 infections.', '4': 'Methods: The main databases were used to search studies published up September 2021, focusing on the role of trace elements during viral infection and on the correct functioning of the brain.', '5': 'Results: The imbalance of important trace elements can accelerate SARS-CoV-2 neurovirulence and increase the neurotoxicity since many neurological processes can be associated with the homeostasis of metal and metalloproteins.', '6': 'Some studies involving animals and humans have suggested the synapse as a vulnerable region of the brain to neurological disorders after viral infection.', '7': 'Considering the combined evidence, some mechanisms have been suggested to understand the relationship between neurological disorders and imbalance of trace elements in the brain after viral infection.', '8': 'Conclusion: Trace elements play important roles in viral infections, such as helping to activate immune cells, produce antibodies, and inhibit virus replication.', '9': 'However, the relationship between trace elements and virus infections is complex since the specific functions of several elements remain largely undefined.', '10': 'Therefore, there is still a lot to be explored to understand the biochemical mechanisms involved between trace elements and viral infections, especially in the brain.'}\n",
            "69: abstract: {'1': 'Postnatal depression is a major public health problem affecting about one in seven women after childbirth.', '2': 'Depression is also common during pregnancy and throughout the perinatal period it is associated with symptoms of anxiety.', '3': 'Apart from the adverse consequences for women themselves becoming depressed when they are going through demanding physical and social changes, there are additional concerns.', '4': \"There is the possible negative impact of maternal depression on the relationship between mother and child and on the child's emotional, behavioural and cognitive development.\", '5': 'Primary prevention and early intervention/secondary prevention strategies are potentially important in view of the frequent contact pregnant women, new mothers and infants have with health services, but the effectiveness of these strategies needs to be tested.', '6': 'In the past year there have been five new studies of antenatal screening for postnatal depression.', '7': 'These studies are consistent with nine earlier studies in showing that there is no evidence to support routine antenatal screening for postnatal depression.', '8': 'Seven new primary prevention/early intervention trials add evidence on a wide range of interventions ranging from practical support to individual interpersonal therapy, but without identifying significant differences in depression as an outcome.', '9': 'Two new trials of secondary prevention, one involving interpersonal therapy and the other including partners in a series of psychoeducational visits, show promise but neither is large enough to form a basis for practice change.', '10': 'Novel interventions, or promising findings, with a strong basis in theory need to be tested in trials which are appropriately sized and which comply with internationally accepted design and reporting guidelines.'}\n",
            "69: abstract: {'1': 'Postpartum depression (PPD) is a common and serious mental health problem that is associated with maternal suffering and numerous negative consequences for offspring.', '2': 'The first six months after delivery may represent a high-risk time for depression.', '3': 'Estimates of prevalence range from 13% to 19%.', '4': 'Risk factors mirror those typically found with major depression, with the exception of postpartum-specific factors such as sensitivity to hormone changes.', '5': 'Controlled trials of psychological interventions have validated a variety of individual and group interventions.', '6': 'Medication often leads to depression improvement, but in controlled trials there are often no significant differences in outcomes between patients in the medication condition and those in placebo or active control conditions.', '7': 'Reviews converge on recommendations for particular antidepressant medications for use while breastfeeding.', '8': 'Prevention of PPD appears to be feasible and effective.', '9': 'Finally, there is a growing movement to integrate mental health screening into routine primary care for pregnant and postpartum women and to follow up this screening with treatment or referral and with follow-up care.', '10': 'Research and clinical recommendations are made throughout this review.'}\n",
            "69: abstract: {'1': 'Nearly 20% of mothers will experience an episode of major or minor depression within the first 3 months postpartum, making it the most common complication of childbearing.', '2': 'Postpartum depression (PPD) is significantly undertreated, and because prospective mothers are especially motivated for self-care, a focus on the prevention of PPD holds promise of clinical efficacy.', '3': 'This study is a qualitative review of existing approaches to prevent PPD.', '4': 'A PubMed search identified studies of methods of PPD prevention.', '5': 'The search was limited to peer-reviewed, published, English-language, randomized controlled trials (RCTs) of biological, psychological, and psychosocial interventions.', '6': 'Eighty articles were initially identified, and 45 were found to meet inclusion criteria.', '7': 'Eight RCTs of biological interventions were identified and 37 RCTs of psychological or psychosocial interventions.', '8': 'Results were mixed, with 20 studies showing clear positive effects of an intervention and 25 showing no effect.', '9': 'Studies differed widely in screening, population, measurement, and intervention.', '10': 'Among biological studies, anti-depressants and nutrients provided the most evidence of successful intervention.', '11': 'Among psychological and psychosocial studies, 13/17 successful trials targeted an at-risk population, and 4/7 trials using interpersonal therapy demonstrated success of the intervention versus control, with a further two small studies showing trends toward statistical significance.', '12': 'Existing approaches to the prevention of PPD vary widely, and given the current literature, it is not possible to identify one approach that is superior to others.', '13': 'Interpersonal therapy trials and trials that targeted an at-risk population appear to hold the most promise for further study.'}\n",
            "69: abstract: {'1': 'Objectives: Both antidepressant medications and psychological therapy are common treatments for depression in postpartum women.', '2': 'Antidepressant treatment may have a number of practical disadvantages, including a preference by women to avoid medication while breastfeeding.', '3': 'Consequently, more information about the relative benefits of the two modalities in the perinatal period is helpful.', '4': 'In the treatment of depressive disorders there is some evidence that combination therapies (pharmacological plus psychological treatment) may be more efficacious than either form of mono-therapy in isolation.', '5': 'However, in the treatment of postnatal depression, such evidence is limited.', '6': 'Method: Forty five postpartum women with a DSM-IV diagnosis of depression were randomised to receive either: 1) cognitive behavioural therapy (CBT); 2) sertraline, or 3) a combination of both treatment modalities.', '7': 'Psychometric measures were collected weekly for 12 weeks, with a follow-up at 24 weeks.', '8': 'Results: Symptoms of depression and anxiety were reduced to a significant degree following all three treatments.', '9': 'CBT mono-therapy was found to be superior to both sertraline mono-therapy and combination therapy after 12 weeks.', '10': 'The CBT mono-therapy group appeared to display the most rapid initial gains after treatment commencement.', '11': 'Conclusions: In this sample, a specialised CBT program for postnatal depression was found to be superior as a mono-therapy compared to sertraline, a commonly prescribed SSRI antidepressant.', '12': 'This is in contrast to previous studies which have found no detectable difference in the efficacies of drug and psychological treatment for postnatal depression.', '13': 'Unlike some previous work, this study allowed a statistically independent evaluation of CBT mono-therapy for postnatal depression compared to both antidepressant and combination therapy.', '14': 'In line with previous studies in postpartum women, there was no detectable advantage of combining pharmacological and psychological treatments in the short term.'}\n",
            "69: abstract: {'1': 'Postpartum depression is one of the most prevalent psychopathologies.', '2': 'Its prevalence is estimated to be between 10% and 15%.', '3': 'Despite its multifactorial etiology, it is known that genetics play an important role in the genesis of this disorder.', '4': 'This paper reviews epidemiological evidence supporting the role of genetics in postpartum depression (PPD).', '5': 'The main objectives of this review are to determine which genes and polymorphisms are associated with PPD and discuss how this association may occur.', '6': 'In addition, this paper explores whether these genes are somehow related to or even the same as those linked to Major Depression (MD).', '7': 'To identify gaps in the current knowledge that require investigation, a systematic review was conducted in the electronic databases PubMed, LILACS and SciELO using the index terms \"postpartum depression\" and \"genetics\".', '8': 'Literature searches for articles in peer-reviewed journals were made until April 2014.', '9': 'PPD was indexed 56 times with genetics.', '10': 'The inclusion criteria were articles in Portuguese, Spanish or English that were available by institutional means or sent by authors upon request; this search resulted in 20 papers.', '11': 'Genes and polymorphisms traditionally related to MD, which are those involved in the serotonin, catecholamine, brain-derived neurotrophic factor and tryptophan metabolism, have been the most studied, and some have been related to PPD.', '12': 'The results are conflicting and some depend on epigenetics, which makes the data incipient.', '13': 'Further studies are required to determine the genes that are involved in PPD and establish the nature of the relationship between these genes and PPD.'}\n",
            "69: abstract: {'1': 'Most interventions to prevent postpartum depression (PPD) focus on the mother rather than the mother-infant dyad.', '2': 'As strong relationships between infant sleep and cry behavior and maternal postpartum mood have been demonstrated by previous research, interventions targeted at the dyad may reduce symptoms of PPD.', '3': 'The goal of the current study was to examine the effectiveness of Practical Resources for Effective Postpartum Parenting (PREPP).', '4': 'PREPP is a new PPD prevention protocol that aims to treat women at risk for PPD by promoting maternally mediated behavioral changes in their infants, while also including mother-focused skills.', '5': 'Results of this randomized control trial (RCT) (n = 54) indicate that this novel, brief intervention was well tolerated and effective in reducing maternal symptoms of anxiety and depression, particularly at 6 weeks postpartum.', '6': 'Additionally, this study found that infants of mothers enrolled in PREPP had fewer bouts of fussing and crying at 6 weeks postpartum than those infants whose mothers were in the Enhanced TAU group.', '7': \"These preliminary results indicate that PREPP has the potential to reduce the incidence of PPD in women at risk and to directly impact the developing mother-child relationship, the mother's view of her child, and child outcomes.\"}\n",
            "69: abstract: {'1': 'Background: Post-partum depression is a serious mood disorder in women that might be triggered by peripartum fluctuations in reproductive hormones.', '2': 'This phase 2 study investigated brexanolone (USAN; formerly SAGE-547 injection), an intravenous formulation of allopregnanolone, a positive allosteric modulator of γ-aminobutyric acid (GABAA) receptors, for the treatment of post-partum depression.', '3': 'Methods: For this double-blind, randomised, placebo-controlled trial, we enrolled self-referred or physician-referred female inpatients (≤6 months post partum) with severe post-partum depression (Hamilton Rating Scale for Depression [HAM-D] total score ≥26) in four hospitals in the USA.', '4': 'Eligible women were randomly assigned (1:1), via a computer-generated randomisation program, to receive either a single, continuous intravenous dose of brexanolone or placebo for 60 h.', '5': 'Patients and investigators were masked to treatment assignments.', '6': 'The primary efficacy endpoint was the change from baseline in the 17-item HAM-D total score at 60 h, assessed in all randomised patients who started infusion of study drug or placebo and who had a completed baseline HAM-D assessment and at least one post-baseline HAM-D assessment.', '7': 'Patients were followed up until day 30.', '8': 'This trial is registered with ClinicalTrials.gov, number NCT02614547.', '9': 'Findings: This trial was done between Dec 15, 2015 (first enrolment), and May 19, 2016 (final visit of the last enrolled patient).', '10': '21 women were randomly assigned to the brexanolone (n=10) and placebo (n=11) groups.', '11': 'At 60 h, mean reduction in HAM-D total score from baseline was 21·0 points (SE 2·9) in the brexanolone group compared with 8·8 points (SE 2·8) in the placebo group (difference -12·2, 95% CI -20·77 to -3·67; p=0·0075; effect size 1·2).', '12': 'No deaths, serious adverse events, or discontinuations because of adverse events were reported in either group.', '13': 'Four of ten patients in the brexanolone group had adverse events compared with eight of 11 in the placebo group.', '14': 'The most frequently reported adverse events in the brexanolone group were dizziness (two patients in the brexanolone group vs three patients in the placebo group) and somnolence (two vs none).', '15': 'Moderate treatment-emergent adverse events were reported in two patients in the brexanolone group (sinus tachycardia, n=1; somnolence, n=1) and in two patients in the placebo group (infusion site pain, n=1; tension headache, n=1); one patient in the placebo group had a severe treatment-emergent adverse event (insomnia).', '16': 'Interpretation: In women with severe post-partum depression, infusion of brexanolone resulted in a significant and clinically meaningful reduction in HAM-D total score, compared with placebo.', '17': 'Our results support the rationale for targeting synaptic and extrasynaptic GABAA receptors in the development of therapies for patients with post-partum depression.', '18': 'A pivotal clinical programme for the investigation of brexanolone in patients with post-partum depression is in progress.'}\n",
            "69: abstract: {'1': 'Objective: Postpartum mood disorders represent a serious problem affecting 10-20% of women and support groups offer a promising intervention modality.', '2': 'The current study examined participant satisfaction with and effectiveness of a peer-facilitated postpartum support group.', '3': 'Intervention: The program consists of a free, peer-support group, developed to increase social support and destigmatise postpartum mood symptoms.', '4': 'The weekly group is co-facilitated by former group attendees and maternal health professionals.', '5': 'Setting: The peer-support program is offered in an urban city in the southeastern United States.', '6': 'Design: To address study aims, a community-based participatory research approach was implemented.', '7': 'Participant satisfaction was assessed via mixed methods analyses.', '8': 'Differences in depression scores at follow-up between program attendees and a community sample were examined via weighted linear regression analysis following propensity score analysis.', '9': 'Finally, within-group change in depression scores for program attendees was examined using a repeated measures ANOVA.', '10': 'Participants: Intake program data were provided by the sponsoring organisation (n = 73) and follow-up data were collected via an online survey from program attendees (n = 45).', '11': 'A community sample was recruited to establish a comparison group (n = 152).', '12': 'Measurements and findings: Participant satisfaction was high with overwhelmingly positive perceptions of the program.', '13': 'Postparticipation depression scores were similar to those of the community sample at follow-up (p = .447).', '14': 'Among attendees, pre-post analyses revealed reductions in depression symptoms with significant interactions for time × complications (p ≤ .001) and time × delivery method (p ≤ .017).', '15': 'Key conclusions: Overall, findings indicate this peer-support program is not only acceptable to program attendees but also they provide a potential mechanism for improving mental health outcomes; however, further evaluation is needed.', '16': 'Findings also emphasise the importance of integrating evaluation procedures into community-based mental health programming to support effectiveness.', '17': 'Implications for practice: Peer-support groups are an acceptable form of intervention for women experiencing postpartum depression.'}\n",
            "69: abstract: {'1': 'Postpartum depression (PPD) is a major public health problem affecting 10-57% of adolescent mothers which can affect not only adolescent mothers but also their infants.', '2': 'Thus, there is a need for interventions to prevent PPD in adolescent mothers.', '3': 'However, recent systematic reviews have been focused on effective interventions to prevent PPD in adult mothers.', '4': 'These interventions may not necessarily be applicable for adolescent mothers.', '5': 'Therefore, the purpose of this review was to examine the effectiveness of the existing interventions to prevent PPD in adolescent mothers.', '6': 'A systematic search was performed in MEDLINE, CINAHL, and SCOPUS databases between January 2000 and March 2017 with English language and studies involving human subjects.', '7': 'Studies reporting on the outcomes of intervention to prevent PPD particularly in adolescent mothers were selected.', '8': 'Non-comparative studies were excluded.', '9': 'From 2002 identified records, 13 studies were included, reporting on 2236 adolescent pregnant women.', '10': 'The evidence from this systematic review suggests that 6 of 13 studies from both psychological and psychosocial interventions including (1) home-visiting intervention, (2) prenatal antenatal and postnatal educational program, (3) CBT psycho-educational, (4) the REACH program based on interpersonal therapy, and (5) infant massage training is successful in reducing rates of PPD symptoms in adolescent mothers in the intervention group than those mothers in the control group.', '11': 'These interventions might be considered for incorporation in antenatal care interventions for adolescent pregnant women.', '12': 'However, this review did not find evidence identifying the most effective intervention for preventing postpartum depression symptoms in adolescent mothers.'}\n",
            "69: abstract: {'1': 'Postpartum depression (PPD) is common, disabling, and treatable.', '2': 'The strongest risk factor is a history of mood or anxiety disorder, especially having active symptoms during pregnancy.', '3': 'As PPD is one of the most common complications of childbirth, it is vital to identify best treatments for optimal maternal, infant, and family outcomes.', '4': 'New understanding of PPD pathophysiology and emerging therapeutics offer the potential for new ways to add to current medications, somatic treatments, and evidence-based psychotherapy.', '5': 'The benefits and potential harms of treatment, including during breastfeeding, are presented.'}\n",
            "70: abstract: {'1': 'Animal and human studies suggest that vitamin B6 deficiency affects both humoral and cell-mediated immune responses.', '2': 'Lymphocyte differentiation and maturation are altered by deficiency, delayed-type hypersensitivity responses are reduced, and antibody production may be indirectly impaired.', '3': 'Although repletion of the vitamin restores these functions, megadoses do not produce benefits beyond those observed with moderate supplementation.', '4': 'Additional human studies indicate that vitamin B6 status may influence tumor growth and disease processes.', '5': 'Deficiency of the vitamin has been associated with immunological changes observed in the elderly, persons infected with human immunodeficiency virus (HIV), and those with uremia or rheumatoid arthritis.', '6': 'Future research efforts should focus on establishing the mechanism underlying the effects of vitamin B6 on immunity and should attempt to establish safe intake levels that optimize immune response.'}\n",
            "70: abstract: {'1': 'The vitamins folic acid, B12 and B6 and B2 are the source of coenzymes which participate in one carbon metabolism.', '2': 'In this metabolism, a carbon unit from serine or glycine is transferred to tetrahydrofolate (THF) to form methylene-THF.', '3': 'This is either used as such for the synthesis of thymidine, which is incorporated into DNA, oxidized to formyl-THF which is used for the synthesis of purines, which are building blocks of RNA and DNA, or it is reduced to methyl-THF which used to methylate homocysteine to form methionine, a reaction which is catalyzed by a B12-containing methyltransferase.', '4': 'Much of the methionine which is formed is converted to S-adenosylmethionine (SAM), a universal donor of methyl groups, including DNA, RNA, hormones, neurotransmitters, membrane lipids, proteins and others.', '5': \"Because of these functions, interest in recent years has been growing particularly in the area of aging and the possibility that certain diseases that afflict the aging population, loss of cognitive function, Alzheimer's disease, cardiovascular disease, cancer and others, may be in part explained by inadequate intake or inadequate status of these vitamins.\", '6': 'Homocysteine, a product of methionine metabolism as well as a precursor of methionine synthesis, was shown recently to be a risk factor for cardiovascular disease, stroke and thrombosis when its concentration in plasma is slightly elevated.', '7': \"There are now data which show association between elevated plasma homocysteine levels and loss of neurocognitive function and Alzheimer's disease.\", '8': 'These associations could be due to a neurotoxic effect of homocysteine or to decreased availability of SAM which results in hypomethylation in the brain tissue.', '9': 'Hypomethylation is also thought to exacerbate depressive tendency in people, and for (colorectal) cancer DNA hypomethylation is thought to be the link between the observed relationship between inadequate folate status and cancer.', '10': 'There are many factors that contribute to the fact that the status of these vitamins in the elderly is inadequate.', '11': 'These factors are in part physiological such as the achlorhydria which affects vitamin B12 absorption and in part socioeconomic and habitual.', '12': 'We need more studies to confirm that these vitamins have important functions in the etiology of these diseases.', '13': 'We also need to establish if these diseases can be prevented or diminished by proper nutrition starting at a younger age.'}\n",
            "70: abstract: {'1': 'Background: Vitamin B6 is thought to be a most versatile coenzyme that participates in more than 100 biochemical reactions.', '2': 'It is involved in amino acid and homocysteine metabolism, glucose and lipid metabolism, neurotransmitter production and DNA/RNA synthesis.', '3': 'Vitamin B6 can also be a modulator of gene expression.', '4': 'Nowadays, clinically evident vitamin B6 deficiency is not a common disorder, at least in the general population.', '5': 'Nevertheless, a subclinical, undiagnosed deficiency may be present in some subjects, particularly in the elderly.', '6': 'Objective: This review gives a complete overview over the metabolism and interactions of vitamin B6.', '7': 'Further, we show which complications and deficiency symptoms can occur due to a lack of vitamin B6 and possibilities for public health and supplemental interventions.', '8': 'Methods: The database Medline (www.ncvi.nlm.nih.gov) was searched for terms like \"vitamin B6\", \"pyridoxal\", \"cancer\", \"homocysteine\", etc.', '9': 'For a complete understanding, we included studies with early findings from the forties as well as recent results from 2006.', '10': 'These studies were summarised and compared in different chapters.', '11': \"Results and conclusion: In fact, it has been proposed that suboptimal vitamin B6 status is associated with certain diseases that particularly afflict the elderly population: impaired cognitive function, Alzheimer's disease, cardiovascular disease, and different types of cancer.\", '12': 'Some of these problems may be related to the elevated homocysteine concentrations associated to vitamin B6 deficiency, but there is also evidence for other mechanisms independent of homocysteine by which a suboptimal vitamin B6 status could increase the risk for these chronic diseases.'}\n",
            "70: abstract: {'1': \"Pyridoxal-5'-phosphate (PLP), the bioactive form of vitamin B6, reportedly functions as a prosthetic group for >4% of classified enzymatic activities of the cell.\", '2': 'It is therefore not surprising that alterations of vitamin B6 metabolism have been associated with multiple human diseases.', '3': 'As a striking example, mutations in the gene coding for antiquitin, an evolutionary old aldehyde dehydrogenase, result in pyridoxine-dependent seizures, owing to the accumulation of a metabolic intermediate that inactivates PLP.', '4': 'In addition, PLP is required for the catabolism of homocysteine by transsulfuration.', '5': 'Hence, reduced circulating levels of B6 vitamers (including PLP as well as its major precursor pyridoxine) are frequently paralleled by hyperhomocysteinemia, a condition that has been associated with an increased risk for multiple cardiovascular diseases.', '6': 'During the past 30 years, an intense wave of clinical investigation has attempted to dissect the putative links between vitamin B6 and cancer.', '7': 'Thus, high circulating levels of vitamin B6, as such or as they reflected reduced amounts of circulating homocysteine, have been associated with improved disease outcome in patients bearing a wide range of hematological and solid neoplasms.', '8': 'More recently, the proficiency of vitamin B6 metabolism has been shown to modulate the adaptive response of tumor cells to a plethora of physical and chemical stress conditions.', '9': 'Moreover, elevated levels of pyridoxal kinase (PDXK), the enzyme that converts pyridoxine and other vitamin B6 precursors into PLP, have been shown to constitute a good, therapy-independent prognostic marker in patients affected by non-small cell lung carcinoma (NSCLC).', '10': 'Here, we will discuss the clinical relevance of vitamin B6 metabolism as a prognostic factor in cancer patients.'}\n",
            "70: abstract: {'1': \"Background: Higher plasma concentrations of the vitamin B-6 marker pyridoxal 5'-phosphate (PLP) have been associated with reduced colorectal cancer (CRC) risk.\", '2': 'Inflammatory processes, including vitamin B-6 catabolism, could explain such findings.', '3': 'Objective: We investigated 3 biomarkers of vitamin B-6 status in relation to CRC risk.', '4': 'Design: This was a prospective case-control study of 613 CRC cases and 1190 matched controls nested within the Northern Sweden Health and Disease Study (n = 114,679).', '5': 'Participants were followed from 1985 to 2009, and the median follow-up from baseline to CRC diagnosis was 8.2 y. PLP, pyridoxal, pyridoxic acid (PA), 3-hydroxykynurenine, and xanthurenic acids (XAs) were measured in plasma with the use of liquid chromatography-tandem mass spectrometry.', '6': 'We calculated relative and absolute risks of CRC for PLP and the ratios 3-hydroxykynurenine:XA (HK:XA), an inverse marker of functional vitamin B-6 status, and PA:(PLP + pyridoxal) (PAr), a marker of inflammation and oxidative stress and an inverse marker of vitamin B-6 status.', '7': 'Results: Plasma PLP concentrations were associated with a reduced CRC risk for the third compared with the first quartile and for PLP sufficiency compared with deficiency [OR: 0.60 (95% CI: 0.44, 0.81) and OR: 0.55 (95% CI: 0.37, 0.81), respectively].', '8': 'HK: XA and PAr were both associated with increased CRC risk [OR: 1.48 (95% CI: 1.08, 2.02) and OR: 1.50 (95% CI: 1.10, 2.04), respectively] for the fourth compared with the first quartile.', '9': 'For HK:XA and PAr, the findings were mainly observed in study participants with <10.5 y of follow-up between sampling and diagnosis.', '10': 'Conclusions: Vitamin B-6 deficiency as measured by plasma PLP is associated with a clear increase in CRC risk.', '11': 'Furthermore, our analyses of novel markers of functional vitamin B-6 status and vitamin B-6-associated oxidative stress and inflammation suggest a role in tumor progression rather than initiation.'}\n",
            "70: abstract: {'1': 'The immune system is critical in preventing infection and cancer, and malnutrition can weaken different aspects of the immune system to undermine immunity.', '2': 'Previous studies suggested that vitamin B6 deficiency could decrease serum antibody production with concomitant increase in IL4 expression.', '3': 'However, evidence on whether vitamin B6 deficiency would impair immune cell differentiation, cytokines secretion, and signal molecule expression involved in JAK/STAT signaling pathway to regulate immune response remains largely unknown.', '4': 'The aim of this study is to investigate the effects of vitamin B6 deficiency on the immune system through analysis of T lymphocyte differentiation, IL-2, IL-4, and INF-Î³ secretion, and SOCS-1 and T-bet gene transcription.', '5': 'We generated a vitamin B6-deficient mouse model via vitamin B6-depletion diet.', '6': 'The results showed that vitamin B6 deficiency retards growth, inhibits lymphocyte proliferation, and interferes with its differentiation.', '7': 'After ConA stimulation, vitamin B6 deficiency led to decrease in IL-2 and increase in IL-4 but had no influence on IFN-Î³.', '8': 'Real-time PCR analysis showed that vitamin B6 deficiency downregulated T-bet and upregulated SOCS-1 transcription.', '9': 'Meanwhile, the appropriate supplement of vitamin B6 could benefit immunity of the organism.'}\n",
            "70: abstract: {'1': 'Vitamin B6 is one of the central molecules in the cells of living organisms.', '2': 'Water-soluble vitamin B6 is widely present in many foods, including meat, fish, nuts, beans, grains, fruits, and vegetables.', '3': 'Additionally, B6 is present in many multivitamin preparations for adults and children and is added as a supplement to foods, power bars, and powders.', '4': 'There are several active compounds or vitamers which fall under the generic B6.', '5': \"These include pyridoxine alcohol, pyridoxal an aldehyde, pyridoxamine, which differs from the first two with an amine group, and a 2,5' phosphate esters.\", '6': \"The major esters are the active coenzyme form and are pyridoxal 5'phosphate (PLP) and pyridoxamine 5'phosphate (PMP).\", '7': 'The primary form of B6 in meats are the esters, and the dominant plant source is pyridoxine, which is less bioavailable.', '8': 'Pyridoxine is the most common form found in multivitamins.', '9': 'As a coenzyme, B6 is involved as a co-factor in over 100 enzymatic reactions, including carbohydrate metabolism, amino acid metabolism, particularly homocysteine, gluconeogenesis, glycogenolysis, and lipid metabolism.', '10': 'Vitamin B6 is also involved in the critical functioning of cells.', '11': 'It plays a significant role in transamination, decarboxylation, initial steps of porphyrin synthesis.', '12': 'Pyridoxine has a role in cognitive development through neurotransmitter synthesis, immune function with interleukin-2 (IL-2) production, and hemoglobin formation.', '13': 'Fetal brain development requires adequate B6, and this continues throughout infancy.', '14': 'Vitamin B6 recommendations are made in accordance with age and life stage with pregnancy and breastfeeding, involving the highest recommended daily allowance.'}\n",
            "70: abstract: {'1': 'Background: a large number of studies have linked vitamin B6 to inflammation and cardiovascular disease in the general population.', '2': 'However, it remains uncertain whether vitamin B6 is associated with cardiovascular outcome independent of inflammation.', '3': \"Methods: we measured plasma pyridoxal 5'-phosphate (PLP), as an indicator of vitamin B6 status, at baseline in a population-based prospective cohort of 6249 participants of the Prevention of Renal and Vascular End-stage Disease (PREVEND) study who were free of cardiovascular disease.\", '4': 'As indicators of low-grade systemic inflammation, we measured high-sensitivity C-reactive protein and GlycA; Results: median plasma PLP was 37.2 (interquartile range, 25.1-57.0) nmol/L. During median follow-up for 8.3 (interquartile range, 7.8-8.9) years, 409 non-fatal and fatal cardiovascular events (composite outcome) occurred.', '5': 'In the overall cohort, log transformed plasma PLP was associated with the composite outcome, independent of adjustment for age, sex, smoking, alcohol consumption, body mass index (BMI), estimated glomerular filtration rate (eGFR), total cholesterol:high-density lipoprotein (HDL)-cholesterol ratio, and blood pressure (adjusted hazard ratio per increment of log plasma PLP, 0.66; 95% confidence interval (CI), 0.47-0.93).', '6': 'However, adjustment for high-sensitivity C-reactive protein and GlycA increased the hazard ratio by 9% and 12% respectively, to non-significant hazard ratios of 0.72 (95% confidence interval, 0.51-1.01) and 0.74 (95% confidence interval, 0.53-1.05).', '7': 'The association of plasma PLP with cardiovascular risk was modified by gender (adjusted Pinteraction = 0.04).', '8': 'When stratified according to gender, in women the prospective association with cardiovascular outcome was independent of age, smoking, alcohol consumption, high-sensitivity C-reactive protein, and GlycA (adjusted hazard ratio, 0.50, 95% confidence interval, 0.27-0.94), while it was not in men (adjusted hazard, 0.99, 95% confidence interval, 0.65-1.51).', '9': 'Conclusions: in this population-based cohort, plasma PLP was associated with cardiovascular outcome, but this association was confounded by traditional risk factors and parameters of inflammation.', '10': 'Notably, the association of low plasma PLP with high risk of adverse cardiovascular outcome was modified by gender, with a stronger and independent association in women.'}\n",
            "70: abstract: {'1': 'We have reported that a subpopulation of patients with schizophrenia have lower levels of vitamin B6 (VB6) in peripheral blood than do healthy controls.', '2': \"In a previous study, we found that VB6 level was inversely proportional to the patient's positive and negative symptom scale (PANSS) score for measuring symptom severity, suggesting that the loss of VB6 might contribute to the development of schizophrenia symptoms.\", '3': 'In the present study, to clarify the relationship between VB6 deficiency and schizophrenia, we generated VB6-deficient (VB6(-)) mice through feeding with a VB6-lacking diet as a mouse model for the subpopulation of schizophrenia patients with VB6 deficiency.', '4': 'After feeding for 4 weeks, plasma VB6 level in VB6(-) mice decreased to 3% of that in control mice.', '5': 'The VB6(-) mice showed social deficits and cognitive impairment.', '6': 'Furthermore, the VB6(-) mice showed a marked increase in 3-methoxy-4-hydroxyphenylglycol (MHPG) in the brain, suggesting enhanced noradrenaline (NA) metabolism in VB6(-) mice.', '7': 'We confirmed the increased NA release in the prefrontal cortex (PFC) and the striatum (STR) of VB6(-) mice through in vivo microdialysis.', '8': 'Moreover, inhibiting the excessive NA release by treatment with VB6 supplementation into the brain and Î±2A adrenoreceptor agonist guanfacine (GFC) suppressed the increased NA metabolism and ameliorated the behavioral deficits.', '9': 'These findings suggest that the behavioral deficits shown in VB6(-) mice are caused by enhancement of the noradrenergic (NAergic) system.'}\n",
            "70: abstract: {'1': 'There is little evidence regarding the association between serum vitamin B6 concentration and subsequent mortality.', '2': 'We aimed to evaluate the association of serum vitamin B6 concentration with all-cause, cardiovascular disease (CVD), and cancer mortality in the general population using data from the National Health and Nutrition Examination Survey (NHANES).', '3': 'Our study examined 12,190 adults participating in NHANES from 2005 to 2010 in the United States.', '4': 'The mortality status was linked to National Death Index (NDI) records up to 31 December 2015.', '5': \"Pyridoxal 5'-phosphate (PLP) is the biologically active form of vitamin B6.\", '6': 'Vitamin B6 status was defined as deficient (PLP < 20 nmol/L), insufficient (PLP â‰¥ 20.0 and <30.0 nmol/L), and sufficient (PLP â‰¥ 30.0 nmol/L).', '7': 'We established Cox proportional-hazards models to estimate the associations of categorized vitamin B6 concentration and log-transformed PLP concentration with all-cause and cause-specific mortality by calculating hazard ratios (HRs) and 95% confidence intervals (95%CIs).', '8': 'In our study, serum vitamin B6 was sufficient in 70.6% of participants, while 12.8% of the subjects were deficient in vitamin B6.', '9': 'During follow-up, a total of 1244 deaths were recorded, including 294 cancer deaths and 235 CVD deaths.', '10': 'After multivariate adjustment in Cox regression, participants with higher serum vitamin B6 had a 15% (HR = 0.85, 95% CI = 0.77, 0.93) reduced risk of all-cause mortality and a 19% (HR = 0.81, 95%CI = 0.68, 0.98) reduced risk for CVD mortality for each unit increment in natural log-transformed PLP.', '11': 'A higher log-transformed PLP was not significantly associated with a lower risk for cancer mortality.', '12': 'Compared with sufficient vitamin B6, deficient (HR = 1.37, 95% CI = 1.17, 1.60) and insufficient (HR = 1.19, 95%CI = 1.02, 1.38) vitamin B6 level were significantly associated with a higher risk for all-cause mortality.', '13': 'There was no significant association for cause-specific mortality.', '14': 'Participants with higher levels of vitamin B6 had a lower risk for all-cause mortality.', '15': 'These findings suggest that maintaining a sufficient level of serum vitamin B6 may lower the all-cause mortality risk in the general population.'}\n",
            "71: abstract: {'1': 'Achondroplasia, the most common form of human dwarfism is a rare condition that occurs in approximately 1:20,000 births.', '2': 'The major clinical outcome of Achondroplasia is attenuated growth, rhizomelic shortening of the long bones and craniofacial abnormalities.', '3': 'As of today there is no pharmacological treatment for Achondroplasia.', '4': 'Some improvement in the patients well being and daily function can be achieved by a surgical limb lengthening procedure.', '5': 'Growth hormone treatment seems to have only modest short term success and to lack long term benefits.', '6': 'Achondroplasia results from a single point mutation in Fibroblast Growth Factor Receptor 3 (FGFR3).', '7': 'In 97% of the patients, there is a Glycine to Arginine substitution at position 380 within the FGFR-3 transmembrane domain leading to receptor overactivation.', '8': 'This FGF receptor tyrosine kinase is expressed by chondrocytes in the growth plate of developing long bones and plays a crucial role in bone growth.', '9': 'Genetic disruption of the FGFR-3 gene in mice leads to a remarkable increase in the length of the vertebral column and long bones.', '10': 'This suggests that overaction of FGFR3 signaling may specifically impair chondrocyte function within the epiphyseal growth plates and cause Achondroplasia.', '11': 'Reconstituted normal bone growth may therefore be achieved by attenuation of FGFR3 signaling in the appropriate cells within the growth plate.', '12': 'It is highly conceivable that drug development strategies aimed either towards blocking extracellular ligand binding or towards intracellular checkpoints along the FGF signal transduction cascade, may prove successful in the treatment of Achondroplasia.', '13': 'This review focuses on the possible approaches for developing a drug for Achondroplasia and related skeletal disorders, using chemical, biochemical and molecular strategies.'}\n",
            "71: abstract: {'1': 'Purpose of review: A summary of management and current research in achondroplasia (OMIM 100800).', '2': 'The most common nonlethal skeletal dysplasia, achondroplasia presents a distinct clinical picture evident at birth.', '3': 'Substantial information is available concerning the natural history of this dwarfing disorder.', '4': 'Diagnosis is made by clinical findings and radiographic features.', '5': 'Characteristic features include short limbs, a relatively large head with frontal bossing and midface hypoplasia, trident hands, muscular hypotonia, and thoracolumbar kyphosis.', '6': 'Children commonly have recurrent ear infections, delayed motor milestones, and eventually develop bowed legs and lumbar lordosis.', '7': 'People with achondroplasia are generally of normal intelligence.', '8': 'Recent findings: The genetic cause of achondroplasia was discovered in 1994.', '9': 'Subsequent research efforts are designed to better characterize the underlying possible biochemical mechanisms responsible for the clinical findings of achondroplasia as well as to develop possible new therapies and/or improve intervention.', '10': 'Summary: Establishing a diagnosis of achondroplasia allows families and clinicians to provide anticipatory care for affected children.', '11': 'Although the primary features of achondroplasia affect the skeleton, a multidisciplinary approach to care for children with achondroplasia helps families and clinicians understand the clinical findings and the natural history of achondroplasia in order to improve the outcome for each patient.'}\n",
            "71: abstract: {'1': 'The most frequent type of rhizomelic dwarfism, achondroplasia (ACH), is caused by mutations in the fibroblast growth factor receptor 3 (FGFR3) gene.', '2': 'Mutations in FGFR3 result in skeletal dysplasias of variable severity, including mild phenotypic effects in hypochondroplasia (HCH), severe phenotypic effects in thanatophoric dysplasia types I (TDI) and II (TDII), and severe but survivable phenotypic effects in severe achondroplasia with developmental delay and acanthosis nigricans (SADDAN).', '3': 'To explore the molecular mechanisms that result in the different phenotypes, we investigated the kinetics of mutated versions of FGFR3.', '4': 'First, we assayed the phosphorylation states of the mutated FGFR3s and found that the level of phosphorylation in TDI-FGFR3 was lower than in ACH-FGFR3, although the other mutants were phosphorylated according to phenotypic severity.', '5': 'Second, we analyzed the duration of the phosphorylation.', '6': 'TDI-FGFR3 was not highly phosphorylated under ligand-free conditions, but the peak phosphorylation levels of TDI-FGFR3 and ACH-FGFR3 were maintained for 30 min after stimulation with FGF-1.', '7': 'Moreover, ligand-dependent phosphorylation of TDI-FGFR3, but not ACH-FGFR3, lasted for more than 8 h after FGF-1 administration.', '8': 'The other mutant proteins showed sustained phosphorylation independent of ligand presence.', '9': 'Third, we investigated the intracellular localization of the mutant proteins.', '10': 'Immunofluorescence analysis showed accumulations of TDII-FGFR3, SADDAN-FGFR3, and a portion of TDI-FGFR3 in the endoplasmic reticulum (ER).', '11': 'Based on these data, we concluded that sustained phosphorylation of FGFR3 causes chondrodysplasia, and the phenotypic severity depends on the proportion of ER-localized mutant FGFR3.', '12': 'In FGFR3 signaling, the transcription factor, signal transducer and activator of transcription 1 (STAT1) inhibit proliferation and induce apoptosis of chondrocytes.', '13': 'Here we reveal that phospholipase C gamma (PLCgamma) mediates FGFR3-induced STAT1 activation.', '14': 'Both PLCgamma and STAT1 were activated by FGFR3 signaling, but a dominant-negative form of PLCgamma (DN-PLCgamma) remarkably reduced STAT1 phosphorylation.', '15': 'Apoptosis assays revealed that the constitutively active forms of FGFR3 (TDII-FGFR3) and STAT1 (STAT1-C) induce apoptosis of chondrogenic ATDC5 cells via caspase activity.', '16': 'DN-PLCgamma reduced the apoptosis of ATDC5 cells expressing TDII-FGFR3, but over-expression of both DN-PLCgamma and STAT1-C induced apoptosis.', '17': 'Therefore, we conclude that a PLCgamma-STAT1 pathway mediates apoptotic signaling by FGFR3.'}\n",
            "71: abstract: {'1': 'This review focuses on the rheumatological features of achondroplasia, which is the most common skeletal dysplasia and the most frequent cause of short-limbed dwarfism.', '2': 'It is inherited in an autosomal dominant manner but results in the majority of cases of de novo mutations.', '3': 'The disease is related to a mutation in the fibroblast growth factor receptor-3 (FGFR3) gene encoding one member of the FGFR subfamily of tyrosine kinase receptors, which results in constitutive activation of the receptor.', '4': 'Biochemical studies of FGFR3 combined with experiments in knock-out mice have demonstrated that FGFR3 is a negative regulator of chondrocytes proliferation and differentiation in growth plate.', '5': 'This mutation induces a disturbance of endochondral bone formation.', '6': 'The diagnosis of achondroplasia is based on typical clinical and radiological features including short stature, macrocephaly with frontal bossing, midface hypoplasia and rhizomelic shortening of the limbs.', '7': 'The most common rheumatological complications of achondroplasia are medullar and radicular compressions due to spinal stenosis and deformities of the lower limbs.', '8': 'Current treatment and future therapies are discussed.'}\n",
            "71: abstract: {'1': 'Achondroplasia (MIM 100800) is the most common non-lethal skeletal dysplasia.', '2': 'Its incidence is between one in 10,000 and one in 30,000.', '3': 'The phenotype is characterized by rhizomelic disproportionate short stature, enlarged head, midface hypoplasia, short hands and lordotic lumbar spine, associated with normal cognitive development.', '4': 'This autosomal-dominant disorder is caused by a gain-of-function mutation in the gene encoding the type 3 receptor for fibroblast growth factor (FGFR3); in more than 95% of cases, the mutation is G380R.', '5': 'The diagnosis is suspected on physical examination and confirmed by different age-related radiological features.', '6': 'Anticipatory and management care by a multidisciplinary team will prevent and treat complications, including cervical cord compression, conductive hearing loss and thoracolumbar gibbosity.', '7': 'Weight counselling, psychosocial guidance and professional integration programmes play an important role in the global quality of life of these patients and their families.'}\n",
            "71: abstract: {'1': 'Fibroblast growth factors (FGFs) and their receptors (FGFRs) play significant roles in vertebrate organogenesis and morphogenesis.', '2': 'FGFR3 is a negative regulator of chondrogenesis and multiple mutations with constitutive activity of FGFR3 result in achondroplasia, one of the most common dwarfisms in humans, but the molecular mechanism remains elusive.', '3': 'In this study, we found that chondrocyte-specific deletion of BMP type I receptor a (Bmpr1a) rescued the bone overgrowth phenotype observed in Fgfr3 deficient mice by reducing chondrocyte differentiation.', '4': 'Consistently, using in vitro chondrogenic differentiation assay system, we demonstrated that FGFR3 inhibited BMPR1a-mediated chondrogenic differentiation.', '5': 'Furthermore, we showed that FGFR3 hyper-activation resulted in impaired BMP signaling in chondrocytes of mouse growth plates.', '6': 'We also found that FGFR3 inhibited BMP-2- or constitutively activated BMPR1-induced phosphorylation of Smads through a mechanism independent of its tyrosine kinase activity.', '7': 'We found that FGFR3 facilitates BMPR1a to degradation through Smurf1-mediated ubiquitination pathway.', '8': 'We demonstrated that down-regulation of BMP signaling by BMPR1 inhibitor dorsomorphin led to the retardation of chondrogenic differentiation, which mimics the effect of FGF-2 on chondrocytes and BMP-2 treatment partially rescued the retarded growth of cultured bone rudiments from thanatophoric dysplasia type II mice.', '9': 'Our findings reveal that FGFR3 promotes the degradation of BMPR1a, which plays an important role in the pathogenesis of FGFR3-related skeletal dysplasia.'}\n",
            "71: abstract: {'1': 'Achondroplasia is a human bone genetic disorder of the growth plate and is the most common form of inherited disproportionate short stature.', '2': 'It is inherited as an autosomal dominant disease with essentially complete penetrance.', '3': 'Of these most have the same point mutation in the gene for fibroblast growth factor receptor 3 (FGFR3) which is a negative regulator of bone growth.', '4': 'The clinical and radiological features of achondroplasia can easily be identified; they include disproportionate short stature with rhizomelic shortening, macrocephaly with frontal bossing, midface hypoplasia, lumbar hyperlordosis, and a trident hand configuration.', '5': 'The majority of achondroplasts have a normal intelligence, but many social and medical complications may compromise a full and productive life.', '6': 'Some of them have serious health consequences related to fluid build up in the brain, head and neck region shortening, or blockage in the upper breathing passage..', '7': 'In this article, we discuss a number of treatments from the surgical limb lengthening approach and the Recombinant Growth Hormone (rhGH) treatment, to future treatments, which include the Natriuretic Peptide C-type (CNP).', '8': 'The discussion is a comparative study of the complications and drawbacks of various experiments using numerous strategies.'}\n",
            "71: abstract: {'1': 'Autosomal dominant mutations in fibroblast growth factor receptor 3 (FGFR3) cause achondroplasia (Ach), the most common form of dwarfism in humans, and related chondrodysplasia syndromes that include hypochondroplasia (Hch), severe achondroplasia with developmental delay and acanthosis nigricans (SADDAN), and thanatophoric dysplasia (TD).', '2': 'FGFR3 is expressed in chondrocytes and mature osteoblasts where it functions to regulate bone growth.', '3': 'Analysis of the mutations in FGFR3 revealed increased signaling through a combination of mechanisms that include stabilization of the receptor, enhanced dimerization, and enhanced tyrosine kinase activity.', '4': 'Paradoxically, increased FGFR3 signaling profoundly suppresses proliferation and maturation of growth plate chondrocytes resulting in decreased growth plate size, reduced trabecular bone volume, and resulting decreased bone elongation.', '5': 'In this review, we discuss the molecular mechanisms that regulate growth plate chondrocytes, the pathogenesis of Ach, and therapeutic approaches that are being evaluated to improve endochondral bone growth in people with Ach and related conditions.'}\n",
            "71: abstract: {'1': 'Fibroblast growth factor receptor 3 (FGFR3)  mutations cause dwarfisms, including achondroplasia (ACH) and thanatophoric dysplasia (TD).', '2': 'The constitutive activation of FGFR3 disrupts the normal process of skeletal growth.', '3': 'Bone-growth anomalies have been identified in skeletal ciliopathies, in which primary cilia (PC) function is disrupted.', '4': 'In human ACH and TD, the impact of FGFR3 mutations on PC in growth plate cartilage remains unknown.', '5': 'Here we showed that in chondrocytes from human (ACH, TD) and mouse Fgfr3Y367C/+ cartilage, the constitutively active FGFR3 perturbed PC length and the sorting and trafficking of intraflagellar transport (IFT) 20 to the PC.', '6': 'We demonstrated that inhibiting FGFR3 with FGFR inhibitor, PD173074, rescued both PC length and IFT20 trafficking.', '7': 'We also studied the impact of rapamycin, an inhibitor of mammalian target of rapamycin (mTOR) pathway.', '8': 'Interestingly, mTOR inhibition also rescued PC length and IFT20 trafficking.', '9': 'Together, we provide evidence that the growth plate defects ascribed to FGFR3-related dwarfisms are potentially due to loss of PC function, and these dwarfisms may represent a novel type of skeletal disorders with defective ciliogenesis.'}\n",
            "71: abstract: {'1': 'Cilia project from almost every cell integrating extracellular cues with signaling pathways.', '2': 'Constitutive activation of FGFR3 signaling produces the skeletal disorders achondroplasia (ACH) and thanatophoric dysplasia (TD), but many of the molecular mechanisms underlying these phenotypes remain unresolved.', '3': 'Here, we report in vivo evidence for significantly shortened primary cilia in ACH and TD cartilage growth plates.', '4': 'Using in vivo and in vitro methodologies, our data demonstrate that transient versus sustained activation of FGF signaling correlated with different cilia consequences.', '5': 'Transient FGF pathway activation elongated cilia, while sustained activity shortened cilia.', '6': 'FGF signaling extended primary cilia via ERK MAP kinase and mTORC2 signaling, but not through mTORC1.', '7': 'Employing a GFP-tagged IFT20 construct to measure intraflagellar (IFT) speed in cilia, we showed that FGF signaling affected IFT velocities, as well as modulating cilia-based Hedgehog signaling.', '8': 'Our data integrate primary cilia into canonical FGF signal transduction and uncover a FGF-cilia pathway that needs consideration when elucidating the mechanisms of physiological and pathological FGFR function, or in the development of FGFR therapeutics.'}\n",
            "72: abstract: {'1': 'OBJECTIVES. To establish a database of literature and other evidence on neonatal screening programmes and technologies for inborn errors of metabolism.', '2': 'To undertake a systematic review of the data as a basis for evaluation of newborn screening for inborn errors of metabolism.', '3': 'To prepare an objective summary of the evidence on the appropriateness and need for various existing and possible neonatal screening programmes for inborn errors of metabolism in relation to the natural history of these diseases.', '4': 'To identify gaps in existing knowledge and make recommendations for required primary research.', '5': 'To make recommendations for the future development and organisation of neonatal screening for inborn errors of metabolism in the UK.', '6': 'HOW THE RESEARCH WAS CONDUCTED. There were three parts to the research.', '7': 'A systematic review of the literature on inborn errors of metabolism, neonatal screening programmes, new technologies for screening and economic factors.', '8': 'Inclusion and exclusion criteria were applied, and a working database of relevant papers was established.', '9': 'All selected papers were read by two or three experts and were critically appraised using a standard format.', '10': 'Seven criteria for a screening programme, based on the principles formulated by Wilson and Jungner (WHO, 1968), were used to summarise the evidence.', '11': 'These were as follows.', '12': 'Clinically and biochemically well-defined disorder.', '13': 'Known incidence in populations relevant to the UK.', '14': 'Disorder associated with significant morbidity or mortality.', '15': 'Effective treatment available.', '16': 'Period before onset during which intervention improves outcome.', '17': 'Ethical, safe, simple and robust screening test.', '18': 'Cost-effectiveness of screening.', '19': 'A questionnaire which was sent to all newborn screening laboratories in the UK.', '20': 'Site visits to assess new methodologies for newborn screening.', '21': 'The classical definition of an inborn error of metabolism was used (i.e., a monogenic disease resulting in deficient activity in a single enzyme in a pathway of intermediary metabolism).', '22': \"RESEARCH FINDINGS. INBORN ERRORS OF METABOLISM. Phenylketonuria (PKU) (incidence 1:12,000) fulfilled all the screening criteria and could be used as the 'gold standard' against which to review other disorders despite significant variation in methodologies, sample collection and timing of screening and inadequacies in the infrastructure for notification and continued care of identified patients.\", '23': 'Of the many disorders of organic acid and fatty acid metabolism, a case can only be made for the introduction of newborn screening for glutaric aciduria type 1 (GA1; estimated incidence 1:40,000) and medium-chain acyl CoA dehydrogenase (MCAD) deficiency (estimated incidence 1:8000-1:15,000).', '24': 'Therapeutic advances for GA1 offer prevention of neurological damage but further investigation is required into the costs and benefits of screening for this disorder.', '25': 'MCAD deficiency is simply and cheaply treatable, preventing possible early death and neurological handicap.', '26': 'Neonatal screening for these diseases is dependent upon the introduction of tandem mass spectrometry (tandem MS).', '27': 'This screening could however also simultaneously detect some other commonly-encountered disorders of organic acid metabolism with a collective incidence of 1:15,000.', '28': 'Neonatal screening for congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency (incidence 1:17,000) has been shown to be beneficial in other countries and similar benefits should accrue in the UK.', '29': 'A national programme of neonatal screening for CAH would be justified, with reassessment after an agreed period.', '30': 'Biotinidase deficiency is of low incidence in the UK (estimated 1:100,000), but this may be outweighed by the simplicity of the screening methodology and the benefits in prevention.'}\n",
            "72: abstract: {'1': 'The aim of newborn screening is to identify presymptomatic healthy infants that will develop significant metabolic or endocrine derangements if left undiagnosed and untreated.', '2': 'The goal of ultimately reducing or eliminating irreversible sequelae is reached by maximizing test sensitivity of the primary newborn screening that measures specific analytes by a number of methodologies.', '3': 'Differentiation of true from false negatives is accomplished by the test specificity.', '4': 'This review discusses disorders for which, in general, there are available therapies and that are detected by routine and expanded newborn screening.', '5': 'Recommendations are presented for evaluation by a primary care physician, with confirmation by a metabolic or endocrinology specialist.', '6': 'Disorders are organized in tabular format by class of pathway or analyte, with attention to typical clinical presentations, confirmatory biochemical and molecular tests, and therapies.', '7': 'There are numerous challenges in clinical follow-up, including diagnosis and appropriate understanding of the consequences of the disorders.', '8': 'The data required to meet these challenges can be acquired only by large scale longitudinal comprehensive studies of outcome in children identified by newborn screening.', '9': 'Only with such data can newborn screening fully serve families.'}\n",
            "72: abstract: {'1': 'The aim of newborn screening is to detect newborns with serious, treatable disorders so as to facilitate appropriate interventions to avoid or ameliorate adverse outcomes.', '2': 'Mass biochemical testing of newborn babies was pioneered in the 1960s with the introduction of screening for phenylketonuria, a rare inborn error of metabolism, tested by using a dried blood spot sample.', '3': 'The next disorder introduced into screening programs was congenital hypothyroidism and a few more much rarer disorders were gradually included.', '4': 'Two recent advances have greatly changed the pace: modification of tandem mass spectrometry and DNA extraction and analysis from newborn screening dried blood spot.', '5': 'These two technologies make the future possibilities of newborn screening seem almost unlimited.', '6': 'Newborn screening tests are usually carried out on a dried blood spot sample, for which there are special analytical considerations.', '7': 'Dried blood spot calibrators and controls, prepared on the same lot number of filter paper, are needed.', '8': 'Methods have a co-efficient of variation of about 10% due to the increased variability of a dried filter paper sample compared with other biochemical samples.', '9': 'The haematocrit is an additional variable not able to be measured.', '10': 'Also of importance is obtaining a balance between the sensitivity and specificity of each assay.', '11': 'Fixing cut-off points for action needs consideration of what is an acceptable percentage of the population to recall for further testing.', '12': 'Few assays are 100% discriminatory.', '13': 'Programs in Australasia currently screen for at least 30 disorders.', '14': 'Detection of these requires not only the assay of a primary marker but often determination of a ratio of that marker with another, or possibly an alternative assay, for example a DNA mutation.', '15': 'The most important disorders screened for are described briefly: phenylketonuria, primary congenital hypothyroidism, cystic fibrosis, the galactosaemias, medium-chain acyl-CoA dehydrogenase deficiency, glutaryl-CoA dehydrogenase deficiency and congenital adrenal hyperplasia, together with several other disorders detectable by tandem mass spectrometry.', '16': 'Newborn screening deals with rare disorders and benefit cannot be shown easily without very large pilot studies.', '17': 'There have been randomised controlled trials of screening for cystic fibrosis, and now several studies are beginning to establish the benefit of tandem mass spectrometry screening for disorders of fatty acid and amino acid metabolism.', '18': 'Two things will influence the new directions for newborn screening: the development of effective treatments for hitherto untreatable disorders, and advancing technology, enabling new testing strategies to be developed.', '19': 'There are novel treatments on the horizon for many discrete disorders.', '20': 'Susceptibility testing has recently been considered for newborn screening application, but is more controversial.', '21': 'Newborn screening has entered a new and exciting phase, with an explosion of new treatments, new technologies, and, possibly in the future, new preventive strategies.'}\n",
            "72: abstract: {'1': 'Early detection of many disorders, mainly inherited, is feasible with population-wide analysis of newborn dried blood spot samples.', '2': 'Phenylketonuria was the prototype disorder for newborn screening (NBS) and early dietary treatment has resulted in vastly improved outcomes for this disorder.', '3': 'Testing for primary hypothyroidism and cystic fibrosis (CF) was later added to NBS programs following the development of robust immunoassays and molecular testing.', '4': 'Current CF testing usually relies on a combined immunoreactive trypsin/mutation detection strategy.', '5': 'Multiplex testing for approximately 25 inborn errors of metabolism using tandem mass spectrometry is a relatively recent addition to NBS.', '6': 'The simultaneous introduction of many disorders has caused some re-evaluation of the traditional guidelines for NBS, because very rare disorders or disorders without good treatments can be included with minimal effort.', '7': 'NBS tests for many other disorders have been developed, but these are less uniformly applied or are currently considered developmental.', '8': 'This review focuses on Australasian NBS practices.'}\n",
            "72: abstract: {'1': 'Newborn dried blood spot screening (NBS) is a core public health service and is the largest application of genetic testing in the United States.', '2': 'NBS is conducted by state public health departments to identify infants with certain genetic, metabolic, and endocrine disorders.', '3': 'Screening is performed in the first few days of life through blood testing.', '4': \"Several drops of blood are taken from the baby's heel and placed on a filter paper card.\", '5': 'The dried blood, on the filter cards, is sent from the newborn nursery to the state health department laboratory, or a commercial partner, where the blood is analyzed.', '6': 'Scientific and technological advances have lead to a significant expansion in the number of tests-from an average of 6 to more than 50--and there is a national trend to further expand the NBS program.', '7': 'This rapid expansion has created significant ethical, legal, and social challenges for the health care system and opportunity for scholarly inquiry to address these issues.', '8': 'The purpose of this chapter is to provide an overview of the NBS programs and to provide an in-depth examination of two significant concerns raised from expanded newborn screening, specifically false-positives and lack of information for parents.', '9': 'Implications for nursing research in managing these ethical dilemmas are discussed.'}\n",
            "72: abstract: {'1': 'Newborn screening is the largest genetic screening program in the United States with approximately four million newborns screened yearly.', '2': 'It has been available and in continuous development for more than 50 years.', '3': 'Each state manages, funds, and maintains its own individual program, which encompasses newborn screening as well as the diagnosis and coordination of care for affected infants and children.', '4': 'The ideal disorder for screening is one in which newborn intervention prevents later disabilities or death for infants who may appear normal at birth.', '5': 'There are 31 core conditions that are currently recommended for incorporation into state screening programs.', '6': \"To obtain a sample, several drops of blood are collected from the newborn's heel and applied to filter paper.\", '7': 'Although testing for core disorders is fairly standardized, more extensive screening varies by state and the rigorous evaluation of new disorders for inclusion in state screening panels is ongoing.', '8': 'As genomic medicine becomes more accessible, screening newborns for chronic diseases that may affect their long-term health will need to be addressed as well as the use of the residual blood spots for research.', '9': 'Obstetric providers should, at some time during pregnancy, review the basic process of newborn screening with parents to prepare them for this testing in the neonatal period.', '10': \"This information can be reviewed as it best suits incorporation in an individual's practice; verbal discussion and the distribution of written materials with resources for further information are encouraged.\"}\n",
            "72: abstract: {'1': 'Newborn screening (NBS) of inborn errors of metabolism (IEM) is a coordinated comprehensive system consisting of education, screening, follow-up of abnormal test results, confirmatory testing, diagnosis, treatment, and evaluation of periodic outcome and efficiency.', '2': 'The ultimate goal of NBS and follow-up programs is to reduce morbidity and mortality from the disorders.', '3': 'Over the past decade, tandem mass spectrometry (MS/MS) has become a key technology in the field of NBS.', '4': 'It has replaced classic screening techniques of one-analysis, one-metabolite, one-disease with one analysis, many-metabolites, and many-diseases.', '5': 'The development of electrospray ionization (ESI), automation of sample handling and data manipulation have allowed the introduction of expanded NBS for the identification of numerous conditions on a single sample and new conditions to be added to the list of disorders being screened for using MS/MS.', '6': 'In the case of a screened positive result, a follow-up analytical test should be performed for confirmation of the primary result.', '7': 'The most common confirmatory follow-up tests are amino acids and acylcarnitine analysis in plasma and organic acid analysis in urine.', '8': 'NBS should be integrated with follow-up and clinical management.', '9': 'Recent improvements in therapy have caused some disorders to be considered as potential candidates for NBS.', '10': 'This review covers some of the basic theory of expanded MS/MS and follow-up confirmatory tests applied for NBS of IEM.'}\n",
            "72: abstract: {'1': 'Inborn errors of metabolism (IEM) are a phenotypically and genetically heterogeneous group of disorders caused by a defect in a metabolic pathway, leading to malfunctioning metabolism and/or the accumulation of toxic intermediate metabolites.', '2': 'To date, more than 1000 different IEM have been identified.', '3': 'While individually rare, the cumulative incidence has been shown to be upwards of 1 in 800.', '4': 'Clinical presentations are protean, complicating diagnostic pathways.', '5': 'IEM are present in all ethnic groups and across every age.', '6': 'Some IEM are amenable to treatment, with promising outcomes.', '7': 'However, high clinical suspicion alone is not sufficient to reduce morbidities and mortalities.', '8': 'In the last decade, due to the advent of tandem mass spectrometry, expanded newborn screening (NBS) has become a mandatory public health strategy in most developed and developing countries.', '9': 'The technology allows inexpensive simultaneous detection of more than 30 different metabolic disorders in one single blood spot specimen at a cost of about USD 10 per baby, with commendable analytical accuracy and precision.', '10': 'The sensitivity and specificity of this method can be up to 99% and 99.995%, respectively, for most amino acid disorders, organic acidemias, and fatty acid oxidation defects.', '11': 'Cost-effectiveness studies have confirmed that the savings achieved through the use of expanded NBS programs are significantly greater than the costs of implementation.', '12': 'The adverse effects of false positive results are negligible in view of the economic health benefits generated by expanded NBS and these could be minimized through increased education, better communication, and improved technologies.', '13': 'Local screening agencies should be given the autonomy to develop their screening programs in order to keep pace with international advancements.', '14': 'The development of biochemical genetics is closely linked with expanded NBS.', '15': 'With ongoing advancements in nanotechnology and molecular genomics, the field of biochemical genetics is still expanding rapidly.', '16': 'The potential of tandem mass spectrometry is extending to cover more disorders.', '17': 'Indeed, the use of genetic markers in T-cell receptor excision circles for severe combined immunodeficiency is one promising example.', '18': 'NBS represents the highest volume of genetic testing.', '19': 'It is more than a test and it warrants systematic healthcare service delivery across the pre-analytical, analytical, and post-analytical phases.', '20': 'There should be a comprehensive reporting system entailing genetic counselling as well as short-term and long-term follow-up.', '21': 'It is essential to integrate existing clinical IEM services with the expanded NBS program to enable close communication between the laboratory, clinicians, and allied health parties.', '22': 'In this review, we will discuss the history of IEM, its clinical presentations in children and adult patients, and its incidence among different ethnicities; the history and recent expansion of NBS, its cost-effectiveness, associated pros and cons, and the ethical issues that can arise; the analytical aspects of tandem mass spectrometry and post-analytical perspectives regarding result interpretation.'}\n",
            "72: abstract: {'1': 'Each year, 4 to 5 million newborns receive state-mandated screening.', '2': 'Although the Advisory Committee on Heritable Disorders in Newborns and Children has identified 34 core conditions that should be incorporated into screening programs, each state manages, funds, and maintains its own program.', '3': 'State programs encompass screening, as well as the diagnosis and coordination of care for newborns with positive findings.', '4': 'Testing for core disorders is fairly standardized, but more extensive screening varies widely by state, and the rigorous evaluation of new screening panels is ongoing.', '5': 'The core panel includes testing for three main categories of disorders: metabolic disorders (e.g., amino acid and urea cycle, fatty acid oxidation, and organic acid disorders); hemoglobinopathies; and a group of assorted conditions, including congenital hearing loss.', '6': 'Family physicians must be familiar with the expanded newborn screening tests to effectively communicate results to parents and formulate interventions.', '7': 'They must also recognize signs of metabolic disorders that may not be detected by screening tests or that may not be a part of standard newborn screening in their state.', '8': 'For infants with positive screening results leading to diagnosis, long-term follow-up involves ongoing parental education, regular medical examinations, management at a metabolic treatment center, and developmental and neuropsychological testing to detect associated disorders in time for early intervention.'}\n",
            "72: abstract: {'1': 'Newborn screening is important for the early detection of many congenital genetic and metabolic disorders, aimed at the earliest possible recognition and management of affected newborns, to prevent the morbidity, mortality, and disabilities associated with an inherited metabolic disorder.', '2': 'This comprehensive system includes; testing, education, follow up, diagnosis, treatment, management, and evaluation.', '3': 'There are major differences among many of the disorders being considered for inclusion in newborn screening programs.', '4': 'In recent times, advances in laboratory technology such as tandem mass spectrometry (MS/MS), which is more specific, sensitive, reliable, and comprehensive than traditional assays, has increased the number of genetic conditions that can be diagnosed through neonatal screening programs at birth.', '5': 'With a single dried filter paper blood spot, MS/MS can identify more than 30 inherited metabolic disorders in around two to three minutes.', '6': 'Advances in the diagnosis and treatment and an increased understanding of the natural history of inborn errors of metabolism have produced pressure to implement expanded newborn screening programs in many countries.', '7': 'Even as many countries throughout the world have made newborn screening mandatory, in Iran, nationwide newborn screening for inherited metabolic disorders other than hypothyroidism has not been initiated, hence, there is little information about these diseases.', '8': 'This article aims to review the recent advances in newborn metabolic screening and its situation in Iran and other countries.'}\n",
            "73: abstract: {'1': 'Background: Surgical pain is managed with multi-modal anaesthesia in total hip replacement (THR) and total knee replacement (TKR).', '2': 'It is unclear whether including local anaesthetic infiltration before wound closure provides additional pain control.', '3': 'Methods: We performed a systematic review of randomised controlled trials of local anaesthetic infiltration in patients receiving THR or TKR.', '4': 'We searched MEDLINE, Embase and Cochrane CENTRAL to December 2012.', '5': 'Two reviewers screened abstracts, extracted data, and contacted authors for unpublished outcomes and data.', '6': 'Outcomes collected were post-operative pain at rest and during activity after 24 and 48 hours, opioid requirement, mobilisation, hospital stay and complications.', '7': 'When feasible, we estimated pooled treatment effects using random effects meta-analyses.', '8': 'Results: In 13 studies including 909 patients undergoing THR, patients receiving local anaesthetic infiltration experienced a greater reduction in pain at 24 hours at rest by standardised mean difference (SMD) -0.61 (95% CI -1.05, -0.16; p = 0.008) and by SMD -0.43 (95% CI -0.78 -0.09; p = 0.014) at 48 hours during activity.', '9': 'In TKR, diverse multi-modal regimens were reported.', '10': 'In 23 studies including 1439 patients undergoing TKR, local anaesthetic infiltration reduced pain on average by SMD -0.40 (95% CI -0.58, -0.22; p < 0.001) at 24 hours at rest and by SMD -0.27 (95% CI -0.50, -0.05; p = 0.018) at 48 hours during activity, compared with patients receiving no infiltration or placebo.', '11': 'There was evidence of a larger reduction in studies delivering additional local anaesthetic after wound closure.', '12': 'There was no evidence of pain control additional to that provided by femoral nerve block.', '13': 'Patients receiving local anaesthetic infiltration spent on average an estimated 0.83 (95% CI 1.54, 0.12; p = 0.022) and 0.87 (95% CI 1.62, 0.11; p = 0.025) fewer days in hospital after THR and TKR respectively, had reduced opioid consumption, earlier mobilisation, and lower incidence of vomiting.', '14': 'Few studies reported long-term outcomes.', '15': 'Conclusions: Local anaesthetic infiltration is effective in reducing short-term pain and hospital stay in patients receiving THR and TKR.', '16': 'Studies should assess whether local anaesthetic infiltration can prevent long-term pain.', '17': 'Enhanced pain control with additional analgesia through a catheter should be weighed against a possible infection risk.'}\n",
            "73: abstract: {'1': 'Total hip and knee arthroplasty is associated with significant perioperative pain, which can adversely affect recovery by increasing risk of complications, length of stay, and cost.', '2': 'Historically, opioids were the mainstay of perioperative pain control.', '3': 'However, opioids are associated with significant downsides.', '4': 'Preemptive use of a multimodal pain management approach has become the standard of care to manage pain after hip and knee arthroplasty.', '5': 'Multimodal pain management uses oral medicines, peripheral nerve blocks, intra-articular injections, and other tools to reduce the need for opioids.', '6': 'Use of a multimodal approach promises to decrease complications, improve outcomes, and increase patient satisfaction after hip and knee arthroplasty.'}\n",
            "73: abstract: {'1': 'Introduction: Postoperative pain management options are of great importance for patients undergoing total hip arthroplasty, as joint replacement surgery is reported to be one of the most painful surgical procedures.', '2': 'This study demonstrates pain outcome until 4 weeks postoperatively and evaluates factors influencing pain in the postoperative course after total hip arthroplasty.', '3': 'Materials and methods: A total of 103 patients were included in this prospective cohort trial and underwent total hip arthroplasty.', '4': 'Postoperative pain was described using a numerical rating scale (NRS); demographic data and perioperative parameters were correlated with postoperative pain.', '5': 'Results: Evaluation of pain scores in the postoperative course showed a constant decrease in the first postoperative week (mean NRS 3.1 on day 1 to mean NRS 2.3 on day 8) and, then, a perpetual increase for 3 days (mean NRS 2.6 on day 9 to mean NRS 2.3 on day 12).', '6': 'Afterwards, a continuous pain-level decrease was stated (continuous to a mean NRS 0.9 on day 29).', '7': 'No correlation was found between the potential influencing factors sex, age, body mass index, duration of surgery, ASA score, and postoperative pain levels, but a high significant correlation could be stated for preoperative pain levels and postoperative pain intensity (pain while moving p < 0.02 to p < 0.05 depending on the time period \"week 1 postoperatively\", \"week 2-4\", or \"week 1-4\"; pain while resting p < 0.001, in all the measured time intervals, respectively).', '8': 'Conclusion: Increasing pain levels after the first week postoperatively, for 3 days, are most likely to be caused by the change to more extensive mobilization and physiotherapy in the rehabilitation unit.', '9': 'No significant influence or correlation on the intensity of postoperative pain could be found while evaluating potential predictors except preoperative pain levels.', '10': \"Pain management has to take these findings into account in the future to further increase patients' satisfaction in the postoperative course after total hip arthroplasty and to adapt pain management programs.\"}\n",
            "73: abstract: {'1': 'Total hip replacement (THR) and, particularly, total knee replacement (TKR), are painful surgical procedures.', '2': 'Effective postoperative pain management leads to a better and earlier functional recovery and prevents chronic pain.', '3': 'Studies on the control of pain during the postoperative rehabilitation period are not common.', '4': 'The aim of this study is to present results of a perioperative anesthetic protocol, and a pain treatment protocol in use in the Orthopaedic and the Rehabilitation intensive units of our Hospital.', '5': '100 patients (50 THR and 50 TKR) were retrospectively included in this observational study.', '6': 'Numeric Rating Scale (NRS) for pain at rest registered in the clinical sheet was retrieved for all patients and analyzed with respect to the spinal anaesthesia given for the surgery, local analgesia, analgesia protocol adopted during the postoperative days in the Orthopaedic Unit, the antalgic treatment given during the stay within the Rehabilitation Unit, the postoperative consumption of rescue pain medication, and any collateral effect due to the analgesic therapy.', '7': 'Patients reached standard functional abilities (walking at least 50 meters and climbing/descending stairs) at a mean length of 8 days without medication-related complications.', '8': 'Mean NRS during the time of stay was 1.3 ± 0.3 for THR and 1.3 ± 0.2 for TKR) and maximum mean NRS was 1.8 ± 0.5 for TKR and 1.8 ± 0.6 for THR.', '9': 'The use of rescue therapy in the rehabilitation guard was correlated with the mean NRS pain and the maximum NRS pain.', '10': 'A very good control of pain with the perioperative anesthetic protocol and pain treatment protocol in use was obtained.'}\n",
            "73: abstract: {'1': 'There are multiple available agents and modalities for controlling pain perioperatively during total joint arthroplasty to improve the patient experience, and their unique mechanisms and applications should be considered for use preoperatively, intraoperatively, and postoperatively, keeping in mind that each has differing efficacy and side-effect profiles.', '2': 'Preoperative pain control or preemptive analgesia using anti-inflammatory drugs and opioid analgesics appears to be effective in reducing postoperative pain, although the recommended timing and type of agents are unclear.', '3': 'With regard to intraoperative anesthetic choice and pain control, spinal anesthesia appears to have fewer systemic risks than general anesthesia, and periarticular injections of local anesthetic agents, regardless of technique, and with or without the addition of sympathetic modulators, opioids, nonsteroidal anti-inflammatory drugs (NSAIDs) or corticosteroids, have been shown to improve pain scores postoperatively and to overall carry a low risk profile.', '4': 'When considering postoperative pain control, there are several modalities including cryotherapy, peripheral nerve blockade, and parenteral and enteral medication options including acetaminophen, cyclooxygenase inhibitors, neuromodulators, tramadol, ketamine, and opioid patches, but there is no clearly preferred medication regimen and individual patient risk profiles must be considered when choosing appropriate pain management agents.', '5': 'Multimodal pain management can decrease opioid usage, improve pain scores, increase patient satisfaction, and enhance early recovery.', '6': 'The ideal preoperative, intraoperative, and postoperative pain medication regimen remains unclear, and an individualized approach to perioperative pain management is recommended.', '7': 'Despite this, good results are demonstrated with the existing variations in pain management protocols in the literature.', '8': 'Treatment of severe postoperative pain in a multimodal fashion carries the risk for serious side effects, including respiratory depression, mental status changes influencing safe gait mechanics, hypotension, renal and hepatic dysfunction, hematologic variations, gastrointestinal considerations including gastric ulcers, constipation or ileus, nausea or vomiting, infection at injection sites, and peripheral nerve injury with peripheral blockade.'}\n",
            "73: abstract: {'1': 'Background: Pain management after total knee arthroplasty and total hip arthroplasty is pivotal, as it determines the outcome of the recovery process after surgery.', '2': 'Ineffective pain control results in many postoperative complications and hinders successful recovery.', '3': 'In recent years, the transition from opioids to a multimodal pain management approach after total knee and total hip arthroplasty has increasingly become an alternative.', '4': 'This is due to the multitude of adverse effects associated with opioids.', '5': 'As a result, the use of non-opioid interventions such as acetaminophen, nonsteroidal anti-inflammatory drugs, cyclooxygenase-2 inhibitors, gabapentinoids, and ketamine, and techniques such as peripheral nerve block and local infiltration analgesia have become more favorable.', '6': 'Objectives: This paper aims to summarize literature around the effectiveness of non-opioid interventions as part of a multimodal pain management after total knee and total hip arthroplasty.', '7': 'Methods: A literature review was conducted to provide evidence-based information with respect to pain management during the postoperative period in order to enhance the pain recovery process.', '8': 'The literature chosen was extracted through the electronic databases PubMed, CINAHL, and Embase.', '9': 'Twenty-seven eligible articles were identified that met the inclusion and exclusion criteria.', '10': 'Results: Literary evidence shows that non-opioid interventions such as acetaminophen, nonsteroidal anti-inflammatory drugs, cyclooxygenase-2 inhibitors, gabapentinoids, ketamine, peripheral nerve blocks, and local infiltration analgesia benefit patients after total knee and total hip arthroplasty for pain management.', '11': 'However, further quality research trials are necessary for more conclusive evidence-based information.', '12': 'Conclusion: Selective literature supports the use of non-opioid interventions as part of a multimodal analgesics regimen for effective pain management after total knee and total hip arthroplasty.'}\n",
            "73: abstract: {'1': 'Background: We implemented local infiltration analgesia (LIA) as a technique of providing post-operative pain management and early mobilization after arthroplasty surgery and have progressively found patients able to go home earlier.', '2': 'This study compares the national data on hip and knee arthroplasty provided by the Royal Australasian College of Surgeons and Medibank Private with our outcomes using LIA and rapid recovery.', '3': 'Methods: Prospective study of one surgeon including 200 knees, and 165 hips in the two years till June 2016.', '4': 'Variables included in comparison to the two groups were: length of stay, percentage of patients transferred to rehabilitation or intensive care unit (ICU), readmitted within 30 days and average separation cost.', '5': 'Results: Hip replacement median length of stay in our series was two nights versus five nights, inpatient rehabilitation 7% versus 36%, ICU admission zero versus 4%, and readmissions 3.9% versus 6.0%, the average hospital separation cost in our series was $17 813 versus $26 734.', '6': 'Knee replacement median length of stay in our study was one night versus five nights, ICU 0.5% versus 3%, rehabilitation 4.5% versus 43%, and readmission 6% versus 7%, the average hospital separation cost in our group was $16 437 versus $27 505.', '7': 'Conclusion: The comprehensive approach of LIA and rapid recovery enables patients to have shorter hospitalization, lower rehabilitation incidence and a resultant reduction in health expenditure.'}\n",
            "73: abstract: {'1': 'Background: Opioid addiction is endemic in the United States.', '2': 'We developed a standardized opioid-prescribing schedule (SOPS) after total hip arthroplasty (THA) and total knee arthroplasty (TKA) and evaluated opioid usage alongside Patient-Reported Outcomes Measurement Information System (PROMIS) pain interference scores.', '3': 'We hypothesized that opioid usage would be less than prescribed and reducing prescription would decrease consumption without negatively impacting the PROMIS scores.', '4': 'Methods: A prospective observational study was performed on all patients undergoing primary THA and TKA from April 7, 2018, to August 10, 2019.', '5': 'Opioid consumption and pain interference were determined 2 weeks after discharge via telephone and email surveys.', '6': 'SOPSs were implemented during the study.', '7': 'Outcomes were compared in patients before and after the SOPS.', '8': 'Results: A total of 715 patients met inclusion criteria; 201 patients completed surveys.', '9': 'Before the SOPS, the mean opioid prescription was 81.2 ± 15.3 tablets for THA and 82.9 ± 10.6 for TKA.', '10': 'The mean usage was 35.1 ± 29.4 tablets and 35.4 ± 33.4, respectively.', '11': 'After the SOPS, the mean usage decreased to 19.4 ± 16.8 (P = .04) and 31.6 ± 20.9 (P = .52), respectively.', '12': 'After implementation of a second SOPS for THA, the mean number of tablets consumed was 21.5 ± 18.6 (P = .05 compared with pre-SOPS).', '13': 'The PROMIS 6B responses in patients who underwent THA demonstrated no significant changes.', '14': 'PROMIS 6B responses for TKA showed an increase in interference with recreational activities (P = .04) and tasks away from home (P = .04), but otherwise had no significant impact on reported scores.', '15': 'Conclusions: Implementation of the SOPS reduced postoperative opioid prescription and consumption without significantly impacting the reported pain interference, supporting the need to decrease opioid prescription after THA and TKA.'}\n",
            "73: abstract: {'1': 'Introduction: Total hip arthroplasty (THA) is reported to be one of the most painful surgical procedures.', '2': 'Perioperative management and rehabilitation patterns are of great importance for the success of the procedure.', '3': 'The aim of this cohort study was the evaluation of function, mobilization and pain scores during the inpatient stay (6 days postoperatively) and 4 weeks after fast-track THA.', '4': 'Materials and methods: A total of 102 consecutive patients were included in this retrospective cohort trial after minimally invasive cementless total hip arthroplasty under spinal anesthesia in a fast-track setup.', '5': 'The extent of mobilization under full-weight-bearing with crutches (walking distance in meters and necessity of nurse aid) and pain values using a numerical rating scale (NRS) were measured.', '6': 'Function was evaluated measuring the range of motion (ROM) and the ability of sitting on a chair, walking and personal hygiene.', '7': 'Furthermore, circumferences of thighs were measured to evaluate the extent of postoperative swelling.', '8': 'The widespread Harris Hip Score (HHS) was used to compare results pre- and 4 weeks postoperatively.', '9': 'Results: Evaluation of pain scores in the postoperative course showed a constant decrease in the first postoperative week (days 1-6 postoperatively).', '10': 'The pain scores before surgery were significantly higher than surgery (day 6), during mobilization (p < 0.001), at rest (p < 0.001) and at night (p < 0.001).', '11': 'All patients were able to mobilize on the day of surgery.', '12': 'In addition, there was a significant improvement in independent activities within the first 6 days postoperatively: sitting on a chair (p < 0.001), walking (p < 0.001) and personal hygiene (p < 0.001).', '13': 'There was no significant difference between the measured preoperative and postoperative (day 6 after surgery) thigh circumferences above the knee joint.', '14': 'Compared to preoperatively, there was a significant (p < 0.001) improvement of the HHS 4 weeks after surgery.', '15': 'In 100% of the cases, the operation was reported to be successful and all of the treated patients would choose a fast-track setup again.', '16': 'Conclusion: Application of a fast-track scheme is effective regarding function and mobilization of patients.', '17': 'Low pain values and rapid improvement of walking distance confirms the success of the fast-track concept in the immediate postoperative course.', '18': 'Future prospective studies have to confirm the results comparing a conventional and a fast-track pathway.'}\n",
            "73: abstract: {'1': 'Multimodal analgesia has become the standard of care for total joint arthroplasty as it provides superior analgesia with fewer side effects than opioid-only protocols.', '2': 'Systemic medications, including nonsteroidal anti-inflammatory drugs, acetaminophen, corticosteroids, and gabapentinoids, and local anesthetics via local infiltration analgesia and peripheral nerve blocks, are the foundation of multimodal analgesia in total joint arthroplasty.', '3': 'Ideally, multimodal analgesia should begin preoperatively and continue throughout the perioperative period and beyond discharge.', '4': 'There is insufficient evidence to support the routine use of intravenous acetaminophen or liposomal bupivacaine as part of multimodal analgesia protocols.'}\n",
            "74: abstract: {'1': 'Objective: To explore the spectrum and frequency of causes for chronic cough in Chinese patients.', '2': 'Methods: 86 patients with chronic cough were enrolled in the study.', '3': 'The diagnostic procedure was based on the anatomical protocol for diagnosing chronic cough designed by Irwin, and additional cytological assay was performed for sputum induced by hypertonic saline aerosol inhalation.', '4': 'The efficacy of therapy specific to the diagnosis was evaluated.', '5': 'Results: Definite diagnosis was made in 77 (89.5%) out of the 86 patients with chronic cough.', '6': 'The most common causes included cough variant asthma (CVA) (24/86, 27.9%), postnasal drip syndrome (PNDs) (22/86, 25.6%), eosinophilic bronchitis (EB) (13/86, 15.1%), and gastroesophageal reflux (GER) (12/86, 14.0%).', '7': 'After active management based on the diagnosis, cough improved in 72 patients (93.5%).', '8': 'Conclusions: In addition to CVA, PNDs and GER, eosinophilic bronchitis is also an important cause of chronic cough.', '9': 'A positive response to the specific therapy is essential to a definite diagnosis.'}\n",
            "74: abstract: {'1': 'Chronic cough is often attributed to reflux, postnasal drip, or asthma.', '2': 'We present 28 patients who had chronic cough or throat-clearing as a manifestation of sensory neuropathy involving the superior or recurrent laryngeal nerve.', '3': 'They had been identified as having sudden-onset cough, laryngospasm, or throat-clearing after viral illness, surgery, or an unknown trigger.', '4': 'Cough and laryngospasm were the most common complaints.', '5': 'Seventy-one percent of the patients had concomitant superior laryngeal nerve or recurrent laryngeal nerve motor neuropathy documented by laryngeal electromyography or videostroboscopy.', '6': 'After a negative workup for reflux, asthma, or postnasal drip, these patients were treated with gabapentin at 100 to 900 mg/d.', '7': 'Symptomatic relief was achieved in 68% of the patients.', '8': 'Sensory neuropathy of the recurrent laryngeal nerve or superior laryngeal nerve should be considered in the workup for chronic cough or larynx irritability.', '9': 'Symptomatic management of patients with cough and laryngospasm due to a suspected sensory neuropathy may include the use of antiseizure medications such as gabapentin.'}\n",
            "74: abstract: {'1': 'Objective: The spectrum and frequency of causes and the diagnostic protocol for chronic cough were explored.', '2': 'Methods: A total of 194 patients with at least 3 weeks of chronic cough and normal chest radiographs were recruited from the outpatient clinic of Guangzhou Institute of Respiratory Diseases between July 2003 to June 2004.', '3': 'The causes were investigated using a well-established protocol.', '4': 'The diagnostic protocol included history inquiring and physical examination, pulmonary function tests, induced sputum cell differentials, 24 h esophageal pH monitoring, CT of the paranasal sinuses or chest, fiberoptic rhinoscopy or bronchoscopy.', '5': 'The final diagnosis was made based on clinical manifestation, examination findings and a positive response to therapy.', '6': 'Results: The cause of chronic cough was defined in 95.4% of the patients, with a single cause found in 153 patients (82.7%), and multiple causes in 32 patients (17.3%).', '7': 'The five most important causes of cough were: eosinophilic bronchitis (n = 51, 22.4%), rhinitis and/or paranasal sinusitis (PNDs, n = 39, 17.1%), cough-variant asthma (n = 31, 13.6%), atopic cough (n = 28, 12.3%), and gastroesophageal reflux (n = 27, 11.8%).', '8': 'Conclusions: The spectrum and frequency of causes of chronic cough in our study is different from the previous reports in western countries.', '9': 'Eosinophilic bronchitis and atopic cough are important causes of chronic cough.', '10': 'A modified diagnostic protocol was established accordingly.'}\n",
            "74: abstract: {'1': \"Chronic throat clearing or a feeling of 'something' at the back of the oropharynx or nasopharynx is a common cause for referral to otorhinolaryngology services.\", '2': 'While treatment of an underlying causative condition might be expected to improve these symptoms, in many cases a clear underlying cause is not found.', '3': 'Currently, there is no recognized treatment which is effective against these troublesome symptoms.', '4': 'This observational study investigated the effectiveness of a regime of sipping ice cold carbonated water to try to break the vicious cycle of throat clearing.', '5': 'Seventy-two patients with these symptoms who had previously been advised to use the regime were contacted with a postal questionnaire.', '6': 'Sixty-three per cent of patients documented an improvement in their symptom severity score.', '7': 'The most severely and most frequently affected patients had the greatest benefit.', '8': 'We conclude that the suggested regime can be effective in breaking the vicious cycle of persistent throat-clearing.'}\n",
            "74: abstract: {'1': 'Objective: To evaluate whether the clinical characteristics of chronic cough were helpful in determining its specific causes.', '2': 'Methods: Patients with chronic cough were evaluated by a validated systematic diagnostic protocol.', '3': 'The patients with identified single cause were divided into 4 groups accordingly: cough-variant asthma (CVA), upper airway cough syndrome (UACS) or post-nasal drip syndrome (PNDS), eosinophilic bronchitis (EB), gastroesophageal reflux related cough (GERC), and the characteristics of the timing, character, onset and associated manifestations of chronic cough in different causes were compared.', '4': 'Results: A total of 196 patients met the inclusion criteria, including 55 with EB, 45 with UACS, 50 with CVA and 46 with GERC.', '5': 'No significant difference was found in age, gender and course among EB, UACS, CVA and GERC.', '6': 'The incidence of nocturnal cough in CVA was 26.0% (13/44), significantly higher than in EB (9.1% (5/55), chi2 = 5.272, P<0.05), UACS (2.2% (1/45), chi2 = 10.657, P<0.01) and GERC (0% (0/46), chi2 = 13.833, P<0.01).', '7': 'The specificity of nocturnal cough for CVA was 95.9%.', '8': 'The sensitivity and specificity of cough associated with meals in GERC was 52.2% (24/46) and 83.3%, and regurgitation associated symptom in GERC were 69.6% (32/46) and 80.0%, which were significantly higher than other groups.', '9': 'The incidence of postnasal drip, rhinitis associated symptom and case history of nasal diseases in UACS were 66.7% (30/45), 88.9% (40/45) and 82.2% (37/45), and the specificity of them were 89.4%, 65.6% and 63.6% respectively.', '10': 'Conclusion: The timing character and some associated symptoms of chronic cough are useful in predicting a single cause.'}\n",
            "74: abstract: {'1': 'Objective: To explore the spectrum and clinical features of causes for chronic cough.', '2': 'Methods: A total of 103 patients with at least 8 weeks of chronic cough and normal chest radiographs were recruited from the outpatient clinic of China-Japan Friendship Hospital Department of Respiratory Diseases between Oct 2005 to Feb 2009.', '3': 'The causes were investigated using a well established protocol according to The Chinese Respiratory Society guidelines for management of cough.', '4': 'The diagnostic protocol included history inquiring and physical examination, pulmonary function tests, induced sputum cell differentials, 24 h esophageal pH monitoring, CT of the paranasal sinuses or chest, fiberoptic rhinoscopy or bronchoscopy.', '5': 'The final diagnosis was made based on clinical manifestations, examination findings and a positive response to therapy.', '6': 'The results were compared with those reported in Guangzhou before.', '7': 'Results: The cause of chronic cough was defined in 95.1% of the patients, of which 83 patients (83.5%) with a single cause, 32 (13.6%) with 2 causes, and 3 (2.9%) with 3 causes.', '8': 'The most important causes of cough were: cough variant asthma (CVA) (n = 41, 33.3%), rhinitis and/or sinusitis (n = 30, 24.4%), gastroesophageal reflux (GERC) (n = 25, 20.3%), medicine related (n = 7, 5.7%), eosinophilic bronchitis (EB) (n = 6, 4.9%), atopic (n = 4, 3.3%), and idiopathic (n = 6, 4.9%).', '9': 'Other causes included pulmonary interstitial fibrosis (n = 2, 1.6%), left heart insufficiency (n = 1, 0.8%) and bronchiectasis (n = 1, 0.8%).', '10': 'There was more nocturnal cough in CVA (80.9%, 36/41) than in other causes (chi2 = 19.81, P<0.01).', '11': 'In CVA, 63.4% (26/41) was complicated with atopic rhinitis, 68.3% (28/41) showed seasonal variations, and 67.8% (19/28) aggravated in the autumn.', '12': 'GERC manifested more day coughs, with 56.0% (14/25) cough associated with taking food and 68.0% (17/25) with reflux symptoms.', '13': 'There was more productive cough in rhinitis and/or sinusitis (73.3% (22/30) ,chi2 = 24.99, P<0.01).', '14': 'The percentages of CVA and GERC were significantly higher than those reported in Guangzhou (chi2 value were 9.52 and 4.56 respectively, P<0.01), but those of EB and atopic cough were significantly lower (p values were 17.61 and 7.86 respectively, P<0.01).', '15': 'Conclusions: The most common causes of chronic cough in our study were CVA, rhinitis and/or sinusitis, GERC, medicine related cough, EB and atopic cough, which were different from previous reports in other cities such as Guangzhou.', '16': 'The spectrum and clinical features of causes for chronic cough are important in the diagnostic procedure of chronic cough.'}\n",
            "74: abstract: {'1': 'Objectives: We identify management strategies for the treatment of upper respiratory tract symptoms stemming from dysfunction of the recurrent laryngeal nerve.', '2': 'Methods: We present a retrospective case series of patients who had symptoms of sensory neuropathy, including persistent dysphonia, laryngospasm, and chronic cough.', '3': 'The patients were followed for symptomatic improvement after initiation of treatment with a neuromodulator.', '4': 'Treatment outcome was defined by improvement or resolution of symptoms on a self-reported outcome scale.', '5': 'Results: Of 12 patients identified, 75% exhibited evidence of motor neuropathy on laryngoscopy and 83% had symptoms related to chronic cough treated with neuromodulator therapy over a mean follow-up of 20.4 months.', '6': 'The median dose of amitriptyline hydrochloride was 25 mg daily, and that of gabapentin was 300 mg 3 times daily.', '7': 'The mean time from the initiation of therapy to a complete response was 2 months.', '8': 'Conclusions: Patients with suspected neuropathy of the recurrent laryngeal nerve frequently respond to neuromodulator therapy.', '9': 'The addition of reflux precautions and acid suppression therapy is helpful in cases of chronic and recurrent laryngospasm.', '10': 'Patients with evidence of motor neuropathy appear to have better outcomes with neuromodulator therapy.'}\n",
            "74: abstract: {'1': 'The aim of the study was to report on the prevalence and severity of laryngopharyngeal symptoms in patients with COPD compared to controls.', '2': 'A total of 27 patients with COPD and 13 controls matched according to age and gender were included.', '3': 'Demographic data included age, gender, history of smoking and history of allergic rhinitis.', '4': 'The Reflux symptom Index described by Belafsky et al. was used.', '5': 'The frequency and average score of each of the laryngopharyngeal symptoms were computed.', '6': 'The mean age of patients was 61.67 Â± 11.09 years.', '7': 'Ninety-two percent were smokers and 11.1 % had allergy rhinitis.', '8': 'The mean of Total Reflux Symptom index in patients was significantly higher compared to controls (12.70 Â± 7.06 vs. 3.00 Â± 2.94).', '9': 'In the COPD group, 18 subjects had a positive Reflux symptom index (>11) compared to one in the control group (p value <0.05).', '10': 'There was also a significant difference between the means of six laryngopharyngeal symptoms in patients vs.', '11': 'Controls: COPD patients had higher degree of hoarseness, throat clearing, excessive throat mucus, cough and sticking sensation in the throat.', '12': 'Laryngopharyngeal reflux is more prevalent in patients vs. Controls: The frequency and severity of laryngopharyngeal symptoms is significantly higher in COPD patients.'}\n",
            "74: abstract: {'1': 'Laryngopharyngeal reflux (LPR) is a complex of symptoms caused by the backflow of gastric contents into the larynx, pharynx, nasopharynx, sinuses and even to the middle ear space.', '2': 'The symptomatology of LPR includes: chronic cough, hoarseness, throat clearing, laryngitis,\"globus pharyngeus\", swallowing disturbances, postnasal drip, \"fetor ex ore\".', '3': 'In the article, the authors present two boys with chronic cough, in one of them the asthma was suspected and antiasthmatic treatment was administrated; in our patients according to the 24-hour pharyngeal pH-metry LPR was diagnosed.', '4': 'The aim of this study was to emphasise that pediatricians should be able to recognise symptoms of LPR.', '5': 'The appropriate diagnosis and treatment leads the symptoms to subside.'}\n",
            "74: abstract: {'1': 'Background/aim: To investigate the clinical features and underlying etiologies of chronic cough (CC).', '2': 'Materials and methods: Five hundred and ten CC patients were enrolled.', '3': 'The phases, characteristics and associated clinical manifestations of CC among the gastroesophageal reflux cough (GERC), cough-variant asthma (CVA), and upper airway cough syndrome (UACS) groups were compared, and the diagnostic values of each group were evaluated by multiple regression analysis.', '4': 'Results: In the 510 patients, 404 had CC with single etiology-GERC (n = 175), CVA (n = 134), and UACS (n = 95).', '5': 'The characteristic features of GERC included gastric acid backflow symptoms such as sour-tasting regurgitation, heartburn, endoscopic esophagitis, poststimulation cough, frequent throat clearing, daytime mono-cough, and feelings of heaviness and pain in the chest.', '6': 'Patients with CVA typically exhibited sensitivity to smog and other irritants; the cough occurred mostly at night, and was associated with positive bronchodilator and provocation test results.', '7': 'The typical features of UACS included a history and/or symptoms of rhinitis, retropharyngeal postnasal drip, and wet cough occurring mostly during the daytime.', '8': 'The diagnostic specificities of above factors were >70%.', '9': 'Conclusion: The most common causes of CC include GERC, CVA, and UACS, and their diagnosis is based on the characteristics of the underlying disease.'}\n",
            "75: abstract: {'1': 'Sickle cell disease (SCD) is a debilitating monogenic blood disorder with a highly variable phenotype characterized by severe pain crises, acute clinical events, and early mortality.', '2': 'Interindividual variation in fetal hemoglobin (HbF) expression is a known and potentially heritable modifier of SCD severity.', '3': 'High HbF levels are correlated with reduced morbidity and mortality.', '4': 'Common single nucleotide polymorphisms (SNPs) at the BCL11A and HBS1L-MYB loci have been implicated previously in HbF level variation in nonanemic European populations.', '5': 'We recently demonstrated an association between a BCL11A SNP and HbF levels in one SCD cohort [Uda M, et al. (2008) Proc Natl Acad Sci USA 105:1620-1625].', '6': 'Here, we genotyped additional BCL11A SNPs, HBS1L-MYB SNPs, and an SNP upstream of (G)gamma-globin (HBG2; the XmnI polymorphism), in two independent SCD cohorts: the African American Cooperative Study of Sickle Cell Disease (CSSCD) and an SCD cohort from Brazil.', '7': 'We studied the effect of these SNPs on HbF levels and on a measure of SCD-related morbidity (pain crisis rate).', '8': 'We strongly replicated the association between these SNPs and HbF level variation (in the CSSCD, P values range from 0.04 to 2 x 10(-42)).', '9': 'Together, common SNPs at the BCL11A, HBS1L-MYB, and beta-globin (HBB) loci account for >20% of the variation in HbF levels in SCD patients.', '10': 'We also have shown that HbF-associated SNPs associate with pain crisis rate in SCD patients.', '11': 'These results provide a clear example of inherited common sequence variants modifying the severity of a monogenic disease.'}\n",
            "75: abstract: {'1': 'Sickle cell disease (SCD) was the first human monogenic disorder to be characterized at the molecular level.', '2': 'It results from the substitution of glutamic acid by valine at position 6 of the β-chain of hemoglobin.', '3': 'The clinical manifestations of SCD arise from the tendency of sickle hemoglobin (known as HbS or α2βS2) to polymerize at reduced oxygen tensions and deform red cells into the characteristic rigid sickle cell shape.', '4': 'Such inflexible red cells cannot pass through the microcirculation efficiently, and this results in anemia (due to destruction of the red cells) and intermittent vasoocclusion causing tissue damage and pain.', '5': 'Although all patients with homozygous SCD have exactly the same molecular defect, there is considerable clinical variation, ranging from death in early childhood to a normal life span with few complications.', '6': 'Genetic modifiers of SCD include α-thalassemia, and it has been known for many years that patients with increased levels of fetal Hb (HbF or α2γ2) often tend to have a relatively mild clinical course because HbF reduces the tendency of HbS to polymerise within the red cell.', '7': 'Increased HbF may result from rare deletions within the β-globin gene cluster or from point mutations in the promoters of the fetal γ-globin genes (hereditary persistence of fetal hemoglobin, HPFH), but additional loci are known to increase HbF levels in adult life.', '8': 'Identifying such loci has been a painstaking task, but a combination of genome-wide analysis within a large kindred and within twin pairs has identified two quantitative trait loci (QTL) with major influences on fetal hemoglobin levels in adults.', '9': 'A significant proportion of the variation in HbF levels and the frequency of painful crises in patients with SCD is accounted for by five common single-nucleotide polymorphisms (SNPs) at these loci.'}\n",
            "75: abstract: {'1': 'We aimed to investigate the clinical and genetic predictors of painful vaso-occlusive crises (VOC) in sickle cell disease (SCD) in Cameroon.', '2': 'Socio-demographics, clinical variables/events and haematological indices were acquired.', '3': 'Genotyping was performed for 40 variants in 17 pain-related genes, three fetal haemoglobin (HbF)-promoting loci, two kidney dysfunctions-related genes, and HBA1/HBA2 genes.', '4': 'Statistical models using regression frameworks were performed in R® .', '5': 'A total of 436 hydoxycarbamide- and opioid-naïve patients were studied; median age was 16 years.', '6': 'Female sex, body mass index, Hb/HbF, blood transfusions, leucocytosis and consultation or hospitalisation rates significantly correlated with VOC.', '7': 'Three pain-related genes variants correlated with VOC (CACNA2D3-rs6777055, P = 0·025; DRD2-rs4274224, P = 0·037; KCNS1-rs734784, P = 0·01).', '8': 'Five pain-related genes variants correlated with hospitalisation/consultation rates.', '9': '(COMT-rs6269, P = 0·027; FAAH-rs4141964, P = 0·003; OPRM1-rs1799971, P = 0·031; ADRB2-rs1042713; P < 0·001; UGT2B7-rs7438135, P = 0·037).', '10': 'The 3·7 kb HBA1/HBA2 deletion correlated with increased VOC (P = 0·002).', '11': 'HbF-promoting loci variants correlated with decreased hospitalisation (BCL11A-rs4671393, P = 0·026; HBS1L-MYB-rs28384513, P = 0·01).', '12': 'APOL1 G1/G2 correlated with increased hospitalisation (P = 0·048).', '13': 'This first study from Africa has provided evidence supporting possible development of genetic risk model for pain in SCD.'}\n",
            "75: abstract: {'1': 'Sickle cell anemia (SCA), albeit monogenic, has heterogeneous phenotypic expression, mainly related to the level of hemoglobin F (HbF).', '2': 'No large cohort studies have ever compared biological parameters in patients with major β-globin haplotypes; ie, Senegal (SEN), Benin (BEN), and Bantu/Central African Republic (CAR).', '3': 'The aim of this study was to evaluate the biological impact of α genes, β haplotypes, and glucose-6-phosphate dehydrogenase (G6PD) activity at baseline and with hydroxyurea (HU).', '4': 'Homozygous HbS patients from the Créteil pediatric cohort with available α-gene and β-haplotype data were included (n = 580; 301 females and 279 males) in this retrospective study.', '5': 'Homozygous β-haplotype patients represented 74% of cases (37.4% CAR/CAR, 24.3% BEN/BEN, and 12.1% SEN/SEN).', '6': 'HU was given to 168 cohort SCA children.', '7': 'Hematological parameters were recorded when HbF was maximal, and changes (ΔHU-T0) were calculated.', '8': 'At baseline, CAR-haplotype and α-gene numbers were independently and negatively correlated with Hb and positively correlated with lactate dehydrogenase.', '9': 'HbF was negatively correlated with CAR-haplotype numbers and positively with BEN- and SEN-haplotype numbers.', '10': 'The BCL11A/rs1427407 \"T\" allele, which is favorable for HbF expression, was positively correlated with BEN- and negatively correlated with CAR-haplotype numbers.', '11': 'With HU treatment, Δ and HbF values were positively correlated with the BEN-haplotype number.', '12': 'BEN/BEN patients had higher HbF and Hb levels than CAR/CAR and SEN/SEN patients.', '13': 'In conclusion, we show that BEN/BEN patients have the best response on HU and suggest that this could be related to the higher prevalence of the favorable BCL11A/rs1427407/T/allele for HbF expression in these patients.'}\n",
            "75: abstract: {'1': 'Introduction: Fetal hemoglobin (HbF) is the major modifier for sickle cell disease (SCD) severity.', '2': 'HbF is modulated mainly by three major quantitative trait loci (QTL) on chromosomes 2, 6, and 11.', '3': 'Methods: Five SNPs in the three QTLs (HBG2, rs7482144; BCL11A, rs1427407 and rs10189857; and HBS1L-MYB intergenic region, rs28384513 and rs9399137) were investigated by multiplex PCR and reverse hybridization, and their roles in HbF and clinical phenotype variability in Iraqi Kurds with SCD were assessed.', '4': 'Results: HBG2 rs7482144 with minor allele frequency (MAF) of 0.133 was the most significant contributor to HbF variability, contributing 18.1%, followed by rs1427407 (MAF of 0.266) and rs9399137 (MAF of 0.137) at 14.3% and 8.8%, respectively.', '5': 'The other two SNPs were not significant contributors.', '6': 'Furthermore, when the cumulative numbers of minor alleles in the three contributing SNPs were assessed, HbF% and hemoglobin concentration increased with increasing number of minor alleles (P < 0.0005 and 0.001, respectively), while serum lactic dehydrogenase, reticulocytes, leukocytes, transfusion, and pain frequencies decreased (P = 0.003, 0.004, <0.0005, <0.0005, and 0.017, respectively).', '7': 'Conclusions: It was demonstrated that SNPs in all three major HbF QTLs contribute significantly to HbF and clinical variability in Iraqi Kurds with SCD and that the cumulative number of minor alleles at contributing SNPs may serve as a better predictor of such variability in this population.'}\n",
            "75: abstract: {'1': 'Background: Our objective was to investigate the combined and differential effects of alpha-thalassemia -3.7 kb deletion and HbF-promoting quantitative trait loci (HbF-QTL) in Senegalese hydroxyurea (HU)-free children and young adults with sickle cell anemia (SCA).', '2': 'Procedure: Steady-state biological parameters and vaso-occlusive crises (VOC) requiring emergency admission were recorded over a 2-year period in 301 children with SCA.', '3': 'The age of the first hospitalized VOC was also recorded.', '4': 'These data were correlated with the alpha-globin and HbF-QTL genotypes.', '5': 'For the latter, three different genetic loci were studied (XmnI, rs7482144; BCL11A, rs1427407; and the HBS1L-MYB region, rs28384513) and a composite score was calculated, ranging from zero (none of these three polymorphisms) to six (all three polymorphisms at the homozygous state).', '6': 'Results: A positive clinical impact of the HbF-QTL score on VOC rate, HbF, leucocytes, and C-reactive protein levels was observed only for patients without alpha-thalassemia deletion.', '7': 'Conversely, combination of homozygous -3.7 kb deletion with three to six HbF-QTL was associated with a higher VOC rate.', '8': 'The age of the first hospitalized VOC was delayed for patients with one or two alpha-thalassemia deletions and at least two HbF-QTL.', '9': 'Conclusion: Alpha-thalassemia -3.7 kb deletion and HbF-QTL are modulating factors of SCA clinical severity that interact with each other.', '10': 'They should be studied and interpreted together and not separately, at least in HU-free children.'}\n",
            "75: abstract: {'1': 'Fetal hemoglobin (HbF) ameliorates clinical severity of sickle cell anemia (SCA).', '2': 'The major loci regulating HbF levels are HBB cluster, BCL11A, and HMIP-2 (HBS1L-MYB).', '3': 'However, the impact of noncoding single-nucleotide polymorphisms (SNPs) in these loci on clinical outcomes and their functional role on regulating HbF levels should be better elucidated.', '4': 'Therefore, we performed comprehensive association analyses of 14 noncoding SNPs in five loci with HbF levels and with clinical outcomes in a cohort of 250 children with SCA from Southeastern Brazil, and further performed functional annotation of these SNPs.', '5': 'We found SNPs independently associated with HbF levels: rs4671393 in BCL11A (β-coefficient = 0.28), rs9399137 in HMIP-2A (β-coefficient = 0.16), and rs4895441 in HMIP-2B (β-coefficient = 0.15).', '6': 'Patients carrying minor (HbF-boosting) alleles for rs1427407, rs93979137, rs4895441, rs9402686, and rs9494145 showed reduced count of reticulocytes (p < 0.01), while those carrying the T allele of rs9494145 showed lower white blood cell count (p = 0.002).', '7': 'Carriers of the minor allele for rs9402686 showed higher peripheral saturation of oxygen (p = 0.002).', '8': 'Patients carrying minor alleles in BCL11A showed lower risk of transfusion incidence rate ratio (IRR ≥ 1.3; p < 0.0001).', '9': 'This effect was independent of HbF effect (p = 0.005).', '10': 'Carriers of minor alleles for rs9399137 and rs9402686 showed lower risk of acute chest syndrome (IRR > 1.3; p ≤ 0.01).', '11': 'Carriers of the reference allele for rs4671393 showed lower risk of infections (IRR = 1.16; p = 0.01).', '12': 'In conclusion, patients carrying HbF-boosting alleles of BCL11A and HMIP-2 were associated with milder clinical phenotypes.', '13': 'Higher HbF concentration may underlie this effect.'}\n",
            "75: abstract: {'1': 'Sickle cell disease (SCD) is a monogenic disease characterized by multisystem morbidity and highly variable clinical course.', '2': 'Inter-individual variability in hemoglobin F (HbF) levels is one of the main modifiers that account for the clinical heterogeneity in SCD.', '3': 'HbF levels are affected by, among other factors, single nucleotide polymorphisms (SNPs) at the BCL11A gene and the HBS1L-MYB intergenic region and Xmn1 gene.', '4': 'Our aim was to investigate HbF-enhancer haplotypes at these loci to obtain a first overview of the genetic situation of SCD patients in Egypt and its impact on the severity of the disease.', '5': 'The study included 100 SCD patients and 100 matched controls.', '6': 'Genotyping of BCL11A (rs1886868 C/T), HBS1L-MYB (rs9389268 A/G) and Xmn1 γG158 (rs7842144 C/T) SNPs showed no statistically significant difference between SCD patients and controls except for the hetero-mutant genotypes of BCL11A which was significantly higher in SCD patients compared with controls.', '7': 'Baseline HbF levels were significantly higher in those with co-inheritance of polymorphic genotypes of BCL11A + HSB1L-MYB and BCL11A + Xmn1.', '8': 'Steady-state HbF levels, used as an indicator of disease severity, were significantly higher in SCD-Sβ patients having the polymorphic genotypes of HSB1L-MYB.', '9': 'Fold change of HbF in both patient groups did not differ between those harboring the wild and the polymorphic genotypes of the studied SNPs.', '10': 'In conclusion, BCL11A, HSB1L, and Xmn1 genetic polymorphisms had no positive impact on baseline HbF levels solely but had if coexisted.', '11': 'Discovery of the molecular mechanisms controlling HbF production could provide a more effective strategy for HbF induction.'}\n",
            "75: abstract: {'1': 'Sickle cell disease (SCD) is a monogenetic disorder due to a single base-pair point mutation in the β-globin gene resulting in the substitution of the amino acid valine for glutamic acid in the β-globin chain.', '2': 'Phenotypic variation in the clinical presentation and disease outcome is a characteristic feature of the disorder.', '3': 'Understanding the pathogenesis and pathophysiology of the disorder is central to the choice of therapeutic development and intervention.', '4': 'In this special edition for newborn screening for haemoglobin disorders, it is pertinent to describe the genetic, pathologic and clinical presentation of sickle cell disease as a prelude to the justification for screening.', '5': 'Through a systematic review of the literature using search terms relating to SCD up till 2019, we identified relevant descriptive publications for inclusion.', '6': 'The scope of this review is mainly an overview of the clinical features of pain, the cardinal symptom in SCD, which present following the drop in foetal haemoglobin as young as five to six months after birth.', '7': 'The relative impact of haemolysis and small-vessel occlusive pathology remains controversial, a combination of features probably contribute to the different pathologies.', '8': 'We also provide an overview of emerging therapies in SCD.'}\n",
            "75: abstract: {'1': 'Sickle cell anemia (SCA) is a disease characterized by abnormal red blood cell rheology.', '2': 'Because of their effects on HbS polymerization and red blood cell deformability, alpha-thalassemia and the residual HbF level are known genetic modifiers of the disease.', '3': 'The aim of our study was to determine if the number of HbF quantitative trait loci (QTL) would also favor a specific sub-phenotype of SCA as it is the case for alpha-thalassemia.', '4': 'Our results confirmed that alpha-thalassemia protected from cerebral vasculopathy but increased the risk for frequent painful vaso-occlusive crises.', '5': 'We also showed that more HbF-QTL may provide an additional and specific protection against cerebral vasculopathy but only for children with alpha-thalassemia (-α/αα or -α/-α genotypes).'}\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "# y_key_to_extract = \"adaptations\"\n",
        "\n",
        "# for data_key, data_serial in data.items():\n",
        "#     for level1_key, level1_data in data_serial.items():\n",
        "#         if y_key_to_extract in level1_data:\n",
        "#           adapt_raw = level1_data[y_key_to_extract]\n",
        "#           print(f\"{data_key}: {y_key_to_extract}: {adapt_raw}\")"
      ],
      "metadata": {
        "id": "roLuA5KOEUc7"
      },
      "execution_count": 221,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "abstract = data[\"1\"][\"25432724\"][\"abstract\"]\n",
        "# adapt = data[\"1\"][\"15902691\"][\"adaptations\"][\"adaptation2\"]"
      ],
      "metadata": {
        "id": "CJgsGan9Q82r"
      },
      "execution_count": 222,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "sent1 =  abstract[\"5\"]\n",
        "# marked_sent = sent1\n",
        "marked_sent = marked_pair = \"[CLS] \" + sent1 + \" [SEP]\"\n",
        "print (f'Sentence: {marked_sent}, Count : {len(marked_sent)}')\n",
        "\n",
        "# sent2 = adapt[\"1\"]\n",
        "# marked_pair = \"[CLS] \" + sent1 + \" [SEP]\" + sent2 + \" [SEP]\"\n",
        "\n",
        "# # Tokenize our sentence with the BERT tokenizer.\n",
        "# tokenized_pair = tokenizer.tokenize(marked_pair)\n",
        "\n",
        "# # Print out the tokens.\n",
        "# print (tokenized_pair)"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "Lws_jqkl-AEK",
        "outputId": "01801001-d6db-4116-869a-dca97ce9f083"
      },
      "execution_count": 223,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Sentence: [CLS] Treatment options include counseling, education, oral medications, botulinum toxin injections, and several surgical procedures. [SEP], Count : 139\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "# Encode the input using the BioBERT tokenizer with attention mask\n",
        "# encoded_input = biobert_tokenizer(marked_sent, return_tensors='pt', padding='max_length', truncation=True, max_length=64)\n",
        "\n",
        "encoded_input = clinBERT_tokenizer(marked_sent, return_tensors='pt', padding='max_length', truncation=True, max_length=64)\n",
        "\n",
        "\n",
        "# # Encode the input using the BioGPT tokenizer with attention mask\n",
        "# encoded_input = bioGPT_tokenizer(marked_sent,\n",
        "#                                  return_tensors='pt',\n",
        "#                                  padding='max_length',\n",
        "#                                  truncation=True,\n",
        "#                                  max_length=64\n",
        "#                                  )\n",
        "\n",
        "# Ensure that the pad_token_id is set for GPT-2\n",
        "# gpt2_tokenizer.pad_token = gpt2_tokenizer.eos_token\n",
        "\n",
        "#Try BioGPT, change eos\n",
        "bioGPT_tokenizer.pad_token = bioGPT_tokenizer.eos_token\n",
        "bioGPT_tokenizer.padding_side ='left'\n",
        "\n",
        "print (f'Encoded inputs: {encoded_input}')"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "PtuH8LBL5aqO",
        "outputId": "2602df4e-9c5e-45db-af61-9aa54704b571"
      },
      "execution_count": 225,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Encoded inputs: {'input_ids': tensor([[   101,    101,  21379,  53121,  12363,  11170,  78067,  10230,    117,\n",
            "          14943,    117,  36965,  10172, 102096,    117,  41960,  78887,  10465,\n",
            "          10114,  76750,  91879,  10107,    117,  10111,  11736,  10326,  60764,\n",
            "          70176,    119,    102,    102,      0,      0,      0,      0,      0,\n",
            "              0,      0,      0,      0,      0,      0,      0,      0,      0,\n",
            "              0,      0,      0,      0,      0,      0,      0,      0,      0,\n",
            "              0,      0,      0,      0,      0,      0,      0,      0,      0,\n",
            "              0]]), 'attention_mask': tensor([[1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1,\n",
            "         1, 1, 1, 1, 1, 1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0,\n",
            "         0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]])}\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "# indexed_tokens = tokenizer.convert_tokens_to_ids(tokenized_pair)\n",
        "# print (indexed_tokens)\n",
        "\n",
        "# for tup in zip(tokenized_pair, indexed_tokens):\n",
        "#     print('{:<12} {:>6,}'.format(tup[0], tup[1]))"
      ],
      "metadata": {
        "id": "vwP_0JIWAv7G"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "bioGPT_model.resize_token_embeddings(len(clinBERT_tokenizer))\n",
        "bioGPT_model.config.pad_token_id = bioGPT_model.config.eos_token_id"
      ],
      "metadata": {
        "id": "KMvnkT_wsZkE"
      },
      "execution_count": 228,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "with torch.no_grad():\n",
        "    beam_output = bioGPT_model.generate(\n",
        "                                input_ids= encoded_input['input_ids'],\n",
        "                                min_length=50,\n",
        "                                max_length=70,\n",
        "                                num_beams=5,\n",
        "                                attention_mask=encoded_input['attention_mask'],\n",
        "                                early_stopping=True\n",
        "                                )\n",
        "\n",
        "generated_text = bioGPT_tokenizer.decode(beam_output[0], skip_special_tokens=True)\n",
        "# Remove any trailing padding tokens\n",
        "generated_text = generated_text.rstrip('<pad>')\n",
        "print (generated_text)"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "Wtkr5vxPkOW2",
        "outputId": "ba59a520-e316-401c-e6ab-b964c45392c8"
      },
      "execution_count": 229,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "cancer cancer ecule <unk>resveratrol propionate <unk>plantar based corticbased illance mutagenic <unk>based د <unk>piglets ple <unk><unk>EB based undifferentiated lenCarbon <unk><unk>use no no.\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "# generated_prompt_ids = gpt2_model.generate(\n",
        "#     max_length=100,  # Adjust max length as needed\n",
        "#     input_ids=encoded_input['input_ids'],\n",
        "#     num_return_sequences=1,  # Number of prompts to generate\n",
        "#     no_repeat_ngram_size=3,  # Avoid repeating n-grams\n",
        "#     attention_mask=encoded_input['attention_mask'],  # Pass the attention mask\n",
        "#     top_k=100,  # Sample from top-k most probable words\n",
        "#     top_p=0.9,  # Sample from top-p cumulative distribution\n",
        "#     temperature=0  # Control randomness (0.2 for more deterministic, higher for more random)\n",
        "# )\n"
      ],
      "metadata": {
        "id": "s19TeurM4Cw5"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "# # Decode and print the generated prompt\n",
        "# gpt2_tokenizer.decode(generated_prompt_ids[0], skip_special_tokens=True, clean_up_tokenization_spaces=True)"
      ],
      "metadata": {
        "id": "lJMHaPmf4PhJ"
      },
      "execution_count": null,
      "outputs": []
    }
  ]
}